#BEGIN_DRUGCARD DB00157

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Unclear how much of an administered dose is absorbed.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Nadide

# CAS_Registry_Number:
606-68-8

# ChEBI_ID:
16908

# Chemical_Formula:
C21H29N7O14P2

# Chemical_IUPAC_Name:
{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}[({[(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). It forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage.(Dorland, 27th ed)

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Dietary supplement
Micronutrient

# Drug_Interactions:
Not Available

# Drug_Reference:
12648681	Lin SJ, Guarente L: Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol. 2003 Apr;15(2):241-6.
17161604	Belenky P, Bogan KL, Brenner C: NAD+ metabolism in health and disease. Trends Biochem Sci. 2007 Jan;32(1):12-9. Epub 2006 Dec 11.
17295611	Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides--small molecules with a multitude of functions. Biochem J. 2007 Mar 1;402(2):205-18.
17465726	Khan JA, Forouhar F, Tao X, Tong L: Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007 May;11(5):695-705.
218616	Biellmann JF, Lapinte C, Haid E, Weimann G: Structure of lactate dehydrogenase inhibitor generated from coenzyme. Biochemistry. 1979 Apr 3;18(7):1212-7.

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-5.1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
NADH

# HET_ID:
NAI

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1

# InChI_Key:
InChIKey=BOPGDPNILDQYTO-NNYOXOHSSA-N

# Indication:
Some evidence suggests that NADH might be useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular disease.

# KEGG_Compound_ID:
C00004

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
157

# Mechanism_Of_Action:
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.

# Melting_Point:
140.0-142.0 Â°C

# Molecular_Weight_Avg:
665.441

# Molecular_Weight_Mono:
665.124771695

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1HWX

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/nad_0179.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164755085

# Pharmacology:
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes.

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
2.95e+00 g/l

# Primary_Accession_No:
DB00157

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
439153

# PubChem_Substance_ID:
46504879

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00041

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Coenzyme I, reduced
Cozymase I, reduced
DPN
DPN+
DPNH
Diphosphopyridine nucleotide
NAD+
NAD-reduced
NADH+H+
NADH2
Nicotinamide adenine dinucleotide
Nicotinaminde-Adenine-Dinucleotide
beta-DPNH
beta-NADH
dihydrodiphosphopyridine nucleotide
dihydronicotinamide adenine dinucleotide
diphosphopyridine nucleotide reduced
nicotinamide adenine dinucleotide reduced

# Synthesis_Reference:
Not Available

# Toxicity:
No reports of overdose, however, high doses of NADH (10 mg a day or more) may cause jitteriness, anxiety, and insomnia.

# Update_Date:
2013-02-08 16:19:08 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
ADH5

# Phase_1_Metabolizing_Enzyme_1_ID:
12

# Phase_1_Metabolizing_Enzyme_1_Name:
Alcohol dehydrogenase class 3

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Alcohol dehydrogenase class 3 chi chain
ANEVIKCKAAVAWEAGKPLSIEEIEVAPPKAHEVRIKIIATAVCHTDAYTLSGADPEGCF
PVILGHEGAGIVESVGEGVTKLKAGDTVIPLYIPQCGECKFCLNPKTNLCQKIRVTQGKG
LMPDGTSRFTCKGKTILHYMGTSTFSEYTVVADISVAKIDPLAPLDKVCLLGCGISTGYG
AAVNTAKLEPGSVCAVFGLGGVGLAVIMGCKVAGASRIIGVDINKDKFARAKEFGATECI
NPQDFSKPIQEVLIEMTDGGVDYSFECIGNVKVMRAALEACHKGWGVSVVVGVAASGEEI
ATRPFQLVTGRTWKGTAFGGWKSVESVPKLVSEYMSKKIKVDEFVTHNLSFDEINKAFEL
MHSGKSIRTVVKI

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11766

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
ADH1A

# Phase_1_Metabolizing_Enzyme_2_ID:
251

# Phase_1_Metabolizing_Enzyme_2_Name:
Alcohol dehydrogenase 1A

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Alcohol dehydrogenase 1A
STAGKVIKCKAAVLWELKKPFSIEEVEVAPPKAHEVRIKMVAVGICGTDDHVVSGTMVTP
LPVILGHEAAGIVESVGEGVTTVKPGDKVIPLAIPQCGKCRICKNPESNYCLKNDVSNPQ
GTLQDGTSRFTCRRKPIHHFLGISTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGY
GSAVNVAKVTPGSTCAVFGLGGVGLSAIMGCKAAGAARIIAVDINKDKFAKAKELGATEC
INPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPDSQN
LSMNPMLLLTGRTWKGAILGGFKSKECVPKLVADFMAKKFSLDALITHVLPFEKINEGFD
LLHSGKSIRTILMF

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P07327

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
ADH4

# Phase_1_Metabolizing_Enzyme_3_ID:
396

# Phase_1_Metabolizing_Enzyme_3_Name:
Alcohol dehydrogenase 4

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Alcohol dehydrogenase 4
GTKGKVIKCKAAIAWEAGKPLCIEEVEVAPPKAHEVRIQIIATSLCHTDATVIDSKFEGL
AFPVIVGHEAAGIVESIGPGVTNVKPGDKVIPLYAPLCRKCKFCLSPLTNLCGKISNLKS
PASDQQLMEDKTSRFTCKGKPVYHFFGTSTFSQYTVVSDINLAKIDDDANLERVCLLGCG
FSTGYGAAINNAKVTPGSTCAVFGLGGVGLSAVMGCKAAGASRIIGIDINSEKFVKAKAL
GATDCLNPRDLHKPIQEVIIELTKGGVDFALDCAGGSETMKAALDCTTAGWGSCTFIGVA
AGSKGLTVFPEELIIGRTINGTFFGGWKSVDSIPKLVTDYKNKKFNLDALVTHTLPFDKI
SEAFDLMNQGKSIRTILIF

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P08319

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
ADH1B

# Phase_1_Metabolizing_Enzyme_4_ID:
444

# Phase_1_Metabolizing_Enzyme_4_Name:
Alcohol dehydrogenase 1B

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Alcohol dehydrogenase 1B
STAGKVIKCKAAVLWEVKKPFSIEDVEVAPPKAYEVRIKMVAVGICRTDDHVVSGNLVTP
LPVILGHEAAGIVESVGEGVTTVKPGDKVIPLFTPQCGKCRVCKNPESNYCLKNDLGNPR
GTLQDGTRRFTCRGKPIHHFLGTSTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGY
GSAVNVAKVTPGSTCAVFGLGGVGLSAVMGCKAAGAARIIAVDINKDKFAKAKELGATEC
INPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPASQN
LSINPMLLLTGRTWKGAVYGGFKSKEGIPKLVADFMAKKFSLDALITHVLPFEKINEGFD
LLHSGKSIRTVLTF

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P00325

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
ADH7

# Phase_1_Metabolizing_Enzyme_5_ID:
579

# Phase_1_Metabolizing_Enzyme_5_Name:
Alcohol dehydrogenase class 4 mu/sigma chain

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Alcohol dehydrogenase class 4 mu/sigma chain
MGTAGKVIKCKAAVLWEQKQPFSIEEIEVAPPKTKEVRIKILATGICRTDDHVIKGTMVS
KFPVIVGHEATGIVESIGEGVTTVKPGDKVIPLFLPQCRECNACRNPDGNLCIRSDITGR
GVLADGTTRFTCKGKPVHHFMNTSTFTEYTVVDESSVAKIDDAAPPEKVCLIGCGFSTGY
GAAVKTGKVKPGSTCVVFGLGGVGLSVIMGCKSAGASRIIGIDLNKDKFEKAMAVGATEC
ISPKDSTKPISEVLSEMTGNNVGYTFEVIGHLETMIDALASCHMNYGTSVVVGVPPSAKM
LTYDPMLLFTGRTWKGCVFGGLKSRDDVPKLVTEFLAKKFDLDQLITHVLPFKKISEGFE
LLNSGQSIRTVLTF

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P40394

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
XDH

# Phase_1_Metabolizing_Enzyme_6_ID:
3947

# Phase_1_Metabolizing_Enzyme_6_Name:
Xanthine dehydrogenase/oxidase

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase
MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR
LQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI
VMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC
MNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS
TLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG
AACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD
LNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE
ELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD
PTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY
ENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK
VTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL
KKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM
LGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR
HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR
LCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL
EGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA
LLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA
SVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG
YSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF
VQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV
GEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT
GVPENCKPWSVRV

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P47989

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
AOX1

# Phase_1_Metabolizing_Enzyme_7_ID:
6020

# Phase_1_Metabolizing_Enzyme_7_Name:
Aldehyde oxidase

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Aldehyde oxidase
MDRASELLFYVNGRKVIEKNVDPETMLLPYLRKKLRLTGTKYGCGGGGCGACTVMISRYN
PITKRIRHHPANACLIPICSLYGAAVTTVEGIGSTHTRIHPVQERIAKCHGTQCGFCTPG
MVMSIYTLLRNHPEPTLDQLTDALGGNLCRCTGYRPIIDACKTFCKTSGCCQSKENGVCC
LDQGINGLPEFEEGSKTSPKLFAEEEFLPLDPTQELIFPPELMIMAEKQSQRTRVFGSER
MMWFSPVTLKELLEFKFKYPQAPVIMGNTSVGPEVKFKGVFHPVIISPDRIEELSVVNHA
YNGLTLGAGLSLAQVKDILADVVQKLPEEKTQMYHALLKHLGTLAGSQIRNMASLGGHII
SRHPDSDLNPILAVGNCTLNLLSKEGKRQIPLNEQFLSKCPNADLKPQEILVSVNIPYSR
KWEFVSAFRQAQRQENALAIVNSGMRVFFGEGDGIIRELCISYGGVGPATICAKNSCQKL
IGRHWNEQMLDIACRLILNEVSLLGSAPGGKVEFKRTLIISFLFKFYLEVSQILKKMDPV
HYPSLADKYESALEDLHSKHHCSTLKYQNIGPKQHPEDPIGHPIMHLSGVKHATGEAIYC
DDMPLVDQELFLTFVTSSRAHAKIVSIDLSEALSMPGVVDIMTAEHLSDVNSFCFFTEAE
KFLATDKVFCVGQLVCAVLADSEVQAKRAAKRVKIVYQDLEPLILTIEESIQHNSSFKPE
RKLEYGNVDEAFKVVDQILEGEIHMGGQEHFYMETQSMLVVPKGEDQEMDVYVSTQFPKY
IQDIVASTLKLPANKVMCHVRRVGGAFGGKVLKTGIIAAVTAFAANKHGRAVRCVLERGE
DMLITGGRHPYLGKYKAGFMNDGRILALDMEHYSNAGASLDESLFVIEMGLLKMDNAYKF
PNLRCRGWACRTNLPSNTAFRGFGFPQAALITESCITEVAAKCGLSPEKVRIINMYKEID
QTPYKQEINAKNLIQCWRECMAMSSYSLRKVAVEKFNAENYWKKKGLAMVPLKFPVGLGS
RAAGQAAALVHIYLDGSVLVTHGGIEMGQGVHTKMIQVVSRELRMPMSNVHLRGTSTETV
PNANISGGSVVADLNGLAVKDACQTLLKRLEPIISKNPKGTWKDWAQTAFDESINLSAVG
YFRGYESDMNWEKGEGQPFEYFVYGAACSEVEIDCLTGDHKNIRTDIVMDVGCSINPAID
IGQIEGAFIQGMGLYTIEELNYSPQGILHTRGPDQYKIPAICDMPTELHIALLPPSQNSN
TLYSSKGLGESGVFLGCSVFFAIHDAVSAARQERGLHGPLTLNSPLTPEKIRMACEDKFT
KMIPRDEPGSYVPWNVPI

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
Q06278

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
ADH6

# Phase_1_Metabolizing_Enzyme_8_ID:
6026

# Phase_1_Metabolizing_Enzyme_8_Name:
Alcohol dehydrogenase 6

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Alcohol dehydrogenase 6
MCTTGQVIRCKAAILWKPGAPFSIEEVEVAPPKAKEVRIKVVATGLCGTEMKVLGSKHLD
LLYPTILGHEGAGIVESIGEGVSTVKPGDKVITLFLPQCGECTSCLNSEGNFCIQFKQSK
TQLMSDGTSRFTCKGKSIYHFGNTSTFCEYTVIKEISVAKIDAVAPLEKVCLISCGFSTG
FGAAINTAKVTPGSTCAVFGLGGVGLSVVMGCKAAGAARIIGVDVNKEKFKKAQELGATE
CLNPQDLKKPIQEVLFDMTDAGIDFCFEAIGNLDVLAAALASCNESYGVCVVVGVLPASV
QLKISGQLFFSGRSLKGSVFGGWKSRQHIPKLVADYMAEKLNLDPLITHTLNLDKINEAV
ELMKTGKW

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P28332

# Phase_1_Metabolizing_Enzyme_9_Gene_Name:
AKR1A1

# Phase_1_Metabolizing_Enzyme_9_ID:
6861

# Phase_1_Metabolizing_Enzyme_9_Name:
Alcohol dehydrogenase [NADP+]

# Phase_1_Metabolizing_Enzyme_9_Protein_Sequence:
>Alcohol dehydrogenase [NADP+]
MAASCVLLHTGQKMPLIGLGTWKSEPGQVKAAVKYALSVGYRHIDCAAIYGNEPEIGEAL
KEDVGPGKAVPREELFVTSKLWNTKHHPEDVEPALRKTLADLQLEYLDLYLMHWPYAFER
GDNPFPKNADGTICYDSTHYKETWKALEALVAKGLVQALGLSNFNSRQIDDILSVASVRP
AVLQVECHPYLAQNELIAHCQARGLEVTAYSPLGSSDRAWRDPDEPVLLEEPVVLALAEK
YGRSPAQILLRWQVQRKVICIPKSITPSRILQNIKVFDFTFSPEEMKQLNALNKNWRYIV
PMLTVDGKRVPRDAGHPLYPFNDPY

# Phase_1_Metabolizing_Enzyme_9_SwissProt_ID:
P14550

# Drug_Target_100_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_100_Chromosome_Location:
Not Available

# Drug_Target_100_Drug_References:
10200266	Au HC, Seo BB, Matsuno-Yagi A, Yagi T, Scheffler IE: The NDUFA1 gene product (MWFE protein) is essential for activity of complex I in mammalian mitochondria. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4354-9.
11864782	Raha S, Myint AT, Johnstone L, Robinson BH: Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase. Free Radic Biol Med. 2002 Mar 1;32(5):421-30.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_100_Essentiality:
Non-Essential

# Drug_Target_100_GenAtlas_ID:
NDUFA1

# Drug_Target_100_GenBank_ID_Gene:
X81900

# Drug_Target_100_GenBank_ID_Protein:
2274974

# Drug_Target_100_GeneCard_ID:
NDUFA1

# Drug_Target_100_Gene_Name:
NDUFA1

# Drug_Target_100_Gene_Sequence:
>213 bp
ATGTGGTTCGAGATTCTCCCCGGACTCTCCGTCATGGGCGTGTGCTTGTTGATTCCAGGA
CTGGCTACTGCGTACATCCACAGGTTCACTAACGGGGGCAAGGAAAAAAGGGTTGCTCAT
TTTGGGTATCACTGGAGTCTGATGGAAAGAGATAGGCGCATCTCTGGAGTTGATCGTTAC
TATGTGTCAAAGGGTTTGGAGAACATTGATTAA

# Drug_Target_100_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_100_General_References:
8938439	Zhuchenko O, Wehnert M, Bailey J, Sun ZS, Lee CC: Isolation, mapping, and genomic structure of an X-linked gene for a subunit of human mitochondrial complex I. Genomics. 1996 Nov 1;37(3):281-8.
9224902	Frattini A, Faranda S, Bagnasco L, Patrosso C, Nulli P, Zucchi I, Vezzoni P: Identification of a new member (ZNF183) of the Ring finger gene family in Xq24-25. Gene. 1997 Jun 19;192(2):291-8.

# Drug_Target_100_HGNC_ID:
HGNC:7683

# Drug_Target_100_HPRD_ID:
02093

# Drug_Target_100_ID:
247

# Drug_Target_100_Locus:
Xq24

# Drug_Target_100_Molecular_Weight:
8073

# Drug_Target_100_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1

# Drug_Target_100_Number_of_Residues:
70

# Drug_Target_100_PDB_ID:
Not Available

# Drug_Target_100_Pathway:
Not Available

# Drug_Target_100_Pfam_Domain_Function:
Not Available

# Drug_Target_100_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1
MWFEILPGLSVMGVCLLIPGLATAYIHRFTNGGKEKRVAHFGYHWSLMERDRRISGVDRY
YVSKGLENID

# Drug_Target_100_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_100_Signals:
None

# Drug_Target_100_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_100_SwissProt_ID:
O15239

# Drug_Target_100_SwissProt_Name:
NDUA1_HUMAN

# Drug_Target_100_Synonyms:
CI-MWFE
Complex I-MWFE
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase MWFE subunit

# Drug_Target_100_Theoretical_pI:
9.12

# Drug_Target_100_Transmembrane_Regions:
5-27

# Drug_Target_101_Cellular_Location:
Not Available

# Drug_Target_101_Chromosome_Location:
Not Available

# Drug_Target_101_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_101_Essentiality:
Non-Essential

# Drug_Target_101_GenAtlas_ID:
MT-ND6

# Drug_Target_101_GenBank_ID_Gene:
J01415

# Drug_Target_101_GenBank_ID_Protein:
2052367

# Drug_Target_101_GeneCard_ID:
MT-ND6

# Drug_Target_101_Gene_Name:
MT-ND6

# Drug_Target_101_Gene_Sequence:
>525 bp
CCTATTCCCCCGAGCAATCTCAATTACAATATATACACCAACAAACAATGTTCAACCAGT
AACTACTACTAATCAACGCCCATAATCATACAAAGCCCCCGCACCAATAGGATCCTCCCG
AATCAACCCTGACCCCTCTCCTTCATAAATTATTCAGCTTCCTACACTATTAAAGTTTAC
CACAACCACCACCCCATCATACTCTTTCACCCACAGCACCAATCCTACCTCCATCGCTAA
CCCCACTAAAACACTCACCAAGACCTCAACCCCTGACCCCCATGCCTCAGGATACTCCTC
AATAGCCATCGCTGTAGTATATCCAAAGACAACCATCATTCCCCCTAAATAAATTAAAAA
AACTATTAAACCCATATAACCTCCCCCAAAATTCAGAATAATAACACACCCGACCACACC
GCTAACAATCAATACTAAACCCCCATAAATAGGAGAAGGCTTAGAAGAAAACCCCACAAA
CCCCATTACTAAACCCACACTCAACAGAAACAAAGCATACATCAT

# Drug_Target_101_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_101_General_References:
10447650	Besch D, Leo-Kottler B, Zrenner E, Wissinger B: Leber's hereditary optic neuropathy: clinical and molecular genetic findings in a patient with a new mutation in the ND6 gene. Graefes Arch Clin Exp Ophthalmol. 1999 Sep;237(9):745-52.
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
11133798	Chinnery PF, Brown DT, Andrews RM, Singh-Kler R, Riordan-Eva P, Lindley J, Applegarth DA, Turnbull DM, Howell N: The mitochondrial ND6 gene is a hot spot for mutations that cause Leber's hereditary optic neuropathy. Brain. 2001 Jan;124(Pt 1):209-18.
11781695	Ravn K, Wibrand F, Hansen FJ, Horn N, Rosenberg T, Schwartz M: An mtDNA mutation, 14453G-->A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. Eur J Hum Genet. 2001 Oct;9(10):805-9.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1417830	Johns DR, Neufeld MJ, Park RD: An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1551-7.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
2043137	Ozawa T, Tanaka M, Sugiyama S, Ino H, Ohno K, Hattori K, Ohbayashi T, Ito T, Deguchi H, Kawamura K, et al.: Patients with idiopathic cardiomyopathy belong to the same mitochondrial DNA gene family of Parkinson's disease and mitochondrial encephalomyopathy. Biochem Biophys Res Commun. 1991 May 31;177(1):518-25.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.
7530363	Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N: Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):532-6.
8016139	Jun AS, Brown MD, Wallace DC: A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6206-10.
8644732	De Vries DD, Went LN, Bruyn GW, Scholte HR, Hofstra RM, Bolhuis PA, van Oost BA: Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. Am J Hum Genet. 1996 Apr;58(4):703-11.
8854108	Leo-Kottler B, Christ-Adler M, Baumann B, Zrenner E, Wissinger B: Leber's hereditary optic neuropathy: clinical and molecular genetic results obtained in a family with a new point mutation at nucleotide position 14498 in the ND 6 gene. Ger J Ophthalmol. 1996 Jul;5(4):233-40.
9452107	Sudoyo H, Sitepu M, Malik S, Poesponegoro HD, Marzuki S: Leber's hereditary optic neuropathy in Indonesia: two families with the mtDNA 11778G>A and 14484T>C mutations. Hum Mutat. 1998;Suppl 1:S271-4.

# Drug_Target_101_HGNC_ID:
HGNC:7462

# Drug_Target_101_HPRD_ID:
Not Available

# Drug_Target_101_ID:
384

# Drug_Target_101_Locus:
-

# Drug_Target_101_Molecular_Weight:
18622

# Drug_Target_101_Name:
NADH-ubiquinone oxidoreductase chain 6

# Drug_Target_101_Number_of_Residues:
174

# Drug_Target_101_PDB_ID:
Not Available

# Drug_Target_101_Pathway:
Not Available

# Drug_Target_101_Pfam_Domain_Function:
PF00499	Oxidored_q3

# Drug_Target_101_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 6
MMYALFLLSVGLVMGFVGFSSKPSPIYGGLVLIVSGVVGCVIILNFGGGYMGLMVFLIYL
GGMMVVFGYTTAMAIEEYPEAWGSGVEVLVSVLVGLAMEVGLVLWVKEYDGVVVVVNFNS
VGSWMIYEGEGSGLIREDPIGAGALYDYGRWLVVVTGWTLFVGVYIVIEIARGN

# Drug_Target_101_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_101_Signals:
None

# Drug_Target_101_Specific_Function:
Not Available

# Drug_Target_101_SwissProt_ID:
P03923

# Drug_Target_101_SwissProt_Name:
NU6M_HUMAN

# Drug_Target_101_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 6

# Drug_Target_101_Theoretical_pI:
3.90

# Drug_Target_101_Transmembrane_Regions:
2-21; 26-48; 55-74; 84-106; 111-128; 148-170

# Drug_Target_102_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein (Probable)

# Drug_Target_102_Chromosome_Location:
Not Available

# Drug_Target_102_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17614984	Bao HG, Zhao CJ, Li JY, Wu Ch: Association of MT-ND5 gene variation with mitochondrial respiratory control ratio and NADH dehydrogenase activity in Tibet chicken embryos. Anim Genet. 2007 Oct;38(5):514-6. Epub 2007 Jul 5.
9071018	Johnson WE, O'Brien SJ: Phylogenetic reconstruction of the Felidae using 16S rRNA and NADH-5 mitochondrial genes. J Mol Evol. 1997;44 Suppl 1:S98-116.

# Drug_Target_102_Essentiality:
Non-Essential

# Drug_Target_102_GenAtlas_ID:
MT-ND5

# Drug_Target_102_GenBank_ID_Gene:
J01415

# Drug_Target_102_GenBank_ID_Protein:
2052366

# Drug_Target_102_GeneCard_ID:
MT-ND5

# Drug_Target_102_Gene_Name:
MT-ND5

# Drug_Target_102_Gene_Sequence:
>1812 bp
ATAACCATGCACACTACTATAACCACCCTAACCCTGACTTCCCTAATTCCCCCCATCCTT
ACCACCCTCGTTAACCCTAACAAAAAAAACTCATACCCCCATTATGTAAAATCCATTGTC
GCATCCACCTTTATTATCAGTCTCTTCCCCACAACAATATTCATGTGCCTAGACCAAGAA
GTTATTATCTCGAACTGACACTGAGCCACAACCCAAACAACCCAGCTCTCCCTAAGCTTC
AAACTAGACTACTTCTCCATAATATTCATCCCTGTAGCATTGTTCGTTACATGGTCCATC
ATAGAATTCTCACTGTGATATATAAACTCAGACCCAAACATTAATCAGTTCTTCAAATAT
CTACTCATCTTCCTAATTACCATACTAATCTTAGTTACCGCTAACAACCTATTCCAACTG
TTCATCGGCTGAGAGGGCGTAGGAATTATATCCTTCTTGCTCATCAGTTGATGATACGCC
CGAGCAGATGCCAACACAGCAGCCATTCAAGCAATCCTATACAACCGTATCGGCGATATC
GGTTTCATCCTCGCCTTAGCATGATTTATCCTACACTCCAACTCATGAGACCCACAACAA
ATAGCCCTTCTAAACGCTAATCCAAGCCTCACCCCACTACTAGGCCTCCTCCTAGCAGCA
GCAGGCAAATCAGCCCAATTAGGTCTCCACCCCTGACTCCCCTCAGCCATAGAAGGCCCC
ACCCCAGTCTCAGCCCTACTCCACTCAAGCACTATAGTTGTAGCAGGAATCTTCTTACTC
ATCCGCTTCCACCCCCTAGCAGAAAATAGCCCACTAATCCAAACTCTAACACTATGCTTA
GGCGCTATCACCACTCTGTTCGCAGCAGTCTGCGCCCTTACACAAAATGACATCAAAAAA
ATCGTAGCCTTCTCCACTTCAAGTCAACTAGGACTCATAATAGTTACAATCGGCATCAAC
CAACCACACCTAGCATTCCTGCACATCTGTACCCACGCCTTCTTCAAAGCCATACTATTT
ATGTGCTCCGGGTCCATCATCCACAACCTTAACAATGAACAAGATATTCGAAAAATAGGA
GGACTACTCAAAACCATACCTCTCACTTCAACCTCCCTCACCATTGGCAGCCTAGCATTA
GCAGGAATACCTTTCCTCACAGGTTTCTACTCCAAAGACCACATCATCGAAACCGCAAAC
ATATCATACACAAACGCCTGAGCCCTATCTATTACTCTCATCGCTACCTCCCTGACAAGC
GCCTATAGCACTCGAATAATTCTTCTCACCCTAACAGGTCAACCTCGCTTCCCCACCCTT
ACTAACATTAACGAAAATAACCCCACCCTACTAAACCCCATTAAACGCCTGGCAGCCGGA
AGCCTATTCGCAGGATTTCTCATTACTAACAACATTTCCCCCGCATCCCCCTTCCAAACA
ACAATCCCCCTCTACCTAAAACTCACAGCCCTCGCTGTCACTTTCCTAGGACTTCTAACA
GCCCTAGACCTCAACTACCTAACCAACAAACTTAAAATAAAATCCCCACTATGCACATTT
TATTTCTCCAACATACTCGGATTCTACCCTAGCATCACACACCGCACAATCCCCTATCTA
GGCCTTCTTACGAGCCAAAACCTGCCCCTACTCCTCCTAGACCTAACCTGACTAGAAAAG
CTATTACCTAAAACAATTTCACAGCACCAAATCTCCACCTCCATCATCACCTCAACCCAA
AAAGGCATAATTAAACTTTACTTCCTCTCTTTCTTCTTCCCACTCATCCTAACCCTACTC
CTAATCACATAA

# Drug_Target_102_General_Function:
Energy production and conversion

# Drug_Target_102_General_References:
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
11553319	Maca-Meyer N, Gonzalez AM, Larruga JM, Flores C, Cabrera VM: Major genomic mitochondrial lineages delineate early human expansions. BMC Genet. 2001;2:13. Epub 2001 Aug 13.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1732158	Brown MD, Voljavec AS, Lott MT, Torroni A, Yang CC, Wallace DC: Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics. 1992 Jan;130(1):163-73.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
1900003	Johns DR, Berman J: Alternative, simultaneous complex I mitochondrial DNA mutations in Leber's hereditary optic neuropathy. Biochem Biophys Res Commun. 1991 Feb 14;174(3):1324-30.
3921850	Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985 Apr 18-24;314(6012):592-7.
6284948	Brown WM, Prager EM, Wang A, Wilson AC: Mitochondrial DNA sequences of primates: tempo and mode of evolution. J Mol Evol. 1982;18(4):225-39.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.
7530363	Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N: Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):532-6.
8213825	Howell N, Halvorson S, Burns J, McCullough DA, Paulton J: When does bilateral optic atrophy become Leber hereditary optic neuropathy? Am J Hum Genet. 1993 Oct;53(4):959-63.
9461455	Rieder MJ, Taylor SL, Tobe VO, Nickerson DA: Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome. Nucleic Acids Res. 1998 Feb 15;26(4):967-73.

# Drug_Target_102_HGNC_ID:
HGNC:7461

# Drug_Target_102_HPRD_ID:
Not Available

# Drug_Target_102_ID:
637

# Drug_Target_102_Locus:
-

# Drug_Target_102_Molecular_Weight:
67027

# Drug_Target_102_Name:
NADH-ubiquinone oxidoreductase chain 5

# Drug_Target_102_Number_of_Residues:
603

# Drug_Target_102_PDB_ID:
Not Available

# Drug_Target_102_Pathway:
Not Available

# Drug_Target_102_Pfam_Domain_Function:
PF00361	Oxidored_q1
PF00662	Oxidored_q1_N
PF06455	NADH5_C

# Drug_Target_102_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 5
MTMHTTMTTLTLTSLIPPILTTLVNPNKKNSYPHYVKSIVASTFIISLFPTTMFMCLDQE
VIISNWHWATTQTTQLSLSFKLDYFSMMFIPVALFVTWSIMEFSLWYMNSDPNINQFFKY
LLIFLITMLILVTANNLFQLFIGWEGVGIMSFLLISWWYARADANTAAIQAILYNRIGDI
GFILALAWFILHSNSWDPQQMALLNANPSLTPLLGLLLAAAGKSAQLGLHPWLPSAMEGP
TPVSALLHSSTMVVAGIFLLIRFHPLAENSPLIQTLTLCLGAITTLFAAVCALTQNDIKK
IVAFSTSSQLGLMMVTIGINQPHLAFLHICTHAFFKAMLFMCSGSIIHNLNNEQDIRKMG
GLLKTMPLTSTSLTIGSLALAGMPFLTGFYSKDHIIETANMSYTNAWALSITLIATSLTS
AYSTRMILLTLTGQPRFPTLTNINENNPTLLNPIKRLAAGSLFAGFLITNNISPASPFQT
TIPLYLKLTALAVTFLGLLTALDLNYLTNKLKMKSPLCTFYFSNMLGFYPSITHRTIPYL
GLLTSQNLPLLLLDLTWLEKLLPKTISQHQISTSIITSTQKGMIKLYFLSFFFPLILTLL
LIT

# Drug_Target_102_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_102_Signals:
None

# Drug_Target_102_Specific_Function:
Not Available

# Drug_Target_102_SwissProt_ID:
P03915

# Drug_Target_102_SwissProt_Name:
NU5M_HUMAN

# Drug_Target_102_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 5

# Drug_Target_102_Theoretical_pI:
9.32

# Drug_Target_102_Transmembrane_Regions:
35-57; 85-107; 120-137; 141-160; 172-191; 211-233; 245-267; 272-294; 301-320; 325-347; 368-387; 407-429; 450-472; 482-504; 583-602

# Drug_Target_103_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_103_Chromosome_Location:
Not Available

# Drug_Target_103_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_103_Essentiality:
Non-Essential

# Drug_Target_103_GenAtlas_ID:
NDUFA4

# Drug_Target_103_GenBank_ID_Gene:
U94586

# Drug_Target_103_GenBank_ID_Protein:
1946692

# Drug_Target_103_GeneCard_ID:
NDUFA4

# Drug_Target_103_Gene_Name:
NDUFA4

# Drug_Target_103_Gene_Sequence:
>246 bp
ATGCTCCGCCAGATCATCGGTCAGGCCAAGAAGCATCCAAGCTTGATCCCCCTCTTTGTA
TTTATTGGAACTGGAGCTACTGGAGCAACACTGTATCTCTTGCGTCTGGCATTGTTCAAT
CCAGATGTTTGTTGGGACAGAAATAACCCAGAGCCCTGGAACAAACTGGGTCCCAATGAT
CAATACAAGTTCTACTCAGTGAATGTGGATTACAGCAAGCTGAAGAAGGAACGTCCAGAT
TTCTAA

# Drug_Target_103_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_103_General_References:
9352085	Kim JW, Lee Y, Kang HB, Chose YK, Chung TW, Chang SY, Lee KS, Choe IS: Cloning of the human cDNA sequence encoding the NADH:ubiquinone oxidoreductase MLRQ subunit. Biochem Mol Biol Int. 1997 Oct;43(3):669-75.

# Drug_Target_103_HGNC_ID:
HGNC:7687

# Drug_Target_103_HPRD_ID:
04831

# Drug_Target_103_ID:
190

# Drug_Target_103_Locus:
7p21.3

# Drug_Target_103_Molecular_Weight:
9370

# Drug_Target_103_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4

# Drug_Target_103_Number_of_Residues:
81

# Drug_Target_103_PDB_ID:
Not Available

# Drug_Target_103_Pathway:
Not Available

# Drug_Target_103_Pfam_Domain_Function:
Not Available

# Drug_Target_103_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4
MLRQIIGQAKKHPSLIPLFVFIGTGATGATLYLLRLALFNPDVCWDRNNPEPWNKLGPND
QYKFYSVNVDYSKLKKERPDF

# Drug_Target_103_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_103_Signals:
None

# Drug_Target_103_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_103_SwissProt_ID:
O00483

# Drug_Target_103_SwissProt_Name:
NDUA4_HUMAN

# Drug_Target_103_Synonyms:
CI-MLRQ
Complex I-MLRQ
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase MLRQ subunit

# Drug_Target_103_Theoretical_pI:
9.84

# Drug_Target_103_Transmembrane_Regions:
15-37

# Drug_Target_104_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_104_Chromosome_Location:
Not Available

# Drug_Target_104_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_104_Essentiality:
Non-Essential

# Drug_Target_104_GenAtlas_ID:
NDUFA6

# Drug_Target_104_GenBank_ID_Gene:
AF047182

# Drug_Target_104_GenBank_ID_Protein:
2909856

# Drug_Target_104_GeneCard_ID:
NDUFA6

# Drug_Target_104_Gene_Name:
NDUFA6

# Drug_Target_104_Gene_Sequence:
>387 bp
ATGGCGGGGAGCGGCGTCCGCCAAGCTACTTCTACCGCCAGCACCTTCGTGAAGCCCATT
TTCAGTCGGGACATGAACGAGGCCAAGCGGAGGGTGCGCGAGCTCTACCGCGCCTGGTAT
CGGGAGGTGCCGAACACTGTGCACCAATTCCAGCTGGACATCACTGTGAAAATGGGACGG
GATAAAGTCCGAGAAATGTTTATGAAGAATGCCCATGTCACAGACCCCAGGGTGGTTGAT
CTTCTGGTCATTAAGGGAAAGATCGAACTGGAAGAAACAATTAAAGTATGGAAGCAGCGG
ACACATGTTATGCGGTTCTTCCATGAAACAGAAGCGCCAAGGCCAAAGGATTTCCTATCC
AAGTTCTATGTTGGCCACGATCCATGA

# Drug_Target_104_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_104_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
9425316	Ton C, Hwang DM, Dempsey AA, Liew CC: Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits. Biochem Biophys Res Commun. 1997 Dec 18;241(2):589-94.

# Drug_Target_104_HGNC_ID:
HGNC:7690

# Drug_Target_104_HPRD_ID:
11884

# Drug_Target_104_ID:
236

# Drug_Target_104_Locus:
22q13.2-q13.31

# Drug_Target_104_Molecular_Weight:
15006

# Drug_Target_104_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6

# Drug_Target_104_Number_of_Residues:
127

# Drug_Target_104_PDB_ID:
Not Available

# Drug_Target_104_Pathway:
Not Available

# Drug_Target_104_Pfam_Domain_Function:
PF05347	Complex1_LYR

# Drug_Target_104_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6
AGSGVRQATSTASTFVKPIFSRDMNEAKRRVRELYRAWYREVPNTVHQFQLDITVKMGRD
KVREMFMKNAHVTDPRVVDLLVIKGKIELEETIKVWKQRTHVMRFFHETEAPRPKDFLSK
FYVGHDP

# Drug_Target_104_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_104_Signals:
None

# Drug_Target_104_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_104_SwissProt_ID:
P56556

# Drug_Target_104_SwissProt_Name:
NDUA6_HUMAN

# Drug_Target_104_Synonyms:
CI-B14
Complex I-B14
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B14 subunit

# Drug_Target_104_Theoretical_pI:
10.64

# Drug_Target_104_Transmembrane_Regions:
None

# Drug_Target_105_Cellular_Location:
Mitochondrion

# Drug_Target_105_Chromosome_Location:
Not Available

# Drug_Target_105_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_105_Essentiality:
Non-Essential

# Drug_Target_105_GenAtlas_ID:
NDUFAB1

# Drug_Target_105_GenBank_ID_Gene:
AF087660

# Drug_Target_105_GenBank_ID_Protein:
4567042

# Drug_Target_105_GeneCard_ID:
NDUFAB1

# Drug_Target_105_Gene_Name:
NDUFAB1

# Drug_Target_105_Gene_Sequence:
>471 bp
ATGGCGTCTCGTGTCCTTTCAGCCTATGTCAGCCGCCTGCCCGCGGCCTTTGCGCCGCTG
CCCCGGGTCCGGATGCTGGCCGTGGCCCGGCCTCTCAGCACTGCTCTCTGCTCCGCGGGG
ACCCAGACGAGGCTCGGGACTTTGCAGCCGGCCTTAGTGCTCGCGCAGGTTCCTGGTAGA
GTTACACAGTTGTGCCGCCAGTATAGCGACATGCCTCCTTTGACGTTAGAGGGCATCCAG
GACCGTGTTCTTTACGTATTGAAACTCTATGACAAGATTGACCCAGAGAAGCTTTCAGTA
AATTCTCATTTTATGAAAGACCTGGGCTTAGACAGTTTGGACCAAGTGGAGATTATCATG
GCCATGGAAGACGAATTTGGGTTTGAAATTCCTGATATAGATGCTGAAAAGTTAATGTGT
CCACAAGAAATTGTAGATTACATTGCAGATAAGAAAGATGTATATGAATAA

# Drug_Target_105_General_Function:
Lipid transport and metabolism

# Drug_Target_105_General_References:
10493829	Loftus BJ, Kim UJ, Sneddon VP, Kalush F, Brandon R, Fuhrmann J, Mason T, Crosby ML, Barnstead M, Cronin L, Deslattes Mays A, Cao Y, Xu RX, Kang HL, Mitchell S, Eichler EE, Harris PC, Venter JC, Adams MD: Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q. Genomics. 1999 Sep 15;60(3):295-308.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_105_HGNC_ID:
HGNC:7694

# Drug_Target_105_HPRD_ID:
11951

# Drug_Target_105_ID:
602

# Drug_Target_105_Locus:
16p12.1

# Drug_Target_105_Molecular_Weight:
17418

# Drug_Target_105_Name:
Acyl carrier protein, mitochondrial

# Drug_Target_105_Number_of_Residues:
156

# Drug_Target_105_PDB_ID:
Not Available

# Drug_Target_105_Pathway:
Not Available

# Drug_Target_105_Pfam_Domain_Function:
PF00550	PP-binding

# Drug_Target_105_Protein_Sequence:
>Acyl carrier protein, mitochondrial precursor
MASRVLSAYVSRLPAAFAPLPRVRMLAVARPLSTALCSAGTQTRLGTLQPALVLAQVPGR
VTQLCRQYSDMPPLTLEGIQDRVLYVLKLYDKIDPEKLSVNSHFMKDLGLDSLDQVEIIM
AMEDEFGFEIPDIDAEKLMCPQEIVDYIADKKDVYE

# Drug_Target_105_Reaction:
Not Available

# Drug_Target_105_Signals:
None

# Drug_Target_105_Specific_Function:
Carrier of the growing fatty acid chain in fatty acid biosynthesis in mitochondria

# Drug_Target_105_SwissProt_ID:
O14561

# Drug_Target_105_SwissProt_Name:
ACPM_HUMAN

# Drug_Target_105_Synonyms:
ACP
Acyl carrier protein, mitochondrial precursor
CI-SDAP
NADH-ubiquinone oxidoreductase 9.6 kDa subunit

# Drug_Target_105_Theoretical_pI:
4.53

# Drug_Target_105_Transmembrane_Regions:
None

# Drug_Target_106_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_106_Chromosome_Location:
Not Available

# Drug_Target_106_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_106_Essentiality:
Non-Essential

# Drug_Target_106_GenAtlas_ID:
NDUFA2

# Drug_Target_106_GenBank_ID_Gene:
AF047185

# Drug_Target_106_GenBank_ID_Protein:
2909862

# Drug_Target_106_GeneCard_ID:
NDUFA2

# Drug_Target_106_Gene_Name:
NDUFA2

# Drug_Target_106_Gene_Sequence:
>300 bp
ATGGCGGCGGCCGCAGCAAGTCGAGGAGTCGGGGCAAAGCTGGGCCTGCGTGAGATTCGC
ATCCACTTATGTCAGCGCTCGCCCGGCAGCCAGGGCGTCAGGGACTTCATTGAGAAACGC
TACGTGGAGCTGAAGAAGGCGAATCCCGACCTACCCATCCTAATCCGCGAATGCTCCGAT
GTGCAGCCCAAGCTCTGGGCCCGCTACGCATTTGGCCAAGAGACGAATGTCCCTTTGAAC
AACTTCAGTGCTGATCAGGTAACCAGAGCCCTGGAGAACGTTCTAAGTGGTAAAGCCTGA

# Drug_Target_106_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_106_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9425316	Ton C, Hwang DM, Dempsey AA, Liew CC: Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits. Biochem Biophys Res Commun. 1997 Dec 18;241(2):589-94.

# Drug_Target_106_HGNC_ID:
HGNC:7685

# Drug_Target_106_HPRD_ID:
11883

# Drug_Target_106_ID:
607

# Drug_Target_106_Locus:
5q31

# Drug_Target_106_Molecular_Weight:
10790

# Drug_Target_106_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2

# Drug_Target_106_Number_of_Residues:
98

# Drug_Target_106_PDB_ID:
1S3A

# Drug_Target_106_Pathway:
Not Available

# Drug_Target_106_Pfam_Domain_Function:
PF05047	L51_S25_CI-B8

# Drug_Target_106_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2
AAAAASRGVGAKLGLREIRIHLCQRSPGSQGVRDFIEKRYVELKKANPDLPILIRECSDV
QPKLWARYAFGQETNVPLNNFSADQVTRALENVLSGKA

# Drug_Target_106_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_106_Signals:
None

# Drug_Target_106_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_106_SwissProt_ID:
O43678

# Drug_Target_106_SwissProt_Name:
NDUA2_HUMAN

# Drug_Target_106_Synonyms:
CI-B8
Complex I-B8
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B8 subunit

# Drug_Target_106_Theoretical_pI:
10.11

# Drug_Target_106_Transmembrane_Regions:
None

# Drug_Target_107_Cellular_Location:
Mitochondrion

# Drug_Target_107_Chromosome_Location:
Not Available

# Drug_Target_107_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9860297	Triepels R, van den Heuvel L, Loeffen J, Smeets R, Trijbels F, Smeitink J: The nuclear-encoded human NADH:ubiquinone oxidoreductase NDUFA8 subunit: cDNA cloning, chromosomal localization, tissue distribution, and mutation detection in complex-I-deficient patients. Hum Genet. 1998 Nov;103(5):557-63.

# Drug_Target_107_Essentiality:
Non-Essential

# Drug_Target_107_GenAtlas_ID:
NDUFA8

# Drug_Target_107_GenBank_ID_Gene:
AF044953

# Drug_Target_107_GenBank_ID_Protein:
5326825

# Drug_Target_107_GeneCard_ID:
NDUFA8

# Drug_Target_107_Gene_Name:
NDUFA8

# Drug_Target_107_Gene_Sequence:
>519 bp
ATGCCGGGGATAGTGGAGCTGCCCACTCTAGAGGAGCTGAAAGTAGATGAGGTGAAAATT
AGTTCTGCTGTGCTTAAAGCTGCGGCCCATCACTATGGAGCTCAATGTGATAAGCCCAAC
AAGGAATTTATGCTCTGCCGCTGGGAAGAGAAAGATCCGAGGCGGTGTTTAGAGGAAGGC
AAACTGGTCAACAAGTGTGCTTTGGACTTCTTTAGGCAGATAAAACGTCACTGTGCAGAG
CCTTTTACAGAATATTGGACTTGCATTGATTATACTGGCCAGCAGTTATTTCGTCACTGT
CGCAAACAGCAGGCAAAGTTTGACGAGTGTGTGCTGGACAAACTGGGCTGGGTGCGGCCT
GACCTGGGAGAACTGTCAAAGGTCACCAAAGTGAAAACAGATCGACCTTTACCGGAGAAT
CCCTATCACTCAAGACCAAGACCGGATCCCAGCCCTGAGATCGAGGGAGATCTGCAGCCT
GCCACACATGGCAGCCGCTTTTATTTCTGGACCAAGTAA

# Drug_Target_107_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_107_General_References:
9150947	Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P: Renal cell carcinoma and normal kidney protein expression. Electrophoresis. 1997 Mar-Apr;18(3-4):599-604.
9860297	Triepels R, van den Heuvel L, Loeffen J, Smeets R, Trijbels F, Smeitink J: The nuclear-encoded human NADH:ubiquinone oxidoreductase NDUFA8 subunit: cDNA cloning, chromosomal localization, tissue distribution, and mutation detection in complex-I-deficient patients. Hum Genet. 1998 Nov;103(5):557-63.

# Drug_Target_107_HGNC_ID:
HGNC:7692

# Drug_Target_107_HPRD_ID:
04525

# Drug_Target_107_ID:
405

# Drug_Target_107_Locus:
9q33.2-q34.11

# Drug_Target_107_Molecular_Weight:
19974

# Drug_Target_107_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8

# Drug_Target_107_Number_of_Residues:
171

# Drug_Target_107_PDB_ID:
Not Available

# Drug_Target_107_Pathway:
Not Available

# Drug_Target_107_Pfam_Domain_Function:
PF06747	CHCH

# Drug_Target_107_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8
PGIVELPTLEELKVDEVKISSAVLKAAAHHYGAQCDKPNKEFMLCRWEEKDPRRCLEEGK
LVNKCALDFFRQIKRHCAEPFTEYWTCIDYTGQQLFRHCRKQQAKFDECVLDKLGWVRPD
LGELSKVTKVKTDRPLPENPYHSRPRPDPSPEIEGDLQPATHGSRFYFWTK

# Drug_Target_107_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_107_Signals:
None

# Drug_Target_107_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_107_SwissProt_ID:
P51970

# Drug_Target_107_SwissProt_Name:
NDUA8_HUMAN

# Drug_Target_107_Synonyms:
CI-19kD
CI-PGIV
Complex I-19kD
Complex I-PGIV
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase 19 kDa subunit

# Drug_Target_107_Theoretical_pI:
7.74

# Drug_Target_107_Transmembrane_Regions:
None

# Drug_Target_108_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_108_Chromosome_Location:
Not Available

# Drug_Target_108_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_108_Essentiality:
Non-Essential

# Drug_Target_108_GenAtlas_ID:
NDUFA3

# Drug_Target_108_GenBank_ID_Gene:
AF044955

# Drug_Target_108_GenBank_ID_Protein:
4164444

# Drug_Target_108_GeneCard_ID:
NDUFA3

# Drug_Target_108_Gene_Name:
NDUFA3

# Drug_Target_108_Gene_Sequence:
>255 bp
ATGGCTGCGAGAGTCGGCGCCTTCCTCAAGAATGCCTGGGACAAGGAGCCAGTGCTGGTC
GTGTCCTTCGTCGTCGGGGGCCTCGCTGTAATTCTGCCCCCATTGAGCCCCTACTTCAAG
TACTCCGTCATGATCAACAAGGCCACGCCCTACAACTACCCAGTGCCCGTCCGTGATGAT
GGGAACATGCCCGACGTGCCCAGCCACCCCCAGGACCCTCAGGGCCCCAGCCTGGAGTGG
CTGAAGAAACTGTGA

# Drug_Target_108_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_108_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_108_HGNC_ID:
HGNC:7686

# Drug_Target_108_HPRD_ID:
04830

# Drug_Target_108_ID:
755

# Drug_Target_108_Locus:
19q13.42

# Drug_Target_108_Molecular_Weight:
9279

# Drug_Target_108_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3

# Drug_Target_108_Number_of_Residues:
84

# Drug_Target_108_PDB_ID:
Not Available

# Drug_Target_108_Pathway:
Not Available

# Drug_Target_108_Pfam_Domain_Function:
Not Available

# Drug_Target_108_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3
MAARVGAFLKNAWDKEPVLVVSFVVGGLAVILPPLSPYFKYSVMINKATPYNYPVPVRDD
GNMPDVPSHPQDPQGPSLEWLKKL

# Drug_Target_108_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_108_Signals:
None

# Drug_Target_108_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_108_SwissProt_ID:
O95167

# Drug_Target_108_SwissProt_Name:
NDUA3_HUMAN

# Drug_Target_108_Synonyms:
CI-B9
Complex I-B9
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B9 subunit

# Drug_Target_108_Theoretical_pI:
8.92

# Drug_Target_108_Transmembrane_Regions:
19-39

# Drug_Target_109_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_109_Chromosome_Location:
Not Available

# Drug_Target_109_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_109_Essentiality:
Non-Essential

# Drug_Target_109_GenAtlas_ID:
NDUFB8

# Drug_Target_109_GenBank_ID_Gene:
AF044958

# Drug_Target_109_GenBank_ID_Protein:
4164448

# Drug_Target_109_GeneCard_ID:
NDUFB8

# Drug_Target_109_Gene_Name:
NDUFB8

# Drug_Target_109_Gene_Sequence:
>561 bp
ATGGCGGTGGCCAGGGCCGGGGTCTTGGGAGTCCAGTGGCTGCAAAGGGCATCCCGGAAC
GTGATGCCGCTGGGCGCACGGACAGCCTCCCACATGACCAAGGACATGTTCCCGGGGCCC
TATCCTAGGACCCCAGAAGAACGGGCCGCCGCCGCCAAGAAGTATAATATGCGTGTGGAA
GACTACGAACCTTACCCGGATGATGGCATGGGGTATGGCGACTACCCGAAGCTCCCTGAC
CGCTCACAGCATGAGAGAGATCCATGGTATAGCTGGGACCAGCCGGGCCTGAGGTTGAAC
TGGGGTGAACCGATGCACTGGCACCTAGACATGTACAACAGGAACCGTGTGGATACATCC
CCCACACCTGTTTCTTGGCATGTCATGTGTATGCAGCTCTTCGGTTTCCTGGCTTTCATG
ATATTCATGTGCTGGGTGGGGGACGTGTACCCTGTCTACCAGCCTGTGGGACCAAAGCAG
TATCCTTACAATAATCTGTACCTGGAACGAGGCGGTGATCCCTCCAAAGAACCAGAGCGG
GTGGTTCACTATGAGATCTGA

# Drug_Target_109_General_Function:
Involved in NADH dehydrogenase activity

# Drug_Target_109_General_References:
10570959	Emahazion T, Jobs M, Howell WM, Siegfried M, Wyoni PI, Prince JA, Brookes AJ: Identification of 167 polymorphisms in 88 genes from candidate neurodegeneration pathways. Gene. 1999 Oct 1;238(2):315-24.
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_109_HGNC_ID:
HGNC:7703

# Drug_Target_109_HPRD_ID:
11886

# Drug_Target_109_ID:
746

# Drug_Target_109_Locus:
10q23.2-q23.33

# Drug_Target_109_Molecular_Weight:
21766

# Drug_Target_109_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial

# Drug_Target_109_Number_of_Residues:
186

# Drug_Target_109_PDB_ID:
Not Available

# Drug_Target_109_Pathway:
Not Available

# Drug_Target_109_Pfam_Domain_Function:
PF05821	NDUF_B8

# Drug_Target_109_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial precursor
MAVARAGVLGVQWLQRASRNVMPLGARTASHMTKDMFPGPYPRTPEERAAAAKKYNMRVE
DYEPYPDDGMGYGDYPKLPDRSQHERDPWYSWDQPGLRLNWGEPMHWHLDMYNRNRVDTS
PTPVSWHVMCMQLFGFLAFMIFMCWVGDVYPVYQPVGPKQYPYNNLYLERGGDPSKEPER
VVHYEI

# Drug_Target_109_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_109_Signals:
None

# Drug_Target_109_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_109_SwissProt_ID:
O95169

# Drug_Target_109_SwissProt_Name:
NDUB8_HUMAN

# Drug_Target_109_Synonyms:
CI-ASHI
Complex I-ASHI
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase 1 beta subcomplex subunit 8, mitochondrial precursor
NADH-ubiquinone oxidoreductase ASHI subunit

# Drug_Target_109_Theoretical_pI:
6.79

# Drug_Target_109_Transmembrane_Regions:
124-146

# Drug_Target_10_Cellular_Location:
Cytoplasm

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
16821840	Baron R, Lioubashevski O, Katz E, Niazov T, Willner I: Logic gates and elementary computing by enzymes. J Phys Chem A. 2006 Jul 13;110(27):8548-53.
17092593	Okochi M, Nakagawa I, Kobayashi T, Hayashi S, Furusaki S, Honda H: Enhanced activity of 3alpha-hydroxysteroid dehydrogenase by addition of the co-solvent 1-butyl-3-methylimidazolium (L)-lactate in aqueous phase of biphasic systems for reductive production of steroids. J Biotechnol. 2007 Feb 1;128(2):376-82. Epub 2006 Oct 12.
17525463	Schirwitz K, Schmidt A, Lamzin VS: High-resolution structures of formate dehydrogenase from Candida boidinii. Protein Sci. 2007 Jun;16(6):1146-56.
17619232	Baumchen C, Roth AH, Biedendieck R, Malten M, Follmann M, Sahm H, Bringer-Meyer S, Jahn D: D-Mannitol production by resting state whole cell biotransformation of D-fructose by heterologous mannitol and formate dehydrogenase gene expression in Bacillus megaterium. Biotechnol J. 2007 Jul 9;.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
ADH5

# Drug_Target_10_GenBank_ID_Gene:
M30471

# Drug_Target_10_GenBank_ID_Protein:
178134

# Drug_Target_10_GeneCard_ID:
ADH5

# Drug_Target_10_Gene_Name:
ADH5

# Drug_Target_10_Gene_Sequence:
>1125 bp
ATGGCGAACGAGGTTATCAAGTGCAAGGCTGCAGTTGCTTGGGAGGCTGGAAAGCCTCTC
TCCATAGAGGAGATAGAGGTGGCACCCCCAAAGGCTCATGAAGTTCGAATCAAGATCATT
GCCACTGCGGTTTGCCACACCGATGCCTATACCCTGAGTGGAGCTGATCCTGAGGGTTGT
TTTCCAGTGATCTTGGGACATGAAGGTGCTGGAATTGTGGAAAGTGTTGGTGAGGGAGTT
ACTAAGCTGAAGGCGGGTGACACTGTCATCCCACTTTACATCCCACAGTGTGGAGAATGC
AAATTTTGTCTAAATCCTAAAACTAACCTTTGCCAGAAGATAAGAGTCACTCAAGGGAAA
GGATTAATGCCAGATGGTACCAGCAGATTTACTTGCAAAGGAAAGACAATTTTGCATTAC
ATGGGAACCAGCACATTTTCTGAATACACAGTTGTGGCTGATATCTCTGTTGCTAAAATA
GATCCTTTAGCACCTTTGGATAAAGTCTGCCTTCTAGGTTGTGGCATTTCAACCGGTTAT
GGTGCTGCTGTGAACACTGCCAAGTTGGAGCCTGGCTCTGTTTGTGCCGTCTTTGGTCTG
GGAGGAGTCGGATTGGCAGTTATCATGGGCTGTAAAGTGGCTGGTGCTTCCCGGATCATT
GGTGTGGACATCAATAAAGATAAATTTGCAAGGGCCAAAGAGTTTGGAGCCACTGAATGT
ATTAACCCTCAGGATTTTAGTAAACCCATCCAGGAAGTGCTCATTGAGATGACCGATGGA
GGAGTGGACTATTCCTTTGAATGTATTGGTAATGTGAAGGTCATGAGAGCAGCACTTGAG
GCATGTCACAAGGGCTGGGGCGTCAGCGTCGTGGTTGGAGTAGCTGCTTCAGGTGAAGAA
ATTGCCACTCGTCCATTCCAGCTGGTAACAGGTCGCACATGGAAAGGCACTGCCTTTGGA
GGATGGAAGAGTGTAGAAAGTGTCCCAAAGTTGGTGTCTGAATATATGTCCAAAAAGATA
AAAGTTGATGAATTTGTGACTCACAATCTGTCTTTTGATGAAATCAACAAAGCCTTTGAA
CTGATGCATTCTGGAAAGAGCATTCGAACTGTTGTAAAGATTTAA

# Drug_Target_10_General_Function:
Energy production and conversion

# Drug_Target_10_General_References:
1446828	Hur MW, Edenberg HJ: Cloning and characterization of the ADH5 gene encoding human alcohol dehydrogenase 5, formaldehyde dehydrogenase. Gene. 1992 Nov 16;121(2):305-11.
2679557	Giri PR, Krug JF, Kozak C, Moretti T, O'Brien SJ, Seuanez HN, Goldman D: Cloning and comparative mapping of a human class III (chi) alcohol dehydrogenase cDNA. Biochem Biophys Res Commun. 1989 Oct 16;164(1):453-60.
2818582	Sharma CP, Fox EA, Holmquist B, Jornvall H, Vallee BL: cDNA sequence of human class III alcohol dehydrogenase. Biochem Biophys Res Commun. 1989 Oct 31;164(2):631-7.
3365377	Kaiser R, Holmquist B, Hempel J, Vallee BL, Jornvall H: Class III human liver alcohol dehydrogenase: a novel structural type equidistantly related to the class I and class II enzymes. Biochemistry. 1988 Feb 23;27(4):1132-40.
8460164	Engeland K, Hoog JO, Holmquist B, Estonius M, Jornvall H, Vallee BL: Mutation of Arg-115 of human class III alcohol dehydrogenase: a binding site required for formaldehyde dehydrogenase activity and fatty acid activation. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2491-4.
8494891	Holmquist B, Moulis JM, Engeland K, Vallee BL: Role of arginine 115 in fatty acid activation and formaldehyde dehydrogenase activity of human class III alcohol dehydrogenase. Biochemistry. 1993 May 18;32(19):5139-44.
9018047	Yang ZN, Bosron WF, Hurley TD: Structure of human chi chi alcohol dehydrogenase: a glutathione-dependent formaldehyde dehydrogenase. J Mol Biol. 1997 Jan 24;265(3):330-43.

# Drug_Target_10_HGNC_ID:
HGNC:253

# Drug_Target_10_HPRD_ID:
00064

# Drug_Target_10_ID:
12

# Drug_Target_10_Locus:
4q21-q25

# Drug_Target_10_Molecular_Weight:
39593

# Drug_Target_10_Name:
Alcohol dehydrogenase class 3

# Drug_Target_10_Number_of_Residues:
373

# Drug_Target_10_PDB_ID:
1MC5

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_10_Protein_Sequence:
>Alcohol dehydrogenase class 3 chi chain
ANEVIKCKAAVAWEAGKPLSIEEIEVAPPKAHEVRIKIIATAVCHTDAYTLSGADPEGCF
PVILGHEGAGIVESVGEGVTKLKAGDTVIPLYIPQCGECKFCLNPKTNLCQKIRVTQGKG
LMPDGTSRFTCKGKTILHYMGTSTFSEYTVVADISVAKIDPLAPLDKVCLLGCGISTGYG
AAVNTAKLEPGSVCAVFGLGGVGLAVIMGCKVAGASRIIGVDINKDKFARAKEFGATECI
NPQDFSKPIQEVLIEMTDGGVDYSFECIGNVKVMRAALEACHKGWGVSVVVGVAASGEEI
ATRPFQLVTGRTWKGTAFGGWKSVESVPKLVSEYMSKKIKVDEFVTHNLSFDEINKAFEL
MHSGKSIRTVVKI

# Drug_Target_10_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Class-III ADH is remarkably ineffective in oxidizing ethanol, but it readily catalyzes the oxidation of long-chain primary alcohols and the oxidation of S-(hydroxymethyl) glutathione

# Drug_Target_10_SwissProt_ID:
P11766

# Drug_Target_10_SwissProt_Name:
ADHX_HUMAN

# Drug_Target_10_Synonyms:
Alcohol dehydrogenase class III
Alcohol dehydrogenase class chi chain
EC 1.1.1.1
EC 1.1.1.284
FDH
Glutathione- dependent formaldehyde dehydrogenase
S- (hydroxymethyl)glutathione dehydrogenase

# Drug_Target_10_Theoretical_pI:
7.54

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_110_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_110_Chromosome_Location:
Not Available

# Drug_Target_110_Drug_References:
16898010	Quiles MJ: Stimulation of chlororespiration by heat and high light intensity in oat plants. Plant Cell Environ. 2006 Aug;29(8):1463-70.
17015645	Gyan S, Shiohira Y, Sato I, Takeuchi M, Sato T: Regulatory loop between redox sensing of the NADH/NAD(+) ratio by Rex (YdiH) and oxidation of NADH by NADH dehydrogenase Ndh in Bacillus subtilis. J Bacteriol. 2006 Oct;188(20):7062-71.
17496098	Brooijmans RJ, Poolman B, Schuurman-Wolters GK, de Vos WM, Hugenholtz J: Generation of a membrane potential by Lactococcus lactis through aerobic electron transport. J Bacteriol. 2007 Jul;189(14):5203-9. Epub 2007 May 11.
17513495	Zhu X, Liu B, Zhou S, Chen YR, Deng Y, Zweier JL, He G: Ischemic preconditioning prevents in vivo hyperoxygenation in postischemic myocardium with preservation of mitochondrial oxygen consumption. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1442-50. Epub 2007 May 18.
17614984	Bao HG, Zhao CJ, Li JY, Wu Ch: Association of MT-ND5 gene variation with mitochondrial respiratory control ratio and NADH dehydrogenase activity in Tibet chicken embryos. Anim Genet. 2007 Oct;38(5):514-6. Epub 2007 Jul 5.

# Drug_Target_110_Essentiality:
Non-Essential

# Drug_Target_110_GenAtlas_ID:
NDUFC2

# Drug_Target_110_GenBank_ID_Gene:
AF087659

# Drug_Target_110_GenBank_ID_Protein:
4191346

# Drug_Target_110_GeneCard_ID:
NDUFC2

# Drug_Target_110_Gene_Name:
NDUFC2

# Drug_Target_110_Gene_Sequence:
>360 bp
ATGATCGCACGGCGGAACCCAGAACCCTTACGGTTTCTGCCGGATGAGGCCCGGAGCCTG
CCCCCGCCCAAGCTGACCGACCCGCGGCTCCTCTACATCGGCTTCTTGGGCTACTGCTCC
GGCCTGATTGATAACCTGATCCGGCGGAGGCCGATCGCGACGGCTGGTTTGCATCGCCAG
CTTCTATATATTACGGCCTTTTTTTTTGCTGGATATTATCTTGTAAAACGTGAAGACTAC
CTGTATGCTGTGAGGGACCGTGAAATGTTTGGATATATGAAATTACATCCAGAGGATTTT
CCTGAAGAAGATAAGAAAACATATGGTGAAATTTTTGAAAAATTCCATCCAATACGTTGA

# Drug_Target_110_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_110_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
11230166	Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J, Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwalder B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein M, Poustka A: Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res. 2001 Mar;11(3):422-35.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_110_HGNC_ID:
HGNC:7706

# Drug_Target_110_HPRD_ID:
11960

# Drug_Target_110_ID:
194

# Drug_Target_110_Locus:
11q14.1

# Drug_Target_110_Molecular_Weight:
14188

# Drug_Target_110_Name:
NADH dehydrogenase [ubiquinone] 1 subunit C2

# Drug_Target_110_Number_of_Residues:
119

# Drug_Target_110_PDB_ID:
Not Available

# Drug_Target_110_Pathway:
Not Available

# Drug_Target_110_Pfam_Domain_Function:
PF06374	NDUF_C2

# Drug_Target_110_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 subunit C2
MIARRNPEPLRFLPDEARSLPPPKLTDPRLLYIGFLGYCSGLIDNLIRRRPIATAGLHRQ
LLYITAFFFAGYYLVKREDYLYAVRDREMFGYMKLHPEDFPEEDKKTYGEIFEKFHPIR

# Drug_Target_110_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_110_Signals:
None

# Drug_Target_110_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_110_SwissProt_ID:
O95298

# Drug_Target_110_SwissProt_Name:
NDUC2_HUMAN

# Drug_Target_110_Synonyms:
CI-B14.5b
Complex I-B14.5b
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase subunit B14.5b

# Drug_Target_110_Theoretical_pI:
9.27

# Drug_Target_110_Transmembrane_Regions:
56-75

# Drug_Target_111_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_111_Chromosome_Location:
Not Available

# Drug_Target_111_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_111_Essentiality:
Non-Essential

# Drug_Target_111_GenAtlas_ID:
NDUFB1

# Drug_Target_111_GenBank_ID_Gene:
AF050638

# Drug_Target_111_GenBank_ID_Protein:
5326820

# Drug_Target_111_GeneCard_ID:
NDUFB1

# Drug_Target_111_Gene_Name:
NDUFB1

# Drug_Target_111_Gene_Sequence:
>177 bp
ATGGTGAACTTACTTCAGATTGTGCGGGACCACTGGGTTCATGTTCTTGTCCCTATGGGA
TTTGTCATTGGATGTTATTTAGACAGAAAGAGTGATGAACGGCTAACTGCCTTCCGGAAC
AAGAGTATGTTATTTAAAAGGGAATTGCAACCCAGTGAAGAAGTTACCTGGAAGTAA

# Drug_Target_111_General_Function:
Involved in NADH dehydrogenase activity

# Drug_Target_111_General_References:
9653160	Mao M, Fu G, Wu JS, Zhang QH, Zhou J, Kan LX, Huang QH, He KL, Gu BW, Han ZG, Shen Y, Gu J, Yu YP, Xu SH, Wang YX, Chen SJ, Chen Z: Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8175-80.

# Drug_Target_111_HGNC_ID:
HGNC:7695

# Drug_Target_111_HPRD_ID:
11952

# Drug_Target_111_ID:
374

# Drug_Target_111_Locus:
14q32.12

# Drug_Target_111_Molecular_Weight:
6961

# Drug_Target_111_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1

# Drug_Target_111_Number_of_Residues:
58

# Drug_Target_111_PDB_ID:
Not Available

# Drug_Target_111_Pathway:
Not Available

# Drug_Target_111_Pfam_Domain_Function:
PF08040	NADH_oxidored

# Drug_Target_111_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1
MVNLLQIVRDHWVHVLVPMGFVIGCYLDRKSDERLTAFRNKSMLFKRELQPSEEVTWK

# Drug_Target_111_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_111_Signals:
None

# Drug_Target_111_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_111_SwissProt_ID:
O75438

# Drug_Target_111_SwissProt_Name:
NDUB1_HUMAN

# Drug_Target_111_Synonyms:
CI-MNLL
Complex I-MNLL
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase MNLL subunit

# Drug_Target_111_Theoretical_pI:
9.34

# Drug_Target_111_Transmembrane_Regions:
None

# Drug_Target_112_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_112_Chromosome_Location:
Not Available

# Drug_Target_112_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_112_Essentiality:
Non-Essential

# Drug_Target_112_GenAtlas_ID:
NDUFS1

# Drug_Target_112_GenBank_ID_Gene:
X61100

# Drug_Target_112_GenBank_ID_Protein:
38079

# Drug_Target_112_GeneCard_ID:
NDUFS1

# Drug_Target_112_Gene_Name:
NDUFS1

# Drug_Target_112_Gene_Sequence:
>2184 bp
ATGTTAAGGATACCTGTAAGAAGGGCCTTAGTAGGCCTTTCTAAGTCTCCTAAAGGATGT
GTTCGAACAACTGCCACAGCAGCAAGCAACTTGATTGAAGTATTTGTTGATGGTCAGTCT
GTCATGGTGGAACCGGGAACGACCGTCCTCCAAGCTTGTGAGAAGGTTGGCATGCAGATC
CCTCGATTCTGTTATCATGAAAGGTTGTCTGTTGCTGGAAACTGCAGGATGTGCCTTGTT
GAAATTGAGAAAGCCCCTAAGGTTGTAGCTGCTTGTGCCATGCCAGTAATGAAGGGTTGG
AATATCCTAACAAACTCAGAAAAATCCAAAAAGGCCAGGGAAGGTGTGATGGAGTTCTTA
TTAGCAAATCACCCATTGGACTGTCCTATTTGTGACCAGGGAGGTGAATGTGATCTGCAG
GACCAGTCCATGATGTTTGGAAATGATAGGAGCCGATTTTTAGAGGGGAAGCGTGCTGTG
GAAGACAAGAACATTGGGCCATTGGTAAAGACCATCATGACAAGATGTATACAGTGTACT
CGCTGCATCAGGTTTGCAAGTGAGATTGCAGGAGTAGATGATTTGGGAACAACAGGCAGA
GGAAATGATATGCAAGTTGGCACATACATTGAAAAGATGTTCATGTCTGAACTGTCTGGG
AATATCATTGATATCTGCCCTGTAGGTGCCCTAACCTCTAAGCCCTATGCCTTTACTGCC
CGGCCTTGGGAAACAAGAAAGACAGAATCCATTGATGTAATGGATGCGGTTGGAAGTAAT
ATTGTGGTTAGCACAAGAACTGGAGAAGTGATGAGGATTTTGCCACGTATGCATGAGGAC
ATCAATGAAGAGTGGATCTCTGATAAAACCAGATTTGCCTATGATGGGCTAAAACGTCAA
AGACTTACCGAGCCAATGGTCAGAAATGAAAAAGGGCTTTTAACCTATACTTCTTGGGAG
GATGCTCTCTCTCGCGTAGCTGGAATGTTGCAGAGTTTTCAAGGCAAAGATGTGGCAGCA
ATTGCAGGTGGCTTGGTGGATGCTGAAGCCCTGGTAGCTCTCAAAGATTTGCTTAATAGA
GTGGACTCTGACACCTTATGCACTGAAGAGGTCTTCCCCACTGCAGGAGCTGGCACAGAT
TTGCGTTCCAATTATCTTCTTAATACTACAATTGCTGGTGTGGAAGAGGCAGATGTTGTT
CTTCTGGTTGGTACAAACCCACGTTTTGAGGCACCACTGTTTAATGCATGGATTCGAAAG
AGCTGGCTGCATAATGACTTAAAAGTGGCCCTTATAGGCAGTCCAGTGGACCTCACTTAC
ACATATGACCACCTGGGAGACTCCCCCAAAATTCTTCAAGACATTGCTTCGGGAAGCCAT
CCATTTAGCCAGGTCCTAAAGGAAGCTAAAAAACCAATGGTGGTTTTAGGCAGTTCTGCA
CTCCAAAGAAATGATGGAGCAGCAATTCTTGCAGCTGTTTCTAGCATTGCACAAAAGATT
CGGATGACTAGTGGTGTTACTGGTGATTGGAAAGTTATGAATATCCTTCATAGGATTGCA
AGTCAAGTAGCTGCTTTGGACCTTGGCTATAAGCCTGGGGTGGAAGCAATTCGGAAGAAC
CCTCCCAAGGTGCTGTTTCTCCTGGGAGCAGATGGAGGTTGTATCACACGACAGGATTTG
CCAAAGGATTGTTTCATTATTTATCAAGGACATCATGGTGATGTTGGGGCTCCCATAGCT
GATGTTATTCTCCCAGGAGCTGCTTACACAGAGAAGTCTGCTACATATGTCAACACTGAG
GGTAGAGCTCAGCAGACTAAGGTAGCAGTGACACCTCCTGGCTTGGCAAGAGAAGACTGG
AAAATTATAAGAGCACTCTCTGAGATTGCTGGAATGACTCTTCCATATGATACTCTGGAT
CAAGTAAGGAACAGATTGGAAGAATTCTCTCCTAATCTTGTTCGATATGATGATATTGAA
GGGGCTAATTACTTCCAGCAAGCAAATGAGCTCTCAAAGCTAGTGAACCAGCAGCTTCTT
GCTGACCCACTTGTTCCACCTCAGCTAACTCTAAAAGACTTCTACATGACAGATTCGATT
AGCAGAGCCTCACAGACAATGGCCAAATGTGTCAAAGCTGTCACAGAGGGTGCCCAGGCA
GTAGAGGAACCATCCATATGCTGA

# Drug_Target_112_General_Function:
Energy production and conversion

# Drug_Target_112_General_References:
1935949	Chow W, Ragan I, Robinson BH: Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH-coenzyme Q reductase. Eur J Biochem. 1991 Nov 1;201(3):547-50.

# Drug_Target_112_HGNC_ID:
HGNC:7707

# Drug_Target_112_HPRD_ID:
01145

# Drug_Target_112_ID:
548

# Drug_Target_112_Locus:
2q33-q34

# Drug_Target_112_Molecular_Weight:
79468

# Drug_Target_112_Name:
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial

# Drug_Target_112_Number_of_Residues:
727

# Drug_Target_112_PDB_ID:
Not Available

# Drug_Target_112_Pathway:
Not Available

# Drug_Target_112_Pfam_Domain_Function:
PF00111	Fer2
PF00384	Molybdopterin

# Drug_Target_112_Protein_Sequence:
>NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial precursor
MLRIPVRKALVGLSKSPKGCVRTTATAASNLIEVFVDGQSVMVEPGTTVLQACEKVGMQI
PRFCYHERLSVAGNCRMCLVEIEKAPKVVAACAMPVMKGWNILTNSEKSKKAREGVMEFL
LANHPLDCPICDQGGECDLQDQSMMFGNDRSRFLEGKRAVEDKNIGPLVKTIMTRCIQCT
RCIRFASEIAGVDDLGTTGRGNDMQVGTYIEKMFMSELSGNIIDICPVGALTSKPYAFTA
RPWETRKTESIDVMDAVGSNIVVSTRTGEVMRILPRMHEDINEEWISDKTRFAYDGLKRQ
RLTEPMVRNEKGLLTYTSWEDALSRVAGMLQSFQGKDVAAIAGGLVDAEALVALKDLLNR
VDSDTLCTEEVFPTAGAGTDLRSNYLLNTTIAGVEEADVVLLVGTNPRFEAPLFNARIRK
SWLHNDLKVALIGSPVDLTYTYDHLGDSPKILQDIASGSHPFSQVLKEAKKPMVVLGSSA
LQRNDGAAILAAVSSIAQKIRMTSGVTGDWKVMNILHRIASQVAALDLGYKPGVEAIRKN
PPKVLFLLGADGGCITRQDLPKDCFIIYQGHHGDVGAPIADVILPGAAYTEKSATYVNTE
GRAQQTKVAVTPPGLAREDWKIIRALSEIAGMTLPYDTLDQVRNRLEEVSPNLVRYDDIE
GANYFQQANELSKLVNQQLLADPLVPPQLTIKDFYMTDSISRASQTMAKCVKAVTEGAQA
VEEPSIC

# Drug_Target_112_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_112_Signals:
None

# Drug_Target_112_Specific_Function:
This is the largest subunit of complex I and it is a component of the iron-sulfur (IP) fragment of the enzyme. It may form part of the active site crevice where NADH is oxidized

# Drug_Target_112_SwissProt_ID:
P28331

# Drug_Target_112_SwissProt_Name:
NDUS1_HUMAN

# Drug_Target_112_Synonyms:
CI-75kD
Complex I-75kD
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial precursor

# Drug_Target_112_Theoretical_pI:
6.11

# Drug_Target_112_Transmembrane_Regions:
None

# Drug_Target_113_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_113_Chromosome_Location:
Not Available

# Drug_Target_113_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_113_Essentiality:
Non-Essential

# Drug_Target_113_GenAtlas_ID:
NDUFB10

# Drug_Target_113_GenBank_ID_Gene:
AF044954

# Drug_Target_113_GenBank_ID_Protein:
4164442

# Drug_Target_113_GeneCard_ID:
NDUFB10

# Drug_Target_113_Gene_Name:
NDUFB10

# Drug_Target_113_Gene_Sequence:
>519 bp
ATGCCGGACAGCTGGGACAAGGATGTGTACCCTGAGCCCCCGCGCCGCACGCCGGTGCAG
CCCAATCCCATCGTCTACATGATGAAAGCGTTCGACCTCATCGTGGACCGACCCGTGACC
CTCGTGAGAGAATTTATAGAGCGGCAGCACGCAAAGAACAGGTATTACTACTACCACCGG
CAGTACCGCCGCGTGCCAGACATCACTGAGTGCAAGGAGGAGGACATCATGTGCATGTAT
GAAGCCGAAATGCAGTGGAAGAGGGACTACAAAGTCGACCAAGAAATTATCAACATTATG
CAGGATCGGCTCAAAGCCTGTCAGCAGAGGGAAGGACAGAACTACCAGCAGAACTGTATC
AAGGAAGTGGAGCAGTTCACCCAGGTGGCCAAGGCCTACCAGGACCGCTATCAGGACCTG
GGGGCCTACAGTTCTGCCAGGAAGTGCCTGGCCAAACAGAGGCAGAGGATGCTGCAAGAG
AGAAAAGCTGCAAAAGAGGCCGCCGCTGCCACCTCCTGA

# Drug_Target_113_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_113_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_113_HGNC_ID:
HGNC:7696

# Drug_Target_113_HPRD_ID:
11958

# Drug_Target_113_ID:
272

# Drug_Target_113_Locus:
16p13.3

# Drug_Target_113_Molecular_Weight:
20646

# Drug_Target_113_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10

# Drug_Target_113_Number_of_Residues:
171

# Drug_Target_113_PDB_ID:
Not Available

# Drug_Target_113_Pathway:
Not Available

# Drug_Target_113_Pfam_Domain_Function:
Not Available

# Drug_Target_113_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10
PDSWDKDVYPEPPRRTPVQPNPIVYMMKAFDLIVDRPVTLVREFIERQHAKNRYYYYHRQ
YRRVPDITECKEEDIMCMYEAEMQWKRDYKVDQEIINIMQDRLKACQQREGQNYQQNCIK
EVEQFTQVAKAYQDRYQDLGAYSSARKCLAKQRQRMLQERKAAKEAAAATS

# Drug_Target_113_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_113_Signals:
None

# Drug_Target_113_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_113_SwissProt_ID:
O96000

# Drug_Target_113_SwissProt_Name:
NDUBA_HUMAN

# Drug_Target_113_Synonyms:
CI-PDSW
Complex I-PDSW
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase PDSW subunit

# Drug_Target_113_Theoretical_pI:
8.65

# Drug_Target_113_Transmembrane_Regions:
None

# Drug_Target_114_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_114_Chromosome_Location:
Not Available

# Drug_Target_114_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_114_Essentiality:
Non-Essential

# Drug_Target_114_GenAtlas_ID:
NDUFB4

# Drug_Target_114_GenBank_ID_Gene:
AF044957

# Drug_Target_114_GenBank_ID_Protein:
4164446

# Drug_Target_114_GeneCard_ID:
NDUFB4

# Drug_Target_114_Gene_Name:
NDUFB4

# Drug_Target_114_Gene_Sequence:
>390 bp
ATGTCGTTCCCAAAGTATAAGCCGTCGAGCCTGCGCACTCTGCCTGAGACCCTCGACCCA
GCCGAATACAACATATCTCCGGAAACCCGGCGGGCGCAAGCCGAGCGGTTGGCCATAAGA
GCCCAGCTGAAACGAGAGTACCTGCTTCAGTACAACGATCCCAACCGCCGAGGGCTCATC
GAAAATCCTGCCTTGCTTCGTTGGGCCTATGCAAGAACAATAAATGTCTATCCTAATTTC
AGACCCACTCCTAAAAACTCACTCATGGGAGCTCTGTGTGGATTTGGGCCCCTCATCTTC
ATTTATTATATTATCAAAACTGAGAGGGATAGGAAAGAAAAACTTATCCAGGAAGGAAAA
TTGGATCGAACATTTCACCTCTCATATTAA

# Drug_Target_114_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_114_General_References:
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_114_HGNC_ID:
HGNC:7699

# Drug_Target_114_HPRD_ID:
11955

# Drug_Target_114_ID:
324

# Drug_Target_114_Locus:
3q13.33

# Drug_Target_114_Molecular_Weight:
15078

# Drug_Target_114_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4

# Drug_Target_114_Number_of_Residues:
128

# Drug_Target_114_PDB_ID:
Not Available

# Drug_Target_114_Pathway:
Not Available

# Drug_Target_114_Pfam_Domain_Function:
PF07225	NDUF_B4

# Drug_Target_114_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4
SFPKYKPSSLRTLPETLDPAEYNISPETRRAQAERLAIRAQLKREYLLQYNDPNRRGLIE
NPALLRWAYARTINVYPNFRPTPKNSLMGALCGFGPLIFIYYIIKTERDRKEKLIQEGKL
DRTFHLSY

# Drug_Target_114_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_114_Signals:
None

# Drug_Target_114_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_114_SwissProt_ID:
O95168

# Drug_Target_114_SwissProt_Name:
NDUB4_HUMAN

# Drug_Target_114_Synonyms:
CI-B15
Complex I-B15
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B15 subunit

# Drug_Target_114_Theoretical_pI:
10.24

# Drug_Target_114_Transmembrane_Regions:
87-104

# Drug_Target_115_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_115_Chromosome_Location:
Not Available

# Drug_Target_115_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_115_Essentiality:
Non-Essential

# Drug_Target_115_GenAtlas_ID:
NDUFB3

# Drug_Target_115_GenBank_ID_Gene:
AF047183

# Drug_Target_115_GenBank_ID_Protein:
2909858

# Drug_Target_115_GeneCard_ID:
NDUFB3

# Drug_Target_115_Gene_Name:
NDUFB3

# Drug_Target_115_Gene_Sequence:
>297 bp
ATGGCCCATGAACATGGACATGAGCATGGACATCATAAAATGGAACTTCCAGATTATAGA
CAATGGAAGATAGAAGGGACACCATTAGAAACTATCCAGAAGAAGCTGGCTGCAAAAGGG
CTAAGGGATCCATGGGGCCGCAATGAAGCTTGGAGATACATGGGTGGCTTTGCAAAGAGT
GTTTCCTTTTCTGATGTATTCTTTAAAGGATTCAAATGGGGATTTGCTGCATTTGTGGTA
GCTGTAGGAGCTGAATATTACCTGGAGTCCCTGAATAAAGATAAGAAGCATCACTGA

# Drug_Target_115_General_Function:
Involved in NADH dehydrogenase activity

# Drug_Target_115_General_References:
9425316	Ton C, Hwang DM, Dempsey AA, Liew CC: Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits. Biochem Biophys Res Commun. 1997 Dec 18;241(2):589-94.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_115_HGNC_ID:
HGNC:7698

# Drug_Target_115_HPRD_ID:
11954

# Drug_Target_115_ID:
313

# Drug_Target_115_Locus:
2q31.3

# Drug_Target_115_Molecular_Weight:
11271

# Drug_Target_115_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3

# Drug_Target_115_Number_of_Residues:
97

# Drug_Target_115_PDB_ID:
Not Available

# Drug_Target_115_Pathway:
Not Available

# Drug_Target_115_Pfam_Domain_Function:
PF08122	NDUF_B12

# Drug_Target_115_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3
AHEHGHEHGHHKMELPDYRQWKIEGTPLETIQKKLAAKGLRDPWGRNEAWRYMGGFAKSV
SFSDVFFKGFKWGFAAFVVAVGAEYYLESLNKDKKHH

# Drug_Target_115_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_115_Signals:
None

# Drug_Target_115_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_115_SwissProt_ID:
O43676

# Drug_Target_115_SwissProt_Name:
NDUB3_HUMAN

# Drug_Target_115_Synonyms:
CI-B12
Complex I-B12
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B12 subunit

# Drug_Target_115_Theoretical_pI:
9.73

# Drug_Target_115_Transmembrane_Regions:
65-87

# Drug_Target_116_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_116_Chromosome_Location:
Not Available

# Drug_Target_116_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_116_Essentiality:
Non-Essential

# Drug_Target_116_GenAtlas_ID:
NDUFB2

# Drug_Target_116_GenBank_ID_Gene:
AF050639

# Drug_Target_116_GenBank_ID_Protein:
4164454

# Drug_Target_116_GeneCard_ID:
NDUFB2

# Drug_Target_116_Gene_Name:
NDUFB2

# Drug_Target_116_Gene_Sequence:
>318 bp
ATGTCCGCTCTGACTCGGCTGGCGTCTTTCGCTCGCGTTGGAGGCCGCCTTTTCAGAAGC
GGCTGCGCACGGACTGCTGGAGATGGTGGAGTCCGTCATGCCGGTGGTGGTGTGCACATT
GAGCCCCGGTATAGACAGTTCCCCCAGCTGACCAGATCCCAGGTGTTCCAGAGCGAGTTC
TTCAGCGGACTCATGTGGTTCTGGATTCTCTGGCGCTTTTGGCATGACTCAGAAGAGGTG
CTGGGTCACTTTCCGTATCCTGATCCTTCCCAGTGGACAGATGAAGAATTAGGTATCCCT
CCTGATGATGAAGACTGA

# Drug_Target_116_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_116_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_116_HGNC_ID:
HGNC:7697

# Drug_Target_116_HPRD_ID:
11953

# Drug_Target_116_ID:
475

# Drug_Target_116_Locus:
7q34

# Drug_Target_116_Molecular_Weight:
12059

# Drug_Target_116_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial

# Drug_Target_116_Number_of_Residues:
105

# Drug_Target_116_PDB_ID:
Not Available

# Drug_Target_116_Pathway:
Not Available

# Drug_Target_116_Pfam_Domain_Function:
Not Available

# Drug_Target_116_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial precursor
MSALTRLASFARVGGRLFRSGCARTAGDGGVRHAGGGVHIEPRYRQFPQLTRSQVFQSEF
FSGLMWFWILWRFWHDSEEVLGHFPYPDPSQWTDEELGIPPDDED

# Drug_Target_116_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_116_Signals:
None

# Drug_Target_116_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_116_SwissProt_ID:
O95178

# Drug_Target_116_SwissProt_Name:
NDUB2_HUMAN

# Drug_Target_116_Synonyms:
CI-AGGG
Complex I-AGGG
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial precursor
NADH-ubiquinone oxidoreductase AGGG subunit

# Drug_Target_116_Theoretical_pI:
5.55

# Drug_Target_116_Transmembrane_Regions:
None

# Drug_Target_117_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_117_Chromosome_Location:
Not Available

# Drug_Target_117_Drug_References:
11864782	Raha S, Myint AT, Johnstone L, Robinson BH: Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase. Free Radic Biol Med. 2002 Mar 1;32(5):421-30.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_117_Essentiality:
Non-Essential

# Drug_Target_117_GenAtlas_ID:
NDUFB7

# Drug_Target_117_GenBank_ID_Gene:
M33374

# Drug_Target_117_GenBank_ID_Protein:
180233

# Drug_Target_117_GeneCard_ID:
NDUFB7

# Drug_Target_117_Gene_Name:
NDUFB7

# Drug_Target_117_Gene_Sequence:
>408 bp
ATGGGGGCGCACCTGGTCCGGCGCTACCTGGGCGATGCTTCGGTGGAGCCCGACCCCCTG
CAGATGCCAACCTTCCCGCCAGACTACGGCTTCCCCGAACGCAAGGAGCGCGAGATGGTG
GCCACACAGCAGGAGATGATGGACGCGAGTGAGGCTCAGCTGCGGGACTACTGCGCCCAC
CACCTCATCCGGCTGCTCAAGTGCAAGCGTGACAGCTTCCCAAGTTGCTGGCCTGCAAGC
AGGAAGCGGCACGACTCGGGACTACTGCGCACCGCAAGCTATGTGATGCGCATGAAGGAG
TTTGAGCGGGACGAGGGCTGCTCCAGCGGAAGAAGCGGCGGGAGAAGAAGGCGGCAAATC
TGCAAAGGCCAGGGACCCGGGGAAGTGGACCCCAAGGTGGCCCTGTAG

# Drug_Target_117_General_Function:
Involved in NADH dehydrogenase activity

# Drug_Target_117_General_References:
10830904	Triepels R, Smeitink J, Loeffen J, Smeets R, Trijbels F, van den Heuvel L: Characterization of the human complex I NDUFB7 and 17.2-kDa cDNAs and mutational analysis of 19 genes of the HP fraction in complex I-deficient-patients. Hum Genet. 2000 Apr;106(4):385-91.
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.
2302251	Wong YC, Tsao SW, Kakefuda M, Bernal SD: cDNA cloning of a novel cell adhesion protein expressed in human squamous carcinoma cells. Biochem Biophys Res Commun. 1990 Jan 30;166(2):984-92.

# Drug_Target_117_HGNC_ID:
HGNC:7702

# Drug_Target_117_HPRD_ID:
11957

# Drug_Target_117_ID:
568

# Drug_Target_117_Locus:
19p13.12-p13.11

# Drug_Target_117_Molecular_Weight:
16271

# Drug_Target_117_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7

# Drug_Target_117_Number_of_Residues:
136

# Drug_Target_117_PDB_ID:
Not Available

# Drug_Target_117_Pathway:
Not Available

# Drug_Target_117_Pfam_Domain_Function:
PF05676	NDUF_B7

# Drug_Target_117_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7
GAHLVRRYLGDASVEPDPLQMPTFPPDYGFPERKEREMVATQQEMMDAQLRLQLRDYCAH
HLIRLLKCKRDSFPNFLACKQERHDWDYCEHRDYVMRMKEFERERRLLQRKKRREKKAAE
LAKGQGPGEVDPKVAL

# Drug_Target_117_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_117_Signals:
None

# Drug_Target_117_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_117_SwissProt_ID:
P17568

# Drug_Target_117_SwissProt_Name:
NDUB7_HUMAN

# Drug_Target_117_Synonyms:
CI-B18
Cell adhesion protein SQM1
Complex I-B18
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B18 subunit

# Drug_Target_117_Theoretical_pI:
9.21

# Drug_Target_117_Transmembrane_Regions:
None

# Drug_Target_118_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_118_Chromosome_Location:
Not Available

# Drug_Target_118_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_118_Essentiality:
Non-Essential

# Drug_Target_118_GenAtlas_ID:
NDUFB9

# Drug_Target_118_GenBank_ID_Gene:
AF044956

# Drug_Target_118_GenBank_ID_Protein:
5326828

# Drug_Target_118_GeneCard_ID:
NDUFB9

# Drug_Target_118_Gene_Name:
NDUFB9

# Drug_Target_118_Gene_Sequence:
>540 bp
ATGGCGTTCTTGGCGTCGGGACCCTACCTGACCCATCAGCAAAAGGTGTTGCGGCTTTAT
AAGCGGGCGCTACGCCACCTCGAGTCGTGGTGCGTCCAGAGAGACAAATACCGATACTTT
GCTTGTTTGATGAGAGCCCGGTTTGAAGAACATAAGAATGAAAAGGATATGGCGAAGGCC
ACCCAGCTGCTGAAGGAGGCCGAGGAAGAATTCTGGTACCGTCAGCATCCACAGCCATAC
ATCTTCCCTGACTCTCCTGGGGGCACCTCCTATGAGAGATACGATTGCTACAAGGTCCCA
GAATGGTGCTTAGATGACTGGCATCCTTCTGAGAAGGCAATGTATCCTGATTACTTTGCC
AAGAGAGAACAGTGGAAGAAACTGCGGAGGGAAAGCTGGGAACGAGAGGTTAAGCAGCTG
CAGGAGGAAACGCCACCTGGTGGTCCTTTAACTGAAGCTTTGCCCCCTGCCCGAAAGGAA
GGTGATTTGCCCCCACTGTGGTGGTATATTGTGACCAGACCCCGGGAGCGGCCCATGTAG

# Drug_Target_118_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_118_General_References:
10077726	Lin X, Wells DE, Kimberling WJ, Kumar S: Human NDUFB9 gene: genomic organization and a possible candidate gene associated with deafness disorder mapped to chromosome 8q13. Hum Hered. 1999 Mar;49(2):75-80.
10944468	Ye Z, Connor JR: cDNA cloning by amplification of circularized first strand cDNAs reveals non-IRE-regulated iron-responsive mRNAs. Biochem Biophys Res Commun. 2000 Aug 18;275(1):223-7.
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.

# Drug_Target_118_HGNC_ID:
HGNC:7704

# Drug_Target_118_HPRD_ID:
03264

# Drug_Target_118_ID:
656

# Drug_Target_118_Locus:
8q13.3

# Drug_Target_118_Molecular_Weight:
21700

# Drug_Target_118_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9

# Drug_Target_118_Number_of_Residues:
178

# Drug_Target_118_PDB_ID:
Not Available

# Drug_Target_118_Pathway:
Not Available

# Drug_Target_118_Pfam_Domain_Function:
PF05347	Complex1_LYR

# Drug_Target_118_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9
AFLASGPYLTHQQKVLRLYKRALRHLESWCVQRDKYRYFACLMRARFEEHKNEKDMAKAT
QLLKEAEEEFWYRQHPQPYIFPDSPGGTSYERYDCYKVPEWCLDDWHPSEKAMYPDYFAK
REQWKKLRRESWEREVKQLQEETPPGGPLTEALPPARKEGDLPPLWWYIVTRPRERPM

# Drug_Target_118_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_118_Signals:
None

# Drug_Target_118_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_118_SwissProt_ID:
Q9Y6M9

# Drug_Target_118_SwissProt_Name:
NDUB9_HUMAN

# Drug_Target_118_Synonyms:
CI-B22
Complex I-B22
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B22 subunit

# Drug_Target_118_Theoretical_pI:
8.56

# Drug_Target_118_Transmembrane_Regions:
None

# Drug_Target_119_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_119_Chromosome_Location:
Not Available

# Drug_Target_119_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_119_Essentiality:
Non-Essential

# Drug_Target_119_GenAtlas_ID:
NDUFS2

# Drug_Target_119_GenBank_ID_Gene:
AF013160

# Drug_Target_119_GenBank_ID_Protein:
3540239

# Drug_Target_119_GeneCard_ID:
NDUFS2

# Drug_Target_119_Gene_Name:
NDUFS2

# Drug_Target_119_Gene_Sequence:
>1392 bp
ATGGCGGCGCTGAGGGCTTTGTGCGGCTTCCGGGGCGTCGCGGCCCAGGTGCTGCGGCCT
GGGGCTGGAGGCCGATTGCCGATTCAGCCCAGCAGAGGTGTTCGGCAGTGGCAGCCAGAT
GTGGAATGGGCACAGCAGTTTGGGGGAGCTGTTATGTACCCAAGCAAAGAAACAGCCCAC
TGGAAGCCTCCACCTTGGAATGATGTGGACCCTCCAAAGGACACAATTGTGAAGAACATT
ACCCTGAACTTTGGGCCCCAACACCCAGCAGCGCATGGTGTCCTGCGACTAGTGATGGAA
TTGAGTGGGGAGATGGTGCGGAAGTGTGATCCTCACATCGGGCTCCTGCACCGAGGCACT
GAGAAGCTCATTGAATACAAGACCTATCTTCAGGCCCTTCCATACTTTGACCGGCTAGAC
TATGTGTCCATGATGTGTAACGAACAGGCCTATTCTCTAGCTGTGGAGAAGTTGCTAAAC
ATCCGGCCTCCTCCTCGGGCACAGTGGATCCGAGTGCTGTTTGGAGAAATCACACGTTTG
TTGAACCACATCATGGCTGTGACCACACATGCCCTGGACCTTGGGGCCATGACCCCTTTC
TTCTGGCTGTTTGAAGAAAGGGAGAAGATGTTTGAGTTCTACGAGCGAGTGTCTGGAGCC
CGAATGCATGCTGCTTATATCCGGCCAGGAGGAGTGCACCAGGACCTACCCCTTGGGCTT
ATGGATGACATTTATCAGTTTTCTAAGAACTTCTCTCTTCGGCTTGATGAGTTGGAGGAG
TTGCTGACCAACAATAGGATCTGGCGAAATCGGACAATTGACATTGGGGTTGTAACAGCA
GAAGAAGCACTTAACTATGGTTTTAGTGGAGTGATGCTTCGGGGCTCAGGCATCCAGTGG
GACCTGCGGAAGACCCAGCCCTATGATGTTTACGACCAGGTTGAGTTTGATGTTCCTGTT
GGTTCTCGAGGGGACTGCTATGATAGGTACCTGTGCCGGGTGGAGGAGATGCGCCAGTCC
CTGAGAATTATCGCACAGTGTCTAAACAAGATGCCTCCTGGGGAGATCAAGGTTGATGAT
GCCAAAGTGTCTCCACCTAAGCGAGCAGAGATGAAGACTTCCATGGAGTCACTGATTCAT
CACTTTAAGTTGTATACTGAGGGCTACCAAGTTCCTCCAGGAGCCACATATACTGCCATT
GAGGCTCCCAAGGGAGAGTTTGGGGTGTACCTGGTGTCTGATGGCAGCAGCCGCCCTTAT
CGATGCAAGATCAAGGCTCCTGGTTTTGCCCATCTGGCTGGTTTGGACAAGATGTCTAAG
GGACACATGTTGGCAGATGTCGTTGCCATCATAGGTACCCAAGATATTGTATTTGGAGAA
GTAGATCGGTGA

# Drug_Target_119_General_Function:
Energy production and conversion

# Drug_Target_119_General_References:
9585441	Procaccio V, de Sury R, Martinez P, Depetris D, Rabilloud T, Soularue P, Lunardi J, Issartel J: Mapping to 1q23 of the human gene (NDUFS2) encoding the 49-kDa subunit of the mitochondrial respiratory Complex I and immunodetection of the mature protein in mitochondria. Mamm Genome. 1998 Jun;9(6):482-4.
9647766	Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J: cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed. Biochem Biophys Res Commun. 1998 Jun 29;247(3):751-8.

# Drug_Target_119_HGNC_ID:
HGNC:7708

# Drug_Target_119_HPRD_ID:
04285

# Drug_Target_119_ID:
803

# Drug_Target_119_Locus:
1q23

# Drug_Target_119_Molecular_Weight:
52546

# Drug_Target_119_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial

# Drug_Target_119_Number_of_Residues:
463

# Drug_Target_119_PDB_ID:
Not Available

# Drug_Target_119_Pathway:
Not Available

# Drug_Target_119_Pfam_Domain_Function:
PF00346	Complex1_49kDa

# Drug_Target_119_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial precursor
MAALRALCGFRGVAAQVLRPGAGVRLPIQPSRGVRQWQPDVEWAQQFGGAVMYPSKETAH
WKPPPWNDVDPPKDTIVKNITLNFGPQHPAAHGVLRLVMELSGEMVRKCDPHIGLLHRGT
EKLIEYKTYLQALPYFDRLDYVSMMCNEQAYSLAVEKLLNIRPPPRAQWIRVLFGEITRL
LNHIMAVTTHALDLGAMTPFFWLFEEREKMFEFYERVSGARMHAAYIRPGGVHQDLPLGL
MDDIYQFSKNFSLRLDELEELLTNNRIWRNRTIDIGVVTAEEALNYGFSGVMLRGSGIQW
DLRKTQPYDVYDQVEFDVPVGSRGDCYDRYLCRVEEMRQSLRIIAQCLNKMPPGEIKVDD
AKVSPPKRAEMKTSMESLIHHFKLYTEGYQVPPGATYTAIEAPKGEFGVYLVSDGSSRPY
RCKIKAPGFAHLAGLDKMSKGHMLADVVAIIGTQDIVFGEVDR

# Drug_Target_119_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_119_Signals:
None

# Drug_Target_119_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_119_SwissProt_ID:
O75306

# Drug_Target_119_SwissProt_Name:
NDUS2_HUMAN

# Drug_Target_119_Synonyms:
CI-49kD
Complex I-49kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase iron-sulfur protein 2, mitochondrial precursor
NADH-ubiquinone oxidoreductase 49 kDa subunit

# Drug_Target_119_Theoretical_pI:
7.61

# Drug_Target_119_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasm

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17222174	Linster CL, Van Schaftingen E: Vitamin C. Biosynthesis, recycling and degradation in mammals. FEBS J. 2007 Jan;274(1):1-22.
17508915	Ido Y: Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal. 2007 Jul;9(7):931-42.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
AKR1B1

# Drug_Target_11_GenBank_ID_Gene:
J04795

# Drug_Target_11_GenBank_ID_Protein:
178487

# Drug_Target_11_GeneCard_ID:
AKR1B1

# Drug_Target_11_Gene_Name:
AKR1B1

# Drug_Target_11_Gene_Sequence:
>951 bp
ATGGCAAGCCGTCTCCTGCTCAACAACGGCGCCAAGATGCCCATCCTGGGGTTGGGTACC
TGGAAGTCCCCTCCAGGGCAGGTGACTGAGGCCGTGAAGGTGGCCATTGACGTCGGGTAC
CGCCACATCGACTGTGCCCATGTGTACCAGAATGAGAATGAGGTGGGGGTGGCCATTCAG
GAGAAGCTCAGGGAGCAGGTGGTGAAGCGTGAGGAGCTCTTCATCGTCAGCAAGCTGTGG
TGCACGTACCATGAGAAGGGCCTGGTGAAAGGAGCCTGCCAGAAGACACTCAGCGACCTG
AAGCTGGACTACCTGGACCTCTACCTTATTCACTGGCCGACTGGCTTTAAGCCTGGGAAG
GAATTTTTCCCATTGGATGAGTCGGGCAATGTGGTTCCCAGTGACACCAACATTCTGGAC
ACGTGGGCGGCCATGGAAGAGCTGGTGGATGAAGGGCTGGTGAAAGCTATTGGCATCTCC
AACTTCAACCATCTCCAGGTGGAGATGATCTTAAACAAACCTGGCTTGAAGTATAAGCCT
GCAGTTAACCAGATTGAGTGCCACCCATATCTCACTCAGGAGAAGTTAATCCAGTACTGC
CAGTCCAAAGGCATCGTGGTGACCGCCTACAGCCCCCTCGGCTCTCCTGACAGGCCCTGG
GCCAAGCCCGAGGACCCTTCTCTCCTGGAGGATCCCAGGATCAAGGCGATCGCAGCCAAG
CACAATAAAACTACAGCCCAGGTCCTGATCCGGTTCCCCATGCAGAGGAACTTGGTGGTG
ATCCCCAAGTCTGTGACACCAGAACGCATTGCTGAGAACTTTAAGGTCTTTGACTTTGAA
CTGAGCAGCCAGGATATGACCACCTTACTCAGCTACAACAGGAACTGGAGGGTCTGTGCC
TTGTTGAGCTGTACCTCCCACAAGGATTACCCCTTCCATGAAGAGTTTTGA

# Drug_Target_11_General_Function:
Involved in oxidoreductase activity

# Drug_Target_11_General_References:
1447221	Borhani DW, Harter TM, Petrash JM: The crystal structure of the aldose reductase.NADPH binary complex. J Biol Chem. 1992 Dec 5;267(34):24841-7.
1621098	Wilson DK, Bohren KM, Gabbay KH, Quiocho FA: An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992 Jul 3;257(5066):81-4.
1901857	Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J Biol Chem. 1991 Apr 15;266(11):6872-7.
2111143	Grundmann U, Bohn H, Obermeier R, Amann E: Cloning and prokaryotic expression of a biologically active human placental aldose reductase. DNA Cell Biol. 1990 Apr;9(3):149-57.
2112546	Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J Biol Chem. 1990 Jun 15;265(17):9788-92.
2492527	Morjana NA, Lyons C, Flynn TG: Aldose reductase from human psoas muscle. Affinity labeling of an active site lysine by pyridoxal 5'-phosphate and pyridoxal 5'-diphospho-5'-adenosine. J Biol Chem. 1989 Feb 15;264(5):2912-9.
2498333	Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem. 1989 Jun 5;264(16):9547-51.
2504709	Chung S, LaMendola J: Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem. 1989 Sep 5;264(25):14775-7.
2510130	Graham A, Hedge PJ, Powell SJ, Riley J, Brown L, Gammack A, Carey F, Markham AF: Nucleotide sequence of cDNA for human aldose reductase. Nucleic Acids Res. 1989 Oct 25;17(20):8368.
8234324	Wilson DK, Tarle I, Petrash JM, Quiocho FA: Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9847-51.
8245005	Tarle I, Borhani DW, Wilson DK, Quiocho FA, Petrash JM: Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110. J Biol Chem. 1993 Dec 5;268(34):25687-93.
8281941	Jaquinod M, Potier N, Klarskov K, Reymann JM, Sorokine O, Kieffer S, Barth P, Andriantomanga V, Biellmann JF, Van Dorsselaer A: Sequence of pig lens aldose reductase and electrospray mass spectrometry of non-covalent and covalent complexes. Eur J Biochem. 1993 Dec 15;218(3):893-903.
8343525	Liu SQ, Bhatnagar A, Ansari NH, Srivastava SK: Identification of the reactive cysteine residue in human placenta aldose reductase. Biochim Biophys Acta. 1993 Aug 7;1164(3):268-72.
8435445	Ferraretto A, Negri A, Giuliani A, De Grada L, Fuhrman Conti AM, Ronchi S: Aldose reductase is involved in long-term adaptation of EUE cells to hyperosmotic stress. Biochim Biophys Acta. 1993 Feb 17;1175(3):283-8.
9195951	Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS: Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem. 1997 Jun 27;272(26):16431-7.
9405046	Harrison DH, Bohren KM, Petsko GA, Ringe D, Gabbay KH: The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry. 1997 Dec 23;36(51):16134-40.

# Drug_Target_11_HGNC_ID:
HGNC:381

# Drug_Target_11_HPRD_ID:
00071

# Drug_Target_11_ID:
822

# Drug_Target_11_Locus:
7q35

# Drug_Target_11_Molecular_Weight:
35723

# Drug_Target_11_Name:
Aldose reductase

# Drug_Target_11_Number_of_Residues:
315

# Drug_Target_11_PDB_ID:
1T40

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_11_Protein_Sequence:
>Aldose reductase
ASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQE
KLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKE
FFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPA
VNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKH
NKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCAL
LSCTSHKDYPFHEEF

# Drug_Target_11_Reaction:
alditol + NAD(P)+ = aldose + NAD(P)H + H+

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies

# Drug_Target_11_SwissProt_ID:
P15121

# Drug_Target_11_SwissProt_Name:
ALDR_HUMAN

# Drug_Target_11_Synonyms:
AR
Aldehyde reductase
EC 1.1.1.21

# Drug_Target_11_Theoretical_pI:
6.99

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_120_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_120_Chromosome_Location:
Not Available

# Drug_Target_120_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_120_Essentiality:
Non-Essential

# Drug_Target_120_GenAtlas_ID:
NDUFB5

# Drug_Target_120_GenBank_ID_Gene:
AF047181

# Drug_Target_120_GenBank_ID_Protein:
2909854

# Drug_Target_120_GeneCard_ID:
NDUFB5

# Drug_Target_120_Gene_Name:
NDUFB5

# Drug_Target_120_Gene_Sequence:
>570 bp
ATGGCGGCCATGAGTTTGTTGCGGCGGGTTTCGGTTACTGCGGTGGCAGCTCTGTCTGGC
CGGCCCCTTGGCACTCGCCTCGGATTTGGGGGCTTCCTCACTCGTGGCTTTCCGAAGGCT
GCTGCTCCTGTTCGACACAGTGGAGACCATGGGAAAAGACTATTTGTCATCAGACCTTCT
AGATTCTATGACAGGCGTTTTTTGAAGTTATTGAGATTCTACATTGCATTGACTGGGATT
CCAGTAGCAATTTTCATAACTCTGGTGAATGTATTCATTGGTCAAGCTGAACTAGCAGAA
ATTCCAGAAGGCTATGTCCCAGAACACTGGGAATATTATAAGCATCCCATATCAAGATGG
ATTGCCCGTAATTTCTATGATAGTCCTGAAAAGATATATGAAAGAACAATGGCCGTCCTT
CAGATTGAAGCTGAAAAGGCTGAATTACGGGTAAAGGAGCTGGAAGTGCGAAAATTGATG
CATGTGAGAGGAGATGGACCCTGGTATTACTATGAGACAATTGACAAGGAACTTATTGAT
CATTCTCCGAAAGCAACTCCTGACAATTAA

# Drug_Target_120_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_120_General_References:
9425316	Ton C, Hwang DM, Dempsey AA, Liew CC: Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits. Biochem Biophys Res Commun. 1997 Dec 18;241(2):589-94.

# Drug_Target_120_HGNC_ID:
HGNC:7700

# Drug_Target_120_HPRD_ID:
11956

# Drug_Target_120_ID:
270

# Drug_Target_120_Locus:
3q26.33

# Drug_Target_120_Molecular_Weight:
21751

# Drug_Target_120_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial

# Drug_Target_120_Number_of_Residues:
189

# Drug_Target_120_PDB_ID:
Not Available

# Drug_Target_120_Pathway:
Not Available

# Drug_Target_120_Pfam_Domain_Function:
Not Available

# Drug_Target_120_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial precursor
MAAMSLLRRVSVTAVAALSGRPLGTRLGFGGFLTRGFPKAAAPVRHSGDHGKRLFVIRPS
RFYDRRFLKLLRFYIALTGIPVAIFITLVNVFIGQAELAEIPEGYVPEHWEYYKHPISRW
IARNFYDSPEKIYERTMAVLQIEAEKAELRVKELEVRKLMHVRGDGPWYYYETIDKELID
HSPKATPDN

# Drug_Target_120_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_120_Signals:
None

# Drug_Target_120_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_120_SwissProt_ID:
O43674

# Drug_Target_120_SwissProt_Name:
NDUB5_HUMAN

# Drug_Target_120_Synonyms:
CI-SGDH
Complex I-SGDH
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase 1 beta subcomplex subunit 5, mitochondrial precursor
NADH-ubiquinone oxidoreductase SGDH subunit

# Drug_Target_120_Theoretical_pI:
10.02

# Drug_Target_120_Transmembrane_Regions:
70-92

# Drug_Target_121_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_121_Chromosome_Location:
Not Available

# Drug_Target_121_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_121_Essentiality:
Non-Essential

# Drug_Target_121_GenAtlas_ID:
NDUFC1

# Drug_Target_121_GenBank_ID_Gene:
AF047184

# Drug_Target_121_GenBank_ID_Protein:
2909860

# Drug_Target_121_GeneCard_ID:
NDUFC1

# Drug_Target_121_Gene_Name:
NDUFC1

# Drug_Target_121_Gene_Sequence:
>231 bp
ATGGCGCCGTCCGCCTTGCTGCGTCCCCTTTCCCGGCTGCTGGCCCCCGCCAGGCTCCCG
AGCGGCCCTTCAGTGCGATCAAAGTTCTACGTGCGAGAGCCGCCGAATGCCAAACCTGAC
TGGCTGAAAGTTGGGTTCACCTTGGGCACCACTGTCTTCTTGTGGATCTATCTCATCAAA
CAACACAATGAAGATATTTTAGAGTACAAAAGAAGAAATGGGCTGGAATAA

# Drug_Target_121_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_121_General_References:
9425316	Ton C, Hwang DM, Dempsey AA, Liew CC: Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits. Biochem Biophys Res Commun. 1997 Dec 18;241(2):589-94.
9653160	Mao M, Fu G, Wu JS, Zhang QH, Zhou J, Kan LX, Huang QH, He KL, Gu BW, Han ZG, Shen Y, Gu J, Yu YP, Xu SH, Wang YX, Chen SJ, Chen Z: Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8175-80.

# Drug_Target_121_HGNC_ID:
HGNC:7705

# Drug_Target_121_HPRD_ID:
11959

# Drug_Target_121_ID:
343

# Drug_Target_121_Locus:
4q28.2-q31.1

# Drug_Target_121_Molecular_Weight:
8734

# Drug_Target_121_Name:
NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial

# Drug_Target_121_Number_of_Residues:
76

# Drug_Target_121_PDB_ID:
Not Available

# Drug_Target_121_Pathway:
Not Available

# Drug_Target_121_Pfam_Domain_Function:
Not Available

# Drug_Target_121_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial precursor
MAPSALLRPLSRLLAPARLPSGPSVRSKFYVREPPNAKPDWLKVGFTLGTTVFLWIYLIK
QHNEDILEYKRRNGLE

# Drug_Target_121_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_121_Signals:
None

# Drug_Target_121_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_121_SwissProt_ID:
O43677

# Drug_Target_121_SwissProt_Name:
NDUC1_HUMAN

# Drug_Target_121_Synonyms:
CI-KFYI
Complex I-KFYI
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase 1 subunit C1, mitochondrial precursor
NADH-ubiquinone oxidoreductase KFYI subunit

# Drug_Target_121_Theoretical_pI:
10.77

# Drug_Target_121_Transmembrane_Regions:
None

# Drug_Target_122_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_122_Chromosome_Location:
Not Available

# Drug_Target_122_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_122_Essentiality:
Non-Essential

# Drug_Target_122_GenAtlas_ID:
NDUFB6

# Drug_Target_122_GenBank_ID_Gene:
AF035840

# Drug_Target_122_GenBank_ID_Protein:
3800740

# Drug_Target_122_GeneCard_ID:
NDUFB6

# Drug_Target_122_Gene_Name:
NDUFB6

# Drug_Target_122_Gene_Sequence:
>387 bp
ATGACGGGGTACACTCCGGATGAGAAACTGCGGCTGCAGCAGCTGCGAGAGCTGAGAAGG
CGATGGCTGAAGGACCAGGAGCTGAGCCCTCGGGAGCCGGTGCTGCCCCCACAGAAGATG
GGGCCTATGGAGAAATTCTGGAATAAATTTTTGGAGAATAAATCCCCTTGGAGGAAAATG
GTCCATGGGGTATACAAAAAGAGTATCTTTGTTTTCACTCATGTACTTGTACCTGTCTGG
ATTATTCATTATTACATGAAGTATCATGTTTCTGAAAAACCATATGGCATAGTTGAAAAG
AAGTCCAGAATATTCCCTGGTGATACAATTCTGGAGACTGGAGAAGTAATTCCACCAATG
AAAGAATTTCCTGATCAACATCATTAA

# Drug_Target_122_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_122_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9760212	Smeitink J, Loeffen J, Smeets R, Triepels R, Ruitenbeek W, Trijbels F, van den Heuvel L: Molecular characterization and mutational analysis of the human B17 subunit of the mitochondrial respiratory chain complex I. Hum Genet. 1998 Aug;103(2):245-50.

# Drug_Target_122_HGNC_ID:
HGNC:7701

# Drug_Target_122_HPRD_ID:
04504

# Drug_Target_122_ID:
417

# Drug_Target_122_Locus:
9p21.1

# Drug_Target_122_Molecular_Weight:
15358

# Drug_Target_122_Name:
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6

# Drug_Target_122_Number_of_Residues:
127

# Drug_Target_122_PDB_ID:
Not Available

# Drug_Target_122_Pathway:
Not Available

# Drug_Target_122_Pfam_Domain_Function:
Not Available

# Drug_Target_122_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6
TGYTPDEKLRLQQLRELRRRWLKDQELSPREPVLPPQKMGPMEKFWNKFLENKSPWRKMV
HGVYKKSIFVFTHVLVPVWIIHYYMKYHVSEKPYGIVEKKSRIFPGDTILETGEVIPPMK
EFPDQHH

# Drug_Target_122_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_122_Signals:
None

# Drug_Target_122_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_122_SwissProt_ID:
O95139

# Drug_Target_122_SwissProt_Name:
NDUB6_HUMAN

# Drug_Target_122_Synonyms:
CI-B17
Complex I-B17
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase B17 subunit

# Drug_Target_122_Theoretical_pI:
10.18

# Drug_Target_122_Transmembrane_Regions:
67-85

# Drug_Target_123_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_123_Chromosome_Location:
Not Available

# Drug_Target_123_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_123_Essentiality:
Non-Essential

# Drug_Target_123_GenAtlas_ID:
NDUFV3

# Drug_Target_123_GenBank_ID_Gene:
X99726

# Drug_Target_123_GenBank_ID_Protein:
6002197

# Drug_Target_123_GeneCard_ID:
NDUFV3

# Drug_Target_123_Gene_Name:
NDUFV3

# Drug_Target_123_Gene_Sequence:
>324 bp
ATGGCTGCCCCGTGTTTGCTGCGGCAAGGACGAGCCGGGGCGCTGAAGACTATGCTCCAG
GAAGCCCAGGTGTTTCGAGGACTTGCTTCTACGGTTTCTTTGTCTGCGGAATCAGGGAAG
AGTGAAAAGGGTCAGCCACAGAATTCCAAGAAGCAAAGTCCACCAAAAAAGCCAGCCCCA
GTGCCTGCTGAGCCGTTTGACAACACTACCTACAAGAACCTGCAGCATCATGACTACAGC
ACGTACACCTTCTTAGACCTCAACCTCGAACTCTCAAAATTCAGGATGCCTCAGCCCTCC
TCAGGCCGGGAGTCACCTCGACAC

# Drug_Target_123_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_123_General_References:
10508479	Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 1999 Nov 12;83(4):456-64.
10950923	Berry A, Scott HS, Kudoh J, Talior I, Korostishevsky M, Wattenhofer M, Guipponi M, Barras C, Rossier C, Shibuya K, Wang J, Kawasaki K, Asakawa S, Minoshima S, Shimizu N, Antonarakis S, Bonne-Tamir B: Refined localization of autosomal recessive nonsyndromic deafness DFNB10 locus using 34 novel microsatellite markers, genomic structure, and exclusion of six known genes in the region. Genomics. 2000 Aug 15;68(1):22-9.
9344673	de Coo RF, Buddiger P, Smeets HJ, van Oost BA: Molecular cloning and characterization of the human mitochondrial NADH:oxidoreductase 10-kDa gene (NDUFV3). Genomics. 1997 Oct 15;45(2):434-7.

# Drug_Target_123_HGNC_ID:
HGNC:7719

# Drug_Target_123_HPRD_ID:
03716

# Drug_Target_123_ID:
30

# Drug_Target_123_Locus:
Not Available

# Drug_Target_123_Molecular_Weight:
11941

# Drug_Target_123_Name:
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial

# Drug_Target_123_Number_of_Residues:
108

# Drug_Target_123_PDB_ID:
Not Available

# Drug_Target_123_Pathway:
Not Available

# Drug_Target_123_Pfam_Domain_Function:
Not Available

# Drug_Target_123_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial precursor
MAAPCLLRQGRAGALKTMLQEAQVFRGLASTVSLSAESGKSEKGQPQNSKKQSPPKKPAP
VPAEPFDNTTYKNLQHHDYSTYTFLDLNLELSKFRMPQPSSGRESPRH

# Drug_Target_123_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_123_Signals:
None

# Drug_Target_123_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_123_SwissProt_ID:
P56181

# Drug_Target_123_SwissProt_Name:
NDUV3_HUMAN

# Drug_Target_123_Synonyms:
CI-9kD
Complex I-9kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase flavoprotein 3, mitochondrial precursor
NADH-ubiquinone oxidoreductase 9 kDa subunit
Renal carcinoma antigen NY-REN- 4

# Drug_Target_123_Theoretical_pI:
10.30

# Drug_Target_123_Transmembrane_Regions:
None

# Drug_Target_124_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_124_Chromosome_Location:
Not Available

# Drug_Target_124_Drug_References:
17017892	Gutierrez-Correa J: Trypanosoma cruzi dihydrolipoamide dehydrogenase as target for phenothiazine cationic radicals. Effect of antioxidants. Curr Drug Targets. 2006 Sep;7(9):1155-79.
17314104	Islam MM, Wallin R, Wynn RM, Conway M, Fujii H, Mobley JA, Chuang DT, Hutson SM: A novel branched-chain amino acid metabolon. Protein-protein interactions in a supramolecular complex. J Biol Chem. 2007 Apr 20;282(16):11893-903. Epub 2007 Feb 21.
17315258	Yan LJ, Yang SH, Shu H, Prokai L, Forster MJ: Histochemical staining and quantification of dihydrolipoamide dehydrogenase diaphorase activity using blue native PAGE. Electrophoresis. 2007 Apr;28(7):1036-45.

# Drug_Target_124_Essentiality:
Non-Essential

# Drug_Target_124_GenAtlas_ID:
DLD

# Drug_Target_124_GenBank_ID_Gene:
J03490

# Drug_Target_124_GenBank_ID_Protein:
307137

# Drug_Target_124_GeneCard_ID:
DLD

# Drug_Target_124_Gene_Name:
DLD

# Drug_Target_124_Gene_Sequence:
>1530 bp
ATGCAGAGCTGGAGTCGTGTGTACTGCTCCTTGGCCAAGAGAGGCCATTTCAATCGAATA
TCTCATGGCCTACAGGGACTTTCTGCAGTGCCTCTGAGAACTTACGCAGATCAGCCGATT
GATGCTGATGTAACAGTTATAGGTTCTGGTCCTGGAGGATATGTTGCTGCTATTAAAGCT
GCCCAGTTAGGCTTCAAGACAGTCTGCATTGAGAAAAATGAAACACTTGGTGGAACATGC
TTGAATGTTGGTTGTATTCCTTCTAAGGCTTTATTGAACAACTCTCATTATTACCATATG
GCCCATGGAACAGATTTTGCATCTAGAGGAATTGAAATGTCCGAAGTTCGCTTGAATTTA
GACAAGATGATGGAGCAGAAGAGTACTGCAGTAAAAGCTTTAACAGGTGGAATTGCCCAC
TTATTCAAACAGAATAAGGTTGTTCATGTCAATGGATATGGAAAGATAACTGGCAAAAAT
CAAGTCACTGCTACGAAAGCTGATGGCGGCACTCAGGTTATTGATACAAAGAACATTCTT
ATAGCCACGGGTTCAGAAGTTACTCCTTTTCCTGGAATCACGATAGATGAAGATACAATA
GTGTCATCTACAGGTGCTTTATCTTTAAAAAAAGTTCCAGAAAAGATGGTTGTTATTGGT
GCAGGAGTAATAGGTGTAGAATTGGGTTCAGTTTGGCAAAGACTTGGTGCAGATGTGACA
GCAGTTGAATTTTTAGGTCATGTAGGTGGAGTTGGAATTGATATGGAGATATCTAAAAAC
TTTCAACGCATCCTTCAAAAACAGGGGTTTAAATTTAAATTGAATACAAAGGTTACTGGT
GCTACCAAGAAGTCAGATGGAAAAATTGATGTTTCTATTGAAGCTGCTTCTGGTGGTAAA
GCTGAAGTTATCACTTGTGATGTACTCTTGGTTTGCATTGGCCGACGACCCTTTACTAAG
AATTTGGGACTAGAAGAGCTGGGAATTGAACTAGATCCTAGAGGTAGAATTCCAGTCAAT
ACCAGATTTCAAACTAAAATTCCAAATATCTATGCCATTGGTGATGTAGTTGCTGGTCCA
ATGCTGGCTCACAAAGCAGAGGATGAAGGCATTATCTGTGTTGAAGGAATGGCTGGTGGT
GCTGTGCACATTGACTACAATTGTGTGCCATCAGTGATTTACACACACCCTGAAGTTGCT
TGGGTTGGCAAATCAGAAGAGCAGTTGAAAGAAGAGGGTATTGAGTACAAAGTTGGGAAA
TTCCCATTTGCTGCTAACAGCAGAGCTAAGACAAATGCTGACACAGATGGCATGGTGAAG
ATCCTTGGGCAGAAATCGACAGACAGAGTACTGGGAGCACATATTCTTGGACCAGGTGCT
GGAGAAATGGTAAATGAAGCTGCTCTTGCTTTGGAATATGGAGCATCCTGTGAAGATATA
GCTAGAGTCTGTCATGCACATCCGACCTTATCAGAAGCTTTTAGAGAAGCAAATCTTGCT
GCGTCATTTGGCAAATCAATCAACTTTTGA

# Drug_Target_124_General_Function:
Energy production and conversion

# Drug_Target_124_General_References:
1332063	Johanning GL, Morris JI, Madhusudhan KT, Samols D, Patel MS: Characterization of the transcriptional regulatory region of the human dihydrolipoamide dehydrogenase gene. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10964-8.
3278312	Pons G, Raefsky-Estrin C, Carothers DJ, Pepin RA, Javed AA, Jesse BW, Ganapathi MK, Samols D, Patel MS: Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase component human alpha-ketoacid dehydrogenase complexes. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1422-6.
3693355	Otulakowski G, Robinson BH: Isolation and sequence determination of cDNA clones for porcine and human lipoamide dehydrogenase. Homology to other disulfide oxidoreductases. J Biol Chem. 1987 Dec 25;262(36):17313-8.
8406489	Feigenbaum AS, Robinson BH: The structure of the human dihydrolipoamide dehydrogenase gene (DLD) and its upstream elements. Genomics. 1993 Aug;17(2):376-81.
8506365	Liu TC, Kim H, Arizmendi C, Kitano A, Patel MS: Identification of two missense mutations in a dihydrolipoamide dehydrogenase-deficient patient. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5186-90.
8968745	Hong YS, Kerr DS, Craigen WJ, Tan J, Pan Y, Lusk M, Patel MS: Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. Hum Mol Genet. 1996 Dec;5(12):1925-30.
9934985	Shaag A, Saada A, Berger I, Mandel H, Joseph A, Feigenbaum A, Elpeleg ON: Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet. 1999 Jan 15;82(2):177-82.

# Drug_Target_124_HGNC_ID:
HGNC:2898

# Drug_Target_124_HPRD_ID:
02006

# Drug_Target_124_ID:
812

# Drug_Target_124_Locus:
7q31-q32

# Drug_Target_124_Molecular_Weight:
54151

# Drug_Target_124_Name:
Dihydrolipoyl dehydrogenase, mitochondrial

# Drug_Target_124_Number_of_Residues:
509

# Drug_Target_124_PDB_ID:
Not Available

# Drug_Target_124_Pathway:
Not Available

# Drug_Target_124_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_124_Protein_Sequence:
>Dihydrolipoyl dehydrogenase, mitochondrial precursor
MQSWSRVYCSLAKRGHFNRISHGLQGLSAVPLRTYADQPIDADVTVIGSGPGGYVAAIKA
AQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHMAHGTDFASRGIEMSEVRLNL
DKMMEQKSTAVKALTGGIAHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNIL
IATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELGSVWQRLGADVT
AVEFLGHVGGVGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSIEAASGGK
AEVITCDVLLVCIGRRPFTKNLGLEELGIELDPRGRIPVNTRFQTKIPNIYAIGDVVAGP
MLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYKVGK
FPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEMVNEAALALEYGASCEDI
ARVCHAHPTLSEAFREANLAASFGKSINF

# Drug_Target_124_Reaction:
protein N6-(dihydrolipoyl)lysine + NAD+ = protein N6-(lipoyl)lysine + NADH + H+ ALL_REAC (other) R00209 R01698 R03815 R07618

# Drug_Target_124_Signals:
None

# Drug_Target_124_Specific_Function:
Lipoamide dehydrogenase is a component of the glycine cleavage system as well as of the alpha-ketoacid dehydrogenase complexes

# Drug_Target_124_SwissProt_ID:
P09622

# Drug_Target_124_SwissProt_Name:
DLDH_HUMAN

# Drug_Target_124_Synonyms:
Dihydrolipoamide dehydrogenase
Dihydrolipoyl dehydrogenase, mitochondrial precursor
EC 1.8.1.4
Glycine cleavage system L protein

# Drug_Target_124_Theoretical_pI:
7.76

# Drug_Target_124_Transmembrane_Regions:
None

# Drug_Target_125_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_125_Chromosome_Location:
Not Available

# Drug_Target_125_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_125_Essentiality:
Non-Essential

# Drug_Target_125_GenAtlas_ID:
NDUFS3

# Drug_Target_125_GenBank_ID_Gene:
AF067139

# Drug_Target_125_GenBank_ID_Protein:
3337441

# Drug_Target_125_GeneCard_ID:
NDUFS3

# Drug_Target_125_Gene_Name:
NDUFS3

# Drug_Target_125_Gene_Sequence:
>795 bp
ATGGCGGCGGCGGCGGTAGCCAGGCTGTGGTGGCGCGGGATCTTGGGGGCCTCGGCGCTG
ACCAGGGGGACTGGGCGACCCTCCGTTCTGTTGCTGCCGGTGAGGCGGGAGAGCGCCGGG
GCCGACACGCGCCCCACTGTCAGACCACGGAATGATGTGGCCCACAAGCAGCTCTCAGCT
TTTGGAGAGTATGTGGCTGAAATCTTGCCCAAGTATGTCCAACAAGTTCAGGTGTCCTGC
TTCAATGAGTTAGAGGTCTGTATCCATCCTGATGGCGTCATCCCAGTGCTGACTTTCCTC
AGGGATCACACCAATGCACAGTTCAAATCTCTGGTTGACTTGACAGCAGTGGACGTCCCA
ACTCGGCAAAACCGTTTTGAGATTGTCTACAACCTGTTGTCTCTGCGCTTCAACTCACGG
ATCCGTGTGAAGACCTACACAGATGAGCTGACGCCCATTGAGTCTGCTGTCTCTGTGTTC
AAGGCAGCCAACTGGTATGAAAGGGAGATCTGGGACATGTTTGGAGTCTTCTTTGCTAAC
CACCCTGATCTAAGAAGGATCCTGACAGATTATGGCTTCGAGGGACATCCTTTCCGGAAA
GACTTTCCTCTATCTGGCTATGTTGAGTTACGTTATGATGATGAAGTGAAGCGGGTGGTG
GCAGAGCCGGTGGAGTTGGCCCAAGAGTTCCGCAAATTTGACCTGAACAGCCCCTGGGAG
GCTTTCCCAGTCTATCGCCAACCCCCGGAGAGTCTCAAGCTTGAAGCCGGAGACAAGAAG
CCTGATGCCAAGTAG

# Drug_Target_125_General_Function:
Energy production and conversion

# Drug_Target_125_General_References:
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.
10967146	Procaccio V, Lescuyer P, Bourges I, Beugnot R, Duborjal H, Depetris D, Mousson B, Montfort MF, Smeets H, De Coo R, Issartel JP: Human NDUFS3 gene coding for the 30-kDa subunit of mitochondrial complex I: genomic organization and expression. Mamm Genome. 2000 Sep;11(9):808-10.
9647766	Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J: cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed. Biochem Biophys Res Commun. 1998 Jun 29;247(3):751-8.

# Drug_Target_125_HGNC_ID:
HGNC:7710

# Drug_Target_125_HPRD_ID:
10355

# Drug_Target_125_ID:
214

# Drug_Target_125_Locus:
11p11.11

# Drug_Target_125_Molecular_Weight:
30242

# Drug_Target_125_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial

# Drug_Target_125_Number_of_Residues:
264

# Drug_Target_125_PDB_ID:
Not Available

# Drug_Target_125_Pathway:
Not Available

# Drug_Target_125_Pfam_Domain_Function:
PF00329	Complex1_30kDa

# Drug_Target_125_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial precursor
MAAAAVARLWWRGILGASALTRGTGRPSVLLLPVRRESAGADTRPTVRPRNDVAHKQLSA
FGEYVAEILPKYVQQVQVSCFNELEVCIHPDGVIPVLTFLRDHTNAQFKSLVDLTAVDVP
TRQNRFEIVYNLLSLRFNSRIRVKTYTDELTPIESAVSVFKAANWYEREIWDMFGVFFAN
HPDLRRILTDYGFEGHPFRKDFPLSGYVELRYDDEVKRVVAEPVELAQEFRKFDLNSPWE
AFPVYRQPPESLKLEAGDKKPDAK

# Drug_Target_125_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_125_Signals:
None

# Drug_Target_125_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_125_SwissProt_ID:
O75489

# Drug_Target_125_SwissProt_Name:
NDUS3_HUMAN

# Drug_Target_125_Synonyms:
CI-30kD
Complex I-30kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase iron-sulfur protein 3, mitochondrial precursor
NADH-ubiquinone oxidoreductase 30 kDa subunit

# Drug_Target_125_Theoretical_pI:
7.62

# Drug_Target_125_Transmembrane_Regions:
None

# Drug_Target_126_Cellular_Location:
Mitochondrion. Cytoplasm

# Drug_Target_126_Chromosome_Location:
Not Available

# Drug_Target_126_Drug_References:
17053903	Wan C, Li S, Wen L, Kong J, Wang K, Zhu Y: Damage of oxidative stress on mitochondria during microspores development in Honglian CMS line of rice. Plant Cell Rep. 2007 Mar;26(3):373-82. Epub 2006 Oct 12.
17502280	Knapp KG, Swartz JR: Evidence for an additional disulfide reduction pathway in Escherichia coli. J Biosci Bioeng. 2007 Apr;103(4):373-6.
17540766	Aon MA, Cortassa S, Maack C, O'Rourke B: Sequential opening of mitochondrial ion channels as a function of glutathione redox thiol status. J Biol Chem. 2007 Jul 27;282(30):21889-900. Epub 2007 May 31.
17550271	Cheng Z, Arscott LD, Ballou DP, Williams CH Jr: The relationship of the redox potentials of thioredoxin and thioredoxin reductase from Drosophila melanogaster to the enzymatic mechanism: reduced thioredoxin is the reductant of glutathione in Drosophila. Biochemistry. 2007 Jul 3;46(26):7875-85. Epub 2007 Jun 6.
17565998	Gazaryan IG, Krasinskaya IP, Kristal BS, Brown AM: Zinc irreversibly damages major enzymes of energy production and antioxidant defense prior to mitochondrial permeability transition. J Biol Chem. 2007 Aug 17;282(33):24373-80. Epub 2007 Jun 12.

# Drug_Target_126_Essentiality:
Non-Essential

# Drug_Target_126_GenAtlas_ID:
GSR

# Drug_Target_126_GenBank_ID_Gene:
X15722

# Drug_Target_126_GenBank_ID_Protein:
31825

# Drug_Target_126_GeneCard_ID:
GSR

# Drug_Target_126_Gene_Name:
GSR

# Drug_Target_126_Gene_Sequence:
>1569 bp
ATGGCCCTGCTGCCCCGAGCCCTGAGCGCCGGCGCGGGACCGAGCTGGCGGCGGGCGGCG
CGCGCCTTCCGAGGCTTCCTGCTGCTTCTGCCCGAGCCCGCGGCCCTCACGCGCGCCCTC
TCCCGTGCCATGGCCTGCAGGCAGGAGCCGCAGCCGCAGGGCCCGCCGCCCGCTGCTGGC
GCCGTGGCCTCCTATGACTACCTGGTGATCGGGGGCGGCTCGGGCGGGCTGGCCAGCGCG
CGCAGGGCGGCCGAGCTGGGTGCCAGGGCCGCCGTGGTGGAGAGCCACAAGCTGGGTGGC
ACTTGCGTGAATGTTGGATGTGTACCCAAAAAGGTAATGTGGAACACAGCTGTCCACTCT
GAATTCATGCATGATCATGCTGATTATGGCTTTCCAAGTTGTGAGGGTAAATTCAATTGG
CGTGTTATTAAGGAAAAGCGGGATGCCTATGTGAGCCGCCTGAATGCCATCTATCAAAAC
AATCTCACCAAGTCCCATATAGAAATCATCCGTGGCCATGCAGCCTTCACGAGTGATCCC
AAGCCCACAATAGAGGTCAGTGGGAAAAAGTACACCGCCCCACACATCCTGATCGCCACA
GGTGGTATGCCCTCCACCCCTCATGAGAGCCAGATCCCCGGTGCCAGCTTAGGAATAACC
AGCGATGGATTTTTTCAGCTGGAAGAATTGCCCGGCCGCAGCGTCATTGTTGGTGCAGGT
TACATTGCTGTGGAGATGGCAGGGATCCTGTCAGCCCTGGGTTCTAAGACATCACTGATG
ATACGGCATGATAAGGTACTTAGAAGTTTTGATTCAATGATCAGCACCAACTGCACGGAG
GAGCTGGAGAACGCTGGCGTGGAGGTGCTGAAGTTCTCCCAGGTCAAGGAGGTTAAAAAG
ACTTTGTCGGGCTTGGAAGTCAGCATGGTTACTGCAGTTCCCGGTAGGCTACCAGTCATG
ACCATGATTCCAGATGTTGACTGCCTGCTCTGGGCCATTGGGCGGGTCCCGAATACCAAG
GACCTGAGTTTAAACAAACTGGGGATTCAAACCGATGACAAGGGTCATATCATCGTAGAC
GAATTCCAGAATACCAACGTCAAAGGCATCTATGCAGTTGGGGATGTATGTGGAAAAGCT
CTTCTTACTCCAGTTGCAATAGCTGCTGGCCGAAAACTTGCCCATCGACTTTTTGAATAT
AAGGAAGATTCCAAATTAGATTATAACAACATCCCAACTGTGGTCTTCAGCCACCCCCCT
ATTGGGACAGTGGGACTCACGGAAGATGAAGCCATTCATAAATATGGAATAGAAAATGTG
AAGACCTATTCAACGAGCTTTACCCCGATGTATCACGCAGTTACCAAAAGGAAAACAAAA
TGTGTGATGAAAATGGTCTGTGCTAACAAGGAAGAAAAGGTGGTTGGGATCCATATGCAG
GGACTTGGGTGTGATGAAATGCTGCAGGGTTTTGCTGTTGCAGTGAAGATGGGAGCAACG
AAGGCAGACTTTGACAACACAGTCGCCATTCACCCTACCTCTTCAGAAGAGCTGGTCACA
CTTCGTTGA

# Drug_Target_126_General_Function:
RNA processing and modification

# Drug_Target_126_General_References:
10708558	Kelner MJ, Montoya MA: Structural organization of the human glutathione reductase gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem Biophys Res Commun. 2000 Mar 16;269(2):366-8.
2185014	Tutic M, Lu XA, Schirmer RH, Werner D: Cloning and sequencing of mammalian glutathione reductase cDNA. Eur J Biochem. 1990 Mar 30;188(3):523-8.
3656429	Karplus PA, Schulz GE: Refined structure of glutathione reductase at 1.54 A resolution. J Mol Biol. 1987 Jun 5;195(3):701-29.
7060551	Krauth-Siegel RL, Blatterspiel R, Saleh M, Schiltz E, Schirmer RH, Untucht-Grau R: Glutathione reductase from human erythrocytes. The sequences of the NADPH domain and of the interface domain. Eur J Biochem. 1982 Jan;121(2):259-67.
7334521	Thieme R, Pai EF, Schirmer RH, Schulz GE: Three-dimensional structure of glutathione reductase at 2 A resolution. J Mol Biol. 1981 Nov 15;152(4):763-82.
8626496	Savvides SN, Karplus PA: Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor. J Biol Chem. 1996 Apr 5;271(14):8101-7.
9174360	Stoll VS, Simpson SJ, Krauth-Siegel RL, Walsh CT, Pai EF: Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. Biochemistry. 1997 May 27;36(21):6437-47.
923580	Krohne-Ehrich G, Schirmer RH, Untucht-Grau R: Glutathione reductase from human erythrocytes. Isolation of the enzyme and sequence analysis of the redox-active peptide. Eur J Biochem. 1977 Oct 17;80(1):65-71.
9546215	Becker K, Savvides SN, Keese M, Schirmer RH, Karplus PA: Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nat Struct Biol. 1998 Apr;5(4):267-71.

# Drug_Target_126_HGNC_ID:
HGNC:4623

# Drug_Target_126_HPRD_ID:
00704

# Drug_Target_126_ID:
714

# Drug_Target_126_Locus:
8p21.1

# Drug_Target_126_Molecular_Weight:
56258

# Drug_Target_126_Name:
Glutathione reductase, mitochondrial

# Drug_Target_126_Number_of_Residues:
522

# Drug_Target_126_PDB_ID:
1BWC

# Drug_Target_126_Pathway:
Not Available

# Drug_Target_126_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_126_Protein_Sequence:
>Glutathione reductase, mitochondrial precursor
MALLPRALSAGAGPSWRRAARAFRGFLLLLPEPAALTRALSRAMACRQEPQPQGPPPAAG
AVASYDYLVIGGGSGGLASARRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHS
EFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDP
KPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAG
YIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKK
TLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVD
EFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPP
IGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQ
GLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR

# Drug_Target_126_Reaction:
2 glutathione + NADP+ = glutathione disulfide + NADPH + H+

# Drug_Target_126_Signals:
None

# Drug_Target_126_Specific_Function:
Maintains high levels of reduced glutathione in the cytosol

# Drug_Target_126_SwissProt_ID:
P00390

# Drug_Target_126_SwissProt_Name:
GSHR_HUMAN

# Drug_Target_126_Synonyms:
EC 1.8.1.7
GR
GRase
Glutathione reductase, mitochondrial precursor

# Drug_Target_126_Theoretical_pI:
8.66

# Drug_Target_126_Transmembrane_Regions:
None

# Drug_Target_127_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_127_Chromosome_Location:
Not Available

# Drug_Target_127_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_127_Essentiality:
Non-Essential

# Drug_Target_127_GenAtlas_ID:
NDUFA12

# Drug_Target_127_GenBank_ID_Gene:
AF217092

# Drug_Target_127_GenBank_ID_Protein:
9651637

# Drug_Target_127_GeneCard_ID:
NDUFA12

# Drug_Target_127_Gene_Name:
NDUFA12

# Drug_Target_127_Gene_Sequence:
>438 bp
ATGGAGTTAGTGCAGGTCCTGAAACGCGGGCTGCAGCAGATCACCGGCCACGGCGGTCTC
CGAGGCTATCTACGGGTTTTTTTCAGGACAAATGATGCGAAGGTTGGTACATTAGTGGGG
GAAGACAAATATGGAAACAAATACTATGAAGACAACAAGCAATTTTTTGGCCGTCACCGA
TGGGTTGTATATACTACTGAAATGAATGGCAAAAACACATTCTGGGATGTGGATGGAAGC
ATGGTGCCTCCTGAATGGCATCGTTGGCTTCACAGTATGACTGATGATCCTCCAACAACA
AAACCACTTACTGCTCGTAAATTCATTTGGACGAACCATAAATTCAACGTGACTGGCACC
CCAGAACAATATGTACCTTATTCTACCACTAGAAAGAAGATTCAGGAGTGGATCCCACCT
TCAACACCTTACAAGTAA

# Drug_Target_127_General_Function:
Energy production and conversion

# Drug_Target_127_General_References:
10830904	Triepels R, Smeitink J, Loeffen J, Smeets R, Trijbels F, van den Heuvel L: Characterization of the human complex I NDUFB7 and 17.2-kDa cDNAs and mutational analysis of 19 genes of the HP fraction in complex I-deficient-patients. Hum Genet. 2000 Apr;106(4):385-91.
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.

# Drug_Target_127_HGNC_ID:
HGNC:23987

# Drug_Target_127_HPRD_ID:
16781

# Drug_Target_127_ID:
829

# Drug_Target_127_Locus:
12q22

# Drug_Target_127_Molecular_Weight:
17115

# Drug_Target_127_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12

# Drug_Target_127_Number_of_Residues:
145

# Drug_Target_127_PDB_ID:
Not Available

# Drug_Target_127_Pathway:
Not Available

# Drug_Target_127_Pfam_Domain_Function:
PF05071	NDUFA12

# Drug_Target_127_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12
MELVQVLKRGLQQITGHGGLRGYLRVFFRTNDAKVGTLVGEDKYGNKYYEDNKQFFGRHR
WVVYTTEMNGKNTFWDVDGSMVPPEWHRWLHSMTDDPPTTKPLTARKFIWTNHKFNVTGT
PEQYVPYSTTRKKIQEWIPPSTPYK

# Drug_Target_127_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_127_Signals:
None

# Drug_Target_127_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_127_SwissProt_ID:
Q9UI09

# Drug_Target_127_SwissProt_Name:
NDUAC_HUMAN

# Drug_Target_127_Synonyms:
13 kDa differentiation- associated protein
CI-B17.2
CIB17.2
Complex I-B17.2
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase subunit B17.2

# Drug_Target_127_Theoretical_pI:
10.10

# Drug_Target_127_Transmembrane_Regions:
None

# Drug_Target_128_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_128_Chromosome_Location:
Not Available

# Drug_Target_128_Drug_References:
10070614	Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L: The human NADH: ubiquinone oxidoreductase NDUFS5 (15 kDa) subunit: cDNA cloning, chromosomal localization, tissue distribution and the absence of mutations in isolated complex I-deficient patients. J Inherit Metab Dis. 1999 Feb;22(1):19-28.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_128_Essentiality:
Non-Essential

# Drug_Target_128_GenAtlas_ID:
NDUFS5

# Drug_Target_128_GenBank_ID_Gene:
AF047434

# Drug_Target_128_GenBank_ID_Protein:
2911482

# Drug_Target_128_GeneCard_ID:
NDUFS5

# Drug_Target_128_Gene_Name:
NDUFS5

# Drug_Target_128_Gene_Sequence:
>321 bp
ATGCCTTTCTTGGACATCCAGAAAAGGTTCGGCCTTAACATAGATCGATGGTTGACAATC
CAGAGTGGTGAACAGCCCTACAAGATGGCTGGTCGATGCCATGCTTTTGAAAAAGAATGG
ATAGAATGTGCACATGGAATCGGTTATACTCGGGCAGAGAAAGAGTGCAAGATAGAATAT
GATGATTTCGTAGAGTGTTTGCTTCGGCAGAAAACGATGAGACGTGCAGGTACCATCAGG
AAGCAGCGGGATAAGCTGATAAAGGAAGGAAAGTACACCCCTCCACCTCACCACATTGGC
AAGGGGGAGCCTCGGCCCTGA

# Drug_Target_128_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_128_General_References:
10070614	Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L: The human NADH: ubiquinone oxidoreductase NDUFS5 (15 kDa) subunit: cDNA cloning, chromosomal localization, tissue distribution and the absence of mutations in isolated complex I-deficient patients. J Inherit Metab Dis. 1999 Feb;22(1):19-28.
9653160	Mao M, Fu G, Wu JS, Zhang QH, Zhou J, Kan LX, Huang QH, He KL, Gu BW, Han ZG, Shen Y, Gu J, Yu YP, Xu SH, Wang YX, Chen SJ, Chen Z: Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8175-80.

# Drug_Target_128_HGNC_ID:
HGNC:7712

# Drug_Target_128_HPRD_ID:
11961

# Drug_Target_128_ID:
99

# Drug_Target_128_Locus:
1p34.2-p33

# Drug_Target_128_Molecular_Weight:
12386

# Drug_Target_128_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 5

# Drug_Target_128_Number_of_Residues:
105

# Drug_Target_128_PDB_ID:
Not Available

# Drug_Target_128_Pathway:
Not Available

# Drug_Target_128_Pfam_Domain_Function:
Not Available

# Drug_Target_128_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 5
PFLDIQKRFGLNIDRWLTIQSGEQPYKMAGRCHAFEKEWIECAHGIGYTRAEKECKIEYD
DFVECLLRQKTMRRAGTIRKQRDKLIKEGKYTPPPHHIGKGEPRP

# Drug_Target_128_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_128_Signals:
None

# Drug_Target_128_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_128_SwissProt_ID:
O43920

# Drug_Target_128_SwissProt_Name:
NDUS5_HUMAN

# Drug_Target_128_Synonyms:
CI-15 kDa
Complex I-15 kDa
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase 15 kDa subunit

# Drug_Target_128_Theoretical_pI:
9.54

# Drug_Target_128_Transmembrane_Regions:
None

# Drug_Target_129_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_129_Chromosome_Location:
Not Available

# Drug_Target_129_Drug_References:
11181577	Petruzzella V, Vergari R, Puzziferri I, Boffoli D, Lamantea E, Zeviani M, Papa S: A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome. Hum Mol Genet. 2001 Mar 1;10(5):529-35.
11860175	Papa S, Sardanelli AM, Scacco S, Petruzzella V, Technikova-Dobrova Z, Vergari R, Signorile A: The NADH: ubiquinone oxidoreductase (complex I) of the mammalian respiratory chain and the cAMP cascade. J Bioenerg Biomembr. 2002 Feb;34(1):1-10.
11864782	Raha S, Myint AT, Johnstone L, Robinson BH: Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase. Free Radic Biol Med. 2002 Mar 1;32(5):421-30.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_129_Essentiality:
Non-Essential

# Drug_Target_129_GenAtlas_ID:
NDUFS4

# Drug_Target_129_GenBank_ID_Gene:
AF020351

# Drug_Target_129_GenBank_ID_Protein:
2655053

# Drug_Target_129_GeneCard_ID:
NDUFS4

# Drug_Target_129_Gene_Name:
NDUFS4

# Drug_Target_129_Gene_Sequence:
>528 bp
ATGGCGGCGGTCTCAATGTCAGTGGTACTGAGGCAGACGTTGTGGCGGAGAAGGGCAGTG
GCTGTAGCTGCCCTTTCCGTTTCCAGGGTTCCGACCAGGTCGTTGAGGACTTCCACATGG
AGATTGGCACAGGACCAGACTCAAGACACACAACTCATAACAGTTGATGAAAAATTGGAT
ATCACTACTTTAACTGGCGTTCCAGAAGAGCATATAAAAACTAGAAAAGTCAGGATCTTT
GTTCCTGCTCGCAATAACATGCAGTCTGGAGTAAACAACACAAAGAAATGGAAGATGGAG
TTTGATACCAGGGAGCGATGGGAAAATCCTTTGATGGGTTGGGCATCAACGGCTGATCCC
TTATCCAACATGGTTCTAACCTTCAGTACTAAAGAAGATGCAGTTTCCTTTGCAGAAAAA
AATGGATGGAGCTATGACATTGAAGAGAGGAAGGTTCCAAAACCCAAGTCCAAGTCTTAT
GGTGCAAACTTTTCTTGGAACAAAAGAACAAGAGTATCCACAAAATAG

# Drug_Target_129_General_Function:
Involved in oxidoreductase activity, acting on NADH or NADPH

# Drug_Target_129_General_References:
9463323	van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J: Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. Am J Hum Genet. 1998 Feb;62(2):262-8.

# Drug_Target_129_HGNC_ID:
HGNC:7711

# Drug_Target_129_HPRD_ID:
04073

# Drug_Target_129_ID:
555

# Drug_Target_129_Locus:
5q11.1

# Drug_Target_129_Molecular_Weight:
20108

# Drug_Target_129_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial

# Drug_Target_129_Number_of_Residues:
175

# Drug_Target_129_PDB_ID:
Not Available

# Drug_Target_129_Pathway:
Not Available

# Drug_Target_129_Pfam_Domain_Function:
PF04800	ETC_C1_NDUFA4

# Drug_Target_129_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial precursor
MAAVSMSVVLRQTLWRRRAVAVAALSVSRVPTRSLRTSTWRLAQDQTQDTQLITVDEKLD
ITTLTGVPEEHIKTRKVRIFVPARNNMQSGVNNTKKWKMEFDTRERWENPLMGWASTADP
LSNMVLTFSTKEDAVSFAEKNGWSYDIEERKVPKPKSKSYGANFSWNKRTRVSTK

# Drug_Target_129_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_129_Signals:
None

# Drug_Target_129_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_129_SwissProt_ID:
O43181

# Drug_Target_129_SwissProt_Name:
NDUS4_HUMAN

# Drug_Target_129_Synonyms:
CI- AQDQ
CI-18 kDa
Complex I-18 kDa
Complex I-AQDQ
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase iron-sulfur protein 4, mitochondrial precursor
NADH-ubiquinone oxidoreductase 18 kDa subunit

# Drug_Target_129_Theoretical_pI:
11.02

# Drug_Target_129_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
HSD17B10

# Drug_Target_12_GenBank_ID_Gene:
U96132

# Drug_Target_12_GenBank_ID_Protein:
2558754

# Drug_Target_12_GeneCard_ID:
HSD17B10

# Drug_Target_12_Gene_Name:
HSD17B10

# Drug_Target_12_Gene_Sequence:
>786 bp
ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG
GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG
GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC
GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA
AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG
TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG
AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA
CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG
GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG
CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG
TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA
GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC
ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG
CCTTGA

# Drug_Target_12_General_Function:
Lipid transport and metabolism

# Drug_Target_12_General_References:
12696021	Ofman R, Ruiter JP, Feenstra M, Duran M, Poll-The BT, Zschocke J, Ensenauer R, Lehnert W, Sass JO, Sperl W, Wanders RJ: 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am J Hum Genet. 2003 May;72(5):1300-7. Epub 2003 Apr 14.
9338779	Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D: An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 1997 Oct 16;389(6652):689-95.
9553139	He XY, Schulz H, Yang SY: A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer's disease. J Biol Chem. 1998 Apr 24;273(17):10741-6.
9671743	Miller AP, Willard HF: Chromosomal basis of X chromosome inactivation: identification of a multigene domain in Xp11.21-p11.22 that escapes X inactivation. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8709-14.

# Drug_Target_12_HGNC_ID:
HGNC:4800

# Drug_Target_12_HPRD_ID:
02223

# Drug_Target_12_ID:
350

# Drug_Target_12_Locus:
Xp11.2

# Drug_Target_12_Molecular_Weight:
26792

# Drug_Target_12_Name:
3-hydroxyacyl-CoA dehydrogenase type-2

# Drug_Target_12_Number_of_Residues:
260

# Drug_Target_12_PDB_ID:
1SO8

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_12_Protein_Sequence:
>3-hydroxyacyl-CoA dehydrogenase type-2
AAACRSVKGLVAVITGGASGLGLATAERLVGQGASAVLLDLPNSGGEAQAKKLGNNCVFA
PADVTSEKDVQTALALAKGKFGRVDVAVNCAGIAVASKTYNLKKGQTHTLEDFQRVLDVN
LMGTFNVIRLVAGEMGQNEPDQGGQRGVIINTASVAAFEGQVGQAAYSASKGGIVGMTLP
IARDLAPIGIRVMTIAPGLFGTPLLTSLPEKVCNFLASQVPFPSRLGDPAEYAHLVQAII
ENPFLNGEVIRLDGAIRMQP

# Drug_Target_12_Reaction:
(S)-3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Binds intracellular amyloid-beta. By interacting with amyloid-beta, it may contribute to the neuronal dysfunction associated with Alzheimer disease (AD)

# Drug_Target_12_SwissProt_ID:
Q99714

# Drug_Target_12_SwissProt_Name:
HCD2_HUMAN

# Drug_Target_12_Synonyms:
3-hydroxy-2-methylbutyryl- CoA dehydrogenase
3-hydroxyacyl- CoA dehydrogenase type II
EC 1.1.1.178
EC 1.1.1.35
Endoplasmic reticulum-associated amyloid beta-peptide-binding protein
Short-chain type dehydrogenase/reductase XH98G2
Type II HADH

# Drug_Target_12_Theoretical_pI:
7.94

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_130_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane
peripheral membrane protein

# Drug_Target_130_Chromosome_Location:
Not Available

# Drug_Target_130_Drug_References:
14662656	Grad LI, Lemire BD: Mitochondrial complex I mutations in Caenorhabditis elegans produce cytochrome c oxidase deficiency, oxidative stress and vitamin-responsive lactic acidosis. Hum Mol Genet. 2004 Feb 1;13(3):303-14. Epub 2003 Dec 8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8288251	Ali ST, Duncan AM, Schappert K, Heng HH, Tsui LC, Chow W, Robinson BH: Chromosomal localization of the human gene encoding the 51-kDa subunit of mitochondrial complex I (NDUFV1) to 11q13. Genomics. 1993 Nov;18(2):435-9.
9571201	Schuelke M, Loeffen J, Mariman E, Smeitink J, van den Heuvel L: Cloning of the human mitochondrial 51 kDa subunit (NDUFV1) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma-interferon inducible protein (IP-30) precursor: is this a link between mitochondrial myopathy and inflammation? Biochem Biophys Res Commun. 1998 Apr 17;245(2):599-606.

# Drug_Target_130_Essentiality:
Non-Essential

# Drug_Target_130_GenAtlas_ID:
NDUFV1

# Drug_Target_130_GenBank_ID_Gene:
Y17379

# Drug_Target_130_GenBank_ID_Protein:
3184148

# Drug_Target_130_GeneCard_ID:
NDUFV1

# Drug_Target_130_Gene_Name:
NDUFV1

# Drug_Target_130_Gene_Sequence:
>1395 bp
ATGCTGGCAACACGGCGGCTGCTCGGCTGGTCGCTTCCCGCGCGGGTATCTGTGCGTTTC
AGCGGCGACACGACAGCACCCAAGAAAACCTCATTTGGCTCGCTGAAGGATGAAGACCGG
ATTTTCACCAACCTGTACGGCCGCCATGACTGGAGGCTGAAAGGTTCCCTGAGTCGAGGT
GACTGGTACAAGACAAAGGAGATCCTGCTGAAGGGGCCCGACTGGATCCTGGGCGAGATC
AAGACATCGGGTTTGAGGGGCCGTGGAGGCGCTGGCTTCCCCACTGGCCTCAAGTGGAGC
TTCATGAATAAGCCCTCAGATGGCAGGCCCAAGTATCTGGTGGTGAACGCAGACGAGGGG
GAGCCGGGCACCTGCAAGGACCGGGAGATCTTACGCCATGATCCTCACAAGCTGCTGGAA
GGCTGCCTGGTGGGGGGCCGGGCCATGGGCGCCCGCGCTGCCTATATCTACATCCGAGGG
GAATTCTACAATGAGGCCTCCAATCTGCAGGTGGCCATCCGAGAGGCCTATGAGGCAGGT
CTGATTGGCAAGAATGCTTGTGGCTCTGGCTATGATTTTGACGTGTTTGTGGTGCGCGGG
GCTGGGGCCTACATCTGTGGAGAGGAGACAGCGCTCATCGAGTCCATTGAGGGCAAGCAG
GGCAAGCCCCGCCTGAAGCCCCCCTTCCCCGCAGACGTGGGAGTGTTTGGCTGCCCCACA
ACTGTGGCCAACGTGGAGACAGTGGCAGTGTCCCCCACAATCTGCCGCCGTGGAGGTACC
TGGTTTGCTGGCTTTGGCAGAGAACGCAACTCAGGCACCAAACTATTCAACATCTCTGGC
CATGTCAACCACCCTTGCACTGTGGAGGAGGAGATGTCTGTGCCCTTGAAAGAACTGATT
GAGAAGCATGCTGGGGGTGTCACGGGCGGCTGGGACAACCTCCTTGCTGTGATCCCTGGC
GGCTCGTCTACCCCACTGATCCCCAAGTCTGTGTGTGAGACGGTGCTGATGGACTTCGAT
GCGCTGGTGCAGGCACAGACAGGCCTGGGCACAGCTGCGGTGATCGTCATGGACCGCTCG
ACGGACATCGTGAAAGCCATCGCCCGCCTCATTGAGTTCTATAAGCACGAGAGCTGTGGC
CAGTGTACCCCATGCCGTGAGGGTGTGGACTGGATGAACAAGGTGATGGCACGTTTCGTG
AGGGGGGATGCCCGGCCGGCCGAGATCGACTCCCTGTGGGAGATCAGCAAGCAGATAGAA
GGCCATACGATTTGTGCTCTGGGTGACGGGGCCGCCTGGCCTGTGCAGGGTCTGATCCGC
CACTTTCGGCCGGAGCTCGAGGAGCGGATGCAGCGGTTTGCCCAGCAGCATCAGGCCCGG
CAGGCTGCCTCTTAG

# Drug_Target_130_General_Function:
Energy production and conversion

# Drug_Target_130_General_References:
10080174	Schuelke M, Smeitink J, Mariman E, Loeffen J, Plecko B, Trijbels F, Stockler-Ipsiroglu S, van den Heuvel L: Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. Nat Genet. 1999 Mar;21(3):260-1.
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.
1478657	Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B: The human mitochondrial NADH: ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13. Genomics. 1992 Dec;14(4):1116-8.
8288251	Ali ST, Duncan AM, Schappert K, Heng HH, Tsui LC, Chow W, Robinson BH: Chromosomal localization of the human gene encoding the 51-kDa subunit of mitochondrial complex I (NDUFV1) to 11q13. Genomics. 1993 Nov;18(2):435-9.
9571201	Schuelke M, Loeffen J, Mariman E, Smeitink J, van den Heuvel L: Cloning of the human mitochondrial 51 kDa subunit (NDUFV1) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma-interferon inducible protein (IP-30) precursor: is this a link between mitochondrial myopathy and inflammation? Biochem Biophys Res Commun. 1998 Apr 17;245(2):599-606.

# Drug_Target_130_HGNC_ID:
HGNC:7716

# Drug_Target_130_HPRD_ID:
01191

# Drug_Target_130_ID:
539

# Drug_Target_130_Locus:
11q13

# Drug_Target_130_Molecular_Weight:
50818

# Drug_Target_130_Name:
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial

# Drug_Target_130_Number_of_Residues:
464

# Drug_Target_130_PDB_ID:
Not Available

# Drug_Target_130_Pathway:
Not Available

# Drug_Target_130_Pfam_Domain_Function:
PF01512	Complex1_51K

# Drug_Target_130_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial precursor
MLATRRLLGWSLPARVSVRFSGDTTAPKKTSFGSLKDEDRIFTNLYGRHDWRLKGSLSRG
DWYKTKEILLKGPDWILGEIKTSGLRGRGGAGFPTGLKWSFMNKPSDGRPKYLVVNADEG
EPGTCKDREILRHDPHKLLEGCLVGGRAMGARAAYIYIRGEFYNEASNLQVAIREAYEAG
LIGKNACGSGYDFDVFVVRGAGAYICGEETALIESIEGKQGKPRLKPPFPADVGVFGCPT
TVANVETVAVSPTICRRGGTWFAGFGRERNSGTKLFNISGHVNHPCTVEEEMSVPLKELI
EKHAGGVTGGWDNLLAVIPGGSSTPLIPKSVCETVLMDFDALVQAQTGLGTAAVIVMDRS
TDIVKAIARLIEFYKHESCGQCTPCREGVDWMNKVMARFVRGDARPAEIDSLWEISKQIE
GHTICALGDGAAWPVQGLIRHFRPELEERMQRFAQQHQARQAAS

# Drug_Target_130_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_130_Signals:
None

# Drug_Target_130_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_130_SwissProt_ID:
P49821

# Drug_Target_130_SwissProt_Name:
NDUV1_HUMAN

# Drug_Target_130_Synonyms:
CI-51kD
Complex I-51kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase flavoprotein 1
NADH dehydrogenase flavoprotein 1, mitochondrial precursor
NADH-ubiquinone oxidoreductase 51 kDa subunit

# Drug_Target_130_Theoretical_pI:
8.29

# Drug_Target_130_Transmembrane_Regions:
None

# Drug_Target_131_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_131_Chromosome_Location:
Not Available

# Drug_Target_131_Drug_References:
10716640	Paunesku T, Chang-Liu CM, Shearin-Jones P, Watson C, Milton J, Oryhon J, Salbego D, Milosavljevic A, Woloschak GE: Identification of genes regulated by UV/salicylic acid. Int J Radiat Biol. 2000 Feb;76(2):189-98.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_131_Essentiality:
Non-Essential

# Drug_Target_131_GenAtlas_ID:
NDUFV2

# Drug_Target_131_GenBank_ID_Gene:
M22538

# Drug_Target_131_GenBank_ID_Protein:
188852

# Drug_Target_131_GeneCard_ID:
NDUFV2

# Drug_Target_131_Gene_Name:
NDUFV2

# Drug_Target_131_Gene_Sequence:
>750 bp
ATGTTCTTCTCCGCGGCGCTCCGGGCCCGGGCGGCTGGCCTCACCGCCCACTGGGGAAGA
CATGTAAGGAATTTGCATAAGACAGCTATGCAAAATGGAGCTGGAGGAGCTTTATTTGTG
CACAGAGATACTCCTGAGAATAACCCTGATACTCCATTTGATTTCACACCAGAAAACTAT
AAGAGGATAGAGGCAATTGTAAAAAACTATCCAGAAGGCCATAAAGCAGCAGCTGTTCTT
CCAGTCCTGGATTTAGCCCAAAGGCAGAATGGGTGGTTGCCCATCTCTGCTATGAACAAG
GTTGCAGAAGTTTTACAAGTACCTCCAATGAGAGTATATGAAGTAGCAACTTTTTATACA
ATGTATAATCGAAAGCCAGTTGGAAAGTATCACATTCAGGTCTGCACTACTACACCCTGC
ATGCTTCGAAACTCTGACAGCATACTGGAGGCCATTCAGAAAAAGCTTGGAATAAAGGTT
GGGGAGACTACACCTGACAAACTTTTCACTCTTATAGAAGTGGAATGTTTAGGGGCCTGT
GTGAACGCACCAATGGTTCAAATAAATGACAATTACTATGAGGATTTGACAGCTAAGGAT
ATTGAAGAAATTATTGATGAGCTCAAGGCTGGCAAAATCCCAAAACCAGGGCCAAGGAGT
GGACGCTTCTCTTGTGAGCCAGCTGGAGGTCTTACCTCTTTGACTGAACCACCCAAGGGA
CCTGGATTTGGTGTACAAGCAGGCCTTTAA

# Drug_Target_131_General_Function:
Energy production and conversion

# Drug_Target_131_General_References:
2500970	Pilkington SJ, Walker JE: Mitochondrial NADH-ubiquinone reductase: complementary DNA sequences of import precursors of the bovine and human 24-kDa subunit. Biochemistry. 1989 Apr 18;28(8):3257-64.

# Drug_Target_131_HGNC_ID:
HGNC:7717

# Drug_Target_131_HPRD_ID:
02757

# Drug_Target_131_ID:
152

# Drug_Target_131_Locus:
18p11.31-p11.2

# Drug_Target_131_Molecular_Weight:
27392

# Drug_Target_131_Name:
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial

# Drug_Target_131_Number_of_Residues:
249

# Drug_Target_131_PDB_ID:
Not Available

# Drug_Target_131_Pathway:
Not Available

# Drug_Target_131_Pfam_Domain_Function:
PF01257	Complex1_24kDa

# Drug_Target_131_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial precursor
MFFSAALRARAAGLTAHWGRHVRNLHKTVMQNGAGGALFVHRDTPENNPDTPFDFTPENY
KRIEAIVKNYPEGHKAAAVLPVLDLAQRQNGWLPISAMNKVAEVLQVPPMRVYEVATFYT
MYNRKPVGKYHIQVCTTTPCMLRNSDSILEAIQKKLGIKVGETTPDKLFTLIEVECLGAC
VNAPMVQINDNYYEDLTAKDIEEIIDELKAGKIPKPGPRSGRFSCEPAGGLTSLTEPPKG
PGFGVQAGL

# Drug_Target_131_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_131_Signals:
None

# Drug_Target_131_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_131_SwissProt_ID:
P19404

# Drug_Target_131_SwissProt_Name:
NDUV2_HUMAN

# Drug_Target_131_Synonyms:
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase flavoprotein 2, mitochondrial precursor
NADH-ubiquinone oxidoreductase 24 kDa subunit

# Drug_Target_131_Theoretical_pI:
8.21

# Drug_Target_131_Transmembrane_Regions:
None

# Drug_Target_132_Cellular_Location:
Mitochondrion
matrix side. Nucleus. May
mitochondrial inner membrane
single-pass membrane protein

# Drug_Target_132_Chromosome_Location:
Not Available

# Drug_Target_132_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_132_Essentiality:
Non-Essential

# Drug_Target_132_GenAtlas_ID:
NDUFA13

# Drug_Target_132_GenBank_ID_Gene:
AF286697

# Drug_Target_132_GenBank_ID_Protein:
11055599

# Drug_Target_132_GeneCard_ID:
NDUFA13

# Drug_Target_132_Gene_Name:
NDUFA13

# Drug_Target_132_Gene_Sequence:
>435 bp
ATGGCGGCGTCAAAGGTGAAGCAGGACATGCCTCCGCCGGGGGGCTATGGGCCCATCGAC
TACAAACGGAACTTGCCGCGTCGAGGACTGTCGGGCTACAGCATGCTGGCCATAGGGATT
GGAACCCTGATCTACGGGCACTGGAGCATAATGAAGTGGAACCGTGAGCGCAGGCGCCTA
CAAATCGAGGACTTCGAGGCTCGCATCGCGCTGTTGCCACTGTTACAGGCAGAAACCGAC
CGGAGGACCTTGCAGATGCTTCGGGAGAACCTGGAGGAGGAGGCCATCATCATGAAGGAC
GTGCCCGACTGGAAGGTGGGGGAGTCTGTGTTCCACACAACCCGCTGGGTGCCCCCCTTG
ATCGGGGAGCTGTACGGGCTGCGCACCACAGAGGAGGCTCTCCATGCCAGCCACGGCTTC
ATGTGGTACACGTAG

# Drug_Target_132_General_Function:
Involved in ATP binding

# Drug_Target_132_General_References:
10810093	Lai CH, Chou CY, Ch'ang LY, Liu CS, Lin W: Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome Res. 2000 May;10(5):703-13.
10924506	Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV: Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem. 2000 Oct 27;275(43):33416-26.
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.

# Drug_Target_132_HGNC_ID:
HGNC:17194

# Drug_Target_132_HPRD_ID:
09452

# Drug_Target_132_ID:
582

# Drug_Target_132_Locus:
19p13.2

# Drug_Target_132_Molecular_Weight:
16567

# Drug_Target_132_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13

# Drug_Target_132_Number_of_Residues:
143

# Drug_Target_132_PDB_ID:
Not Available

# Drug_Target_132_Pathway:
Not Available

# Drug_Target_132_Pfam_Domain_Function:
PF06212	GRIM-19

# Drug_Target_132_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13
AASKVKQDMPPPGGYGPIDYKRNLPRRGLSGYSMLAIGIGTLIYGHWSIMKWNRERRRLQ
IEDFEARIALLPLLQAETDRRTLQMLRENLEEEAIIMKDVPDWKVGESVFHTTRWVPPLI
GELYGLRTTEEALHASHGFMWYT

# Drug_Target_132_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_132_Signals:
None

# Drug_Target_132_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death. This apoptotic activity is inhibited by interaction with viral IRF1. Prevents the transactivation of STAT3 target genes. May play a role in CARD15- mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes

# Drug_Target_132_SwissProt_ID:
Q9P0J0

# Drug_Target_132_SwissProt_Name:
NDUAD_HUMAN

# Drug_Target_132_Synonyms:
CI-B16.6
Cell death- regulatory protein GRIM-19
Complex I-B16.6
EC 1.6.5.3
EC 1.6.99.3
GRIM-19
Gene associated with retinoic- interferon-induced mortality 19 protein
NADH-ubiquinone oxidoreductase B16.6 subunit

# Drug_Target_132_Theoretical_pI:
8.84

# Drug_Target_132_Transmembrane_Regions:
29-50

# Drug_Target_133_Cellular_Location:
Not Available

# Drug_Target_133_Chromosome_Location:
Not Available

# Drug_Target_133_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_133_Essentiality:
Non-Essential

# Drug_Target_133_GenAtlas_ID:
CDO1

# Drug_Target_133_GenBank_ID_Gene:
Z31357

# Drug_Target_133_GenBank_ID_Protein:
467561

# Drug_Target_133_GeneCard_ID:
CDO1

# Drug_Target_133_Gene_Name:
CDO1

# Drug_Target_133_Gene_Sequence:
>603 bp
ATGGAACAGACCGAAGTGCTGAAGCCACGGACCCTGGCTGATCTGATCCGCATCCTGCAC
CAGCTCTTTGCCGGCGATGAGGTCAATGTAGAGGAGGTGCAGGCCATCATGGAAGCCTAC
GAGAGCGACCCCATCGAGTGGGCAATGTACGCCAAGTTCGACCAGTACAGGTATACCCGA
AATCTTGTGGATCAAGGAAATGGAAAATTTAATCTGATGATTCTCTGTTGGGGTGAAGGA
CATGGCAGCAGTATTCATGATCATACCAACTCCCACTGCTTTCTGAAGATGCTACAGGGA
AATCTAAAGGAGACATTATTTGCCTGGCCTGACAAAAAATCCAATGAGATGGTCAAGAAG
TCTGAAAGAGTCTTGAGGGAAAACCAGTGTGCCTACATCAATGATTCCATTGGCTTACAT
CGAGTAGAGAACATCAGCCATACGGAACCTGCTGTGAGCCTTCACTTGTACAGTCCACCT
TTTGATACATGCCATGCCTTTGATCAAAGAACAGGACATAAAAACAAAGTCACAATGACA
TTCCATAGTAAATTTGGAATCAGAACTCCAAATGCAACTTCGGGCTCGCTGGAGAACAAC
TAA

# Drug_Target_133_General_Function:
Involved in iron ion binding

# Drug_Target_133_General_References:
7524679	McCann KP, Akbari MT, Williams AC, Ramsden DB: Human cysteine dioxygenase type I: primary structure derived from base sequencing of cDNA. Biochim Biophys Acta. 1994 Nov 16;1209(1):107-10.
9497919	Ramsden DB, Kapadi A, Fitch NJ, Farmer MJ, Bennett P, Williams AC: Human cysteine dioxygenase type I (CDO-I; EC 1.13.11.20): 5' flanking region and intron-exon structure of the gene. Mol Pathol. 1997 Oct;50(5):269-71.

# Drug_Target_133_HGNC_ID:
HGNC:1795

# Drug_Target_133_HPRD_ID:
06806

# Drug_Target_133_ID:
626

# Drug_Target_133_Locus:
5q22-q23

# Drug_Target_133_Molecular_Weight:
22972

# Drug_Target_133_Name:
Cysteine dioxygenase type 1

# Drug_Target_133_Number_of_Residues:
200

# Drug_Target_133_PDB_ID:
Not Available

# Drug_Target_133_Pathway:
Not Available

# Drug_Target_133_Pfam_Domain_Function:
PF05995	CDO_I

# Drug_Target_133_Protein_Sequence:
>Cysteine dioxygenase type 1
MEQTEVLKPRTLADLIRILHQLFAGDEVNVEEVQAIMEAYESDPTEWAMYAKFDQYRYTR
NLVDQGNGKFNLMILCWGEGHGSSIHDHTNSHCFLKMLQGNLKETLFAWPDKKSNEMVKK
SERVLRENQCAYINDSIGLHRVENISHTEPAVSLHLYSPPFDTCHAFDQRTGHKNKVTMT
FHSKFGIRTPNATSGSLENN

# Drug_Target_133_Reaction:
L-cysteine + O2 = 3-sulfinoalanine

# Drug_Target_133_Signals:
None

# Drug_Target_133_Specific_Function:
Not Available

# Drug_Target_133_SwissProt_ID:
Q16878

# Drug_Target_133_SwissProt_Name:
CDO1_HUMAN

# Drug_Target_133_Synonyms:
CDO
CDO-I
Cysteine dioxygenase type I
EC 1.13.11.20

# Drug_Target_133_Theoretical_pI:
6.58

# Drug_Target_133_Transmembrane_Regions:
None

# Drug_Target_134_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_134_Chromosome_Location:
Not Available

# Drug_Target_134_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_134_Essentiality:
Non-Essential

# Drug_Target_134_GenAtlas_ID:
NDUFS6

# Drug_Target_134_GenBank_ID_Gene:
AF044959

# Drug_Target_134_GenBank_ID_Protein:
3348137

# Drug_Target_134_GeneCard_ID:
NDUFS6

# Drug_Target_134_Gene_Name:
NDUFS6

# Drug_Target_134_Gene_Sequence:
>375 bp
ATGGCGGCGGCGATGACCTTCTGCCGGCTGCTGAACCGGTGTGGCGAGGCGGCGCGGAGC
CTGCCCCTGGGCGCCAGGTGTTTCGGGGTGCGGGTCTCGCCGACCGGGGAGAAGGTCACG
CACACTGGCCAGGTTTATGATGATAAAGACTACAGGAGAATTCGGTTTGTAGGTCGTCAG
AAAGAGGTGAATGAAAACTTTGCCATTGATTTGATAGCAGAGCAGCCCGTGAGCGAGGTG
GAGACTCGGGTGATAGCGTGCGATGGCGGCGGGGGAGCTCTTGGCCACCCAAAAGTGTAT
ATAAACTTGGACAAAGAAACAAAAACCGGCACATGCGGTTACTGTGGGCTCCAGTTCAGA
CAGCACCACCACTAG

# Drug_Target_134_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_134_General_References:
9647766	Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J: cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed. Biochem Biophys Res Commun. 1998 Jun 29;247(3):751-8.

# Drug_Target_134_HGNC_ID:
HGNC:7713

# Drug_Target_134_HPRD_ID:
10356

# Drug_Target_134_ID:
104

# Drug_Target_134_Locus:
5p15.33

# Drug_Target_134_Molecular_Weight:
13712

# Drug_Target_134_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial

# Drug_Target_134_Number_of_Residues:
124

# Drug_Target_134_PDB_ID:
Not Available

# Drug_Target_134_Pathway:
Not Available

# Drug_Target_134_Pfam_Domain_Function:
Not Available

# Drug_Target_134_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial precursor
MAAAMTFCRLLNRCGEAARSLPLGARCFGVRVSPTGEKVTHTGQVYDDKDYRRIRFVGRQ
KEVNENFAIDLIAEQPVSEVETRVIACDGGGGALGHPKVYINLDKETKTGTCGYCGLQFR
QHHH

# Drug_Target_134_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_134_Signals:
None

# Drug_Target_134_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_134_SwissProt_ID:
O75380

# Drug_Target_134_SwissProt_Name:
NDUS6_HUMAN

# Drug_Target_134_Synonyms:
CI-13kD-A
Complex I-13kD-A
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase iron-sulfur protein 6, mitochondrial precursor
NADH-ubiquinone oxidoreductase 13 kDa-A subunit

# Drug_Target_134_Theoretical_pI:
8.38

# Drug_Target_134_Transmembrane_Regions:
None

# Drug_Target_135_Cellular_Location:
Not Available

# Drug_Target_135_Chromosome_Location:
Not Available

# Drug_Target_135_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_135_Essentiality:
Non-Essential

# Drug_Target_135_GenAtlas_ID:
NDUFA4L2

# Drug_Target_135_GenBank_ID_Gene:
AF164796

# Drug_Target_135_GenBank_ID_Protein:
8895095

# Drug_Target_135_GeneCard_ID:
NDUFA4L2

# Drug_Target_135_Gene_Name:
NDUFA4L2

# Drug_Target_135_Gene_Sequence:
>264 bp
ATGGCAGGAGCCAGTCTTGGGGCCCGCTTCTACCGGCAGATCAAAAGACATCCGGGGATC
ATCCCGATGATCGGCTTAATCTGCCTGGGCATGGGCAGCGCTGCGCTTTACTTGCTGCGA
CTCGCCCTTCGCAGCCCCGACGTCTGCTGGGACAGAAAGAACAACCCGGAGCCCTGGAAC
CGCCTGAGCCCCAATGACCAATACAAGTTCCTTGCAGTTTCCACTGACTATAAGAAGCTG
AAGAAGGACCGGCCAGACTTCTAA

# Drug_Target_135_General_Function:
Not Available

# Drug_Target_135_General_References:
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.

# Drug_Target_135_HGNC_ID:
HGNC:29836

# Drug_Target_135_HPRD_ID:
14249

# Drug_Target_135_ID:
353

# Drug_Target_135_Locus:
12q13.3

# Drug_Target_135_Molecular_Weight:
9966

# Drug_Target_135_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2

# Drug_Target_135_Number_of_Residues:
87

# Drug_Target_135_PDB_ID:
Not Available

# Drug_Target_135_Pathway:
Not Available

# Drug_Target_135_Pfam_Domain_Function:
Not Available

# Drug_Target_135_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2
MAGASLGARFYRQIKRHPGIIPMIGLICLGMGSAALYLLRLALRSPDVCWDRKNNPEPWN
RLSPNDQYKFLAVSTDYKKLKKDRPDF

# Drug_Target_135_Reaction:
Not Available

# Drug_Target_135_Signals:
None

# Drug_Target_135_Specific_Function:
Not Available

# Drug_Target_135_SwissProt_ID:
Q9NRX3

# Drug_Target_135_SwissProt_Name:
NUA4L_HUMAN

# Drug_Target_135_Synonyms:
NADH-ubiquinone oxidoreductase MLRQ subunit homolog
NUOMS

# Drug_Target_135_Theoretical_pI:
10.46

# Drug_Target_135_Transmembrane_Regions:
20-42

# Drug_Target_136_Cellular_Location:
Not Available

# Drug_Target_136_Chromosome_Location:
Not Available

# Drug_Target_136_Drug_References:
11086155	Albracht SP, Hedderich R: Learning from hydrogenases: location of a proton pump and of a second FMN in bovine NADH--ubiquinone oxidoreductase (Complex I). FEBS Lett. 2000 Nov 17;485(1):1-6.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9576793	Jose Quiles M, Cuello J: Association of ferredoxin-NADP oxidoreductase with the chloroplastic pyridine nucleotide dehydrogenase complex in barley leaves Plant Physiol. 1998 May;117(1):235-44.
9837812	Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, Trijbels F, Hamel B, Mullaart R, van den Heuvel L: The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am J Hum Genet. 1998 Dec;63(6):1598-608.

# Drug_Target_136_Essentiality:
Non-Essential

# Drug_Target_136_GenAtlas_ID:
NDUFS8

# Drug_Target_136_GenBank_ID_Gene:
U65579

# Drug_Target_136_GenBank_ID_Protein:
1935056

# Drug_Target_136_GeneCard_ID:
NDUFS8

# Drug_Target_136_Gene_Name:
NDUFS8

# Drug_Target_136_Gene_Sequence:
>633 bp
ATGCGCTGCCTGACCACGCCTATGCTGCTGCGGGCCCTGGCCCAGGCTGCACGTGCAGGA
CCTCCTGGTGGCCGGAGCCTCCACAGCAGTGCAGTGGCAGCCACCTACAAGTATGTGAAC
ATGCAGGATCCCGAGATGGACATGAAGTCAGTGACTGACCGGGCAGCCCGCACCCTGCTG
TGGACTGAGCTCTTCCGAGGCCTGGGCATGACCCTGAGCTACCTGTTCCGGGAACCGGCC
ACCATCAACTACCCGTTCGAGAAGGGCCCGCTGAGCCCTCGCTTCCGTGGGGAGCATGCG
CTGCGCCGGTACCCATCCGGGGAGGAGCGTTGCATTGCCTGCAAGCTCTGCGAGGCCATC
TGCCCCGCCCAGGCCATCACCATCGAGGCTGAGCCAAGAGCTGATGGCAGCCGCCGGACC
ACCCGCTATGACATCGACATGACCAAGTGCATCTACTGCGGCTTCTGCCAGGAGGCCTGT
CCCGTGGATGCCATCGTCGAGGGCCCCAACTTTGAGTTCTCCACGGAGACCCATGAGGAG
CTGCTGTACAACAAGGAGAAGTTGCTCAACAACGGGGACAAGTGGGAGGCCGAGATCGCC
GCCAACATCCAGGCTGACTACTTGTATCGGTGA

# Drug_Target_136_General_Function:
Energy production and conversion

# Drug_Target_136_General_References:
9116042	Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP: cDNA sequence and chromosomal localization of the NDUFS8 human gene coding for the 23 kDa subunit of the mitochondrial complex I. Biochim Biophys Acta. 1997 Mar 20;1351(1-2):37-41.
9666055	de Sury R, Martinez P, Procaccio V, Lunardi J, Issartel JP: Genomic structure of the human NDUFS8 gene coding for the iron-sulfur TYKY subunit of the mitochondrial NADH:ubiquinone oxidoreductase. Gene. 1998 Jul 17;215(1):1-10.
9837812	Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, Trijbels F, Hamel B, Mullaart R, van den Heuvel L: The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am J Hum Genet. 1998 Dec;63(6):1598-608.

# Drug_Target_136_HGNC_ID:
HGNC:7715

# Drug_Target_136_HPRD_ID:
03683

# Drug_Target_136_ID:
41

# Drug_Target_136_Locus:
11q13

# Drug_Target_136_Molecular_Weight:
23705

# Drug_Target_136_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial

# Drug_Target_136_Number_of_Residues:
210

# Drug_Target_136_PDB_ID:
Not Available

# Drug_Target_136_Pathway:
Not Available

# Drug_Target_136_Pfam_Domain_Function:
PF00037	Fer4

# Drug_Target_136_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial precursor
MRCLTTPMLLRALAQAARAGPPGGRSLHSSAVAATYKYVNMQDPEMDMKSVTDRAARTLL
WTELFRGLGMTLSYLFREPATINYPFEKGPLSPRFRGEHALRRYPSGEERCIACKLCEAI
CPAQAITIEAEPRADGSRRTTRYDIDMTKCIYCGFCQEACPVDAIVEGPNFEFSTETHEE
LLYNKEKLLNNGDKWEAEIAANIQADYLYR

# Drug_Target_136_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_136_Signals:
None

# Drug_Target_136_Specific_Function:
May donate electrons to ubiquinone

# Drug_Target_136_SwissProt_ID:
O00217

# Drug_Target_136_SwissProt_Name:
NDUS8_HUMAN

# Drug_Target_136_Synonyms:
CI-23kD
Complex I-23kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase iron-sulfur protein 8, mitochondrial precursor
NADH-ubiquinone oxidoreductase 23 kDa subunit
TYKY subunit

# Drug_Target_136_Theoretical_pI:
6.27

# Drug_Target_136_Transmembrane_Regions:
None

# Drug_Target_137_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
peripheral membrane protein

# Drug_Target_137_Chromosome_Location:
Not Available

# Drug_Target_137_Drug_References:
11246504	Ngo S, Kong S, Kirlich A, McKinnon RA, Stupans I: Cytochrome P450 4A, peroxisomal enzymes and nicotinamide cofactors in koala liver. Comp Biochem Physiol C Toxicol Pharmacol. 2000 Dec;127(3):327-34.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_137_Essentiality:
Non-Essential

# Drug_Target_137_GenAtlas_ID:
CYP4A11

# Drug_Target_137_GenBank_ID_Gene:
L04751

# Drug_Target_137_GenBank_ID_Protein:
181397

# Drug_Target_137_GeneCard_ID:
CYP4A11

# Drug_Target_137_Gene_Name:
CYP4A11

# Drug_Target_137_Gene_Sequence:
>1560 bp
ATGAGTGTCTCTGTGCTGAGCCCCAGCAGACTCCTGGGTGATGTCTCTGGAATCCTCCAA
GCGGCCTCCCTGCTCATTCTGCTTCTGCTGCTGATCAAGGCAGTTCAGCTCTACCTGCAC
AGGCAGTGGCTGCTCAAAGCCCTCCAGCAGTTCCCGTGCCCTCCCTCCCACTGGCTCTTC
GGGCACATCCAGGAGCTCCAACAGGACCAGGAGCTACAACGGATTCAGAAATGGGTGGAG
ACATTCCCAAGTGCCTGTCCTCATTGGCTATGGGGAGGCAAAGTTCGTGTCCAGCTCTAT
GACCCTGACTATATGAAGGTGATTCTGGGGAGATCAGACCCGAAATCCCATGGTTCCTAC
AGATTCCTGGCTCCATGGATTGGGTACGGCTTGCTCCTGTTGAATGGGCAGACATGGTTC
CAGCATCGACGGATGCTGACCCCAGCCTTCCACTATGACATCCTGAAGCCCTATGTGGGG
CTCATGGCAGACTCTGTACGAGTGATGCTGGACAAATGGGAAGAGCTCCTTGGCCAGGAT
TCCCCTCTGGAGGTCTTTCAGCACGTCTCCTTGATGACCCTGGACACCATCATGAAGTGT
GCCTTCAGCCATCAGGGCAGCATCCAGGTGGACAGGAATTCTCAGTCCTACATACAGGCC
ATTAGTGACCTGAACAACCTGGTTTTTTCCCGTGTGAGGAATGCCTTTCACCAGAATGAC
ACCATCTACAGCCTGACCTCTGCTGGCCGCTGGACACACCGCGCCTGCCAGCTGGCCCAT
CAGCACACAGACCAAGTGATCCAACTGAGGAAGGCTCAACTACAGAAGGAGGGGGAGCTG
GAGAAGATCAAGAGGAAGAGGCATTTGGATTTTCTGGATATCCTCCTCTTGGCCAAAATG
GAGAATGGGAGCATCTTGTCAGACAAGGACCTCCGTGCTGAGGTGGACACGTTCATGTTT
GAGGGCCACGACACCACAGCCAGTGGGATCTCCTGGATCCTCTATGCTCTGGCCACACAC
CCCAAGCATCAGGAGAGGTGCCGGGAGGAGATCCACAGCCTCCTGGGTGATGGAGCCTCC
ATCACCTGGAACCACCTGGACCAGATGCCCTACACCACCATGTGCATTAAGGAGGCACTG
AGGCTCTACCCACCGGTGCCAGGCATTGGCAGAGAGCTCAGCACTCCCGTCACCTTCCCT
GATGGGCGCTCCTTGCCCAAAGGTATCATGGTCCTCCTCTCCATTTATGGCCTTCACCAC
AACCCAAAAGTGTGGCCCAACCCAGAGGTGTTTGACCCTTTCCGTTTTGCACCGGGTTCT
GCTCAACACAGCCACGCTTTCCTGCCCTTCTCAGGAGGATCAAGGAACTGCATTGGGAAA
CAATTTGCCATGAACGAGCTGAAGGTGGCCACGGCCCTGACCCTGCTCCGCTTTGAGCTG
CTGCCTGATCCCACCAGGATCCCCATCCCCATTGCACGACTTGTGTTGAAATCCAAAAAT
GGAATCCACCTGCGTCTCAGGAGGCTCCCTAACCCTTGTGAAGACAAGGACCAGCTTTGA

# Drug_Target_137_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_137_General_References:
11139583	Hoch U, Ortiz De Montellano PR: Covalently linked heme in cytochrome p4504a fatty acid hydroxylases. J Biol Chem. 2001 Apr 6;276(14):11339-46. Epub 2001 Jan 3.
11821421	LeBrun LA, Hoch U, Ortiz de Montellano PR: Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family. J Biol Chem. 2002 Apr 12;277(15):12755-61. Epub 2002 Jan 30.
12464262	Bellamine A, Wang Y, Waterman MR, Gainer JV 3rd, Dawson EP, Brown NJ, Capdevila JH: Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch Biochem Biophys. 2003 Jan 1;409(1):221-7.
1739747	Kawashima H, Kusunose E, Kubota I, Maekawa M, Kusunose M: Purification and NH2-terminal amino acid sequences of human and rat kidney fatty acid omega-hydroxylases. Biochim Biophys Acta. 1992 Jan 24;1123(2):156-62.
7679927	Palmer CN, Richardson TH, Griffin KJ, Hsu MH, Muerhoff AS, Clark JE, Johnson EF: Characterization of a cDNA encoding a human kidney, cytochrome P-450 4A fatty acid omega-hydroxylase and the cognate enzyme expressed in Escherichia coli. Biochim Biophys Acta. 1993 Feb 20;1172(1-2):161-6.
7798189	Kawashima H, Kusunose E, Kikuta Y, Kinoshita H, Tanaka S, Yamamoto S, Kishimoto T, Kusunose M: Purification and cDNA cloning of human liver CYP4A fatty acid omega-hydroxylase. J Biochem (Tokyo). 1994 Jul;116(1):74-80.
8274222	Imaoka S, Ogawa H, Kimura S, Gonzalez FJ: Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid omega-hydroxylase expressed in human kidney. DNA Cell Biol. 1993 Dec;12(10):893-9.
8363569	Bell DR, Plant NJ, Rider CG, Na L, Brown S, Ateitalla I, Acharya SK, Davies MH, Elias E, Jenkins NA, et al.: Species-specific induction of cytochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem J. 1993 Aug 15;294 ( Pt 1):173-80.

# Drug_Target_137_HGNC_ID:
HGNC:2642

# Drug_Target_137_HPRD_ID:
03201

# Drug_Target_137_ID:
468

# Drug_Target_137_Locus:
1p33

# Drug_Target_137_Molecular_Weight:
59349

# Drug_Target_137_Name:
Cytochrome P450 4A11

# Drug_Target_137_Number_of_Residues:
519

# Drug_Target_137_PDB_ID:
Not Available

# Drug_Target_137_Pathway:
Not Available

# Drug_Target_137_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_137_Protein_Sequence:
>Cytochrome P450 4A11 precursor
MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLF
GHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSY
RFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQD
SPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQND
TIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKM
ENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGAS
ITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHH
NPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFEL
LPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL

# Drug_Target_137_Reaction:
octane + reduced rubredoxin + O2 = 1-octanol + oxidized rubredoxin + H2O

# Drug_Target_137_Signals:
None

# Drug_Target_137_Specific_Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity towards prostaglandins A1 and E1

# Drug_Target_137_SwissProt_ID:
Q02928

# Drug_Target_137_SwissProt_Name:
CP4AB_HUMAN

# Drug_Target_137_Synonyms:
CYP4AII
CYPIVA11
Cytochrome P450 4A11 precursor
EC 1.14.15.3
Fatty acid omega-hydroxylase
Lauric acid omega-hydroxylase
P-450 HK omega
P450-HL-omega

# Drug_Target_137_Theoretical_pI:
8.99

# Drug_Target_137_Transmembrane_Regions:
15-32; 118-140

# Drug_Target_138_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_138_Chromosome_Location:
Not Available

# Drug_Target_138_Drug_References:
16368957	Shi S, Ehrt S: Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect Immun. 2006 Jan;74(1):56-63.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_138_Essentiality:
Non-Essential

# Drug_Target_138_GenAtlas_ID:
DLAT

# Drug_Target_138_GenBank_ID_Gene:
Y00978

# Drug_Target_138_GenBank_ID_Protein:
35360

# Drug_Target_138_GeneCard_ID:
DLAT

# Drug_Target_138_Gene_Name:
DLAT

# Drug_Target_138_Gene_Sequence:
>1848 bp
CGAGTGACCTCGCGATCTGGCCCGGCTCCCGCTCGTCGCAACAGCGTGACTACAGGGTAT
GGCGGGGTCCGGGCACTGTGCGGCTGGACCCCCAGTTCTGGGGCCACGCCGCGGAACCGC
TTACTGCTGCAGCTTTTGGGGTCGCCCGGCCGCCGCTATTACAGTCTTCCCCCGCATCAG
AAGGTTCCATTGCCTTCTCTTTCCCCCACAATGCAGGCAGGCACCATAGCCCGTTGGAAA
AAAAAAGAGGGGGACAAAATCAATGAAGGTGACCTAATTGCAGAGGTTGAAACTGATAAA
GCCACTGTTGGATTTGAGAGCCTGGAGGAGTGTTATATGGCAAAGATACTTGTTGCTGAA
GGTACCAGGGATGTTCCCATCGGAGCGATCATCTGTATCACAGTTGGCAAGCCTGAGGAT
ATTGAGGCCTTTAAAAATTATACACTGGATTCCTCAGCAGCACCTACCCCACAAGCGGCC
CCAGCACCAACCCCTGCTGCCACTGCTTCGCCACCTACACCTTCTGCTCAGGCTCCTGGT
AGCTCATATCCCCCTCACATGCAGGTACTTCTTCCTGCCCTCTCTCCCACCATGACCATG
GGCACAGTTCAGAGATGGGAAAAAAAAGTGGGTGAGAAGCTAAGTGAAGGAGACTTACTG
GCAGAGATAGAAACTGACAAAGCCACTATAGGTTTTGAAGTACAGGAAGAAGGTTATCTG
GCAAAAATCCTGGTCCCTGAAGGCACAAGAGATGTCCCTCTAGGAACCCCACTCTGTATC
ATTGTAGAAAAAGAGGCAGATATATCAGCATTTGCTGACTATAGGCCAACCGAAGTAACA
GATTTAAAACCACAAGTGCCACCACCTACCCCACCCCCGGTGGCCGCTGTTCCTCCAACT
CCCCAGCCTTTAGCTCCTACACCTTCAGCACCCTGCCCAGCTACTCCTGCTGGACCAAAG
GGAAGGGTGTTTGTTAGCCCTCTTGCAAAGAAGTTGGCAGTAGAGAAAGGGATTGATCTT
ACACAAGTAAAAGGGACAGGACCAGATGGTAGAATCACCAAGAAGGATATCGACTCTTTT
GTGCCTAGTAAAGTTGCTCCTGCTCCGGCAGCTGTTGTGCCTCCCACAGGTCCTGGAATG
GCACCAGTTCCTACAGGTGTCTTCACAGATATCCCAATCAGCAACATTCGTCGGGTTATT
GCACAGCGATTAATGCAATCAAAGCAAACCATACCTCATTATTACCTTTCTATCGATGTA
AATATGGGAGAAGTTTTGTTGGTACGGAAAGAACTTAATAAGATATTAGAAGGGAGAAGC
AAAATTTCTGTCAATGACTTCATCATAAAAGCTTCAGCTTTGGCATGTTTAAAAGTTCCC
GAAGCAAATTCTTCTTGGATGGACACAGTTATAAGACAAAATCATGTTGTTGATGTCAGT
GTTGCGGTCAGTACTCCTGCAGGACTCATCACACCTATTGTGTTTAATGCACATATAAAA
GGAGTGGAAACCATTGCTAATGATGTTGTTTCTTTAGCAACCAAAGCAAGAGAGGGTAAA
CTACAGCCACATGAATTCCAGGGTGGCACTTTTACGATCTCCAATTTAGGAATGTTTGGA
ATTAAGAATTTCTCTGCTATTATTAACCCACCTCAAGCATGTATTTTGGCAATTGGTGCT
TCAGAGGATAAACTGGTCCCTGCAGATAATGAAAAAGGGTTTGATGTGGCTAGCATGATG
TCTGTTACACTCAGTTGTGATCACCGGGTGGTGGATGGAGCAGTTGGAGCCCAGTGGCTT
GCTGAGTTTAGAAAGTACCTTGAAAAACCTATCACTATGTTGTTGTAA

# Drug_Target_138_General_Function:
Energy production and conversion

# Drug_Target_138_General_References:
3174635	Coppel RL, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, Whittingham S, Gershwin ME: Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7317-21.
3191998	Thekkumkara TJ, Ho L, Wexler ID, Pons G, Liu TC, Patel MS: Nucleotide sequence of a cDNA for the dihydrolipoamide acetyltransferase component of human pyruvate dehydrogenase complex. FEBS Lett. 1988 Nov 21;240(1-2):45-8.
9649469	Howard MJ, Fuller C, Broadhurst RW, Perham RN, Tang JG, Quinn J, Diamond AG, Yeaman SJ: Three-dimensional structure of the major autoantigen in primary biliary cirrhosis. Gastroenterology. 1998 Jul;115(1):139-46.

# Drug_Target_138_HGNC_ID:
HGNC:2896

# Drug_Target_138_HPRD_ID:
10578

# Drug_Target_138_ID:
74

# Drug_Target_138_Locus:
11q23.1

# Drug_Target_138_Molecular_Weight:
65782

# Drug_Target_138_Name:
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial

# Drug_Target_138_Number_of_Residues:
614

# Drug_Target_138_PDB_ID:
1FYC

# Drug_Target_138_Pathway:
Not Available

# Drug_Target_138_Pfam_Domain_Function:
PF00198	2-oxoacid_dh
PF00364	Biotin_lipoyl
PF02817	E3_binding

# Drug_Target_138_Protein_Sequence:
>Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial precursor
MSPHCSTTYLRTLGRTTMFWKTTEGRDGKMAVQEFSEFGLLLQLLGSPGRRYYSLPPHQK
VPLPSLSPTMQAGTIARWEKKEGDKINEGDLIAEVETDKATVGFESLEECYMAKILVAEG
TRDVPIGAIICITVGKPEDIEAFKNYTLDSSAAPTPQAAPAPTPAATASPPTPSAQAPGS
SYPPHMQVLLPALSPTMTMGTVQRWEKKVGEKLSEGDLLAEIETDKATIGFEVQEEGYLA
KILVPEGTRDVPLGTPLCIIVEKEADISAFADYRPTEVTDLKPQVPPPTPPPVAAVPPTP
QPLAPTPSTPCPATPAGPKGRVFVDPLAKKLAVEKGIDLTQVKGTGPDGRITKKDIDSFV
PSKVAPAPAAVVPPTGPGMAPVPTGVFTDIPISNIRRVIAQRLMQSKQTIPHYYLSIDVN
MGEVLLVRKELNKILEGRSKISVNDFIIKASALACLKVPEANSSWMDTVIRQNHVVDVSV
AVSTPAGLITPIVFNAHIKGVETIANDVVSLATKAREGKLQPHEFQGGTFTISNLGMFGI
KNFSAIINPPQACILAIGASEDKLVPADNEKGFDVASMMSVTLSCDHRVVDGAVGAQWLA
EFRKYLEKPITMLL

# Drug_Target_138_Reaction:
acetyl-CoA + enzyme N6-(dihydrolipoyl)lysine = CoA + enzyme N6-(S-acetyldihydrolipoyl)lysine

# Drug_Target_138_Signals:
None

# Drug_Target_138_Specific_Function:
The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components:pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_138_SwissProt_ID:
P10515

# Drug_Target_138_SwissProt_Name:
ODP2_HUMAN

# Drug_Target_138_Synonyms:
70 kDa mitochondrial autoantigen of primary biliary cirrhosis
Dihydrolipoamide S- acetyltransferase component of pyruvate dehydrogenase complex
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial precursor
E2
EC 2.3.1.12
M2 antigen complex 70 kDa subunit
PBC
PDC- E2
PDCE2
Pyruvate dehydrogenase complex E2 subunit

# Drug_Target_138_Theoretical_pI:
5.95

# Drug_Target_138_Transmembrane_Regions:
None

# Drug_Target_139_Cellular_Location:
Mitochondrion

# Drug_Target_139_Chromosome_Location:
Not Available

# Drug_Target_139_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_139_Essentiality:
Non-Essential

# Drug_Target_139_GenAtlas_ID:
AMT

# Drug_Target_139_GenBank_ID_Gene:
D13811

# Drug_Target_139_GenBank_ID_Protein:
391721

# Drug_Target_139_GeneCard_ID:
AMT

# Drug_Target_139_Gene_Name:
AMT

# Drug_Target_139_Gene_Sequence:
>1212 bp
ATGCAGAGGGCTGTAAGTGTGGTGGCCCGTCTGGGCTTTCGCCTGCAGGCATTCCCCCCG
GCCTTGTGTCGTCCACTTAGTTGCGCACAGGAGGTGCTCCGCAGGACACCGCTCTATGAC
TTCCACCTGGCCCACGGCGGGAAAATGGTGGCGTTTGCGGGTTGGAGTCTGCCAGTGCAG
TACCGGGACAGTCACACTGACTCGCACCTGCACACACGCCAGCACTGCTCGCTCTTTGAC
GTGTCTCATATGCTGCAGACCAAGATACTTGGTAGTGACCGGGTGAAGCTGATGGAGAGT
CTAGTGGTTGGAGACATTGCAGAGCTAAGACCAAACCAGGGGACACTGTCGCTGTTTACC
AACGAGGCTGGAGGCATCTTAGATGACTTGATTGTAACCAATACTTCTGAGGGCCACCTG
TATGTGGTGTCCAACGCTGGCTGCTGGGAGAAAGATTTGGCCCTCATGCAGGACAAGGTC
AGGGAGCTTCAGAACCAGGGCAGAGATGTGGGCCTGGAGGTGTTGGATAATGCCCTGCTA
GCTCTGCAAGGCCCCACTGCAGCCCAGGTACTACAGGCCGGCGTGGCAGATGACCTGAGG
AAACTGCCCTTCATGACCAGTGCTGTGATGGAGGTGTTTGGCGTGTCTGGCTGCCGCGTG
ACCCGCTGTGGCTACACAGGAGAGGATGGTGTGGAGATCTCGGTGCCGGTAGCGGGGGCA
GTTCACCTGGCAACAGCTATTCTGAAAAACCCAGAGGTGAAGCTGGCAGGGCTGGCAGCC
AGGGACAGCCTGCGCCTGGAGGCAGGCCTCTGCCTGTATGGGAATGACATTGATGAACAC
ACTACACCTGTGGAGGGCAGCCTCAGTTGGACACTGGGGAAGCGCCGCCGAGCTGCTATG
GACTTCCCTGGAGCCAAGGTCATTGTTCCCCAGCTGAAGGGCAGGGTGCAGCGGAGGCGT
GTGGGGTTGATGTGTGAGGGGGCCCCCATGCGGGCACACAGTCCCATCCTGAACATGGAG
GGTACCAAGATTGGTACTGTGACTAGTGGCTGCCCCTCCCCCTCTCTGAAGAAGAATGTG
GCGATGGGTTATGTGCCCTGCGAGTACAGTCGTCCAGGGACAATGCTGCTGGTAGAGGTG
CGGCGGAAGCAGCAGATGGCTGTAGTCAGCAAGATGCCCTTTGTGCCCACAAACTACTAT
ACCCTCAAGTGA

# Drug_Target_139_General_Function:
Amino acid transport and metabolism

# Drug_Target_139_General_References:
10873393	Toone JR, Applegarth DA, Coulter-Mackie MB, James ER: Biochemical and molecular investigations of patients with nonketotic hyperglycinemia. Mol Genet Metab. 2000 Jun;70(2):116-21.
11286506	Toone JR, Applegarth DA, Coulter-Mackie MB, James ER: Recurrent mutations in P- and T-proteins of the glycine cleavage complex and a novel T-protein mutation (N145I): a strategy for the molecular investigation of patients with nonketotic hyperglycinemia (NKH). Mol Genet Metab. 2001 Apr;72(4):322-5.
7916605	Hayasaka K, Nanao K, Takada G, Okamura-Ikeda K, Motokawa Y: Isolation and sequence determination of cDNA encoding human T-protein of the glycine cleavage system. Biochem Biophys Res Commun. 1993 Apr 30;192(2):766-71.
8005589	Nanao K, Okamura-Ikeda K, Motokawa Y, Danks DM, Baumgartner ER, Takada G, Hayasaka K: Identification of the mutations in the T-protein gene causing typical and atypical nonketotic hyperglycinemia. Hum Genet. 1994 Jun;93(6):655-8.
8188235	Nanao K, Takada G, Takahashi E, Seki N, Komatsu Y, Okamura-Ikeda K, Motokawa Y, Hayasaka K: Structure and chromosomal localization of the aminomethyltransferase gene (AMT) Genomics. 1994 Jan 1;19(1):27-30.
9600239	Kure S, Mandel H, Rolland MO, Sakata Y, Shinka T, Drugan A, Boneh A, Tada K, Matsubara Y, Narisawa K: A missense mutation (His42Arg) in the T-protein gene from a large Israeli-Arab kindred with nonketotic hyperglycinemia. Hum Genet. 1998 Apr;102(4):430-4.
9621520	Kure S, Shinka T, Sakata Y, Osamu N, Takayanagi M, Tada K, Matsubara Y, Narisawa K: A one-base deletion (183delC) and a missense mutation (D276H) in the T-protein gene from a Japanese family with nonketotic hyperglycinemia. J Hum Genet. 1998;43(2):135-7.

# Drug_Target_139_HGNC_ID:
HGNC:473

# Drug_Target_139_HPRD_ID:
01997

# Drug_Target_139_ID:
13

# Drug_Target_139_Locus:
3p21.2-p21.1

# Drug_Target_139_Molecular_Weight:
43947

# Drug_Target_139_Name:
Aminomethyltransferase, mitochondrial

# Drug_Target_139_Number_of_Residues:
403

# Drug_Target_139_PDB_ID:
Not Available

# Drug_Target_139_Pathway:
Not Available

# Drug_Target_139_Pfam_Domain_Function:
PF01571	GCV_T

# Drug_Target_139_Protein_Sequence:
>Aminomethyltransferase, mitochondrial precursor
MQRAVSVVARLGFRLQAFPPALCRPLSCAQEVLRRTPLYDFHLAHGGKMVAFAGWSLPVQ
YRDSHTDSHLHTRQHCSLFDVSHMLQTKILGSDRVKLMESLVVGDIAELRPNQGTLSLFT
NEAGGILDDLIVTNTSEGHLYVVSNAGCWEKDLALMQDKVRELQNQGRDVGLEVLDNALL
ALQGPTAAQVLQAGVADDLRKLPFMTSAVMEVFGVSGCRVTRCGYTGEDGVEISVPVAGA
VHLATAILKNPEVKLAGLAARDSLRLEAGLCLYGNDIDEHTTPVEGSLSWTLGKRRRAAM
DFPGAKVIVPQLKGRVQRRRVGLMCEGAPMRAHSPILNMEGTKIGTVTSGCPSPSLKKNV
AMGYVPCEYSRPGTMLLVEVRRKQQMAVVSKMPFVPTNYYTLK

# Drug_Target_139_Reaction:
[protein]-S8-aminomethyldihydrolipoyllysine + tetrahydrofolate = [protein]-dihydrolipoyllysine + 5,10-methylenetetrahydrofolate + NH3

# Drug_Target_139_Signals:
None

# Drug_Target_139_Specific_Function:
The glycine cleavage system catalyzes the degradation of glycine

# Drug_Target_139_SwissProt_ID:
P48728

# Drug_Target_139_SwissProt_Name:
GCST_HUMAN

# Drug_Target_139_Synonyms:
Aminomethyltransferase, mitochondrial precursor
EC 2.1.2.10
GCVT
Glycine cleavage system T protein

# Drug_Target_139_Theoretical_pI:
8.69

# Drug_Target_139_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
16898590	Markova EV, Zotova NV, Savchenko AA, Titova NM, Slepov EV, Cherdantsev DV, Konovalenko AN: [Lymphocyte metabolism in patients with acute pancreatitis with different genotypes of GSTM1 and GSTT1 genes] Biomed Khim. 2006 May-Jun;52(3):317-26.
17203264	Gallarta F, Sainz FJ, Saenz C: Fluorescent sensing layer for the determination of L-malic acid in wine. Anal Bioanal Chem. 2007 Mar;387(6):2297-305. Epub 2007 Jan 4.
17487443	Yennaco LJ, Hu Y, Holden JF: Characterization of malate dehydrogenase from the hyperthermophilic archaeon Pyrobaculum islandicum. Extremophiles. 2007 Sep;11(5):741-6. Epub 2007 May 9.
17603759	Rzem R, Vincent MF, Van Schaftingen E, Veiga-da-Cunha M: L: -2-Hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis. 2007 Jun 21;.
17619232	Baumchen C, Roth AH, Biedendieck R, Malten M, Follmann M, Sahm H, Bringer-Meyer S, Jahn D: D-Mannitol production by resting state whole cell biotransformation of D-fructose by heterologous mannitol and formate dehydrogenase gene expression in Bacillus megaterium. Biotechnol J. 2007 Jul 9;.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
MDH2

# Drug_Target_13_GenBank_ID_Gene:
AF047470

# Drug_Target_13_GenBank_ID_Protein:
2906146

# Drug_Target_13_GeneCard_ID:
MDH2

# Drug_Target_13_Gene_Name:
MDH2

# Drug_Target_13_Gene_Sequence:
>1017 bp
ATGCTCTCCGCCCTCGCCCGGCCTGTCAGCGCTGCTCTCCGCCGCAGCTTCAGCACCTCA
GCCCAGAACAATGCTAAAGTAGCTGTGCTAGGGGCCTCTGGAGGCATCGGGCAGCCACTT
TCACTTCTCCTGAAGAACAGCCCCTTGGTGAGCCGCCTGACCCTCTATGATATCGCGCAC
ACACCCGGAGTGGCCGCAGATCTGAGCCACATCGAGACCAAAGCCGCTGTGAAAGGCTAC
CTCGGACCTGAACAGCTGCCTGACTGCCTGAAAGGTTGTGATGTGGTAGTTATTCCGGCT
GGAGTCCCCAGAAAGCCAGGCATGACCCGGGACGACCTGTTCAACACCAATGCCACGATT
GTGGCCACCCTGACCGCTGCCTGTGCCCAGCACTGCCCGGAAGCCATGATCTGCGTCATT
GCCAATCCGGTTAATTCCACCATCCCCATCACAGCAGAAGTTTTCAAGAAGCATGGAGTG
TACAACCCCAACAAAATCTTCGGCGTGACGACCCTGGACATCGTCAGAGCCAACACCTTT
GTTGCAGAGCTGAAGGGTTTGGATCCAGCTCGAGTCAACGTCCCTGTCATTGGTGGCCAT
GCTGGGAAGACCATCATCCCCCTGATCTCTCAGTGCACCCCCAAGGTGGACTTTCCCCAG
GACCAGCTGACAGCACTCACTGGGCGGATCCAGGAGGCCGGCACGGAGGTGGTCAAGGCT
AAAGCCGGAGCAGGCTCTGCCACCCTCTCCATGGCGTATGCCGGCGCCCGCTTTGTCTTC
TCCCTTGTGGATGCAATGAATGGAAAGGAAGGTGTTGTGGAATGTTCCTTCGTTAAGTCA
CAGGAAACGGAATGTACCTACTTCTCCACACCGCTGCTGCTTGGGAAAAAGGGCATCGAG
AAGAACCTGGGCATCGGCAAAGTCTCCTCTTTTGAGGAGAAGATGATCTCGGATGCCATC
CCCGAGCTGAAGGCCTCCATCAAGAAGGGGGAAGATTTCGTGAAGACCCTGAAGTGA

# Drug_Target_13_General_Function:
Energy production and conversion

# Drug_Target_13_General_References:
Not Available

# Drug_Target_13_HGNC_ID:
HGNC:6971

# Drug_Target_13_HPRD_ID:
01099

# Drug_Target_13_ID:
857

# Drug_Target_13_Locus:
7p12.3-q11.2

# Drug_Target_13_Molecular_Weight:
35532

# Drug_Target_13_Name:
Malate dehydrogenase, mitochondrial

# Drug_Target_13_Number_of_Residues:
338

# Drug_Target_13_PDB_ID:
1MLD

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_13_Protein_Sequence:
>Malate dehydrogenase, mitochondrial precursor
MLSALARPVSAALRRSFSTSAQNNAKVAVLGASGGIGQPLSLLLKNSPLVSRLTLYDIAH
TPGVAADLSHIETKAAVKGYLGPEQLPDCLKGCDVVVIPAGVPRKPGMTRDDLFNTNATI
VATLTAACAQHCPEAMICVIANPVNSTIPITAEVFKKHGVYNPNKIFGVTTLDIVRANTF
VAELKGLDPARVNVPVIGGHAGKTIIPLISQCTPKVDFPQDQLTALTGRIQEAGTEVVKA
KAGAGSATLSMAYAGARFVFSLVDAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKGIE
KNLGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK

# Drug_Target_13_Reaction:
(S)-malate + NAD+ = oxaloacetate + NADH + H+

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Not Available

# Drug_Target_13_SwissProt_ID:
P40926

# Drug_Target_13_SwissProt_Name:
MDHM_HUMAN

# Drug_Target_13_Synonyms:
EC 1.1.1.37
Malate dehydrogenase, mitochondrial precursor

# Drug_Target_13_Theoretical_pI:
8.90

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_140_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein (Probable)

# Drug_Target_140_Chromosome_Location:
Not Available

# Drug_Target_140_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_140_Essentiality:
Non-Essential

# Drug_Target_140_GenAtlas_ID:
SC4MOL

# Drug_Target_140_GenBank_ID_Gene:
U60205

# Drug_Target_140_GenBank_ID_Protein:
1408206

# Drug_Target_140_GeneCard_ID:
SC4MOL

# Drug_Target_140_Gene_Name:
SC4MOL

# Drug_Target_140_Gene_Sequence:
>882 bp
ATGGCAACAAATGAAAGTGTCAGCATCTTTAGTTCAGCATCCTTGGCTGTGGAATATGTA
GATTCACTTTTACCTGAGAATCCTCTGCAAGAACCATTTAAAAATGCTTGGAACTATATG
TTGAATAATTATACAAAGTTCCAGATTGCAACATGGGGATCCCTTATAGTTCATGAAGCC
CTTTATTTCTTATTCTGTTTACCTGGATTTTTATTTCAATTTATACCTTATATGAAAAAA
TACAAAATTCAAAAGGATAAGCCAGAGACATGGGAAAACCAATGGAAGTGTTTCAAAGTT
CTTCTCTTTAATCACTTCTGTATCCAGCTGCCTTTGATTTGTGGAACCTATTATTTTACA
GAGTATTTCAATATTCCTTATGATTGGGAAAGAATGCCAAGATGGTATTTTCTTTTGGCA
AGATGCTTTGGTTGTGCAGTCATTGAAGATACTTGGCACTATTTTCTGCATAGACTCTTA
CACCACAAAAGAATATACAAGTATATTCATAAAGTTCATCATGAGTTTCAGGCTCCATTT
GGAATGGAAGCTGAATATGCACATCCTTTGGAGACTCTAATTCTTGGAACTGGATTTTTC
ATTGGAATCGTGCTTTTGTGTGATCATGTAATTCTTCTTTGGGCATGGGTGACCATTCGT
TTATTAGAAACTATTGATGTCCATAGTGGTTATGATATTCCTCTCAACCCTTTAAATCTG
ATCCCTTTCTATGCTGGTTCTCGGCATCATGATTTCCACCACATGAACTTCATTGGAAAC
TATGCTTCAACATTTACATGGTGGGATCGAATTTTTGGAACAGACTCTCAGTATAATGCC
TATAATGAAAAGAGGAAGAAGTTTGAGAAAAAGACTGAATAA

# Drug_Target_140_General_Function:
Lipid transport and metabolism

# Drug_Target_140_General_References:
8663358	Li L, Kaplan J: Characterization of yeast methyl sterol oxidase (ERG25) and identification of a human homologue. J Biol Chem. 1996 Jul 12;271(28):16927-33.

# Drug_Target_140_HGNC_ID:
HGNC:10545

# Drug_Target_140_HPRD_ID:
07396

# Drug_Target_140_ID:
107

# Drug_Target_140_Locus:
4q32-q34

# Drug_Target_140_Molecular_Weight:
35216

# Drug_Target_140_Name:
C-4 methylsterol oxidase

# Drug_Target_140_Number_of_Residues:
293

# Drug_Target_140_PDB_ID:
Not Available

# Drug_Target_140_Pathway:
Not Available

# Drug_Target_140_Pfam_Domain_Function:
PF01598	Sterol_desat

# Drug_Target_140_Protein_Sequence:
>C-4 methylsterol oxidase
MATNESVSIFSSASLAVEYVDSLLPENPLQEPFKNAWNYMLNNYTKFQIATWGSLIVHEA
LYFLFCLPGFLFQFIPYMKKYKIQKDKPETWENQWKCFKVLLFNHFCIQLPLICGTYYFT
EYFNIPYDWERMPRWYFLLARCFGCAVIEDTWHYFLHRLLHHKRIYKYIHKVHHEFQAPF
GMEAEYAHPLETLILGTGFFIGIVLLCDHVILLWAWVTIRLLETIDVHSGYDIPLNPLNL
IPFYAGSRHHDFHHMNFIGNYASTFTWWDRIFGTDSQYNAYNEKRKKFEKKTE

# Drug_Target_140_Reaction:
(1) 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol + NAD(P)H + H+ + O2 = 4beta-hydroxymethyl-4alpha-methyl-5alpha-cholest-7-en-3beta-ol + NAD(P)+ + H2O

# Drug_Target_140_Signals:
None

# Drug_Target_140_Specific_Function:
Not Available

# Drug_Target_140_SwissProt_ID:
Q15800

# Drug_Target_140_SwissProt_Name:
ERG25_HUMAN

# Drug_Target_140_Synonyms:
EC 1.14.13.72
Methylsterol monooxygenase

# Drug_Target_140_Theoretical_pI:
7.25

# Drug_Target_140_Transmembrane_Regions:
55-75
100-120
199-219

# Drug_Target_141_Cellular_Location:
Microsome

# Drug_Target_141_Chromosome_Location:
Not Available

# Drug_Target_141_Drug_References:
12699699	Auclair K, Huang HW, Moenne-Loccoz P, Ortiz de Montellano PR: Cloning and expression of a heme binding protein from the genome of Saccharomyces cerevisiae. Protein Expr Purif. 2003 Apr;28(2):340-9.
12897089	Calo LA, Pagnin E, Davis PA, Sartori M, Semplicini A: Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant. 2003 Aug;18(8):1518-25.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_141_Essentiality:
Non-Essential

# Drug_Target_141_GenAtlas_ID:
HMOX1

# Drug_Target_141_GenBank_ID_Gene:
X06985

# Drug_Target_141_GenBank_ID_Protein:
35173

# Drug_Target_141_GeneCard_ID:
HMOX1

# Drug_Target_141_Gene_Name:
HMOX1

# Drug_Target_141_Gene_Sequence:
>867 bp
ATGGAGCGTCCGCAACCCGACAGCATGCCCCAGGATTTGTCAGAGGCCCTGAAGGAGGCC
ACCAAGGAGGTGCACACCCAGGCAGAGAATGCTGAGTTCATGAGGAACTTTCAGAAGGGC
CAGGTGACCCGAGACGGCTTCAAGCTGGTGATGGCCTCCCTGTACCACATCTATGTGGCC
CTGGAGGAGGAGATTGAGCGCAACAAGGAGAGCCCAGTCTTCGCCCCTGTCTACTTCCCA
GAAGAGCTGCACCGCAAGGCTGCCCTGGAGCAGGACCTGGCCTTCTGGTACGGGCCCCGC
TGGCAGGAGGTCATCCCCTACACACCAGCCATGCAGCGCTATGTGAAGCGGCTCCACGAG
GTGGGGCGCACAGAGCCCGAGCTGCTGGTGGCCCACGCCTACACCCGCTACCTGGGTGAC
CTGTCTGGGGGCCAGGTGCTCAAAAAGATTGCCCAGAAAGCCCTGGACCTGCCCAGCTCT
GGCGAGGGCCTGGCCTTCTTCACCTTCCCCAACATTGCCAGTGCCACCAAGTTCAAGCAG
CTCTACCGCTCCCGCATGAACTCCCTGGAGATGACTCCCGCAGTCAGGCAGAGGGTGATA
GAAGAGGCCAAGACTGCGTTCCTGCTCAACATCCAGCTCTTTGAGGAGTTGCAGGAGCTG
CTGACCCATGACACCAAGGACCAGAGCCCCTCACGGGCACCAGGGCTTCGCCAGCGGGCC
AGCAACAAAGTGCAAGATTCTGCCCCCGTGGAGACTCCCAGAGGGAAGCCCCCACTCAAC
ACCCGCTCCCAGGCTCCGCTTCTCCGATGGGTCCTTACACTCAGCTTTCTGGTGGCGACA
GTTGCTGTAGGGCTTTATGCCATGTGA

# Drug_Target_141_General_Function:
Involved in heme oxygenase (decyclizing) activity

# Drug_Target_141_General_References:
10467099	Schuller DJ, Wilks A, Ortiz de Montellano PR, Poulos TL: Crystal structure of human heme oxygenase-1. Nat Struct Biol. 1999 Sep;6(9):860-7.
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
2537723	Shibahara S, Sato M, Muller RM, Yoshida T: Structural organization of the human heme oxygenase gene and the function of its promoter. Eur J Biochem. 1989 Feb 15;179(3):557-63.
2911585	Keyse SM, Tyrrell RM: Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci U S A. 1989 Jan;86(1):99-103.
3345742	Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S: Human heme oxygenase cDNA and induction of its mRNA by hemin. Eur J Biochem. 1988 Feb 1;171(3):457-61.

# Drug_Target_141_HGNC_ID:
HGNC:5013

# Drug_Target_141_HPRD_ID:
00782

# Drug_Target_141_ID:
810

# Drug_Target_141_Locus:
22q12|22q13.1

# Drug_Target_141_Molecular_Weight:
32819

# Drug_Target_141_Name:
Heme oxygenase 1

# Drug_Target_141_Number_of_Residues:
288

# Drug_Target_141_PDB_ID:
1T5P

# Drug_Target_141_Pathway:
Not Available

# Drug_Target_141_Pfam_Domain_Function:
PF01126	Heme_oxygenase

# Drug_Target_141_Protein_Sequence:
>Heme oxygenase 1
MERPQPDSMPQDLSEALKEATKEVHTQAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVA
LEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHE
VGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQ
LYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQSPSRAPGLRQRA
SNKVQDSAPVETPRGKPPLNTRSQAPLLRWVLTLSFLVATVAVGLYAM

# Drug_Target_141_Reaction:
heme + 3 AH2 + 3 O2 = biliverdin + Fe2+ + CO + 3 A + 3 H2O

# Drug_Target_141_Signals:
None

# Drug_Target_141_Specific_Function:
Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed

# Drug_Target_141_SwissProt_ID:
P09601

# Drug_Target_141_SwissProt_Name:
HMOX1_HUMAN

# Drug_Target_141_Synonyms:
EC 1.14.99.3
HO-1

# Drug_Target_141_Theoretical_pI:
8.68

# Drug_Target_141_Transmembrane_Regions:
265-287

# Drug_Target_142_Cellular_Location:
Microsome

# Drug_Target_142_Chromosome_Location:
Not Available

# Drug_Target_142_Drug_References:
16986858	Tanaka M, Ohkubo K, Fukuzumi S: DNA cleavage by UVA irradiation of NADH with dioxygen via radical chain processes. J Phys Chem A. 2006 Sep 28;110(38):11214-8.
17157188	Goldstone AB, Liochev SI, Fridovich I: Inactivation of copper, zinc superoxide dismutase by H2O2 : mechanism of protection. Free Radic Biol Med. 2006 Dec 15;41(12):1860-3. Epub 2006 Sep 19.

# Drug_Target_142_Essentiality:
Non-Essential

# Drug_Target_142_GenAtlas_ID:
HMOX2

# Drug_Target_142_GenBank_ID_Gene:
D21243

# Drug_Target_142_GenBank_ID_Protein:
443771

# Drug_Target_142_GeneCard_ID:
HMOX2

# Drug_Target_142_Gene_Name:
HMOX2

# Drug_Target_142_Gene_Sequence:
>951 bp
ATGTCAGCGGAAGTGGAAACCTCAGAGGGGGTAGACGAGTCAGAAAAAAAGAACTCTGGG
GCCCTAGAAAAGGAGAACCAAATGAGAATGGCTGACCTCTCGGAGCTCCTGAAGGAAGGG
ACCAAGGAAGCACACGACCGGGCAGAAAACACCCAGTTTGTCAAGGACTTCTTGAAAGGC
AACATTAAGAAGGAGCTGTTTAAGCTGGCCACCACGGCACTTTACTTCACATACTCAGCC
CTCGAGGAGGAAATGGAGCGCAACAAGGACCATCCAGCCTTTGCCCCTTTGTACTTCCCC
ATGGAGCTGCACCGGAAGGAGGCGCTGACCAAGGACATGGAGTATTTCTTTGGTGAAAAC
TGGGAGGAGCAGGTGCAGTGCCCCAAGGCTGCCCAGAAGTACGTGGAGCGGATCCACTAC
ATAGGGCAGAACGAGCCGGAGCTACTGGTGGCCCATGCATACACCCGCTACATGGGGGAT
CTCTCGGGGGGCCAGGTGCTGAAGAAGGTGGCCCAGCGAGCACTGAAACTCCCCAGCACA
GGGGAAGGGACCCAGTTCTACCTGTTTGAGAATGTGGACAATGCCCAGCAGTTCAAGCAG
CTCTACCGGGCCAGGATGAACGCCCTGGACCTGAACATGAAGACCAAAGAGAGGATCGTG
GAGGAGGCCAACAAGGCTTTTGAGTATAACATGCAGATATTCAATGAACTGGACCAGGCC
GGCTCCACACTGGCCAGAGAGACCTTGGAGGATGGGTTCCCTGTACACGATGGGAAAGGA
GACATGCGTAAATGCCCTTTCTACGCTGCTGAACAAGACAAAGGTGCCCTGGAGGGCAGC
AGCTGTCCCTTCCGAACAGCTATGGCTGTGCTGAGGAAGCCCAGCCTCCAGTTCATCCTG
GCCGCTGGTGTGGCCCTAGCTGCTGGACTCTTGGCCTGGTACTACATGTGA

# Drug_Target_142_General_Function:
Involved in heme oxygenase (decyclizing) activity

# Drug_Target_142_General_References:
1575508	McCoubrey WK Jr, Ewing JF, Maines MD: Human heme oxygenase-2: characterization and expression of a full-length cDNA and evidence suggesting that the two HO-2 transcripts may differ by choice of polyadenylation signal. Arch Biochem Biophys. 1992 May 15;295(1):13-20.
7890772	Ishikawa K, Takeuchi N, Takahashi S, Matera KM, Sato M, Shibahara S, Rousseau DL, Ikeda-Saito M, Yoshida T: Heme oxygenase-2. Properties of the heme complex of the purified tryptic fragment of recombinant human heme oxygenase-2. J Biol Chem. 1995 Mar 17;270(11):6345-50.

# Drug_Target_142_HGNC_ID:
HGNC:5014

# Drug_Target_142_HPRD_ID:
00783

# Drug_Target_142_ID:
644

# Drug_Target_142_Locus:
16p13.3

# Drug_Target_142_Molecular_Weight:
36033

# Drug_Target_142_Name:
Heme oxygenase 2

# Drug_Target_142_Number_of_Residues:
316

# Drug_Target_142_PDB_ID:
Not Available

# Drug_Target_142_Pathway:
Not Available

# Drug_Target_142_Pfam_Domain_Function:
PF01126	Heme_oxygenase

# Drug_Target_142_Protein_Sequence:
>Heme oxygenase 2
MSAEVETSEGVDESEKKNSGALEKENQMRMADLSELLKEGTKEAHDRAENTQFVKDFLKG
NIKKELFKLATTALYFTYSALEEEMERNKDHPAFAPLYFPMELHRKEALTKDMEYFFGEN
WEEQVQCPKAAQKYVERIHYIGQNEPELLVAHAYTRYMGDLSGGQVLKKVAQRALKLPST
GEGTQFYLFENVDNAQQFKQLYRARMNALDLNMKTKERIVEEANKAFEYNMQIFNELDQA
GSTLARETLEDGFPVHDGKGDMRKCPFYAAEQDKGALEGSSCPFRTAMAVLRKPSLQFIL
AAGVALAAGLLAWYYM

# Drug_Target_142_Reaction:
heme + 3 AH2 + 3 O2 = biliverdin + Fe2+ + CO + 3 A + 3 H2O

# Drug_Target_142_Signals:
None

# Drug_Target_142_Specific_Function:
Heme oxygenase 2 could be implicated in the production of carbon monoxide in brain where it could act as a neurotransmitter

# Drug_Target_142_SwissProt_ID:
P30519

# Drug_Target_142_SwissProt_Name:
HMOX2_HUMAN

# Drug_Target_142_Synonyms:
EC 1.14.99.3
HO-2

# Drug_Target_142_Theoretical_pI:
5.09

# Drug_Target_142_Transmembrane_Regions:
296-315

# Drug_Target_143_Cellular_Location:
Not Available

# Drug_Target_143_Chromosome_Location:
Not Available

# Drug_Target_143_Drug_References:
17595315	Pandey AV, Kempna P, Hofer G, Mullis PE, Fluck CE: Modulation of Human CYP19A1 Activity by Mutant NADPH P450 Oxidoreductase. Mol Endocrinol. 2007 Oct;21(10):2579-95. Epub 2007 Jun 26.

# Drug_Target_143_Essentiality:
Non-Essential

# Drug_Target_143_GenAtlas_ID:
CYP17A1

# Drug_Target_143_GenBank_ID_Gene:
M14564

# Drug_Target_143_GenBank_ID_Protein:
181342

# Drug_Target_143_GeneCard_ID:
CYP17A1

# Drug_Target_143_Gene_Name:
CYP17A1

# Drug_Target_143_Gene_Sequence:
>1527 bp
ATGTGGGAGCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTGTTTTGGCCCAAGAGA
AGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTG
CCATTCCTCCCCAGACATGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAATAT
GGCCCCATCTATTCTGTTCGTATGGGCACCAAGACTACAGTGATTGTCGGCCACCACCAG
CTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAGGACTTCTCTGGGCGGCCTCAAATGGCA
ACTCTAGACATCGCGTCCAACAACCGTAAGGGTATCGCCTTCGCTGACTCTGGCGCACAC
TGGCAGCTGCATCGAAGGCTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAG
AAGCTGGAGAAGATCATTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACCCAC
AACGGACAGTCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAACCAATGTCATCTCC
TTGATCTGCTTCAATACCTCCTACAAGAATGGGGACCCTGAGTTGAATGTCATACAGAAT
TACAATGAAGGCATCATAGACAACCTGAGCAAAGACAGCCTGGTGGACCTAGTCCCCTGG
TTGAAGATTTTCCCCAACAAAACCCTGGAAAAATTAAAGAGCCATGTTAAAATACGAAAT
GATCTGCTGAATAAAATACTTGAAAATTACAAGGAGAAATTCCGGAGTGACTCTATCACC
AACATGCTGGACACACTGATGCAAGCCAAGATGAACTCAGATAATGGCAATGCTGGCCCA
GATCAAGATTCAGAGCTGCTTTCAGATAACCACATTCTCACCACCATAGGGGACATCTTT
GGGGCTGGCGTGGAGACCACCACCTCTGTGGTTAAATGGACCCTGGCCTTCCTGCTGCAC
AATCCTCAGGTGAAGAAGAAGCTCTACGAGGAGATTGACCAGAATGTGGGTTTCAGCCGC
ACACCAACTATCAGTGACCGTAACCGTCTCCTCCTGCTGGAGGCCACCATCCGAGAGGTG
CTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAGGCCAACGTTGACTCCAGC
ATCGGTGAGTTTGCTGTGGACAAGGGCACAGAAGTTATCATCAATCTGTGGGCGCTGCAT
CACAATGAGAAGGAGTGGCACCAGCCGGATCAGTTCATGCCTGAGCGTTTCTTGAATCCA
GCGGGGACCCAGCTCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGC
TCCTGTATAGGTGAGATCCTGGCCCGCCAGGAGCTCTTCCTCATCATGGCCTGGCTGCTG
CAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCTGGAAGGCATCCCC
AAGGTGGTCTTTCTGATCGACTCTTTCAAAGTGAAGATCAAGGTGCGCCAGGCCTGGAGG
GAAGCCCAGGCTGAGGGTAGCACCTAA

# Drug_Target_143_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_143_General_References:
10406467	Auchus RJ, Miller WL: Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol. 1999 Jul;13(7):1169-82.
10720067	Biason-Lauber A, Kempken B, Werder E, Forest MG, Einaudi S, Ranke MB, Matsuo N, Brunelli V, Schonle EJ, Zachmann M: 17alpha-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. J Clin Endocrinol Metab. 2000 Mar;85(3):1226-31.
11549685	Gupta MK, Geller DH, Auchus RJ: Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency. J Clin Endocrinol Metab. 2001 Sep;86(9):4416-23.
11836339	Di Cerbo A, Biason-Lauber A, Savino M, Piemontese MR, Di Giorgio A, Perona M, Savoia A: Combined 17alpha-Hydroxylase/17,20-lyase deficiency caused by Phe93Cys mutation in the CYP17 gene. J Clin Endocrinol Metab. 2002 Feb;87(2):898-905.
12466376	Van Den Akker EL, Koper JW, Boehmer AL, Themmen AP, Verhoef-Post M, Timmerman MA, Otten BJ, Drop SL, De Jong FH: Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab. 2002 Dec;87(12):5714-21.
1515452	Yanase T, Waterman MR, Zachmann M, Winter JS, Simpson ER, Kagimoto M: Molecular basis of apparent isolated 17,20-lyase deficiency: compound heterozygous mutations in the C-terminal region (Arg(496)----Cys, Gln(461)----Stop) actually cause combined 17 alpha-hydroxylase/17,20-lyase deficiency. Biochim Biophys Acta. 1992 Aug 25;1139(4):275-9.
1714904	Lin D, Harikrishna JA, Moore CC, Jones KL, Miller WL: Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency. J Biol Chem. 1991 Aug 25;266(24):15992-8.
1740503	Ahlgren R, Yanase T, Simpson ER, Winter JS, Waterman MR: Compound heterozygous mutations (Arg 239----stop, Pro 342----Thr) in the CYP17 (P45017 alpha) gene lead to ambiguous external genitalia in a male patient with partial combined 17 alpha-hydroxylase/17,20-lyase deficiency. J Clin Endocrinol Metab. 1992 Mar;74(3):667-72.
1964490	Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL: Tissue-specific, cyclic adenosine 3',5'-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol. 1990 Dec;4(12):1972-9.
2808364	Yanase T, Kagimoto M, Suzuki S, Hashiba K, Simpson ER, Waterman MR: Deletion of a phenylalanine in the N-terminal region of human cytochrome P-450(17 alpha) results in partial combined 17 alpha-hydroxylase/17,20-lyase deficiency. J Biol Chem. 1989 Oct 25;264(30):18076-82.
2843762	Kagimoto M, Winter JS, Kagimoto K, Simpson ER, Waterman MR: Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol. 1988 Jun;2(6):564-70.
3025870	Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE, Miller WL: Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(2):407-11.
3274893	Bradshaw KD, Waterman MR, Couch RT, Simpson ER, Zuber MX: Characterization of complementary deoxyribonucleic acid for human adrenocortical 17 alpha-hydroxylase: a probe for analysis of 17 alpha-hydroxylase deficiency. Mol Endocrinol. 1987 May;1(5):348-54.
3500022	Picado-Leonard J, Miller WL: Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA. 1987 Oct;6(5):439-48.
8027220	Fardella CE, Hum DW, Homoki J, Miller WL: Point mutation of Arg440 to His in cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency. J Clin Endocrinol Metab. 1994 Jul;79(1):160-4.
8245018	Monno S, Ogawa H, Date T, Fujioka M, Miller WL, Kobayashi M: Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17 alpha-hydroxylase deficiency. J Biol Chem. 1993 Dec 5;268(34):25811-7.
8345056	Fardella CE, Zhang LH, Mahachoklertwattana P, Lin D, Miller WL: Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17 alpha-hydroxylase deficiency. J Clin Endocrinol Metab. 1993 Aug;77(2):489-93.
8396144	Imai T, Globerman H, Gertner JM, Kagawa N, Waterman MR: Expression and purification of functional human 17 alpha-hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17 alpha-hydroxylase/17,20-lyase deficiency. J Biol Chem. 1993 Sep 15;268(26):19681-9.
8550762	Laflamme N, Leblanc JF, Mailloux J, Faure N, Labrie F, Simard J: Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. J Clin Endocrinol Metab. 1996 Jan;81(1):264-8.

# Drug_Target_143_HGNC_ID:
HGNC:2593

# Drug_Target_143_HPRD_ID:
01944

# Drug_Target_143_ID:
380

# Drug_Target_143_Locus:
10q24.3

# Drug_Target_143_Molecular_Weight:
57371

# Drug_Target_143_Name:
Cytochrome P450 17A1

# Drug_Target_143_Number_of_Residues:
508

# Drug_Target_143_PDB_ID:
Not Available

# Drug_Target_143_Pathway:
Not Available

# Drug_Target_143_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_143_Protein_Sequence:
>Cytochrome P450 17A1
MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKY
GPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAH
WQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVIS
LICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRN
DLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIF
GAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREV
LRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNP
AGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIP
KVVFLIDSFKVKIKVRQAWREAQAEGST

# Drug_Target_143_Reaction:
a steroid + AH2 + O2 = a 17alpha-hydroxysteroid + A + H2O

# Drug_Target_143_Signals:
None

# Drug_Target_143_Specific_Function:
Conversion of pregnenolone and progesterone to their 17- alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty

# Drug_Target_143_SwissProt_ID:
P05093

# Drug_Target_143_SwissProt_Name:
CP17A_HUMAN

# Drug_Target_143_Synonyms:
CYPXVII
EC 1.14.99.9
P450-C17
P450c17
Steroid 17-alpha-hydroxylase/17,20 lyase
Steroid 17-alpha-monooxygenase

# Drug_Target_143_Theoretical_pI:
8.87

# Drug_Target_143_Transmembrane_Regions:
None

# Drug_Target_144_Cellular_Location:
Melanosome
melanosomal membrane
single- pass type I membrane protein

# Drug_Target_144_Chromosome_Location:
Not Available

# Drug_Target_144_Drug_References:
16790533	Zafar KS, Siegel D, Ross D: A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol. 2006 Sep;70(3):1079-86. Epub 2006 Jun 21.
17292452	Jadhav JP, Parshetti GK, Kalme SD, Govindwar SP: Decolourization of azo dye methyl red by Saccharomyces cerevisiae MTCC 463. Chemosphere. 2007 Jun;68(2):394-400. Epub 2007 Feb 9.

# Drug_Target_144_Essentiality:
Non-Essential

# Drug_Target_144_GenAtlas_ID:
TYR

# Drug_Target_144_GenBank_ID_Gene:
M27160

# Drug_Target_144_GenBank_ID_Protein:
340037

# Drug_Target_144_GeneCard_ID:
TYR

# Drug_Target_144_Gene_Name:
TYR

# Drug_Target_144_Gene_Sequence:
>1590 bp
ATGCTCCTGGCTGTTTTGTACTGCCTGCTGTGGAGTTTCCAGACCTCCGCTGGCCATTTC
CCTAGAGCCTGTGTCTCCTCTAAGAACCTGATGGAGAAGGAATGCTGTCCACCGTGGAGC
GGGGACAGGAGTCCCTGTGGCCAGCTTTCAGGCAGAGGTTCCTGTCAGAATATCCTTCTG
TCCAATGCACCACTTGGGCCTCAATTTCCCTTCACAGGGGTGGATGACCGGGAGTCGTGG
CCTTCCGTCTTTTATAATAGGACCTGCCAGTGCTCTGGCAACTTCATGGGATTCAACTGT
GGAAACTGCAAGTTTGGCTTTTGGGGACCAAACTGCACAGAGAGACGACTCTTGGTGAGA
AGAAACATCTTCGATTTGAGTGCCCCAGAGAAGGACAAATTTTTTGCCTACCTCACTTTA
GCAAAGCATACCATCAGCTCAGACTATGTCATCCCCATAGGGACCTATGGCCAAATGAAA
AATGGATCAACACCCATGTTTAACGACATCAATATTTATGACCTCTTTGTCTGGATGCAT
TATTATGTGTCAATGGATGCACTGCTTGGGGGATCTGAAATCTGGAGAGACATTGATTTT
GCCCATGAAGCACCAGCTTTTCTGCCTTGGCATAGACTCTTCTTGTTGCGGTGGGAACAA
GAAATCCAGAAGCTGACAGGAGATGAAAACTTCACTATTCCATATTGGGACTGGCGGGAT
GCAGAAAAGTGTGACATTTGCACAGATGAGTACATGGGAGGTCAGCACCCCACAAATCCT
AACTTACTCAGCCCAGCATCATTCTTCTCCTCTTGGCAGATTGTCTGTAGCCGATTGGAG
GAGTACAACAGCCATCAGTCTTTATGCAATGGAACGCCCGAGGGACCTTTACGGCGTAAT
CCTGGAAACCATGACAAATCCAGAACCCCAAGGCTCCCCTCTTCAGCTGATGTAGAATTT
TGCCTGAGTTTGACCCAATATGAATCTGGTTCCATGGATAAAGCTGCCAATTTCAGCTTT
AGAAATACACTGGAAGGATTTGCTAGTCCACTTACTGGGATAGCGGATGCCTCTCAAAGC
AGCATGCACAATGCCTTGCACATCTATATGAATGGAACAATGTCCCAGGTACAGGGATCT
GCCAACGATCCTATCTTCCTTCTTCACCATGCATTTGTTGACAGTATTTTTGAGCAGTGG
CTCCGAAGGCACCGTCCTCTTCAAGAAGTTTATCCAGAAGCCAATGCACCCATTGGACAT
AACCGGGAATCCTACATGGTTCCTTTTATACCACTGTACAGAAATGGTGATTTCTTTATT
TCATCCAAAGATCTGGGCTATGACTATAGCTATCTACAAGATTCAGACCCAGACTCTTTT
CAAGACTACATTAAGTCCTATTTGGAACAAGCGAGTCGGATCTGGTCATGGCTCCTTGGG
GCGGCGATGGTAGGGGCCGTCCTCACTGCCCTGCTGGCAGGGCTTGTGAGCTTGCTGTGT
CGTCACAAGAGAAAGCAGCTTCCTGAAGAAAAGCAGCCACTCCTCATGGAGAAAGAGGAT
TACCACAGCTTGTATCAGAGCCATTTATAA

# Drug_Target_144_General_Function:
Involved in oxidoreductase activity

# Drug_Target_144_General_References:
10094567	Oetting WS, King RA: Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999;13(2):99-115.
10571953	Tsai CH, Tsai FJ, Wu JY, Lin SP, Chang JG, Yang CF, Lee CC: Insertion/deletion mutations of type I oculocutaneous albinism in chinese patients from Taiwan. Hum Mutat. 1999 Dec;14(6):542.
10987646	Passmore LA, Kaesmann-Kellner B, Weber BH: Novel and recurrent mutations in the tyrosinase gene and the P gene in the German albino population. Hum Genet. 1999 Sep;105(3):200-10.
11153699	Martinez-Arias R, Comas D, Andres A, Abello MT, Domingo-Roura X, Bertranpetit J: The tyrosinase gene in gorillas and the albinism of 'Snowflake'. Pigment Cell Res. 2000 Dec;13(6):467-70.
11214319	Murphy WJ, Eizirik E, Johnson WE, Zhang YP, Ryder OA, O'Brien SJ: Molecular phylogenetics and the origins of placental mammals. Nature. 2001 Feb 1;409(6820):614-8.
11295837	Camand O, Marchant D, Boutboul S, Pequignot M, Odent S, Dollfus H, Sutherland J, Levin A, Menasche M, Marsac C, Dufier JL, Heon E, Abitbol M: Mutation analysis of the tyrosinase gene in oculocutaneous albinism. Hum Mutat. 2001 Apr;17(4):352.
11858948	Nakamura E, Miyamura Y, Matsunaga J, Kano Y, Dakeishi-Hara M, Tanita M, Kono M, Tomita Y: A novel mutation of the tyrosinase gene causing oculocutaneous albinism type 1 (OCA1). J Dermatol Sci. 2002 Feb;28(2):102-5.
1487241	Oetting WS, King RA: Molecular analysis of type I-A (tyrosinase negative) oculocutaneous albinism. Hum Genet. 1992 Nov;90(3):258-62.
1642278	Tripathi RK, Strunk KM, Giebel LB, Weleber RG, Spritz RA: Tyrosinase gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism define two clusters of missense substitutions. Am J Med Genet. 1992 Jul 15;43(5):865-71.
1711223	Chintamaneni CD, Halaban R, Kobayashi Y, Witkop CJ Jr, Kwon BS: A single base insertion in the putative transmembrane domain of the tyrosinase gene as a cause for tyrosinase-negative oculocutaneous albinism. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5272-6.
1899321	Spritz RA, Strunk KM, Hsieh CL, Sekhon GS, Francke U: Homozygous tyrosinase gene mutation in an American black with tyrosinase-negative (type IA) oculocutaneous albinism. Am J Hum Genet. 1991 Feb;48(2):318-24.
1900309	Giebel LB, Tripathi RK, King RA, Spritz RA: A tyrosinase gene missense mutation in temperature-sensitive type I oculocutaneous albinism. A human homologue to the Siamese cat and the Himalayan mouse. J Clin Invest. 1991 Mar;87(3):1119-22.
1903356	Giebel LB, Strunk KM, Spritz RA: Organization and nucleotide sequences of the human tyrosinase gene and a truncated tyrosinase-related segment. Genomics. 1991 Mar;9(3):435-45.
1903591	Giebel LB, Tripathi RK, Strunk KM, Hanifin JM, Jackson CE, King RA, Spritz RA: Tyrosinase gene mutations associated with type IB ("yellow") oculocutaneous albinism. Am J Hum Genet. 1991 Jun;48(6):1159-67.
1943686	King RA, Mentink MM, Oetting WS: Non-random distribution of missense mutations within the human tyrosinase gene in type I (tyrosinase-related) oculocutaneous albinism. Mol Biol Med. 1991 Feb;8(1):19-29.
1970634	Giebel LB, Strunk KM, King RA, Hanifin JM, Spritz RA: A frequent tyrosinase gene mutation in classic, tyrosinase-negative (type IA) oculocutaneous albinism. Proc Natl Acad Sci U S A. 1990 May;87(9):3255-8.
2342539	Spritz RA, Strunk KM, Giebel LB, King RA: Detection of mutations in the tyrosinase gene in a patient with type IA oculocutaneous albinism. N Engl J Med. 1990 Jun 14;322(24):1724-8.
2480811	Kikuchi H, Miura H, Yamamoto H, Takeuchi T, Dei T, Watanabe M: Characteristic sequences in the upstream region of the human tyrosinase gene. Biochim Biophys Acta. 1989 Dec 22;1009(3):283-6.
2499655	Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN: Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med. 1989 Jun 1;169(6):2029-42.
2504160	Takeda A, Tomita Y, Okinaga S, Tagami H, Shibahara S: Functional analysis of the cDNA encoding human tyrosinase precursor. Biochem Biophys Res Commun. 1989 Aug 15;162(3):984-90.
2823263	Kwon BS, Haq AK, Pomerantz SH, Halaban R: Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7473-7.
7902671	Tripathi RK, Bundey S, Musarella MA, Droetto S, Strunk KM, Holmes SA, Spritz RA: Mutations of the tyrosinase gene in Indo-Pakistani patients with type I (tyrosinase-deficient) oculocutaneous albinism (OCA). Am J Hum Genet. 1993 Dec;53(6):1173-9.
7955413	Breimer LH, Winder AF, Jay B, Jay M: Initiation codon mutation of the tyrosinase gene as a cause of human albinism. Clin Chim Acta. 1994 Jun;227(1-2):17-22.
8128955	Gershoni-Baruch R, Rosenmann A, Droetto S, Holmes S, Tripathi RK, Spritz RA: Mutations of the tyrosinase gene in patients with oculocutaneous albinism from various ethnic groups in Israel. Am J Hum Genet. 1994 Apr;54(4):586-94.
8340755	Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489-95.
8477259	Oetting WS, King RA: Molecular basis of type I (tyrosinase-related) oculocutaneous albinism: mutations and polymorphisms of the human tyrosinase gene. Hum Mutat. 1993;2(1):1-6.
8644824	Summers CG, Oetting WS, King RA: Diagnosis of oculocutaneous albinism with molecular analysis. Am J Ophthalmol. 1996 Jun;121(6):724-6.
9158138	Morell R, Spritz RA, Ho L, Pierpont J, Guo W, Friedman TB, Asher JH Jr: Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). Hum Mol Genet. 1997 May;6(5):659-64.
9259202	Spritz RA, Oh J, Fukai K, Holmes SA, Ho L, Chitayat D, France TD, Musarella MA, Orlow SJ, Schnur RE, Weleber RG, Levin AV: Novel mutations of the tyrosinase (TYR) gene in type I oculocutaneous albinism (OCA1). Hum Mutat. 1997;10(2):171-4.

# Drug_Target_144_HGNC_ID:
HGNC:12442

# Drug_Target_144_HPRD_ID:
06086

# Drug_Target_144_ID:
279

# Drug_Target_144_Locus:
11q14-q21

# Drug_Target_144_Molecular_Weight:
60394

# Drug_Target_144_Name:
Tyrosinase

# Drug_Target_144_Number_of_Residues:
529

# Drug_Target_144_PDB_ID:
Not Available

# Drug_Target_144_Pathway:
Not Available

# Drug_Target_144_Pfam_Domain_Function:
PF00264	Tyrosinase

# Drug_Target_144_Protein_Sequence:
>Tyrosinase precursor
MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILL
SNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVR
RNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMH
YYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRD
AEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRN
PGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQS
SMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGH
NRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLG
AAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL

# Drug_Target_144_Reaction:
L-tyrosine + L-dopa + O2 = L-dopa + dopaquinone + H2O

# Drug_Target_144_Signals:
1-18

# Drug_Target_144_Specific_Function:
This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the rate-limiting conversions of tyrosine to DOPA, DOPA to DOPA-quinone and possibly 5,6-dihydroxyindole to indole-5,6 quinone

# Drug_Target_144_SwissProt_ID:
P14679

# Drug_Target_144_SwissProt_Name:
TYRO_HUMAN

# Drug_Target_144_Synonyms:
EC 1.14.18.1
LB24-AB
Monophenol monooxygenase
SK29-AB
Tumor rejection antigen AB
Tyrosinase precursor

# Drug_Target_144_Theoretical_pI:
6.05

# Drug_Target_144_Transmembrane_Regions:
477-497

# Drug_Target_14_Cellular_Location:
Cytoplasm

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17006762	O'Brien J, Kla KM, Hopkins IB, Malecki EA, McKenna MC: Kinetic parameters and lactate dehydrogenase isozyme activities support possible lactate utilization by neurons. Neurochem Res. 2007 Apr-May;32(4-5):597-607. Epub 2006 Sep 28.
17308685	Draghia AC: Histochemical and histopathological study of the gastric mucosa in the portal hypertensive gastropathy. Rom J Morphol Embryol. 2006;47(3):259-62.
17555402	Semenza GL: Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J. 2007 Jul 1;405(1):1-9.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
LDHA

# Drug_Target_14_GenBank_ID_Gene:
X02152

# Drug_Target_14_GenBank_ID_Protein:
34313

# Drug_Target_14_GeneCard_ID:
LDHA

# Drug_Target_14_Gene_Name:
LDHA

# Drug_Target_14_Gene_Sequence:
>999 bp
ATGGCAACTCTAAAGGATCAGCTGATTTATAATCTTCTAAAGGAAGAACAGACCCCCCAG
AATAAGATTACAGTTGTTGGGGTTGGTGCTGTTGGCATGGCCTGTGCCATCAGTATCTTA
ATGAAGGACTTGGCAGATGAACTTGCTCTTGTTGATGTCATCGAAGACAAATTGAAGGGA
GAGATGATGGATCTCCAACATGGCAGCCTTTTCCTTAGAACACCAAAGATTGTCTCTGGC
AAAGACTATAATGTAACTGCAAACTCCAAGCTGGTCATTATCACGGCTGGGGCACGTCAG
CAAGAGGGAGAAAGCCGTCTTAATTTGGTCCAGCGTAACGTGAACATATTTAAATTCATC
ATTCCTAATGTTGTAAAATACAGCCCGAACTGCAAGTTGCTTATTGTTTCAAATCCAGTG
GATATCTTGACCTACGTGGCTTGGAAGATAAGTGGTTTTCCCAAAAACCGTGTTATTGGA
AGTGGTTGCAATCTGGATTCAGCCCGATTCCGTTACCTGATGGGGGAAAGGCTGGGAGTT
CACCCATTAAGCTGTCATGGGTGGGTCCTTGGGGAACATGGAGATTCCAGTGTGCCTGTA
TGGAGTGGAATGAATGTTGCTGGTGTCTCTCTGAAGACTCTGCACCCAGATTTAGGGACT
GATAAAGATAAGGAACAGTGGAAAGAGGTTCACAAGCAGGTGGTTGAGAGTGCTTATGAG
GTGATCAAACTCAAAGGCTACACATCCTGGGCTATTGGACTCTCTGTAGCAGATTTGGCA
GAGAGTATAATGAAGAATCTTAGGCGGGTGCACCCAGTTTCCACCATGATTAAGGGTCTT
TACGGAATAAAGGATGATGTCTTCCTTAGTGTTCCTTGCATTTTGGGACAGAATGGAATC
TCAGACCTTGTGAAGGTGACTCTGACTTCTGAGGAAGAGGCCCGTTTGAAGAAGAGTGCA
GATACACTTTGGGGGATCCAAAAGGAGCTGCAATTTTAA

# Drug_Target_14_General_Function:
Energy production and conversion

# Drug_Target_14_General_References:
10508479	Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 1999 Nov 12;83(4):456-64.
1445373	Sudo K, Maekawa M, Shioya M, Ikeda K, Takahashi N, Isogai Y, Li SS, Kanno T, Machida K, Toriumi J: Molecular analysis of genetic mutation in electrophoretic variant of human lactate dehydrogenase-A(M) subunit. Biochem Int. 1992 Sep;27(6):1051-7.
1959923	Maekawa M, Sudo K, Li SS, Kanno T: Genotypic analysis of families with lactate dehydrogenase A (M) deficiency by selective DNA amplification. Hum Genet. 1991 Nov;88(1):34-8.
3000353	Chung FZ, Tsujibo H, Bhattacharyya U, Sharief FS, LI SS: Genomic organization of human lactate dehydrogenase-A gene. Biochem J. 1985 Nov 1;231(3):537-41.
3838278	Tsujibo H, Tiano HF, Li SS: Nucleotide sequences of the cDNA and an intronless pseudogene for human lactate dehydrogenase-A isozyme. Eur J Biochem. 1985 Feb 15;147(1):9-15.
7908613	Maekawa M, Sudo K, Kobayashi A, Sugiyama E, Li SS, Kanno T: Fast-type electrophoretic variant of lactate dehydrogenase M(A) and comparison with other missense mutations in lactate dehydrogenase M(A) and H(B) genes. Clin Chem. 1994 Apr;40(4):665-8.

# Drug_Target_14_HGNC_ID:
HGNC:6535

# Drug_Target_14_HPRD_ID:
01025

# Drug_Target_14_ID:
473

# Drug_Target_14_Locus:
11p15.4

# Drug_Target_14_Molecular_Weight:
36558

# Drug_Target_14_Name:
L-lactate dehydrogenase A chain

# Drug_Target_14_Number_of_Residues:
331

# Drug_Target_14_PDB_ID:
1I10

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_14_Protein_Sequence:
>L-lactate dehydrogenase A chain
ATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGE
MMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFII
PNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVH
PLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEV
IKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGIS
DLVKVTLTSEEEARLKKSADTLWGIQKELQF

# Drug_Target_14_Reaction:
(S)-lactate + NAD+ = pyruvate + NADH + H+

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Not Available

# Drug_Target_14_SwissProt_ID:
P00338

# Drug_Target_14_SwissProt_Name:
LDHA_HUMAN

# Drug_Target_14_Synonyms:
EC 1.1.1.27
LDH muscle subunit
LDH-A
LDH-M
Proliferation-inducing gene 19 protein
Renal carcinoma antigen NY-REN-59

# Drug_Target_14_Theoretical_pI:
8.45

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
ME2

# Drug_Target_15_GenBank_ID_Gene:
M55905

# Drug_Target_15_GenBank_ID_Protein:
187300

# Drug_Target_15_GeneCard_ID:
ME2

# Drug_Target_15_Gene_Name:
ME2

# Drug_Target_15_Gene_Sequence:
>1755 bp
ATGTTGTCCCGGTTAAGAGTAGTTTCCACCACTTGTACTTTGGCATGTCGACATTTGCAC
ATAAAAGAAAAAGGCAAGCCACTTATGCTGAACCCAAGAACAAACAAGGGAATGGCATTT
ACTTTACAAGAACGACAAATGCTTGGTCTTCAAGGACTTCTACCTCCCAAAATAGAGACA
CAAGATATTCAAGCCTTACGATTTCATAGAAACTTGAAGAAAATGACTAGCCCTTTGGAA
AAATATATCTACATAATGGGAATACAAGAAAGAAATGAGAAATTGTTTTATAGAATACTG
CAAGATGACATTGAGAGTTTAATGCCAATTGTATATACACCGACGGTTGGTCTTGCCTGC
TCCCAGTATGGACACATCTTTAGAAGACCTAAGGGATTATTTATTTCGATCTCAGACAGA
GGTCATGTTAGATCAATTGTGGATAACTGGCCAGAAAATCATGTTAAGGCTGTTGTAGTG
ACTGATGGAGAGAGAATTCTGGGTCTTGGAGATCTGGGTGTCTATGGAATGGGAATTCCA
GTAGGAAAACTTTGTTTGTATACAGCTTGTGCAGGAATACGGCCTGATAGATGCCTGCCA
GTGTGTATTGATGTGGGAACTGATAATATCGCACTCTTAAAAGACCCATTTTACATGGGC
TTGTACCAGAAACGAGATCGCACACAACAGTATGATGACCTGATTGATGAGTTTATGAAA
GCTATTACTGACAGATATGGCCGGAACACACTCATTCAGTTCGAAGACTTTGGAAATCAT
AATGCATTCAGGTTCTTGAGAAAGTACCGAGAAAAATATTGTACTTTCAATGATGATATT
CAAGGGACAGCTGCAGTAGCTCTAGCAGGTCTTCTTGCAGCACAAAAAGTTATTAGTAAA
CCAATCTCCGAACACAAAATCTTATTCCTTGGAGCAGGAGAGGCTGCTCTTGGAATTGCA
AATCTTATAGTTATGTCTATGGTAGAAAATGGCCTGTCAGAACAAGAGGCACAAAAGAAA
ATCTGGATGTTTGACAAGTATGGTTTATTAGTTAAGGGACGGAAAGCAAAAATAGATAGT
TATCAGGAACCATTTACTCACTCAGCCCCAGAGAGCATACCTGATACTTTTGAAGATGCA
GTGAATATACTGAAGCCTTCAACTATTATTGGAGTTGCAGGTGCTGGCCGTCTTTTCACT
CCTGATGTAATCAGAGCCATGGCCTCTATCAATGAAAGGCCTGTAATATTTGCATTAAGT
AATCCTACAGCACAGGCAGAGTGCACGGCTGAAGAAGCATATACACTTACAGAGGGCAGG
TGTTTGTTTGCCAGTGGCAGTCCATTTGGGCCAGTGAAACTTACAGATGGGCGAGTCTTT
ACACCAGGTCAAGGAAACAATGTTTATATTTTTCCAGGTGTGGCTTTAGCTGTTATTCTC
TGTAACACCCGGCATATTAGTGACAGTGTTTTCCTAGAAGCTGCAAAGGCCCTGACAAGC
CAATTGACAGATGAAGAGCTAGCCCAAGGGAGACTTTACCCACCGCTTGCTAATATTCAG
GAAGTTTCTATTAACATTGCTATTAAAGTTACAGAATACCTATATGCTAATAAAATGGCT
TTCCGATACCCAGAACCTGAAGACAAGGCCAAATATGTTAAAGAAAGAACATGGCGGAGT
GAATATGATTCCCTGCTGCCAGATGTGTATGAATGGCCAGAATCTGCATCAAGCCCTCCT
GTGATAACAGAATAG

# Drug_Target_15_General_Function:
Energy production and conversion

# Drug_Target_15_General_References:
11401430	Yanaihara N, Kohno T, Takakura S, Takei K, Otsuka A, Sunaga N, Takahashi M, Yamazaki M, Tashiro H, Fukuzumi Y, Fujimori Y, Hagiwara K, Tanaka T, Yokota J: Physical and transcriptional map of a 311-kb segment of chromosome 18q21, a candidate lung tumor suppressor locus. Genomics. 2001 Mar 1;72(2):169-79.
12121650	Yang Z, Lanks CW, Tong L: Molecular mechanism for the regulation of human mitochondrial NAD(P)+-dependent malic enzyme by ATP and fumarate. Structure. 2002 Jul;10(7):951-60.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
12962632	Tao X, Yang Z, Tong L: Crystal structures of substrate complexes of malic enzyme and insights into the catalytic mechanism. Structure. 2003 Sep;11(9):1141-50.
1993674	Loeber G, Infante AA, Maurer-Fogy I, Krystek E, Dworkin MB: Human NAD(+)-dependent mitochondrial malic enzyme. cDNA cloning, primary structure, and expression in Escherichia coli. J Biol Chem. 1991 Feb 15;266(5):3016-21.

# Drug_Target_15_HGNC_ID:
HGNC:6984

# Drug_Target_15_HPRD_ID:
01103

# Drug_Target_15_ID:
166

# Drug_Target_15_Locus:
6p25-p24|18q21

# Drug_Target_15_Molecular_Weight:
65444

# Drug_Target_15_Name:
NAD-dependent malic enzyme, mitochondrial

# Drug_Target_15_Number_of_Residues:
584

# Drug_Target_15_PDB_ID:
1QR6

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00390	malic
PF03949	Malic_M

# Drug_Target_15_Protein_Sequence:
>NAD-dependent malic enzyme, mitochondrial precursor
MLSRLRVVSTTCTLACRHLHIKEKGKPLMLNPRTNKGMAFTLQERQMLGLQGLLPPKIET
QDIQALRFHRNLKKMTSPLEKYIYIMGIQERNEKLFYRILQDDIESLMPIVYTPTVGLAC
SQYGHIFRRPKGLFISISDRGHVRSIVDNWPENHVKAVVVTDGERILGLGDLGVYGMGIP
VGKLCLYTACAGIRPDRCLPVCIDVGTDNIALLKDPFYMGLYQKRDRTQQYDDLIDEFMK
AITDRYGRNTLIQFEDFGNHNAFRFLRKYREKYCTFNDDIQGTAAVALAGLLAAQKVISK
PISEHKILFLGAGEAALGIANLIVMSMVENGLSEQEAQKKIWMFDKYGLLVKGRKAKIDS
YQEPFTHSAPESIPDTFEDAVNILKPSTIIGVAGAGRLFTPDVIRAMASINERPVIFALS
NPTAQAECTAEEAYTLTEGRCLFASGSPFGPVKLTDGRVFTPGQGNNVYIFPGVALAVIL
CNTRHISDSVFLEAAKALTSQLTDEELAQGRLYPPLANIQEVSINIAIKVTEYLYANKMA
FRYPEPEDKAKYVKERTWRSEYDSLLPDVYEWPESASSPPVITE

# Drug_Target_15_Reaction:
(S)-malate + NAD+ = pyruvate + CO2 + NADH

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Not Available

# Drug_Target_15_SwissProt_ID:
P23368

# Drug_Target_15_SwissProt_Name:
MAOM_HUMAN

# Drug_Target_15_Synonyms:
EC 1.1.1.38
Malic enzyme 2
NAD-ME
NAD-dependent malic enzyme, mitochondrial precursor

# Drug_Target_15_Theoretical_pI:
7.67

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Peroxisome

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
12517343	Haapalainen AM, Koski MK, Qin YM, Hiltunen JK, Glumoff T: Binary structure of the two-domain (3R)-hydroxyacyl-CoA dehydrogenase from rat peroxisomal multifunctional enzyme type 2 at 2.38 A resolution. Structure. 2003 Jan;11(1):87-97.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
HSD17B4

# Drug_Target_16_GenBank_ID_Gene:
X87176

# Drug_Target_16_GenBank_ID_Protein:
1050517

# Drug_Target_16_GeneCard_ID:
HSD17B4

# Drug_Target_16_Gene_Name:
HSD17B4

# Drug_Target_16_Gene_Sequence:
>2211 bp
ATGGGCTCACCGCTGAGGTTCGACGGGCGGGTGGTACTGGTCACCGGCGCGGGGGCAGGA
TTGGGCCGAGCCTATGCCCTGGCTTTTGCAGAAAGAGGAGCGTTAGTTGTTGTGAATGAT
TTGGGAGGGGACTTCAAAGGAGTTGGTAAAGGCTCCTTAGCTGCTGATAAGGTTGTTGAA
GAAATAAGAAGGAGAGGTGGAAAAGCAGTGGCCAACTATGATTCAGTGGAAGAAGGAGAG
AAGGTTGTGAAGACAGCCCTGGATGCTTTTGGAAGAATAGATGTTGTGGTCAACAATGCT
GGAATTCTGAGGGATCGTTCCTTTGCTAGGATAAGTGATGAAGACTGGGATATAATCCAC
AGAGTTCATTTGCGGGGTTCATTCCAAGTGACACGGGCAGCATGGGAACACATGAAGAAA
CAGAAGTATGGAAGGATTATTATGACTTCATCAGCTTCAGGAATATATGGCAACTTTGGC
CAGGCCAATTATAGTGCTGCAAAGTTGGGTCTTCTGGGCCTTGCAAATTCTCTTGCAATT
GAAGGCAGGAAAAGCAACATTCATTGTAACACCATTGCTCCTAATGCGGGATCACGGATG
ACTCAGACAGTTATGCCTGAAGATCTTGTGGAAGCCCTGAAGCCAGAGTATGTGGCACCT
CTTGTCCTTTGGCTTTGTCACGAGAGTTGTGAGGAGAATGGTGGCTTGTTTGAGGTTGGA
GCAGGATGGATTGGAAAATTACGCTGGGAGCGGACTCTTGGAGCTATTGTAAGACAAAAG
AATCACCCAATGACTCCTGAGGCAGTCAAGGCTAACTGGAAGAAGATCTGTGACTTTGAG
AATGCCAGCAAGCCTCAGAGTATCCAAGAATCAACTGGCAGTATAATTGAAGTTCTGAGT
AAAATAGATTCAGAAGGAGGAGTTTCAGCAAATCATACTAGTCGTGCAACGTCTACAGCA
ACATCAGGATTTGCTGGAGCTATTGGCCAGAAACTCCCTCCATTTTCTTATGCTTATACG
GAACTGGAAGCTATTATGTATGCCCTTGGAGTGGGAGCGTCAATCAAGGATCCAAAAGAT
TTGAAATTTATTTATGAAGGAAGTTCTGATTTCTCCTGTTTGCCCACCTTCGGAGTTATC
ATAGGTCAGAAATCTATGATGGGTGGAGGATTAGCAGAAATTCCTGGACTTTCAATCAAC
TTTGCAAAGGTTCTTCATGGAGAGCAGTACTTAGAGTTATATAAACCACTTCCCAGAGCA
GGAAAATTAAAATGTGAAGCAGTTGTTGCTGATGTCCTAGATAAAGGATCCGGTGTAGTG
ATTATTATGGATGTCTATTCTTATTCTGAGAAGGAACTTATATGCCACAATCAGTTCTCT
CTCTTTCTTGTTGGCTCTGGAGGCTTTGGTGGAAAACGGACATCAGACAAAGTCAAGGTA
GCTGTAGCCATACCTAATAGACCTCCTGATGCTGTACTTACAGATACCACCTCTCTTAAT
CAGGCTGCTTTGTACCGCCTCAGTGGAGACTGGAATCCCTTACACATTGATCCTAACTTT
GCTAGTCTAGCAGGTTTTGACAAGCCCATATTACATGGATTATGTACATTTGGATTTTCT
GCCAGGCGTGTGTTACAGCAGTTTGCAGATAATGATGTGTCAAGATTCAAGGCAATTAAG
GCTCGTTTTGCAAAACCAGTATATCCAGGACAAACTCTACAAACTGAGATGTGGAAGGAA
GGAAACAGAATTCATTTTCAAACCAAGGTCCAAGAAACTGGAGACATTGTCATTTCAAAT
GCATATGTGGATCTTGCACCAACATCTGGTACTTCAGCTAAGACACCCTCTGAGGGCGGG
AAGCTTCAGAGTACCTTTGTATTTGAGGAAATAGGACGCCGCCTAAAGGATATTGGGCCT
GAGGTGGTGAAGAAAGTAAATGCTGTATTTGAGTGGCATATAACCAAAGGCGGAAATATT
GGGGCTAAGTGGACTATTGACCTGAAAAGTGGTTCTGGAAAAGTGTACCAAGGCCCTGCA
AAAGGTGCTGCTGATACAACAATCATACTTTCAGATGAAGATTTCATGGAGGTGGTCCTG
GGCAAGCTTGACCCTCAGAAGGCATTCTTTAGTGGCAGGCTGAAGGCCAGAGGGAACATC
ATGCTGAGCCAGAAACTTCAGATGATTCTTAAAGACTACGCCAAGCTCTGA

# Drug_Target_16_General_Function:
Lipid transport and metabolism

# Drug_Target_16_General_References:
11700068	Haapalainen AM, van Aalten DM, Merilainen G, Jalonen JE, Pirila P, Wierenga RK, Hiltunen JK, Glumoff T: Crystal structure of the liganded SCP-2-like domain of human peroxisomal multifunctional enzyme type 2 at 1.75 A resolution. J Mol Biol. 2001 Nov 9;313(5):1127-38.
7487879	Adamski J, Normand T, Leenders F, Monte D, Begue A, Stehelin D, Jungblut PW, de Launoit Y: Molecular cloning of a novel widely expressed human 80 kDa 17 beta-hydroxysteroid dehydrogenase IV. Biochem J. 1995 Oct 15;311 ( Pt 2):437-43.
8902629	Jiang LL, Kobayashi A, Matsuura H, Fukushima H, Hashimoto T: Purification and properties of human D-3-hydroxyacyl-CoA dehydratase: medium-chain enoyl-CoA hydratase is D-3-hydroxyacyl-CoA dehydratase. J Biochem (Tokyo). 1996 Sep;120(3):624-32.
9089413	Jiang LL, Miyazawa S, Souri M, Hashimoto T: Structure of D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein. J Biochem (Tokyo). 1997 Feb;121(2):364-9.
9880674	Leenders F, Dolez V, Begue A, Moller G, Gloeckner JC, de Launoit Y, Adamski J: Structure of the gene for the human 17beta-hydroxysteroid dehydrogenase type IV. Mamm Genome. 1998 Dec;9(12):1036-41.

# Drug_Target_16_HGNC_ID:
HGNC:5213

# Drug_Target_16_HPRD_ID:
03514

# Drug_Target_16_ID:
454

# Drug_Target_16_Locus:
5q21

# Drug_Target_16_Molecular_Weight:
79556

# Drug_Target_16_Name:
Peroxisomal multifunctional enzyme type 2

# Drug_Target_16_Number_of_Residues:
735

# Drug_Target_16_PDB_ID:
1ZBQ

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00106	adh_short
PF01575	MaoC_dehydratas
PF02036	SCP2

# Drug_Target_16_Protein_Sequence:
>Peroxisomal multifunctional enzyme type 2
GSPLRFDGRVVLVTGAGAGLGRAYALAFAERGALVVVNDLGGDFKGVGKGSLAADKVVEE
IRRRGGKAVANYDSVEEGEKVVKTALDAFGRIDVVVNNAGILRDRSFARISDEDWDIIHR
VHLRGSFQVTRAAWEHMKKQKYGRIIMTSSASGIYGNFGQANYSAAKLGLLGLANSLAIE
GRKSNIHCNTIAPNAGSRMTQTVMPEDLVEALKPEYVAPLVLWLCHESCEENGGLFEVGA
GWIGKLRWERTLGAIVRQKNHPMTPEAVKANWKKICDFENASKPQSIQESTGSIIEVLSK
IDSEGGVSANHTSRATSTATSGFAGAIGQKLPPFSYAYTELEAIMYALGVGASIKDPKDL
KFIYEGSSDFSCLPTFGVIIGQKSMMGGGLAEIPGLSINFAKVLHGEQYLELYKPLPRAG
KLKCEAVVADVLDKGSGVVIIMDVYSYSEKELICHNQFSLFLVGSGGFGGKRTSDKVKVA
VAIPNRPPDAVLTDTTSLNQAALYRLSGDWNPLHIDPNFASLAGFDKPILHGLCTFGFSA
RRVLQQFADNDVSRFKAIKARFAKPVYPGQTLQTEMWKEGNRIHFQTKVQETGDIVISNA
YVDLAPTSGTSAKTPSEGGKLQSTFVFEEIGRRLKDIGPEVVKKVNAVFEWHITKGGNIG
AKWTIDLKSGSGKVYQGPAKGAADTTIILSDEDFMEVVLGKLDPQKAFFSGRLKARGNIM
LSQKLQMILKDYAKL

# Drug_Target_16_Reaction:
(S)-3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Bifunctional enzyme acting on the peroxisomal beta- oxidation pathway for fatty acids. Catalyzes the formation of 3- ketoacyl-CoA intermediates from both straight-chain and 2-methyl- branched-chain fatty acids

# Drug_Target_16_SwissProt_ID:
P51659

# Drug_Target_16_SwissProt_Name:
DHB4_HUMAN

# Drug_Target_16_Synonyms:
17-beta-HSD 4
17-beta-hydroxysteroid dehydrogenase 4
3- hydroxyacyl-CoA dehydrogenase
3-alpha,7- alpha,12-alpha-trihydroxy-5-beta-cholest-24-enoyl-CoA hydratase
D-3-hydroxyacyl-CoA dehydratase
D-bifunctional protein
DBP
EC 1.1.1.35
EC 4.2.1.107
MFE-2

# Drug_Target_16_Theoretical_pI:
9.21

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
LDHAL6B

# Drug_Target_17_GenBank_ID_Gene:
AY009108

# Drug_Target_17_GenBank_ID_Protein:
12331000

# Drug_Target_17_GeneCard_ID:
LDHAL6B

# Drug_Target_17_Gene_Name:
LDHAL6B

# Drug_Target_17_Gene_Sequence:
>1146 bp
ATGAGTTGGACTGTGCCTGTTGTGCGGGCCAGCCAGAGAGTGAGCTCGGTGGGAGCGAAT
TTCCTATGCCTGGGGATGGCCCTGTGTCCGCGTCAAGCAACGCGCATCCCGCTCAACGGC
ACCTGGCTCTTCACCCCCGTGAGCAAGATGGCGACTGTGAAGAGTGAGCTTATTGAGCGT
TTCACTTCCGAGAAGCCCGTTCATCACAGTAAGGTCTCCATCATAGGAACTGGATCGGTG
GGCATGGCCTGCGCTATCAGCATCTTATTAAAAGGCTTGAGTGATGAACTTGCCCTTGTG
GATCTTGATGAAGACAAACTGAAGGGTGAGACGATGGATCTTCAACATGGCAGCCCTTTC
ACGAAAATGCCAAATATTGTTTGTAGCAAAGATTACTTTGTCACAGCAAACTCCAACCTA
GTGATTATCACAGCAGGTGCACGCCAAGAAAAGGGAGAAACGCGCCTTAATTTAGTCCAG
CGAAATGTGGCCATCTTCAAGTTAATGATTTCCAGTATTGTCCAGTACAGCCCCCACTGC
AAACTGATTATTGTTTCCAATCCAGTGGATATCTTAACTTATGTAGCTTGGAAGTTGAGT
GCATTTCCCAAAAACCGTATTATTGGAAGCGGCTGTAATCTGGATACTGCTCGTTTTCGT
TTCTTGATTGGACAAAAGCTTGGTATCCATTCTGAAAGCTGCCATGGATGGATCCTCGGA
GAGCATGGAGACTCAAGTGTTCCTGTGTGGAGTGGAGTGAACATAGCTGGTGTCCCTTTG
AAGGATCTGAACTCTGATATAGGAACTGATAAAGATCCTGAGCAATGGAAAAATGTCCAC
AAAGAAGTGACTGCAACTGCCTATGAGATTATTAAAATGAAAGGTTATACTTCTTGGGCC
ATTGGCCTATCTGTGGCCGATTTAACAGAAAGTATTTTGAAGAATCTTAGGAGAATACAT
CCAGTTTCCACCATAATTAAGGGCCTCTATGGAATAGATGAAGAAGTATTCCTCAGTATT
CCTTGTATCCTGGGAGAGAACGGTATTACCAACCTTATAAAGATAAAGCTGACCCCTGAA
GAAGAGGCCCATCTGAAAAAAAGTGCAAAAACACTCTGGGAAATTCAGAATAAGCTTAAG
CTTTAA

# Drug_Target_17_General_Function:
Energy production and conversion

# Drug_Target_17_General_References:
Not Available

# Drug_Target_17_HGNC_ID:
HGNC:21481

# Drug_Target_17_HPRD_ID:
13981

# Drug_Target_17_ID:
112

# Drug_Target_17_Locus:
15q22.2

# Drug_Target_17_Molecular_Weight:
41943

# Drug_Target_17_Name:
L-lactate dehydrogenase A-like 6B

# Drug_Target_17_Number_of_Residues:
381

# Drug_Target_17_PDB_ID:
Not Available

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_17_Protein_Sequence:
>L-lactate dehydrogenase A-like 6B
MSWTVPVVRASQRVSSVGANFLCLGMALCPRQATRIPLNGTWLFTPVSKMATVKSELIER
FTSEKPVHHSKVSIIGTGSVGMACAISILLKGLSDELALVDLDEDKLKGETMDLQHGSPF
TKMPNIVCSKDYFVTANSNLVIITAGARQEKGETRLNLVQRNVAIFKLMISSIVQYSPHC
KLIIVSNPVDILTYVAWKLSAFPKNRIIGSGCNLDTARFRFLIGQKLGIHSESCHGWILG
EHGDSSVPVWSGVNIAGVPLKDLNSDIGTDKDPEQWKNVHKEVTATAYEIIKMKGYTSWA
IGLSVADLTESILKNLRRIHPVSTIIKGLYGIDEEVFLSIPCILGENGITNLIKIKLTPE
EEAHLKKSAKTLWEIQNKLKL

# Drug_Target_17_Reaction:
(S)-lactate + NAD+ = pyruvate + NADH + H+

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Not Available

# Drug_Target_17_SwissProt_ID:
Q9BYZ2

# Drug_Target_17_SwissProt_Name:
LDH6B_HUMAN

# Drug_Target_17_Synonyms:
EC 1.1.1.27

# Drug_Target_17_Theoretical_pI:
8.89

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Cytoplasm

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
182529	Spielmann H, Eibs HG, Mentzel C: Rapid purification of lactate dehydrogenase X from mouse testes by two steps of affinity chromatography on oxamate-sepharose. Experientia. 1976 Aug 15;32(8):1085-6.
2751392	Gu Y, Davis DR, Lin YC: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Arch Androl. 1989;22(2):131-6.
3735252	Morris ID, Higgins C, Matlin SA: Inhibition of testicular LDH-X from laboratory animals and man by gossypol and its isomers. J Reprod Fertil. 1986 Jul;77(2):607-12.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
LDHC

# Drug_Target_18_GenBank_ID_Gene:
J02938

# Drug_Target_18_GenBank_ID_Protein:
307120

# Drug_Target_18_GeneCard_ID:
LDHC

# Drug_Target_18_Gene_Name:
LDHC

# Drug_Target_18_Gene_Sequence:
>999 bp
ATGTCAACTGTCAAGGAGCAGCTAATTGAGAAGCTAATTGAGGATGATGAAAACTCCCAG
TGTAAAATTACTATTGTTGGAACTGGTGCCGTAGGCATGGCTTGTGCTATTAGTATCTTA
CTGAAGGATTTGGCTGATGAACTTGCCCTTGTTGATGTTGCATTGGACAAACTGAAGGGA
GAAATGATGGATCTTCAGCATGGCAGTCTTTTCTTTAGTACTTCAAAGGTTACTTCTGGA
AAAGATTACAGTGTATCTGCAAACTCCAGAATAGTTATTGTCACAGCAGGTGCAAGGCAG
CAGGAGGGAGAAACTCGCCTTGCCCTGGTCCAACGTAATGTGGCTATAATGAAAATAATC
ATTCCTGCCATAGTCCATTATAGTCCTGATTGTAAAATTCTTGTTGTTTCAAATCCAGTG
GATATTTTGACATATATAGTCTGGAAGATAAGTGGCTTACCTGTAACTCGTGTAATTGGA
AGTGGTTGTAATCTAGACTCTGCCCGTTTCCGTTACCTAATTGGAGAAAAGTTGGGTGTC
CACCCCACAAGCTGCCATGGTTGGATTATTGGAGAACATGGTGATTCTAGTGTGCCCTTA
TGGAGTGGGGTGAATGTTGCTGGTGTTGCTCTGAAGACTCTGGACCCTAAATTAGGAACG
GATTCAGATAAGGAACACTGGAAAAATATCCATAAACAAGTTATTCAAAGTGCCTATGAA
ATTATCAAGCTGAAGGGGTATACCTCTTGGGCTATTGGACTGTCTGTGATGGATCTGGTA
GGATCCATTTTGAAAAATCTTAGGAGAGTGCACCCAGTTTCCACCATGGTTAAGGGATTA
TATGGAATAAAAGAAGAACTCTTTCTCAGTATCCCTTGTGTCTTGGGGCGGAATGGTGTC
TCAGATGTTGTGAAAATTAACTTGAATTCTGAGGAGGAGGCCCTTTTCAAGAAGAGTGCA
GAAACACTTTGGAATATTCAAAAGGATCTAATATTTTAA

# Drug_Target_18_General_Function:
Energy production and conversion

# Drug_Target_18_General_References:
2440048	Millan JL, Driscoll CE, LeVan KM, Goldberg E: Epitopes of human testis-specific lactate dehydrogenase deduced from a cDNA sequence. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5311-5.
2930531	Takano T, Li SS: Human testicular lactate dehydrogenase-C gene is interrupted by six introns at positions homologous to those of LDH-A (muscle) and LDH-B (heart) genes. Biochem Biophys Res Commun. 1989 Mar 15;159(2):579-83.

# Drug_Target_18_HGNC_ID:
HGNC:6544

# Drug_Target_18_HPRD_ID:
01027

# Drug_Target_18_ID:
167

# Drug_Target_18_Locus:
11p15.5-p15.3

# Drug_Target_18_Molecular_Weight:
36181

# Drug_Target_18_Name:
L-lactate dehydrogenase C chain

# Drug_Target_18_Number_of_Residues:
331

# Drug_Target_18_PDB_ID:
Not Available

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_18_Protein_Sequence:
>L-lactate dehydrogenase C chain
STVKEQLIEKLIEDDENSQCKITIVGTGAVGMACAISILLKDLADELALVDVALDKLKGE
MMDLQHGSLFFSTSKITSGKDYSVSANSRIVIVTAGARQQEGETRLALVQRNVAIMKSII
PAIVHYSPDCKILVVSNPVDILTYIVWKISGLPVTRVIGSGCNLDSARFRYLIGEKLGVH
PTSCHGWIIGEHGDSSVPLWSGVNVAGVALKTLDPKLGTDSDKEHWKNIHKQVIQSAYEI
IKLKGYTSWAIGLSVMDLVGSILKNLRRVHPVSTMVKGLYGIKEELFLSIPCVLGRNGVS
DVVKINLNSEEEALFKKSAETLWNIQKDLIF

# Drug_Target_18_Reaction:
(S)-lactate + NAD+ = pyruvate + NADH + H+

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Not Available

# Drug_Target_18_SwissProt_ID:
P07864

# Drug_Target_18_SwissProt_Name:
LDHC_HUMAN

# Drug_Target_18_Synonyms:
EC 1.1.1.27
LDH testis subunit
LDH-C
LDH-X

# Drug_Target_18_Theoretical_pI:
7.53

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Cytoplasm

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
12054772	Razeto A, Kochhar S, Hottinger H, Dauter M, Wilson KS, Lamzin VS: Domain closure, substrate specificity and catalysis of D-lactate dehydrogenase from Lactobacillus bulgaricus. J Mol Biol. 2002 Apr 19;318(1):109-19.
16198644	Mdluli K, Booth MP, Brady RL, Rumsby G: A preliminary account of the properties of recombinant human Glyoxylate reductase (GRHPR), LDHA and LDHB with glyoxylate, and their potential roles in its metabolism. Biochim Biophys Acta. 2005 Dec 1;1753(2):209-16. Epub 2005 Aug 22.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4303363	Clausen J: Lactate dehydrogenase isoenzymes of sperm cells and tests. Biochem J. 1969 Jan;111(2):207-18.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
LDHB

# Drug_Target_19_GenBank_ID_Gene:
X13794

# Drug_Target_19_GenBank_ID_Protein:
1200083

# Drug_Target_19_GeneCard_ID:
LDHB

# Drug_Target_19_Gene_Name:
LDHB

# Drug_Target_19_Gene_Sequence:
>1005 bp
ATGGCAACTCTTAAGGAAAAACTCATTGCACCAGTTGCGGAAGAAGAGGCAACAGTTCCA
AACAATAAGATCACTGTAGTGGGTGTTGGACAAGTTGGTATGGCGTGTGCTATCAGCATT
CTGGGAAAGTCTCTGGCTGATGAACTTGCTCTTGTGGATGTTTTGGAAGATAAGCTTAAA
GGAGAAATGATGGATCTGCAGCATGGGAGCTTATTTCTTCAGACACCTAAAATTGTGGCA
GATAAAGATTATTCTGTGACCGCCAATTCTAAGATTGTAGTGGTAACTGCAGGAGTCCGT
CAGCAAGAAGGGGAGAGTCGGCTCAATCTGGTGCAGAGAAATGTTAATGTCTTCAAATTC
ATTATTCCTCAGATCGTCAAGTACAGTCCTGATTGCATCATAATTGTGGTTTCCAACCCA
GTGGACATTCTTACGTATGTTACCTGGAAACTAAGTGGATTACCCAAACACCGCGTGATT
GGAAGTGGATGTAATCTGGATTCTGCTAGATTTCGCTACCTTATGGCTGAAAAACTTGGC
ATTCATCCCAGCAGCTGCCATGGATGGATTTTGGGGGAACATGGCGACTCAAGTGTGGCT
GTGTGGAGTGGTGTGAATGTGGCAGGTGTTTCTCTCCAGGAATTGAATCCAGAAATGGGA
ACTGACAATGATAGTGAAAATTGGAAGGAAGTGCATAAGATGGTGGTTGAAAGTGCCTAT
GAAGTCATCAAGCTAAAAGGATATACCAACTGGGCTATTGGATTAAGTGTGGCTGATCTT
ATTGAATCCATGTTGAAAAATCTATCCAGGATTCATCCCGTGTCAACAATGGTAAAGGGG
ATGTATGGCATTGAGAATGAAGTCTTCCTGAGCCTTCCATGTATCCTCAATGCCCGGGGA
TTAACCAGCGTTATCAACCAGAAGCTAAAGGATGATGAGGTTGCTCAGCTCAAGAAAAGT
GCAGATACCCTGTGGGACATCCAGAAGGACCTAAAAGACCTGTGA

# Drug_Target_19_General_Function:
Energy production and conversion

# Drug_Target_19_General_References:
10211631	Sudo K, Maekawa M, Houki N, Okuda T, Akizuki S, Magara T, Kawano K: A novel in-frame deletion mutation in a case of lactate dehydrogenase (LD) H subunit deficiency showing an atypical LD isoenzyme pattern in serum and erythrocytes. Clin Biochem. 1999 Mar;32(2):137-41.
10508479	Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 1999 Nov 12;83(4):456-64.
11509017	Takatani T, Takaoka N, Tatsumi M, Kawamoto H, Okuno Y, Morita K, Masutani T, Murakawa K, Okamoto Y: A novel missense mutation in human lactate dehydrogenase B-subunit gene. Mol Genet Metab. 2001 Aug;73(4):344-8.
1587525	Sudo K, Maekawa M, Tomonaga A, Tsukada T, Nakayama T, Kitamura M, Li SS, Kanno T, Toriumi J: Molecular characterization of genetic mutations in human lactate dehydrogenase (LDH) B (H) variant. Hum Genet. 1992 May;89(2):158-62.
2334429	Sudo K, Maekawa M, Ikawa S, Machida K, Kitamura M, Li SS: A missense mutation found in human lactate dehydrogenase-B (H) variant gene. Biochem Biophys Res Commun. 1990 Apr 30;168(2):672-6.
2930497	Takeno T, Li SS: Structure of the human lactate dehydrogenase B gene. Biochem J. 1989 Feb 1;257(3):921-4.
3435492	Sakai I, Sharief FS, Pan YC, Li SS: The cDNA and protein sequences of human lactate dehydrogenase B. Biochem J. 1987 Dec 15;248(3):933-6.
8314553	Maekawa M, Sudo K, Kitajima M, Matsuura Y, Li SS, Kanno T: Analysis of a genetic mutation in an electrophoretic variant of the human lactate dehydrogenase-B(H) subunit. Hum Genet. 1993 Jun;91(5):423-6.
8462975	Maekawa M, Sudo K, Kitajima M, Matsuura Y, Li SS, Kanno T: Detection and characterization of new genetic mutations in individuals heterozygous for lactate dehydrogenase-B(H) deficiency using DNA conformation polymorphism analysis and silver staining. Hum Genet. 1993 Mar;91(2):163-8.
8611651	Shonnard GC, Hud NV, Mohrenweiser HW: Arginine to tryptophan substitution in the active site of a human lactate dehydrogenase variant--LDHB GUA1: postulated effects on subunit structure and catalysis. Biochim Biophys Acta. 1996 Jan 17;1315(1):9-14.
9929983	Hidaka K, Ueda N, Hirata I, Watanabe Y, Minatogawa Y, Iuchi I: First case of missense mutation (LDH-H:R171P) in exon 4 of the lactate dehydrogenase gene detected in a Japanese patient. J Hum Genet. 1999;44(1):69-72.

# Drug_Target_19_HGNC_ID:
HGNC:6541

# Drug_Target_19_HPRD_ID:
01026

# Drug_Target_19_ID:
77

# Drug_Target_19_Locus:
12p12.2-p12.1

# Drug_Target_19_Molecular_Weight:
36508

# Drug_Target_19_Name:
L-lactate dehydrogenase B chain

# Drug_Target_19_Number_of_Residues:
333

# Drug_Target_19_PDB_ID:
1I0Z

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_19_Protein_Sequence:
>L-lactate dehydrogenase B chain
ATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLADELALVDVLEDKLKG
EMMDLQHGSLFLQTPKIVADKDYSVTANSKIVVVTAGVRQQEGESRLNLVQRNVNVFKFI
IPQIVKYSPDCIIIVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYLMAEKLGI
HPSSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSENWKEVHKMVVESAYE
VIKLKGYTNWAIGLSVADLIESMLKNLSRIHPVSTMVKGMYGIENEVFLSLPCILNARGL
TSVINQKLKDDEVAQLKKSADTLWDIQKDLKDL

# Drug_Target_19_Reaction:
(S)-lactate + NAD+ = pyruvate + NADH + H+

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Not Available

# Drug_Target_19_SwissProt_ID:
P07195

# Drug_Target_19_SwissProt_Name:
LDHB_HUMAN

# Drug_Target_19_Synonyms:
EC 1.1.1.27
LDH heart subunit
LDH-B
LDH-H
Renal carcinoma antigen NY-REN-46

# Drug_Target_19_Theoretical_pI:
5.93

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
1472079	Alary J, Cravedi JP, Baradat M, Carrera G: Mechanism of cadmium-decreased glucuronidation in the rat. Biochem Pharmacol. 1992 Dec 1;44(11):2139-47.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3804697	Castellani AA, De Luca G, Rindi S, Salvini R, Tira ME: Regulatory mechanisms of UDP-glucuronic acid biosynthesis in cultured human skin fibroblasts. Ital J Biochem. 1986 Sep-Oct;35(5):296-303.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
UGDH

# Drug_Target_1_GenBank_ID_Gene:
AF061016

# Drug_Target_1_GenBank_ID_Protein:
3127127

# Drug_Target_1_GeneCard_ID:
UGDH

# Drug_Target_1_Gene_Name:
UGDH

# Drug_Target_1_Gene_Sequence:
>1485 bp
ATGTTTGAAATTAAGAAGATCTGTTGCATCGGTGCAGGCTATGTTGGAGGACCCACATGT
AGTGTCATTGCTCATATGTGTCCTGAAATCAGGGTAACGGTTGTTGATGTCAATGAATCA
AGAATCAATGCGTGGAATTCTCCTACACTTCCTATTTATGAGCCAGGACTAAAAGAAGTG
GTAGAATCCTGTCGAGGAAAAAATCTTTTTTTTTCTACCAATATTGATGATGCCATCAAA
GAAGCTGATCTTGTATTTATTTCTGTGAATACTCCAACAAAAACCTATGGAATGGGGAAA
GGCCGGGCAGCAGATCTGAAGTATATTGAAGCTTGTGCTAGACGCATTGTGCAAAACTCA
AATGGGTACAAAATTGTGACTGAGAAAAGCACAGTTCCAGTGCGGGCAGCAGAAAGTATC
CGTCGCATATTTGATGCAAACACAAAACCCAACTTGAATTTACAGGTGCTGTCCAACCCT
GAGTTTCTGGCAGAGGGAACAGCCATCAAGGACCTAAAGAACCCAGACAGAGTACTGATT
GGAGGGGATGAAACTCCAGAGGGCCAGAGAGCTGTGCAGGCCCTGTGTGCTGTATATGAG
CACTGGGTTCCCAGAGAAAAGATCCTCACCACTAATACTTGGTCTTCAGAGCTTTCCAAA
CTGGCAGCAAATGCTTTTCTTGCCCAGAGAATAAGCAGCATTAACTCCATAAGTGCTCTG
TGTGAAGCAACAGGAGCTGATGTAGAAGAGGTAGCAACAGCGATTGGAATGGACCAGAGA
ATTGGAAACAAGTTTCTAAAAGCCAGTGTTGGGTTTGGTGGGAGCTGTTTCCAAAAGGAT
GTTCTGAATTTGGTTTATCTCTGTGAGGCTCTGAATTTGCCAGAAGTAGCTCGTTATTGG
CAGCAGGTCATAGACATGAATGACTACCAGAGGAGGAGGTTTGCTTCCCGGATCATAGAT
AGTCTGTTTAATACAGTAACTGATAAGAAGATAGCTATTTTGGGATTTGCATTCAAAAAG
GACACTGGTGATACAAGAGAATCTTCTAGTATATATATTAGCAAATATTTGATGGATGAA
GGTGCACATCTACATATATATGATCCAAAAGTACCTAGGGAACAAATAGTTGTGGATCTT
TCTCATCCAGGTGTTTCAGAGGATGACCAAGTGTCCCGGCTCGTGACCATTTCCAAGGAT
CCATATGAAGCATGTGATGGTGCCCATGCTGTTGTTATTTGCACTGAGTGGGACATGTTT
AAGGAATTGGATTATGAACGCATTCATAAAAAAATGCTAAAGCCAGCCTTTATCTTCGAT
GGACGGCGTGTCCTGGATGGGCTCCACAATGAACTACAAACCATTGGCTTCCAGATTGAA
ACAATTGGCAAAAAGGTGTCTTCAAAGAGAATTCCATATGCTCCTTCTGGTGAAATTCCG
AAGTTTAGTCTTCAAGATCCACCTAACAAGAAACCTAAAGTGTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
9737970	Spicer AP, Kaback LA, Smith TJ, Seldin MF: Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem. 1998 Sep 25;273(39):25117-24.
9850599	Peng HL, Lou MD, Chang ML, Chang HY: cDNA cloning and expression analysis of the human UDPglucose dehydrogenase. Proc Natl Sci Counc Repub China B. 1998 Oct;22(4):166-72.

# Drug_Target_1_HGNC_ID:
HGNC:12525

# Drug_Target_1_HPRD_ID:
04535

# Drug_Target_1_ID:
711

# Drug_Target_1_Locus:
4p15.1

# Drug_Target_1_Molecular_Weight:
55025

# Drug_Target_1_Name:
UDP-glucose 6-dehydrogenase

# Drug_Target_1_Number_of_Residues:
494

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00984	UDPG_MGDP_dh
PF03720	UDPG_MGDP_dh_C
PF03721	UDPG_MGDP_dh_N

# Drug_Target_1_Protein_Sequence:
>UDP-glucose 6-dehydrogenase
MFEIKKICCIGAGYVGGPTCSVIAHMCPEIRVTVVDVNESRINAWNSPTLPIYEPGLKEV
VESCRGKNLFFSTNIDDAIKEADLVFISVNTPTKTYGMGKGRAADLKYIEACARRIVQNS
NGYKIVTEKSTVPVRAAESIRRIFDANTKPNLNLQVLSNPEFLAEGTAIKDLKNPDRVLI
GGDETPEGQRAVQALCAVYEHWVPREKILTTNTWSSELSKLAANAFLAQRISSINSISAL
CEATGADVEEVATAIGMDQRIGNKFLKASVGFGGSCFQKDVLNLVYLCEALNLPEVARYW
QQVIDMNDYQRRRFASRIIDSLFNTVTDKKIAILGFAFKKDTGDTRESSSIYISKYLMDE
GAHLHIYDPKVPREQIVVDLSHPGVSEDDQVSRLVTISKDPYEACDGAHAVVICTEWDMF
KELDYERIHKKMLKPAFIFDGRRVLDGLHNELQTIGFQIETIGKKVSSKRIPYAPSGEIP
KFSLQDPPNKKPKV

# Drug_Target_1_Reaction:
UDP-glucose + 2 NAD+ + H2O = UDP-glucuronate + 2 NADH + 2 H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
O60701

# Drug_Target_1_SwissProt_Name:
UGDH_HUMAN

# Drug_Target_1_Synonyms:
EC 1.1.1.22
UDP-Glc dehydrogenase
UDP-GlcDH
UDPGDH

# Drug_Target_1_Theoretical_pI:
7.13

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Peroxisome

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
EHHADH

# Drug_Target_20_GenBank_ID_Gene:
L07077

# Drug_Target_20_GenBank_ID_Protein:
452045

# Drug_Target_20_GeneCard_ID:
EHHADH

# Drug_Target_20_Gene_Name:
EHHADH

# Drug_Target_20_Gene_Sequence:
>2172 bp
ATGGCCGAGTATACGCGGCTGCACAACGCCTTGGCGCTAATCCGCCTCCGAAACCCGCCG
GTCAACGCGATCAGTACGACTTTACTCCGTGATATAAAAGAAGGACTACAGAAAGCTGGA
AGAGACCATACAATAAAAGCCATTGTGATTTGTGGAGCAGAGGGCAAATTTTCTGCAGGT
GCTGATATTCGTGGCTTCAGTGCTCCTAGGACATTTGGCCTTATACTGGGACATGTAGTA
GATGAAATACAGAGAAATGAGAAGCCCGTGGTGGCAGCAATCCAAGGCATGGCTTTCGGA
GGGGGACTAGAGCTGGCCCTGGGCTGTCACTATAGGATTGCCCACGCAGACGCTCAAGTT
GGCTTACCAGAAGTTACACTTGGACTTCTCCCTGGTGCAAGAGGAACCCAGCTTCTCCCC
AGACTCACTGGAGTTCCTGCTGCACTTGACTTAATTACCTCAGGAAGACGTATTTTAGCA
GATGAAGCACTCAAGCTGGGCATTCTAGATAAAGTTGTAAACTCAGACCCGGTTGAAGAA
GCAATCAGATTTGCTCAGAGAGTTTCAGATCAACCTCTAGAATCCCGTAGACTCTGCAAC
AAGCCAATTCAGAGCTTGCCCAACATGGACAGCATTTTTAGTGAGGCCCTCTTGAAGATG
CGGAGGCAGCACCCTGGGTGTCTTGCACAGGAGGCTTGTGTCCGTGCAGTCCAGGCTGCT
GTGCAGTATCCCTATGAAGTGGGCATCAAGAAGGAGGAGGAGCTGTTTCTATATCTTTTG
CAATCAGGGCAGGCTAGAGCCCTGCAATATGCTTTCTTCGCTGAAAGGAAAGCAAATAAG
TGGTCAACTCCCTCCGGAGCATCGTGGAAAACAGCATCAGCGCGGCCTGTCTCCTCAGTT
GGTGTTGTTGGCTTGGGAACAATGGGCCGAGGCATTGTCATTTCTTTTGCAAGGGCCAGG
ATTCCTGTGATTGGTGTAGACTCGGACAAAAACCAGCTAGCAACTGCAAACAAGATGATA
ACCTCTGTCTTGGAAAAAGAAGCCTCCAAAATGCAACAGAGCGGCCACCCTTGGTCAGGA
CCAAAACCCAGGTTAACTTCATCTGTGAAGGAGCTTGGTGGTGTAGATTTAGTCATTGAA
GCAGTATTTGAGGAAATGAGCCTGAAGAAGCAGGTCTTTGCTGAACTCTCAGCTGTGTGC
AAACCAGAAGCATTTTTGTGCACTAATACTTCAGCCCTGGATGTTGATGAGATTGCTTCT
TCCACTGATCGTCCTCACTTGGTCATTGGCACCCACTTCTTTTCGCCAGCTCATGTCATG
AAGTTGTTAGAGGTTATTCCCAGCCAATACTCTTCCCCCACTACCATTGCCACTGTTATG
AACTTATCAAAAAAGATTAAAAAGATTGGAGTCGTTGTAGGCAACTGTTTTGGATTTGTG
GGGAATCGAATGTTGAATCCTTACTACAATCAGGCATATTTCTTGTTAGAAGAAGGCAGC
AAACCAGAGGAGGTAGATCAGGTGCTGGAAGAGTTTGGTTTTAAAATGGGACCTTTTAGA
GTGTCTGATCTTGCTGGGTTGGATGTGGGCTGGAAATCTAGAAAGGGGCAAGGTCTTACT
GGACCTACATTGCTTCCAGGAACTCCTGCCCGAAAAAGGGGTAATAGGAGGTACTGCCCA
ATTCCTGATGTGCTCTGTGAATTAGGACGATTTGGCCAGAAGACAGGTAAGGGTTGGTAT
CAATATGACAAGCCATTGGGTAGGATTCACAAACCTGATCCCTGGCTTTCCACATTCCTA
TCACGGTATAGAAAACCCCATCACATTGAACCACGTACCATTAGCCAGGATGAGATCCTT
GAACGCTGCTTATATTCACTTATCAATGAAGCATTCCGTATCTTGGGAGAAGGGATAGCT
GCTAGCCCAGAGCACATTGATGTTGTCTATTTACATGGATATGGATGCGCAAGGCACAAG
GGCGGGCCCATGTTCTATGCTTCCACAGTTGGGTTGCCCACAGTTCTAGAGAAATTGCAG
AAATATTACAGGCAGAACCCTGATATTCCCCAACTGGAGCCAAGTGACTATCTAAAAAAA
CTGGCTTCTCAGGGAAACCCTCCCCTGAAAGAATGGCAAAGCTTGGCAGGCTCCCCTAGC
AGTAAATTGTGA

# Drug_Target_20_General_Function:
Lipid transport and metabolism

# Drug_Target_20_General_References:
1651711	Chen GL, Balfe A, Erwa W, Hoefler G, Gaertner J, Aikawa J, Chen WW: Import of human bifunctional enzyme into peroxisomes of human hepatoma cells in vitro. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1084-91.
8188243	Hoefler G, Forstner M, McGuinness MC, Hulla W, Hiden M, Krisper P, Kenner L, Ried T, Lengauer C, Zechner R, et al.: cDNA cloning of the human peroxisomal enoyl-CoA hydratase: 3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme and localization to chromosome 3q26.3-3q28: a free left Alu Arm is inserted in the 3' noncoding region. Genomics. 1994 Jan 1;19(1):60-7.

# Drug_Target_20_HGNC_ID:
HGNC:3247

# Drug_Target_20_HPRD_ID:
06125

# Drug_Target_20_ID:
643

# Drug_Target_20_Locus:
3q26.3-q28

# Drug_Target_20_Molecular_Weight:
79209

# Drug_Target_20_Name:
Peroxisomal bifunctional enzyme

# Drug_Target_20_Number_of_Residues:
722

# Drug_Target_20_PDB_ID:
Not Available

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00378	ECH
PF00725	3HCDH
PF02737	3HCDH_N

# Drug_Target_20_Protein_Sequence:
>Peroxisomal bifunctional enzyme
AEYTRLHNALALIRLRNPPVNAISTTLLRDIKEGLQKAGRDHTIKAIVICGAEGKFSAGA
DIRGFSAPRTFGLILGHVVDEIQRNEKPVVAAIQGMAFGGGLELALGCHYRIAHADAQVG
LPEVTLGLLPGARGTQLLPRLTGVPAALDLITSGRRILADEALKLGILDKVVNSDPVEEA
IRFAQRVSDQPLESRRLCNKPIQSLPNMDSIFSEALLKMRRQHPGCLAQEACVRAVQAAV
QYPYEVGIKKEEELFLYLLQSGQARALQYAFFAERKANKWSTPSGASWKTASARPVSSVG
VVGLGTMGRGIVISFARARIPVIGVDSDKNQLATANKMITSVLEKEASKMQQSGHPWSGP
KPRLTSSVKELGGVDLVIEAVFEEMSLKKQVFAELSAVCKPEAFLCTNTSALDVDEIASS
TDRPHLVIGTHFFSPAHVMKLLEVIPSQYSSPTTIATVMNLSKKIKKIGVVVGNCFGFVG
NRMLNPYYNQAYFLLEEGSKPEEVDQVLEEFGFKMGPFRVSDLAGLDVGWKSRKGQGLTG
PTLLPGTPARKRGNRRYCPIPDVLCELGRFGQKTGKGWYQYDKPLGRIHKPDPWLSTFLS
RYRKPHHIEPRTISQDEILERCLYSLINEAFRILGEGIAASPEHIDVVYLHGYGCARHKG
GPMFYASTVGLPTVLEKLQKYYRQNPDIPQLEPSDYLKKLASQGNPPLKEWQSLAGSPSS
KL

# Drug_Target_20_Reaction:
(S)-3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Not Available

# Drug_Target_20_SwissProt_ID:
Q08426

# Drug_Target_20_SwissProt_Name:
ECHP_HUMAN

# Drug_Target_20_Synonyms:
EC 4.2.1.17
PBE
PBFE

# Drug_Target_20_Theoretical_pI:
9.49

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
17202348	Norman JP, Perry SW, Kasischke KA, Volsky DJ, Gelbard HA: HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons. J Immunol. 2007 Jan 15;178(2):869-76.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
HADH

# Drug_Target_21_GenBank_ID_Gene:
X96752

# Drug_Target_21_GenBank_ID_Protein:
1483511

# Drug_Target_21_GeneCard_ID:
HADH

# Drug_Target_21_Gene_Name:
HADH

# Drug_Target_21_Gene_Sequence:
>945 bp
ATGGCCTTCGTCACCAGGCAGTTCATGCGTTCCGTGTCCTCCTCGTCCACCGCCTCGGCC
TCGGCCAAGAAGATAATCGTCAAGCACGTGACGGTCATCGGCGGCGGGCTGATGGGCGCC
GGCATTGCCCAGGTTGCTGCAGCAACTGGTCACACAGTAGTGTTGGTAGACCAGACAGAG
GACATCCTGGCAAAATCCAAAAAGGGAATTGAGGAAAGCCTTAGGAAAGTGGCAAAGAAG
AAGTTTGCAGAAAACCCTAAGGCCGGCGATGAATTTGTGGAGAAGACCCTGAGCACCATA
GCGACCAGCACGGATGCAGCCTCCGTTGTCCACAGCACAGACTTGGTGGTGGAAGCCATC
GTGGAGAATCTGAAGGTGAAAAACGAGCTCTTCAAAAGGCTGGACAAGTTTGCTGCTGAA
CATACAATCTTTGCCAGCAACACTTCCTCCTTGCATATTACAAGCATAGCTAATGCCACC
ACCAGACAAGACCGATTCGCTGGCCTCCATTTCTTCAACCCAGTGCCTGTCATGAAACTT
GTGGAGGTCATTAAAACACCAATGACCAGCCAGAAGACATTTGAATCTTTGGTAGACTTT
AGCAAAGCCCTAGGAAAGCATCCTGTTTCTTGCAAGGACACTCCTGGGTTTATTGTGAAC
CGCCTCCTGGTTCCATACCTCATGGAAGCAATCAGGCTGTATGAACGAGGTGACGCATCC
AAAGAAGACATTGACACTGCTATGAAATTAGGAGCCGGTTACCCCATGGGCCCATTTGAG
CTTCTAGATTATGTCGGACTGGATACTACGAAGTTCATCGTGGATGGGTGGCATGAAATG
GATGCAGAGAACCCATTACATCAGCCCAGCCCATCCTTAAATAAGCTGGTAGCAGAGAAC
AAGTTCGGCAAGAAGACTGGAGAAGGATTTTACAAATACAAGTGA

# Drug_Target_21_General_Function:
Lipid transport and metabolism

# Drug_Target_21_General_References:
10231530	Barycki JJ, O'Brien LK, Bratt JM, Zhang R, Sanishvili R, Strauss AW, Banaszak LJ: Biochemical characterization and crystal structure determination of human heart short chain L-3-hydroxyacyl-CoA dehydrogenase provide insights into catalytic mechanism. Biochemistry. 1999 May 4;38(18):5786-98.
10840044	Barycki JJ, O'Brien LK, Strauss AW, Banaszak LJ: Sequestration of the active site by interdomain shifting. Crystallographic and spectroscopic evidence for distinct conformations of L-3-hydroxyacyl-CoA dehydrogenase. J Biol Chem. 2000 Sep 1;275(35):27186-96.
8687463	Vredendaal PJ, van den Berg IE, Malingre HE, Stroobants AK, Olde Weghuis DE, Berger R: Human short-chain L-3-hydroxyacyl-CoA dehydrogenase: cloning and characterization of the coding sequence. Biochem Biophys Res Commun. 1996 Jun 25;223(3):718-23.

# Drug_Target_21_HGNC_ID:
HGNC:4799

# Drug_Target_21_HPRD_ID:
08372

# Drug_Target_21_ID:
419

# Drug_Target_21_Locus:
4q22-q26

# Drug_Target_21_Molecular_Weight:
34278

# Drug_Target_21_Name:
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial

# Drug_Target_21_Number_of_Residues:
314

# Drug_Target_21_PDB_ID:
1F0Y

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00725	3HCDH
PF02737	3HCDH_N

# Drug_Target_21_Protein_Sequence:
>Short chain 3-hydroxyacyl-CoA dehydrogenase, mitochondrial precursor
MAFVTRQFMRSVSSSSTASASAKKIIVKHVTVIGGGLMGAGIAQVAAATGHTVVLVDQTE
DILAKSKKGIEESLRKVAKKKFAENPKAGDEFVEKTLSTIATSTDAASVVHSTDLVVEAI
VENLKVKNELFKRLDKFAAEHTIFASNTSSLQITSIANATTRQDRFAGLHFFNPVPVMKL
VEVIKTPMTSQKTFESLVDFSKALGKHPVSCKDTPGFIVNRLLVPYLMEAIRLYERGDAS
KEDIDTAMKLGAGYPMGPFELLDYVGLDTTKFIVDGWHEMDAENPLHQPSPSLNKLVAEN
KFGKKTGEGFYKYK

# Drug_Target_21_Reaction:
(S)-3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Plays an essential role in the mitochondrial beta- oxidation of short chain fatty acids. Exerts it highest activity toward 3-hydroxybutyryl-CoA

# Drug_Target_21_SwissProt_ID:
Q16836

# Drug_Target_21_SwissProt_Name:
HCDH_HUMAN

# Drug_Target_21_Synonyms:
EC 1.1.1.35
HCDH
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial precursor
Medium and short chain L-3-hydroxyacyl-coenzyme A dehydrogenase
Short chain 3-hydroxyacyl-CoA dehydrogenase

# Drug_Target_21_Theoretical_pI:
9.41

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
16740313	Luo C, Wang X, Long J, Liu J: An NADH-tetrazolium-coupled sensitive assay for malate dehydrogenase in mitochondria and crude tissue homogenates. J Biochem Biophys Methods. 2006 Aug 31;68(2):101-11. Epub 2006 Apr 26.
17080607	Wei H, Dhanaraj AL, Arora R, Rowland LJ, Fu Y, Sun L: Identification of cold acclimation-responsive Rhododendron genes for lipid metabolism, membrane transport and lignin biosynthesis: importance of moderately abundant ESTs in genomic studies. Plant Cell Environ. 2006 Apr;29(4):558-70.
17603759	Rzem R, Vincent MF, Van Schaftingen E, Veiga-da-Cunha M: L: -2-Hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis. 2007 Jun 21;.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
ME3

# Drug_Target_22_GenBank_ID_Gene:
X79440

# Drug_Target_22_GenBank_ID_Protein:
535012

# Drug_Target_22_GeneCard_ID:
ME3

# Drug_Target_22_Gene_Name:
ME3

# Drug_Target_22_Gene_Sequence:
>1815 bp
ATGGGTGCCGCGCTGGGGACAGGCACGCGGCTGGCTCCCTGGCCGGGCCGGGCCTGCGGC
GCCCTCCCGCGCTGGACACCCACCGCGCCCGCCCAAGGCTGCCACTCCAAGCCTGGCCCG
GCGCGCCCTGTGCCCCTGAAGAAGCGCGGATACGATGTCACCAGGAACCCTCATCTCAAC
AAGGGGATGGCCTTTACCCTTGAAGAAAGGCTGCAGCTTGGAATCCACGGCCTAATCCCG
CCCTGCTTTCTGAGCCAGGACGTCCAGCTCCTCCGAATCATGAGATATTACGAGCGGCAG
CAGAGTGACCTGGACAAGTACATCATTCTCATGACACTCCAAGACCGGAACGAGAAGCTC
TTCTACCGAGTGCTGACTTCGGATGTGGAGAAGTTCATGCCAATCGTGTACACGCCTACC
GTGGGGCTGGCCTGTCAGCACTATGGCCTGACTTTCCGCAGGCCCCGTGGACTGTTCATC
ACCATTCATGACAAAGGTCATCTTGCAACAATGCTGAATTCTTGGCCAGAAGACAATATT
AAGGCCGTGGTGGTGACTGATGGGGAGCGCATCCTGGGCCTGGGAGACCTGGGCTGCTAC
GGCATGGGCATCCCTGTGGGCAAGCTGGCCCTGTACACGGCATGCGGAGGGGTGAACCCG
CAGCAGTGCCTCCCTGTGCTGCTGGACGTCGGCACCAACAATGAGGAGCTGCTCAGAGAC
CCTCTGTACATCGGCCTGAAACACCAGCGCGTGCACGGGAAGGCATACGATGACTTGCTG
GATGAGTTCATGCAGGCTGTGACAGACAAGTTTGGAATAAATTGCCTCATCCAATTTGAA
GACTTCGCCAATGCCAATGCCTTCCGCCTGCTCAACAAATACCGTAACAAGTACTGCATG
TTCAATGATGACATCCAAGGCACAGCCTCCGTTGCTGTGGCAGGGATCTTGGCTGCTCTG
CGAATCACCAACAACAAGCTTTCCAATCACGTGTTTGTTTTCCAAGGTGCAGGCGAGGCA
GCTATGGGCATTGCCCACCTCCTTGTCATGGCCCTAGAGAAAGAAGGTGTACCGAAGGCA
GAGGCCACAAGAAAGATCTGGATGGTGGACTCTAAAGGGCTCATTGTCAAGGGGAGGAGC
CACCTGAACCATGAAAAGGAGATGTTTGCCCAAGACCATCCTGAAGTCAACTCCCTGGAG
GAGGTGGTGAGGCTGGTGAAGCCCACAGCCATCATAGGTGTTGCTGCCATCGCAGGAGCC
TTCACGGAGCAGATTCTGAGGGACATGGCCTCCTTCCACGAGCGCCCTATCATCTTTGCC
CTGAGCAACCCCACCAGCAAGGCCGAGTGCACGGCTGAGAAGTGCTACCGGGTCACCGAG
GGCCGAGGGATTTTTGCCAGTGGAAGTCCTTTTAAGAGTGTGACTCTGGAAGATGGCAAG
ACCTTCATTCCTGGGCAGGGAAACAATGCTTACGTGTTCCCCGGGGTGGCACTGGGAGTC
ATCGCCGGCGGGATCCGGCACATCCCAGATGAGATCTTCCTCCTGACAGCAGAGCAAATT
GCCCAGGAAGTCTCTGAGCAGCATCTGTCCCAGGGGAGACTCTATCCACCACTCAGCACC
ATCCGAGACGTGTCTTTGAGAATTGCCATCAAAGTTCTCGACTACGCGTACAAACACAAC
CTGGCTTCCTACTACCCAGAGCCTAAGGACAAGGAGGCTTTTGTAAGATCCCTGGTCTAC
ACTCCAGACTATGACTCCTTTACACTGGACAGCTACACTTGGCCCAAGGAAGCCATGAAT
GTTCAGACGGTCTGA

# Drug_Target_22_General_Function:
Energy production and conversion

# Drug_Target_22_General_References:
7818469	Loeber G, Maurer-Fogy I, Schwendenwein R: Purification, cDNA cloning and heterologous expression of the human mitochondrial NADP(+)-dependent malic enzyme. Biochem J. 1994 Dec 15;304 ( Pt 3):687-92.

# Drug_Target_22_HGNC_ID:
HGNC:6985

# Drug_Target_22_HPRD_ID:
06862

# Drug_Target_22_ID:
363

# Drug_Target_22_Locus:
11cen-q22.3

# Drug_Target_22_Molecular_Weight:
67055

# Drug_Target_22_Name:
NADP-dependent malic enzyme, mitochondrial

# Drug_Target_22_Number_of_Residues:
604

# Drug_Target_22_PDB_ID:
Not Available

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00390	malic
PF03949	Malic_M

# Drug_Target_22_Protein_Sequence:
>NADP-dependent malic enzyme, mitochondrial precursor
MGAALGTGTRLAPWPGRACGALPRWTPTAPAQGCHSKPGPARPVPLKKRGYDVTRNPHLN
KGMAFTLEERLQLGIHGLIPPCFLSQDVQLLRIMRYYERQQSDLDKYIILMTLQDRNEKL
FYRVLTSDVEKFMPIVYTPTVGLACQHYGLTFRRPRGLFITIHDKGHLATMLNSWPEDNI
KAVVVTDGERILGLGDLGCYGMGIPVGKLALYTACGGVNPQQCLPVLLDVGTNNEELLRD
PLYIGLKHQRVHGKAYDDLLDEFMQAVTDKFGINCLIQFEDFANANAFRLLNKYRNKYCM
FNDDIQGTASVAVAGILAALRITNNKLSNHVFVFQGAGEAAMGIAHLLVMALEKEGVPKA
EATRKIWMVDSKGLIVKGRSHLNHEKEMFAQDHPEVNSLEEVVRLVKPTAIIGVAAIAGA
FTEQILRDMASFHERPIIFALSNPTSKAECTAEKCYRVTEGRGIFASGSPFKSVTLEDGK
TFIPGQGNNAYVFPGVALGVIAGGIRHIPDEIFLLTAEQIAQEVSEQHLSQGRLYPPLST
IRDVSLRIAIKVLDYAYKHNLASYYPEPKDKEAFVRSLVYTPDYDSFTLDSYTWPKEAMN
VQTV

# Drug_Target_22_Reaction:
(S)-malate + NADP+ = pyruvate + CO2 + NADPH

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Not Available

# Drug_Target_22_SwissProt_ID:
Q16798

# Drug_Target_22_SwissProt_Name:
MAON_HUMAN

# Drug_Target_22_Synonyms:
EC 1.1.1.40
Malic enzyme 3
NADP-ME
NADP-dependent malic enzyme, mitochondrial precursor

# Drug_Target_22_Theoretical_pI:
7.92

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2550053	Rudy B, Dubois H, Mink R, Trommer WE, McIntyre JO, Fleischer S: Coenzyme binding by 3-hydroxybutyrate dehydrogenase, a lipid-requiring enzyme: lecithin acts as an allosteric modulator to enhance the affinity for coenzyme. Biochemistry. 1989 Jun 27;28(13):5354-66.
38961	Smith CM, Plaut GW: Activities of NAD-specific and NADP-specific isocitrate dehydrogenases in rat-liver mitochondria. Studies with D-threo-alpha-methylisocitrate. Eur J Biochem. 1979 Jun;97(1):283-95.
8533882	Tabata M, Totani M: A chemiluminescence-flow injection analysis of serum 3-hydroxybutyrate using a bioreactor consisting of 3-hydroxybutyrate dehydrogenase and NADH oxidase. Anal Biochem. 1995 Jul 20;229(1):133-8.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
BDH1

# Drug_Target_23_GenBank_ID_Gene:
M93107

# Drug_Target_23_GenBank_ID_Protein:
177198

# Drug_Target_23_GeneCard_ID:
BDH1

# Drug_Target_23_Gene_Name:
BDH1

# Drug_Target_23_Gene_Sequence:
>1032 bp
GGCCTGCGGCCTCCGCCACCCGGACGCTTCTCACGGCTCCCAGGAAAAACCCTAAGTGCC
TGTGATAGAGAAAATGGAGCAAGACGCCCACTATTGCTTGGTTCTACTTCCTTTATCCCG
ATTGGCCGTCGGACTTATGCCAGTGCGGCGGAGCCGGTTGGCAGCAAAGCTGTCCTGGTC
ACAGGCTGTGACTCTGGATTTGGGTTCTCATTGGCCAAGCATCTGCATTCAAAAGGCTTC
CTTGTGTTTGCTGGCTGCTTGATGAAGGACAAAGGCCATGATGGGGTCAAGGAGCTGGAC
AGCCTAAACAGTGACCGATTGAGAACCGTCCAGCTCAATGTCTTCAGAAGCGAAGAGGTG
GAGAAAGTGGTGGGAGATTGTCCGTTCGAGCCTGAAGGACCTGAGAAAGGCATGTGGGGG
CTCGTTAACAATGCCGGCATCTCAACGTTCGGGGAGGTGGAGTTCACCAGCCTGGAGACC
TACAAGCAGGTGGCAGAAGTGAACCTTTGGGGCACAGTGCGGATGACGAAATCCTTTCTC
CCCCTCATCCGAAGGGCCAAAGGCCGCGTCGTCAATATCAGCAGCATGCTGGGCCGCATG
GCCAACCCGGCCCGCTCCCCGTACTGCATCACCAAGTTCGGGGTAGAGGCTTTCTCGGAC
TGCCTGCGCTATGAGATGTACCCCCTGGGCGTGAAGGTCAGCGTGGTGGAGCCCGGCAAC
TTCATCGCTGCCACCAGCCTTTACAACCCTGAGAGCATTCAGGCCATCGCCAAGAAGATG
TGGGAGGAGCTGCCTGAGGTCGTGCGCAAGGACTACGGCAAGAAGTACTTTGATGAAAAG
ATCGCCAAGATGGAGACCTACTGCAGCAGTGGCTCCACAGACACGTCCCCTGTCATCGAT
GCTGTCACACACGCCCTGACCGCCACCACCCCCTACACCCGCTACCACCCCATGGACTAC
TACTGGTGGCTGCGAATGCAGATCATGACCCACTTGCCTGGAGCCATCTCCGACATGATC
TACATCCGCTGA

# Drug_Target_23_General_Function:
Lipid transport and metabolism

# Drug_Target_23_General_References:
1639787	Marks AR, McIntyre JO, Duncan TM, Erdjument-Bromage H, Tempst P, Fleischer S: Molecular cloning and characterization of (R)-3-hydroxybutyrate dehydrogenase from human heart. J Biol Chem. 1992 Aug 5;267(22):15459-63.

# Drug_Target_23_HGNC_ID:
HGNC:1027

# Drug_Target_23_HPRD_ID:
04344

# Drug_Target_23_ID:
196

# Drug_Target_23_Locus:
3q29

# Drug_Target_23_Molecular_Weight:
38158

# Drug_Target_23_Name:
D-beta-hydroxybutyrate dehydrogenase, mitochondrial

# Drug_Target_23_Number_of_Residues:
343

# Drug_Target_23_PDB_ID:
Not Available

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_23_Protein_Sequence:
>D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor
MLATRLSRPLSRLPGKTLSACDRENGARRPLLLGSTSFIPIGRRTYASAAEPVGSKAVLV
TGCDSGFGFSLAKHLHSKGFLVFAGCLMKDKGHDGVKELDSLNSDRLRTVQLNVCSSEEV
EKVVEIVRSSLKDPEKGMWGLVNNAGISTFGEVEFTSLETYKQVAEVNLWGTVRMTKSFL
PLIRRAKGRVVNISSMLGRMANPARSPYCITKFGVEAFSDCLRYEMYPLGVKVSVVEPGN
FIAATSLYSPESIQAIAKKMWEELPEVVRKDYGKKYFDEKIAKMETYCSSGSTDTSPVID
AVTHALTATTPYTRYHPMDYYWWLRMQIMTHLPGAISDMIYIR

# Drug_Target_23_Reaction:
(R)-3-hydroxybutanoate + NAD+ = acetoacetate + NADH + H+

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Not Available

# Drug_Target_23_SwissProt_ID:
Q02338

# Drug_Target_23_SwissProt_Name:
BDH_HUMAN

# Drug_Target_23_Synonyms:
3-hydroxybutyrate dehydrogenase
BDH
D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor
EC 1.1.1.30

# Drug_Target_23_Theoretical_pI:
9.24

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Cytoplasm

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
16983536	Drew DP, Lunde C, Lahnstein J, Fincher GB: Heterologous expression of cDNAs encoding monodehydroascorbate reductases from the moss, Physcomitrella patens and characterization of the expressed enzymes. Planta. 2007 Mar;225(4):945-54.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
MDH1

# Drug_Target_24_GenBank_ID_Gene:
D55654

# Drug_Target_24_GenBank_ID_Protein:
1255604

# Drug_Target_24_GeneCard_ID:
MDH1

# Drug_Target_24_Gene_Name:
MDH1

# Drug_Target_24_Gene_Sequence:
>1005 bp
ATGTCTGAACCAATCAGAGTCCTTGTGACTGGAGCAGCTGGTCAAATTGCATATTCACTG
CTGTACAGTATTGGAAATGGATCTGTCTTTGGTAAAGATCAGCCTATAATTCTTGTGCTG
TTGGATATCACCCCCATGATGGGTGTCCTGGACGGTGTCCTAATGGAACTGCAAGACTGT
GCCCTTCCCCTCCTGAAAGATGTCATCGCAACAGATAAAGAAGACGTTGCCTTCAAAGAC
CTGGATGTGGCCATTCTTGTGGGCTCCATGCCAAGAAGGGAAGGCATGGAGAGAAAAGAT
TTACTGAAAGCAAATGTGAAAATCTTCAAATCCCAGGGTGCAGCCTTAGATAAATACGCC
AAGAAGTCAGTTAAGGTTATTGTTGTGGGTAATCCAGCCAATACCAACTGCCTGACTGCT
TCCAAGTCAGCTCCATCCATCCCCAAGGAGAACTTCAGTTGCTTGACTCGTTTGGATCAC
AACCGAGCTAAAGCTCAAATTGCTCTTAAACTTGGTGTGACTGCTAATGATGTAAAGAAT
GTCATTATCTGGGGAAACCATTCCTCGACTCAGTATCCAGATGTCAACCATGCCAAGGTG
AAATTGCAAGGAAAGGAAGTTGGTGTTTATGAAGCTCTGAAAGATGACAGCTGGCTCAAG
GGAGAATTTGTCACGACTGTGCAGCAGCGTGGCGCTGCTGTCATCAAGGCTCGAAAACTA
TCCAGTGCCATGTCTGCTGCAAAAGCCATCTGTGACCACGTCAGGGACATCTGGTTTGGA
ACCCCAGAGGGAGAGTTTGTGTCCATGGGTGTTATCTCTGATGGCAACTCCTATGGTGTT
CCTGATGATCTGCTCTACTCATTCCCTGTTGTAATCAAGAATAAGACCTGGAAGTTTGTT
GAAGGTCTCCCTATTAATGATTTCTCACGTGAGAAGATGGATCTTACTGCAAAGGAACTG
ACAGAAGAAAAAGAAAGTGCTTTTGAATTTCTTTCCTCTGCCTGA

# Drug_Target_24_General_Function:
Energy production and conversion

# Drug_Target_24_General_References:
7895732	Corbett JM, Wheeler CH, Baker CS, Yacoub MH, Dunn MJ: The human myocardial two-dimensional gel protein database: update 1994. Electrophoresis. 1994 Nov;15(11):1459-65.
8786100	Tanaka T, Inazawa J, Nakamura Y: Molecular cloning and mapping of a human cDNA for cytosolic malate dehydrogenase (MDH1). Genomics. 1996 Feb 15;32(1):128-30.

# Drug_Target_24_HGNC_ID:
HGNC:6970

# Drug_Target_24_HPRD_ID:
01100

# Drug_Target_24_ID:
646

# Drug_Target_24_Locus:
2p13.3

# Drug_Target_24_Molecular_Weight:
36295

# Drug_Target_24_Name:
Malate dehydrogenase, cytoplasmic

# Drug_Target_24_Number_of_Residues:
333

# Drug_Target_24_PDB_ID:
5MDH

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_24_Protein_Sequence:
>Malate dehydrogenase, cytoplasmic
SEPIRVLVTGAAGQIAYSLLYSIGNGSVFGKDQPIILVLLDITPMMGVLDGVLMELQDCA
LPLLKDVIATDKEDVAFKDLDVAILVGSMPRREGMERKDLLKANVKIFKSQGAALDKYAK
KSVKVIVVGNPANTNCLTASKSAPSIPKENFSCLTRLDHNRAKAQIALKLGVTANDVKNV
IIWGNHSSTQYPDVNHAKVKLQGKEVGVYEALKDDSWLKGEFVTTVQQRGAAVIKARKLS
SAMSAAKAICDHVRDIWFGTPEGEFVSMGVISDGNSYGVPDDLLYSFPVVIKNKTWKFVE
GLPINDFSREKMDLTAKELTEEKESAFEFLSSA

# Drug_Target_24_Reaction:
(S)-malate + NAD+ = oxaloacetate + NADH + H+

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
Not Available

# Drug_Target_24_SwissProt_ID:
P40925

# Drug_Target_24_SwissProt_Name:
MDHC_HUMAN

# Drug_Target_24_Synonyms:
Cytosolic malate dehydrogenase
EC 1.1.1.37

# Drug_Target_24_Theoretical_pI:
7.45

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Mitochondrion

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
HIBADH

# Drug_Target_25_GenBank_ID_Gene:
AC007130

# Drug_Target_25_GenBank_ID_Protein:
Not Available

# Drug_Target_25_GeneCard_ID:
HIBADH

# Drug_Target_25_Gene_Name:
HIBADH

# Drug_Target_25_Gene_Sequence:
Not Available

# Drug_Target_25_General_Function:
Lipid transport and metabolism

# Drug_Target_25_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
8313870	Hughes GJ, Frutiger S, Paquet N, Pasquali C, Sanchez JC, Tissot JD, Bairoch A, Appel RD, Hochstrasser DF: Human liver protein map: update 1993. Electrophoresis. 1993 Nov;14(11):1216-22.

# Drug_Target_25_HGNC_ID:
HGNC:4907

# Drug_Target_25_HPRD_ID:
12238

# Drug_Target_25_ID:
141

# Drug_Target_25_Locus:
7p15.2

# Drug_Target_25_Molecular_Weight:
35329

# Drug_Target_25_Name:
3-hydroxyisobutyrate dehydrogenase, mitochondrial

# Drug_Target_25_Number_of_Residues:
336

# Drug_Target_25_PDB_ID:
Not Available

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF03446	NAD_binding_2

# Drug_Target_25_Protein_Sequence:
>3-hydroxyisobutyrate dehydrogenase, mitochondrial precursor
MAASLRLLGAASGLRYWSRRLRPAAGSFAAVCSRSVASKTPVGFIGLGNMGNPMAKNLMK
HGYPLIIYDVFPDACKEFQDAGEQVVSSPADVAEKADRIITMLPTSINAIEAYSGANGIL
KKVKKGSLLIDSSTIDPAVSKELAKEVEKMGAVFMDAPVSGGVGAARSGNLTFMVGGVED
EFAAAQELLGCMGSNVVYCGAVGTGQAAKICNNMLLAISMIGTAEAMNLGIRLGLDPKLL
AKILNMSSGRCWSSDTYNPVPGVMDGVPSANNYQGGFGTTLMAKDLGLAQDSATSTKSPI
LLGSLAHQIYRMMCAKGYSKKDFSSVFQFLREEETF

# Drug_Target_25_Reaction:
3-hydroxy-2-methylpropanoate + NAD+ = 2-methyl-3-oxopropanoate + NADH + H+

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
Not Available

# Drug_Target_25_SwissProt_ID:
P31937

# Drug_Target_25_SwissProt_Name:
3HIDH_HUMAN

# Drug_Target_25_Synonyms:
3-hydroxyisobutyrate dehydrogenase, mitochondrial precursor
EC 1.1.1.31
HIBADH

# Drug_Target_25_Theoretical_pI:
8.26

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Not Available

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
237755	Inano H, Tamaoki B: Relationship between steroids and pyridine nucleotides in the oxido-reduction catalyzed by the 17 beta-hydroxysteroid dehydrogenase purified from the porcine testicular microsomal fraction. Eur J Biochem. 1975 May 6;53(2):319-26.

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
HSD17B3

# Drug_Target_26_GenBank_ID_Gene:
U05659

# Drug_Target_26_GenBank_ID_Protein:
531162

# Drug_Target_26_GeneCard_ID:
HSD17B3

# Drug_Target_26_Gene_Name:
HSD17B3

# Drug_Target_26_Gene_Sequence:
>933 bp
ATGGGGGACGTCCTGGAACAGTTCTTCATCCTCACAGGGCTGCTGGTGTGCCTGGCCTGC
CTGGCGAAGTGCGTGAGATTCTCCAGATGTGTTTTACTGAACTACTGGAAAGTTTTGCCA
AAGTCTTTCTTGCGGTCAATGGGACAGTGGGCAGTGATCACTGGAGCAGGCGATGGAATT
GGGAAAGCGTACTCGTTCGAGCTAGCAAAACGTGGACTCAATGTTGTCCTTATTAGCCGG
ACGCTGGAAAAACTAGAGGCCATTGCCACAGAGATCGAGCGGACTACAGGGAGGAGTGTG
AAGATTATACAAGCAGATTTTACAAAAGATGACATCTACGAGCATATTAAAGAAAAACTT
GCAGGCTTAGAAATTGGAATTTTAGTCAACAATGTCGGAATGCTTCCAAACCTTCTCCCA
AGCCATTTCCTGAACGCACCGGATGAAATCCAGAGCCTCATCCATTGTAACATCACCTCC
GTAGTCAAGATGACACAGCTAATTCTGAAACATATGGAATCAAGGCAGAAAGGTCTCATC
CTGAACATTTCTTCTGGGATAGCCCTGTTTCCTTGGCCTCTCTACTCCATGTACTCAGCT
TCCAAGGCGTTTGTGTGCGCATTTTCCAAGGCCCTGCAAGAGGAATATAAAGCAAAAGAA
GTCATCATCCAGGTGCTGACCCCATATGCTGTCTCGACTGCAATGACAAAGTATCTAAAT
ACAAATGTGATAACCAAGACTGCTGATGAGTTTGTCAAAGAGTCATTGAATTATGTCACA
ATTGGAGGTGAAACCTGTGGCTGCCTTGCCCATGAAATCTTGGCGGGCTTTCTGAGCCTG
ATCCCGGCCTGGGCCTTCTACAGCGGTGCCTTCCAAAGGCTGCTCCTGACACACTATGTG
GCATACCTGAAGCTCAACACCAAGGTCAGGTAG

# Drug_Target_26_General_Function:
Involved in oxidoreductase activity

# Drug_Target_26_General_References:
11158067	Lindqvist A, Hughes IA, Andersson S: Substitution mutation C268Y causes 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab. 2001 Feb;86(2):921-3.
8075637	Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, Elliston KO, Wilson JD, Russell DW, Andersson S: Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet. 1994 May;7(1):34-9.
8550739	Andersson S, Geissler WM, Wu L, Davis DL, Grumbach MM, New MI, Schwarz HP, Blethen SL, Mendonca BB, Bloise W, Witchel SF, Cutler GB Jr, Griffin JE, Wilson JD, Russel DW: Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab. 1996 Jan;81(1):130-6.
9709959	Moghrabi N, Hughes IA, Dunaif A, Andersson S: Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab. 1998 Aug;83(8):2855-60.
9758445	Bilbao JR, Loridan L, Audi L, Gonzalo E, Castano L: A novel missense (R80W) mutation in 17-beta-hydroxysteroid dehydrogenase type 3 gene associated with male pseudohermaphroditism. Eur J Endocrinol. 1998 Sep;139(3):330-3.

# Drug_Target_26_HGNC_ID:
HGNC:5212

# Drug_Target_26_HPRD_ID:
05716

# Drug_Target_26_ID:
372

# Drug_Target_26_Locus:
9q22

# Drug_Target_26_Molecular_Weight:
34516

# Drug_Target_26_Name:
Estradiol 17-beta-dehydrogenase 3

# Drug_Target_26_Number_of_Residues:
310

# Drug_Target_26_PDB_ID:
Not Available

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_26_Protein_Sequence:
>Estradiol 17-beta-dehydrogenase 3
MGDVLEQFFILTGLLVCLACLAKCVRFSRCVLLNYWKVLPKSFLRSMGQWAVITGAGDGI
GKAYSFELAKRGLNVVLISRTLEKLEAIATEIERTTGRSVKIIQADFTKDDIYEHIKEKL
AGLEIGILVNNVGMLPNLLPSHFLNAPDEIQSLIHCNITSVVKMTQLILKHMESRQKGLI
LNISSGIALFPWPLYSMYSASKAFVCAFSKALQEEYKAKEVIIQVLTPYAVSTAMTKYLN
TNVITKTADEFVKESLNYVTIGGETCGCLAHEILAGFLSLIPAWAFYSGAFQRLLLTHYV
AYLKLNTKVR

# Drug_Target_26_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Favors the reduction of androstenedione to testosterone. Uses NADPH while the two other EDH17B enzymes use NADH

# Drug_Target_26_SwissProt_ID:
P37058

# Drug_Target_26_SwissProt_Name:
DHB3_HUMAN

# Drug_Target_26_Synonyms:
17-beta-HSD 3
EC 1.1.1.62
Testicular 17-beta-hydroxysteroid dehydrogenase

# Drug_Target_26_Theoretical_pI:
8.84

# Drug_Target_26_Transmembrane_Regions:
5-27; 178-200; 269-291

# Drug_Target_27_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein. Peroxisome
pero

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
14511985	Li S, Wagner CA, Friesen JA, Borst DW: 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the lobster mandibular organ: regulation by the eyestalk. Gen Comp Endocrinol. 2003 Nov;134(2):147-55.
15152097	Hedl M, Rodwell VW: Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii. Protein Sci. 2004 Jun;13(6):1693-7.
15755483	Huber R, Riepe MW: Improved posthypoxic recovery in vitro on treatment with drugs used for secondary stroke prevention. Neuropharmacology. 2005 Mar;48(4):558-65.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
HMGCR

# Drug_Target_27_GenBank_ID_Gene:
M11058

# Drug_Target_27_GenBank_ID_Protein:
306865

# Drug_Target_27_GeneCard_ID:
HMGCR

# Drug_Target_27_Gene_Name:
HMGCR

# Drug_Target_27_Gene_Sequence:
>2667 bp
ATGTTGTCAAGACTTTTTCGAATGCATGGCCTCTTTGTGGCCTCCCATCCCTGGGAAGTC
ATAGTGGGGACAGTGACACTGACCATCTGCATGATGTCCATGAACATGTTTACTGGTAAC
AATAAGATCTGTGGTTGGAATTATGAATGTCCAAAGTTTGAAGAGGATGTTTTGAGCAGT
GACATTATAATTCTGACAATAACACGATGCATAGCCATCCTGTATATTTACTTCCAGTTC
CAGAATTTACGTCAACTTGGATCAAAATATATTTTGGGTATTGCTGGCCTTTTCACAATT
TTCTCAAGTTTTGTATTCAGTACAGTTGTCATTCACTTCTTAGACAAAGAATTGACAGGC
TTGAATGAAGCTTTGCCCTTTTTCCTACTTTTGATTGACCTTTCCAGAGCAAGCACATTA
GCAAAGTTTGCCCTCAGTTCCAACTCACAGGATGAAGTAAGGGAAAATATTGCTCGTGGA
ATGGCAATTTTAGGTCCTACGTTTACCCTCGATGCTCTTGTTGAATGTCTTGTGATTGGA
GTTGGTACCATGTCAGGGGTACGTCAGCTTGAAATTATGTGCTGCTTTGGCTGCATGTCA
GTTCTTGCCAACTACTTCGTGTTCATGACTTTCTTCCCAGCTTGTGTGTCCTTGGTATTA
GAGCTTTCTCGGGAAAGCCGCGAGGGTCGTCCAATTTGGCAGCTCAGCCATTTTGCCCGA
GTTTTAGAAGAAGAAGAAAATAAGCCGAATCCTGTAACTCAGAGGGTCAAGATGATTATG
TCTCTAGGCTTGGTTCTTGTTCATGCTCACAGTCGCTGGATAGCTGATCCTTCTCCTCAA
AACAGTACAGCAGATACTTCTAAGGTTTCATTAGGACTGGATGAAAATGTGTCCAAGAGA
ATTGAACCAAGTGTTTCCCTCTGGCAGTTTTATCTCTCTAAAATGATCAGCATGGATATT
GAACAAGTTATTACCCTAAGTTTAGCTCTCCTTCTGGCTGTCAAGTACATCTTCTTTGAA
CAAACAGAGACAGAATCTACACTCTCATTAAAAAACCCTATCACATCTCCTGTAGTGACA
CAAAAGAAAGTCCCAGACAATTGTTGTAGACGTGAACCTATGCTGGTCAGAAATAACCAG
AAATGTGATTCAGTAGAGGAAGAGACAGGGATAAACCGAGAAAGAAAAGTTGAGGTTATA
AAACCCTTAGTGGCTGAAACAGATACCCCAAACAGAGCTACATTTGTGGTTGGTAACTCC
TCCTTACTCGATACTTCATCAGTACTGGTGACACAGGAACCTGAAATTGAACTTCCCAGG
GAACCTCGGCCTAATGAAGAATGTCTACAGATACTTGGGAATGCAGAGAAAGGTGCAAAA
TTCCTTAGTGATGCTGAGATCATCCAGTTAGTCAATGCTAAGCATATCCCAGCCTACAAG
TTGGAAACTCTGATGGAAACTCATGAGCGTGGTGTATCTATTCGCCGACAGTTACTTTCC
AAGAAGCTTTCAGAACCTTCTTCTCTCCAGTACCTACCTTACAGGGATTATAATTACTCC
TTGGTGATGGGAGCTTGTTGTGAGAATGTTATTGGATATATGCCCATCCCTGTTGGAGTG
GCAGGACCCCTTTGCTTAGATGAAAAAGAATTTCAGGTTCCAATGGCAACAACAGAAGGT
TGTCTTGTGGCCAGCACCAATAGAGGCTGCAGAGCAATAGGTCTTGGTGGAGGTGCCAGC
AGCCGAGTCCTTGCAGATGGGATGACTCGTGGCCCAGTTGTGCGTCTTCCACGTGCTTGT
GACTCTGCAGAAGTGAAAGCCTGGCTCGAAACATCTGAAGGGTTCGCAGTGATAAAGGAG
GCATTTGACAGCACTAGCAGATTTGCACGTCTACAGAAACTTCATACAAGTATAGCTGGA
CGCAACCTTTATATCCGTTTCCAGTCCAGGTCAGGGGATGCCATGGGGATGAACATGATT
TCAAAGGGTACAGAGAAAGCACTTTCAAAACTTCACGAGTATTTCCCTGAAATGCAGATT
CTAGCCGTTAGTGGTAACTATTGTACTGACAAGAAACCTGCTGCTATAAATTGGATAGAG
GGAAGAGGAAAATCTGTTGTTTGTGAAGCTGTCATTCCAGCCAAGGTTGTCAGAGAAGTA
TTAAAGACTACCACAGAGGCTATGATTGAGGTCAACATTAACAAGAATTTAGTGGGCTCT
GCCATGGCTGGGAGCATAGGAGGCTACAACGCCCATGCAGCAAACATTGTCACCGCCATC
TACATTGCCTGTGGACAGGATGCAGCACAGAATGTTGGTAGTTCAAACTGTATTACTTTA
ATGGAAGCAAGTGGTCCCACAAATGAAGATTTATATATCAGCTGCACCATGCCATCTATA
GAGATAGGAACGGTGGGTGGTGGGACCAACCTACTACCTCAGCAAGCCTGTTTGCAGATG
CTAGGTGTTCAAGGAGCATGCAAAGATAATCCTGGGGAAAATGCCCGGCAGCTTGCCCGA
ATTGTGTGTGGGACCGTAATGGCTGGGGAATTGTCACTTATGGCAGCATTGGCAGCAGGA
CATCTTGTCAAAAGTCACATGATTCACAACAGGTCGAAGATCAATTTACAAGACCTCCAA
GGAGCTTGCACCAAGAAGACAGCCTGA

# Drug_Target_27_General_Function:
Lipid transport and metabolism

# Drug_Target_27_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
10698924	Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J: Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J. 2000 Mar 1;19(5):819-30.
2991281	Luskey KL, Stevens B: Human 3-hydroxy-3-methylglutaryl coenzyme A reductase. Conserved domains responsible for catalytic activity and sterol-regulated degradation. J Biol Chem. 1985 Aug 25;260(18):10271-7.

# Drug_Target_27_HGNC_ID:
HGNC:5006

# Drug_Target_27_HPRD_ID:
00836

# Drug_Target_27_ID:
631

# Drug_Target_27_Locus:
5q13.3-q14

# Drug_Target_27_Molecular_Weight:
97477

# Drug_Target_27_Name:
3-hydroxy-3-methylglutaryl-coenzyme A reductase

# Drug_Target_27_Number_of_Residues:
888

# Drug_Target_27_PDB_ID:
1HWL

# Drug_Target_27_Pathway:
Alendronate pathway	SMP00095
Atorvastatin Pathway	SMP00131
Cerivastatin Pathway	SMP00111
Fluvastatin Pathway	SMP00119
Ibandronate Pathway	SMP00079
Lovastatin Pathway	SMP00099
Pamidronate Pathway	SMP00117
Pravastatin Pathway	SMP00089
Risedronate Pathway	SMP00112
Rosuvastatin Pathway	SMP00092
Zoledronate Pathway	SMP00107

# Drug_Target_27_Pfam_Domain_Function:
PF00368	HMG-CoA_red

# Drug_Target_27_Protein_Sequence:
>3-hydroxy-3-methylglutaryl-coenzyme A reductase
MLSRLFRMHGLFVASHPWEVIVGTVTLTICMMSMNMFTGNNKICGWNYECPKFEEDVLSS
DIIILTITRCIAILYIYFQFQNLRQLGSKYILGIAGLFTIFSSFVFSTVVIHFLDKELTG
LNEALPFFLLLIDLSRASTLAKFALSSNSQDEVRENIARGMAILGPTFTLDALVECLVIG
VGTMSGVRQLEIMCCFGCMSVLANYFVFMTFFPACVSLVLELSRESREGRPIWQLSHFAR
VLEEEENKPNPVTQRVKMIMSLGLVLVHAHSRWIADPSPQNSTADTSKVSLGLDENVSKR
IEPSVSLWQFYLSKMISMDIEQVITLSLALLLAVKYIFFEQTETESTLSLKNPITSPVVT
QKKVPDNCCRREPMLVRNNQKCDSVEEETGINRERKVEVIKPLVAETDTPNRATFVVGNS
SLLDTSSVLVTQEPEIELPREPRPNEECLQILGNAEKGAKFLSDAEIIQLVNAKHIPAYK
LETLMETHERGVSIRRQLLSKKLSEPSSLQYLPYRDYNYSLVMGACCENVIGYMPIPVGV
AGPLCLDEKEFQVPMATTEGCLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRAC
DSAEVKAWLETSEGFAVIKEAFDSTSRFARLQKLHTSIAGRNLYIRFQSRSGDAMGMNMI
SKGTEKALSKLHEYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREV
LKTTTEAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITL
MEASGPTNEDLYISCTMPSIEIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLAR
IVCGTVMAGELSLMAALAAGHLVKSHMIHNRSKINLQDLQGACTKKTA

# Drug_Target_27_Reaction:
(R)-mevalonate + CoA + 2 NADP+ = (S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
This transmembrane glycoprotein is involved in the control of cholesterol biosynthesis. It is the rate-limiting enzyme of sterol biosynthesis

# Drug_Target_27_SwissProt_ID:
P04035

# Drug_Target_27_SwissProt_Name:
HMDH_HUMAN

# Drug_Target_27_Synonyms:
EC 1.1.1.34
HMG-CoA reductase

# Drug_Target_27_Theoretical_pI:
6.72

# Drug_Target_27_Transmembrane_Regions:
10-39
57-78
90-114
124-149
160-187
192-220
315-339

# Drug_Target_28_Cellular_Location:
Cytoplasm

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
17197218	McKinlay JB, Shachar-Hill Y, Zeikus JG, Vieille C: Determining Actinobacillus succinogenes metabolic pathways and fluxes by NMR and GC-MS analyses of 13C-labeled metabolic product isotopomers. Metab Eng. 2007 Mar;9(2):177-92. Epub 2006 Nov 17.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
ME1

# Drug_Target_28_GenBank_ID_Gene:
X77244

# Drug_Target_28_GenBank_ID_Protein:
495123

# Drug_Target_28_GeneCard_ID:
ME1

# Drug_Target_28_Gene_Name:
ME1

# Drug_Target_28_Gene_Sequence:
>1719 bp
ATGGAGCCCGAAGCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGACACGG
AACCCTCACCTCAACAAGGACTTGGCCTTTACCCTGGAAGAGAGACAGCAATTGAACATT
CATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCAGGTTCTTAGAGTAGTAAAA
AATTTCGAGCATCTGAACTCTGACTTTGACAGGTATCTTCTCTTAATGGATCTCCAAGAT
AGAAATGAAAAACTCTTTTATAGAGTGCTGACATCTGACATTGAGAAATTCATGCCTATT
GTTTATACTCCCACTGTGGGTCTGGCTTGCCAACAATATAGTTTGGTGTTTCGGAAGCCA
AGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAGTTCTCAATGCATGG
CCAGAAGATGTCATCAAGGCCATTGTGGTGACTGATGGAGAGCGTATTCTTGGCTTGGGA
GACCTTGGCTGTAATGGAATGGGCATCCCTGTGGGTAAATTGGCTCTATATACAGCTTGC
GGAGGGATGAATCCTCAAGAATGTCTGCCTGTCATTCTGGATGTGGGAACCGAAAATGAG
GAGTTACTTAAAGATCCACTCTACATTGGACTACGGCAGAGAAGAGTAAGAGGTTCTGAA
TATGATGATTTTTTGGACGAATTCATGGAGGCAGTTTCTTCCAAGTATGGCATGAATTGC
CTTATTCAGTTTGAAGATTTTGCCAATGTGAATGCATTTCGTCTCCTGAACAAGTATCGA
AACCAGTATTGCACATTCAATGATGATATTCAAGGAACAGCATCTGTTGCAGTTGCAGGT
CTCCTTGCAGCTCTTCGAATAACCAAGAACAAACTGTCTGATCAAACAATACTATTCCAA
GGAGCTGGAGAGGCTGCCCTAGGGATTGCACACCTGATTGTGATGGCCTTGGAAAAAGAA
GGTTTACCAAAAGAGAAAGCCATCAAAAAGATATGGCTGGTTGATTCAAAAGGATTAATA
GTTAAGGGACGTGCTTCCTTAACACAAGAGAAAGAGAAGTTTGCCCATGAACATGAAGAA
ATGAAGAACCTAGAAGCCATTGTTCAAGAAATAAAACCAACTGCCCTCATAGGAGTTGCT
GCAATTGGTGGTGCATTCTCAGAACAAATTCTCAAAGATATGGCTGCCTTCAATGAACGG
CCTATTATTTTTGCTTTGAGTAATCCAACTAGCAAAGCAGAATGTTCTGCAGAGCAGTGC
TACAAAATAACCAAGGGACGTGCAATTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACT
CTTCCAAATGGACAGACCCTATATCCTGGCCAAGGCAACAATTCCTACGTGTTCCCTGGA
GTTGCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGATAATATTTTCCTCACT
ACTGCTGAGGTTATAGCTCAGCAAGTGTCAGATAAACACTTGGAAGAGGGTCGGCTTTAT
CCTCCTTTGAATACCATTAGAGATGTTTCTCTGAAAATTGCAGAAAAGATTGTGAAAGAT
GCATACCAAGAAAAGACAGCCACAGTTTATCCTGAACCGCAAAACAAAGAAGCATTTGTC
CGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCT
GAAGAGGTGCAGAAAATACAGACCAAAGTTGACCAGTAG

# Drug_Target_28_General_Function:
Energy production and conversion

# Drug_Target_28_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7622060	Gonzalez-Manchon C, Ferrer M, Ayuso MS, Parrilla R: Cloning, sequencing and functional expression of a cDNA encoding a NADP-dependent malic enzyme from human liver. Gene. 1995 Jul 4;159(2):255-60.
8187880	Loeber G, Dworkin MB, Infante A, Ahorn H: Characterization of cytosolic malic enzyme in human tumor cells. FEBS Lett. 1994 May 16;344(2-3):181-6.
8804575	Chou WY, Huang SM, Chang GG: Nonidentity of the cDNA sequence of human breast cancer cell malic enzyme to that from the normal human cell. J Protein Chem. 1996 Apr;15(3):273-9.

# Drug_Target_28_HGNC_ID:
HGNC:6983

# Drug_Target_28_HPRD_ID:
01102

# Drug_Target_28_ID:
666

# Drug_Target_28_Locus:
6q12

# Drug_Target_28_Molecular_Weight:
64150

# Drug_Target_28_Name:
NADP-dependent malic enzyme

# Drug_Target_28_Number_of_Residues:
572

# Drug_Target_28_PDB_ID:
Not Available

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00390	malic
PF03949	Malic_M

# Drug_Target_28_Protein_Sequence:
>NADP-dependent malic enzyme
MEPEAPRRRHTHQRGYLLTRNPHLNKDLAFTLEERQQLNIHGLLPPSFNSQEIQVLRVVK
NFEHLNSDFDRYLLLMDLQDRNEKLFYRVLTSDIEKFMPIVYTPTVGLACQQYSLVFRKP
RGLFITIHDRGHIASVLNAWPEDVIKAIVVTDGERILGLGDLGCNGMGIPVGKLALYTAC
GGMNPQECLPVILDVGTENEELLKDPLYIGLRQRRVRGSEYDDFLDEFMEAVSSKYGMNC
LIQFEDFANVNAFRLLNKYRNQYCTFNDDIQGTASVAVAGLLAALRITKNKLSDQTILFQ
GAGEAALGIAHLIVMALEKEGLPKEKAIKKIWLVDSKGLIVKGRASLTQEKEKFAHEHEE
MKNLEAIVQEIKPTALIGVAAIGGAFSEQILKDMAAFNERPIIFALSNPTSKAECSAEQC
YKITKGRAIFASGSPFDPVTLPNGQTLYPGQGNNSYVFPGVALGVVACGLRQITDNIFLT
TAEVIAQQVSDKHLEEGRLYPPLNTIRDVSLKIAEKIVKDAYQEKTATVYPEPQNKEAFV
RSQMYSTDYDQILPDCYSWPEEVQKIQTKVDQ

# Drug_Target_28_Reaction:
(S)-malate + NADP+ = pyruvate + CO2 + NADPH

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Not Available

# Drug_Target_28_SwissProt_ID:
P48163

# Drug_Target_28_SwissProt_Name:
MAOX_HUMAN

# Drug_Target_28_Synonyms:
EC 1.1.1.40
Malic enzyme 1
NADP-ME

# Drug_Target_28_Theoretical_pI:
6.01

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Not Available

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
12183470	Grant GA, Hu Z, Xu XL: Cofactor binding to Escherichia coli D-3-phosphoglycerate dehydrogenase induces multiple conformations which alter effector binding. J Biol Chem. 2002 Oct 18;277(42):39548-53. Epub 2002 Aug 14.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2692566	Grant GA: A new family of 2-hydroxyacid dehydrogenases. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1371-4.
945314	Goldsmith LA, O'Barr T: Serine biosynthesis in human hair follicles by the phosphorylated pathway: follicular 3-phosphoglycerate dehydrogenase. J Invest Dermatol. 1976 Jun;66(6):360-6.

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
PHGDH

# Drug_Target_29_GenBank_ID_Gene:
AF006043

# Drug_Target_29_GenBank_ID_Protein:
2674062

# Drug_Target_29_GeneCard_ID:
PHGDH

# Drug_Target_29_Gene_Name:
PHGDH

# Drug_Target_29_Gene_Sequence:
>1602 bp
ATGGCTTTTGCAAATCTGCGGAAAGTGCTCATCAGTGACAGCCTGGACCCTTGCTGCCGG
AAGATCTTGCAAGAGGGAGGGCTGCAGGTGGTGGAAAAGCAGAACCTTAGCAAAGAGGAG
CTGATAGCGGAGCTGCAGGACTGTGAAGGCCTTATTGTTCGCTCTGCCACCAAGGTGACC
GCTGATGTCATCAACGCAGCTGAGAAACTCCAGGTGGTGGGCAGGGCTGGCACAGGTGTG
GACAATGTGGATCTGGAGGCCGCAACAAGGAAGGGCATCTTGGTTATGAACACCCCCAAT
GGGAACAGCCTCAGTGCCGCAGAACTCACTTGTGGAATGATCATGTGCCTGGCCAGGCAG
ATTCCCCAGGCGACGGCTTCGATGAAGGACGGCAAATGGGAGCGGAAGAAGTTCATGGGA
ACAGAGCTGAATGGAAAGACCCTGGGAATTCTTGGCCTGGGCAGGATTGGGAGAGAGGTA
GCTACCCGGATGCAGTCCTTTGGGATGAAGACTATAGGGTATGACCCCATCATTTCCCCA
GAGGTCTCGGCCTCCTTTGGTGTTCAGCAGCTGCCCCTGGAGGAGATCTGGCCTCTCTGT
GATTTCATCACTGTGCACACTCCTCTCCTGCCCTCCACGACAGGCTTGCTGAATGACAAC
ACCTTTGCCCAGTGCAAGAAGGGGGTGCGTGTGGTGAACTGTGCCCGTGGAGGGATCGTG
GACGAAGGCGCCCTGCTCCGGGCCCTGCAGTCTGGCCAGTGTGCCGGGGCTGCACTGGAC
GTGTTTACGGAAGAGCCGCCACGGGACCGGGCCTTGGTGGACCATGAGAATGTCATCAGC
TGTCCCCACCTGGGTGCCAGCACCAAGGAGGCTCAGAGCCGCTGTGGGGAGGAAATTGCT
GTTCAGTTCGTGGACATGGTGAAGGGGAAATCTCTCACGGGGGTTGTGAATGCCCAGGCC
CTTACCAGTGCCTTCTCTCCACACACCAAGCCTTGGATTGGTCTGGCAGAAGCTCTGGGG
ACACTGATGCGAGCCTGGGCTGGGTCCCCCAAAGGGACCATCCAGGTGATAACACAGGGA
ACATCCCTGAAGAATGCTGGGAACTGCCTAAGCCCCGCAGTCATTGTCGGCCTCCTGAAA
GAGGCTTCCAAGCAGGCGGATGTGAACTTGGTGAACGCTAAGCTGCTGGTGAAAGAGGCT
GGCCTCAATGTCACCACCTCCCACAGCCCTGCTGCACCAGGGGAGCAAGGCTTCGGGGAA
TGCCTCCTGGCCGTGGCCCTGGCAGGCGCCCCTTACCAGGCTGTGGGCTTGGTCCAAGGC
ACTACACCTGTACTGCAGGGGCTCAATGGAGCTGTCTTCAGGCCAGAAGTGCCTCTCCGC
AGGGACCTGCCCCTGCTCCTATTCCGGACTCAGACCTCTGACCCTGCAATGCTGCCTACC
ATGATTGGCCTCCTGGCAGAGGCAGGCGTGCGGCTGCTGTCCTACCAGACTTCACTGGTG
TCAGATGGGGAGACCTGGCACGTCATGGGCATCTCCTCCTTGCTGCCCAGCCTGGAAGCG
TGGAAGCAGCATGTGACTGAAGCCTTCCAGTTCCACTTCTAA

# Drug_Target_29_General_Function:
Coenzyme transport and metabolism

# Drug_Target_29_General_References:
10713460	Cho HM, Jun DY, Bae MA, Ahn JD, Kim YH: Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene. Gene. 2000 Mar 7;245(1):193-201.
11055895	Klomp LW, de Koning TJ, Malingre HE, van Beurden EA, Brink M, Opdam FL, Duran M, Jaeken J, Pineda M, Van Maldergem L, Poll-The BT, van den Berg IE, Berger R: Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis. Am J Hum Genet. 2000 Dec;67(6):1389-99. Epub 2000 Oct 27.

# Drug_Target_29_HGNC_ID:
HGNC:8923

# Drug_Target_29_HPRD_ID:
06047

# Drug_Target_29_ID:
180

# Drug_Target_29_Locus:
1p12

# Drug_Target_29_Molecular_Weight:
56520

# Drug_Target_29_Name:
D-3-phosphoglycerate dehydrogenase

# Drug_Target_29_Number_of_Residues:
532

# Drug_Target_29_PDB_ID:
Not Available

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00389	2-Hacid_dh
PF02826	2-Hacid_dh_C

# Drug_Target_29_Protein_Sequence:
>D-3-phosphoglycerate dehydrogenase
AFANLRKVLISDSLDPCCRKILQDGGLQVVEKQNLSKEELIAELQDCEGLIVRSATKVTA
DVINAAEKLQVVGRAGTGVDNVDLEAATRKGILVMNTPNGNSLSAAELTCGMIMCLARQI
PQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPE
VSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVD
EGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAV
QFVDMVKGKSLTGVVNAQALTSAFSPHTKPWIGLAEALGTLMRAWAGSPKGTIQVITQGT
SLKNAGNCLSPAVIVGLLKEASKQADVNLVNAKLLVKEAGLNVTTSHSPAAPGEQGFGEC
LLAVALAGAPYQAVGLVQGTTPVLQGLNGAVFRPEVPLRRDLPLLLFRTQTSDPAMLPTM
IGLLAEAGVRLLSYQTSLVSDGETWHVMGISSLLPSLEAWKQHVTEAFQFHF

# Drug_Target_29_Reaction:
(1) 3-phospho-D-glycerate + NAD+ = 3-phosphonooxypyruvate + NADH + H+

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Not Available

# Drug_Target_29_SwissProt_ID:
O43175

# Drug_Target_29_SwissProt_Name:
SERA_HUMAN

# Drug_Target_29_Synonyms:
3-PGDH
EC 1.1.1.95

# Drug_Target_29_Theoretical_pI:
6.70

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16760478	Bieganowski P, Seidle HF, Wojcik M, Brenner C: Synthetic lethal and biochemical analyses of NAD and NADH kinases in Saccharomyces cerevisiae establish separation of cellular functions. J Biol Chem. 2006 Aug 11;281(32):22439-45. Epub 2006 Jun 7.
16897483	Manriquez D, El-Sharkawy I, Flores FB, El-Yahyaoui F, Regad F, Bouzayen M, Latche A, Pech JC: Two highly divergent alcohol dehydrogenases of melon exhibit fruit ripening-specific expression and distinct biochemical characteristics. Plant Mol Biol. 2006 Jul;61(4-5):675-85.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ADH1A

# Drug_Target_2_GenBank_ID_Gene:
M12271

# Drug_Target_2_GenBank_ID_Protein:
178092

# Drug_Target_2_GeneCard_ID:
ADH1A

# Drug_Target_2_Gene_Name:
ADH1A

# Drug_Target_2_Gene_Sequence:
>1128 bp
ATGAGCACAGCAGGAAAAGTAATCAAATGCAAAGCAGCTGTGCTATGGGAGTTAAAGAAA
CCCTTTTCCATTGAGGAGGTGGAGGTTGCACCTCCTAAGGCCCATGAAGTTCGTATTAAG
ATGGTGGCTGTAGGAATCTGTGGCACAGATGACCACGTGGTTAGTGGTACCATGGTGACC
CCACTTCCTGTGATTTTAGGCCATGAGGCAGCCGGCATCGTGGAGAGTGTTGGAGAAGGG
GTGACTACAGTCAAACCAGGTGATAAAGTCATCCCACTCGCTATTCCTCAGTGTGGAAAA
TGCAGAATTTGTAAAAACCCGGAGAGCAACTACTGCTTGAAAAACGATGTAAGCAATCCT
CAGGGGACCCTGCAGGATGGCACCAGCAGGTTCACCTGCAGGAGGAAGCCCATCCACCAC
TTCCTTGGCATCAGCACCTTCTCACAGTACACAGTGGTGGATGAAAATGCAGTAGCCAAA
ATTGATGCAGCCTCGCCTCTAGAGAAAGTCTGTCTCATTGGCTGTGGATTTTCAACTGGT
TATGGGTCTGCAGTCAATGTTGCCAAGGTCACCCCAGGCTCTACCTGTGCTGTGTTTGGC
CTGGGAGGGGTCGGCCTATCTGCTATTATGGGCTGTAAAGCAGCTGGGGCAGCCAGAATC
ATTGCGGTGGACATCAACAAGGACAAATTTGCAAAGGCCAAAGAGTTGGGGGCCACTGAA
TGCATCAACCCTCAAGACTACAAGAAACCCATCCAGGAGGTGCTAAAGGAAATGACTGAT
GGAGGTGTGGATTTTTCATTTGAAGTCATCGGTCGGCTTGACACCATGATGGCTTCCCTG
TTATGTTGTCATGAGGCATGTGGCACAAGTGTCATCGTAGGGGTACCTCCTGATTCCCAA
AACCTCTCAATGAACCCTATGCTGCTACTGACTGGACGTACCTGGAAGGGAGCTATTCTT
GGTGGCTTTAAAAGTAAAGAATGTGTCCCAAAACTTGTGGCTGATTTTATGGCTAAGAAG
TTTTCATTGGATGCATTAATAACCCATGTTTTACCTTTTGAAAAAATAAATGAAGGATTT
GACCTGCTTCACTCTGGGAAAAGTATCCGTACCATTCTGATGTTTTGA

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
2347582	Yasunami M, Kikuchi I, Sarapata D, Yoshida A: The human class I alcohol dehydrogenase gene cluster: three genes are tandemly organized in an 80-kb-long segment of the genome. Genomics. 1990 Jun;7(2):152-8.
2920825	Matsuo Y, Yokoyama S: Molecular structure of the human alcohol dehydrogenase 1 gene. FEBS Lett. 1989 Jan 16;243(1):57-60.
2935875	Ikuta T, Szeto S, Yoshida A: Three human alcohol dehydrogenase subunits: cDNA structure and molecular and evolutionary divergence. Proc Natl Acad Sci U S A. 1986 Feb;83(3):634-8.
3013304	von Bahr-Lindstrom H, Hoog JO, Heden LO, Kaiser R, Fleetwood L, Larsson K, Lake M, Holmquist B, Holmgren A, Hempel J, et al.: cDNA and protein structure for the alpha subunit of human liver alcohol dehydrogenase. Biochemistry. 1986 May 6;25(9):2465-70.

# Drug_Target_2_HGNC_ID:
HGNC:249

# Drug_Target_2_HPRD_ID:
00063

# Drug_Target_2_ID:
251

# Drug_Target_2_Locus:
4q21-q23

# Drug_Target_2_Molecular_Weight:
39728

# Drug_Target_2_Name:
Alcohol dehydrogenase 1A

# Drug_Target_2_Number_of_Residues:
374

# Drug_Target_2_PDB_ID:
1HSO

# Drug_Target_2_Pathway:
Cyclophosphamide Pathway	SMP00447
Disulfiram Pathway	SMP00429

# Drug_Target_2_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_2_Protein_Sequence:
>Alcohol dehydrogenase 1A
STAGKVIKCKAAVLWELKKPFSIEEVEVAPPKAHEVRIKMVAVGICGTDDHVVSGTMVTP
LPVILGHEAAGIVESVGEGVTTVKPGDKVIPLAIPQCGKCRICKNPESNYCLKNDVSNPQ
GTLQDGTSRFTCRRKPIHHFLGISTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGY
GSAVNVAKVTPGSTCAVFGLGGVGLSAIMGCKAAGAARIIAVDINKDKFAKAKELGATEC
INPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPDSQN
LSMNPMLLLTGRTWKGAILGGFKSKECVPKLVADFMAKKFSLDALITHVLPFEKINEGFD
LLHSGKSIRTILMF

# Drug_Target_2_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P07327

# Drug_Target_2_SwissProt_Name:
ADH1A_HUMAN

# Drug_Target_2_Synonyms:
Alcohol dehydrogenase alpha subunit
EC 1.1.1.1

# Drug_Target_2_Theoretical_pI:
8.02

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Membrane
single-pass membrane protein

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
HSD17B7

# Drug_Target_30_GenBank_ID_Gene:
AF098786

# Drug_Target_30_GenBank_ID_Protein:
6721095

# Drug_Target_30_GeneCard_ID:
HSD17B7

# Drug_Target_30_Gene_Name:
HSD17B7

# Drug_Target_30_Gene_Sequence:
>1026 bp
ATGCGAAAGGTGGTTTTGATCACCGGGGCTAGCAGTGGCATTGGCCTGGCCCTCTGCAAG
CGGCTGCTGGCGGAAGATGATGAGCTTCATCTGTGTTTGGCGTGCAGGAACATGAGCAAG
GCAGAAGCTGTCTGTGCTGCTCTGCTGGCCTCTCACCCCACTGCTGAGGTCACCATTGTC
CAGGTGGATGTCAGCAACCTGCAGTCGGTCTTCCGGGCCTCCAAGGAACTTAAGCAAAGG
TTTCAGAGATTAGACTGTATATATCTAAATGCTGGGATCATGCCTAATCCACAACTAAAT
ATCAAAGCACTTTTCTTTGGCCTCTTTTCAAGAAAAGTGATTCATATGTTCTCCACAGCT
GAAGGCCTGCTGACCCAGGGTGATAAGATCACTGCTGATGGACTTCAGGAGGTGTTTGAG
ACCAATGTCTTTGGCCATTTTATCCTGATTCGGGAACTGGAGCCTCTCCTCTGTCACAGT
GACAATCCATCTCAGCTCATCTGGACATCATCTCGCAGTGCAAGGAAATCTAATTTCAGC
CTCGAGGACTTCCAGCACAGCAAAGGCAAGGAACCCTACAGCTCTTCCAAATATGCCACT
GACCTTTTGAGTGTGGCTTTGAACAGGAACTTCAACCAGCAGGGTCTCTATTCCAATGTG
GCCTGTCCAGGTACAGCATTGACCAATTTGACATATGGAATTCTGCCTCCGTTTATATGG
ACGCTGTTGATGCCGGCAATATTGCTACTTCGCTTTTTTGCAAATGCATTCACTTTGACA
CCATATAATGGAACAGAAGCTCTGGTATGGCTTTTCCACCAAAAGCCTGAATCTCTCAAT
CCTCTGATCAAATATCTGAGTGCCACCACTGGCTTTGGAAGAAATTATATTATGACCCAG
AAGATGGACCTAGATGAAGACACTGCTGAAAAATTTTATCAAAAGTTACTGGAACTGGAA
AAGCACATTAGGGTCACTATTCAAAAAACAGATAATCAGGCCAGGCTCAGTGGCTCATGC
CTATAA

# Drug_Target_30_General_Function:
Lipid transport and metabolism

# Drug_Target_30_General_References:
10544267	Krazeisen A, Breitling R, Imai K, Fritz S, Moller G, Adamski J: Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1). FEBS Lett. 1999 Oct 29;460(2):373-9.
12829805	Marijanovic Z, Laubner D, Moller G, Gege C, Husen B, Adamski J, Breitling R: Closing the gap: identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol Endocrinol. 2003 Sep;17(9):1715-25. Epub 2003 Jun 26.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_30_HGNC_ID:
HGNC:5215

# Drug_Target_30_HPRD_ID:
05996

# Drug_Target_30_ID:
206

# Drug_Target_30_Locus:
1q23

# Drug_Target_30_Molecular_Weight:
38207

# Drug_Target_30_Name:
3-keto-steroid reductase

# Drug_Target_30_Number_of_Residues:
341

# Drug_Target_30_PDB_ID:
Not Available

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_30_Protein_Sequence:
>3-keto-steroid reductase
MRKVVLITGASSGIGLALCKRLLAEDDELHLCLACRNMSKAEAVCAALLASHPTAEVTIV
QVDVSNLQSVFRASKELKQRFQRLDCIYLNAGIMPNPQLNIKALFFGLFSRKVIHMFSTA
EGLLTQGDKITADGLQEVFETNVFGHFILIRELEPLLCHSDNPSQLIWTSSRSARKSNFS
LEDFQHSKGKEPYSSSKYATDLLSVALNRNFNQQGLYSNVACPGTALTNLTYGILPPFIW
TLLMPAILLLRFFANAFTLTPYNGTEALVWLFHQKPESLNPLIKYLSATTGFGRNYIMTQ
KMDLDEDTAEKFYQKLLELEKHIRVTIQKTDNQARLSGSCL

# Drug_Target_30_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Responsible for the reduction of the keto group on the C-3 of sterols

# Drug_Target_30_SwissProt_ID:
P56937

# Drug_Target_30_SwissProt_Name:
DHB7_HUMAN

# Drug_Target_30_Synonyms:
17-beta-HSD 7
17-beta-hydroxysteroid dehydrogenase 7
EC 1.1.1.270
EC 1.1.1.62
Estradiol 17-beta- dehydrogenase 7

# Drug_Target_30_Theoretical_pI:
8.21

# Drug_Target_30_Transmembrane_Regions:
230-250

# Drug_Target_31_Cellular_Location:
Mitochondrion

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
14189899	SANWAL BD, ZINK MW, STACHOW CS: NICOTINAMIDE ADENINE DINUCLEOTIDE-SPECIFIC ISOCITRIC DEHYDROGENASE. A POSSIBLE REGULATORY PROTEIN. J Biol Chem. 1964 May;239:1597-603.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4292141	Stein AM, Stein JH, Kirkman SK: Diphosphopyridine nucleotide specific isocitric dehydrogenase of mammalian mitochondria. I. On the roles of pyridine nucleotide transhydrogenase and the isocitric dehydrogenases in the respiration of mitochondria of normal and neoplastic tissues. Biochemistry. 1967 May;6(5):1370-9.
4380379	Rose ZB: The stereochemistry of the nicotinamide adenine dinucleotide-specific isocitric dehydrogenase reaction. J Biol Chem. 1966 May 25;241(10):2311-3.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
IDH3G

# Drug_Target_31_GenBank_ID_Gene:
Z68907

# Drug_Target_31_GenBank_ID_Protein:
1167849

# Drug_Target_31_GeneCard_ID:
IDH3G

# Drug_Target_31_Gene_Name:
IDH3G

# Drug_Target_31_Gene_Sequence:
>1182 bp
ATGGCGCTGAAGGTAGCGACCGTCGCCGGCAGCGCCGCGAAGGCGGTGCTCGGGCCAGCC
CTTCTCTGCCGTCCCTGGGAGGTTCTAGGCGCCCACGAGGTCCCCTCGAGGAACATCTTT
TCAGAACAAACAATTCCTCCGTCCGCTAAGTATGGCGGGCGGCACACGGTGACCATGATC
CCAGGGGATGGCATCGGGCCAGAGCTCATGCTGCATGTCAAGTCCGTCTTCAGGCACGCA
TGTGTACCAGTGGACTTTGAAGAGGTGCACGTGAGTTCCAATGCTGATGAAGAGGACATT
CGCAATGCCATCATGGCCATCCGCCGGAACCGCGTGGCCCTGAAGGGCAACATCGAAACC
AACCATAACCTGCCACCGTCGCACAAATCTCGAAACAACATCCTTCGCACCAGCCTGGAC
CTCTATGCCAACGTCATCCACTGTAAGAGCCTTCCAGGCGTGGTGACCCGGCACAAGGAC
ATAGACATCCTCATTGTCCGGGAGAACACAGAGGGCGAGTACAGCAGCCTGGAGCATGAG
AGTGTGGCGGGAGTGGTGGAGAGCCTGAAGATCATCACCAAGGCCAAGTCCCTGCGCATT
GCCGAGTATGCCTTCAAGCTGGCGCAGGAGAGCGGGCGCAAGAAAGTGACGGCCGTGCAC
AAGGCCAACATCATGAAACTGGGCGATGGGCTTTTCCTCCAGTGCTGCAGGGAGGTGGCA
GCCCGCTACCCTCAGATCACCTTCGAGAACATGATTGTGGATAACACCACCATGCAGCTG
GTGTCCCGGCCCCAGCAGTTTGATGTCATGGTGATGCCCAATCTCTATGGCAACATCGTC
AACAATGTCTGCGCGGGACTGGTCGGGGGCCCAGGCCTTGTGGCTGGGGCCAACTATGGC
CATGTGTACGCGGTGTTTGAAACAGCTACGAGGAACACCGGCAAGAGTATCGCCAATAAG
AACATCGCCAACCCCACGGCCACCCTGCTGGCCAGCTGCATGATGCTGGACCACCTCAAG
CTGCACTCCTATGCCACCTCCATCCGTAAGGCTGTCCTGGCATCCATGGACAATGAGAAT
ATGCACACTCCGGACATCGGGGGCCAGGGCACAACATCTGAAGCCATCCAGGACGTCATC
CGCCACATCCGCGTCATCAACGGCCGGGCCGTGGAGGCCTAG

# Drug_Target_31_General_Function:
Energy production and conversion

# Drug_Target_31_General_References:
10601238	Kim YO, Koh HJ, Kim SH, Jo SH, Huh JW, Jeong KS, Lee IJ, Song BJ, Huh TL: Identification and functional characterization of a novel, tissue-specific NAD(+)-dependent isocitrate dehydrogenase beta subunit isoform. J Biol Chem. 1999 Dec 24;274(52):36866-75.
11256614	Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S: Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing. EMBO Rep. 2000 Sep;1(3):287-92.
9286695	Brenner V, Nyakatura G, Rosenthal A, Platzer M: Genomic organization of two novel genes on human Xq28: compact head to head arrangement of IDH gamma and TRAP delta is conserved in rat and mouse. Genomics. 1997 Aug 15;44(1):8-14.

# Drug_Target_31_HGNC_ID:
HGNC:5386

# Drug_Target_31_HPRD_ID:
02100

# Drug_Target_31_ID:
848

# Drug_Target_31_Locus:
Xq28

# Drug_Target_31_Molecular_Weight:
42795

# Drug_Target_31_Name:
Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial

# Drug_Target_31_Number_of_Residues:
393

# Drug_Target_31_PDB_ID:
Not Available

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF00180	Iso_dh

# Drug_Target_31_Protein_Sequence:
>Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial precursor
MALKVATVAGSAAKAVLGPALLCRPWEVLGAHEVPSRNIFSEQTIPPSAKYGGRHTVTMI
PGDGIGPELMLHVKSVFRHACVPVDFEEVHVSSNADEEDIRNAIMAIRRNRVALKGNIET
NHNLPPSHKSRNNILRTSLDLYANVIHCKSLPGVVTRHKDIDILIVRENTEGEYSSLEHE
SVAGVVESLKIITKAKSLRIAEYAFKLAQESGRKKVTAVHKANIMKLGDGLFLQCCREVA
ARYPQITFENMIVDNTTMQLVSRPQQFDVMVMPNLYGNIVNNVCAGLVGGPGLVAGANYG
HVYAVFETATRNTGKSIANKNIANPTATLLASCMMLDHLKLHSYATSIRKAVLASMDNEN
MHTPDIGGQGTTSEAIQDVIRHIRVINGRAVEA

# Drug_Target_31_Reaction:
isocitrate + NAD+ = 2-oxoglutarate + CO2 + NADH

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Not Available

# Drug_Target_31_SwissProt_ID:
P51553

# Drug_Target_31_SwissProt_Name:
IDH3G_HUMAN

# Drug_Target_31_Synonyms:
EC 1.1.1.41
Isocitrate dehydrogenase subunit gamma, mitochondrial precursor
Isocitric dehydrogenase
NAD(+)-specific ICDH

# Drug_Target_31_Theoretical_pI:
8.66

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Mitochondrion

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
14189899	SANWAL BD, ZINK MW, STACHOW CS: NICOTINAMIDE ADENINE DINUCLEOTIDE-SPECIFIC ISOCITRIC DEHYDROGENASE. A POSSIBLE REGULATORY PROTEIN. J Biol Chem. 1964 May;239:1597-603.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4292141	Stein AM, Stein JH, Kirkman SK: Diphosphopyridine nucleotide specific isocitric dehydrogenase of mammalian mitochondria. I. On the roles of pyridine nucleotide transhydrogenase and the isocitric dehydrogenases in the respiration of mitochondria of normal and neoplastic tissues. Biochemistry. 1967 May;6(5):1370-9.
4380379	Rose ZB: The stereochemistry of the nicotinamide adenine dinucleotide-specific isocitric dehydrogenase reaction. J Biol Chem. 1966 May 25;241(10):2311-3.

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
IDH3B

# Drug_Target_32_GenBank_ID_Gene:
U49283

# Drug_Target_32_GenBank_ID_Protein:
2737886

# Drug_Target_32_GeneCard_ID:
IDH3B

# Drug_Target_32_Gene_Name:
IDH3B

# Drug_Target_32_Gene_Sequence:
>1158 bp
ATGGCGGTATTGAGCGGAGTCCGCTGGCTGACCCGAGCGCTGGTCTCCGCCGGGAACCCT
GGGGCATGGAGAGGTCTGAGTACCTCGGCCGCGGCGCACGCTGCATCGCGGAGCCAGGCC
GAGGACGTGAGGGTGGAGGGCTCCTTTCCCGTGACCATGCTTCCGGGAGACGGTGTGGGG
CCTGAGCTGATGCACGCCGTCAAGGAGGTGTTCAAGGCTGCCGCTGTCCCAGTGGAGTTC
CAGGAGCACCACCTGAGTGAGGTGCAGAATATGGCATCTGAGGAGAAGCTGGAGCAGGTG
CTGAGTTCCATGAAGGAGAACAAAGTGGCCATCATTGGAAAGATTCATACCCCGATGGAG
TATAAGGGGGAGCTAGCCTCCTATGATATGCGGCTGAGGCGTAAGTTGGACTTATTTGCC
AACGTAGTCCATGTGAAGTCACTTCCTGGGTATATGACTCGGCACAACAATCTAGACCTG
GTGATCATTCGAGAGCAGACAGAAGGGGAGTACAGCTCTCTGGAACATGAGAGTGCAAGG
GGTGTGATTGAGTGTTTGAAGATTGTCACACGAGCCAAGTCTCAGCGGATTGCAAAGTTC
GCCTTTGACTATGCCACCAAGAAGGGGCGGGGCAAGGTCACTGCTGTCCACAAGGCCAAC
ATCATGAAACTTGGGGATGGGTTGTTCCTGCAGTGCTGTGAGGAAGTTGCTGAACTGTAC
CCCAAAATCAAATTTGAGACAATGATCATAGACAACTGCTGCATGCAGCTGGTGCAGAAT
CCTTACCAGTTTGATGTGCTTGTGATGCCCAATCTCTATGGGAACATTATTGACAATCTG
GCTGCTGGCCTGGTTGGGGGAGCTGGTGTGGTCCCTGGTGAGAGCTATAGTGCAGAATAC
GCAGTCTTTGAGACGGGTGCCCGGCACCCATTTGCCCAGGCAGTGGGCAGGAATATAGCC
AATCCCACGGCCATGCTGCTGTCGGCTTCCAACATGCTGCGGCATCTTAATCTTGAGTAT
CACTCCAGCATGATCGCAGATGCGGTGAAGAAGGTGATCAAAGTTGGCAAGGTGCGGACT
CGAGACATGGGCGGCTACAGCACCACAACCGACTTCATCAAGTCTGTCATCGGTCACCTG
CAGACTAAAGGGAGCTAG

# Drug_Target_32_General_Function:
Energy production and conversion

# Drug_Target_32_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.

# Drug_Target_32_HGNC_ID:
HGNC:5385

# Drug_Target_32_HPRD_ID:
05163

# Drug_Target_32_ID:
616

# Drug_Target_32_Locus:
20p13

# Drug_Target_32_Molecular_Weight:
42212

# Drug_Target_32_Name:
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial

# Drug_Target_32_Number_of_Residues:
385

# Drug_Target_32_PDB_ID:
Not Available

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF00180	Iso_dh

# Drug_Target_32_Protein_Sequence:
>Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial precursor
MAVLSGVRWLTRALVSAGNPGAWRGLSTSAAAHAASRSQAEDVRVEGSFPVTMLPGDGVG
PELMHAVKEVFKAAAVPVEFQEHHLSEVQNMASEEKLEQVLSSMKENKVAIIGKIHTPME
YKGELASYDMRLRRKLDLFANVVHVKSLPGYMTRHNNLDLVIIREQTEGEYSSLEHESAR
GVIECLKIVTRAKSQRIAKFAFDYATKKGRGKVTAVHKANIMKLGDGLFLQCCEEVAELY
PKIKFETMIIDNCCMQLVQNPYQFDVLVMPNLYGNIIDNLAAGLVGGAGVVPGESYSAEY
AVFETGARHPFAQAVGRNIANPTAMLLSASNMLRHLNLEYHSSMIADAVKKVIKVGKVRT
RDMGGYSTTTDFIKSVIGHLQTKGS

# Drug_Target_32_Reaction:
isocitrate + NAD+ = 2-oxoglutarate + CO2 + NADH

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Not Available

# Drug_Target_32_SwissProt_ID:
O43837

# Drug_Target_32_SwissProt_Name:
IDH3B_HUMAN

# Drug_Target_32_Synonyms:
EC 1.1.1.41
Isocitrate dehydrogenase subunit beta, mitochondrial precursor
Isocitric dehydrogenase
NAD(+)-specific ICDH

# Drug_Target_32_Theoretical_pI:
8.66

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Mitochondrion

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
13152105	PLAUT GW, SUNG SC: Diphosphopyridine nucleotide isocitric dehydrogenase from animal tissues. J Biol Chem. 1954 Mar;207(1):305-14.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4292141	Stein AM, Stein JH, Kirkman SK: Diphosphopyridine nucleotide specific isocitric dehydrogenase of mammalian mitochondria. I. On the roles of pyridine nucleotide transhydrogenase and the isocitric dehydrogenases in the respiration of mitochondria of normal and neoplastic tissues. Biochemistry. 1967 May;6(5):1370-9.
4380379	Rose ZB: The stereochemistry of the nicotinamide adenine dinucleotide-specific isocitric dehydrogenase reaction. J Biol Chem. 1966 May 25;241(10):2311-3.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
IDH3A

# Drug_Target_33_GenBank_ID_Gene:
U07681

# Drug_Target_33_GenBank_ID_Protein:
706839

# Drug_Target_33_GeneCard_ID:
IDH3A

# Drug_Target_33_Gene_Name:
IDH3A

# Drug_Target_33_Gene_Sequence:
>1101 bp
ATGGCTGGGCCCGCGTGGATCTCCAAGGTCTCTCGGCTGCTGGGGGCATTCCACAACCCA
AAACAGGTGACCAGAGGTTTTACTGGTGGTGTTCAGACAGTAACTTTAATTCCAGGAGAT
GGTATTGGCCCAGAAATTTCAGCTGCAGTTATGAAGATTTTTGATGCTGCCAAAGCACCT
ATTCAGTGGGAGGAGCGGAACGTCACTGCCATTCAAGGACCTGGAGGAAAGTGGATGATC
CCTTCAGAGGCTAAAGAGTCCATGGATAAGAACAAGATGGGCTTGAAAGGCCCTTTGAAG
ACCCCAATAGCAGCCGGTCACCCATCTATGAATTTACTGCTGCGCAAAACATTTGACCTT
TACGCGAATGTCCGACCATGTGTCTCTATCGAAGGCTATAAAACCCCTTACACCGATGTA
AATATTGTGACCATTCGAGAGAACACAGAAGGAGAATACAGTGGAATTGAGCATGTGATT
GTTGATGGAGTCGTGCAGAGTATCAAGCTCATCACCGAGGGGGCGAGCAAGCGCATTGCT
GAGTTTGCCTTTGAGTATGCCCGGAACAACCACCGGAGCAACGTCACGGCGGTGCACAAA
GCCAACATCATGCGGATGTCAGATGGGCTTTTTCTACAAAAATGCAGGGAAGTTGCAGAA
AGCTGTAAAGATATTAAATTTAATGAGATGTACCTTGATACAGTATGTTTGAATATGGTA
CAAGATCCTTCCCAATTTGATGTTCTTGTTATGCCAAATTTGTATGGAGACATCCTTAGT
GACTTGTGTGCAGGATTGATCGGAGGTCTCGGTGTGACACCAAGTGGCAACATTGGAGCC
AATGGGGTTGCAATTTTTGAGTCGGTTCATGGGACGGCTCCAGACATTGCAGGCAAGGAC
ATGGCGAATCCCACAGCCCTCCTGCTCAGTGCCGTGATGATGCTGCGCCACATGGGACTT
TTTGACCATGCTGCAAGAATTGAGGCTGCGTGTTTTGCTACAATTAAGGACGGAAAGAGC
TTGACAAAAGATTTGGGAGGCAATGCAAAATGCTCAGACTTCACAGAGGAAATCTGTCGC
CGAGTAAAAGATTTAGATTAA

# Drug_Target_33_General_Function:
Energy production and conversion

# Drug_Target_33_General_References:
7755589	Kim YO, Oh IU, Park HS, Jeng J, Song BJ, Huh TL: Characterization of a cDNA clone for human NAD(+)-specific isocitrate dehydrogenase alpha-subunit and structural comparison with its isoenzymes from different species. Biochem J. 1995 May 15;308 ( Pt 1):63-8.

# Drug_Target_33_HGNC_ID:
HGNC:5384

# Drug_Target_33_HPRD_ID:
03094

# Drug_Target_33_ID:
14

# Drug_Target_33_Locus:
15q25.1-q25.2

# Drug_Target_33_Molecular_Weight:
39592

# Drug_Target_33_Name:
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial

# Drug_Target_33_Number_of_Residues:
366

# Drug_Target_33_PDB_ID:
Not Available

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
PF00180	Iso_dh

# Drug_Target_33_Protein_Sequence:
>Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial precursor
MAGPAWISKVSRLLGAFHNPKQVTRGFTGGVQTVTLIPGDGIGPEISAAVMKIFDAAKAP
IQWEERNVTAIQGPGGKWMIPSEAKESMDKNKMGLKGPLKTPIAAGHPSMNLLLRKTFDL
YANVRPCVSIEGYKTPYTDVNIVTIRENTEGEYSGIEHVIVDGVVQSIKLITEGASKRIA
EFAFEYARNNHRSNVTAVHKANIMRMSDGLFLQKCREVAESCKDIKFNEMYLDTVCLNMV
QDPSQFDVLVMPNLYGDILSDLCAGLIGGLGVTPSGNIGANGVAIFESVHGTAPDIAGKD
MANPTALLLSAVMMLRHMGLFDHAARIEAACFATIKDGKSLTKDLGGNAKCSDFTEEICR
RVKDLD

# Drug_Target_33_Reaction:
isocitrate + NAD+ = 2-oxoglutarate + CO2 + NADH

# Drug_Target_33_Signals:
None

# Drug_Target_33_Specific_Function:
Not Available

# Drug_Target_33_SwissProt_ID:
P50213

# Drug_Target_33_SwissProt_Name:
IDH3A_HUMAN

# Drug_Target_33_Synonyms:
EC 1.1.1.41
Isocitrate dehydrogenase subunit alpha, mitochondrial precursor
Isocitric dehydrogenase
NAD(+)-specific ICDH

# Drug_Target_33_Theoretical_pI:
6.93

# Drug_Target_33_Transmembrane_Regions:
None

# Drug_Target_34_Cellular_Location:
Cytoplasm

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2615366	Pineda JA, Murdock GL, Watson RJ, Warren JC: Stereospecificity of hydrogen transfer by bovine testicular 20 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem. 1989 Dec;33(6):1223-8.
3164265	Rimsay RL, Murphy GW, Martin CJ, Orr JC: The 20 alpha-hydroxysteroid dehydrogenase of Streptomyces hydrogenans. Eur J Biochem. 1988 Jun 1;174(2):437-42.
3463506	Fukuda T, Hirato K, Yanaihara T, Nakayama T: Microsomal 20 alpha-hydroxysteroid dehydrogenase activity for progesterone in human placenta. Endocrinol Jpn. 1986 Jun;33(3):361-8.

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
HSD17B1

# Drug_Target_34_GenBank_ID_Gene:
X13440

# Drug_Target_34_GenBank_ID_Protein:
23365

# Drug_Target_34_GeneCard_ID:
HSD17B1

# Drug_Target_34_Gene_Name:
HSD17B1

# Drug_Target_34_Gene_Sequence:
>987 bp
ATGGCCCGCACCGTGGTGCTCATCACCGGCTGTTCCTCGGGCATCGGCCTGCACTTGGCC
GTACGTCTGGCTTCAGATCCATCCCAGAGCTTCAAAGTGTATGCCACGTTGAGGGACCTG
AAAACACAGGGCCGGCTGTGGGAGGCGGCCCGGGCCCTGGCATGCCCTCCGGGATCCCTG
GAGACGTTGCAGCTGGACGTAAGGGACTCAAAATCCGTGGCCGCTGCCCGGGAACGCGTG
ACTGAGGGCCGCGTGGACGTGCTGGTGTGTAACGCAGGCCTGGGCCTGCTGGGGCCGCTG
GAGGCGCTGGGGGAGGACGCCGTGGCCTCTGTGCTGGACGTGAATGTAGTAGGGACTGTG
CGGATGCTGCAGGCCTTCCTGCCAGACATGAAGAGGCGCGGTTCGGGACGCGTGTTGGTG
ACCGGGAGCGTGGGAGGATTGATGGGGCTGCCTTTCAATGACGTTTATTGCGCCAGCAAG
TTCGCGCTCGAAGGCTTATGCGAGAGTCTGGCGGTTCTGCTGCTGCCCTTTGGGGTCCAC
TTGAGCCTGATCGAGTGCGGCCCAGTGCACACCGCCTTCATGGAGAAGGTGTTGGGCAGC
CCAGAGGAGGTGCTGGACCGCACGGACATCCACACCTTCCACCGCTTCTACCAATACCTC
GCCCACAGCAAGCAAGTCTTTCGCGAGGCGGCGCAGAACCCTGAGGAGGTGGCGGAGGTC
TTCCTCACCGCTTTGCGCGCCCCGAAGCCGACCCTGCGCTACTTCACCACCGAGCGCTTC
CTGCCCCTGCTGCGGATGCGCCTGGACGACCCCAGCGGCTCCAACTACGTCACCGCCATG
CACCGGGAAGTGTTCGGCGACGTTCCGGCAAAGGCCGAGGCTGGGGCCGAGGCTGGGGGC
GGGGCCGGGCCTGGGGCAGAGGACGAGGCCGGGCGCAGTGCGGTGGGGGACCCTGAGCTC
GGCGATCCTCCGGCCGCCCCGCAGTAA

# Drug_Target_34_General_Function:
Lipid transport and metabolism

# Drug_Target_34_General_References:
10625652	Han Q, Campbell RL, Gangloff A, Huang YW, Lin SX: Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/c-19 steroid discrimination and enzyme-induced strain. J Biol Chem. 2000 Jan 14;275(2):1105-11.
1327779	Peltoketo H, Isomaa V, Vihko R: Genomic organization and DNA sequences of human 17 beta-hydroxysteroid dehydrogenase genes and flanking regions. Localization of multiple Alu sequences and putative cis-acting elements. Eur J Biochem. 1992 Oct 1;209(1):459-66.
2197970	Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Cote J, Leblanc G, Lagace L, Berube D, et al.: Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase. Ann N Y Acad Sci. 1990;595:40-52.
2330005	Luu-The V, Labrie C, Simard J, Lachance Y, Zhao HF, Couet J, Leblanc G, Labrie F: Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. Mol Endocrinol. 1990 Feb;4(2):268-75.
2547159	Baker ME: Human placental 17 beta-hydroxysteroid dehydrogenase is homologous to NodG protein of Rhizobium meliloti. Mol Endocrinol. 1989 May;3(5):881-4.
2779584	Luu The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G, Cote J, Berube D, Gagne R, et al.: Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta. Mol Endocrinol. 1989 Aug;3(8):1301-9.
2846351	Peltoketo H, Isomaa V, Maentausta O, Vihko R: Complete amino acid sequence of human placental 17 beta-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett. 1988 Oct 24;239(1):73-7.
3955020	Galdes A, Auld DS, Vallee BL: Elucidation of the chemical nature of the steady-state intermediates in the mechanism of carboxypeptidase A. Biochemistry. 1986 Feb 11;25(3):646-51.
4719204	Nicolas JC, Harris JI: Human placental 17 -oestradiol dehydrogenase. Sequence of a tryptic peptide containing an essential cysteine. FEBS Lett. 1973 Jan 15;29(2):173-6.
5045524	Burns DJ, Engel LL, Bethune JL: Amino acid composition and subunit structure. Human placental 17 -estradiol dehydrogenase. Biochemistry. 1972 Jul 4;11(14):2699-703.
6578212	Murdock GL, Chin CC, Offord RE, Bradshaw RA, Warren JC: Human placental estradiol 17 beta-dehydrogenase. Identification of a single histidine residue affinity-labeled by both 3-bromoacetoxyestrone and 12 beta-bromoacetoxy-4-estrene-3,17-dione. J Biol Chem. 1983 Oct 10;258(19):11460-4.
7663947	Ghosh D, Pletnev VZ, Zhu DW, Wawrzak Z, Duax WL, Pangborn W, Labrie F, Lin SX: Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure. 1995 May 15;3(5):503-13.
8389226	Normand T, Narod S, Labrie F, Simard J: Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. Hum Mol Genet. 1993 Apr;2(4):479-83.
8805577	Breton R, Housset D, Mazza C, Fontecilla-Camps JC: The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure. 1996 Aug 15;4(8):905-15.
9525918	Mazza C, Breton R, Housset D, Fontecilla-Camps JC: Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 1998 Apr 3;273(14):8145-52.

# Drug_Target_34_HGNC_ID:
HGNC:5210

# Drug_Target_34_HPRD_ID:
00185

# Drug_Target_34_ID:
217

# Drug_Target_34_Locus:
17q11-q21

# Drug_Target_34_Molecular_Weight:
34849

# Drug_Target_34_Name:
Estradiol 17-beta-dehydrogenase 1

# Drug_Target_34_Number_of_Residues:
327

# Drug_Target_34_PDB_ID:
1QYX

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_34_Protein_Sequence:
>Estradiol 17-beta-dehydrogenase 1
ARTVVLITGCSSGIGLHLAVRLASDPSQSFKVYATLRDLKTQGRLWEAARALACPPGSLE
TLQLDVRDSKSVAAARERVTEGRVDVLVCNAGLGLLGPLEALGEDAVASVLDVNVVGTVR
MLQAFLPDMKRRGSGRVLVTGSVGGLMGLPFNDVYCASKFALEGLCESLAVLLLPFGVHL
SLIECGPVHTAFMEKVLGSPEEVLDRTDIHTFHRFYQYLAHSKQVFREAAQNPEEVAEVF
LTALRAPKPTLRYFTTERFLPLLRMRLDDPSGSNYVTAMHREVFGDVPAKAEAGAEAGGG
AGPGAEDEAGRSAVGDPELGDPPAAPQ

# Drug_Target_34_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH

# Drug_Target_34_SwissProt_ID:
P14061

# Drug_Target_34_SwissProt_Name:
DHB1_HUMAN

# Drug_Target_34_Synonyms:
17-beta- hydroxysteroid dehydrogenase type 1
17-beta-HSD 1
20 alpha-hydroxysteroid dehydrogenase
20-alpha-HSD
E2DH
EC 1.1.1.62
Placental 17- beta-hydroxysteroid dehydrogenase

# Drug_Target_34_Theoretical_pI:
5.42

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Membrane
single-pass type II membrane protein (Potential)

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2615366	Pineda JA, Murdock GL, Watson RJ, Warren JC: Stereospecificity of hydrogen transfer by bovine testicular 20 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem. 1989 Dec;33(6):1223-8.
3463506	Fukuda T, Hirato K, Yanaihara T, Nakayama T: Microsomal 20 alpha-hydroxysteroid dehydrogenase activity for progesterone in human placenta. Endocrinol Jpn. 1986 Jun;33(3):361-8.
8529651	Wintergalen N, Thole HH, Galla HJ, Schlegel W: Prostaglandin-E2 9-reductase from corpus luteum of pseudopregnant rabbit is a member of the aldo-keto reductase superfamily featuring 20 alpha-hydroxysteroid dehydrogenase activity. Eur J Biochem. 1995 Nov 15;234(1):264-70.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
HSD17B2

# Drug_Target_35_GenBank_ID_Gene:
L11708

# Drug_Target_35_GenBank_ID_Protein:
306462

# Drug_Target_35_GeneCard_ID:
HSD17B2

# Drug_Target_35_Gene_Name:
HSD17B2

# Drug_Target_35_Gene_Sequence:
>1164 bp
ATGAGCACTTTCTTCTCGGACACAGCATGGATCTGCCTGGCTGTCCCCACAGTACTATGT
GGGACAGTATTTTGCAAATACAAGAAGAGCTCAGGGCAGCTGTGGAGCTGGATGGTCTGC
CTGGCAGGCCTCTGTGCAGTCTGCCTGCTCATCCTGTCCCCTTTTTGGGGCTTGATCCTC
TTCTCGGTGTCATGCTTCCTCATGTATACTTACTTATCTGGCCAAGAATTGTTACCTGTG
GATCAGAAGGCAGTCCTGGTGACAGGTGGTGATTGCGGGCTTGGCCATGCTTTGTGCAAG
TATCTGGATGAGCTGGGCTTCACGGTATTTGCCGGAGTTTTGAATGAAAATGGCCCAGGA
GCTGAGGAATTGCGAAGAACCTGCTCTCCGCGCCTCTCGGTGCTCCAAATGGACATCACG
AAGCCAGTGCAGATAAAAGATGCTTACAGCAAGGTTGCAGCAATGCTGCAGGACAGAGGA
CTGTGGGCTGTGATCAACAATGCTGGGGTGCTTGGCTTTCCAACTGATGGGGAGCTTCTT
CTTATGACTGACTACAAACAATGCATGGCCGTGAACTTCTTTGGAACTGTGGAGGTCACA
AAGACGTTTTTGCCTCTTCTTAGAAAATCCAAAGGGAGGCTGGTGAATGTCAGCAGCATG
GGAGGAGGGGCCCCAATGGAAAGGCTGGCATCTTATGGCTCATCAAAGGCGGCTGTGACC
ATGTTCTCATCAGTTATGAGACTGGAGCTTTCCAAGTGGGGAATTAAAGTTGCTTCCATC
CAACCTGGAGGCTTCCTAACAAATATCGCAGGCACCAGTGACAAGTGGGAAAAGCTGGAG
AAGGACATTCTGGACCACCTCCCCGCTGAGGTACAGGAAGACTACGGCCAGGACTACATC
TTAGCACAGCGGAATTTCCTCCTATTGATCAACTCGTTAGCCAGCAAGGACTTCTCTCCG
GTGCTGCGGGACATCCAGCATGCTATCTTGGCGAAGAGCCCTTTTGCCTATTACACGCCA
GGGAAAGGCGCTTACTTGTGGATCTGCCTTGCTCACTATTTGCCTATTGGCATATATGAT
TACTTTGCTAAAAGACATTTTGGCCAAGACAAGCCCATGCCCAGAGCTCTAAGAATGCCT
AACTACAAGAAAAAGGCCACCTAG

# Drug_Target_35_General_Function:
Lipid transport and metabolism

# Drug_Target_35_General_References:
7546291	Labrie Y, Durocher F, Lachance Y, Turgeon C, Simard J, Labrie C, Labrie F: The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. DNA Cell Biol. 1995 Oct;14(10):849-61.
8099587	Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S: Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem. 1993 Jun 15;268(17):12964-9.

# Drug_Target_35_HGNC_ID:
HGNC:5211

# Drug_Target_35_HPRD_ID:
00186

# Drug_Target_35_ID:
9

# Drug_Target_35_Locus:
16q24.1-q24.2

# Drug_Target_35_Molecular_Weight:
42786

# Drug_Target_35_Name:
Estradiol 17-beta-dehydrogenase 2

# Drug_Target_35_Number_of_Residues:
387

# Drug_Target_35_PDB_ID:
Not Available

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_35_Protein_Sequence:
>Estradiol 17-beta-dehydrogenase 2
MSTFFSDTAWICLAVPTVLCGTVFCKYKKSSGQLWSWMVCLAGLCAVCLLILSPFWGLIL
FSVSCFLMYTYLSGQELLPVDQKAVLVTGGDCGLGHALCKYLDELGFTVFAGVLNENGPG
AEELRRTCSPRLSVLQMDITKPVQIKDAYSKVAAMLQDRGLWAVINNAGVLGFPTDGELL
LMTDYKQCMAVNFFGTVEVTKTFLPLLRKSKGRLVNVSSMGGGAPMERLASYGSSKAAVT
MFSSVMRLELSKWGIKVASIQPGGFLTNIAGTSDKWEKLEKDILDHLPAEVQEDYGQDYI
LAQRNFLLLINSLASKDFSPVLRDIQHAILAKSPFAYYTPGKGAYLWICLAHYLPIGIYD
YFAKRHFGQDKPMPRALRMPNYKKKAT

# Drug_Target_35_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Capable of catalyzing the interconversion of testosterone and androstenedione, as well as estradiol and estrone. Also has 20-alpha-HSD activity. Uses NADH while EDH17B3 uses NADPH

# Drug_Target_35_SwissProt_ID:
P37059

# Drug_Target_35_SwissProt_Name:
DHB2_HUMAN

# Drug_Target_35_Synonyms:
17-beta-HSD 2
20 alpha- hydroxysteroid dehydrogenase
20-alpha-HSD
E2DH
EC 1.1.1.62
Microsomal 17-beta-hydroxysteroid dehydrogenase

# Drug_Target_35_Theoretical_pI:
8.62

# Drug_Target_35_Transmembrane_Regions:
4-24

# Drug_Target_36_Cellular_Location:
Membrane
peripheral membrane protein

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
17608724	Dalfo D, Marques N, Albalat R: Analysis of the NADH-dependent retinaldehyde reductase activity of amphioxus retinol dehydrogenase enzymes enhances our understanding of the evolution of the retinol dehydrogenase family. FEBS J. 2007 Jul;274(14):3739-52. Epub 2007 Jul 2.

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
RDH5

# Drug_Target_36_GenBank_ID_Gene:
U43559

# Drug_Target_36_GenBank_ID_Protein:
1616654

# Drug_Target_36_GeneCard_ID:
RDH5

# Drug_Target_36_Gene_Name:
RDH5

# Drug_Target_36_Gene_Sequence:
>957 bp
ATGTGGCTGCCTCTTCTGCTGGGTGCCTTACTCTGGGCAGTGCTGTGGTTGCTCAGGGAC
CGGCAGAGCCTGCCCGCCAGCAATGCCTTTGTCTTCATCACCGGCTGTGACTCAGGCTTT
GGGCGCCTTCTGGCACTGCAGCTGGACCAGAGAGGCTTCCGAGTCCTGGCCAGCTGCCTG
ACCCCCTCCGGGGCCGAGGACCTGCAGCGGGTGGCCTCCTCCCGCCTCCACACCACCCTG
TTGGATATCACTGATCCCCAGAGCGTCCAGCAGGCAGCCAAGTGGGTGGAGATGCACGTT
AAGGAAGCAGGGCTTTTTGGTCTGGTGAATAATGCTGGTGTGGCTGGTATCATCGGACCC
ACACCATGGCTGACCCGGGACGATTTCCAGCGGGTGCTGAATGTGAACACAATGGGTCCC
ATCGGGGTCACCCTTGCCCTGCTGCCTCTGCTGCAGCAAGCCCGGGGCCGGGTGATCAAC
ATCACCAGCGTCCTGGGTCGCCTGGCAGCCAATGGTGGGGGCTACTGTGTCTCCAAATTT
GGCCTGGAGGCCTTCTCTGACAGCCTGAGGCGGGATGTAGCTCATTTTGGGATACGAGTC
TCCATCGTGGAGCCTGGCTTCTTCCGAACCCCTGTGACCAACCTGGAGAGTCTGGAGAAA
ACCCTGCAGGCCTGCTGGGCACGGCTGCCTCCTGCCACACAGGCCCACTATGGGGGGGCC
TTCCTCACCAAGTACCTGAAAATGCAACAGCGCATCATGAACCTGATCTGTGACCCGGAC
CTAACCAAGGTGAGCCGATGCCTGGAGCATGCCCTGACTGCTCGACACCCCCGAACCCGC
TACAGCCCAGGTTGGGATGCCAAGCTGCTCTGGCTGCCTGCCTCCTACCTGCCAGCCAGC
CTGGTGGATGCTGTGCTCACCTGGGTCCTTCCCAAGCCTGCCCAAGCAGTCTACTGA

# Drug_Target_36_General_Function:
Lipid transport and metabolism

# Drug_Target_36_General_References:
10369264	Yamamoto H, Simon A, Eriksson U, Harris E, Berson EL, Dryja TP: Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nat Genet. 1999 Jun;22(2):188-91.
10617778	Gonzalez-Fernandez F, Kurz D, Bao Y, Newman S, Conway BP, Young JE, Han DP, Khani SC: 11-cis retinol dehydrogenase mutations as a major cause of the congenital night-blindness disorder known as fundus albipunctatus. Mol Vis. 1999 Dec 30;5:41.
11053295	Nakamura M, Hotta Y, Tanikawa A, Terasaki H, Miyake Y: A high association with cone dystrophy in Fundus albipunctatus caused by mutations of the RDH5 gene. Invest Ophthalmol Vis Sci. 2000 Nov;41(12):3925-32.
11078852	Kuroiwa S, Kikuchi T, Yoshimura N: A novel compound heterozygous mutation in the RDH5 gene in a patient with fundus albipunctatus. Am J Ophthalmol. 2000 Nov;130(5):672-5.
11470705	Driessen CA, Janssen BP, Winkens HJ, Kuhlmann LD, Van Vugt AH, Pinckers AJ, Deutman AF, Janssen JJ: Null mutation in the human 11-cis retinol dehydrogenase gene associated with fundus albipunctatus. Ophthalmology. 2001 Aug;108(8):1479-84.
12788147	Hotta K, Nakamura M, Kondo M, Ito S, Terasaki H, Miyake Y, Hida T: Macular dystrophy in a Japanese family with fundus albipunctatus. Am J Ophthalmol. 2003 Jun;135(6):917-9.
12967826	Yamamoto H, Yakushijin K, Kusuhara S, Escano MF, Nagai A, Negi A: A novel RDH5 gene mutation in a patient with fundus albipunctatus presenting with macular atrophy and fading white dots. Am J Ophthalmol. 2003 Sep;136(3):572-4.
8884265	Simon A, Lagercrantz J, Bajalica-Lagercrantz S, Eriksson U: Primary structure of human 11-cis retinol dehydrogenase and organization and chromosomal localization of the corresponding gene. Genomics. 1996 Sep 15;36(3):424-30.

# Drug_Target_36_HGNC_ID:
HGNC:9940

# Drug_Target_36_HPRD_ID:
03370

# Drug_Target_36_ID:
627

# Drug_Target_36_Locus:
12q13-q14

# Drug_Target_36_Molecular_Weight:
34979

# Drug_Target_36_Name:
11-cis retinol dehydrogenase

# Drug_Target_36_Number_of_Residues:
318

# Drug_Target_36_PDB_ID:
Not Available

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_36_Protein_Sequence:
>11-cis retinol dehydrogenase
MWLPLLLGALLWAVLWLLRDRQSLPASNAFVFITGCDSGFGRLLALQLDQRGFRVLASCL
TPSGAEDLQRVASSRLHTTLLDITDPQSVQQAAKWVEMHVKEAGLFGLVNNAGVAGIIGP
TPWLTRDDFQRVLNVNTMGPIGVTLALLPLLQQARGRVINITSVLGRLAANGGGYCVSKF
GLEAFSDSLRRDVAHFGIRVSIVEPGFFRTPVTNLESLEKTLQACWARLPPATQAHYGGA
FLTKYLKMQQRIMNLICDPDLTKVSRCLEHALTARHPRTRYSPGWDAKLLWLPASYLPAS
LVDAVLTWVLPKPAQAVY

# Drug_Target_36_Reaction:
retinol + NAD+ = retinal + NADH + H+

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Stereospecific 11-cis retinol dehydrogenase, which catalyzes the final step in the biosynthesis of 11-cis retinaldehyde, the universal chromophore of visual pigments. Active in the presence of NAD as cofactor but not in the presence of NADP

# Drug_Target_36_SwissProt_ID:
Q92781

# Drug_Target_36_SwissProt_Name:
RDH1_HUMAN

# Drug_Target_36_Synonyms:
11-cis RDH
EC 1.1.1.105

# Drug_Target_36_Theoretical_pI:
9.70

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum lumen. Microsomes, endoplasmic reticulum lumen

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
16898590	Markova EV, Zotova NV, Savchenko AA, Titova NM, Slepov EV, Cherdantsev DV, Konovalenko AN: [Lymphocyte metabolism in patients with acute pancreatitis with different genotypes of GSTM1 and GSTT1 genes] Biomed Khim. 2006 May-Jun;52(3):317-26.
17171348	Lu Y, Mei L: Co-expression of P450 BM3 and glucose dehydrogenase by recombinant Escherichia coli and its application in an NADPH-dependent indigo production system. J Ind Microbiol Biotechnol. 2007 Mar;34(3):247-53. Epub 2006 Dec 14.
17269701	Siu E, Won K, Park CB: Electrochemical Regeneration of NADH Using Conductive Vanadia-Silica Xerogels. Biotechnol Prog. 2007 Feb 2;23(1):293-296.
17298031	Zhang M, Mullens C, Gorski W: Coimmobilization of dehydrogenases and their cofactors in electrochemical biosensors. Anal Chem. 2007 Mar 15;79(6):2446-50. Epub 2007 Feb 14.
17531229	Takenaka M, Verbitskiy D, van der Merwe JA, Zehrmann A, Plessmann U, Urlaub H, Brennicke A: In vitro RNA editing in plant mitochondria does not require added energy. FEBS Lett. 2007 Jun 12;581(14):2743-7. Epub 2007 May 21.

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
H6PD

# Drug_Target_37_GenBank_ID_Gene:
AJ012590

# Drug_Target_37_GenBank_ID_Protein:
4186038

# Drug_Target_37_GeneCard_ID:
H6PD

# Drug_Target_37_Gene_Name:
H6PD

# Drug_Target_37_Gene_Sequence:
>2376 bp
ATGTGGAATATGCTCATAGTGGCGATGTGCTTGGCCCTTCTGGGCTGCCTGCAAGCCCAG
GAGCTCCAGGGACATGTCTCCATAATCCTGCTGGGAGCAACTGGGGACCTGGCTAAGAAG
TACTTATGGCAGGGACTGTTCCAGCTGTACCTGGATGAAGCGGGGAGGGGTCACAGTTTT
AGCTTCCATGGAGCTGCTCTGACAGCCCCCAAGCAGGGTCAAGAGCTCATGGCCAAGGCC
CTGGAATCCCTCTCCTGCCCCAAGGACATGGCACCCAGTCACTGTGCAGAGCACAAGGAT
CAGTTCCTGCAGCTGAGCCAGTACCGCCAACTGAAGACGGCCGAGGACTATCAGGCCCTG
AACAAGGACATCGAGGCACAGCTCCAGCACGCAGGCCTCCGGGAGGCTGGCAGGATCTTC
TACTTCTCAGTGCCACCCTTCGCCTATGAAGACATTGCCCGCAACATCAACAGTAGCTGC
CGGCCAGGCCCGGGCGCCTGGCTGCGGGTTGTCCTTGAGAAACCCTTTGGCCATGACCAC
TTCTCAGCCCAGCAGCTGGCCACAGAACTCGGGACCTTTTTCCAGGAGGAGGAGATGTAC
CGGGTGGACCATTACTTAGGCAAGCAGGCTGTGGCGCAGATCCTGCCTTTCCGAGACCAG
AACCGCAAGGCTTTGGACGGCCTCTGGAACCGGCACCATGTGGAGCGGGTGGAGATCATC
ATGAAAGAGACCGTGGATGCTGAAGGCCGCACCAGCTTCTATGAGGAGTACGGTGTCATT
CGCGACGTCCTCCAGAACCATCTGACGGAGGTCCTCACCCTCGTGGCCATGGAGCTGCCC
CACAATGTCAGCAGTGCGGAGGCTGTGCTGCGGCACAAGCTTCAGGTCTTCCAGGCGCTG
CGGGGCCTGCAGAGGGGCAGTGCCGTCGTGGGCCAGTACCAGTCTTACAGTGAGCAGGTG
CGCAGAGAGCTGCAGAAGCCAGACAGCTTCCACAGCCTGACGCCGACCTTCGCAGGTGTC
CTAGTGCACATTGACAACCTTCGCTGGGAGGGCGTGCCTTTCATCCTGATGTCTGGCAAA
GCCTTGGACGAGAGAGTGGGCTACGCTCGGATCTTGTTCAAGAACCAGGCCTGCTGTGTG
CAGAGCGAAAAGCACTGGGCCGCGGCGCAGAGCCAGTGCCTGCCCCGGCAGCTCGTCTTC
CACATCGGCCATGGCGACCTGGGCAGCCCTGCCGTGCTGGTCAGCAGGAACCTGTTCAGG
CCCTCCCTGCCCTCCAGCTGGAAGGAAATGGAGGGACCACCTGGGCTCCGCCTTTTCGGC
AGCCCTCTGTCCGATTACTACGCCTACAGCCCTGTGCGGGAGCGGGACGCCCACTCCGTC
CTCTTATCCCATATCTTCCATGGCCGGAAGAATTTCTTCATCACCACAGAGAACTTGCTG
GCCTCCTGGAACTTCTGGACCCCTCTGCTGGAGAGCCTGGCCCATAAGGCCCCACGCCTC
TACCCTGGAGGAGCTGAGAATGGCCGTCTGTTGGACTTTGAGTTCAGTAGCGGCCGGTTG
TTCTTTTCCCAGCAGCAGCCGGAGCAGCTGGTGCCAGGGCCAGGGCCGGCCCCAATGCCC
AGTGACTTCCAGGTCCTCAGGGCCAAGTACCGAGAGAGCCCGCTGGTCTCCGCCTGGTCC
GAGGAGCTGATCTCTAAGCTGGCTAATGACATCGAGGCCACCGCTGTGCGAGCCGTGCGG
CGCTTTGGCCAGTTCCACCTGGCACTGTCGGGGGGCTCGAGCCCCGTGGCCCTGTTCCAG
CAGCTGGCCACGGCGCACTATGGCTTCCCCTGGGCCCACACGCACCTGTGGCTGGTTGAC
GAGCGCTGCGTCCCACTCTCAGACCCGGAGTCCAACTTCCAGGGCCTGCAGGCCCACCTG
CTGCAGCACGTCCGGATCCCCTACTACAACATCCACCCCATGCCTGTGCACCTGCAGCAG
CGGCTCTGCGCCGAGGAGGACCAGGGCGCCCAGATCTATGCCAGGGAGATCTCAGCCCTG
GTGGCCAACAGCAGCTTCGACCTGGTGCTGCTGGGCATGGGTGCCGACGGGCACACAGCC
TCCCTCTTCCCACAGTCACCCACTGGCCTGGATGGCGAGCAGCTGGTCGTGCTGACCACG
AGCCCCTCCCAGCCACACCGCCGCATGAGCCTTAGCCTGCCTCTCATCAACCGCGCCAAG
AAGGTGGCAGTCCTGGTCATGGGCAGGATGAAGCGTGAGATCACCACGCTGGTGAGCCGG
GTGGGCCATGAGCCCAAGAAGTGGCCCATCTCGGGTGTCCTGCCGCACTCCGGCCAGCTG
GTGTGGTACATGGACTACGACGCCTTCCTGGGATGA

# Drug_Target_37_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_37_General_References:
10349511	Mason PJ, Stevens D, Diez A, Knight SW, Scopes DA, Vulliamy TJ: Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Blood Cells Mol Dis. 1999 Feb;25(1):30-7.

# Drug_Target_37_HGNC_ID:
HGNC:4795

# Drug_Target_37_HPRD_ID:
00681

# Drug_Target_37_ID:
393

# Drug_Target_37_Locus:
1p36

# Drug_Target_37_Molecular_Weight:
88894

# Drug_Target_37_Name:
GDH/6PGL endoplasmic bifunctional protein [Includes: Glucose 1-dehydrogenase

# Drug_Target_37_Number_of_Residues:
791

# Drug_Target_37_PDB_ID:
Not Available

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00479	G6PD_N
PF01182	Glucosamine_iso
PF02781	G6PD_C

# Drug_Target_37_Protein_Sequence:
>GDH/6PGL endoplasmic bifunctional protein precursor [Includes: Glucose 1-dehydrogenase
MWNMLIVAMCLALLGCLQAQELQGHVSIILLGATGDLAKKYLWQGLFQLYLDEAGRGHSF
SFHGAALTAPKQGQELMAKALESLSCPKDMAPSHCAEHKDQFLQLSQYRQLKTAEDYQAL
NKDIEAQLQHAGLREAGRIFYFSVPPFAYEDIARNINSSCRPGPGAWLRVVLEKPFGHDH
FSAQQLATELGTFFQEEEMYRVDHYLGKQAVAQILPFRDQNRKALDGLWNRHHVERVEII
MKETVDAEGRTSFYEEYGVIRDVLQNHLTEVLTLVAMELPHNVSSAEAVLRHKLQVFQAL
RGLQRGSAVVGQYQSYSEQVRRELQKPDSFHSLTPTFAAVLVHIDNLRWEGVPFILMSGK
ALDERVGYARILFKNQACCVQSEKHWAAAQSQCLPRQLVFHIGHGDLGSPAVLVSRNLFR
PSLPSSWKEMEGPPGLRLFGSPLSDYYAYSPVRERDAHSVLLSHIFHGRKNFFITTENLL
ASWNFWTPLLESLAHKAPRLYPGGAENGRLLDFEFSSGRLFFSQQQPEQLVPGPGPAPMP
SDFQVLRAKYRESPLVSAWSEELISKLANDIEATAVRAVRRFGQFHLALSGGSSPVALFQ
QLATAHYGFPWAHTHLWLVDERCVPLSDPESNFQGLQAHLLQHVRIPYYNIHPMPVHLQQ
RLCAEEDQGAQIYAREISALVANSSFDLVLLGMGADGHTASLFPQSPTGLDGEQLVVLTT
SPSQPHRRMSLSLPLINRAKKVAVLVMGRMKREITTLVSRVGHEPKKWPISGVLPHSGQL
VWYMDYDAFLG

# Drug_Target_37_Reaction:
beta-D-glucose + NAD(P)+ = D-glucono-1,5-lactone + NAD(P)H + H+

# Drug_Target_37_Signals:
1-19

# Drug_Target_37_Specific_Function:
Oxidizes glucose-6-phosphate and glucose, as well as other hexose-6-phosphates

# Drug_Target_37_SwissProt_ID:
O95479

# Drug_Target_37_SwissProt_Name:
G6PE_HUMAN

# Drug_Target_37_Synonyms:
6- phosphogluconolactonase
EC 1.1.1.47
EC 3.1.1.31
GDH/6PGL endoplasmic bifunctional protein [Includes: Glucose 1-dehydrogenase precursor
Hexose-6-phosphate dehydrogenase

# Drug_Target_37_Theoretical_pI:
7.31

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Not Available

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
HSD17B8

# Drug_Target_38_GenBank_ID_Gene:
BT007239

# Drug_Target_38_GenBank_ID_Protein:
30583317

# Drug_Target_38_GeneCard_ID:
HSD17B8

# Drug_Target_38_Gene_Name:
HSD17B8

# Drug_Target_38_Gene_Sequence:
>786 bp
ATGGCGTCTCAGCTCCAGAACCGACTCCGCTCCGCACTGGCCTTGGTCACAGGTGCGGGG
AGCGGCATCGGCCGAGCGGTCAGTGTACGCCTGGCCGGAGAGGGGGCCACCGTAGCTGCC
TGCGACCTGGACCGGGCAGCGGCACAGGAGACGGTGCGGCTGCTGGGCGGGCCAGGGAGC
AAGGAGGGGCCGCCCCGAGGGAACCATGCTGCCTTCCAGGCTGACGTGTCTGAGGCCAGG
GCCGCCAGGTGCCTGCTGGAACAAGTGCAGGCCTGCTTTTCTCGCCCACCATCTGTCGTT
GTGTCCTGTGCGGGCATCACCCAGGATGAGTTTCTGCTGCACATGTCTGAGGATGACTGG
GACAAAGTCATAGCTGTCAACCTCAAGGGCACCTTCCTAGTCACTCAGGCTGCAGCACAA
GCCCTGGTGTCCAATGGTTGTCGTGGTTCCATCATCAACATCAGTAGCATCGTAGGAAAG
GTGGGGAACGTGGGGCAGACAAACTATGCAGCATCCAAGGCTGGAGTGATTGGGCTGACC
CAGACCGCAGCCCGGGAGCTTGGACGACATGGGATCCGCTGTAACTCTGTCCTCCCAGGG
TTCATTGCAACACCCATGACACAGAAAGTGCCACAGAAAGTGGTGGACAAGATTACTGAA
ATGATCCCGATGGGACACTTGGGGGACCCTGAGGATGTGGCAGATGTGGTCGCATTCTTG
GCATCTGAAGATAGTGGATACATCACAGGGACCTCAGTGGAAGTCACTGGAGGTCTTTTC
ATGTAG

# Drug_Target_38_General_Function:
Lipid transport and metabolism

# Drug_Target_38_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
8812499	Ando A, Kikuti YY, Shigenari A, Kawata H, Okamoto N, Shiina T, Chen L, Ikemura T, Abe K, Kimura M, Inoko H: cDNA cloning of the human homologues of the mouse Ke4 and Ke6 genes at the centromeric end of the human MHC region. Genomics. 1996 Aug 1;35(3):600-2.

# Drug_Target_38_HGNC_ID:
HGNC:3554

# Drug_Target_38_HPRD_ID:
03248

# Drug_Target_38_ID:
635

# Drug_Target_38_Locus:
6p21.3

# Drug_Target_38_Molecular_Weight:
26974

# Drug_Target_38_Name:
Estradiol 17-beta-dehydrogenase 8

# Drug_Target_38_Number_of_Residues:
261

# Drug_Target_38_PDB_ID:
Not Available

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_38_Protein_Sequence:
>Estradiol 17-beta-dehydrogenase 8
MASQLQNRLRSALALVTGAGSGIGRAVSVRLAGEGATVAACDLDRAAAQETVRLLGGPGS
KEGPPRGNHAAFQADVSEARAARCLLEQVQACFSRPPSVVVSCAGITQDEFLLHMSEDDW
DKVIAVNLKGTFLVTQAAAQALVSNGCRGSIINISSIVGKVGNVGQTNYAASKAGVIGLT
QTAARELGRHGIRCNSVLPGFIATPMTQKVPQKVVDKITEMIPMGHLGDPEDVADVVAFL
ASEDSGYITGTSVEVTGGLFM

# Drug_Target_38_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
Uses estradiol as its preferred substrate

# Drug_Target_38_SwissProt_ID:
Q92506

# Drug_Target_38_SwissProt_Name:
DHB8_HUMAN

# Drug_Target_38_Synonyms:
17- beta-hydroxysteroid dehydrogenase 8
17-beta-HSD 8
EC 1.1.1.62
Ke-6
Protein Ke6

# Drug_Target_38_Theoretical_pI:
6.50

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Cytoplasm

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
11037109	Atalla A, Breyer-Pfaff U, Maser E: Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica. 2000 Aug;30(8):755-69.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
AKR1C4

# Drug_Target_39_GenBank_ID_Gene:
S68287

# Drug_Target_39_GenBank_ID_Protein:
4261710

# Drug_Target_39_GeneCard_ID:
AKR1C4

# Drug_Target_39_Gene_Name:
AKR1C4

# Drug_Target_39_Gene_Sequence:
>972 bp
ATGGATCCCAAATATCAGCGTGTAGAGCTAAATGATGGTCATTTCATGCCCGTATTGGGA
TTTGGCACCTATGCACCTCCAGAGGTTCCGAGGAACAGAGCTGTAGAGGTCACCAAATTA
GCAATAGAAGCTGGCTTCCGCCATATTGATTCTGCTTATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTGCACTTTCTTTCAACCACAGATGGTCCAACCAGCCTTGGAA
AGCTCACTGAAAAAACTTCAACTGGACTATGTTGACCTCTATCTTCTTCATTTCCCAATG
GCTCTCAAGCCAGGTGAGACGCCACTACCAAAAGATGAAAATGGAAAAGTAATATTCGAC
ACAGTGGATCTCTCTGCCACATGGGAGGTCATGGAGAAGTGTAAGGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCAAACTTCAACTGCAGGCAGCTGGAGATGATCCTCAACAAGCCA
GGACTCAAGTACAAGCCTGTCTGCAACCAGGTAGAATGTCATCCTTACCTCAACCAGAGC
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCCACAGTGCTCTGGGA
ACCCAACGACATAAACTATGGGTGGACCCAAACTCCCCAGTTCTTTTGGAGGACCCAGTT
CTTTGTGCCTTAGCAAAGAAACACAAACGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGGATCAGAGAGAAC
ATCCAGGTTTTTGAATTCCAGTTGACATCAGAGGATATGAAAGTTCTAGATGGTCTAAAC
AGAAATTATCGATATGTTGTCATGGATTTTCTTATGGACCATCCTGATTATCCATTTTCA
GATGAATATTAG

# Drug_Target_39_General_Function:
Involved in oxidoreductase activity

# Drug_Target_39_General_References:
10634139	Kume T, Iwasa H, Shiraishi H, Yokoi T, Nagashima K, Otsuka M, Terada T, Takagi T, Hara A, Kamataki T: Characterization of a novel variant (S145C/L311V) of 3alpha-hydroxysteroid/dihydrodiol dehydrogenase in human liver. Pharmacogenetics. 1999 Dec;9(6):763-71.
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
11158055	Dufort I, Labrie F, Luu-The V: Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J Clin Endocrinol Metab. 2001 Feb;86(2):841-6.
1530633	Binstock JM, Iyer RB, Hamby CV, Fried VA, Schwartz IS, Weinstein BI, Southren AL: Human hepatic 3 alpha-hydroxysteroid dehydrogenase: possible identity with human hepatic chlordecone reductase. Biochem Biophys Res Commun. 1992 Sep 16;187(2):760-6.
2187532	Winters CJ, Molowa DT, Guzelian PS: Isolation and characterization of cloned cDNAs encoding human liver chlordecone reductase. Biochemistry. 1990 Jan 30;29(4):1080-7.
7626489	Khanna M, Qin KN, Cheng KC: Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and molecular cloning of multiple cDNAs encoding structurally related proteins in humans. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):41-6.
7650035	Khanna M, Qin KN, Wang RW, Cheng KC: Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem. 1995 Aug 25;270(34):20162-8.
8172617	Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K, Hara A: Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J. 1994 Apr 15;299 ( Pt 2):545-52.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.

# Drug_Target_39_HGNC_ID:
HGNC:387

# Drug_Target_39_HPRD_ID:
07040

# Drug_Target_39_ID:
487

# Drug_Target_39_Locus:
10p15-p14

# Drug_Target_39_Molecular_Weight:
37095

# Drug_Target_39_Name:
Aldo-keto reductase family 1 member C4

# Drug_Target_39_Number_of_Residues:
323

# Drug_Target_39_PDB_ID:
Not Available

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_39_Protein_Sequence:
>Aldo-keto reductase family 1 member C4
MDPKYQRVELNDGHFMPVLGFGTYAPPEVPRNRAVEVTKLAIEAGFRHIDSAYLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWCTFFQPQMVQPALESSLKKLQLDYVDLYLLHFPM
ALKPGETPLPKDENGKVIFDTVDLSATWEVMEKCKDAGLAKSIGVSNFNCRQLEMILNKP
GLKYKPVCNQVECHPYLNQSKLLDFCKSKDIVLVAHSALGTQRHKLWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRENIQVFEFQLTSEDMKVLDGLN
RNYRYVVMDFLMDHPDYPFSDEY

# Drug_Target_39_Reaction:
androsterone + NAD(P)+ = 5alpha-androstane-3,17-dione + NAD(P)H + H+

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha- androstan-3alpha,17beta-diol (3-alpha-diol). Also has some 20- alpha-hydroxysteroid dehydrogenase activity. The biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leads to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route

# Drug_Target_39_SwissProt_ID:
P17516

# Drug_Target_39_SwissProt_Name:
AK1C4_HUMAN

# Drug_Target_39_Synonyms:
3-alpha-HSD1
3-alpha-hydroxysteroid dehydrogenase type I
CDR
Chlordecone reductase
DD4
Dihydrodiol dehydrogenase 4
EC 1.1.1.-
EC 1.1.1.225
EC 1.1.1.50
HAKRA

# Drug_Target_39_Theoretical_pI:
7.19

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17343568	Klimacek M, Hellmer H, Nidetzky B: Catalytic mechanism of Zn2+-dependent polyol dehydrogenases: kinetic comparison of sheep liver sorbitol dehydrogenase with wild-type and Glu154-->Cys forms of yeast xylitol dehydrogenase. Biochem J. 2007 Jun 15;404(3):421-9.
17508915	Ido Y: Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal. 2007 Jul;9(7):931-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SORD

# Drug_Target_3_GenBank_ID_Gene:
U07361

# Drug_Target_3_GenBank_ID_Protein:
520450

# Drug_Target_3_GeneCard_ID:
SORD

# Drug_Target_3_Gene_Name:
SORD

# Drug_Target_3_Gene_Sequence:
>1074 bp
ATGGCGGCGGCGGCCAAGCCCAACAACCTTTCCCTGGTGGTGCACGGACCGGGGGACTTG
CGCCTGGAGAACTATCCTATCCCTGAACCAGGCCCAAATGAGGTCTTGCTGAGGATGCAT
TCTGTTGGAATCTGTGGCTCAGATGTCCACTACTGGGAGTATGGTCGAATTGGGAATTTT
ATTGTGAAAAAGCCCATGGTGCTGGGACATGAAGCTTCGGGAACAGTCGAAAAAGTGGGA
TCATCGGTAAAGCACCTAAAACCAGGTGATCGTGTTGCCATCGAGCCTGGTGCTCCCCGA
GAAAATGATGAATTCTGCAAGATGGGCCGATACAATCTGTCACCTTCCATCTTCTTCTGT
GCCACGCCCCCCGATGACGGGAACCTCTGCCGGTTCTATAAGCACAATGCAGCCTTTTGT
TACAAGCTTCCTGACAATGTCACCTTTGAGGAAGGCGCCCTGATCGAGCCACTTTCTGTG
GGGATCCATGCCTGCAGGAGAGGCGGAGTTACCCTGGGACACAAGGTCCTTGTGTGTGGA
GCTGGGCCAATCGGGATGGTCACTTTGCTCGTGGCCAAAGCAATGGGAGCAGCTCAAGTA
GTGGTGACTGATCTGTCTGCTACCCGATTGTCCAAAGCCAAGGAGATTGGGGCTGATTTA
GTCCTCCAGATCTCCAAGGAGAGCCCTCAGGAAATCGCCAGGAAAGTAGAAGGTCAGCTG
GGGTGCAAGCCGGAAGTCACCATCGAGTGCACGGGGGCAGAGGCCTCCATCCAGGCGGGC
ATCTACGCCACTCGCTCTGGTGGGACCCTCGTGCTTGTGGGGCTGGGCTCTGAGATGACC
ACCGTACCCCTACTGCATGCAGCCATCCGGGAGGTGGATATCAAGGGCGTGTTTCGATAC
TGCAACACGTGGCCAGTGGCGATTTCGATGCTTGCGTCCAAGTCTGTGAATGTAAAACCC
CTCGTCACCCATAGGTTTCCTCTGGAGAAAGCTCTGGAGGCCTTTGAAACATTTAAAAAG
GGATTGGGGTTGAAAATCATGCTCAAGTGTGACCCCAGTGACCAGAATCCCTGA

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
2691249	Karlsson C, Maret W, Auld DS, Hoog JO, Jornvall H: Variability within mammalian sorbitol dehydrogenases. The primary structure of the human liver enzyme. Eur J Biochem. 1989 Dec 22;186(3):543-50.
7782086	Iwata T, Popescu NC, Zimonjic DB, Karlsson C, Hoog JO, Vaca G, Rodriguez IR, Carper D: Structural organization of the human sorbitol dehydrogenase gene (SORD). Genomics. 1995 Mar 1;26(1):55-62.
8088829	Lee FK, Cheung MC, Chung S: The human sorbitol dehydrogenase gene: cDNA cloning, sequence determination, and mapping by fluorescence in situ hybridization. Genomics. 1994 May 15;21(2):354-8.
9183016	Carr IM, Markham AF, Coletta PL: Identification and characterisation of a sequence related to human sorbitol dehydrogenase. Eur J Biochem. 1997 May 1;245(3):760-7.

# Drug_Target_3_HGNC_ID:
HGNC:11184

# Drug_Target_3_HPRD_ID:
01679

# Drug_Target_3_ID:
328

# Drug_Target_3_Locus:
15q15.3

# Drug_Target_3_Molecular_Weight:
38166

# Drug_Target_3_Name:
Sorbitol dehydrogenase

# Drug_Target_3_Number_of_Residues:
356

# Drug_Target_3_PDB_ID:
1PL8

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_3_Protein_Sequence:
>Sorbitol dehydrogenase
AAAAKPNNLSLVVHGPGDLRLENYPIPEPGPNEVLLRMHSVGICGSDVHYWEYGRIGNFI
VKKPMVLGHEASGTVEKVGSSVKHLKPGDRVAIEPGAPRENDEFCKMGRYNLSPSIFFCA
TPPDDGNLCRFYKHNAAFCYKLPDNVTFEEGALIEPLSVGIHACRRGGVTLGHKVLVCGA
GPIGMVTLLVAKAMGAAQVVVTDLSATRLSKAKEIGADLVLQISKESPQEIARKVEGLLG
CKPEVTIECTGAEASIQAGIYATRSGGTLVLVGLGSEMTTVPLLHAAIREVDIKGVFRYC
NTWPVAISMLASKSVNVKPLVTHRFPLEKALEAFETFKKGLGLKIMLKCDPSDQNP

# Drug_Target_3_Reaction:
L-iditol + NAD+ = L-sorbose + NADH + H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q00796

# Drug_Target_3_SwissProt_Name:
DHSO_HUMAN

# Drug_Target_3_Synonyms:
EC 1.1.1.14
L-iditol 2-dehydrogenase

# Drug_Target_3_Theoretical_pI:
8.06

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
17496727	Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, Hutchinson IV, Burckart GJ: A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007 Apr;17(4):283-90.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
IMPDH2

# Drug_Target_40_GenBank_ID_Gene:
J04208

# Drug_Target_40_GenBank_ID_Protein:
307066

# Drug_Target_40_GeneCard_ID:
IMPDH2

# Drug_Target_40_Gene_Name:
IMPDH2

# Drug_Target_40_Gene_Sequence:
>1545 bp
ATGGCCGACTACCTGATTAGTGGGGGCACGTCCTACGTGCCAGACGACGGACTCACAGCA
CAGCAGCTCTTCAACTGCGGAGACGGCCTCACCTACAATGACTTTCTCATTCTCCCTGGG
TACATCGACTTCACTGCAGACCAGGTGGACCTGACTTCTGCTCTGACCAAGAAAATCACT
CTTAAGACCCCACTGGTTTCCTCTCCCATGGACACAGTCACAGAGGCTGGGATGGCCATA
GCAATGGCGCTTACAGGCGGTATTGGCTTCATCCACCACAACTGTACACCTGAATTCCAG
GCCAATGAAGTTCGGAAAGTGAAGAAATATGAACAGGGATTCATCACAGACCCTGTGGTC
CTCAGCCCCAAGGATCGCGTGCGGGATGTTTTTGAGGCCAAGGCCCGGCATGGTTTCTGC
GGTATCCCAATCACAGACACAGGCCGGATGGGGAGCCGCTTGGTGGGCATCATCTCCTCC
AGGGACATTGATTTTCTCAAAGAGGAGGAACATGACTGTTTCTTGGAAGAGATAATGACA
AAGAGGGAAGACTTGGTGGTAGCCCCCCGCAGCATCACACTGAAGGAGGCAAATGAAATT
CTGCAGCGCAGCAAGAAGGGAAAGTTGCCCATTGTAAATGAAGATGATGAGCTTGTGGCC
ATCATTGCCCGGACAGACCTGAAGAAGAATCGGGACTACCCACTAGCCTCCAAAGATGCC
AAGAAACAGCTGCTGTGTGGGGCAGCCATTGGCACTCATGAGGATGACAAGTATAGGCTG
GACTTGCTCGCCCAGGCTGGTGTGGATGTAGTGGTTTTGGACTCTTCCCAGGGAAATTCC
ATCTTCCAGATCAATATGATCAAGTACATCAAAGACAAATACCCTAATCTCCAAGTCATT
GGAGGCAATGTGGTCACTGCTGCCCAGGCCAAGAACCTCATTGATGCAGGTGTGGATGCC
CTGCGGGTGGGCATGGGAAGTGGCTCCATCTGCATTACGCAGGAAGTGCTGGCCTGTGGG
CGGCCCCAAGCAACAGCAGTGTACAAGGTGTCAGAGTATGCACGGCGCTTTGGTGTTCCG
GTCATTGCTGATGGAGGAATCCAAAATGTGGGTCATATTGCGAAAGCCTTGGCCCTTGGG
GCCTCCACAGTCATGATGGGCTCTCTCCTGGCTGCCACCACTGAGGCCCCTGGTGAATAC
TTCTTTTCCGATGGGATCCGGCTAAAGAAATATCGCGGTATGGGTTCTCTCGATGCCATG
GACAAGCACCTCAGCAGCCAGAACAGATATTTCAGTGAAGCTGACAAAATCAAAGTGGCC
CAGGGAGTGTCTGGTGCTGTGCAGGACAAAGGGTCAATCCACAAATTTGTCCCTTACCTG
ATTGCTGGCATCCAACACTCATGCCAGGACATTGGTGCCAAGAGCTTGACCCAAGTCCGA
GCCATGATGTACTCTGGGGAGCTTAAGTTTGAGAAGAGAACGTCCTCAGCCCAGGTGGAA
GGTGGCGTCCATAGCCTCCATTCGTATGAGAAGCGGCTTTTCTGA

# Drug_Target_40_General_Function:
Nucleotide transport and metabolism

# Drug_Target_40_General_References:
10097070	Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM: Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3531-6.
1969416	Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990 Mar 25;265(9):5292-5.
2902093	Collart FR, Huberman E: Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs. J Biol Chem. 1988 Oct 25;263(30):15769-72.
7763314	Hager PW, Collart FR, Huberman E, Mitchell BS: Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol. 1995 May 11;49(9):1323-9.
7896827	Zimmermann AG, Spychala J, Mitchell BS: Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene. J Biol Chem. 1995 Mar 24;270(12):6808-14.
7999076	Glesne DA, Huberman E: Cloning and sequence of the human type II IMP dehydrogenase gene. Biochem Biophys Res Commun. 1994 Nov 30;205(1):537-44.
8098009	Glesne D, Collart F, Varkony T, Drabkin H, Huberman E: Chromosomal localization and structure of the human type II IMP dehydrogenase gene (IMPDH2). Genomics. 1993 Apr;16(1):274-7.

# Drug_Target_40_HGNC_ID:
HGNC:6053

# Drug_Target_40_HPRD_ID:
00895

# Drug_Target_40_ID:
796

# Drug_Target_40_Locus:
3p21.2

# Drug_Target_40_Molecular_Weight:
55806

# Drug_Target_40_Name:
Inosine-5'-monophosphate dehydrogenase 2

# Drug_Target_40_Number_of_Residues:
514

# Drug_Target_40_PDB_ID:
1NFB

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF00478	IMPDH
PF00571	CBS

# Drug_Target_40_Protein_Sequence:
>Inosine-5'-monophosphate dehydrogenase 2
MADYLISGGTSYVPDDGLTAQQLFNCGDGLTYNDFLILPGYIDFTADQVDLTSALTKKIT
LKTPLVSSPMDTVTEAGMAIAMALTGGIGFIHHNCTPEFQANEVRKVKKYEQGFITDPVV
LSPKDRVRDVFEAKARHGFCGIPITDTGRMGSRLVGIISSRDIDFLKEEEHDCFLEEIMT
KREDLVVAPAGITLKEANEILQRSKKGKLPIVNEDDELVAIIARTDLKKNRDYPLASKDA
KKQLLCGAAIGTHEDDKYRLDLLAQAGVDVVVLDSSQGNSIFQINMIKYIKDKYPNLQVI
GGNVVTAAQAKNLIDAGVDALRVGMGSGSICITQEVLACGRPQATAVYKVSEYARRFGVP
VIADGGIQNVGHIAKALALGASTVMMGSLLAATTEAPGEYFFSDGIRLKKYRGMGSLDAM
DKHLSSQNRYFSEADKIKVAQGVSGAVQDKGSIHKFVPYLIAGIQHSCQDIGAKSLTQVR
AMMYSGELKFEKRTSSAQVEGGVHSLHSYEKRLF

# Drug_Target_40_Reaction:
inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
Rate limiting enzyme in the de novo synthesis of guanine nucleotides and therefore is involved in the regulation of cell growth. It may also have a role in the development of malignancy and the growth progression of some tumors

# Drug_Target_40_SwissProt_ID:
P12268

# Drug_Target_40_SwissProt_Name:
IMDH2_HUMAN

# Drug_Target_40_Synonyms:
EC 1.1.1.205
IMP dehydrogenase 2
IMPD 2
IMPDH-II

# Drug_Target_40_Theoretical_pI:
6.90

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Cytoplasm

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2146972	Pineda JA, Murdock GL, Watson RJ, Warren JC: Stereospecificity of hydrogen transfer between progesterone and cofactor by human placental estradiol-17 beta dehydrogenase. J Steroid Biochem Mol Biol. 1990 Sep;37(1):65-70.
2615366	Pineda JA, Murdock GL, Watson RJ, Warren JC: Stereospecificity of hydrogen transfer by bovine testicular 20 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem. 1989 Dec;33(6):1223-8.
6584048	Nicolas JC, Boussioux AM, Boularan AM, Descomps B, Crastes de Paulet A: Bioluminescent assay of femtomole levels of estrone and estradiol. Anal Biochem. 1983 Nov;135(1):141-5.

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
AKR1C3

# Drug_Target_41_GenBank_ID_Gene:
S68288

# Drug_Target_41_GenBank_ID_Protein:
4261711

# Drug_Target_41_GeneCard_ID:
AKR1C3

# Drug_Target_41_Gene_Name:
AKR1C3

# Drug_Target_41_Gene_Sequence:
>972 bp
ATGGATTCCAAACAGCAGTGTGTAAAGCTAAATGATGGCCACTTCATGCCTGTATTGGGA
TTTGGCACCTATGCACCTCCAGAGGTTCCGAGAAGTAAAGCTTTGGAGGTCACAAAATTA
GCAATAGAAGCTGGGTTCCGCCATATAGATTCTGCTCATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTTGAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTCCACTTTTCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AACTCACTGAAGAAAGCTCAATTGGACTATGTTGACCTCTATCTTATTCATTCTCCAATG
TCTCTAAAGCCAGGTGAGGAACTTTCACCAACAGATGAAAATGGAAAAGTAATATTTGAC
ATAGTGGATCTCTGTACCACCTGGGAGGCCATGGAGAAGTGTAAGGATGCAGGATTGGCC
AAGTCCATTGGGGTATCAAACTTCAACCGCAGGCAGCTGGAGATCATCCTCAACAAGCCA
GGACTCAAGTACAAGCCTGTCTGCAACCAGGTAGAATGTCATCCGTATTTCAACCGGAGT
AAATTGCTAGATTTCTGCAAGTCGAAAGATATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCTCAACGAGACAAACGATGGGTGGACCCGAACTCCCCGGTCCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTTTTTGAGTTCCAGTTGACTGCAGAGGACATGAAAGCCATAGATGGCCTAGAC
AGAAATCTCCACTATTTTAACAGTGATAGTTTTGCTAGCCACCCTAATTATCCATATTCA
GATGAATATTAA

# Drug_Target_41_General_Function:
Involved in oxidoreductase activity

# Drug_Target_41_General_References:
10557352	Griffin LD, Mellon SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13512-7.
10622721	Suzuki-Yamamoto T, Nishizawa M, Fukui M, Okuda-Ashitaka E, Nakajima T, Ito S, Watanabe K: cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett. 1999 Dec 3;462(3):335-40.
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
11165022	Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K, Palackal N: Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49.
7626489	Khanna M, Qin KN, Cheng KC: Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and molecular cloning of multiple cDNAs encoding structurally related proteins in humans. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):41-6.
7650035	Khanna M, Qin KN, Wang RW, Cheng KC: Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem. 1995 Aug 25;270(34):20162-8.
7788527	Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H, et al.: Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1995;2(1):37-43.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
9415401	Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM: Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol. 1997 Dec;11(13):1971-84.
9927279	Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V: Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology. 1999 Feb;140(2):568-74.

# Drug_Target_41_HGNC_ID:
HGNC:386

# Drug_Target_41_HPRD_ID:
04911

# Drug_Target_41_ID:
650

# Drug_Target_41_Locus:
10p15-p14

# Drug_Target_41_Molecular_Weight:
36845

# Drug_Target_41_Name:
Aldo-keto reductase family 1 member C3

# Drug_Target_41_Number_of_Residues:
323

# Drug_Target_41_PDB_ID:
1XF0

# Drug_Target_41_Pathway:
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Valdecoxib Pathway	SMP00116

# Drug_Target_41_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_41_Protein_Sequence:
>Aldo-keto reductase family 1 member C3
MDSKQQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPM
SLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLD
RNLHYFNSDSFASHPNYPYSDEY

# Drug_Target_41_Reaction:
estradiol-17beta + NAD(P)+ = estrone + NAD(P)H + H+

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9alpha,11beta- PGF2 to PGD2. Functions as a bi-directional 3alpha-, 17beta- and 20alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone

# Drug_Target_41_SwissProt_ID:
P42330

# Drug_Target_41_SwissProt_Name:
AK1C3_HUMAN

# Drug_Target_41_Synonyms:
17-beta-HSD 5
17-beta-hydroxysteroid dehydrogenase type 5
3-alpha- hydroxysteroid dehydrogenase type 2
3-alpha-HSD type 2
3-alpha-HSD type II, brain
Chlordecone reductase homolog HAKRb
DD-3
DD3
Dihydrodiol dehydrogenase 3
Dihydrodiol dehydrogenase type I
EC 1.-.-.-
EC 1.1.1.188
EC 1.1.1.213
EC 1.1.1.62
EC 1.3.1.20
Estradiol 17-beta-dehydrogenase
HA1753
PGFS
Prostaglandin F synthase
Trans-1,2- dihydrobenzene-1,2-diol dehydrogenase

# Drug_Target_41_Theoretical_pI:
8.06

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Cytoplasm

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
17463062	Gao L, He P, Sha J, Liu C, Dai L, Hui N, Ni X: Corticotropin-releasing hormone receptor type 1 and type 2 mediate differential effects on 15-hydroxy prostaglandin dehydrogenase expression in cultured human chorion trophoblasts. Endocrinology. 2007 Aug;148(8):3645-54. Epub 2007 Apr 26.

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
HPGD

# Drug_Target_42_GenBank_ID_Gene:
L76465

# Drug_Target_42_GenBank_ID_Protein:
1203984

# Drug_Target_42_GeneCard_ID:
HPGD

# Drug_Target_42_Gene_Name:
HPGD

# Drug_Target_42_Gene_Sequence:
>801 bp
ATGCACGTGAACGGCAAAGTGGCGCTGGTGACCGGCGCGGCTCAGGGCATAGGCAGAGCC
TTTGCAGAGGCGCTGCTGCTTAAGGGCGCCAAGGTAGCGCTGGTGGATTGGAATCTTGAA
GCAGGTGTACAGTGTAAAGCTGCCCTGCATGAGCAATTTGAACCTCAGAAGACTCTGTTC
ATCCAGTGCGATGTGGCTGACCAGCAACAACTGAGAGACACTTTTAGAAAAGTTGTAGAC
CACTTTGGAAGACTGGACATTTTGGTCAATAATGCTGGAGTGAATAATGAGAAAAACTGG
GAAAAAACTCTGCAAATTAATTTGGTTTCTGTTATCAGTGGAACCTATCTTGGTTTGGAT
TACATGAGTAAGCAAAATGGAGGTGAAGGCGGCATCATTATCAATATGTCATCTTTAGCA
GGACTCATGCCCGTTGCACAGCAGCCGGTTTATTGTGCTTCAAAGCATGGCATAGTTGGA
TTCACACGCTCAGCAGCGTTGGCTGCTAATCTTATGAACAGTGGTGTGAGACTGAATGCC
ATTTGTCCAGGCTTTGTTAACACAGCCATCCTTGAATCAATTGAAAAAGAAGAAAACATG
GGACAATATATAGAATATAAGGATCATATCAAGGATATGATTAAATACTATGGAATTTTG
GACCCACCATTGATTGCCAATGGATTGATAACACTCATTGAAGATGATGCTTTAAATGGT
GCTATTATGAAGATCACAACTTCTAAGGGAATTCATTTTCAAGACTATGATACAACTCCA
TTTCAAGCAAAAACCCAATGA

# Drug_Target_42_General_Function:
Lipid transport and metabolism

# Drug_Target_42_General_References:
1697582	Ensor CM, Yang JY, Okita RT, Tai HH: Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. J Biol Chem. 1990 Sep 5;265(25):14888-91.
2025296	Ensor CM, Tai HH: Site-directed mutagenesis of the conserved tyrosine 151 of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase yields a catalytically inactive enzyme. Biochem Biophys Res Commun. 1991 Apr 30;176(2):840-5.
2337593	Krook M, Marekov L, Jornvall H: Purification and structural characterization of placental NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase. The primary structure reveals the enzyme to belong to the short-chain alcohol dehydrogenase family. Biochemistry. 1990 Jan 23;29(3):738-43.
8482380	Krook M, Ghosh D, Duax W, Jornvall H: Three-dimensional model of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase and relationships to the NADP(+)-dependent enzyme (carbonyl reductase). FEBS Lett. 1993 May 10;322(2):139-42.

# Drug_Target_42_HGNC_ID:
HGNC:5154

# Drug_Target_42_HPRD_ID:
03406

# Drug_Target_42_ID:
609

# Drug_Target_42_Locus:
4q34-q35

# Drug_Target_42_Molecular_Weight:
28978

# Drug_Target_42_Name:
15-hydroxyprostaglandin dehydrogenase [NAD+]

# Drug_Target_42_Number_of_Residues:
266

# Drug_Target_42_PDB_ID:
Not Available

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_42_Protein_Sequence:
>15-hydroxyprostaglandin dehydrogenase [NAD+]
MHVNGKVALVTGAAQGIGRAFAEALLLKGAKVALVDWNLEAGVQCKAALDEQFEPQKTLF
IQCDVADQQQLRDTFRKVVDHFGRLDILVNNAGVNNEKNWEKTLQINLVSVISGTYLGLD
YMSKQNGGEGGIIINMSSLAGLMPVAQQPVYCASKHGIVGFTRSAALAANLMNSGVRLNA
ICPGFVNTAILESIEKEENMGQYIEYKDHIKDMIKYYGILDPPLIANGLITLIEDDALNG
AIMKITTSKGIHFQDYDTTPFQAKTQ

# Drug_Target_42_Reaction:
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-13-enoate + NADH + H+

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
Inactivation of prostaglandins

# Drug_Target_42_SwissProt_ID:
P15428

# Drug_Target_42_SwissProt_Name:
PGDH_HUMAN

# Drug_Target_42_Synonyms:
EC 1.1.1.141
PGDH
Prostaglandin dehydrogenase 1

# Drug_Target_42_Theoretical_pI:
5.65

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Not Available

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
TSTA3

# Drug_Target_43_GenBank_ID_Gene:
U58766

# Drug_Target_43_GenBank_ID_Protein:
1381179

# Drug_Target_43_GeneCard_ID:
TSTA3

# Drug_Target_43_Gene_Name:
TSTA3

# Drug_Target_43_Gene_Sequence:
>966 bp
ATGGGTGAACCCCAGGGATCCATGCGGATTCTAGTGACAGGGGGCTCTGGGCTGGTAGGC
AAAGCCATCCAGAAGGTGGTAGCAGATGGAGCTGGACTTCCTGGAGAGGACTGGGTGTTT
GTCTCCTCTAAAGACGCCGATCTCACGGATACAGCACAGACCCGCGCCCTGTTTGAGAAG
GTCCAACCCACACACGTCATCCATCTTGCTGCAATGGTGGGGGGCCTGTTCCGGAATATC
AAATACAATTTGGACTTCTGGAGGAAAAACGTGCACATGAACGACAACGTCCTGCACTCG
GCCTTTGAGGTGGGGGCCCGCAAGGTGGTGTCCTGCCTGTCCACCTGTATCTTCCCTGAC
AAGACGACCTACCCGATAGATGAGACCATGATCCACAATGGGCCTCCCCACAACAGCAAT
TTTGGGTACTCGTATGCCAAGAGGATGATCGACGTGCAGAACAGGGCCTACTTCCAGCAG
TACGGCTGCACCTTCACCGCTGTCATCCCCACCAACGTTTTCGGGCCCCACGACAACTTC
AACATCGAGGATGGCCACGTGCTGCCTGGCCTCATCCACAAGGTGCACCTGGCCAAGAGC
AGCGGCTCGGCCCTGACGGTGTGGGGTACAGGGAATCCGCGGAGGCAGTTCATATACTCG
CTGGACCTGGCCCAGCTCTTTATCTGGGTCCTGCGGGAGTACAATGAAGTGGAGCCCATC
ATCCTCTCCGTGGGCGAGGAAGATGAGGTCTCCATCAAGGAGGCAGCCGAGGCGGTGGTG
GAGGCCATGGACTTCCATGGGGAAGTCACCTTTGATACAACCAAGTCGGATGGGCAGTTT
AAGAAGACAGCCAGTAACAGCAAGCTGAGGACCTACCTGCCCGACTTCCGGTTCACACCC
TTCAAGCAGGCGGTGAAGGAGACCTGTGCTTGGTTCACTGACAACTACGAGCAGGCCCGG
AAGTGA

# Drug_Target_43_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_43_General_References:
7803801	Camardella L, Carratore V, Ciardiello MA, Damonte G, Benatti U, De Flora A: Primary structure of human erythrocyte nicotinamide adenine dinucleotide phosphate (NADP[H])-binding protein FX: identification with the mouse tum- transplantation antigen P35B. Blood. 1995 Jan 1;85(1):264-7.
8910301	Tonetti M, Sturla L, Bisso A, Benatti U, De Flora A: Synthesis of GDP-L-fucose by the human FX protein. J Biol Chem. 1996 Nov 1;271(44):27274-9.

# Drug_Target_43_HGNC_ID:
HGNC:12390

# Drug_Target_43_HPRD_ID:
00654

# Drug_Target_43_ID:
729

# Drug_Target_43_Locus:
8q24.3

# Drug_Target_43_Molecular_Weight:
35893

# Drug_Target_43_Name:
GDP-L-fucose synthetase

# Drug_Target_43_Number_of_Residues:
321

# Drug_Target_43_PDB_ID:
Not Available

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_43_Protein_Sequence:
>GDP-L-fucose synthetase
MGEPQGSMRILVTGGSGLVGKAIQKVVADGAGLPGEDWVFVSSKDADLTDTAQTRALFEK
VQPTHVIHLAAMVGGLFRNIKYNLDFWRKNVHMNDNVLHSAFEVGARKVVSCLSTCIFPD
KTTYPIDETMIHNGPPHNSNFGYSYAKRMIDVQNRAYFQQYGCTFTAVIPTNVFGPHDNF
NIEDGHVLPGLIHKVHLAKSSGSALTVWGTGNPRRQFIYSLDLAQLFIWVLREYNEVEPI
ILSVGEEDEVSIKEAAEAVVEAMDFHGEVTFDTTKSDGQFKKTASNSKLRTYLPDFRFTP
FKQAVKETCAWFTDNYEQARK

# Drug_Target_43_Reaction:
GDP-L-fucose + NADP+ = GDP-4-dehydro-6-deoxy-D-mannose + NADPH + H+

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Two step NADP-dependent conversion of GDP-4-dehydro-6- deoxy-D-mannose to GDP-fucose, involving an epimerase and a reductase reaction

# Drug_Target_43_SwissProt_ID:
Q13630

# Drug_Target_43_SwissProt_Name:
FCL_HUMAN

# Drug_Target_43_Synonyms:
EC 1.1.1.271
GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4- reductase
Protein FX
Red cell NADP(H)- binding protein

# Drug_Target_43_Theoretical_pI:
6.59

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Cytoplasm

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
11060293	Burczynski ME, Sridhar GR, Palackal NT, Penning TM: The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J Biol Chem. 2001 Jan 26;276(4):2890-7. Epub 2000 Nov 1.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2615366	Pineda JA, Murdock GL, Watson RJ, Warren JC: Stereospecificity of hydrogen transfer by bovine testicular 20 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem. 1989 Dec;33(6):1223-8.
3463506	Fukuda T, Hirato K, Yanaihara T, Nakayama T: Microsomal 20 alpha-hydroxysteroid dehydrogenase activity for progesterone in human placenta. Endocrinol Jpn. 1986 Jun;33(3):361-8.

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
AKR1C1

# Drug_Target_44_GenBank_ID_Gene:
M86609

# Drug_Target_44_GenBank_ID_Protein:
181549

# Drug_Target_44_GeneCard_ID:
AKR1C1

# Drug_Target_44_Gene_Name:
AKR1C1

# Drug_Target_44_Gene_Sequence:
>972 bp
ATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTG
GCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTG
TCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC
ACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA
GGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC
AGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT
GATGAATATTAA

# Drug_Target_44_General_Function:
Involved in oxidoreductase activity

# Drug_Target_44_General_References:
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
11013348	Zhang Y, Dufort I, Rheault P, Luu-The V: Characterization of a human 20alpha-hydroxysteroid dehydrogenase. J Mol Endocrinol. 2000 Oct;25(2):221-8.
12899831	Couture JF, Legrand P, Cantin L, Luu-The V, Labrie F, Breton R: Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol. 2003 Aug 15;331(3):593-604.
7626489	Khanna M, Qin KN, Cheng KC: Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and molecular cloning of multiple cDNAs encoding structurally related proteins in humans. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):41-6.
8132567	Lou H, Hammond L, Sharma V, Sparkes RS, Lusis AJ, Stolz A: Genomic organization and chromosomal localization of a novel human hepatic dihydrodiol dehydrogenase with high affinity bile acid binding. J Biol Chem. 1994 Mar 18;269(11):8416-22.
8172617	Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K, Hara A: Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J. 1994 Apr 15;299 ( Pt 2):545-52.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
8486699	Stolz A, Hammond L, Lou H, Takikawa H, Ronk M, Shively JE: cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. J Biol Chem. 1993 May 15;268(14):10448-57.

# Drug_Target_44_HGNC_ID:
HGNC:384

# Drug_Target_44_HPRD_ID:
07194

# Drug_Target_44_ID:
139

# Drug_Target_44_Locus:
10p15-p14

# Drug_Target_44_Molecular_Weight:
36789

# Drug_Target_44_Name:
Aldo-keto reductase family 1 member C1

# Drug_Target_44_Number_of_Residues:
323

# Drug_Target_44_PDB_ID:
1MRQ

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_44_Protein_Sequence:
>Aldo-keto reductase family 1 member C1
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY

# Drug_Target_44_Reaction:
17alpha,20alpha-dihydroxypregn-4-en-3-one + NAD(P)+ = 17alpha-hydroxyprogesterone + NAD(P)H + H+

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Converts progesterone to its inactive form, 20alpha- dihydroxyprogesterone (20alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. May play a role in myelin formation

# Drug_Target_44_SwissProt_ID:
Q04828

# Drug_Target_44_SwissProt_Name:
AK1C1_HUMAN

# Drug_Target_44_Synonyms:
20-alpha- hydroxysteroid dehydrogenase
20-alpha-HSD
Chlordecone reductase homolog HAKRC
DD1/DD2
Dihydrodiol dehydrogenase 1/2
EC 1.1.1.-
EC 1.1.1.149
EC 1.3.1.20
HBAB
High- affinity hepatic bile acid-binding protein
Trans- 1,2-dihydrobenzene-1,2-diol dehydrogenase

# Drug_Target_44_Theoretical_pI:
7.99

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass type II membrane protein

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8585102	Hermans JJ, Steckel B, Thijssen HH, Janssen BJ, Netter KJ, Maser E: Comparison of 11 beta-hydroxysteroid dehydrogenase in spontaneously hypertensive and Wistar-Kyoto rats. Steroids. 1995 Nov;60(11):773-9.
9141556	Diederich S, Hanke B, Oelkers W, Bahr V: Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction. J Clin Endocrinol Metab. 1997 May;82(5):1598-602.

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
HSD11B1

# Drug_Target_45_GenBank_ID_Gene:
M76665

# Drug_Target_45_GenBank_ID_Protein:
179475

# Drug_Target_45_GeneCard_ID:
HSD11B1

# Drug_Target_45_Gene_Name:
HSD11B1

# Drug_Target_45_Gene_Sequence:
>879 bp
ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTACTACTAC
TATTCTGCAAACGAGGAATTCAGACCAGAGATGCTCCAAGGAAAGAAAGTGATTGTCACA
GGGGCCAGCAAAGGGATCGGAAGAGAGATGGCTTATCATCTGGCGAAGATGGGAGCCCAT
GTGGTGGTGACAGCGAGGTCAAAAGAAACTCTACAGAAGGTGGTATCCCACTGCCTGGAG
CTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATGGAAGACATGACCTTCGCAGAG
CAATTTGTTGCCCAAGCAGGAAAGCTCATGGGAGGACTAGACATGCTCATTCTCAACCAC
ATCACCAACACTTCTTTGAATCTTTTTCATGATGATATTCACCATGTGCGCAAAAGCATG
GAAGTCAACTTCCTCAGTTACGTGGTCCTGACTGTAGCTGCCTTGCCCATGCTGAAGCAG
AGCAATGGAAGCATTGTTGTCGTCTCCTCTCTGGCTGGGAAAGTGGCTTATCCAATGGTT
GCTGCCTATTCTGCAAGCAAGTTTGCTTTGGATGGGTTCTTCTCCTCCATCAGAAAGGAA
TATTCAGTGTCCAGGGTCAATGTATCAATCACTCTCTGTGTTCTTGGCCTCATAGACACA
GAAACAGCCATGAAGGCAGTTTCTGGGATAGTCCATATGCAAGCAGCTCCAAAGGAGGAA
TGTGCCCTGGAGATCATCAAAGGGGGAGCTCTGCGCCAAGAAGAAGTGTATTATGACAGC
TCACTCTGGACCACTCTTCTGATCAGAAATCCATGCAGGAAGATCCTGGAATTTCTCTAC
TCAACGAGCTATAATATGGACAGATTCATAAACAAGTAG

# Drug_Target_45_General_Function:
Lipid transport and metabolism

# Drug_Target_45_General_References:
1885595	Tannin GM, Agarwal AK, Monder C, New MI, White PC: The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem. 1991 Sep 5;266(25):16653-8.

# Drug_Target_45_HGNC_ID:
HGNC:5208

# Drug_Target_45_HPRD_ID:
07042

# Drug_Target_45_ID:
364

# Drug_Target_45_Locus:
1q32-q41

# Drug_Target_45_Molecular_Weight:
32270

# Drug_Target_45_Name:
Corticosteroid 11-beta-dehydrogenase isozyme 1

# Drug_Target_45_Number_of_Residues:
291

# Drug_Target_45_PDB_ID:
1XU9

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_45_Protein_Sequence:
>Corticosteroid 11-beta-dehydrogenase isozyme 1
AFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHV
VVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHI
TNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVA
AYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEEC
ALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK

# Drug_Target_45_Reaction:
an 11beta-hydroxysteroid + NADP+ = an 11-oxosteroid + NADPH + H+

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7- ketocholesterol to 7-beta-hydroxycholesterol

# Drug_Target_45_SwissProt_ID:
P28845

# Drug_Target_45_SwissProt_Name:
DHI1_HUMAN

# Drug_Target_45_Synonyms:
11-DH
11-beta-HSD1
11-beta-hydroxysteroid dehydrogenase 1
EC 1.1.1.146

# Drug_Target_45_Theoretical_pI:
8.77

# Drug_Target_45_Transmembrane_Regions:
7-23

# Drug_Target_46_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass membrane protein. Mitochondrion

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
1911436	Thomas JL, Myers RP, Strickler RC: Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog. J Steroid Biochem Mol Biol. 1991 Oct;39(4A):471-7.
239964	Fan DF, Troen P: Studies of the human testis. VII. Conversion of pregnenolone to progesterone. J Clin Endocrinol Metab. 1975 Sep;41(3):563-74.
3476810	Widenius TV, Orava MM, Vihko RK, Ylikahri RH, Eriksson CJ: Inhibition of testosterone biosynthesis by ethanol: multiple sites and mechanisms in dispersed Leydig cells. J Steroid Biochem. 1987 Aug;28(2):185-8.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
HSD3B2

# Drug_Target_46_GenBank_ID_Gene:
M67466

# Drug_Target_46_GenBank_ID_Protein:
184401

# Drug_Target_46_GeneCard_ID:
HSD3B2

# Drug_Target_46_Gene_Name:
HSD3B2

# Drug_Target_46_Gene_Sequence:
>1119 bp
ATGGGCTGGAGCTGCCTTGTGACAGGAGCAGGAGGGCTTCTGGGTCAGAGGATCGTCCGC
CTGTTGGTGGAAGAGAAGGAACTGAAGGAGATCAGGGCCTTGGACAAGGCCTTCAGACCA
GAATTGAGAGAGGAATTTTCTAAGCTCCAGAACAGGACCAAGCTGACTGTACTTGAAGGA
GACATTCTGGATGAGCCATTCCTGAAAAGAGCCTGCCAGGACGTCTCGGTCGTCATCCAC
ACCGCCTGTATCATTGATGTCTTTGGTGTCACTCACAGAGAGTCCATCATGAATGTCAAT
GTGAAAGGTACCCAGCTACTGTTGGAGGCCTGTGTCCAAGCCAGTGTGCCAGTCTTCATC
TACACCAGTAGCATAGAGGTAGCCGGGCCCAACTCCTACAAGGAAATCATCCAGAACGGC
CACGAAGAAGAGCCTCTGGAAAACACATGGCCCACTCCATACCCGTACAGCAAAAAGCTT
GCTGAGAAGGCTGTGCTGGCGGCTAATGGGTGGAATCTAAAAAATGGTGATACCTTGTAC
ACTTGTGCGTTAAGACCCACATATATCTATGGGGAAGGAGGCCCATTCCTTTCTGCCAGT
ATAAATGAGGCCCTGAACAACAATGGGATCCTGTCAAGTGTTGGAAAGTTCTCTACAGTC
AACCCAGTCTATGTTGGCAACGTGGCCTGGGCCCACATTCTGGCCTTGAGGGCTCTGCGG
GACCCCAAGAAGGCCCCAAGTGTCCGAGGTCAATTCTATTACATCTCAGATGACACGCCT
CACCAAAGCTATGATAACCTTAATTACATCCTGAGCAAAGAGTTTGGCCTCCGCCTTGAT
TCCAGATGGAGCCTTCCTTTAACCCTGATGTACTGGATTGGCTTCCTGCTGGAAGTAGTG
AGCTTCCTACTCAGCCCAATTTACTCCTATCAACCCCCCTTCAACCGCCACACAGTCACA
TTATCAAATAGTGTGTTCACCTTCTCTTACAAGAAGGCTCAGCGAGATCTGGCGTATAAG
CCACTCTACAGCTGGGAGGAAGCCAAGCAGAAAACCGTGGAGTGGGTTGGTTCCCTTGTG
GACCGGCACAAGGAGACCCTGAAGTCCAAGACTCAGTGA

# Drug_Target_46_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_46_General_References:
10599696	Moisan AM, Ricketts ML, Tardy V, Desrochers M, Mebarki F, Chaussain JL, Cabrol S, Raux-Demay MC, Forest MG, Sippell WG, Peter M, Morel Y, Simard J: New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab. 1999 Dec;84(12):4410-25.
10651755	Marui S, Castro M, Latronico AC, Elias LL, Arnhold IJ, Moreira AC, Mendonca BB: Mutations in the type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clin Endocrinol (Oxf). 2000 Jan;52(1):67-75.
10843183	Alos N, Moisan AM, Ward L, Desrochers M, Legault L, Leboeuf G, Van Vliet G, Simard J: A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty. J Clin Endocrinol Metab. 2000 May;85(5):1968-74.
12050213	Pang S, Wang W, Rich B, David R, Chang YT, Carbunaru G, Myers SE, Howie AF, Smillie KJ, Mason JI: A novel nonstop mutation in the stop codon and a novel missense mutation in the type II 3beta-hydroxysteroid dehydrogenase (3beta-HSD) gene causing, respectively, nonclassic and classic 3beta-HSD deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2002 Jun;87(6):2556-63.
1741954	Lachance Y, Luu-The V, Verreault H, Dumont M, Rheaume E, Leblanc G, Labrie F: Structure of the human type II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) gene: adrenal and gonadal specificity. DNA Cell Biol. 1991 Dec;10(10):701-11.
1944309	Rheaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, Trudel C, Luu-The V, Simard J, Labrie F: Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol. 1991 Aug;5(8):1147-57.
7608265	Mebarki F, Sanchez R, Rheaume E, Laflamme N, Simard J, Forest MG, Bey-Omar F, David M, Labrie F, Morel Y: Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab. 1995 Jul;80(7):2127-34.
7633426	Katsumata N, Tanae A, Yasunaga T, Horikawa R, Tanaka T, Hibi I: A novel missense mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene in a family with classical salt-wasting congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency. Hum Mol Genet. 1995 Apr;4(4):745-6.
7633460	Tajima T, Fujieda K, Nakae J, Shinohara N, Yoshimoto M, Baba T, Kinoshita E, Igarashi Y, Oomura T: Molecular analysis of type II 3 beta-hydroxysteroid dehydrogenase gene in Japanese patients with classical 3 beta-hydroxysteroid dehydrogenase deficiency. Hum Mol Genet. 1995 May;4(5):969-71.
7833923	Sanchez R, Mebarki F, Rheaume E, Laflamme N, Forest MG, Bey-Omard F, David M, Morel Y, Labrie F, Simard J: Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. Hum Mol Genet. 1994 Sep;3(9):1639-45.
7893703	Rheaume E, Sanchez R, Mebarki F, Gagnon E, Carel JC, Chaussain JL, Morel Y, Labrie F, Simard J: Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. Biochemistry. 1995 Mar 7;34(9):2893-900.
7962268	Rheaume E, Sanchez R, Simard J, Chang YT, Wang J, Pang S, Labrie F: Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1994 Oct;79(4):1012-8.
8060486	Russell AJ, Wallace AM, Forest MG, Donaldson MD, Edwards CR, Sutcliffe RG: Mutation in the human gene for 3 beta-hydroxysteroid dehydrogenase type II leading to male pseudohermaphroditism without salt loss. J Mol Endocrinol. 1994 Apr;12(2):225-37.
8126127	Sanchez R, Rheaume E, Laflamme N, Rosenfield RL, Labrie F, Simard J: Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency. J Clin Endocrinol Metab. 1994 Mar;78(3):561-7.
8185809	Mendonca BB, Russell AJ, Vasconcelos-Leite M, Arnhold IJ, Bloise W, Wajchenberg BL, Nicolau W, Sutcliffe RG, Wallace AM: Mutation in 3 beta-hydroxysteroid dehydrogenase type II associated with pseudohermaphroditism in males and premature pubarche or cryptic expression in females. J Mol Endocrinol. 1994 Feb;12(1):119-22.
8316254	Simard J, Rheaume E, Sanchez R, Laflamme N, de Launoit Y, Luu-The V, van Seters AP, Gordon RD, Bettendorf M, Heinrich U, et al.: Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency. Mol Endocrinol. 1993 May;7(5):716-28.
9719627	Nayak S, Lee PA, Witchel SF: Variants of the type II 3beta-hydroxysteroid dehydrogenase gene in children with premature pubic hair and hyperandrogenic adolescents. Mol Genet Metab. 1998 Jul;64(3):184-92.

# Drug_Target_46_HGNC_ID:
HGNC:5218

# Drug_Target_46_HPRD_ID:
01941

# Drug_Target_46_ID:
66

# Drug_Target_46_Locus:
1p13.1

# Drug_Target_46_Molecular_Weight:
41921

# Drug_Target_46_Name:
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II

# Drug_Target_46_Number_of_Residues:
371

# Drug_Target_46_PDB_ID:
Not Available

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF01073	3Beta_HSD

# Drug_Target_46_Protein_Sequence:
>3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type II
GWSCLVTGAGGLLGQRIVRLLVEEKELKEIRALDKAFRPELREEFSKLQNRTKLTVLEGD
ILDEPFLKRACQDVSVVIHTACIIDVFGVTHRESIMNVNVKGTQLLLEACVQASVPVFIY
TSSIEVAGPNSYKEIIQNGHEEEPLENTWPTPYPYSKKLAEKAVLAANGWNLKNGDTLYT
CALRPTYIYGEGGPFLSASINEALNNNGILSSVGKFSTVNPVYVGNVAWAHILALRALRD
PKKAPSVRGQFYYISDDTPHQSYDNLNYILSKEFGLRLDSRWSLPLTLMYWIGFLLEVVS
FLLSPIYSYQPPFNRHTVTLSNSVFTFSYKKAQRDLAYKPLYSWEEAKQKTVEWVGSLVD
RHKETLKSKTQ

# Drug_Target_46_Reaction:
a 3beta-hydroxy-Delta5-steroid + NAD+ = a 3-oxo-Delta5-steroid + NADH + H+

# Drug_Target_46_Signals:
None

# Drug_Target_46_Specific_Function:
3beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids

# Drug_Target_46_SwissProt_ID:
P26439

# Drug_Target_46_SwissProt_Name:
3BHS2_HUMAN

# Drug_Target_46_Synonyms:
3-beta-hydroxy-5-ene steroid dehydrogenase
3-beta-hydroxy-Delta(5)-steroid dehydrogenase
EC 1.1.1.145
EC 5.3.3.1
Progesterone reductase
Steroid Delta-isomerase

# Drug_Target_46_Theoretical_pI:
8.17

# Drug_Target_46_Transmembrane_Regions:
286-306

# Drug_Target_47_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass membrane protein. Mitochondrion

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2362440	Thomas JL, Myers RP, Rosik LO, Strickler RC: Affinity alkylation of human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase by 2 alpha-bromoacetoxyprogesterone: evidence for separate dehydrogenase and isomerase sites on one protein. J Steroid Biochem. 1990 Jun;36(1-2):117-23.
2961942	Ishii-Ohba H, Inano H, Tamaoki B: Testicular and adrenal 3 beta-hydroxy-5-ene-steroid dehydrogenase and 5-ene-4-ene isomerase. J Steroid Biochem. 1987;27(4-6):775-9.
3476810	Widenius TV, Orava MM, Vihko RK, Ylikahri RH, Eriksson CJ: Inhibition of testosterone biosynthesis by ethanol: multiple sites and mechanisms in dispersed Leydig cells. J Steroid Biochem. 1987 Aug;28(2):185-8.

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
HSD3B1

# Drug_Target_47_GenBank_ID_Gene:
M27137

# Drug_Target_47_GenBank_ID_Protein:
306889

# Drug_Target_47_GeneCard_ID:
HSD3B1

# Drug_Target_47_Gene_Name:
HSD3B1

# Drug_Target_47_Gene_Sequence:
>1122 bp
ATGACGGGCTGGAGCTGCCTTGTGACAGGAGCAGGAGGGTTTCTGGGACAGAGGATCATC
CGCCTCTTGGTGAAGGAGAAGGAGCTGAAGGAGATCAGGGTCTTGGACAAGGCCTTCGGA
CCAGAATTGAGAGAGGAATTTTCTAAACTCCAGAACAAGACCAAGCTGACAGTGCTGGAA
GGAGACATTCTGGATGAGCCATTCCTGAAGAGAGCCTGCCAGGACGTCTCGGTCATCATC
CACACCGCCTGTATCATTGATGTCTTCGGTGTCACTCACAGAGAGTCTATCATGAATGTC
AATGTGAAAGGTACCCAGCTCCTGTTAGAGGCCTGTGTCCAAGCTAGTGTGCCAGTCTTC
ATCTACACCAGTAGCATAGAGGTAGCCGGGCCCAACTCCTACAAGGAAATCATCCAGAAT
GGCCATGAAGAAGAGCCTCTGGAAAACACATGGCCCGCTCCATACCCACACAGCAAAAAG
CTTGCTGAGAAGGCTGTACTGGCGGCTAACGGGTGGAATCTGAAAAACGGCGGCACCCTG
TACACTTGTGCCTTACGACCCATGTATATCTATGGGGAAGGAAGCCGATTCCTTTCTGCT
AGTATAAACGAGGCCCTGAACAACAATGGGATCCTGTCAAGTGTTGGAAAGTTCTCCACT
GTTAACCCAGTCTATGTTGGCAATGTGGCCTGGGCCCACATTCTGGCCTTGAGGGCCCTG
CAGGACCCCAAGAAGGCCCCAAGCATCCGAGGACAGTTCTACTATATCTCAGATGACACG
CCTCACCAAAGCTATGATAACCTTAATTACACCCTGAGCAAAGAGTTCGGCCTCCGCCTT
GATTCCAGATGGAGCTTTCCTTTATCCCTGATGTATTGGATTGGCTTCCTGCTGGAAATA
GTGAGCTTCCTACTCAGGCCAATTTACACCTATCGACCGCCCTTCAACCGCCACATAGTC
ACATTGTCAAATAGCGTATTCACCTTCTCTTATAAGAAGGCTCAGCGAGATCTGGCGTAT
AAGCCACTCTACAGCTGGGAGGAAGCCAAGCAGAAAACGGTGGAGTGGGTTGGTTCCCTT
GTGGACCGGCACAAGGAGACCCTGAAGTCCAAGACTCAGTGA

# Drug_Target_47_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_47_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
1401999	Dumont M, Luu-The V, Dupont E, Pelletier G, Labrie F: Characterization, expression, and immunohistochemical localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in human skin. J Invest Dermatol. 1992 Oct;99(4):415-21.
1920284	Nickson DA, McBride MW, Zeinali S, Hawes CS, Petropoulos A, Mueller UW, Sutcliffe RG: Molecular cloning and expression of human trophoblast antigen FDO161G and its identification as 3 beta-hydroxy-5-ene steroid dehydrogenase. J Reprod Fertil. 1991 Sep;93(1):149-56.
2082186	Lorence MC, Corbin CJ, Kamimura N, Mahendroo MS, Mason JI: Structural analysis of the gene encoding human 3 beta-hydroxysteroid dehydrogenase/delta 5----4-isomerase. Mol Endocrinol. 1990 Dec;4(12):1850-5.
2139411	Lorence MC, Murry BA, Trant JM, Mason JI: Human 3 beta-hydroxysteroid dehydrogenase/delta 5----4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology. 1990 May;126(5):2493-8.
2243100	Lachance Y, Luu-The V, Labrie C, Simard J, Dumont M, de Launoit Y, Guerin S, Leblanc G, Labrie F: Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. J Biol Chem. 1990 Nov 25;265(33):20469-75.
2779585	Luu The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC, Labrie F: Full length cDNA structure and deduced amino acid sequence of human 3 beta-hydroxy-5-ene steroid dehydrogenase. Mol Endocrinol. 1989 Aug;3(8):1310-2.

# Drug_Target_47_HGNC_ID:
HGNC:5217

# Drug_Target_47_HPRD_ID:
04920

# Drug_Target_47_ID:
57

# Drug_Target_47_Locus:
1p13.1

# Drug_Target_47_Molecular_Weight:
42121

# Drug_Target_47_Name:
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I

# Drug_Target_47_Number_of_Residues:
372

# Drug_Target_47_PDB_ID:
Not Available

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF01073	3Beta_HSD

# Drug_Target_47_Protein_Sequence:
>3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type I
TGWSCLVTGAGGFLGQRIIRLLVKEKELKEIRVLDKAFGPELREEFSKLQNKTKLTVLEG
DILDEPFLKRACQDVSVIIHTACIIDVFGVTHRESIMNVNVKGTQLLLEACVQASVPVFI
YTSSIEVAGPNSYKEIIQNGHEEEPLENTWPAPYPHSKKLAEKAVLAANGWNLKNGGTLY
TCALRPMYIYGEGSRFLSASINEALNNNGILSSVGKFSTVNPVYVGNVAWAHILALRALQ
DPKKAPSIRGQFYYISDDTPHQSYDNLNYTLSKEFGLRLDSRWSFPLSLMYWIGFLLEIV
SFLLRPIYTYRPPFNRHIVTLSNSVFTFSYKKAQRDLAYKPLYSWEEAKQKTVEWVGSLV
DRHKETLKSKTQ

# Drug_Target_47_Reaction:
a 3beta-hydroxy-Delta5-steroid + NAD+ = a 3-oxo-Delta5-steroid + NADH + H+

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
3beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids

# Drug_Target_47_SwissProt_ID:
P14060

# Drug_Target_47_SwissProt_Name:
3BHS1_HUMAN

# Drug_Target_47_Synonyms:
3- beta-HSD I
3-beta-hydroxy-5-ene steroid dehydrogenase
3-beta-hydroxy-Delta(5)-steroid dehydrogenase
Delta-5-3-ketosteroid isomerase
EC 1.1.1.145
EC 5.3.3.1
Progesterone reductase
Steroid Delta- isomerase
Trophoblast antigen FDO161G

# Drug_Target_47_Theoretical_pI:
8.98

# Drug_Target_47_Transmembrane_Regions:
287-307

# Drug_Target_48_Cellular_Location:
Not Available

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
16384941	Bowne SJ, Sullivan LS, Mortimer SE, Hedstrom L, Zhu J, Spellicy CJ, Gire AI, Hughbanks-Wheaton D, Birch DG, Lewis RA, Heckenlively JR, Daiger SP: Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):34-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
IMPDH1

# Drug_Target_48_GenBank_ID_Gene:
J05272

# Drug_Target_48_GenBank_ID_Protein:
307067

# Drug_Target_48_GeneCard_ID:
IMPDH1

# Drug_Target_48_Gene_Name:
IMPDH1

# Drug_Target_48_Gene_Sequence:
>1545 bp
ATGGCGGACTACCTGATCAGCGGCGGCACCGGCTACGTGCCCGAGGATGGGCTCACCGCG
CAGCAGCTCTTCGCCAGCGCCGACGACCTCACCTACAACGACTTCCTGATTCTCCCAGGA
TTCATAGACTTCATAGCTGATGAGGTGGACCTGACCTCAGCCCTGACCCGGAAGATCACG
CTGAAGACGCCACTCATCTCCTCCCCCATGGACACTGTGACAGAGGCTGACATGGCCATT
GCCATGGCTCTGATGGGAGGTATTGGGTTCATTCACCACAACTGCACCCCAGAGTTCCAG
GCCAATGAAGTACGCAAGGTCAAGAACTTTGAACAGGGCTTCATCACGGACCCTGTGGTG
CTGAGCCCCTCGCACACTGTGGGCGATGTGCTGGAGGCCAAGATGCGGCATGGCTTCTCT
GGCATCCCCATCACTGAGACGGGCACCATGGGCAGCAAGCTGGTGGGCATCGTCACCTCC
CGAGACATCGACTTTCTTGCTGAGAAGGACCACACCACCCTCCTCAGTGAGGTGATGACG
CCAAGGATTGAACTGGTGGTGGCTCCAGCAGGTGTGACGTTGAAAGAGGCAAATGAGATC
CTGCAGCGTAGCAAGAAAGGGAAGCTGCCTATCGTCAATGATTGCGATGAGCTGGTGGCC
ATCATCGCCCGCACCGACCTGAAGAAGAATCGAGACTACCCTCTGGCCTCCAAGGATTCC
CAGAAGCAGCTGCTCTGTGGGGCAGCTGTGGGCACCCGTGAGGATGACAAATACCGTCTG
GACCTGCTGACCCAGGCGGGGGTCGACGTCATAGTCTTCCACTCGTCCCAAGGGAATTCG
GTGTATCAGATCGCCATGGTGCATTACATCAAACAGAAGTACCCCCACCTCCAGGTGATT
GGGGGGAACGTGGTGACAGCAGCCCAGGCCAAGAACCTGATTGATGCTGGTGTGGACGGG
CTGCGCGTGGGCATGGGCTGCGGCTCCATCTGCATCACCCAGGAAGTGATGGCCTGTGGT
CGGCCCCAGGGCACTGCTGTGTACAAGGTGGCTGAGTATGCCCGGCGCTTTGGTGTGCCC
ATCATAGCCGATGGCGGCATCCAGACCGTGGGACACGTGGTCAAGGCCCTGGCCCTTGGA
GCCTCCACAGTGATGATGGGCTCCCTGCTGGCCGCCACTACGGAGGCCCCTGGCGAGTAC
TTCTTCTCAGACGGGGTGCGGCTCAAGAAGTACCGGGGCATGGGCTCACTGGATCCCATG
GAGAAGAGCAGCAGCAGCCAGAAACGATACTTCAGCGAGGGGGATAAAGTGAAGATCGCA
CAGGGTGTCTCGGGCTCCATCCAGGACAAAGGATCCATTCAGAAGTTCGTGCCCTACCTC
ATAGCAGGCATCCAACACGGCTGCCAGGATATCGGGGCCCGCAGCCTGTCTGTCCTTCGG
TCCATGATGTACTCAGGAGAGCTCAAGTTTGAGAAGCGGACCATGTCGCCCCAGATTGAG
GGTGGTGTCCATGGCCTGCACTCTTACGAAAAGCGGCTGTACTGA

# Drug_Target_48_General_Function:
Nucleotide transport and metabolism

# Drug_Target_48_General_References:
11875049	Kennan A, Aherne A, Palfi A, Humphries M, McKee A, Stitt A, Simpson DA, Demtroder K, Orntoft T, Ayuso C, Kenna PF, Farrar GJ, Humphries P: Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum Mol Genet. 2002 Mar 1;11(5):547-57.
11875050	Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Daiger SP: Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet. 2002 Mar 1;11(5):559-68.
1969416	Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990 Mar 25;265(9):5292-5.
7763314	Hager PW, Collart FR, Huberman E, Mitchell BS: Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol. 1995 May 11;49(9):1323-9.

# Drug_Target_48_HGNC_ID:
HGNC:6052

# Drug_Target_48_HPRD_ID:
08853

# Drug_Target_48_ID:
838

# Drug_Target_48_Locus:
7q31.3-q32

# Drug_Target_48_Molecular_Weight:
55407

# Drug_Target_48_Name:
Inosine-5'-monophosphate dehydrogenase 1

# Drug_Target_48_Number_of_Residues:
514

# Drug_Target_48_PDB_ID:
1JCN

# Drug_Target_48_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Thioguanine Pathway	SMP00430

# Drug_Target_48_Pfam_Domain_Function:
PF00478	IMPDH
PF00571	CBS

# Drug_Target_48_Protein_Sequence:
>Inosine-5'-monophosphate dehydrogenase 1
MADYLISGGTGYVPEDGLTAQQLFASADGLTYNDFLILPGFIDFIADEVDLTSALTRKIT
LKTPLISSPMDTVTEADMAIAMALMGGIGFIHHNCTPEFQANEVRKVKKFEQGFITDPVV
LSPSHTVGDVLEAKMRHGFSGIPITETGTMGSKLVGIVTSRDIDFLAEKDHTTLLSEVMT
PRIELVVAPAGVTLKEANEILQRSKKGKLPIVNDCDELVAIIARTDLKKNRDYPLASKDS
QKQLLCGAAVGTREDDKYRLDLLTQAGVDVIVLDSSQGNSVYQIAMVHYIKQKYPHLQVI
GGNVVTAAQAKNLIDAGVDGLRVGMGCGSICITQEVMACGRPQGTAVYKVAEYARRFGVP
IIADGGIQTVGHVVKALALGASTVMMGSLLAATTEAPGEYFFSDGVRLKKYRGMGSLDAM
EKSSSSQKRYFSEGDKVKIAQGVSGSIQDKGSIQKFVPYLIAGIQHGCQDIGARSLSVLR
SMMYSGELKFEKRTMSAQIEGGVHGLHSYEKRLY

# Drug_Target_48_Reaction:
inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
Rate limiting enzyme in the de novo synthesis of guanine nucleotides and therefore is involved in the regulation of cell growth. It may also have a role in the development of malignancy and the growth progression of some tumors

# Drug_Target_48_SwissProt_ID:
P20839

# Drug_Target_48_SwissProt_Name:
IMDH1_HUMAN

# Drug_Target_48_Synonyms:
EC 1.1.1.205
IMP dehydrogenase 1
IMPD 1
IMPDH-I

# Drug_Target_48_Theoretical_pI:
6.90

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Mitochondrion

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
HADHA

# Drug_Target_49_GenBank_ID_Gene:
D16480

# Drug_Target_49_GenBank_ID_Protein:
862457

# Drug_Target_49_GeneCard_ID:
HADHA

# Drug_Target_49_Gene_Name:
HADHA

# Drug_Target_49_Gene_Sequence:
>2292 bp
ATGGTGGCCTGCCGGGCGATTGGCATCCTCAGCCGCTTTTCTGCCTTCAGGATCCTCCGC
TCCCGAGGTTATATATGCCGCAATTTTACAGGGTCTTCTGCTTTGCTGACCAGAACCCAT
ATTAACTATGGAGTCAAAGGGGATGTGGCAGTTGTTCGAATTAACTCTCCCAATTCAAAG
GTAAATACACTGAGTAAAGAGCTACATTCAGAGTTCTCAGAAGTTATGAATGAAATCTGG
GCTAGTGATCAAATCAGAAGTGCCGTCCTTATCTCATCAAAGCCAGGCTGCTTTATTGCA
GGTGCTGATATCAACATGTTAGCCGCTTGCAAGACCCTTCAAGAAGTAACACAGCTATCA
CAAGAAGCACAGAGAATAGTTGAGAAACTTGAAAAGTCCACAAAGCCTATTGTGGCTGCC
ATCAATGGATCCTGCGTGGGAGGAGGACTTGAGGTTGCCATTTCATGCCAATACAGAATA
GCAACAAAAGACAGAAAAACAGTATTAGGTACCCCTGAAGTTTTGCTGGGGGCCTTACCA
GGAGCAGGAGGCACACAAAGGCTGCCCAAAATGGTGGGTGTGCCTGCTGCTTTGGACATG
ATGCTGACTGGTAGAAGCATTCGTGCAGACAGGGCAAAGAAAATGGGACTGGTTGACCAA
CTGGTGGAACCCCTGGGACCAGGACTAAAACCTCCAGAGGAACGGACAATAGAATACCTA
GAAGAAGTTGCAATTACTTTTGCCAAAGGACTAGCTGATAAGAAGATCTCTCCAAAGAGA
GACAAGGGATTGGTGGAAAAATTGACAGCGTATGCCATGACTATTCCATTTGTCAGGCAA
CAGGTTTACAAAAAAGTGGAAGAAAAAGTGCGAAAGCAGACTAAAGGCCTTTATCCTGCA
CCTCTGAAAATAATTGATGTGGTAAAGACTGGAATTGAGCAAGGGAGTGATGCCGGTTAT
CTCTGTGAATCTCAGAAATTTGGAGAGCTTGTAATGACCAAAGAATCAAAGGCCTTGATG
GGACTCTACCATGGTCAGGTCCTGTGCAAGAAGAATAAATTTGGAGCTCCACAGAAGGAT
GTTAAGCATCTGGCTATTCTTGGTGCAGGGCTGATGGGAGCAGGCATCGCCCAAGTCTCC
GTGGATAAGGGGCTAAAGACTATACTTAAAGATGCCACCCTCACTGCGCTAGACCGAGGA
CAGCAACAAGTGTTCAAAGGATTGAATGACAAAGTGAAGAAGAAAGCTCTAACATCATTT
GAAAGGGATTCCATCTTCAGCAACTTGACTGGGCAGCTTGATTACCAAGGTTTTGAAAAG
GCCGACATGGTGATTGAAGCTGTGTTTGAGGACCTTAGTCTTAAGCACAGAGTGCTAAAG
GAAGTAGAAGCGGTGATTCCAGATCACTGTATCTTTGCCAGTAACACATCTGCTCTCCCA
ATCAGTGAAATCGCTGCTGTCAGCAAAAGACCTGAGAAGGTGATTGGCATGCACTACTTC
TCTCCCGTGGACAAGATGCAGCTGCTGGAGATTATCACGACCGAGAAAACTTCCAAAGAC
ACCAGTGCTTCAGCTGTAGCAGTTGGTCTCAAGCAGGGGAAGGTCATCATTGTGGTTAAG
GATGGACCTGGCTTCTATACTACCAGGTGTCTTGCGCCCATGATGTCTGAAGTCATCCGA
ATCCTCCAGGAAGGAGTTGACCCGAAGAAGCTGGATTCCCTGACCACAAGCTTTGGCTTT
CCTGTGGGTGCCGCCACACTGGTGGATGAAGTTGGTGTGGATGTAGCGAAACATGTGGCG
GAAGATCTGGGCAAAGTCTTTGGGGAGCGGTTTGGAGGTGGAAACCCAGAACTGCTGACA
CAGATGGTGTCCAAGGGCTTCCTAGGTCGTAAATCTGGGAAGGGCTTTTACATCTATCAG
GAGGGTGTGAAGAGGAAGGATTTGAATTCTGACATGGATAGTATTTTAGCGAGTCTGAAG
CTGCCTCCTAAGTCTGAAGTCTCATCAGACGAAGACATCCAGTTCCGCCTGGTGACAAGA
TTTGTGAATGAGGCAGTCATGTGCCTGCAAGAGGGGATCTCGGCCACACCTGCAGAGGGA
GACATCGGAGCCGTCTTTGGGCTTGGCTTCCCGCCTTGTCTGGGAGGGCCTTTCCGCTTT
GTGGATCTGTATGGCGCCCAGAAGATAGTGGACCGGCTCAAGAAATATGAAGCTGCCTAT
GGAAAACAGTTCACCCCATGCCAGCTGCTAGCTGACCATGCTAACAGCCCTAACAAGAAG
TTCTACCAGTGA

# Drug_Target_49_General_Function:
Lipid transport and metabolism

# Drug_Target_49_General_References:
7846063	Sims HF, Brackett JC, Powell CK, Treem WR, Hale DE, Bennett MJ, Gibson B, Shapiro S, Strauss AW: The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):841-5.
7918661	Zhang QX, Baldwin GS: Structures of the human cDNA and gene encoding the 78 kDa gastrin-binding protein and of a related pseudogene. Biochim Biophys Acta. 1994 Oct 18;1219(2):567-75.
8135828	Kamijo T, Aoyama T, Komiyama A, Hashimoto T: Structural analysis of cDNAs for subunits of human mitochondrial fatty acid beta-oxidation trifunctional protein. Biochem Biophys Res Commun. 1994 Mar 15;199(2):818-25.

# Drug_Target_49_HGNC_ID:
HGNC:4801

# Drug_Target_49_HPRD_ID:
02934

# Drug_Target_49_ID:
288

# Drug_Target_49_Locus:
2p23

# Drug_Target_49_Molecular_Weight:
83001

# Drug_Target_49_Name:
Trifunctional enzyme subunit alpha, mitochondrial

# Drug_Target_49_Number_of_Residues:
763

# Drug_Target_49_PDB_ID:
Not Available

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF00378	ECH
PF00725	3HCDH
PF02737	3HCDH_N

# Drug_Target_49_Protein_Sequence:
>Trifunctional enzyme subunit alpha, mitochondrial precursor
MVACRAIGILSRFSAFRILRSRGYICRNFTGSSALLTRTHINYGVKGDVAVVRINSPNSK
VNTLSKELHSEFSEVMNEIWASDQIRSAVLISSKPGCFIAGADINMLAACKTLQEVTQLS
QEAQRIVEKLEKSTKPIVAAINGSCLGGGLEVAISCQYRIATKDRKTVLGTPEVLLGALP
GAGGTQRLPKMVGVPAALDMMLTGRSIRADRAKKMGLVDQLVEPLGPGLKPPEERTIEYL
EEVAITFAKGLADKKISPKRDKGLVEKLTAYAMTIPFVRQQVYKKVEEKVRKQTKGLYPA
PLKIIDVVKTGIEQGSDAGYLCESQKFGELVMTKESKALMGLYHGQVLCKKNKFGAPQKD
VKHLAILGAGLMGAGIAQVSVDKGLKTILKDATLTALDRGQQQVFKGLNDKVKKKALTSF
ERDSIFSNLTGQLDYQGFEKADMVIEAVFEDLSLKHRVLKEVEAVIPDHCIFASNTSALP
ISEIAAVSKRPEKVIGMHYFSPVDKMQLLEIITTEKTSKDTSASAVAVGLKQGKVIIVVK
DGPGFYTTRCLAPMMSEVIRILQEGVDPKKLDSLTTSFGFPVGAATLVDEVGVDVAKHVA
EDLGKVFGERFGGGNPELLTQMVSKGFLGRKSGKGFYIYQEGVKRKDLNSDMDSILASLK
LPPKSEVSSDEDIQFRLVTRFVNEAVMCLQEGILATPAEGDIGAVFGLGFPPCLGGPFRF
VDLYGAQKIVDRLKKYEAAYGKQFTPCQLLADHANSPNKKFYQ

# Drug_Target_49_Reaction:
(S)-3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Bifunctional subunit

# Drug_Target_49_SwissProt_ID:
P40939

# Drug_Target_49_SwissProt_Name:
ECHA_HUMAN

# Drug_Target_49_Synonyms:
78 kDa gastrin-binding protein
TP-alpha
Trifunctional enzyme subunit alpha, mitochondrial precursor

# Drug_Target_49_Theoretical_pI:
9.52

# Drug_Target_49_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
11306066	Plapp BV, Mitchell JL, Berst KB: Mouse alcohol dehydrogenase 4: kinetic mechanism, substrate specificity and simulation of effects of ethanol on retinoid metabolism. Chem Biol Interact. 2001 Jan 30;130-132(1-3):445-56.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
1938903	Thielen J, Ciriacy M: Biochemical basis of mitochondrial acetaldehyde dismutation in Saccharomyces cerevisiae. J Bacteriol. 1991 Nov;173(21):7012-7.
3593480	Widenius TV: Ethanol-induced inhibition of testosterone biosynthesis in vitro: lack of acetaldehyde effect. Alcohol Alcohol. 1987;22(1):17-22.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ADH4

# Drug_Target_4_GenBank_ID_Gene:
M15943

# Drug_Target_4_GenBank_ID_Protein:
178121

# Drug_Target_4_GeneCard_ID:
ADH4

# Drug_Target_4_Gene_Name:
ADH4

# Drug_Target_4_Gene_Sequence:
>1179 bp
ATGGGCACCAAGGGCAAAGTTATTAAATGCAAAGCAGCCATCGCCTGGGAAGCAGGCAAG
CCCCTTTGCATTGAAGAGGTTGAAGTAGCTCCCCCCAAGGCTCATGAAGTTCGCATTCAG
ATCATTGCTACCTCCCTGTGCCATACTGATGCCAGTGTTATCGATTCTAAATTTGAGGGC
CTAGCTTTCCCAGTGATCGTTGGCCATGAGGCTGCAGGTATTGTGGAAAGTATTGGGCCA
GGAGTGACCAACGTCAAACCAGGTGACAAAGTAATTCCACTTTATGCACCTCTATGTAGA
AAATGCAAGTTTTGTCTGAGTCCACTCACAAATTTGTGTGGGAAAATCAGTAATCTCAAA
AGTCCTGCTAGTGATCAACAACTAATGGAAGACAAAACCAGCAGGTTTACCTGCAAAGGA
AAACCAGTTTACCATTTCTTTGGAACCAGTACATTCTCTCAGTACACTGTGGTGTCAGAT
ATCAATCTTGCCAAAATAGATGATGATGCAAATTTAGAGAGAGTTTGTCTGCTTGGATGT
GGGTTTTCAACTGGCTATGGGGCTGCAATCAACAATGCCAAGGTCACCCCTGGTTCGACT
TGTGCTGTCTTTGGCCTAGGAGGTGTGGGTCTTTCTGCTGTAATGGGTTGTAAAGCAGCA
GGAGCTTCCAGAATCATAGGTATTGACATCAACAGTGAGAAGTTTGTGAAGGCTAAAGCC
CTGGGAGCCACTGACTGCCTCAATCCTAGAGACTTACATAAACCGATCCAGGAAGTTATC
ATTGAATTGACCAAGGGAGGTGTGGATTTTGCCCTTGACTGTGCAGGTGGATCTGAAACC
ATGAAAGCAGCCCTGGACTGTACAACCGCAGGCTGGGGATCATGTACTTTCATTGGAGTA
GCTGCTGGTAGCAAAGGATTGACTATTTTTCCAGAGGAGCTAATAATCGGCCGTACTATA
AATGGAACATTCTTTGGTGGTTGGAAAAGTGTAGATTCTATCCCAAAGCTGGTCACTGAC
TATAAGAATAAGAAATTCAATCTGGATGCATTGGTGACCCATACCCTGCCTTTTGACAAA
ATCAGTGAGGCATTTGACCTAATGAACCAAGGAAAAAGCGTCCGAACAATCCTCATCTTT
GGAAGATGCCAGGAGCAATTCAGAATACTATCTGATTGA

# Drug_Target_4_General_Function:
Energy production and conversion

# Drug_Target_4_General_References:
1889753	von Bahr-Lindstrom H, Jornvall H, Hoog JO: Cloning and characterization of the human ADH4 gene. Gene. 1991 Jul 22;103(2):269-74.
3036213	Hoog JO, von Bahr-Lindstrom H, Heden LO, Holmquist B, Larsson K, Hempel J, Vallee BL, Jornvall H: Structure of the class II enzyme of human liver alcohol dehydrogenase: combined cDNA and protein sequence determination of the pi subunit. Biochemistry. 1987 Apr 7;26(7):1926-32.

# Drug_Target_4_HGNC_ID:
HGNC:252

# Drug_Target_4_HPRD_ID:
00068

# Drug_Target_4_ID:
396

# Drug_Target_4_Locus:
4q21-q24|4q22

# Drug_Target_4_Molecular_Weight:
40091

# Drug_Target_4_Name:
Alcohol dehydrogenase 4

# Drug_Target_4_Number_of_Residues:
379

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_4_Protein_Sequence:
>Alcohol dehydrogenase 4
GTKGKVIKCKAAIAWEAGKPLCIEEVEVAPPKAHEVRIQIIATSLCHTDATVIDSKFEGL
AFPVIVGHEAAGIVESIGPGVTNVKPGDKVIPLYAPLCRKCKFCLSPLTNLCGKISNLKS
PASDQQLMEDKTSRFTCKGKPVYHFFGTSTFSQYTVVSDINLAKIDDDANLERVCLLGCG
FSTGYGAAINNAKVTPGSTCAVFGLGGVGLSAVMGCKAAGASRIIGIDINSEKFVKAKAL
GATDCLNPRDLHKPIQEVIIELTKGGVDFALDCAGGSETMKAALDCTTAGWGSCTFIGVA
AGSKGLTVFPEELIIGRTINGTFFGGWKSVDSIPKLVTDYKNKKFNLDALVTHTLPFDKI
SEAFDLMNQGKSIRTILIF

# Drug_Target_4_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
P08319

# Drug_Target_4_SwissProt_Name:
ADH4_HUMAN

# Drug_Target_4_Synonyms:
Alcohol dehydrogenase class II pi chain
EC 1.1.1.1

# Drug_Target_4_Theoretical_pI:
8.01

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
16961761	Quintanilla ME, Israel Y, Sapag A, Tampier L: The UChA and UChB rat lines: metabolic and genetic differences influencing ethanol intake. Addict Biol. 2006 Sep;11(3-4):310-23.
17488809	Quintanilla ME, Tampier L, Sapag A, Gerdtzen Z, Israel Y: Sex differences, alcohol dehydrogenase, acetaldehyde burst, and aversion to ethanol in the rat: a systems perspective. Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E531-7. Epub 2007 May 8.

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
ALDH2

# Drug_Target_50_GenBank_ID_Gene:
X05409

# Drug_Target_50_GenBank_ID_Protein:
28606

# Drug_Target_50_GeneCard_ID:
ALDH2

# Drug_Target_50_Gene_Name:
ALDH2

# Drug_Target_50_Gene_Sequence:
>1551 bp
ATGTTGCGCGCTGCCGCCGCTCGGGCCCCGCCTGGCCGCCGCCTCTTGTCAGCCGCCGCC
ACCCAGGCCGTGCCTGCCCCCAACCAGCAGCCCGAGGTCTTCTGCAACCAGATTTTCATA
AACAATGAATGGCACGATGCCGTCAGCAGGAAAACATTCCCCACCGTCAATCCGTCCACT
GGAGAGGTCATCTGTCAGGTAGCTGAAGGGGACAAGGAAGATGTGGACAAGGCACGTGAA
GGCCGCCCGGGCGCCTTCCAGCTGGGCTCACCTTGGCGCCGCATGGACGCATCACACAGC
GGCCGGCTGCTGAACCGCCTGGCCGATCTGATCGAGCGGGACCGGACCTACCTGGCGGCC
TTGGAGACCCTGGACAATGGCAAGCCCTATGTCATCTCCTACCTGGTGGATTTGGACATG
GTCCTCAAATGTCTCCGGTATTATGCCGGCTGGGCTGATAAGTACCACGGGAAAACCATC
CCCATTGACGGAGACTTCTTCAGCTACACACGCCATGAACCTGTGGGGGTGTGCGGGCAG
ATCATTCCGTGGAATTTCCCGCTCCTGATGCAAGCATGGAAGCTGGGCCCAGCCTTGGCA
ACTGGAAACGTGGTTGTGATGAAGGTAGCTGAGCAGACACCCCTCACCGCCCTCTATGTG
GCCAACCTGATCAAGGAGGCTGGCTTTCCCCCTGGTGTGGTCAACATTGTGCCTGGATTT
GGCCCCACGGCTGGGGCCGCCATTGCCTCCCATGAGGATGTGGACAAAGTGGCATTCACA
GGCTCCACTGAGATTGGCCGCGTAATCCAGGTTGCTGCTGGGAGCAGCAACCTCAAGAGA
GTGACCTTGGAGCTGGGGGGGAAGAGCCCCAACATCATCATGTCAGATGCCGATATGGAT
TGGGCCGTGGAACAGGCCCACTTCGCCCTGTTCTTCAACCAGGGCCAGTGCTGCTGTGCC
GGCTCCCGGACCTTCGTGCAGGAGGACATCTATGATGAGTTTGTGGTGCGGAGCGTTGCC
CGGGCCAAGTCTCGGGTGGTCGGGAACCCCTTTGATAGCAAGACCGAGCAGGGGCCGCAG
GTGGATGAAACTCAGTTTAAGAAGATCCTCGGCTACATCAACACGGGGAAGCAAGAGGGG
GCGAAGCTGCTGTGTGGTGGGGGCATTGCTGCTGACCGTGGTTACTTCATCCAGCCCACT
GTGTTTGGAGATGTGCAGGATGGCATGACCATCGCCAAGGAGGAGATCTTCGGGCCAGTG
ATGCAGATCCTGAAGTTCAAGACCATAGAGGAGGTTGTTGGGAGAGCCAACAATTCCACG
TACGGGCTGGCCGCAGCTGTCTTCACAAAGGATTTGGACAAGGCCAATTACCTGTCCCAG
GCCCTCCAGGCGGGCACTGTGTGGGTCAACTGCTATGATGTGTTTGGAGCCCAGTCACCC
TTTGGTGGCTACAAGATGTCGGGGAGTGGCCGGGAGTTGGGCGAGTACGGGCTGCAGGCA
TACACTGAAGTGAAAACTGTCACAGTCAAAGTGCCTCAGAAGAACTCATAA

# Drug_Target_50_General_Function:
Energy production and conversion

# Drug_Target_50_General_References:
10631996	Ni L, Zhou J, Hurley TD, Weiner H: Human liver mitochondrial aldehyde dehydrogenase: three-dimensional structure and the restoration of solubility and activity of chimeric forms. Protein Sci. 1999 Dec;8(12):2784-90.
2838413	Hsu LC, Bendel RE, Yoshida A: Genomic structure of the human mitochondrial aldehyde dehydrogenase gene. Genomics. 1988 Jan;2(1):57-65.
2987944	Hsu LC, Tani K, Fujiyoshi T, Kurachi K, Yoshida A: Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3771-5.
3562250	Braun T, Bober E, Singh S, Agarwal DP, Goedde HW: Isolation and sequence analysis of a full length cDNA clone coding for human mitochondrial aldehyde dehydrogenase. Nucleic Acids Res. 1987 Apr 10;15(7):3179.
3582651	Braun T, Bober E, Singh S, Agarwal DP, Goedde HW: Evidence for a signal peptide at the amino-terminal end of human mitochondrial aldehyde dehydrogenase. FEBS Lett. 1987 May 11;215(2):233-6.
3610592	Agarwal DP, Goedde HW: Human aldehyde dehydrogenase isozymes and alcohol sensitivity. Isozymes Curr Top Biol Med Res. 1987;16:21-48.
3653404	Hempel J, Hoog JO, Jornvall H: Mitochondrial aldehyde dehydrogenase. Homology of putative targeting sequence to that of carbamyl phosphate synthetase I revealed by correlation of cDNA and protein data. FEBS Lett. 1987 Sep 28;222(1):95-8.
4015823	Yoshida A, Ikawa M, Hsu LC, Tani K: Molecular abnormality and cDNA cloning of human aldehyde dehydrogenases. Alcohol. 1985 Jan-Feb;2(1):103-6.
4065146	Hempel J, Kaiser R, Jornvall H: Mitochondrial aldehyde dehydrogenase from human liver. Primary structure, differences in relation to the cytosolic enzyme, and functional correlations. Eur J Biochem. 1985 Nov 15;153(1):13-28.
6582480	Yoshida A, Huang IY, Ikawa M: Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A. 1984 Jan;81(1):258-61.
8561277	Novoradovsky A, Tsai SJ, Goldfarb L, Peterson R, Long JC, Goldman D: Mitochondrial aldehyde dehydrogenase polymorphism in Asian and American Indian populations: detection of new ALDH2 alleles. Alcohol Clin Exp Res. 1995 Oct;19(5):1105-10.

# Drug_Target_50_HGNC_ID:
HGNC:404

# Drug_Target_50_HPRD_ID:
00003

# Drug_Target_50_ID:
147

# Drug_Target_50_Locus:
12q24.2

# Drug_Target_50_Molecular_Weight:
56382

# Drug_Target_50_Name:
Aldehyde dehydrogenase, mitochondrial

# Drug_Target_50_Number_of_Residues:
517

# Drug_Target_50_PDB_ID:
1OF7

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_50_Protein_Sequence:
>Aldehyde dehydrogenase, mitochondrial precursor
MLRAAARFGPRLGRRLLSAAATQAVPAPNQQPEVFCNQIFINNEWHDAVSRKTFPTVNPS
TGEVICQVAEGDKEDVDKAVKAARAAFQLGSPWRRMDASHRGRLLNRLADLIERDRTYLA
ALETLDNGKPYVISYLVDLDMVLKCLRYYAGWADKYHGKTIPIDGDFFSYTRHEPVGVCG
QIIPWNFPLLMQAWKLGPALATGNVVVMKVAEQTPLTALYVANLIKEAGFPPGVVNIVPG
FGPTAGAAIASHEDVDKVAFTGSTEIGRVIQVAAGSSNLKRVTLELGGKSPNIIMSDADM
DWAVEQAHFALFFNQGQCCCAGSRTFVQEDIYDEFVERSVARAKSRVVGNPFDSKTEQGP
QVDETQFKKILGYINTGKQEGAKLLCGGGIAADRGYFIQPTVFGDVQDGMTIAKEEIFGP
VMQILKFKTIEEVVGRANNSTYGLAAAVFTKDLDKANYLSQALQAGTVWVNCYDVFGAQS
PFGGYKMSGSGRELGEYGLQAYTEVKTVTVKVPQKNS

# Drug_Target_50_Reaction:
an aldehyde + NAD+ + H2O = an acid + NADH + H+

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Not Available

# Drug_Target_50_SwissProt_ID:
P05091

# Drug_Target_50_SwissProt_Name:
ALDH2_HUMAN

# Drug_Target_50_Synonyms:
ALDH class 2
ALDH-E2
ALDHI
Aldehyde dehydrogenase, mitochondrial precursor
EC 1.2.1.3

# Drug_Target_50_Theoretical_pI:
7.05

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Microsome

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
1727721	Mercer WR, Krozowski ZS: Localization of an 11 beta hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney. Endocrinology. 1992 Jan;130(1):540-3.
8585102	Hermans JJ, Steckel B, Thijssen HH, Janssen BJ, Netter KJ, Maser E: Comparison of 11 beta-hydroxysteroid dehydrogenase in spontaneously hypertensive and Wistar-Kyoto rats. Steroids. 1995 Nov;60(11):773-9.

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
HSD11B2

# Drug_Target_51_GenBank_ID_Gene:
U14631

# Drug_Target_51_GenBank_ID_Protein:
565082

# Drug_Target_51_GeneCard_ID:
HSD11B2

# Drug_Target_51_Gene_Name:
HSD11B2

# Drug_Target_51_Gene_Sequence:
>1218 bp
ATGGAGCGCTGGCCTTGGCCGTCGGGCGGCGCCTGGCTGCTCGTGGCTGCCCGCGCGCTG
CTGCAGCTGCTGCGCTCAGACCTGCGTCTGGGCCGCCCGCTGCTGGCGGCGCTGGCGCTG
CTGGCCGCGCTCGACTGGCTGTGCCAGCGCCTGCTGCCCCCGCCGGCCGCACTCGCCGTG
CTGGCCGCCGCCGGCTGGATCGCGTTGTCCCGCCTGGCGCGCCCGCAGCGCCTGCCGGTG
GCCACTCGCGCGGTGCTCATCACCGGCTGTGACTCTGGTTTTGGCAAGGAGACGGCCAAG
AAACTGGACTCCATGGGCTTCACGGTGCTGGCCACCGTATTGGAGTTGAACAGCCCCGGT
GCCATCGAGCTGCGTACCTGCTGCTCCCCTCGCCTAAGGCTGCTGCAGATGGACCTGACC
AAACCAGGAGACATTAGCCGCTTGCTAGAGTTCACCAAGGCCCACACCACCAGCACCGGC
CTGTGGGGCCTCGTCAACAACGCAGGCCACAATGAAGTAGTTGCTGATGCGGAGCTGTCT
CCAGTGGCCACTTTCCGTAGCTGCATGGAGGTGAATTTCTTTGGCGCGCTCGAGCTGACC
AAGGGCCTCCTGCCCCTGCTGCGCAGCTCAAGGGGCCGCATCGTGACTGTGGGGAGCCCA
GCGGGGGACATGCCATATCCGTGCTTGGGGGCCTATGGAACCTCCAAAGCGGCCGTGGCG
CTACTCATGGACACATTCAGCTGTGAACTCCTTCCCTGGGGGGTCAAGGTCAGCATCATC
CAGCCTGGCTGCTTCAAGACAGAGTCAGTGAGAAACGTGGGTCAGTGGGAAAAGCGCAAG
CAATTGCTGCTGGCCAACCTGCCTCAAGAGCTGCTGCAGGCCTACGGCAAGGACTACATC
GAGCACTTGCATGGGCAGTTCCTGCACTCGCTACGCCTGGCCATGTCCGACCTCACCCCA
GTTGTAGATGCCATCACAGATGCGCTGCTGGCAGCTCGGCCCCGCCGCCGCTATTACCCC
GGCCAGGGCCTGGGGCTCATGTACTTCATCCACTACTACCTGCCTGAAGGCCTGCGGCGC
CGCTTCCTGCAGGCCTTCTTCATCAGTCACTGTCTGCCTCGAGCACTGCAGCCTGGCCAG
CCTGGCACTACCCCACCACAGGACGCAGCCCAGGACCCAAACCTGAGCCCCGGCCCTTCC
CCAGCAGTGGCTCGGTGA

# Drug_Target_51_General_Function:
Lipid transport and metabolism

# Drug_Target_51_General_References:
10489390	Morineau G, Marc JM, Boudi A, Galons H, Gourmelen M, Corvol P, Pascoe L, Fiet J: Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11betaHSD2 causing apparent mineralocorticoid excess. Hypertension. 1999 Sep;34(3):435-41.
10523339	Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G, Moudgil A, Travis LB, Palermo M, Shackleton C, White PC: Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension. 1999 Oct;34(4 Pt 1):638-42.
11238516	Odermatt A, Dick B, Arnold P, Zaehner T, Plueschke V, Deregibus MN, Repetto H, Frey BM, Frey FJ, Ferrari P: A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. J Clin Endocrinol Metab. 2001 Mar;86(3):1247-52.
11350956	Odermatt A, Arnold P, Frey FJ: The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J Biol Chem. 2001 Jul 27;276(30):28484-92. Epub 2001 May 11.
2889032	Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR: Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987 Oct 10;2(8563):821-4.
7593417	Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Neiberger RE, et al.: Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995 Nov;80(11):3145-50.
7608290	Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI: A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995 Jul;80(7):2263-6.
7670488	Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC: Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995 Aug;10(4):394-9.
7859916	Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS: Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994 Nov;105(2):R11-7.
8530071	Agarwal AK, Rogerson FM, Mune T, White PC: Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics. 1995 Sep 1;29(1):195-9.
8611140	Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR: Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochem J. 1996 Feb 1;313 ( Pt 3):1007-17.
9398712	Kitanaka S, Katsumata N, Tanae A, Hibi I, Takeyama K, Fuse H, Kato S, Tanaka T: A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1997 Dec;82(12):4054-8.
9661590	Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, De Santis C, New MI: Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998 Jul;83(7):2244-54.
9683587	Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM: Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Am J Hum Genet. 1998 Aug;63(2):370-9.
9707624	Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, Krozowski ZS, Shackleton CH, Bradlow L, Wiens T, New MI: A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10200-5.
9851783	Rogoff D, Smolenicka Z, Bergada I, Vallejo G, Barontini M, Heinrich JJ, Ferrari P: The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998 Dec;83(12):4391-3.

# Drug_Target_51_HGNC_ID:
HGNC:5209

# Drug_Target_51_HPRD_ID:
01958

# Drug_Target_51_ID:
145

# Drug_Target_51_Locus:
16q22

# Drug_Target_51_Molecular_Weight:
44127

# Drug_Target_51_Name:
Corticosteroid 11-beta-dehydrogenase isozyme 2

# Drug_Target_51_Number_of_Residues:
405

# Drug_Target_51_PDB_ID:
Not Available

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_51_Protein_Sequence:
>Corticosteroid 11-beta-dehydrogenase isozyme 2
MERWPWPSGGAWLLVAARALLQLLRSDLRLGRPLLAALALLAALDWLCQRLLPPPAALAV
LAAAGWIALSRLARPQRLPVATRAVLITGCDSGFGKETAKKLDSMGFTVLATVLELNSPG
AIELRTCCSPRLRLLQMDLTKPGDISRVLEFTKAHTTSTGLWGLVNNAGHNEVVADAELS
PVATFRSCMEVNFFGALELTKGLLPLLRSSRGRIVTVGSPAGDMPYPCLGAYGTSKAAVA
LLMDTFSCELLPWGVKVSIIQPGCFKTESVRNVGQWEKRKQLLLANLPQELLQAYGKDYI
EHLHGQFLHSLRLAMSDLTPVVDAITDALLAARPRRRYYPGQGLGLMYFIHYYLPEGLRR
RFLQAFFISHCLPRALQPGQPGTTPPQDAAQDPNLSPGPSPAVAR

# Drug_Target_51_Reaction:
Not Available

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids

# Drug_Target_51_SwissProt_ID:
P80365

# Drug_Target_51_SwissProt_Name:
DHI2_HUMAN

# Drug_Target_51_Synonyms:
11-DH2
11-beta-HSD2
11-beta-hydroxysteroid dehydrogenase type 2
EC 1.1.1.-
NAD- dependent 11-beta-hydroxysteroid dehydrogenase

# Drug_Target_51_Theoretical_pI:
9.58

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_52_Chromosome_Location:
Not Available

# Drug_Target_52_Drug_References:
12416991	Trauger JW, Jiang A, Stearns BA, LoGrasso PV: Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry. 2002 Nov 12;41(45):13451-9.
12810547	Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM: Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology. 2003 Jul;144(7):2922-32.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
AKR1C2

# Drug_Target_52_GenBank_ID_Gene:
U05598

# Drug_Target_52_GenBank_ID_Protein:
531160

# Drug_Target_52_GeneCard_ID:
AKR1C2

# Drug_Target_52_Gene_Name:
AKR1C2

# Drug_Target_52_Gene_Sequence:
>972 bp
ATGGATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGTCAAATTG
GCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTG
TCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC
ACAGTGGATCTCTGTGCCACGTGGGAGGCCATGGAGAAGTGTAAAGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGAGATGATCCTCAACAAGCCA
GGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC
AGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT
GATGAATATTAA

# Drug_Target_52_General_Function:
Involved in oxidoreductase activity

# Drug_Target_52_General_References:
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
7959017	Qin KN, Khanna M, Cheng KC: Structure of a gene coding for human dihydrodiol dehydrogenase/bile acid-binding protein. Gene. 1994 Nov 18;149(2):357-61.
8011662	Ciaccio PJ, Tew KD: cDNA and deduced amino acid sequences of a human colon dihydrodiol dehydrogenase. Biochim Biophys Acta. 1994 Jun 28;1186(1-2):129-32.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
9716498	Shiraishi H, Ishikura S, Matsuura K, Deyashiki Y, Ninomiya M, Sakai S, Hara A: Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2) and tissue distribution of its mRNA. Biochem J. 1998 Sep 1;334 ( Pt 2):399-405.

# Drug_Target_52_HGNC_ID:
HGNC:385

# Drug_Target_52_HPRD_ID:
11857

# Drug_Target_52_ID:
686

# Drug_Target_52_Locus:
10p15-p14

# Drug_Target_52_Molecular_Weight:
36736

# Drug_Target_52_Name:
Aldo-keto reductase family 1 member C2

# Drug_Target_52_Number_of_Residues:
323

# Drug_Target_52_PDB_ID:
1IHI

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_52_Protein_Sequence:
>Aldo-keto reductase family 1 member C2
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY

# Drug_Target_52_Reaction:
androsterone + NAD(P)+ = 5alpha-androstane-3,17-dione + NAD(P)H + H+

# Drug_Target_52_Signals:
None

# Drug_Target_52_Specific_Function:
Works in concert with the 5alpha/5beta-steroid reductases to convert steroid hormones into the 3alpha/5alpha and 3alpha/5beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT) to 5-alpha-androstane-3alpha,17beta-diol (3-alpha-diol)

# Drug_Target_52_SwissProt_ID:
P52895

# Drug_Target_52_SwissProt_Name:
AK1C2_HUMAN

# Drug_Target_52_Synonyms:
3-alpha-HSD3
Chlordecone reductase homolog HAKRD
DD/BABP
DD2
Dihydrodiol dehydrogenase 2
Dihydrodiol dehydrogenase/bile acid-binding protein
EC 1.-.-.-
EC 1.1.1.213
EC 1.3.1.20
Trans-1,2- dihydrobenzene-1,2-diol dehydrogenase
Type III 3- alpha-hydroxysteroid dehydrogenase

# Drug_Target_52_Theoretical_pI:
7.55

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Not Available

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
15805545	Cunningham D, Swartzlander D, Liyanarachchi S, Davuluri RV, Herman GE: Changes in gene expression associated with loss of function of the NSDHL sterol dehydrogenase in mouse embryonic fibroblasts. J Lipid Res. 2005 Jun;46(6):1150-62. Epub 2005 Apr 1.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
NSDHL

# Drug_Target_53_GenBank_ID_Gene:
U47105

# Drug_Target_53_GenBank_ID_Protein:
4457237

# Drug_Target_53_GeneCard_ID:
NSDHL

# Drug_Target_53_Gene_Name:
NSDHL

# Drug_Target_53_Gene_Sequence:
>1122 bp
ATGGAACCAGCAGTTAGCGAGCCAATGAGAGACCAAGTCGCACGGACTCATTTGACAGAG
GACACTCCCAAAGTGAATGCTGACATAGAAAAGGTTAACCAGAATCAGGCCAAGAGATGC
ACAGTGATCGGTGGCTCTGGATTCCTGGGGCAGCACATGGTGGAGCAGTTGCTGGCAAGA
GGATATGCTGTCAATGTATTTGATATCCAGCAAGGGTTTGATAATCCCCAGGTGCGGTTC
TTTCTGGGTGACCTCTGCAGCCGACAGGATCTGTACCCAGCTCTGAAAGGTGTAAACACA
GTTTTCCACTGTGCGTCACCCCCACCATCCAGTAACAACAAGGAGCTCTTTTATAGAGTG
AATTACATTGGCACCAAGAATGTCATTGAAACTTGCAAAGAGGCTGGGGTTCAGAAACTC
ATTTTAACCAGCAGTGCCAGTGTCATCTTTGAGGGCGTCGATATCAAGAATGGAACTGAA
GACCTTCCCTATGCCATGAAACCCATTGACTACTACACAGAGACTAAGATCTTACAGGAG
AGGGCAGTTCTGGGCGCCAACGATCCTGAGAAGAATTTCTTAACCACAGCCATCCGCCCT
CATGGCATTTTCGGCCCAAGGGACCCGCAGTTGGTACCCATCCTCATCGAGGCAGCCAGG
AACGGCAAGATGAAGTTCGTGATTGGAAATGGGAAGAACTTGGTGGACTTCACCTTTGTG
GAGAACGTGGTCCATGGACACATCCTGGCGGCAGAGCAGCTCTCCCGAGACTCGACACTG
GGTGGGAAGGCATTTCACATCACCAATGATGAGCCCATCCCTTTCTGGACATTCCTGTCT
CGCATCCTGACAGGCCTCAATTATGAGGCCCCCAAGTACCACATCCCCTACTGGGTGGCC
TACTACCTGGCCCTCCTGCTATCCCTGCTGGTGATGGTGATCAGTCCTGTCATCCAGCTG
CAGCCCACCTTCACACCCATGCGGGTCGCACTGGCTGGCACATTCCACTACTACAGCTGC
GAGAGAGCCAAAAAGGCCATGGGCTACCAGCCACTAGTGACCATGGATGATGCTATGGAG
AGGACCGTGCAGAGCTTTCGCCACCTGCGGAGGGTCAAGTGA

# Drug_Target_53_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_53_General_References:
10710235	Konig A, Happle R, Bornholdt D, Engel H, Grzeschik KH: Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am J Med Genet. 2000 Feb 14;90(4):339-46.
10854409	Mallon AM, Platzer M, Bate R, Gloeckner G, Botcherby MR, Nordsiek G, Strivens MA, Kioschis P, Dangel A, Cunningham D, Straw RN, Weston P, Gilbert M, Fernando S, Goodall K, Hunter G, Greystrong JS, Clarke D, Kimberley C, Goerdes M, Blechschmidt K, Rump A, Hinzmann B, Mundy CR, Miller W, Poustka A, Herman GE, Rhodes M, Denny P, Rosenthal A, Brown SD: Comparative genome sequence analysis of the Bpa/Str region in mouse and Man. Genome Res. 2000 Jun;10(6):758-75.
8828036	Levin ML, Chatterjee A, Pragliola A, Worley KC, Wehnert M, Zhuchenko O, Smith RF, Lee CC, Herman GE: A comparative transcription map of the murine bare patches (Bpa) and striated (Str) critical regions and human Xq28. Genome Res. 1996 Jun;6(6):465-77.

# Drug_Target_53_HGNC_ID:
HGNC:13398

# Drug_Target_53_HPRD_ID:
02229

# Drug_Target_53_ID:
50

# Drug_Target_53_Locus:
Xq28

# Drug_Target_53_Molecular_Weight:
41901

# Drug_Target_53_Name:
Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating

# Drug_Target_53_Number_of_Residues:
373

# Drug_Target_53_PDB_ID:
Not Available

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF01073	3Beta_HSD

# Drug_Target_53_Protein_Sequence:
>Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating
MEPAVSEPMRDQVARTHLTEDTPKVNADIEKVNQNQAKRCTVIGGSGFLGQHMVEQLLAR
GYAVNVFDIQQGFDNPQVRFFLGDLCSRQDLYPALKGVNTVFHCASPPPSSNNKELFYRV
NYIGTKNVIETCKEAGVQKLILTSSASVIFEGVDIKNGTEDLPYAMKPIDYYTETKILQE
RAVLGANDPEKNFLTTAIRPHGIFGPRDPQLVPILIEAARNGKMKFVIGNGKNLVDFTFV
ENVVHGHILAAEQLSRDSTLGGKAFHITNDEPIPFWTFLSRILTGLNYEAPKYHIPYWVA
YYLALLLSLLVMVISPVIQLQPTFTPMRVALAGTFHYYSCERAKKAMGYQPLVTMDDAME
RTVQSFRHLRRVK

# Drug_Target_53_Reaction:
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate + NAD(P)+ = 4alpha-methyl-5alpha-cholest-7-en-3-one + CO2 + NAD(P)H

# Drug_Target_53_Signals:
None

# Drug_Target_53_Specific_Function:
Not Available

# Drug_Target_53_SwissProt_ID:
Q15738

# Drug_Target_53_SwissProt_Name:
NSDHL_HUMAN

# Drug_Target_53_Synonyms:
EC 1.1.1.170
H105e3 protein

# Drug_Target_53_Theoretical_pI:
8.20

# Drug_Target_53_Transmembrane_Regions:
298-318

# Drug_Target_54_Cellular_Location:
Not Available

# Drug_Target_54_Chromosome_Location:
Not Available

# Drug_Target_54_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
ALDH3B2

# Drug_Target_54_GenBank_ID_Gene:
U37519

# Drug_Target_54_GenBank_ID_Protein:
1051281

# Drug_Target_54_GeneCard_ID:
ALDH3B2

# Drug_Target_54_Gene_Name:
ALDH3B2

# Drug_Target_54_Gene_Sequence:
>1158 bp
ATGAAGGATGAACCACGGTCCACGAACCTGTTCATGAAGCTGGACTCGGTCTTCATCTGG
AAGGAACCCTTTGGCCTGGTCCTCATCATCGCACCCTGGAACTACCCATTGAACCTGACC
CTGGTGCTCCTGGTGGGCACCCTCCCCGCAGGGAATTGCGTGGTGCTGAAGCCGTCAGAA
ATCAGCCAGGGCACAGAGAAGGTCCTGGCTGAGGTGCTGCCCCAGTACCTGGACCAGAGC
TGCTTTGCCGTGGTGCTGGGCGGACCCCAGGAGACAGGGCAGCTGCTAGAGCACAAGTTG
GACTACATCTTCTTCACAGGGAGCCCTCGTGTGGGCAAGATTGTCATGACTGCTGCCACC
AAGCACCTGACGCCTGTCACCCTGGAGCTGGGGGGCAAGAACCCCTGCTACGTGGACGAC
AACTGCGACCCCCAGACCGTGGCCAACCGCGTGGCCTGGTTCTGCTACTTCAATGCCGGC
CAGACCTGCGTGGCCCCTGACTACGTCCTGTGCAGCCCCGAGATGCAGGAGAGGCTGCTG
CCCGCCCTGCAGAGCACCATCACCCGTTTCTATGGCGACGACCCCCAGAGCTCCCCAAAC
CTGGGCCGCATCATCAACCAGAAACAGTTCCAGCGGCTGCGGGCATTGCTGGGCTGCGGC
CGCGTGGCCATTGGGGGCCAGAGCAACGAGAGCGATCGCTACATCGCCCCCACGGTGCTG
GTGGACGTGCAGGAGACGGAGCCTGTGATGCAGGAGGAGATCTTCGGGCCCATCCTGCCC
ATCGTGAACGTGCAGAGCGTGGACGAGGCCATCAAGTTCATCAACCGGCAGGAGAAGCCC
CTGGCCCTGTACGCCTTCTCCAACAGCAGACAGGTTGTGAACCAGATGCTGGAGCGGACC
AGCAGCGGCAGCTTTGGAGGCAATGAGGGCTTCACCTACATATCTCTGCTGTCCGTGCCA
TTCGGGGGAGTCGGCCACAGTGGGATGGGCCGGTACCACGGCAAGTTCACCTTCGACACC
TTCTCCCACCACCGCACCTGCCTGCTCGCCCCCTCCGGCCTGGAGAAATTAAAGGAGATC
CGCTACCCACCCTATACCGACTGGAACCAGCAGCTGTTACGCTGGGGCATGGGCTCCCAG
AGCTGCACCCTCCTGTGA

# Drug_Target_54_General_Function:
Energy production and conversion

# Drug_Target_54_General_References:
7484374	Hsu LC, Chang WC, Lin SW, Yoshida A: Cloning and characterization of genes encoding four additional human aldehyde dehydrogenase isozymes. Adv Exp Med Biol. 1995;372:159-68.
8890755	Hsu LC, Chang WC: Sequencing and expression of the human ALDH8 encoding a new member of the aldehyde dehydrogenase family. Gene. 1996 Oct 3;174(2):319-22.

# Drug_Target_54_HGNC_ID:
HGNC:411

# Drug_Target_54_HPRD_ID:
03559

# Drug_Target_54_ID:
216

# Drug_Target_54_Locus:
11q13

# Drug_Target_54_Molecular_Weight:
42670

# Drug_Target_54_Name:
Aldehyde dehydrogenase 3B2

# Drug_Target_54_Number_of_Residues:
385

# Drug_Target_54_PDB_ID:
Not Available

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_54_Protein_Sequence:
>Aldehyde dehydrogenase 3B2
MKDEPRSTNLFMKLDSVFIWKEPFGLVLIIAPWNYPLNLTLVLLVGALAAGNCVVLKPSE
ISQGTEKVLAEVLPQYLDQSCFAVVLGGPQETGQLLEHKLDYIFFTGSPRVGKIVMTAAT
KHLTPVTLELGGKNPCYVDDNCDPQTVANRVAWFCYFNAGQTCVAPDYVLCSPEMQERLL
PALQSTITRFYGDDPQSSPNLGRIINQKQFQRLRALLGCGRVAIGGQSNESDRYIAPTVL
VDVQETEPVMQEEIFGPILPIVNVQSVDEAIKFINRQEKPLALYAFSNSSQVVNQMLERT
SSGSFGGNEGFTYISLLSVPFGGVGHSGMGRYHGKFTFDTFSHHRTCLLAPSGLEKLKEI
RYPPYTDWNQQLLRWGMGSQSCTLL

# Drug_Target_54_Reaction:
an aldehyde + NAD(P)+ + H2O = an acid + NAD(P)H + H+

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Not Available

# Drug_Target_54_SwissProt_ID:
P48448

# Drug_Target_54_SwissProt_Name:
AL3B2_HUMAN

# Drug_Target_54_Synonyms:
Aldehyde dehydrogenase 8
EC 1.2.1.5

# Drug_Target_54_Theoretical_pI:
5.97

# Drug_Target_54_Transmembrane_Regions:
None

# Drug_Target_55_Cellular_Location:
Mitochondrion

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
1898092	Kedishvili NY, Popov KM, Harris RA: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Arch Biochem Biophys. 1991 Oct;290(1):21-6.

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
ALDH6A1

# Drug_Target_55_GenBank_ID_Gene:
AJ249994

# Drug_Target_55_GenBank_ID_Protein:
7160985

# Drug_Target_55_GeneCard_ID:
ALDH6A1

# Drug_Target_55_Gene_Name:
ALDH6A1

# Drug_Target_55_Gene_Sequence:
>1608 bp
ATGGCGGCGCTATTGGCGGCGGCGGCAGTGCGAGCCCGGATCCTGCAGGTTTCTTCCAAG
GTGAAATCCAGTCCCACCTGGTATTCAGCATCTTCCTTCTCTTCTTCAGTGCCAACTGTA
AAGCTCTTCATTGGTGGGAAATTCGTTGAATCCAAAAGTGACAAATGGATCGATATCCAC
AACCCAGCCACCAATGAGGTCATTGGTCGGGTCCCTCAGGCCACCAAGGCAGAAATGGAT
GCAGCCATTGCTTCCTGCAAACGTGCTTTTCCTGCATGGGCAGACACTTCAGTATTAAGC
CGCCAGCAGGTCTTGCTCCGCTATCAACAACTTATTAAAGAAAACTTGAAAGAAATTGCC
AAGTTAATCACATTGGAACAAGGGAAGACCCTAGCTGATGCTGAAGGAGATGTATTTCGA
GGCCTTCAGGTGGTTGAGCATGCCTGTAGTGTGACATCCCTCATGATGGGAGAGACCATG
CCATCCATCACCAAAGACATGGACCTTTATTCCTACCGTCTGCCTCTGGGAGTGTGTGCA
GGCATTGCTCCATTCAATTTTCCTGCCATGATCCCCCTTTGGATGTTTCCCATGGCCATG
GTGTGTGGAAATACCTTCCTAATGAAACCATCTGAGCGAGTCCCTGGAGCAACTATGCTT
CTTGCTAAGTTGCTCCAGGATTCTGGTGCCCCTGATGGAACATTAAACATCATCCATGGA
CAGCATGAAGCTGTAAATTTTATTTGCGATCATCCGGACATCAAAGCAATCAGCTTTGTG
GGATCCAACAAGGCAGGAGAGTATATCTTCGAGAGAGGATCAAGACATGGCAAGAGGGTT
CAAGCCAATATGGGAGCCAAGAACCATGGGGTAGTCATGCCAGATGCCAATAAGGAAAAT
ACCCTGAACCAGCTGGTTGGGGCAGCATTTGGAGCTGCTGGTCAGCGCTGCATGGCTCTT
TCAACAGCAGTCCTTGTGGGAGAAGCCAAGAAGTGGCTGCCAGAGCTGGTGGAGCATGCC
AAAAACCTGAGAGTCAATGCAGGAGATCAGCCTGGAGCTGATCTTGGCCCTCTGATCACT
CCCCAGGCCAAAGAGCGAGTCTGTAATCTGATTGATAGTGGAACAAAGGAGGGAGCTTCC
ATCCTTCTTGATGGACGAAAAATTAAAGTGAAAGGCTATGAAAATGGCAACTTTGTTGGA
CCAACCATCATCTCGAATGTCAAGCCAAATATGACCTGTTACAAAGAGGAGATTTTTGGT
CCAGTTCTTGTGGTTCTGGAGACAGAAACATTGGATGAAGCCATCCAGATTGTAAATAAC
AACCCATATGGAAATGGAACTGCCATCTTCACCACCAATGGAGCCACTGCTCGGAAATAT
GCCCACTTGGTGGATGTTGGACAGGTGGGAGTGAATGTCCCCATTCCAGTGCCTTTGCCA
ATGTTCTCATTCACCGGCTCTCGATCCTCCTTCAGGGGAGACACCAATTTCTATGGCAAA
CAGGGCATCCAATTCTACACTCAGTTAAAGACCATTACTTCTCAGTGGAAAGAAGAAGAT
GCTACTCTTTCCTCACCTGCTGTTGTCATGCCTACCATGGGCCGTTAG

# Drug_Target_55_General_Function:
Energy production and conversion

# Drug_Target_55_General_References:
10947204	Chambliss KL, Gray RG, Rylance G, Pollitt RJ, Gibson KM: Molecular characterization of methylmalonate semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2000 Jul;23(5):497-504.
1527093	Kedishvili NY, Popov KM, Rougraff PM, Zhao Y, Crabb DW, Harris RA: CoA-dependent methylmalonate-semialdehyde dehydrogenase, a unique member of the aldehyde dehydrogenase superfamily. cDNA cloning, evolutionary relationships, and tissue distribution. J Biol Chem. 1992 Sep 25;267(27):19724-9.

# Drug_Target_55_HGNC_ID:
HGNC:7179

# Drug_Target_55_HPRD_ID:
04416

# Drug_Target_55_ID:
258

# Drug_Target_55_Locus:
14q24.3

# Drug_Target_55_Molecular_Weight:
57840

# Drug_Target_55_Name:
Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial

# Drug_Target_55_Number_of_Residues:
535

# Drug_Target_55_PDB_ID:
Not Available

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_55_Protein_Sequence:
>Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial precursor
MAALLAAAAVRARILQVSSKVKSSPTWYSASSFSSSVPTVKLFIGGKFVESKSDKWIDIH
NPATNEVIGRVPQATKAEMDAAIASCKRAFPAWADTSVLSRQQVLLRYQQLIKENLKEIA
KLITLEQGKTLADAEGDVFRGLQVVEHACSVTSLMMGETMPSITKDMDLYSYRLPLGVCA
GIAPFNFPAMIPLWMFPMAMVCGNTFLMKPSERVPGATMLLAKLLQDSGAPDGTLNIIHG
QHEAVNFICDHPDIKAISFVGSNKAGEYIFERGSRHGKRVQANMGAKNHGVVMPDANKEN
TLNQLVGAAFGAAGQRCMALSTAVLVGEAKKWLPELVEHAKNLRVNAGDQPGADLGPLIT
PQAKERVCNLIDSGTKEGASILLDGRKIKVKGYENGNFVGPTIISNVKPNMTCYKEEIFG
PVLVVLETETLDEAIQIVNNNPYGNGTAIFTTNGATARKYAHLVDVGQVGVNVPIPVPLP
MFSFTGSRSSFRGDTNFYGKQGIQFYTQLKTITSQWKEEDATLSSPAVVMPTMGR

# Drug_Target_55_Reaction:
3-oxopropanoate + CoA + NAD(P)+ = acetyl-CoA + CO2 + NAD(P)H

# Drug_Target_55_Signals:
None

# Drug_Target_55_Specific_Function:
Plays a role in valine and pyrimidine metabolism. Binds fatty acyl-CoA

# Drug_Target_55_SwissProt_ID:
Q02252

# Drug_Target_55_SwissProt_Name:
MMSA_HUMAN

# Drug_Target_55_Synonyms:
EC 1.2.1.18
EC 1.2.1.27
MMSDH
Malonate-semialdehyde dehydrogenase [acylating]
Methylmalonate-semialdehyde dehydrogenase , mitochondrial precursor

# Drug_Target_55_Theoretical_pI:
8.69

# Drug_Target_55_Transmembrane_Regions:
174-196

# Drug_Target_56_Cellular_Location:
Cytoplasm

# Drug_Target_56_Chromosome_Location:
Not Available

# Drug_Target_56_Drug_References:
16583981	Wroczynski P, Nowak M, Wierzchowski J, Szubert A, Polanski J: Activities of cytosolic aldehyde dehydrogenase isozymes in colon cancer: determination using selective, fluorimetric assays. Acta Pol Pharm. 2005 Nov-Dec;62(6):427-33.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_56_Essentiality:
Non-Essential

# Drug_Target_56_GenAtlas_ID:
ALDH3A1

# Drug_Target_56_GenBank_ID_Gene:
M74542

# Drug_Target_56_GenBank_ID_Protein:
178402

# Drug_Target_56_GeneCard_ID:
ALDH3A1

# Drug_Target_56_Gene_Name:
ALDH3A1

# Drug_Target_56_Gene_Sequence:
>1362 bp
ATGAGCAAGATCAGCGAGGCCGTGAAGCGCGCCCGCGCCGCCTTCAGCTCGGGCAGGACC
CGTCCGCTGCAGTTCCGATTCCAGCAGCTGGAGGCGCTGCAGCGCCTGATCCAGGAGCAG
GAGCAGGAGCTGGTGGGCGCGCTGGCCGCAGACCTGCACAAGAATGAATGGAACGCCTAC
TATGAGGAGGTGGTGTACGTCCTAGAGGAGATCGAGTACATGATCCAGAAGCTCCCTGAG
TGGGCCGCGGATGAGCCCGTGGAGAAGACGCCCCAGACTCAGCAGGACGAGCTCTACATC
CACTCGGAGCCACTGGGCGTGGTCCTCGTCATTGGCACCTGGAACTACCCCTTCAACCTC
ACCATCCAGCCCATGGTGGGCGCCATCGCTGCAGGGAACGCAGTGGTCCTCAAGCCCTCG
GAGCTGAGTGAGAACATGGCGAGCCTGCTGGCTACCATCATCCCCCAGTACCTGGACAAG
GATCTGTACCCAGTAATCAATGGGGGTGTCCCTGAGACCACGGAGCTGCTCAAGGAGAGG
TTCGACCATATCCTGTACACGGGCAGCACGGGGGTGGGGAAGATCATCATGACGGCTGCT
GCCAAGCACCTGACCCCTGTCACGCTGGAGCTGGGAGGGAAGAGTCCCTGCTACGTGGAC
AAGAACTGTGACCTGGACGTGGCCTGCCGACGCATCGCCTGGGGGAAATTCATGAACAGT
GGCCAGACCTGCGTGGCCCCAGACTACATCCTCTGTGACCCCTCGATCCAGAACCAAATT
GTGGAGAAGCTCAAGAAGTCACTGAAAGAGTTCTACGGGGAAGATGCTAAGAAATCCCGG
GACTATGGAAGAATCATTAGTGCCCGGCACTTCCAGAGGGTGATGGGCCTGATTGAGGGC
CAGAAGGTGGCTTATGGGGGCACCGGGGATGCCGCCACTCGCTACATAGCCCCCACCATC
CTCACGGACGTGGACCCCCAGTCCCCGGTGATGCAAGAGGAGATCTTCGGGCCTGTGCTG
CCCATCGTGTGCGTGCGCAGCCTGGAGGAGGCCATCCAGTTCATCAACCAGCGTGAGAAG
CCCCTGGCCCTCTACATGTTCTCCAGCAACGACAAGGTGATTAAGAAGATGATTGCAGAG
ACATCCAGTGGTGGGGTGGCGGCCAACGATGTCATCGTCCACATCACCTTGCACTCTCTG
CCCTTCGGGGGCGTGGGGAACAGCGGCATGGGATCCTACCATGGCAAGAAGAGCTTCGAG
ACTTTCTCTCACCGCCGCTCTTGCCTGGTGAGGCCTCTGATGAATGATGAAGGCCTGAAG
GTCAGATACCCCCCGAGCCCGGCCAAGATGACCCAGCACTGA

# Drug_Target_56_General_Function:
Energy production and conversion

# Drug_Target_56_General_References:
1737758	Hsu LC, Chang WC, Shibuya A, Yoshida A: Human stomach aldehyde dehydrogenase cDNA and genomic cloning, primary structure, and expression in Escherichia coli. J Biol Chem. 1992 Feb 15;267(5):3030-7.
2037078	Yin SJ, Vagelopoulos N, Wang SL, Jornvall H: Structural features of stomach aldehyde dehydrogenase distinguish dimeric aldehyde dehydrogenase as a 'variable' enzyme. 'Variable' and 'constant' enzymes within the alcohol and aldehyde dehydrogenase families. FEBS Lett. 1991 May 20;283(1):85-8.
8493892	Hsu LC, Yoshida A: Human stomach aldehyde dehydrogenase, ALDH3. Adv Exp Med Biol. 1993;328:141-52.
9250352	Tsukamoto N, Chang C, Yoshida A: Mutations associated with Sjogren-Larsson syndrome. Ann Hum Genet. 1997 May;61(Pt 3):235-42.

# Drug_Target_56_HGNC_ID:
HGNC:405

# Drug_Target_56_HPRD_ID:
00004

# Drug_Target_56_ID:
792

# Drug_Target_56_Locus:
17p11.2

# Drug_Target_56_Molecular_Weight:
50380

# Drug_Target_56_Name:
Aldehyde dehydrogenase, dimeric NADP-preferring

# Drug_Target_56_Number_of_Residues:
453

# Drug_Target_56_PDB_ID:
Not Available

# Drug_Target_56_Pathway:
Cyclophosphamide Pathway	SMP00447
Ifosfamide Pathway	SMP00448

# Drug_Target_56_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_56_Protein_Sequence:
>Aldehyde dehydrogenase, dimeric NADP-preferring
MSKISEAVKRARAAFSSGRTRPLQFRIQQLEALQRLIQEQEQELVGALAADLHKNEWNAY
YEEVVYVLEEIEYMIQKLPEWAADEPVEKTPQTQQDELYIHSEPLGVVLVIGTWNYPFNL
TIQPMVGAIAAGNAVVLKPSELSENMASLLATIIPQYLDKDLYPVINGGVPETTELLKER
FDHILYTGSTGVGKIIMTAAAKHLTPVTLELGGKSPCYVDKNCDLDVACRRIAWGKFMNS
GQTCVAPDYILCDPSIQNQIVEKLKKSLKEFYGEDAKKSRDYGRIISARHFQRVMGLIEG
QKVAYGGTGDAATRYIAPTILTDVDPQSPVMQEEIFGPVLPIVCVRSLEEAIQFINQREK
PLALYMFSSNDKVIKKMIAETSSGGVAANDVIVHITLHSLPFGGVGNSGMGSYHGKKSFE
TFSHRRSCLVRPLMNDEGLKVRYPPSPAKMTQH

# Drug_Target_56_Reaction:
an aldehyde + NAD(P)+ + H2O = an acid + NAD(P)H + H+

# Drug_Target_56_Signals:
None

# Drug_Target_56_Specific_Function:
ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation. This protein preferentially oxidizes aromatic aldehyde substrates. It may play a role in the oxidation of toxic aldehydes

# Drug_Target_56_SwissProt_ID:
P30838

# Drug_Target_56_SwissProt_Name:
AL3A1_HUMAN

# Drug_Target_56_Synonyms:
ALDH class 3
ALDHIII
EC 1.2.1.5

# Drug_Target_56_Theoretical_pI:
6.52

# Drug_Target_56_Transmembrane_Regions:
None

# Drug_Target_57_Cellular_Location:
Cytoplasm

# Drug_Target_57_Chromosome_Location:
Not Available

# Drug_Target_57_Drug_References:
11872149	Russo J, Barnes A, Berger K, Desgrosellier J, Henderson J, Kanters A, Merkov L: 4-(N,N-dipropylamino)benzaldehyde inhibits the oxidation of all-trans retinal to all-trans retinoic acid by ALDH1A1, but not the differentiation of HL-60 promyelocytic leukemia cells exposed to all-trans retinal. BMC Pharmacol. 2002;2:4. Epub 2002 Feb 12.
16583981	Wroczynski P, Nowak M, Wierzchowski J, Szubert A, Polanski J: Activities of cytosolic aldehyde dehydrogenase isozymes in colon cancer: determination using selective, fluorimetric assays. Acta Pol Pharm. 2005 Nov-Dec;62(6):427-33.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_57_Essentiality:
Non-Essential

# Drug_Target_57_GenAtlas_ID:
ALDH1A1

# Drug_Target_57_GenBank_ID_Gene:
M31994

# Drug_Target_57_GenBank_ID_Protein:
178372

# Drug_Target_57_GeneCard_ID:
ALDH1A1

# Drug_Target_57_Gene_Name:
ALDH1A1

# Drug_Target_57_Gene_Sequence:
>1506 bp
ATGTCATCCTCAGGCACGCCAGACTTACCTGTCCTACTCACCGATTTGAAGATTCAATAT
ACTAAGATCTTCATAAACAATGAATGGCATGATTCAGTGAGTGGCAAGAAATTTCCTGTC
TTTAATCCTGCAACTGAGGAGGAGCTCTGCCAGGTAGAAGAAGGAGATAAGGAGGATGTT
GACAAGGCAGTGAAGGCCGCAAGACAGGCTTTTCAGATTGGATCTCCGTGGCGTACTATG
GATGCTTCCGAGAGGGGGCGACTATTATACAAGTTGGCTGATTTAATCGAAAGAGATCGT
CTGCTGCTGGCGACAATGGAGTCAATGAATGGTGGAAAACTCTATTCCAATGCATATCTG
AATGATTTAGCAGGCTGCATCAAAACATTGCGCTACTGTGCAGGTTGGGCTGACAAGATC
CAGGGCCGTACAATACCAATTGATGGAAATTTTTTTACATATACAAGACATGAACCTATT
GGTGTATGTGGCCAAATCATTCCTTGGAATTTCCCGTTGGTTATGCTCATTTGGAAGATA
GGGCCTGCACTGAGCTGTGGAAACACAGTGGTTGTCAAACCAGCAGAGCAAACTCCTCTC
ACTGCTCTCCACGTGGCATCTTTAATAAAAGAGGCAGGGTTTCCTCCTGGAGTAGTGAAT
ATTGTTCCTGGTTATGGGCCTACAGCAGGGGCAGCCATTTCTTCTCACATGGATATAGAC
AAAGTAGCCTTCACAGGATCAACAGAGGTTGGCAAGTTGATCAAAGAAGCTGCCGGGAAA
AGCAATCTGAAGAGGGTGACCCTGGAGCTTGGAGGAAAGAGCCCTTGCATTGTGTTAGCT
GATGCCGACTTGGACAATGCTGTTGAATTTGCACACCATGGGGTATTCTACCACCAGGGC
CAGTGTTGTATAGCCGCATCCAGGATTTTTGTGGAAGAATCAATTTATGATGAGTTTGTT
CGAAGGAGTGTTGAGCGGGCTAAGAAGTATATCCTTGGAAATCCTCTGACCCCAGGAGTC
ACTCAAGGCCCTCAGATTGACAAGGAACAATATGATAAAATACTTGACCTCATTGAGAGT
GGGAAGAAAGAAGGGGCCAAACTGGAATGTGGAGGAGGCCCGTGGGGGAATAAAGGCTAC
TTTGTCCAGCCCACAGTGTTCTCTAATGTTACAGATGAGATGCGCATTGCCAAAGAGGAG
ATTTTTGGACCAGTGCAGCAAATCATGAAGTTTAAATCTTTAGATGACGTGATCAAAAGA
GCAAACAATACTTTCTATGGCTTATCAGCAGGAGTGTTTACCAAAGACATTGATAAAGCC
ATAACAATCTCCTCTGCTCTGCAGGCAGGAACAGTGTGGGTGAATTGCTATGGCGTGGTA
AGTGCCCAGTGCCCCTTTGGTGGATTCAAGATGTCTGGAAATGGAAGAGAACTGGGAGAG
TACGGTTTCCATGAATATACAGAGGTCAAAACAGTCACAGTGAAAATCTCTCAGAAGAAC
TCATAA

# Drug_Target_57_General_Function:
Energy production and conversion

# Drug_Target_57_General_References:
2591967	Hsu LC, Chang WC, Yoshida A: Genomic structure of the human cytosolic aldehyde dehydrogenase gene. Genomics. 1989 Nov;5(4):857-65.
2776714	Agarwal DP, Cohn P, Goedde HW, Hempel J: Aldehyde dehydrogenase from human erythrocytes: structural relationship to the liver cytosolic isozyme. Enzyme. 1989;42(1):47-52.
2987944	Hsu LC, Tani K, Fujiyoshi T, Kurachi K, Yoshida A: Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3771-5.
3676276	Abriola DP, Fields R, Stein S, MacKerell AD Jr, Pietruszko R: Active site of human liver aldehyde dehydrogenase. Biochemistry. 1987 Sep 8;26(18):5679-84.
4015823	Yoshida A, Ikawa M, Hsu LC, Tani K: Molecular abnormality and cDNA cloning of human aldehyde dehydrogenases. Alcohol. 1985 Jan-Feb;2(1):103-6.
6723659	Hempel J, von Bahr-Lindstrom H, Jornvall H: Aldehyde dehydrogenase from human liver. Primary structure of the cytoplasmic isoenzyme. Eur J Biochem. 1984 May 15;141(1):21-35.
8214422	Zheng CF, Wang TT, Weiner H: Cloning and expression of the full-length cDNAS encoding human liver class 1 and class 2 aldehyde dehydrogenase. Alcohol Clin Exp Res. 1993 Aug;17(4):828-31.
8493914	Yoshida A, Hsu LC, Yanagawa Y: Biological role of human cytosolic aldehyde dehydrogenase 1: hormonal response, retinal oxidation and implication in testicular feminization. Adv Exp Med Biol. 1993;328:37-44.

# Drug_Target_57_HGNC_ID:
HGNC:402

# Drug_Target_57_HPRD_ID:
00001

# Drug_Target_57_ID:
611

# Drug_Target_57_Locus:
9q21.13

# Drug_Target_57_Molecular_Weight:
54731

# Drug_Target_57_Name:
Retinal dehydrogenase 1

# Drug_Target_57_Number_of_Residues:
500

# Drug_Target_57_PDB_ID:
1BXS

# Drug_Target_57_Pathway:
Cyclophosphamide Pathway	SMP00447
Ifosfamide Pathway	SMP00448

# Drug_Target_57_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_57_Protein_Sequence:
>Retinal dehydrogenase 1
SSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVD
KAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLN
DLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIG
PALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDK
VAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQ
CCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESG
KKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRA
NNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEY
GFHEYTEVKTVTVKISQKNS

# Drug_Target_57_Reaction:
retinal + NAD+ + H2O = retinoate + NADH + 2 H+

# Drug_Target_57_Signals:
None

# Drug_Target_57_Specific_Function:
Binds free retinal and cellular retinol-binding protein- bound retinal. Can convert/oxidize retinaldehyde to retinoic acid

# Drug_Target_57_SwissProt_ID:
P00352

# Drug_Target_57_SwissProt_Name:
AL1A1_HUMAN

# Drug_Target_57_Synonyms:
ALDH-E1
ALHDII
Aldehyde dehydrogenase family 1 member A1
Aldehyde dehydrogenase, cytosolic
EC 1.2.1.36
RALDH 1
RalDH1

# Drug_Target_57_Theoretical_pI:
6.71

# Drug_Target_57_Transmembrane_Regions:
None

# Drug_Target_58_Cellular_Location:
Cytoplasm

# Drug_Target_58_Chromosome_Location:
Not Available

# Drug_Target_58_Drug_References:
12492483	Graciet E, Lebreton S, Camadro JM, Gontero B: Characterization of native and recombinant A4 glyceraldehyde 3-phosphate dehydrogenase. Kinetic evidence for confromation changes upon association with the small protein CP12. Eur J Biochem. 2003 Jan;270(1):129-36.
15488735	Maeda K, Nagata H, Nonaka A, Kataoka K, Tanaka M, Shizukuishi S: Oral streptococcal glyceraldehyde-3-phosphate dehydrogenase mediates interaction with Porphyromonas gingivalis fimbriae. Microbes Infect. 2004 Nov;6(13):1163-70.
16239728	Ismail SA, Park HW: Structural analysis of human liver glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr. 2005 Nov;61(Pt 11):1508-13. Epub 2005 Oct 19.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_58_Essentiality:
Non-Essential

# Drug_Target_58_GenAtlas_ID:
GAPDHS

# Drug_Target_58_GenBank_ID_Gene:
AJ005371

# Drug_Target_58_GenBank_ID_Protein:
3046742

# Drug_Target_58_GeneCard_ID:
GAPDHS

# Drug_Target_58_Gene_Name:
GAPDHS

# Drug_Target_58_Gene_Sequence:
>1227 bp
ATGTCGAAGCGCGACATCGTCCTCACCAATGTCACCGTTGTCCAGTTGCTGCGACAGCCG
TGCCCGGTGACCAGAGCACCGCCCCCACCTGAGCCTAAGGCTGAAGTAGAGCCCCAGCCA
CAACCAGAGCCCACACCAGTCAGGGAGGAAATAAAGCCACCACCGCCACCACTGCCTCCT
CACCCCGCTACTCCTCCTCCTAAGATGGTGTCTGTGGCCCGGGAGCTGACTGTGGGCATC
AATGGATTTGGACGCATCGGTCGCCTGGTCCTGCGCGCCTGCATGGAGAAGGGTGTTAAG
GTGGTGGCTGTGAATGATCCATTCATTGACCCGGAATACATGGTGTACATGTTTAAGTAT
GACTCCACCCACGGCCGATACAAGGGAAGTGTGGAATTCAGGAATGGACAACTGGTCGTG
GACAACCATGAGATCTCTGTCTACCAGTGCAAAGAGCCCAAACAGATCCCCTGGAGGGCT
GTCGGGAGCCCCTACGTGGTGGAGTCCACAGGCGTGTACCTCTCCATACAGGCAGCTTCG
GACCACATCTCTGCAGGTGCTCAACGTGTGGTCATCTCCGCGCCCTCACCGGATGCACCA
ATGTTCGTCATGGGTGTCAATGAAAATGACTATAACCCTGGCTCCATGAACATTGTGAGC
AACGCGTCCTGCACCACCAACTGTTTGGCTCCCCTCGCCAAAGTCATCCACGAGCGATTT
GGGATCGTGGAAGGGTTGATGACCACAGTCCATTCCTACACGGCCACCCAGAAGACAGTG
GACGGGCCATCAAGGAAGGCCTGGCGAGATGGGCGGGGTGCCCACCAGAACATCATCCCA
GCCTCCACTGGGGCTGCGAAAGCTGTGACCAAAGTCATCCCAGAGCTCAAAGGGAAGCTG
ACAGGGATGGCGTTCCGGGTACCAACCCCGGATGTGTCTGTCGTGGACCTGACCTGCCGC
CTCGCCCAGCCTGCCCCCTACTCAGCCATCAAGGAGGCTGTAAAAGCAGCAGCCAAGGGG
CCCATGGCTGGCATCCTTGCCTACACCGAGGATGAGGTCGTCTCTACGGACTTCCTCGGT
GATACCCACTCGTCCATCTTCGATGCTAAGGCCGGCATTGCGCTCAATGACAATTTCGTG
AAGCTCATTTCATGGTACGACAACGAATATGGCTACAGTCACCGGGTGGTCGACCTCCTC
CGCTACATGTTCAGCCGAGACAAGTGA

# Drug_Target_58_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_58_General_References:
10714828	Welch JE, Brown PL, O'Brien DA, Magyar PL, Bunch DO, Mori C, Eddy EM: Human glyceraldehyde 3-phosphate dehydrogenase-2 gene is expressed specifically in spermatogenic cells. J Androl. 2000 Mar-Apr;21(2):328-38.

# Drug_Target_58_HGNC_ID:
HGNC:24864

# Drug_Target_58_HPRD_ID:
13566

# Drug_Target_58_ID:
794

# Drug_Target_58_Locus:
19q13.1

# Drug_Target_58_Molecular_Weight:
44502

# Drug_Target_58_Name:
Glyceraldehyde-3-phosphate dehydrogenase, testis-specific

# Drug_Target_58_Number_of_Residues:
408

# Drug_Target_58_PDB_ID:
Not Available

# Drug_Target_58_Pathway:
Not Available

# Drug_Target_58_Pfam_Domain_Function:
PF00044	Gp_dh_N
PF02800	Gp_dh_C

# Drug_Target_58_Protein_Sequence:
>Glyceraldehyde-3-phosphate dehydrogenase, testis-specific
MSKRDIVLTNVTVVQLLRQPCPVTRAPPPPEPKAEVEPQPQPEPTPVREEIKPPPPPLPP
HPATPPPKMVSVARELTVGINGFGRIGRLVLRACMEKGVKVVAVNDPFIDPEYMVYMFKY
DSTHGRYKGSVEFRNGQLVVDNHEISVYQCKEPKQIPWRAVGSPYVVESTGVYLSIQAAS
DHISAGAQRVVISAPSPDAPMFVMGVNENDYNPGSMNIVSNASCTTNCLAPLAKVIHERF
GIVEGLMTTVHSYTATQKTVDGPSRKAWRDGRGAHQNIIPASTGAAKAVTKVIPELKGKL
TGMAFRVPTPDVSVVDLTCRLAQPAPYSAIKEAVKAAAKGPMAGILAYTEDEVVSTDFLG
DTHSSIFDAKAGIALNDNFVKLISWYDNEYGYSHRVVDLLRYMFSRDK

# Drug_Target_58_Reaction:
D-glyceraldehyde 3-phosphate + phosphate + NAD+ = 3-phospho-D-glyceroyl phosphate + NADH + H+

# Drug_Target_58_Signals:
None

# Drug_Target_58_Specific_Function:
May play an important role in regulating the switch between different pathways for energy production during spermiogenesis and in the spermatozoon. Required for sperm motility and male fertility

# Drug_Target_58_SwissProt_ID:
O14556

# Drug_Target_58_SwissProt_Name:
G3PT_HUMAN

# Drug_Target_58_Synonyms:
EC 1.2.1.12
GAPDH-2
Spermatogenic cell-specific glyceraldehyde 3-phosphate dehydrogenase 2
Spermatogenic glyceraldehyde-3-phosphate dehydrogenase

# Drug_Target_58_Theoretical_pI:
8.34

# Drug_Target_58_Transmembrane_Regions:
None

# Drug_Target_59_Cellular_Location:
Cytoplasm

# Drug_Target_59_Chromosome_Location:
Not Available

# Drug_Target_59_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3129020	Prieto MI, Martin J, Balana-Fouce R, Garrido-Pertierra A: Properties of gamma-aminobutyraldehyde dehydrogenase from Escherichia coli. Biochimie. 1987 Nov-Dec;69(11-12):1161-8.
7584606	Testore G, Colombatto S, Silvagno F, Bedino S: Purification and kinetic characterization of gamma-aminobutyraldehyde dehydrogenase from rat liver. Int J Biochem Cell Biol. 1995 Nov;27(11):1201-10.

# Drug_Target_59_Essentiality:
Non-Essential

# Drug_Target_59_GenAtlas_ID:
ALDH9A1

# Drug_Target_59_GenBank_ID_Gene:
U34252

# Drug_Target_59_GenBank_ID_Protein:
1049219

# Drug_Target_59_GeneCard_ID:
ALDH9A1

# Drug_Target_59_Gene_Name:
ALDH9A1

# Drug_Target_59_Gene_Sequence:
>1482 bp
ATGAGCACTGGCACCTTCGTCGTGTCGCAGCCGCTCAATTACCGCGGCGGGGCCGCTGGA
GCCGGCGGACGCTCCGGTACCGAGAAAGCTTTCGAGCCAGCAACCGGCCGAGTGATAGCT
ACTTTCACATGTTCAGGAGAAAAGGAAGTAAATTTGGCTGTTCAAAATGCAAAGGCTGCT
TTTAAAATATGGAGTCAAAAATCTGGCATGGAGCGTTGCCGAATCCTTTTGGAGGCTGCC
AGGATAATAAGGGAACGGGAGGATGAAATTGCTACTATGGAGTGCATCAACAATGGCAAG
TCCATCTTTGAGGCCCGCTTGGACATTGACATTTCCTGGCAGTGCCTGGAGTATTATGCG
GGCTTGGCTGCATCCATGGCTGGTGAACACATCCAGCTCCCAGGTGGATCGTTTGGTTAT
ACCAGAAGAGAACCACTTGGGGTATGTGTGGGAATAGGAGCATGGAACTACCCCTTTCAG
ATTGCCTCTTGGAAGTCGGCTCCAGCATTAGCCTGTGGTAATGCCATGGTCTTTAAACCT
TCTCCCTTTACACCTGTTTCTGCATTGCTACTGGCTGAAATCTACAGTGAGGCTGGTGTA
CCTCCTGGGCTCTTCAATGTGGTGCAGGGAGGGGCTGCCACAGGCCAGTTTCTGTGTCAG
CATCCCGATGTGGCCAAAGTCTCCTTCACTGGAAGTGTGCCCACTGGCATGAAGATCATG
GAGATGTCAGCTAAAGGAATCAAACCTGTTACCTTGGAACTTGGAGGCAAATCTCCACTC
ATCATCTTCTCAGACTGTGATATGAACAATGCTGTAAAGGGGGCGCTGATGGCCAACTTC
CTCACACAAGGCCAGGTTTGCTGTAATGGCACAAGAGTATTTGTGCAGAAAGAAATTCTT
GATAAATTTACAGAGGAAGTGGTGAAACAGACCCAAAGGATTAAAATTGGAGATCCCCTT
CTGGAAGATACAAGGATGGGTCCACTCATCAACCGACCACACCTGGAGCGAGTCCTTGGG
TTTGTCAAAGTGGCAAAGGAGCAGGGTGCTAAAGTGTTATGTGGTGGAGATATATATGTA
CCTGAAGATCCCAAATTAAAGGATGGATATTACATGAGACCTTGTGTATTAACTAATTGC
AGAGACGACATGACCTGTGTGAAGGAAGAGATCTTTGGGCCTGTTATGTCCATTTTATCA
TTTGACACTGAAGCTGAGGTTCTAGAAAGAGCCAATGATACCACTTTTGGACTAGCAGCT
GGCGTCTTTACCAGGGACATCCAACGGGCTCATAGAGTGGTAGCTGAGCTTCAGGCTGGG
ACGTGCTTCATTAACAACTATAACGTCAGCCCAGTGGAGTTGCCCTTTGGTGGATATAAG
AAGTCAGGATTTGGCAGAGAGAACGGCCGTGTGACAATCGAATATTATTCACAGCTGAAG
ACTGTGTGTGTGGAGATGGGTGATGTGGAATCTGCTTTTTGA

# Drug_Target_59_General_Function:
Energy production and conversion

# Drug_Target_59_General_References:
10702312	Vaz FM, Fouchier SW, Ofman R, Sommer M, Wanders RJ: Molecular and biochemical characterization of rat gamma-trimethylaminobutyraldehyde dehydrogenase and evidence for the involvement of human aldehyde dehydrogenase 9 in carnitine biosynthesis. J Biol Chem. 2000 Mar 10;275(10):7390-4.
2925663	Kurys G, Ambroziak W, Pietruszko R: Human aldehyde dehydrogenase. Purification and characterization of a third isozyme with low Km for gamma-aminobutyraldehyde. J Biol Chem. 1989 Mar 15;264(8):4715-21.
8269919	Kurys G, Shah PC, Kikonygo A, Reed D, Ambroziak W, Pietruszko R: Human aldehyde dehydrogenase. cDNA cloning and primary structure of the enzyme that catalyzes dehydrogenation of 4-aminobutyraldehyde. Eur J Biochem. 1993 Dec 1;218(2):311-20.
8645224	Kikonyogo A, Pietruszko R: Aldehyde dehydrogenase from adult human brain that dehydrogenates gamma-aminobutyraldehyde: purification, characterization, cloning and distribution. Biochem J. 1996 May 15;316 ( Pt 1):317-24.
8786138	Lin SW, Chen JC, Hsu LC, Hsieh CL, Yoshida A: Human gamma-aminobutyraldehyde dehydrogenase (ALDH9): cDNA sequence, genomic organization, polymorphism, chromosomal localization, and tissue expression. Genomics. 1996 Jun 15;34(3):376-80.

# Drug_Target_59_HGNC_ID:
HGNC:412

# Drug_Target_59_HPRD_ID:
04109

# Drug_Target_59_ID:
316

# Drug_Target_59_Locus:
1q23.1

# Drug_Target_59_Molecular_Weight:
53802

# Drug_Target_59_Name:
4-trimethylaminobutyraldehyde dehydrogenase

# Drug_Target_59_Number_of_Residues:
494

# Drug_Target_59_PDB_ID:
Not Available

# Drug_Target_59_Pathway:
Not Available

# Drug_Target_59_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_59_Protein_Sequence:
>4-trimethylaminobutyraldehyde dehydrogenase
MSTGTFVVSQPLNYRGGARVEPADASGTEKAFEPATGRVIATFTCSGEKEVNLAVQNAKA
AFKIWSQKSGMERCRILLEAARIIREREDEIATMECINNGKSIFEARLDIDISWQCLEYY
AGLAASMAGEHIQLPGGSFGYTRREPLGVCVGIGAWNYPFQIASWKSAPALACGNAMVFK
PSPFTPVSALLLAEIYSEAGVPPGLFNVVQGGAATGQFLCQHPDVAKVSFTGSVPTGMKI
MEMSAKGIKPVTLELGGKSPLIIFSDCDMNNAVKGALMANFLTQGQVCCNGTRVFVQKEI
LDKFTEEVVKQTQRIKIGDPLLEDTRMGPLINRPHLERVLGFVKVAKEQGAKVLCGGDIY
VPEDPKLKDGYYMRPCVLTNCRDDMTCVKEEIFGPVMSILSFDTEAEVLERANDTTFGLA
AGVFTRDIQRAHRVVAELQAGTCFINNYNVSPVELPFGGYKKSGFGRENGRVTIEYYSQL
KTVCVEMGDVESAF

# Drug_Target_59_Reaction:
an aldehyde + NAD+ + H2O = an acid + NADH + H+

# Drug_Target_59_Signals:
None

# Drug_Target_59_Specific_Function:
Converts gamma-trimethylaminobutyraldehyde into gamma- butyrobetaine. Catalyzes the irreversible oxidation of a broad range of aldehydes to the corresponding acids in an NAD-dependent reaction

# Drug_Target_59_SwissProt_ID:
P49189

# Drug_Target_59_SwissProt_Name:
AL9A1_HUMAN

# Drug_Target_59_Synonyms:
Aldehyde dehydrogenase 9A1
Aldehyde dehydrogenase E3 isozyme
EC 1.2.1.19
EC 1.2.1.3
EC 1.2.1.47
Gamma-aminobutyraldehyde dehydrogenase
R- aminobutyraldehyde dehydrogenase
TMABADH

# Drug_Target_59_Theoretical_pI:
5.61

# Drug_Target_59_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
12604203	Plapp BV, Berst KB: Specificity of human alcohol dehydrogenase 1C*2 (gamma2gamma2) for steroids and simulation of the uncompetitive inhibition of ethanol metabolism. Chem Biol Interact. 2003 Feb 1;143-144:183-93.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
ADH1C

# Drug_Target_5_GenBank_ID_Gene:
X04299

# Drug_Target_5_GenBank_ID_Protein:
28404

# Drug_Target_5_GeneCard_ID:
ADH1C

# Drug_Target_5_Gene_Name:
ADH1C

# Drug_Target_5_Gene_Sequence:
>1128 bp
ATGAGCACAGCAGGAAAAGTAATCAAATGCAAAGCAGCTGTGCTATGGGAGTTAAAGAAA
CCCTTTTCCATTGAGGAGGTAGAGGTTGCACCTCCTAAGGCTCATGAAGTTCGCATTAAG
ATGGTGGCTGCAGGAATCTGTCGTTCAGATGAGCATGTGGTTAGTGGCAACCTGGTGACC
CCCCTTCCTGTGATTTTAGGCCATGAGGCAGCCGGCATCGTGGAAAGTGTTGGAGAAGGG
GTGACTACAGTCAAACCAGGTGATAAAGTCATCCCGCTCTTTACTCCTCAGTGTGGAAAA
TGCAGAATTTGCAAAAACCCAGAAAGCAACTACTGCTTGAAAAATGATCTAGGCAATCCT
CGGGGGACCCTGCAGGATGGCACCAGGAGGTTCACCTGCAGCGGGAAGCCCATCCACCAC
TTCGTCGGCGTCAGCACCTTCTCCCAGTACACAGTGGTGGATGAGAATGCAGTAGCCAAA
ATTGATGCAGCCTCGCCCCTGGAGAAAGTCTGCCTCATTGGCTGTGGATTTTCGACTGGT
TATGGGTCTGCAGTCAAAGTTGCCAAGGTCACCCCAGGGTCTACCTGTGCTGTGTTTGGC
CTGGGAGGGGTCGGCCTATCTGTTGTTATGGGCTGTAAAGCAGCTGGAGCAGCCAGAATC
ATTGCTGTGGACATCAACAAGGACAAATTTGCAAAGGCTAAAGAGTTGGGTGCCACTGAA
TGCATCAACCCTCAAGACTACAAGAAACCCATTCAGGAAGTGCTAAAGGAAATGACTGAT
GGAGGTGTGGATTTTTCGTTTGAAGTCATCGGTCAGCTTGACACCATGATGGCTTCCCTG
TTATGTTGTCATGAGGCATGTGGCACAAGTGTCATTGTAGGGGTACCTCCTGATTCCCAG
AACCTCTCAATAAACCCTATGCTGCTACTGACTGGACGCACGTGGAAAGGAGCTATTTTT
GGAGGCTTTAAGAGTAAAGAATCTGTCCCCAAACTTGTGGCTGACTTTATGGCTAAGAAG
TTTTCACTGGATGCATTAATAACAAATGTTTTACCTTTTGAAAAAATAAATGAAGGATTT
GACCTGCTTCGCTCTGGAAAGAGTATCCGTACCGTCCTGACGTTTTGA

# Drug_Target_5_General_Function:
Energy production and conversion

# Drug_Target_5_General_References:
1524834	Yokoyama S, Matsuo Y, Rajasekharan S, Yokoyama R: Molecular structure of the human alcohol dehydrogenase 3 gene. Jpn J Genet. 1992 Apr;67(2):167-71.
2935875	Ikuta T, Szeto S, Yoshida A: Three human alcohol dehydrogenase subunits: cDNA structure and molecular and evolutionary divergence. Proc Natl Acad Sci U S A. 1986 Feb;83(3):634-8.
3758060	Hoog JO, Heden LO, Larsson K, Jornvall H, von Bahr-Lindstrom H: The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase. cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties. Eur J Biochem. 1986 Sep 1;159(2):215-8.
6391921	Buhler R, Hempel J, Kaiser R, de Zalenski C, von Wartburg JP, Jornvall H: Human liver alcohol dehydrogenase. 2. The primary structure of the gamma 1 protein chain. Eur J Biochem. 1984 Dec 17;145(3):447-53.

# Drug_Target_5_HGNC_ID:
HGNC:251

# Drug_Target_5_HPRD_ID:
00066

# Drug_Target_5_ID:
517

# Drug_Target_5_Locus:
4q21-q23

# Drug_Target_5_Molecular_Weight:
39737

# Drug_Target_5_Name:
Alcohol dehydrogenase 1C

# Drug_Target_5_Number_of_Residues:
374

# Drug_Target_5_PDB_ID:
1HT0

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_5_Protein_Sequence:
>Alcohol dehydrogenase 1C
STAGKVIKCKAAVLWELKKPFSIEEVEVAPPKAHEVRIKMVAAGICRSDEHVVSGNLVTP
LPVILGHEAAGIVESVGEGVTTVKPGDKVIPLFTPQCGKCRICKNPESNYCLKNDLGNPR
GTLQDGTRRFTCSGKPIHHFVGVSTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGY
GSAVKVAKVTPGSTCAVFGLGGVGLSVVMGCKAAGAARIIAVDINKDKFAKAKELGATEC
INPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPDSQN
LSINPMLLLTGRTWKGAIFGGFKSKESVPKLVADFMAKKFSLDALITNILPFEKINEGFD
LLRSGKSIRTVLTF

# Drug_Target_5_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
P00326

# Drug_Target_5_SwissProt_Name:
ADH1G_HUMAN

# Drug_Target_5_Synonyms:
Alcohol dehydrogenase gamma subunit
EC 1.1.1.1

# Drug_Target_5_Theoretical_pI:
8.38

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_60_Cellular_Location:
Cytoplasm

# Drug_Target_60_Chromosome_Location:
Not Available

# Drug_Target_60_Drug_References:
16241904	Graham CE, Brocklehurst K, Pickersgill RW, Warren MJ: Characterization of retinaldehyde dehydrogenase 3. Biochem J. 2006 Feb 15;394(Pt 1):67-75.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_60_Essentiality:
Non-Essential

# Drug_Target_60_GenAtlas_ID:
ALDH1A3

# Drug_Target_60_GenBank_ID_Gene:
U07919

# Drug_Target_60_GenBank_ID_Protein:
544482

# Drug_Target_60_GeneCard_ID:
ALDH1A3

# Drug_Target_60_Gene_Name:
ALDH1A3

# Drug_Target_60_Gene_Sequence:
>1539 bp
ATGGCCACCGCTAACGGGGCCGTGGAAAACGGGCAGCCGGACGGGAAGCCGCCGGCCCTG
CCGCGCCCCATCCGCAACCTGGAGGTCAAGTTCACCAAGATATTTATCAACAATGAATGG
CACGAATCCAAGAGTGGGAAAAAGTTTGCTACATGTAACCCTTCAACTCGGGAGCAAATA
TGTGAAGTGGAAGAAGGAGATAAGCCCGACGTGGACAAGGCTGTGGAGGCTGCACAGGTT
GCCTTCCAGAGGGGCTCGCCATGGCGCCGGCTGGATGCCCTGAGTCGTGGGCGGCTGCTG
CACCAGCTGGCTGACCTGGTGGAGAGGGACCGCGCCACCTTGGCCGCCCTGGAGACGATG
GATACAGGGAAGCCATTTCTTCATGCTTTTTTCATCGACCTGGAGGGCTGTATTAGAACC
CTCAGATACTTTGCAGGGTGGGCAGACAAAATCCAGGGCAAGACCATCCCCACAGATGAC
AACGTCGTATGCTTCACCAGGCATGAGCCCATTGGTGTCTGTGGGGCCATCACTCCATGG
AACTTCCCCCTGCTGATGCTGGTGTGGAAGCTGGCACCCGCCCTCTGCTGTGGGAACACC
ATGGTCCTGAAGCCTGCGGAGCAGACACCTCTCACCGCCCTTTATCTCGGCTCTCTGATC
AAAGAGGCCGGGTTCCCTCCAGGAGTGGTGAACATTGTGCCAGGATTCGGGCCCACAGTG
GGAGCAGCAATTTCTTCTCACCCTCAGATCAACAAGATCGCCTTCACCGGCTCCACAGAG
GTTGGAAAACTGGTTAAAGAAGCTGCGTCCCGGAGCAATCTGAAGCGGGTGACGCTGGAG
CTGGGGGGGAAGAACCCCTGCATCGTGTGTGCGGACGCTGACTTGGACTTGGCAGTGGAG
TGTGCCCATCAGGGAGTGTTCTTCAACCAAGGCCAGTGTTGCACGGCAGCCTCCAGGGTG
TTCGTGGAGGAGCAGGTCTACTCTGAGTTTGTCAGGCGGAGCGTGGAGTATGCCAAGAAA
CGGCCCGTGGGAGACCCCTTCGATGTCAAAACAGAACAGGGGCCTCAGATTGATCAAAAG
CAGTTCGACAAAATCTTAGAGCTGATCGAGAGTGGGAAGAAGGAAGGGGCCAAGCTGGAA
TGCGGGGGCTCAGCCATGGAAGACAAGGGGCTCTTCATCAAACCCACTGTCTTCTCAGAA
GTCACAGACAACATGCGGATTGCCAAAGAGGAGATTTTCGGGCCAGTGCAACCAATACTG
AAGTTCAAAAGTATCGAAGAAGTGATAAAAAGAGCGAATAGCACCGACTATGGACTCACA
GCAGCCGTGTTCACAAAAAATCTCGACAAAGCCCTGAAGTTGGCTTCTGCCTTAGAGTCT
GGAACGGTCTGGATCAACTGCTACAACGCCCTCTATGCACAGGCTCCATTTGGTGGCTTT
AAAATGTCAGGAAATGGCAGAGAACTAGGTGAATACGCTTTGGCCGAATACACAGAAGTG
AAAACTGTCACCATCAAACTTGGCGACAAGAACCCCTGA

# Drug_Target_60_General_Function:
Energy production and conversion

# Drug_Target_60_General_References:
7698756	Hsu LC, Chang WC, Hiraoka L, Hsieh CL: Molecular cloning, genomic organization, and chromosomal localization of an additional human aldehyde dehydrogenase gene, ALDH6. Genomics. 1994 Nov 15;24(2):333-41.

# Drug_Target_60_HGNC_ID:
HGNC:409

# Drug_Target_60_HPRD_ID:
02713

# Drug_Target_60_ID:
640

# Drug_Target_60_Locus:
15q26.3

# Drug_Target_60_Molecular_Weight:
56109

# Drug_Target_60_Name:
Aldehyde dehydrogenase 1A3

# Drug_Target_60_Number_of_Residues:
512

# Drug_Target_60_PDB_ID:
Not Available

# Drug_Target_60_Pathway:
Not Available

# Drug_Target_60_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_60_Protein_Sequence:
>Aldehyde dehydrogenase 1A3
MATANGAVENGQPDRKPPALPRPIRNLEVKFTKIFINNEWHESKSGKKFATCNPSTREQI
CEVEEGDKPDVDKAVEAAQVAFQRGSPWRRLDALSRGRLLHQLADLVERDRATLAALETM
DTGKPFLHAFFIDLEGCIRTLRYFAGWADKIQGKTIPTDDNVVCFTRHEPIGVCGAITPW
NFPLLMLVWKLAPALCCGNTMVLKPAEQTPLTALYLGSLIKEAGFPPGVVNIVPGFGPTV
GAAISSHPQINKIAFTGSTEVGKLVKEAASRSNLKRVTLELGGKNPCIVCADADLDLAVE
CAHQGVFFNQGQCCTAASRVFVEEQVYSEFVRRSVEYAKKRPVGDPFDVKTEQGPQIDQK
QFDKILELIESGKKEGAKLECGGSAMEDKGLFIKPTVFSEVTDNMRIAKEEIFGPVQPIL
KFKSIEEVIKRANSTDYGLTAAVFTKNLDKALKLASALESGTVWINCYNALYAQAPFGGF
KMSGNGRELGEYALAEYTEVKTVTIKLGDKNP

# Drug_Target_60_Reaction:
an aldehyde + NAD(P)+ + H2O = an acid + NAD(P)H + H+

# Drug_Target_60_Signals:
None

# Drug_Target_60_Specific_Function:
Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Seems to be the key enzyme in the formation of an RA gradient along the dorso-ventral axis during the early eye development and also in the development of the olfactory system

# Drug_Target_60_SwissProt_ID:
P47895

# Drug_Target_60_SwissProt_Name:
AL1A3_HUMAN

# Drug_Target_60_Synonyms:
Aldehyde dehydrogenase 6
EC 1.2.1.5
RALDH-3
Retinaldehyde dehydrogenase 3

# Drug_Target_60_Theoretical_pI:
7.29

# Drug_Target_60_Transmembrane_Regions:
None

# Drug_Target_61_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_61_Chromosome_Location:
Not Available

# Drug_Target_61_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_61_Essentiality:
Non-Essential

# Drug_Target_61_GenAtlas_ID:
ALDH1B1

# Drug_Target_61_GenBank_ID_Gene:
M63967

# Drug_Target_61_GenBank_ID_Protein:
1263008

# Drug_Target_61_GeneCard_ID:
ALDH1B1

# Drug_Target_61_Gene_Name:
ALDH1B1

# Drug_Target_61_Gene_Sequence:
>1554 bp
ATGCTGCGCTTCCTGGCACCCCGGCTGCTTAGCCTCCAGGGCAGGACCGCCCTCTACTCC
TCGGCAGCAGCCCTCCCAAGCCCCATTCTGAACCCAGACATCCCCTACAACCAGCTGTTC
ATCAACAATGAATGGCAAGATGCAGTCAGCAAGAAGACCTTCCCGACGGTCAACCCTACC
ACCGGGGAGGTCATCGGGCACGTGGCTGAAGGTGACCGGGCTGATGTGGATCGGGCCGTG
AAAGCAGCCCGGGAAGCCTTCCGCCTGGGGTCCCCATGGCGCCGGATGGATGCCTCTGAG
CGGGGCCGGCTGCTGAACCTCCTGGCAGACCTAGTGGAGCGGGATCGAGTCTACTTGGCC
TCACTCGAGACCTTGGACAATGGGAAGCCTTTCCAAGAGTCTTACGCCTTGGACTTGGAT
GAGGTCATCAAGGTGTATCGGTACTTTGCTGGCTGGGCTGACAAGTGGCATGGCAAGACC
ATCCCCATGCATGGCCAGCATTTCTGCTTCACCCGGCATGAGCCCGTTGGTGTCTGTGGC
CAGATCATCCCGTGGAACTTCCCCTTGGTCATGCAGGGTTGGAAACTTGCCCCGGCACTC
GCCACAGGCAACACTGTGGTTATGAAGGTGGCAGAGCAGACCCCCCTCTCTGCCCTGTAT
TTGGCCTCCCTCATCAAGGAGGCAGGCTTTCCCCCTGGGGTGGTGAACATCATCACGGGG
TATGGCCCAACAGCAGGTGCGGCCATCGCCCAGCACATGGATGTTGACAAAGTTGCCTTC
ACCGGTTCCACCGAGGTGGGCCACCTGATCCAGAAAGCAGCTGGCGATTCCAACCTCAAG
AGAGTCACCCTGGAGCTGGGTGGTAAGAGCCCCAGCATCGTGCTGGCCGATGCTGACATG
GAGCATGCCGTGGAGCAGTGCCACGAAGCCCTGTTCTTCAACATGGGCCAGTGCTGCTGT
GCTGGCTCCCGGACCTTCGTGGAAGAATCCATCTACAATGAGTTTCTCGAGAGAACCGTG
GAGAAAGCAAAGCAGAGGAAAGTGGGGAACCCCTTTGAGCTGGACACCCAGCAGGGGCCT
CAGGTGGACAAGGAGCAGTTTGAACGAGTCCTAGGCTACATCCAGCTTGGCCAGAAGGAG
GGCGCAAAACTCCTCTGTGGCGGAGAGCGTTTCGGGGAGCGTGGTTTCTTCATCAAGCCT
ACTGTCTTTGGTGGCGTGCAGGATGACATGAGAATTGCCAAAGAGGAGATCTTTGGGCCT
GTGCAGCCCCTGTTCAAGTTCAAGAAGATTGAGGAGGTGGTTGAGAGGGCCAACAACACC
AGGTATGGCCTGGCTGCGGCTGTGTTCACCCGGGATCTGGACAAGGCCATGTACTTCACC
CAGGCACTCCAGGCCGGGACCGTGTGGGTAAACACCTACAACATCGTCACCTGCCACACG
CCATTTGGAGGGTTTAAGGAATCTGGAAACGGGAGGGAGCTGGGTGAGGATGGGCTTAAG
GCCTACACAGAGGTAAAGACGGTCACCATCAAGGTTCCTCAGAAGAACTCGTAA

# Drug_Target_61_General_Function:
Energy production and conversion

# Drug_Target_61_General_References:
2061311	Hsu LC, Chang WC: Cloning and characterization of a new functional human aldehyde dehydrogenase gene. J Biol Chem. 1991 Jul 5;266(19):12257-65.
8244338	Sherman D, Dave V, Hsu LC, Peters TJ, Yoshida A: Diverse polymorphism within a short coding region of the human aldehyde dehydrogenase-5 (ALDH5) gene. Hum Genet. 1993 Nov;92(5):477-80.

# Drug_Target_61_HGNC_ID:
HGNC:407

# Drug_Target_61_HPRD_ID:
00005

# Drug_Target_61_ID:
531

# Drug_Target_61_Locus:
9p11.1

# Drug_Target_61_Molecular_Weight:
57218

# Drug_Target_61_Name:
Aldehyde dehydrogenase X, mitochondrial

# Drug_Target_61_Number_of_Residues:
517

# Drug_Target_61_PDB_ID:
Not Available

# Drug_Target_61_Pathway:
Disulfiram Pathway	SMP00429

# Drug_Target_61_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_61_Protein_Sequence:
>Aldehyde dehydrogenase X, mitochondrial precursor
MLRFLAPRLLSLQGRTALYSSAAALPSPILNPDIPYNQLFINNEWQDAVSKKTFPTVNPT
TGEVIGHVAEGDRADVDRAVKAAREAFRLGSPWRRMDASERGRLLNLLADLVERDRVYLA
SLETLDNGKPFQESYALDLDEVIKVYRYFAGWADKWHGKTIPMHGQHFCFTRHEPVGVCG
QIIPWNFPLVMQGWKLAPALATGNTVVMKVAEQTPLSALYLASLIKEAGFPPGVVNIITG
YGPTAGAAIAQHMDVDKVAFTGSTEVGHLIQKAAGDSNLKRVTLELGGKSPSIVLADADM
EHAVEQCHEALFFNMGQCCCAGSRTFVEESIYNEFLERTVEKAKQRKVGNPFELDTQQGP
QVDKEQFERVLGYIQLGQKEGAKLLCGGERFGERGFFIKPTVFGGVQDDMRIAKEEIFGP
VQPLFKFKKIEEVVERANNTRYGLAAAVFTRDLDKAMYFTQALQAGTVWVNTYNIVTCHT
PFGGFKESGNGRELGEDGLKAYTEVKTVTIKVPQKNS

# Drug_Target_61_Reaction:
an aldehyde + NAD+ + H2O = an acid + NADH + H+

# Drug_Target_61_Signals:
None

# Drug_Target_61_Specific_Function:
ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation

# Drug_Target_61_SwissProt_ID:
P30837

# Drug_Target_61_SwissProt_Name:
AL1B1_HUMAN

# Drug_Target_61_Synonyms:
ALDH class 2
Aldehyde dehydrogenase X, mitochondrial precursor
Aldehyde dehydrogenase family 1 member B1
EC 1.2.1.3

# Drug_Target_61_Theoretical_pI:
6.85

# Drug_Target_61_Transmembrane_Regions:
None

# Drug_Target_62_Cellular_Location:
Not Available

# Drug_Target_62_Chromosome_Location:
Not Available

# Drug_Target_62_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_62_Essentiality:
Non-Essential

# Drug_Target_62_GenAtlas_ID:
ALDH3B1

# Drug_Target_62_GenBank_ID_Gene:
U10868

# Drug_Target_62_GenBank_ID_Protein:
601780

# Drug_Target_62_GeneCard_ID:
ALDH3B1

# Drug_Target_62_Gene_Name:
ALDH3B1

# Drug_Target_62_Gene_Sequence:
>1407 bp
ATGGACCCCCTTGGGGACACGCTGCGGCGACTGCGGGAGGCCTTCCACGCGGGGCGCACG
CGGCCAGCTGAGTTCCGGGCTGCGCAGCTCCAAGGCCTGGGCCGCTTCCTGCAAGAAAAC
AAGCAGCTTCTGCACGACGCACTGGCCCAGGACCTGCACAAGTCAGCCTTCGAGTCGGAG
GTGTCTGAGGTTGCCATCAGCCAGGGCGAGGTCACCCTGGCCCTCAGGAACCTCCGGGCC
TGGATGAAGGACGAGCGTGTGCCCAAGAACCTGGCCACGCAGCTGGACTCCGCCTTCATC
CGGAAGGAGCCCTTTGGCCTGGTCCTCATCATTGCGCCCTGGAACTATCCGCTGAACCTG
ACGCTGGTGCCCCTCGTGGGAGCCCTCGCTGCAGGGAACTGTGTGGTGCTGAAGCCATCG
GAGATTAGCAAGAACGTCGAGAAGATCCTGGCCGAGGTGCTGCCCCAATACGTGGACCAG
AGCTGCTTTGCTGTGGTGCTGGGCGGGCCCCAGGAGACGGGGCAGCTGCTAGAGCACAGG
TTCGACTACATCTTCTTCACAGGGAGCCCTCGTGTGGGCAAGATTGTTATGACTGCTGCC
GCCAAGCACCTGACACCTGTCACCCTGGAGCTGGGGGGCAAGAACCCTTGCTACGTGGAC
GACAACTGCGACCCCCAGACCGTGGCCAACCGCGTGGCCTGGTTCCGCTACTTCAACGCC
GGCCAGACCTGCGTGGCCCCCGACTACGTCCTATGCAGCCCTGAGATGCAGGAGAGGCTG
CTGCCTGCCCTGCAGAGCACCATCACCCGTTTCTATGGCGACGACCCCCAGAGCTCCCCA
AACCTGGGCCGCATCATCAACCAGAAACAGTTCCAGCGGCTGCGGGCATTGCTGGGCTGC
GGCCGTGTGGCCATTGGGGGCCAGAGCGATGAGAGCGATCGCTACATCGCCCCCACGGTG
CTGGTGGATGTGCAGGAGATGGAGCCTGTGATGCAGGAGGAGATCTTCGGGCCCATCCTG
CCCATCGTGAACGTGCAGAGCTTGGACGAGGCCATCGAGTTCATCAACCGGCGGGAGAAG
CCCCTGGCCCTGTACGCCTTCTCCAACAGCAGCCAGGTGGTCAAGCGGGTGCTGACCCAG
ACCAGCAGCGGGGGCTTCTGTGGGAACGACGGCTTCATGCACATGACCCTGGCCAGCCTG
CCTTTTGGAGGAGTGGGTGCCAGTGGGATGGGCCGGTACCATGGCAAGTTCTCCTTCGAC
ACCTTCTCCCACCATCGCGCCTGCCTCCTGCGCAGCCCGGGGATGGAGAAGCTCAACGCC
CTCCGCTACCCGCCGCAATCGCCGCGCCGCCTGAGGATGCTGCTGGTGGCCATGGAGGCC
CAAGGCTGCAGCTGCACACTGCTCTGA

# Drug_Target_62_General_Function:
Energy production and conversion

# Drug_Target_62_General_References:
7828891	Hsu LC, Chang WC, Yoshida A: Cloning of a cDNA encoding human ALDH7, a new member of the aldehyde dehydrogenase family. Gene. 1994 Dec 30;151(1-2):285-9.

# Drug_Target_62_HGNC_ID:
HGNC:410

# Drug_Target_62_HPRD_ID:
02716

# Drug_Target_62_ID:
496

# Drug_Target_62_Locus:
11q13

# Drug_Target_62_Molecular_Weight:
51840

# Drug_Target_62_Name:
Aldehyde dehydrogenase 3B1

# Drug_Target_62_Number_of_Residues:
468

# Drug_Target_62_PDB_ID:
Not Available

# Drug_Target_62_Pathway:
Not Available

# Drug_Target_62_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_62_Protein_Sequence:
>Aldehyde dehydrogenase 3B1
MDPLGDTLRRLREAFHAGRTRPAEFRAAQLQGLGRFLQENKQLLHDALAQDLHKSAFESE
VSEVAISQGEVTLALRNLRAWMKDERVPKNLATQLDSAFIRKEPFGLVLIIAPWNYPLNL
TLVPLVGALAAGNCVVLKPSEISKNVEKILAEVLPQYVDQSCFAVVLGGPQETGQLLEHR
FDYIFFTGSPRVGKIVMTAAAKHLTPVTLELGGKNPCYVDDNCDPQTVANRVAWFRYFNA
GQTCVAPDYVLCSPEMQERLLPALQSTITRFYGDDPQSSPNLGRIINQKQFQRLRALLGC
GRVAIGGQSDESDRYIAPTVLVDVQEMEPVMQEEIFGPILPIVNVQSLDEAIEFINRREK
PLALYAFSNSSQVVKRVLTQTSSGGFCGNDGFMHMTLASLPFGGVGASGMGRYHGKFSFD
TFSHHRACLLRSPGMEKLNALRYPPQSPRRLRMLLVAMEAQGCSCTLL

# Drug_Target_62_Reaction:
an aldehyde + NAD(P)+ + H2O = an acid + NAD(P)H + H+

# Drug_Target_62_Signals:
None

# Drug_Target_62_Specific_Function:
Not Available

# Drug_Target_62_SwissProt_ID:
P43353

# Drug_Target_62_SwissProt_Name:
AL3B1_HUMAN

# Drug_Target_62_Synonyms:
Aldehyde dehydrogenase 7
EC 1.2.1.5

# Drug_Target_62_Theoretical_pI:
7.67

# Drug_Target_62_Transmembrane_Regions:
None

# Drug_Target_63_Cellular_Location:
Cytoplasm

# Drug_Target_63_Chromosome_Location:
Not Available

# Drug_Target_63_Drug_References:
16898590	Markova EV, Zotova NV, Savchenko AA, Titova NM, Slepov EV, Cherdantsev DV, Konovalenko AN: [Lymphocyte metabolism in patients with acute pancreatitis with different genotypes of GSTM1 and GSTT1 genes] Biomed Khim. 2006 May-Jun;52(3):317-26.
17031544	Trost P, Fermani S, Marri L, Zaffagnini M, Falini G, Scagliarini S, Pupillo P, Sparla F: Thioredoxin-dependent regulation of photosynthetic glyceraldehyde-3-phosphate dehydrogenase: autonomous vs. CP12-dependent mechanisms. Photosynth Res. 2006 Sep;89(2-3):263-75. Epub 2006 Sep 22.
17194030	Swearengin TA, Fibuch EE, Seidler NW: Sevoflurane modulates the activity of glyceraldehyde 3-phosphate dehydrogenase. J Enzyme Inhib Med Chem. 2006 Oct;21(5):575-9.
17508915	Ido Y: Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal. 2007 Jul;9(7):931-42.

# Drug_Target_63_Essentiality:
Non-Essential

# Drug_Target_63_GenAtlas_ID:
GAPDH

# Drug_Target_63_GenBank_ID_Gene:
X01677

# Drug_Target_63_GenBank_ID_Protein:
31645

# Drug_Target_63_GeneCard_ID:
GAPDH

# Drug_Target_63_Gene_Name:
GAPDH

# Drug_Target_63_Gene_Sequence:
>1008 bp
ATGGGGAAGGTGAAGGTCGGAGTCAACGGATTTGGTCGTATTGGGCGCCTGGTCACCAGG
GCTGCTTTTAACTCTGGTAAAGTGGATATTGTTGCCATCAATGACCCCTTCATTGACCTC
AACTACATGGTTTACATGTTCCAATATGATTCCACCCATGGCAAATTCCATGGCACCGTC
AAGGCTGAGAACGGGAAGCTTGTCATCAATGGAAATCCCATCACCATCTTCCAGGAGCGA
GATCCCTCCAAAATCAAGTGGGGCGATGCTGGCGCTGAGTACGTCGTGGAGTCCACTGGC
GTCTTCACCACCATGGAGAAGGCTGGGGCTCATTTGCAGGGGGGAGCCAAAAGGGTCATC
ATCTCTGCCCCCTCTGCTGATGCCCCCATGTTCGTCATGGGTGTGAACCATGAGAAGTAT
GACAACAGCCTCAAGATCATCAGCAATGCCTCCTGCACCACCAACTGCTTAGCACCCCTG
GCCAAGGTCATCCATGACAACTTTGGTATCGTGGAAGGACTCATGACCACAGTCCATGCC
ATCACTGCCACCCAGAAGACTGTGGATGGCCCCTCCGGGAAACTGTGGCGTGATGGCCGC
GGGGCTCTCCAGAACATCATCCCTGCCTCTACTGGCGCTGCCAAGGCTGTGGGCAAGGTC
ATCCCTGAGCTAGACGGGAAGCTCACTGGCATGGCCTTCCGTGTCCCCACTGCCAACGTG
TCAGTGGTGGACCTGACCTGCCGTCTAGAAAAACCTGCCAAATATGATGACATCAAGAAG
GTGGTGAAGCAGGCGTCGGAGGGCCCCCTCAAAGGCATCCTGGGCTACACTGAGCACCAG
GTGGTCTCCTCTGACTTCAACAGCGACACCCACTCCTCCACCTTTGACGCTGGGGCTGGC
ATTGCCCTCAACGACCACTTTGTCAAGCTCATTTCCTGGTATGACAACGAATTTGGCTAC
AGCAACAGGGTGGTGGACCTCATGGCCCACATGGCCTCCAAGGAGTAA

# Drug_Target_63_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_63_General_References:
10944468	Ye Z, Connor JR: cDNA cloning by amplification of circularized first strand cDNAs reveals non-IRE-regulated iron-responsive mRNAs. Biochem Biophys Res Commun. 2000 Aug 18;275(1):223-7.
1193541	Nowak K, Kuczek M, Ostropolska L, Malarska A, Wolny M, Baranowski T: The covalent structure of glyceraldehyde-phosphate dehydrogenase from human muscles. Isolation and amino acid sequences of peptides from tryptic digest. Hoppe Seylers Z Physiol Chem. 1975 Jul;356(7):1181-3.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1924305	Meyer-Siegler K, Mauro DJ, Seal G, Wurzer J, deRiel JK, Sirover MA: A human nuclear uracil DNA glycosylase is the 37-kDa subunit of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8460-4.
2987855	Tso JY, Sun XH, Kao TH, Reece KS, Wu R: Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 1985 Apr 11;13(7):2485-502.
3027061	Allen RW, Trach KA, Hoch JA: Identification of the 37-kDa protein displaying a variable interaction with the erythroid cell membrane as glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem. 1987 Jan 15;262(2):649-53.
3170585	Ercolani L, Florence B, Denaro M, Alexander M: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem. 1988 Oct 25;263(30):15335-41.
3664468	Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K, Sakiyama S: Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 1987 Nov 1;47(21):5616-9.
6096136	Hanauer A, Mandel JL: The glyceraldehyde 3 phosphate dehydrogenase gene family: structure of a human cDNA and of an X chromosome linked pseudogene; amazing complexity of the gene family in mouse. EMBO J. 1984 Nov;3(11):2627-33.
6096821	Arcari P, Martinelli R, Salvatore F: The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res. 1984 Dec 11;12(23):9179-89.
7030790	Nowak K, Wolny M, Banas T: The complete amino acid sequence of human muscle glyceraldehyde 3-phosphate dehydrogenase. FEBS Lett. 1981 Nov 16;134(2):143-6.
7498159	Kovalyov LI, Shishkin SS, Efimochkin AS, Kovalyova MA, Ershova ES, Egorov TA, Musalyamov AK: The major protein expression profile and two-dimensional protein database of human heart. Electrophoresis. 1995 Jul;16(7):1160-9.
957435	Mercer WD, Winn SI, Watson HC: Twinning in crystals of human skeletal muscle D-glyceraldehyde-3-phosphate dehydrogenase. J Mol Biol. 1976 Jun 14;104(1):277-83.

# Drug_Target_63_HGNC_ID:
HGNC:4141

# Drug_Target_63_HPRD_ID:
00713

# Drug_Target_63_ID:
599

# Drug_Target_63_Locus:
12p13

# Drug_Target_63_Molecular_Weight:
35922

# Drug_Target_63_Name:
Glyceraldehyde-3-phosphate dehydrogenase

# Drug_Target_63_Number_of_Residues:
334

# Drug_Target_63_PDB_ID:
1J0X

# Drug_Target_63_Pathway:
Not Available

# Drug_Target_63_Pfam_Domain_Function:
PF00044	Gp_dh_N
PF02800	Gp_dh_C

# Drug_Target_63_Protein_Sequence:
>Glyceraldehyde-3-phosphate dehydrogenase
GKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVK
AENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVII
SAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAI
TATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVS
VVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGI
ALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE

# Drug_Target_63_Reaction:
D-glyceraldehyde 3-phosphate + phosphate + NAD+ = 3-phospho-D-glyceroyl phosphate + NADH + H+

# Drug_Target_63_Signals:
None

# Drug_Target_63_Specific_Function:
Not Available

# Drug_Target_63_SwissProt_ID:
P04406

# Drug_Target_63_SwissProt_Name:
G3P_HUMAN

# Drug_Target_63_Synonyms:
EC 1.2.1.12
GAPDH

# Drug_Target_63_Theoretical_pI:
8.73

# Drug_Target_63_Transmembrane_Regions:
None

# Drug_Target_64_Cellular_Location:
Cytoplasm

# Drug_Target_64_Chromosome_Location:
Not Available

# Drug_Target_64_Drug_References:
10320326	Lamb AL, Newcomer ME: The structure of retinal dehydrogenase type II at 2.7 A resolution: implications for retinal specificity. Biochemistry. 1999 May 11;38(19):6003-11.
11872149	Russo J, Barnes A, Berger K, Desgrosellier J, Henderson J, Kanters A, Merkov L: 4-(N,N-dipropylamino)benzaldehyde inhibits the oxidation of all-trans retinal to all-trans retinoic acid by ALDH1A1, but not the differentiation of HL-60 promyelocytic leukemia cells exposed to all-trans retinal. BMC Pharmacol. 2002;2:4. Epub 2002 Feb 12.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_64_Essentiality:
Non-Essential

# Drug_Target_64_GenAtlas_ID:
ALDH1A2

# Drug_Target_64_GenBank_ID_Gene:
AB015226

# Drug_Target_64_GenBank_ID_Protein:
3970842

# Drug_Target_64_GeneCard_ID:
ALDH1A2

# Drug_Target_64_Gene_Name:
ALDH1A2

# Drug_Target_64_Gene_Sequence:
>1557 bp
ATGACTTCCAGCAAGATAGAGATGCCCGGCGAGGTGAAGGCCGACCCCGCCGCCCTCATG
GCGTCGCTGCACCTCCTGCCGTCGCCCACGCCCAATCTCGAAATTAAGTACACCAAGATC
TTTATAAACAACGAGTGGCAGAACTCAGAGAGTGGGAGAGTGTTCCCTGTCTATAATCCA
GCCACAGGAGAACAGGTGTGTGAAGTTCAAGAAGCAGACAAGGCAGATATAGACAAAGCA
GTGCAGGCAGCCCGCCTGGCTTTCTCTCTTGGTTCAGTGTGGAGAAGGATGGATGCTTCA
GAAAGGGGACGTCTGTTGGATAAGCTTGCAGACTTGGTGGAACGGGACAGGGCAGTTCTT
GCAACCATGGAATCCCTAAATGGTGGCAAACCATTCCTGCAAGCTTTTTATGTGGATTTG
CAGGGCGTCATCAAAACCTTTCGATATTACGCAGGCTGGGCTGATAAAATTCATGGGATG
ACCATTCCTGTAGATGGAGACTATTTTACCTTTACAAGACATGAACCCATTGGAGTGTGT
GGACAGATCATCCCATGGAACTTCCCCCTGCTGATGTTTGCCTGGAAAATAGCTCCAGCT
TTGTGCTGTGGCAATACAGTAGTTATTAAGCCAGCAGAGCAAACACCACTCAGTGCACTC
TACATGGGAGCCCTCATCAAGGAGGCTGGCTTTCCTCCCGGGGTCATCAATATTTTGCCA
GGATATGGGCCAACGGCTGGGGCAGCAATAGCTTCTCACATTGGCATAGACAAGATTGCA
TTCACAGGGTCTACTGAGGTTGGAAAGCTTATCCAAGAAGCAGCTGGAAGAAGTAATTTG
AAGAGAGTAACTCTGGAACTTGGAGGCAAAAGTCCTAATATTATTTTTGCTGATGCTGAC
TTGGACTATGCTGTGGAGCAGGCCCACCAGGGTGTGTTCTTCAATCAAGGTCAGTGCTGC
ACTGCAGGCTCTCGCATCTTCGTGGAGGAGTCCATCTATGAGGAGTTTGTGAGAAGAAGC
GTGGAGCGGGCCAAGAGGCGCATAGTGGGGAGTCCCTTTGACCCCACCACTGAGCAGGGT
CCCCAGATTGATAAGAAACAGTACAACAAGATCTTGGAACTCATCCAGAGTGGTGTGGCT
GAGGGCGCCAAGCTGGAATGTGGAGGCAAAGGACTGGGCCGAAAGGGGTTTTTCATTGAG
CCCACAGTGTTTTCCAACGTCACTGATGATATGCGGATTGCCAAGGAGGAGATCTTTGGC
CCTGTTCAGGAAATTTTGAGATTTAAGACGATGGATGAAGTTATCGAAAGAGCCAATAAC
TCAGACTTTGGACTCGTAGCAGCTGTCTTTACTAATGACATCAACAAGGCCCTCACAGTG
TCTTCTGCAATGCAAGCTGGGACTGTTTGGATCAATTGTTACAATGCCTTAAATGCCCAG
AGCCCCTTTGGGGGATTCAAGATGTCTGGAAATGGGAGAGAAATGGGAGAATTTGGCTTG
CGGGAGTACTCAGAAGTTAAGACGGTGACAGTAAAGATCCCCCAGAAGAACTCCTAA

# Drug_Target_64_General_Function:
Energy production and conversion

# Drug_Target_64_General_References:
9819382	Ono Y, Fukuhara N, Yoshie O: TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3. Mol Cell Biol. 1998 Dec;18(12):6939-50.

# Drug_Target_64_HGNC_ID:
HGNC:15472

# Drug_Target_64_HPRD_ID:
04733

# Drug_Target_64_ID:
569

# Drug_Target_64_Locus:
15q22.1

# Drug_Target_64_Molecular_Weight:
56725

# Drug_Target_64_Name:
Retinal dehydrogenase 2

# Drug_Target_64_Number_of_Residues:
518

# Drug_Target_64_PDB_ID:
1BI9

# Drug_Target_64_Pathway:
Not Available

# Drug_Target_64_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_64_Protein_Sequence:
>Retinal dehydrogenase 2
MTSSKIEMPGEVKADPAALMASLHLLPSPTPNLEIKYTKIFINNEWQNSESGRVFPVYNP
ATGEQVCEVQEADKADIDKAVQAARLAFSLGSVWRRMDASERGRLLDKLADLVERDRAVL
ATMESLNGGKPFLQAFYVDLQGVIKTFRYYAGWADKIHGMTIPVDGDYFTFTRHEPIGVC
GQIIPWNFPLLMFAWKIAPALCCGNTVVIKPAEQTPLSALYMGALIKEAGFPPGVINILP
GYGPTAGAAIASHIGIDKIAFTGSTEVGKLIQEAAGRSNLKRVTLELGGKSPNIIFADAD
LDYAVEQAHQGVFFNQGQCCTAGSRIFVEESIYEEFVRRSVERAKRRVVGSPFDPTTEQG
PQIDKKQYNKILELIQSGVAEGAKLECGGKGLGRKGFFIEPTVFSNVTDDMRIAKEEIFG
PVQEILRFKTMDEVIERANNSDFGLVAAVFTNDINKALTVSSAMQAGTVWINCYNALNAQ
SPFGGFKMSGNGREMGEFGLREYSEVKTVTVKIPQKNS

# Drug_Target_64_Reaction:
retinal + NAD+ + H2O = retinoate + NADH + 2 H+

# Drug_Target_64_Signals:
None

# Drug_Target_64_Specific_Function:
Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Does metabolize octanal and decanal but does not metabolize citral, benzaldehyde, acetaldehyde and propanal efficiently

# Drug_Target_64_SwissProt_ID:
O94788

# Drug_Target_64_SwissProt_Name:
AL1A2_HUMAN

# Drug_Target_64_Synonyms:
Aldehyde dehydrogenase family 1 member A2
EC 1.2.1.36
RALDH 2
RALDH(II)
RalDH2
Retinaldehyde-specific dehydrogenase type 2

# Drug_Target_64_Theoretical_pI:
5.84

# Drug_Target_64_Transmembrane_Regions:
None

# Drug_Target_65_Cellular_Location:
Endoplasmic reticulum
cytoplasmic sid
endoplasmic reticulum membrane
single-pass membrane protein

# Drug_Target_65_Chromosome_Location:
Not Available

# Drug_Target_65_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6603890	Bognar A, Meighen E: Mechanism of a long-chain fatty aldehyde dehydrogenase induced during the development of bioluminescence in Beneckea harveyi. Can J Biochem Cell Biol. 1983 May;61(5):301-6.

# Drug_Target_65_Essentiality:
Non-Essential

# Drug_Target_65_GenAtlas_ID:
ALDH3A2

# Drug_Target_65_GenBank_ID_Gene:
L47162

# Drug_Target_65_GenBank_ID_Protein:
1082036

# Drug_Target_65_GeneCard_ID:
ALDH3A2

# Drug_Target_65_Gene_Name:
ALDH3A2

# Drug_Target_65_Gene_Sequence:
>1458 bp
ATGGAGCTCGAAGTCCGGCGGGTCCGACAGGCGTTCCTGTCCGGCCGGTCGCGACCTCTG
CGGTTTCGGCTGCAGCAGCTGGAGGCCCTGCGGAGGATGGTGCAGGAGCGCGAGAAGGAT
ATCCTGACGGCCATCGCCGCCGACCTGTGCAAGAGTGAATTCAATGTGTACAGTCAGGAA
GTCATTACTGTCCTTGGGGAAATTGATTTTATGCTTGAGAATCTTCCTGAATGGGTTACT
GCTAAACCAGTTAAGAAGAACGTGCTCACCATGCTGGATGAGGCCTATATTCAGCCACAG
CCTCTGGGAGTGGTGCTGATAATCGGAGCTTGGAATTACCCCTTCGTTCTCACCATTCAG
CCACTGATAGGAGCCATCGCTGCAGGAAATGCTGTGATTATAAAGCCTTCTGAACTGAGT
GAAAATACAGCCAAGATCTTGGCAAAGCTTCTCCCTCAGTATTTAGACCAGGATCTCTAT
ATTGTTATTAATGGTGGTGTTGAGGAAACCACGGAGCTCCTGAAGCAGCGATTTGACCAC
ATTTTCTATACGGGAAACACTGCGGTTGGCAAAATTGTCATGGAAGCTGCTGCCAAGCAT
CTGACCCCTGTGACTCTTGAACTGGGAGGGAAAAGTCCATGTTATATTGATAAAGATTGT
GACCTGGACATTGTTTGCAGACGCATAACCTGGGGAAAATACATGAATTGTGGCCAAACC
TGCATTGCACCCGACTATATTCTCTGTGAAGCATCCCTCCAAAATCAAATTGTATGGAAG
ATTAAGGAAACAGTGAAGGAATTTTATGGAGAAAATATAAAAGAGTCTCCTGATTATGAA
AGGATCATCAATCTTCGTCATTTTAAGAGGATACTAAGTTTGCTTGAAGGACAAAAGATA
GCTTTTGGTGGGGAGACTGATGAGGCCACACGCTACATAGCCCCAACAGTACTTACCGAT
GTTGATCCTAAAACCAAGGTGATGCAAGAAGAAATTTTTGGACCAATTCTTCCAATAGTG
CCTGTGAAAAATGTAGATGAGGCCATAAATTTCATAAATGAACGTGAAAAGCCTCTGGCT
CTTTATGTATTTTCGCATAACCATAAGCTCATCAAACGGATGATTGATGAGACATCCAGT
GGAGGTGTCACAGGCAATGACGTCATTATGCACTTCACGCTCAACTCTTTCCCATTTGGA
GGAGTGGGTTCCAGTGGGATGGGAGCTTATCACGGAAAACATAGTTTTGATACTTTTTCT
CATCAGCGTCCCTGTTTATTAAAAAGTTTAAAGAGAGAAGGTGCTAACAAACTCAGATAT
CCTCCCAACAGCCAGTCAAAGGTGGATTGGGGGAAATTTTTTCTCTTGAAACGGTTCAAC
AAAGAAAAACTCGGTCTCCTGTTGCTCACTTTCCTGGGTATTGTAGCCGCTGTGCTTGTC
AAGGCAGAATATTACTGA

# Drug_Target_65_General_Function:
Energy production and conversion

# Drug_Target_65_General_References:
8528251	De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, Markova N, Rizzo WB: Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet. 1996 Jan;12(1):52-7.
9027499	Rogers GR, Markova NG, De Laurenzi V, Rizzo WB, Compton JG: Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH). Genomics. 1997 Jan 15;39(2):127-35.
9070922	Chang C, Yoshida A: Human fatty aldehyde dehydrogenase gene (ALDH10): organization and tissue-dependent expression. Genomics. 1997 Feb 15;40(1):80-5.
9254849	Sillen A, Jagell S, Wadelius C: A missense mutation in the FALDH gene identified in Sjogren-Larsson syndrome patients originating from the northern part of Sweden. Hum Genet. 1997 Aug;100(2):201-3.
9829906	Sillen A, Anton-Lamprecht I, Braun-Quentin C, Kraus CS, Sayli BS, Ayuso C, Jagell S, Kuster W, Wadelius C: Spectrum of mutations and sequence variants in the FALDH gene in patients with Sjogren-Larsson syndrome. Hum Mutat. 1998;12(6):377-84.

# Drug_Target_65_HGNC_ID:
HGNC:403

# Drug_Target_65_HPRD_ID:
07188

# Drug_Target_65_ID:
662

# Drug_Target_65_Locus:
17p11.2

# Drug_Target_65_Molecular_Weight:
54849

# Drug_Target_65_Name:
Fatty aldehyde dehydrogenase

# Drug_Target_65_Number_of_Residues:
485

# Drug_Target_65_PDB_ID:
Not Available

# Drug_Target_65_Pathway:
Not Available

# Drug_Target_65_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_65_Protein_Sequence:
>Fatty aldehyde dehydrogenase
MELEVRRVRQAFLSGRSRPLRFRLQQLEALRRMVQEREKDILTAIAADLCKSEFNVYSQE
VITVLGEIDFMLENLPEWVTAKPVKKNVLTMLDEAYIQPQPLGVVLIIGAWNYPFVLTIQ
PLIGAIAAGNAVIIKPSELSENTAKILAKLLPQYLDQDLYIVINGGVEETTELLKQRFDH
IFYTGNTAVGKIVMEAAAKHLTPVTLELGGKSPCYIDKDCDLDIVCRRITWGKYMNCGQT
CIAPDYILCEASLQNQIVWKIKETVKEFYGENIKESPDYERIINLRHFKRILSLLEGQKI
AFGGETDEATRYIAPTVLTDVDPKTKVMQEEIFGPILPIVPVKNVDEAINFINEREKPLA
LYVFSHNHKLIKRMIDETSSGGVTGNDVIMHFTLNSFPFGGVGSSGMGAYHGKHSFDTFS
HQRPCLLKSLKREGANKLRYPPNSQSKVDWGKFFLLKRFNKEKLGLLLLTFLGIVAAVLV
KAEYY

# Drug_Target_65_Reaction:
an aldehyde + NAD+ + H2O = an acid + NADH + H+

# Drug_Target_65_Signals:
None

# Drug_Target_65_Specific_Function:
Catalyzes the oxidation of long-chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length

# Drug_Target_65_SwissProt_ID:
P51648

# Drug_Target_65_SwissProt_Name:
AL3A2_HUMAN

# Drug_Target_65_Synonyms:
Aldehyde dehydrogenase 10
Aldehyde dehydrogenase family 3 member A2
Aldehyde dehydrogenase, microsomal
EC 1.2.1.3

# Drug_Target_65_Theoretical_pI:
7.99

# Drug_Target_65_Transmembrane_Regions:
464-480

# Drug_Target_66_Cellular_Location:
Not Available

# Drug_Target_66_Chromosome_Location:
Not Available

# Drug_Target_66_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_66_Essentiality:
Non-Essential

# Drug_Target_66_GenAtlas_ID:
ALDH5A1

# Drug_Target_66_GenBank_ID_Gene:
Y11192

# Drug_Target_66_GenBank_ID_Protein:
3766467

# Drug_Target_66_GeneCard_ID:
ALDH5A1

# Drug_Target_66_Gene_Name:
ALDH5A1

# Drug_Target_66_Gene_Sequence:
>1608 bp
ATGGCGACCTGCATTTGGCTGCGGAGCTGTGGGGCCCGGCGCCTCGGGTCGACGTTTCCA
GGCTGCCGCCTCCGCCCCCGCGCCGGCGGCCTGGTCCCTGCCTCCGGGCCTGCGCCCGGC
CCGGCCCAGCTCCGCTGCTACGCTGGGCGCCTGGCGGGCCTCTCTGCGGCGCTGCTGCGC
ACCGACAGCTTCGTGGGCGGCCGCTGGCTCCCGGCCGCCGCCACCTTCCCCGTGCAAGAC
CCGGCCAGCGGCGCCGCTCTGGGCATGGTAGCCGACTGCGGGGTGCGAGAGGCCCGCGCC
GCCGTGCGCGCTGCCTACGAGGCTTTCTGCCGCTGGAGGGAGGTCTCCGCCAAGGAGAGG
AGTTCATTACTTCGGAAGTGGTACAATTTAATGATACAAAATAAGGATGACCTTGCCAGA
ATAATCACAGCTGAAAGTGGAAAGCCACTGAAGGAGGCACATGGAGAAATTCTCTATTCC
GCCTTTTTCCTAGAGTGGTTCTCTGAGGAAGCCCGCCGTGTTTACGGAGACATTATCCAC
ACCCCGGCAAAGGACAGGCGGGCCCTGGTCCTCAAGCAGCCCATAGGCGTGGCTGCAGTC
ATCACCCCGTGGAATTTCCCCAGTGCCATGATCACCCGGAAGGTGGGGGCCGCCCTGGCA
GCCGGCTGTACTGTCGTGGTGAAGCCTGCCGAAGACACGCCCTTCTCCGCCCTGGCCCTG
GCTGAGCTTGCAAGCCAGGCTGGGATTCCTTCAGGTGTATACAATGTTATTCCCTGTTCT
CGAAAGAATGCCAAGGAAGTAGGGGAGGCAATTTGTACTGATCCTCTGGTGTCCAAAATT
TCCTTTACTGGTTCAACAACTACAGGAAAGATCCTGTTGCACCACGCAGCAAACTCTGTG
AAAAGGGTCTCTATGGAGCTGGGCGGCCTTGCTCCATTTATAGTATTTGACAGTGCCAAC
GTGGACCAGGCTGTAGCAGGGGCCATGGCATCTAAATTTAGGAACACTGGACAGACTTGT
GTTTGCTCAAACCAATTCTTGGTGCAAAGGGGCATCCATGATGCCTTTGTAAAAGCATTC
GCCGAGGCCATGAAGAAGAACCTGCGCGTAGGTAATGGATTTGAGGAAGGAACTACTCAG
GGCCCATTAATTAATGAAAAAGCGGTAGAAAAGGTGGAGAAACAGGTGAATGATGCCGTT
TCTAAAGGTGCCACCGTTGTGACAGGTGGAAAACGACACCAACTTGGAAAAAATTTCTTT
GAGCCTACCCTGCTGTGCAATGTCACCCAGGACATGCTGTGCACTCATGAAGAGACTTTC
GGGCCTCTGGCACCAGTTATCAAGTTCGATACAGAGGAGGAGGCTATAGCAATCGCTAAC
GCAGCTGATGTTGGGTTAGCAGGTTATTTTTACTCTCAAGACCCAGCCCAGATCTGGAGA
GTGGCAGAGCAGCTGGAAGTGGGCATGGTTGGCGTCAACGAAGGATTAATTTCCTCTGTG
GAGTGCCCTTTTGGTGGAGTGAAGCAGTCCGGCCTTGGGCGAGAGGGGTCCAAGTATGGC
ATTGATGAGTATCTGGAACTCAAGTATGTGTGTTACGGGGGCTTGTAG

# Drug_Target_66_General_Function:
Energy production and conversion

# Drug_Target_66_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7814412	Chambliss KL, Caudle DL, Hinson DD, Moomaw CR, Slaughter CA, Jakobs C, Gibson KM: Molecular cloning of the mature NAD(+)-dependent succinic semialdehyde dehydrogenase from rat and human. cDNA isolation, evolutionary homology, and tissue expression. J Biol Chem. 1995 Jan 6;270(1):461-7.
9059628	Trettel F, Malaspina P, Jodice C, Novelletto A, Slaughter CA, Caudle DL, Hinson DD, Chambliss KL, Gibson KM: Human succinic semialdehyde dehydrogenase. Molecular cloning and chromosomal localization. Adv Exp Med Biol. 1997;414:253-60.
9683595	Chambliss KL, Hinson DD, Trettel F, Malaspina P, Novelletto A, Jakobs C, Gibson KM: Two exon-skipping mutations as the molecular basis of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria). Am J Hum Genet. 1998 Aug;63(2):399-408.

# Drug_Target_66_HGNC_ID:
HGNC:408

# Drug_Target_66_HPRD_ID:
08361

# Drug_Target_66_ID:
170

# Drug_Target_66_Locus:
6p22.2-p22.3

# Drug_Target_66_Molecular_Weight:
57215

# Drug_Target_66_Name:
Succinate semialdehyde dehydrogenase, mitochondrial

# Drug_Target_66_Number_of_Residues:
535

# Drug_Target_66_PDB_ID:
Not Available

# Drug_Target_66_Pathway:
Not Available

# Drug_Target_66_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_66_Protein_Sequence:
>Succinate semialdehyde dehydrogenase, mitochondrial precursor
MATCIWLRSCGARRLGSTFPGCRLRPRAGGLVPASGPAPGPAQLRCYAGRLAGLSAALLR
TDSFVGGRWLPAAATFPVQDPASGAALGMVADCGVREARAAVRAAYEAFCRWREVSAKER
SSLLRKWYNLMIQNKDDLARIITAESGKPLKEAHGEILYSAFFLEWFSEEARRVYGDIIH
TPAKDRRALVLKQPIGVAAVITPWNFPSAMITRKVGAALAAGCTVVVKPAEDTPFSALAL
AELASQAGIPSGVYNVIPCSRKNAKEVGEAICTDPLVSKISFTGSTTTGKILLHHAANSV
KRVSMELGGLAPFIVFDSANVDQAVAGAMASKFRNTGQTCVCSNQFLVQRGIHDAFVKAF
AEAMKKNLRVGNGFEEGTTQGPLINEKAVEKVEKQVNDAVSKGATVVTGGKRHQLGKNFF
EPTLLCNVTQDMLCTHEETFGPLAPVIKFDTEEEAIAIANAADVGLAGYFYSQDPAQIWR
VAEQLEVGMVGVNEGLISSVECPFGGVKQSGLGREGSKYGIDEYLELKYVCYGGL

# Drug_Target_66_Reaction:
succinate semialdehyde + NAD+ + H2O = succinate + NADH + 2 H+

# Drug_Target_66_Signals:
None

# Drug_Target_66_Specific_Function:
Not Available

# Drug_Target_66_SwissProt_ID:
P51649

# Drug_Target_66_SwissProt_Name:
SSDH_HUMAN

# Drug_Target_66_Synonyms:
EC 1.2.1.24
NAD(+)-dependent succinic semialdehyde dehydrogenase
Succinate semialdehyde dehydrogenase, mitochondrial precursor

# Drug_Target_66_Theoretical_pI:
8.37

# Drug_Target_66_Transmembrane_Regions:
None

# Drug_Target_67_Cellular_Location:
Not Available

# Drug_Target_67_Chromosome_Location:
Not Available

# Drug_Target_67_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9355735	de La Fuente JL, Rumbero A, Martin JF, Liras P: Delta-1-piperideine-6-carboxylate dehydrogenase, a new enzyme that forms alpha-aminoadipate in Streptomyces clavuligerus and other cephamycin C-producing actinomycetes. Biochem J. 1997 Oct 1;327 ( Pt 1):59-64.

# Drug_Target_67_Essentiality:
Non-Essential

# Drug_Target_67_GenAtlas_ID:
ALDH7A1

# Drug_Target_67_GenBank_ID_Gene:
S74728

# Drug_Target_67_GenBank_ID_Protein:
797410

# Drug_Target_67_GeneCard_ID:
ALDH7A1

# Drug_Target_67_Gene_Name:
ALDH7A1

# Drug_Target_67_Gene_Sequence:
>1536 bp
ATGTCCACTCTCCTCATCAATCAGCCCCAGTATGCGTGGCTGAAAGAGCTGGGGCTCCGC
GAGGAAAACGAGGGCGTGTATAATGGAAGCTGGGGAGGCCGGGGAGAGGTTATTACGACC
TATTGCCCCGCTAACAACGAGCCAATAGCAAGAGTCCGACAGGCCAGTGTGGCAGACTAT
GAAGAAACTGTAAAGAAAGCAAGAGAAGCATGGAAAATCTGGGCAGATATTCCTGCTCCA
AAACGAGGAGAAATAGTAAGACAGATTGGCGATGCCTTGCGGGAGAAGATCCAAGTACTA
GGAAGCTTGGTGTCTTTGGAGATGGGGAAAATCTTAGTGGAAGGTGTGGGTGAAGTTCAG
GAGTATGTGGATATCTGTGACTATGCTGTTGGTTTATCAAGGATGATTGGAGGACCTATC
TTGCCTTCTGAAAGATCTGGCCATGCACTGATTGAGCAGTGGAATCCCGTAGGCCTGGTT
GGAATCATCACGGCATTCAATTTCCCTGTGGCAGTGTATGGTTGGAACAACGCCATCGCC
ATGATCTGTGGAAATGTCTGCCTCTGGAAAGGAGCTCCAACCACTTCCCTCATTAGTGTG
GCTGTCACAAAGATAATAGCCAAGGTTCTGGAGGACAACAAGCTGCCTGGTGCAATTTGT
TCCTTGACTTGTGGTGGAGCAGATATTGGCACAGCAATGGCCAAAGATGAACGAGTGAAC
CTGCTGTCCTTCACTGGGAGCACTCAGGTGGGAAAACAGGTGGGCCTGATGGTGCAGGAG
AGGTTTGGGAGAAGTCTGTTGGAACTTGGAGGAAACAATGCCATTATTGCCTTTGAAGAT
GCAGACCTCAGCTTAGTTGTTCCATCAGCTCTCTTCGCTGCTGTGGGAACAGCTGGCCAG
AGGTGTACCACTGCGAGGCGACTGTTTATACATGAAAGCATCCATGATGAGGTTGTAAAC
AGACTTAAAAAGGCCTATGCACAGATCCGAGTTGGGAACCCATGGGACCCTAATGTTCTC
TATGGGCCACTCCACACCAAGCAGGCAGTGAGCATGTTTCTTGGAGCAGTGGAAGAAGCA
AAGAAAGAAGGTGGCACAGTGGTCTATGGGGGCAAGGTTATGGATCGCCCTGGAAATTAT
GTAGAACCGACAATTGTGACAGGTCTTGGCCACGATGCGTCCATTGCACACACAGAGACT
TTCGCTCCGATTCTCTATGTCTTTAAATTCAAGAATGAAGAAGAGGTCTTTGCATGGAAT
AATGAAGTAAAACAGGGACTTTCAAGTAGCATCTTTACCAAAGATCTGGGCAGAATCTTT
CGCTGGCTTGGACCTAAAGGATCAGACTGTGGCATTGTAAATGTCAACATTCCAACAAGT
GGGGCTGAGATTGGAGGTGCCTTTGGAGGAGAAAAGCACACTGGTGGTGGCAGGGAGTCT
GGCAGTGATGCCTGGAAACAGTACATGAGAAGGTCTACTTGTACTATCAACTACAGTAAA
GACCTTCCTCTGGCCCAAGGAATCAAGTTTCAGTAA

# Drug_Target_67_General_Function:
Energy production and conversion

# Drug_Target_67_General_References:
8088832	Lee P, Kuhl W, Gelbart T, Kamimura T, West C, Beutler E: Homology between a human protein and a protein of the green garden pea. Genomics. 1994 May 15;21(2):371-8.
9417906	Skvorak AB, Robertson NG, Yin Y, Weremowicz S, Her H, Bieber FR, Beisel KW, Lynch ED, Beier DR, Morton CC: An ancient conserved gene expressed in the human inner ear: identification, expression analysis, and chromosomal mapping of human and mouse antiquitin (ATQ1). Genomics. 1997 Dec 1;46(2):191-9.

# Drug_Target_67_HGNC_ID:
HGNC:877

# Drug_Target_67_HPRD_ID:
00124

# Drug_Target_67_ID:
149

# Drug_Target_67_Locus:
5q31

# Drug_Target_67_Molecular_Weight:
55236

# Drug_Target_67_Name:
Alpha-aminoadipic semialdehyde dehydrogenase

# Drug_Target_67_Number_of_Residues:
510

# Drug_Target_67_PDB_ID:
Not Available

# Drug_Target_67_Pathway:
Not Available

# Drug_Target_67_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_67_Protein_Sequence:
>Aldehyde dehydrogenase family 7 member A1
STLLINQPQYAWLKELGLREENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYE
ETVKKAREAWKIWADIPAPKRGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQE
YVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAM
ICGNVCLWKGAPTTSLISVAVTKIIAKVLEDNKLPGAICSLTCGGADIGTAMAKDERVNL
LSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQR
CTTARRLFIHESIHDEVVNRLKKAYAQIRVGNPWDPNVLYGPLHTKQAVSMFLGAVEEAK
KEGGTVVYGGKVMDRPGNYVEPTIVTGLGHDASIAHTETFAPILYVFKFKNEEEVFAWNN
EVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESG
SDAWKQYMRRSTCTINYSKDLPLAQGIKFQ

# Drug_Target_67_Reaction:
L-2-aminoadipate 6-semialdehyde + NAD(P)+ + H2O = L-2-aminoadipate + NAD(P)H + H+

# Drug_Target_67_Signals:
None

# Drug_Target_67_Specific_Function:
Not Available

# Drug_Target_67_SwissProt_ID:
P49419

# Drug_Target_67_SwissProt_Name:
AL7A1_HUMAN

# Drug_Target_67_Synonyms:
Aldehyde dehydrogenase family 7 member A1
Alpha-AASA dehydrogenase
Antiquitin-1
Delta1-piperideine-6-carboxylate dehydrogenease
EC 1.2.1.31
P6c dehydrogenase

# Drug_Target_67_Theoretical_pI:
6.86

# Drug_Target_67_Transmembrane_Regions:
None

# Drug_Target_68_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_68_Chromosome_Location:
Not Available

# Drug_Target_68_Drug_References:
17559398	Deng D, Li X, Fang X, Sun G: Characterization of two components of the 2-naphthoate monooxygenase system from Burkholderia sp. strain JT1500. FEMS Microbiol Lett. 2007 Aug;273(1):22-7. Epub 2007 Jun 7.

# Drug_Target_68_Essentiality:
Non-Essential

# Drug_Target_68_GenAtlas_ID:
BLVRB

# Drug_Target_68_GenBank_ID_Gene:
D26308

# Drug_Target_68_GenBank_ID_Protein:
1384068

# Drug_Target_68_GeneCard_ID:
BLVRB

# Drug_Target_68_Gene_Name:
BLVRB

# Drug_Target_68_Gene_Sequence:
>621 bp
ATGGCCGTCAAGAAGATCGCGATCTTCGGCGCCACTGGCCAGACCGGGCTCACCACCCTG
GCGCAGGCGGTGCAAGCAGGTTACGAAGTGACAGTGCTGGTGCGGGACTCCTCCAGGCTG
CCATCAGAGGGGCCCCGGCCGGCCCACGTGGTAGTGGGAGATGTTCTGCAGGCAGCCGAT
GTGGACAAGACCGTGGCTGGGCAGGACGCTGTCATCGTGCTGCTGGGCACCCGCAATGAC
CTCAGTCCCACGACAGTGATGTCCGAGGGCGCCCGGAACATTGTGGCAGCCATGAAGGCT
CATGGTGTGGACAAGGTCGTGGCCTGCACCTCGGCTTTCCTGCTCTGGGACCCTACCAAG
GTGCCCCCACGACTGCAGGCTGTGACTGATGACCACATCCGGATGCACAAGGTGCTGCGG
GAATCAGGCCTGAAGTACGTGGCTGTGATGCCGCCACACATAGGAGACCAGCCACTAACT
GGGGCGTACACAGTGACCCTGGATGGACGAGGGCCCTCAAGGGTCATCTCCAAACATGAC
CTGGGCCATTTCATGCTGCGCTGCCTCACCACCGATGAGTACGACGGACACAGCACCTAC
CCCTCCCACCAGTACCAGTAG

# Drug_Target_68_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_68_General_References:
11224564	Pereira PJ, Macedo-Ribeiro S, Parraga A, Perez-Luque R, Cunningham O, Darcy K, Mantle TJ, Coll M: Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol. 2001 Mar;8(3):215-20.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
7929092	Yamaguchi T, Komoda Y, Nakajima H: Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
8117274	Chikuba K, Yubisui T, Shirabe K, Takeshita M: Cloning and nucleotide sequence of a cDNA of the human erythrocyte NADPH-flavin reductase. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1170-6.
8280170	Yamaguchi T, Komuro A, Nakano Y, Tomita M, Nakajima H: Complete amino acid sequence of biliverdin-IX beta reductase from human liver. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1518-23.
8313871	Golaz O, Hughes GJ, Frutiger S, Paquet N, Bairoch A, Pasquali C, Sanchez JC, Tissot JD, Appel RD, Walzer C, et al.: Plasma and red blood cell protein maps: update 1993. Electrophoresis. 1993 Nov;14(11):1223-31.
8687377	Shalloe F, Elliott G, Ennis O, Mantle TJ: Evidence that biliverdin-IX beta reductase and flavin reductase are identical. Biochem J. 1996 Jun 1;316 ( Pt 2):385-7.
8799475	Komuro A, Tobe T, Hashimoto K, Nakano Y, Yamaguchi T, Nakajima H, Tomita M: Molecular cloning and expression of human liver biliverdin-IX beta reductase. Biol Pharm Bull. 1996 Jun;19(6):796-804.

# Drug_Target_68_HGNC_ID:
HGNC:1063

# Drug_Target_68_HPRD_ID:
02967

# Drug_Target_68_ID:
654

# Drug_Target_68_Locus:
19q13.1-q13.2

# Drug_Target_68_Molecular_Weight:
21988

# Drug_Target_68_Name:
Flavin reductase

# Drug_Target_68_Number_of_Residues:
205

# Drug_Target_68_PDB_ID:
1HE5

# Drug_Target_68_Pathway:
Not Available

# Drug_Target_68_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_68_Protein_Sequence:
>Flavin reductase
AVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADV
DKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKV
PPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDL
GHFMLRCLTTDEYDGHSTYPSHQYQ

# Drug_Target_68_Reaction:
bilirubin + NAD(P)+ = biliverdin + NAD(P)H + H+

# Drug_Target_68_Signals:
None

# Drug_Target_68_Specific_Function:
Catalyzes electron transfer from reduced pyridine nucleotides to flavins as well as methylene blue, pyrroloquinoline quinone, riboflavin, or methemoglobin. Possible role in protecting cells from oxidative damage or in regulating iron metabolism. In the liver, converts biliverdin to bilirubin

# Drug_Target_68_SwissProt_ID:
P30043

# Drug_Target_68_SwissProt_Name:
BLVRB_HUMAN

# Drug_Target_68_Synonyms:
BVR-B
Biliverdin reductase B
Biliverdin-IX beta-reductase
EC 1.3.1.24
EC 1.5.1.30
FLR
FR
GHBP
Green heme-binding protein
NADPH-dependent diaphorase
NADPH-flavin reductase

# Drug_Target_68_Theoretical_pI:
7.76

# Drug_Target_68_Transmembrane_Regions:
None

# Drug_Target_69_Cellular_Location:
Not Available

# Drug_Target_69_Chromosome_Location:
Not Available

# Drug_Target_69_Drug_References:
11479381	Murahama M, Yoshida T, Hayashi F, Ichino T, Sanada Y, Wada K: Purification and characterization of Delta(1)-pyrroline-5-carboxylate reductase isoenzymes, indicating differential distribution in spinach (Spinacia oleracea L.) leaves. Plant Cell Physiol. 2001 Jul;42(7):742-50.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_69_Essentiality:
Non-Essential

# Drug_Target_69_GenAtlas_ID:
PYCR2

# Drug_Target_69_GenBank_ID_Gene:
AF087859

# Drug_Target_69_GenBank_ID_Protein:
33150582

# Drug_Target_69_GeneCard_ID:
PYCR2

# Drug_Target_69_Gene_Name:
PYCR2

# Drug_Target_69_Gene_Sequence:
>963 bp
ATGAGCGTGGGCTTCATCGGGGCCGGCCAGCTGGCTAATGCTCTGGCGCGGGGCTTCACG
GCCGCAGCATTCCTGTCGGCTCACAAGATAATAGCCAGCTCCCCAGAAATGAACCTGCCC
ACGGTGTCCGCGCTCAGGAAGATGGGTGTGAACCTGACACGCAGCAACAAGGAGACGGTG
AAGCACAGCGACGTCCTGTTTCTGGCTGTGAAGCACATTATCATCCCCTTCATCCTGGAT
GAGATTGGGGCCGACGTGCAAGCCAGACACATCGTGGTCTCCTGTGCGGCTGGTGTCACC
ATCAGCTCTGTGGAGAAGAAGCTGATGGCATTCCAGCCAGCCCCCAAAGTGATTCGCTGC
ATGACCAACACACCTGTGGTAGTGCAGGAAGGCGCTACAGTGTACGCCACGGGCACCCAT
GCCCTGGTGGAGGATGGGCAGCTCCTGGAGCAGCTCATGAGCAGCGTGGGCTTCTGCACT
GAGGTGGAAGAGGACCTCATCGATGCCGTCACGGGGCTCAGTGGCAGCGGGCCTGCCTAT
GCATTCATGGCTCTGGACGCATTGGCTGATGGTGGGGTGAAGATGGGTTTGCCACGGCGC
CTGGCAATCCAACTCGGGGCCCAGGCTTTGCTGGGAGCTGCCAAGATGCTGCTGGACTCG
GAGCAGCATCCATGCCAGCTTAAGGACAATGTCTGCTCCCCTGGGGGAGCCACCATCCAC
GCCCTGCACTTTCTAGAGAGTGGGGGCTTCCGCTCTCTGCTCATCAATGCAGTTGAGGCC
TCCTGTATCCGAACACGAGAGCTACAGTCCATGGCCGACCAAGAAAAGATCTCCCCAGCT
GCCCTTAAGAAGACCCTCTTAGACAGAGTGAAGCTGGAATCCCCCACAGTCTCCACACTG
ACCCCCTCCAGCCCAGGGAAGCTCCTCACAAGAAGCCTGGCCCTGGGAGGCAAGAAGGAC
TAA

# Drug_Target_69_General_Function:
Amino acid transport and metabolism

# Drug_Target_69_General_References:
Not Available

# Drug_Target_69_HGNC_ID:
HGNC:30262

# Drug_Target_69_HPRD_ID:
17939

# Drug_Target_69_ID:
802

# Drug_Target_69_Locus:
1q42.12

# Drug_Target_69_Molecular_Weight:
33638

# Drug_Target_69_Name:
Pyrroline-5-carboxylate reductase 2

# Drug_Target_69_Number_of_Residues:
320

# Drug_Target_69_PDB_ID:
Not Available

# Drug_Target_69_Pathway:
Not Available

# Drug_Target_69_Pfam_Domain_Function:
PF03807	F420_oxidored

# Drug_Target_69_Protein_Sequence:
>Pyrroline-5-carboxylate reductase 2
MSVGFIGAGQLAYALARGFTAAGILSAHKIIASSPEMNLPTVSALRKMGVNLTRSNKETV
KHSDVLFLAVKPHIIPFILDEIGADVQARHIVVSCAAGVTISSVEKKLMAFQPAPKVIRC
MTNTPVVVQEGATVYATGTHALVEDGQLLEQLMSSVGFCTEVEEDLIDAVTGLSGSGPAY
AFMALDALADGGVKMGLPRRLAIQLGAQALLGAAKMLLDSEQHPCQLKDNVCSPGGATIH
ALHFLESGGFRSLLINAVEASCIRTRELQSMADQEKISPAALKKTLLDRVKLESPTVSTL
TPSSPGKLLTRSLALGGKKD

# Drug_Target_69_Reaction:
L-proline + NAD(P)+ = 1-pyrroline-5-carboxylate + NAD(P)H + H+

# Drug_Target_69_Signals:
None

# Drug_Target_69_Specific_Function:
Not Available

# Drug_Target_69_SwissProt_ID:
Q96C36

# Drug_Target_69_SwissProt_Name:
P5CR2_HUMAN

# Drug_Target_69_Synonyms:
EC 1.5.1.2
P5C reductase 2
P5CR 2

# Drug_Target_69_Theoretical_pI:
7.87

# Drug_Target_69_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
16897483	Manriquez D, El-Sharkawy I, Flores FB, El-Yahyaoui F, Regad F, Bouzayen M, Latche A, Pech JC: Two highly divergent alcohol dehydrogenases of melon exhibit fruit ripening-specific expression and distinct biochemical characteristics. Plant Mol Biol. 2006 Jul;61(4-5):675-85.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
ADH1B

# Drug_Target_6_GenBank_ID_Gene:
M24317

# Drug_Target_6_GenBank_ID_Protein:
178098

# Drug_Target_6_GeneCard_ID:
ADH1B

# Drug_Target_6_Gene_Name:
ADH1B

# Drug_Target_6_Gene_Sequence:
>1128 bp
ATGAGCACAGCAGGAAAAGTAATCAAATGCAAAGCAGCTGTGCTATGGGAGGTAAAGAAA
CCCTTTTCCATTGAGGATGTGGAGGTTGCACCTCCTAAGGCTTATGAAGTTCGCATTAAG
ATGGTGGCTGTAGGAATCTGTCGCACAGATGACCACGTGGTTAGTGGCAACCTGGTGACC
CCCCTTCCTGTGATTTTAGGCCATGAGGCAGCCGGCATCGTGGAGAGTGTTGGAGAAGGG
GTGACTACAGTCAAACCAGGTGATAAAGTCATCCCGCTCTTTACTCCTCAGTGTGGAAAA
TGCAGAGTTTGTAAAAACCCGGAGAGCAACTACTGCTTGAAAAATGATCTAGGCAATCCT
CGGGGGACCCTGCAGGATGGCACCAGGAGGTTCACCTGCAGGGGGAAGCCCATTCACCAC
TTCCTTGGCACCAGCACCTTCTCCCAGTACACGGTGGTGGATGAGAATGCAGTGGCCAAA
ATTGATGCAGCCTCGCCCCTGGAGAAAGTCTGCCTCATTGGCTGTGGATTCTCGACTGGT
TATGGGTCTGCAGTTAACGTTGCCAAGGTCACCCCAGGCTCTACCTGTGCTGTGTTTGGC
CTGGGAGGGGTCGGCCTATCTGCTGTTATGGGCTGTAAAGCAGCTGGAGCAGCCAGAATC
ATTGCGGTGGACATCAACAAGGACAAAAAAGCAAAGGCCAAAGAGTTGGGTGCCACTGAA
TGCATCAACCCTCAAGACTACAAGAAACCCATCCAGGAAGTGCTAAAGGAAATGACTGAT
GGAGGTGTGGATTTTTCGTTTGAAGTCATCGGTCGGCTTGACACCATGATGGCTTCCCTG
TTATGTTGTCATGAGGCATGTGGCACAAGCGTCATCGTAGGGGTACCTCCTGCTTCCCAG
AACCTCTCAATAAACCCTATGCTGCTACTGACTGGACGCACCTGGAAGGGGGCTGTTTAT
GGTGGCTTTAAGAGTAAAGAAGGTATCCCAAAACTTGTGGCTGATTTTATGGCTAAGAAG
TTTTCACTGGATGCGTTAATAACCCATGTTTTACCTTTTGAAAAAATAAATGAAGGATTT
GACCTGCTTCACTCTGGGAAAAGTATCCGTACCGTCCTGACGTTTTGA

# Drug_Target_6_General_Function:
Energy production and conversion

# Drug_Target_6_General_References:
10733556	Borras E, Coutelle C, Rosell A, Fernandez-Muixi F, Broch M, Crosas B, Hjelmqvist L, Lorenzo A, Gutierrez C, Santos M, Szczepanek M, Heilig M, Quattrocchi P, Farres J, Vidal F, Richart C, Mach T, Bogdal J, Jornvall H, Seitz HK, Couzigou P, Pares X: Genetic polymorphism of alcohol dehydrogenase in europeans: the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1. Hepatology. 2000 Apr;31(4):984-9.
11274460	Niederhut MS, Gibbons BJ, Perez-Miller S, Hurley TD: Three-dimensional structures of the three human class I alcohol dehydrogenases. Protein Sci. 2001 Apr;10(4):697-706.
1896463	Hurley TD, Bosron WF, Hamilton JA, Amzel LM: Structure of human beta 1 beta 1 alcohol dehydrogenase: catalytic effects of non-active-site substitutions. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8149-53.
2547609	Matsuo Y, Yokoyama R, Yokoyama S: The genes for human alcohol dehydrogenases beta 1 and beta 2 differ by only one nucleotide. Eur J Biochem. 1989 Aug 1;183(2):317-20.
2679216	Carr LG, Xu Y, Ho WH, Edenberg HJ: Nucleotide sequence of the ADH2(3) gene encoding the human alcohol dehydrogenase beta 3 subunit. Alcohol Clin Exp Res. 1989 Aug;13(4):594-6.
2935533	Duester G, Smith M, Bilanchone V, Hatfield GW: Molecular analysis of the human class I alcohol dehydrogenase gene family and nucleotide sequence of the gene encoding the beta subunit. J Biol Chem. 1986 Feb 15;261(5):2027-33.
2935875	Ikuta T, Szeto S, Yoshida A: Three human alcohol dehydrogenase subunits: cDNA structure and molecular and evolutionary divergence. Proc Natl Acad Sci U S A. 1986 Feb;83(3):634-8.
3000832	Heden LO, Hoog JO, Larsson K, Lake M, Lagerholm E, Holmgren A, Vallee BL, Jornvall H, von Bahr-Lindstrom H: cDNA clones coding for the beta-subunit of human liver alcohol dehydrogenase have differently sized 3'-non-coding regions. FEBS Lett. 1986 Jan 6;194(2):327-32.
3397059	Xu YL, Carr LG, Bosron WF, Li TK, Edenberg HJ: Genotyping of human alcohol dehydrogenases at the ADH2 and ADH3 loci following DNA sequence amplification. Genomics. 1988 Apr;2(3):209-14.
3619918	Burnell JC, Carr LG, Dwulet FE, Edenberg HJ, Li TK, Bosron WF: The human beta 3 alcohol dehydrogenase subunit differs from beta 1 by a Cys for Arg-369 substitution which decreases NAD(H) binding. Biochem Biophys Res Commun. 1987 Aug 14;146(3):1127-33.
6374651	Jornvall H, Hempel J, Vallee BL, Bosron WF, Li TK: Human liver alcohol dehydrogenase: amino acid substitution in the beta 2 beta 2 Oriental isozyme explains functional properties, establishes an active site structure, and parallels mutational exchanges in the yeast enzyme. Proc Natl Acad Sci U S A. 1984 May;81(10):3024-8.
6391920	Hempel J, Buhler R, Kaiser R, Holmquist B, de Zalenski C, von Wartburg JP, Vallee B, Jornvall H: Human liver alcohol dehydrogenase. 1. The primary structure of the beta 1 beta 1 isoenzyme. Eur J Biochem. 1984 Dec 17;145(3):437-45.
8201622	Hurley TD, Bosron WF, Stone CL, Amzel LM: Structures of three human beta alcohol dehydrogenase variants. Correlations with their functional differences. J Mol Biol. 1994 Jun 10;239(3):415-29.
8663387	Davis GJ, Bosron WF, Stone CL, Owusu-Dekyi K, Hurley TD: X-ray structure of human beta3beta3 alcohol dehydrogenase. The contribution of ionic interactions to coenzyme binding. J Biol Chem. 1996 Jul 19;271(29):17057-61.

# Drug_Target_6_HGNC_ID:
HGNC:250

# Drug_Target_6_HPRD_ID:
00065

# Drug_Target_6_ID:
444

# Drug_Target_6_Locus:
4q21-q23

# Drug_Target_6_Molecular_Weight:
39724

# Drug_Target_6_Name:
Alcohol dehydrogenase 1B

# Drug_Target_6_Number_of_Residues:
374

# Drug_Target_6_PDB_ID:
1HSZ

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_6_Protein_Sequence:
>Alcohol dehydrogenase 1B
STAGKVIKCKAAVLWEVKKPFSIEDVEVAPPKAYEVRIKMVAVGICRTDDHVVSGNLVTP
LPVILGHEAAGIVESVGEGVTTVKPGDKVIPLFTPQCGKCRVCKNPESNYCLKNDLGNPR
GTLQDGTRRFTCRGKPIHHFLGTSTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGY
GSAVNVAKVTPGSTCAVFGLGGVGLSAVMGCKAAGAARIIAVDINKDKFAKAKELGATEC
INPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPASQN
LSINPMLLLTGRTWKGAVYGGFKSKEGIPKLVADFMAKKFSLDALITHVLPFEKINEGFD
LLHSGKSIRTVLTF

# Drug_Target_6_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P00325

# Drug_Target_6_SwissProt_Name:
ADH1B_HUMAN

# Drug_Target_6_Synonyms:
Alcohol dehydrogenase beta subunit
EC 1.1.1.1

# Drug_Target_6_Theoretical_pI:
8.38

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_70_Cellular_Location:
Not Available

# Drug_Target_70_Chromosome_Location:
Not Available

# Drug_Target_70_Drug_References:
16777263	Wang ZQ, Yuan YZ, Ou JQ, Lin QH, Zhang CF: Glutamine synthetase and glutamate dehydrogenase contribute differentially to proline accumulation in leaves of wheat (Triticum aestivum) seedlings exposed to different salinity. J Plant Physiol. 2007 Jun;164(6):695-701. Epub 2006 Jun 14.
17474756	Forlani G, Giberti S, Berlicki L, Petrollino D, Kafarski P: Plant P5C reductase as a new target for aminomethylenebisphosphonates. J Agric Food Chem. 2007 May 30;55(11):4340-7. Epub 2007 May 3.

# Drug_Target_70_Essentiality:
Non-Essential

# Drug_Target_70_GenAtlas_ID:
PYCR1

# Drug_Target_70_GenBank_ID_Gene:
M77836

# Drug_Target_70_GenBank_ID_Protein:
189498

# Drug_Target_70_GeneCard_ID:
PYCR1

# Drug_Target_70_Gene_Name:
PYCR1

# Drug_Target_70_Gene_Sequence:
>960 bp
ATGAGCGTGGGCTTCATCGGCGCTGGCCAGCTGGCTTTTGCCCTGGCCAAGGGCTTCACA
GCAGCAGGCGTCTTGGCTGCCCACAAGATAATGGCTAGCTCCCCAGACATGGACCTGGCC
ACAGTTTCTGCTCTCAGGAAGATGGGGGTGAAGTTGACACCCCACAACAAGGAGACGGTG
CAGCACAGTGATGTGCTCTTCCTGGCTGTGAAGCCACACATCATCCCCTTCATCCTGGAT
GAAATAGGCGCCGACATTGAGGACAGACACATTGTGGTGTCCTGCGCGGCCGGCGTCACC
ATCAGCTCCATTGAGAAGAAGCTGTCAGCGTTTCGGCCAGCCCCCAGGGTCATCCGCTGC
ATGACCAACACTCCAGTCGTGGTGCGGGAGGGGGCCACCGTGTATGCCACAGGCACGCAC
GCCCAGGTGGAGGACGGGAGGCTCATGGAGCAGCTGCTGAGCACGGTGGGCTTCTGCACG
GAGGTGGAAGAGGACCTGATTGATGCCGTCACGGGGCTCAGTGGCAGCGGCCCCGCCTAC
GCATTCACAGCCCTGGATGCCCTGGCTGATGGGGGTGTGAAGATGGGACTTCCAAGGCGC
CTGGCAGTCCGCCTCGGGGCCCAGGCCCTCCTGGGGGCTGCCAAGATGCTGCTGCACTCA
GAACAGCACCCAGGCCAGCTCAAGGACAACGTCAGCTCTCCTGGTGGGGCCACCATCCAT
GCCTTGCATGTGCTGGAGAGTGGGGGCTTCCGCTCCCTGCTCATCAACGCTGTGGAGGCC
TCCTGCATCCGCACACGGGAGCTGCAGTCCATGGCTGACCAGGAGCAGGTGTCACCAGCC
GCCATCAAGAAGACCATCCTGGACAAGGTGAAGCTGGACTCCCCTGCAGGGACCGCTCTG
TCGCCTTCTGGCCACACCAAGCTGCTCCCCCGCAGCCTGGCCCCAGCGGGCAAGGATTGA

# Drug_Target_70_General_Function:
Amino acid transport and metabolism

# Drug_Target_70_General_References:
1730675	Dougherty KM, Brandriss MC, Valle D: Cloning human pyrroline-5-carboxylate reductase cDNA by complementation in Saccharomyces cerevisiae. J Biol Chem. 1992 Jan 15;267(2):871-5.

# Drug_Target_70_HGNC_ID:
HGNC:9721

# Drug_Target_70_HPRD_ID:
01528

# Drug_Target_70_ID:
248

# Drug_Target_70_Locus:
17q25.3

# Drug_Target_70_Molecular_Weight:
33361

# Drug_Target_70_Name:
Pyrroline-5-carboxylate reductase 1

# Drug_Target_70_Number_of_Residues:
319

# Drug_Target_70_PDB_ID:
Not Available

# Drug_Target_70_Pathway:
Not Available

# Drug_Target_70_Pfam_Domain_Function:
PF03807	F420_oxidored

# Drug_Target_70_Protein_Sequence:
>Pyrroline-5-carboxylate reductase 1
MSVGFIGAGQLAFALAKGFTAAGVLAAHKIMASSPDMDLATVSALRKMGVKLTPHNKETV
QHSDVLFLAVKPHIIPFILDEIGADIEDRHIVVSCAAGVTISSIEKKLSAFRPAPRVIRC
MTNTPVVVREGATVYATGTHAQVEDGRLMEQLLSSVGFCTEVEEDLIDAVTGLSGSGPAY
AFTALDALADGGVKMGLPRRLAVRLGAQALLGAAKMLLHSEQHPGQLKDNVSSPGGATIH
ALHVLESGGFRSLLINAVEASCIRTRELQSMADQEQVSPAAIKKTILDKVKLDSPAGTAL
SPSGHTKLLPRSLAPAGKD

# Drug_Target_70_Reaction:
L-proline + NAD(P)+ = 1-pyrroline-5-carboxylate + NAD(P)H + H+

# Drug_Target_70_Signals:
None

# Drug_Target_70_Specific_Function:
Not Available

# Drug_Target_70_SwissProt_ID:
P32322

# Drug_Target_70_SwissProt_Name:
P5CR1_HUMAN

# Drug_Target_70_Synonyms:
EC 1.5.1.2
P5C reductase 1
P5CR 1

# Drug_Target_70_Theoretical_pI:
7.69

# Drug_Target_70_Transmembrane_Regions:
None

# Drug_Target_71_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_71_Chromosome_Location:
Not Available

# Drug_Target_71_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_71_Essentiality:
Non-Essential

# Drug_Target_71_GenAtlas_ID:
GLUD1

# Drug_Target_71_GenBank_ID_Gene:
X07674

# Drug_Target_71_GenBank_ID_Protein:
31707

# Drug_Target_71_GeneCard_ID:
GLUD1

# Drug_Target_71_Gene_Name:
GLUD1

# Drug_Target_71_Gene_Sequence:
>1677 bp
ATGTACCGCTACCTGGGCGAAGCGCTGTTGCTGTCCCGGGCCGGGCCCGCTGCCCTGGGC
TCGGCGTCCGCCGACTCGGCCGCGTTGCTGGGCTGGGCCCGGGGACAGCCCGCCGCCGCC
CCGCAGCCGGGGCTGGCATTGGCCGCCCGGCGCCACTACAGCGAGGCGGTGGCCGACCGC
GAGGACGACCCCAACTTCTTCAAGATGGTGGAGGGCTTCTTCGATCGCGGCGCCAGCATC
GTGGAGGACAAGCTGGTGGAGGACCTGAGGACCCGGGAGAGCGAGGAGCAGAAGCGGAAC
CGGGTGCGCGGCATCCTGCGGATCATCAAGCCCTGCAACCATGTGCTGAGTCTCTCCTTC
CCCATCCGGCGCGACGACGGCTCCTGGGAGGTCATCGAAGGCTACCGGGCCCAGCACAGC
CAGCACCGCACGCCCTGCAAGGGAGGTATCCGTTACAGCACTGATGTGAGTGTAGATGAA
GTAAAAGCTTTGGCTTCTCTGATGACATACAAGTGTGCAGTGGTTGATGTGCCGTTTGGG
GGTGCTAAAGCTGGTGTTAAGATCAATCCCAAGAACTATACTGATAATGAATTGGAAAAG
ATCACAAGGAGGTTCACCATGGAGCTAGCAAAAAAGGGCTTTATTGGTCCTGGCATTGAT
GTGCCTGCTCCAGACATGAGCACAGGTGAGCGGGAGATGTCCTGGATCGCTGATACCTAT
GCCAGCACCATAGGGCACTATGATATTAATGCACACGCCTGTGTTACTGGTAAACCCATC
AGCCAAGGGGGAATCCATGGACGCATCTCTGCTACTGGCCGTGGTGTCTTCCATGGGATT
GAAAATTTCATCAATGAAGCTTCTTACATGAGCATTTTAGGAATGACACCAGGGTTTGGA
GATAAAACATTTGTTGTTCAGGGATTTGGTAATGTGGGCCTACACTCTATGAGATATTTA
CATCGTTTTGGTGCTAAATGTATTGCTGTTGGTGAGTCTGATGGGAGTATATGGAATCCA
GATGGTATTGACCCAAAGGAACTGGAAGACTTCAAATTGCAACATGGGTCCATTCTGGGC
TTCCCCAAGGCAAAGCCCTATGAAGGAAGCATCTTGGAGGCCGACTGTGACATACTGATC
CCAGCTGCCAGTGAGAAGCAGTTGACCAAATCCAACGCACCCAGAGTCAAAGCCAAGATC
ATTGCTGAAGGTGCCAATGGGCCAACAACTCCAGAAGCTGACAAGATCTTCCTGGAGAGA
AACATTATGGTTATTCCAGATCTCTACTTGAATGCTGGAGGAGTGACAGTATCTTACTTT
GAGTGGCTGAAGAATCTAAATCATGTCAGCTATGGCCGTTTGACCTTCAAATATGAAAGG
GATTCTAACTACCACTTGCTCATGTCTGTTCAAGAGAGTTTAGAAAGAAAATTTGGAAAG
CATGGTGGAACTATTCCCATTGTACCCACGGCAGAGTTCCAAGACAGGATATCGGGTGCA
TCTGAGAAAGACATCGTGCACTCTGGCTTGGCATACACAATGGAGCGTTCTGCCAGGCAA
ATTATGCGCACAGCCATGAAGTATAACCTGGGATTGGACCTGAGAACAGCTGCCTATGTT
AATGCCATTGAGAAAGTCTTCAAAGTGTACAATGAAGCTGGTGTGACCTTCACATAG

# Drug_Target_71_General_Function:
Replication, recombination and repair

# Drug_Target_71_General_References:
10338089	Meissner T, Beinbrech B, Mayatepek E: Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Hum Mutat. 1999;13(5):351-61.
10636977	Miki Y, Taki T, Ohura T, Kato H, Yanagisawa M, Hayashi Y: Novel missense mutations in the glutamate dehydrogenase gene in the congenital hyperinsulinism-hyperammonemia syndrome. J Pediatr. 2000 Jan;136(1):69-72.
11214910	Santer R, Kinner M, Passarge M, Superti-Furga A, Mayatepek E, Meissner T, Schneppenheim R, Schaub J: Novel missense mutations outside the allosteric domain of glutamate dehydrogenase are prevalent in European patients with the congenital hyperinsulinism-hyperammonemia syndrome. Hum Genet. 2001 Jan;108(1):66-71.
11254391	Smith TJ, Peterson PE, Schmidt T, Fang J, Stanley CA: Structures of bovine glutamate dehydrogenase complexes elucidate the mechanism of purine regulation. J Mol Biol. 2001 Mar 23;307(2):707-20.
11297618	MacMullen C, Fang J, Hsu BY, Kelly A, de Lonlay-Debeney P, Saudubray JM, Ganguly A, Smith TJ, Stanley CA: Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab. 2001 Apr;86(4):1782-7.
11903050	Fang J, Hsu BY, MacMullen CM, Poncz M, Smith TJ, Stanley CA: Expression, purification and characterization of human glutamate dehydrogenase (GDH) allosteric regulatory mutations. Biochem J. 2002 Apr 1;363(Pt 1):81-7.
12054821	Smith TJ, Schmidt T, Fang J, Wu J, Siuzdak G, Stanley CA: The structure of apo human glutamate dehydrogenase details subunit communication and allostery. J Mol Biol. 2002 May 3;318(3):765-77.
12653548	Banerjee S, Schmidt T, Fang J, Stanley CA, Smith TJ: Structural studies on ADP activation of mammalian glutamate dehydrogenase and the evolution of regulation. Biochemistry. 2003 Apr 1;42(12):3446-56.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
3368458	Mavrothalassitis G, Tzimagiorgis G, Mitsialis A, Zannis V, Plaitakis A, Papamatheakis J, Moschonas N: Isolation and characterization of cDNA clones encoding human liver glutamate dehydrogenase: evidence for a small gene family. Proc Natl Acad Sci U S A. 1988 May;85(10):3494-8.
3377777	Amuro N, Yamaura M, Goto Y, Okazaki T: Molecular cloning and nucleotide sequence of the cDNA for human liver glutamate dehydrogenase precursor. Biochem Biophys Res Commun. 1988 May 16;152(3):1395-400.
3399399	Nakatani Y, Schneider M, Banner C, Freese E: Complete nucleotide sequence of human glutamate dehydrogenase cDNA. Nucleic Acids Res. 1988 Jul 11;16(13):6237.
3426581	Nakatani Y, Banner C, von Herrath M, Schneider ME, Smith HH, Freese E: Comparison of human brain and liver glutamate dehydrogenase cDNAS. Biochem Biophys Res Commun. 1987 Dec 16;149(2):405-10.
3585334	Banner C, Silverman S, Thomas JW, Lampel KA, Vitkovic L, Huie D, Wenthold RJ: Isolation of a human brain cDNA for glutamate dehydrogenase. J Neurochem. 1987 Jul;49(1):246-52.
429360	Julliard JH, Smith EL: Partial amino acid sequence of the glutamate dehydrogenase of human liver and a revision of the sequence of the bovine enzyme. J Biol Chem. 1979 May 10;254(9):3427-38.
8314555	Tzimagiorgis G, Leversha MA, Chroniary K, Goulielmos G, Sargent CA, Ferguson-Smith M, Moschonas NK: Structure and expression analysis of a member of the human glutamate dehydrogenase (GLUD) gene family mapped to chromosome 10p11.2. Hum Genet. 1993 Jun;91(5):433-8.
8486350	Michaelidis TM, Tzimagiorgis G, Moschonas NK, Papamatheakis J: The human glutamate dehydrogenase gene family: gene organization and structural characterization. Genomics. 1993 Apr;16(1):150-60.
9571255	Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998 May 7;338(19):1352-7.

# Drug_Target_71_HGNC_ID:
HGNC:4335

# Drug_Target_71_HPRD_ID:
11748

# Drug_Target_71_ID:
201

# Drug_Target_71_Locus:
10q23.3

# Drug_Target_71_Molecular_Weight:
61399

# Drug_Target_71_Name:
Glutamate dehydrogenase 1, mitochondrial

# Drug_Target_71_Number_of_Residues:
558

# Drug_Target_71_PDB_ID:
1L1F

# Drug_Target_71_Pathway:
Not Available

# Drug_Target_71_Pfam_Domain_Function:
PF00208	ELFV_dehydrog
PF02812	ELFV_dehydrog_N

# Drug_Target_71_Protein_Sequence:
>Glutamate dehydrogenase 1, mitochondrial precursor
MYRYLGEALLLSRAGPAALGSASADSAALLGWARGQPAAAPQPGLALAARRHYSEAVADR
EDDPNFFKMVEGFFDRGASIVEDKLVEDLRTRESEEQKRNRVRGILRIIKPCNHVLSLSF
PIRRDDGSWEVIEGYRAQHSQHRTPCKGGIRYSTDVSVDEVKALASLMTYKCAVVDVPFG
GAKAGVKINPKNYTDNELEKITRRFTMELAKKGFIGPGIDVPAPDMSTGEREMSWIADTY
ASTIGHYDINAHACVTGKPISQGGIHGRISATGRGVFHGIENFINEASYMSILGMTPGFG
DKTFVVQGFGNVGLHSMRYLHRFGAKCIAVGESDGSIWNPDGIDPKELEDFKLQHGSILG
FPKAKPYEGSILEADCDILIPAASEKQLTKSNAPRVKAKIIAEGANGPTTPEADKIFLER
NIMVIPDLYLNAGGVTVSYFEWLKNLNHVSYGRLTFKYERDSNYHLLMSVQESLERKFGK
HGGTIPIVPTAEFQDRISGASEKDIVHSGLAYTMERSARQIMRTAMKYNLGLDLRTAAYV
NAIEKVFKVYNEAGVTFT

# Drug_Target_71_Reaction:
L-glutamate + H2O + NAD(P)+ = 2-oxoglutarate + NH3 + NAD(P)H + H+

# Drug_Target_71_Signals:
None

# Drug_Target_71_Specific_Function:
May be involved in learning and memory reactions by increasing the turnover of the excitatory neurotransmitter glutamate

# Drug_Target_71_SwissProt_ID:
P00367

# Drug_Target_71_SwissProt_Name:
DHE3_HUMAN

# Drug_Target_71_Synonyms:
EC 1.4.1.3
GDH
Glutamate dehydrogenase 1, mitochondrial precursor

# Drug_Target_71_Theoretical_pI:
7.91

# Drug_Target_71_Transmembrane_Regions:
None

# Drug_Target_72_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_72_Chromosome_Location:
Not Available

# Drug_Target_72_Drug_References:
1116996	Taylor SI, Mukherjee C, Jungas RL: Regulation of pyruvate dehydrogenase in isolated rat liver mitochondria. Effects of octanoate, oxidation-reduction state, and adenosine triphosphate to adenosine diphosphate ratio. J Biol Chem. 1975 Mar 25;250(6):2028-35.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_72_Essentiality:
Non-Essential

# Drug_Target_72_GenAtlas_ID:
PDHB

# Drug_Target_72_GenBank_ID_Gene:
M34479

# Drug_Target_72_GenBank_ID_Protein:
189760

# Drug_Target_72_GeneCard_ID:
PDHB

# Drug_Target_72_Gene_Name:
PDHB

# Drug_Target_72_Gene_Sequence:
>1080 bp
ATGGCGGCGGTGTCTGGCTTGGTGCGGAGACCCCTTCGGGAGGTCTCCGGGCTGCTGAAG
AGGCGCTTTCACTGGACCGCGCCGGCTGCGCTGCAGGTGACAGTTCGTGATGCTATAAAT
CAGGGTATGGATGAGGAGCTGGAAAGAGATGAGAAGGTATTTCTGCTTGGAGAAGAAGTT
GCCCAGTATGATGGGGCATACAAGGTTAGTCGAGGGCTGTGGAAGAAATATGGAGACAAG
AGGATTATTGACACTCCCATATCAGAGATGGGCTTTGCTGGAATTGCTGTAGGTGCAGCT
ATGGCTGGGTTGCGGCCCATTTGTGAATTTATGACCTTCAATTTCTCCATGCAAGCCATT
GACCAGGTTATAAACTCAGCTGCCAAGACCTACTACATGTCTGGTGGCCTTCAGCCTGTG
CCTATAGTCTTCAGGGGACCCAATGGTGCCTCAGCAGGTGTAGCTGCCCAGCACTCACAG
TGCTTTGCTGCCTGGTATGGGCACTGCCCAGGCTTAAAGGTGGTCAGTCCCTGGAATTCA
GAGGATGCTAAAGGACTTATTAAATCAGCCATTCGGGATAACAATCCAGTGGTGGTGCTA
GAGAATGAATTGATGTATGGGGTTCCTTTTGAATTTCCTCCGGAAGCTCAGTCAAAAGAT
TTTCTGATTCCTATTGGAAAAGCCAAAATAGAAAGGCAAGGAACACATATAACTGTGGTT
TCCCATTCAAGACCTGTGGGCCACTGCTTAGAAGCTGCAGCAGTGCTATCTAAAGAAGGA
GTTGAATGTGAGGTGATAAATATGCGTACCATTAGACCAATGGACATGGAAACCATAGAA
GCCAGTGTCATGAAGACAAATCATCTTGTAACTGTGGAAGGAGGCTGGCCACAGTTTGGA
GTAGGAGCTGAAATCTGTGCCAGGATCATGGAAGGTCCTGCGTTCAATTTCCTGGATGCT
CCTGCTGTTCGTGTCACTGGTGCTGATGTCCCTATGCCTTATGCAAAGATTCTAGAGGAC
AACTCTATACCTCAGGTCAAAGACATCATATTTGCAATAAAGAAAACATTAAATATTTAG

# Drug_Target_72_General_Function:
Energy production and conversion

# Drug_Target_72_General_References:
11230166	Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J, Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwalder B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein M, Poustka A: Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res. 2001 Mar;11(3):422-35.
12651851	Ciszak EM, Korotchkina LG, Dominiak PM, Sidhu S, Patel MS: Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase. J Biol Chem. 2003 Jun 6;278(23):21240-6. Epub 2003 Mar 21.
1702713	Chun K, Mackay N, Willard HF, Robinson BH: Isolation, characterization and chromosomal localization of cDNA clones for the E1 beta subunit of the pyruvate dehydrogenase complex. Eur J Biochem. 1990 Dec 12;194(2):587-92.
2295468	Muno D, Kominami E, Ishii H, Usui K, Saifuku K, Sakakibara Y, Namihisa T: Isolation of tryptic fragment of antigen from mitochondrial inner membrane proteins reacting with antimitochondrial antibody in sera of patients with primary biliary cirrhosis. Hepatology. 1990 Jan;11(1):16-23.
2323578	Ho L, Patel MS: Cloning and cDNA sequence of the beta-subunit component of human pyruvate dehydrogenase complex. Gene. 1990 Feb 14;86(2):297-302.
2376596	Huh TL, Casazza JP, Huh JW, Chi YT, Song BJ: Characterization of two cDNA clones for pyruvate dehydrogenase E1 beta subunit and its regulation in tricarboxylic acid cycle-deficient fibroblast. J Biol Chem. 1990 Aug 5;265(22):13320-6.
2377599	Koike K, Urata Y, Koike M: Molecular cloning and characterization of human pyruvate dehydrogenase beta subunit gene. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5594-7.
2829898	Ho L, Javed AA, Pepin RA, Thekkumkara TJ, Raefsky C, Mole JE, Caliendo AM, Kwon MS, Kerr DS, Patel MS: Identification of a cDNA clone for the beta-subunit of the pyruvate dehydrogenase component of human pyruvate dehydrogenase complex. Biochem Biophys Res Commun. 1988 Feb 15;150(3):904-8.
3422424	Koike K, Ohta S, Urata Y, Kagawa Y, Koike M: Cloning and sequencing of cDNAs encoding alpha and beta subunits of human pyruvate dehydrogenase. Proc Natl Acad Sci U S A. 1988 Jan;85(1):41-5.
7895732	Corbett JM, Wheeler CH, Baker CS, Yacoub MH, Dunn MJ: The human myocardial two-dimensional gel protein database: update 1994. Electrophoresis. 1994 Nov;15(11):1459-65.

# Drug_Target_72_HGNC_ID:
HGNC:8808

# Drug_Target_72_HPRD_ID:
01530

# Drug_Target_72_ID:
110

# Drug_Target_72_Locus:
3p21.1-p14.2

# Drug_Target_72_Molecular_Weight:
39220

# Drug_Target_72_Name:
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial

# Drug_Target_72_Number_of_Residues:
359

# Drug_Target_72_PDB_ID:
1NI4

# Drug_Target_72_Pathway:
Not Available

# Drug_Target_72_Pfam_Domain_Function:
PF02779	Transket_pyr
PF02780	Transketolase_C

# Drug_Target_72_Protein_Sequence:
>Pyruvate dehydrogenase E1 component subunit beta, mitochondrial precursor
MAAVSGLVRRPLREVSGLLKRRFHWTAPAAVQVTVRDAINQGMDEELERDEKVFLLGEEV
AQYDGAYKVSRGLWKKYGDKRIIDTPISEMGFAGIAVGAAMAGLRPICEFMTFNFSMQAI
DQVINSAAKTYYMSGGLQPVPIVFRGPNGASAGVAAQHSQCFAAWYGHCPGLKVVSPWNS
EDAKGLIKSAIRDNNPVVVLENELMYGVPFEFPPEAQSKDFLIPIGKAKIERQGTHITVV
SHSRPVGHCLEAAAVLSKEGVECEVINMRTIRPMDMETIEASVMKTNHLVTVEGGWPQFG
VGAEICARIMEGPAFNFLDAPAVRVTGADVPMPYAKILEDNSIPQVKDIIFAIKKTLNI

# Drug_Target_72_Reaction:
pyruvate + [dihydrolipoyllysine-residue acetyltransferase] lipoyllysine = [dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine + CO2

# Drug_Target_72_Signals:
None

# Drug_Target_72_Specific_Function:
The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components:pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_72_SwissProt_ID:
P11177

# Drug_Target_72_SwissProt_Name:
ODPB_HUMAN

# Drug_Target_72_Synonyms:
EC 1.2.4.1
PDHE1-B
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial precursor

# Drug_Target_72_Theoretical_pI:
6.63

# Drug_Target_72_Transmembrane_Regions:
None

# Drug_Target_73_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_73_Chromosome_Location:
Not Available

# Drug_Target_73_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_73_Essentiality:
Non-Essential

# Drug_Target_73_GenAtlas_ID:
PDHA2

# Drug_Target_73_GenBank_ID_Gene:
M86808

# Drug_Target_73_GenBank_ID_Protein:
190790

# Drug_Target_73_GeneCard_ID:
PDHA2

# Drug_Target_73_Gene_Name:
PDHA2

# Drug_Target_73_Gene_Sequence:
>1167 bp
ATGCTGGCCGCCTTCATCTCCCGCGTGTTGAGGCGAGTTGCCCAGAAATCAGCTCGCAGA
GTGCTGGTGGCATCCCGTAACTCCTCAAATGACGCTACATTTGAAATTAAGAAATGTGAT
CTTTATCTGTTGGAAGAGGGTCCCCCTGTCACTACAGTGCTCACTAGGGCGGAGGGGCTT
AAATACTACAGGATGATGCTGACTGTTCGCCGCATGGAATTGAAGGCAGATCAGCTGTAC
AAACAGAAATTCATTCGCGGTTTCTGTCACCTGTGCGATGGTCAGGAAGCTTGTTGCGTG
GGCCTTGAGGCCGGCATAAACCCCTCGGATCACGTCATTACATCCTATAGGGCTCATGGT
GTGTGCTATACTCGGGGACTTTCTGTCCGATCCATTCTCGCAGAGCTGACGGGAAGAAGA
GGAGGTTGTGCTAAAGGAAAAGGAGGATCGATGCATATGTATACCAAGAACTTCTATGGG
GGCAATGGCATCGTCGGTGCACAGGGCCCCCTGGGCGCTGGCATTGCTCTGGCCTGTAAA
TATAAAGGAAACGATGAGATCTGTTTGACTTTATATGGGGATGGCGCTGCGAATCAGGGG
CAGATAGCCGAAGCTTTCAATATGGCAGCTTTATGGAAATTACCTTGTGTTTTCATCTGT
GAGAATAACCTATATGGAATGGGAACATCTACTGAGAGAGCAGCAGCCAGCCCTGATTAC
TACAAGAGGGGCAATTTTATCCCTGGGCTAAAGGTCGATGGAATGGATGTTCTGTGTGTT
CGTGAGGCAACAAAATTTGCAGCTAACTACTGTAGATCTGGAAAGGGGCCCATACTGATG
GAGCTGCAAACCTACCGTTATCATGGACACAGTATGAGTGATCCTGGAGTCAGTTATCGT
ACACGAGAAGAAATTCAGGAAGTAAGAAGTAAGAGGGATCCTATAATAATTCTCCAAGAT
AGAATGGTAAACAGCAAGCTCGCCACTGTGGAAGAATTAAAGGAAATTGGGGCTGAGGTG
AGGAAAGAAATTGATGATGCTGCCCAGTTTGCTACCACTGATCCTGAGCCACATTTGGAA
GAATTAGGCCATCACATCTACAGCAGTGATTCATCTTTTGAAGTTCGTGGTGCAAATCCA
TGGATCAAGTTTAAGTCCGTCAGTTAA

# Drug_Target_73_General_Function:
Energy production and conversion

# Drug_Target_73_General_References:
2249846	Dahl HH, Brown RM, Hutchison WM, Maragos C, Brown GK: A testis-specific form of the human pyruvate dehydrogenase E1 alpha subunit is coded for by an intronless gene on chromosome 4. Genomics. 1990 Oct;8(2):225-32.

# Drug_Target_73_HGNC_ID:
HGNC:8807

# Drug_Target_73_HPRD_ID:
01531

# Drug_Target_73_ID:
671

# Drug_Target_73_Locus:
4q22-q23

# Drug_Target_73_Molecular_Weight:
42934

# Drug_Target_73_Name:
Pyruvate dehydrogenase E1 component alpha subunit, testis-specific form, mitochondrial

# Drug_Target_73_Number_of_Residues:
388

# Drug_Target_73_PDB_ID:
Not Available

# Drug_Target_73_Pathway:
Not Available

# Drug_Target_73_Pfam_Domain_Function:
PF00676	E1_dh

# Drug_Target_73_Protein_Sequence:
>Pyruvate dehydrogenase E1 component alpha subunit, testis-specific form, mitochondrial precursor
MLAAFISRVLRRVAQKSARRVLVASRNSSNDATFEIKKCDLYLLEEGPPVTTVLTRAEGL
KYYRMMLTVRRMELKADQLYKQKFIRGFCHLCDGQEACCVGLEAGINPSDHVITSYRAHG
VCYTRGLSVRSILAELTGRRGGCAKGKGGSMHMYTKNFYGGNGIVGAQGPLGAGIALACK
YKGNDEICLTLYGDGAANQGQIAEAFNMAALWKLPCVFICENNLYGMGTSTERAAASPDY
YKRGNFIPGLKVDGMDVLCVREATKFAANYCRSGKGPILMELQTYRYHGHSMSDPGVSYR
TREEIQEVRSKRDPIIILQDRMVNSKLATVEELKEIGAEVRKEIDDAAQFATTDPEPHLE
ELGHHIYSSDSSFEVRGANPWIKFKSVS

# Drug_Target_73_Reaction:
pyruvate + [dihydrolipoyllysine-residue acetyltransferase] lipoyllysine = [dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine + CO2

# Drug_Target_73_Signals:
None

# Drug_Target_73_Specific_Function:
The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components:pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_73_SwissProt_ID:
P29803

# Drug_Target_73_SwissProt_Name:
ODPAT_HUMAN

# Drug_Target_73_Synonyms:
EC 1.2.4.1
PDHE1-A type II
Pyruvate dehydrogenase E1 component alpha subunit, testis-specific form, mitochondrial precursor

# Drug_Target_73_Theoretical_pI:
8.56

# Drug_Target_73_Transmembrane_Regions:
None

# Drug_Target_74_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_74_Chromosome_Location:
Not Available

# Drug_Target_74_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_74_Essentiality:
Non-Essential

# Drug_Target_74_GenAtlas_ID:
PDHA1

# Drug_Target_74_GenBank_ID_Gene:
M27257

# Drug_Target_74_GenBank_ID_Protein:
387009

# Drug_Target_74_GeneCard_ID:
PDHA1

# Drug_Target_74_Gene_Name:
PDHA1

# Drug_Target_74_Gene_Sequence:
>1173 bp
ATGAGGAAGATGCTCGCCGCCGTCTCCCGCGTGCTGTCTGGCGCTTCTCAGAAGCCGGCA
AGCAGAGTGCTGGTAGCATCCCGTAATTTTGCAAATGATGCTACATTTGAAATTAAGAAA
TGTGACCTTCACCGGCTGGAAGAAGGCCCTCCTGTCACAACAGTGCTCACCAGGGAGGAT
GGGCTCAAATACTACAGGATGATGCAGACTGTACGCCGAATGGAGTTGAAAGCAGATCAG
CTGTATAAACAGAAAATTATTCGTGGTTTCTGTCACTTGTGTGATGGTCAGGAAGCTTGC
TGTGTGGGCCTGGAGGCCGGCATCAACCCCACAGACCATCTCATCACAGCCTACCGGGCT
CACGGCTTTACTTTCACCCGGGGCCTTTCCGTCCGAGAAATTCTCGCAGAGCTTACAGGA
CGAAAAGGAGGTTGTGCTAAAGGGAAAGGAGGATCGATGCACATGTATGCCAAGAACTTC
TACGGGGGCAATGGCATCGTGGGAGCGCAGGTGCCCCTGGGCGCTGGGATTGCTCTAGCC
TGTAAGTATAATGGAAAAGATGAGGTCTGCCTGACTTTATATGGCGATGGTGCTGCTAAC
CAGGGCCAGATATTCGAAGCTTACAACATGGCAGCTTTGTGGAAATTACCTTGTATTTTC
ATCTGTGAGAATAATCGCTATGGAATGGGAACGTCTGTTGAGAGAGCGGCAGCCAGCACT
GATTACTACAAGAGAGGCGATTTCATTCCTGGGCTGAGAGTGGATGGAATGGATATCCTG
TGCGTCCGAGAGGCAACAAGGTTTGCTGCTGCCTATTGTAGATCTGGGAAGGGGCCCATC
CTGATGGAGCTGCAGACTTACCGTTACCACGGACACAGTATGAGTGACCCTGGAGTCAGT
TACCGTACACGAGAAGAAATTCAGGAAGTAAGAAGTAAGAGTGACCCTATTATGCTTCTC
AAGGACAGGATGGTGAACAGCAATCTTGCCAGTGTGGAAGAACTAAAGGAAATTGATGTG
GAAGTGAGGAAGGAGATTGAGGATGCTGCCCAGTTTGCCACGGCCGATCCTGAGCCACCT
TTGGAAGAGCTGGGCTACCACATCTACTCCAGCGACCCACCTTTTGAAGTTCGTGGTGCC
AATCAGTGGATCAAGTTTAAGTCAGTCAGTTAA

# Drug_Target_74_General_Function:
Energy production and conversion

# Drug_Target_74_General_References:
10077682	Harris EE, Hey J: X chromosome evidence for ancient human histories. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3320-4.
12651851	Ciszak EM, Korotchkina LG, Dominiak PM, Sidhu S, Patel MS: Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase. J Biol Chem. 2003 Jun 6;278(23):21240-6. Epub 2003 Mar 21.
1293379	Dahl HH, Hansen LL, Brown RM, Danks DM, Rogers JG, Brown GK: X-linked pyruvate dehydrogenase E1 alpha subunit deficiency in heterozygous females: variable manifestation of the same mutation. J Inherit Metab Dis. 1992;15(6):835-47.
1301207	Dahl HH, Brown GK, Brown RM, Hansen LL, Kerr DS, Wexler ID, Patel MS, De Meirleir L, Lissens W, Chun K, et al.: Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha gene. Hum Mutat. 1992;1(2):97-102.
1338114	Ito M, Huq AH, Naito E, Saijo T, Takeda E, Kuroda Y: Mutation of E1 alpha gene in a female patient with pyruvate dehydrogenase deficiency due to rapid degradation of E1 protein. J Inherit Metab Dis. 1992;15(6):848-56.
1551669	De Meirleir L, Lissens W, Vamos E, Liebaers I: Pyruvate dehydrogenase (PDH) deficiency caused by a 21-base pair insertion mutation in the E1 alpha subunit. Hum Genet. 1992 Mar;88(6):649-52.
1909401	Hansen LL, Brown GK, Kirby DM, Dahl HH: Characterization of the mutations in three patients with pyruvate dehydrogenase E1 alpha deficiency. J Inherit Metab Dis. 1991;14(2):140-51.
2227443	Koike K, Urata Y, Matsuo S, Koike M: Characterization and nucleotide sequence of the gene encoding the human pyruvate dehydrogenase alpha-subunit. Gene. 1990 Sep 14;93(2):307-11.
2745444	Maragos C, Hutchison WM, Hayasaka K, Brown GK, Dahl HH: Structural organization of the gene for the E1 alpha subunit of the human pyruvate dehydrogenase complex. J Biol Chem. 1989 Jul 25;264(21):12294-8.
2748588	Ho L, Wexler ID, Liu TC, Thekkumkara TJ, Patel MS: Characterization of cDNAs encoding human pyruvate dehydrogenase alpha subunit. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5330-4.
2828359	De Meirleir L, MacKay N, Lam Hon Wah AM, Robinson BH: Isolation of a full-length complementary DNA coding for human E1 alpha subunit of the pyruvate dehydrogenase complex. J Biol Chem. 1988 Feb 5;263(4):1991-5.
3034892	Dahl HH, Hunt SM, Hutchison WM, Brown GK: The human pyruvate dehydrogenase complex. Isolation of cDNA clones for the E1 alpha subunit, sequence analysis, and characterization of the mRNA. J Biol Chem. 1987 May 25;262(15):7398-403.
3422424	Koike K, Ohta S, Urata Y, Kagawa Y, Koike M: Cloning and sequencing of cDNAs encoding alpha and beta subunits of human pyruvate dehydrogenase. Proc Natl Acad Sci U S A. 1988 Jan;85(1):41-5.
7545958	Hansen LL, Horn N, Dahl HH, Kruse TA: Pyruvate dehydrogenase deficiency caused by a 33 base pair duplication in the PDH E1 alpha subunit. Hum Mol Genet. 1994 Jun;3(6):1021-2.
7573035	Takakubo F, Cartwright P, Hoogenraad N, Thorburn DR, Collins F, Lithgow T, Dahl HH: An amino acid substitution in the pyruvate dehydrogenase E1 alpha gene, affecting mitochondrial import of the precursor protein. Am J Hum Genet. 1995 Oct;57(4):772-80.
7757088	Hemalatha SG, Kerr DS, Wexler ID, Lusk MM, Kaung M, Du Y, Kolli M, Schelper RL, Patel MS: Pyruvate dehydrogenase complex deficiency due to a point mutation (P188L) within the thiamine pyrophosphate binding loop of the E1 alpha subunit. Hum Mol Genet. 1995 Feb;4(2):315-8.
7887409	Chun K, MacKay N, Petrova-Benedict R, Federico A, Fois A, Cole DE, Robertson E, Robinson BH: Mutations in the X-linked E1 alpha subunit of pyruvate dehydrogenase: exon skipping, insertion of duplicate sequence, and missense mutations leading to the deficiency of the pyruvate dehydrogenase complex. Am J Hum Genet. 1995 Mar;56(3):558-69.
7967473	Awata H, Endo F, Tanoue A, Kitano A, Matsuda I: Characterization of a point mutation in the pyruvate dehydrogenase E1 alpha gene from two boys with primary lactic acidaemia. J Inherit Metab Dis. 1994;17(2):189-95.
8032855	Matthews PM, Brown RM, Otero LJ, Marchington DR, LeGris M, Howes R, Meadows LS, Shevell M, Scriver CR, Brown GK: Pyruvate dehydrogenase deficiency. Clinical presentation and molecular genetic characterization of five new patients. Brain. 1994 Jun;117 ( Pt 3):435-43.
8199595	Dahl HH, Brown GK: Pyruvate dehydrogenase deficiency in a male caused by a point mutation (F205L) in the E1 alpha subunit. Hum Mutat. 1994;3(2):152-5.
8498846	Matthews PM, Marchington DR, Squier M, Land J, Brown RM, Brown GK: Molecular genetic characterization of an X-linked form of Leigh's syndrome. Ann Neurol. 1993 Jun;33(6):652-5.
8504306	Chun K, MacKay N, Petrova-Benedict R, Robinson BH: Mutations in the X-linked E1 alpha subunit of pyruvate dehydrogenase leading to deficiency of the pyruvate dehydrogenase complex. Hum Mol Genet. 1993 Apr;2(4):449-54.
8664900	Lissens W, De Meirleir L, Seneca S, Benelli C, Marsac C, Poll-The BT, Briones P, Ruitenbeek W, van Diggelen O, Chaigne D, Ramaekers V, Liebaers I: Mutation analysis of the pyruvate dehydrogenase E1 alpha gene in eight patients with a pyruvate dehydrogenase complex deficiency. Hum Mutat. 1996;7(1):46-51.
8844217	Tripatara A, Kerr DS, Lusk MM, Kolli M, Tan J, Patel MS: Three new mutations of the pyruvate dehydrogenase alpha subunit: a point mutation (M181V), 3 bp deletion (-R282), and 16 bp insertion/frameshift (K358SVS-->TVDQS). Hum Mutat. 1996;8(2):180-2.
9671272	Otero LJ, Brown RM, Brown GK: Arginine 302 mutations in the pyruvate dehydrogenase E1alpha subunit gene: identification of further patients and in vitro demonstration of pathogenicity. Hum Mutat. 1998;12(2):114-21.

# Drug_Target_74_HGNC_ID:
HGNC:8806

# Drug_Target_74_HPRD_ID:
02420

# Drug_Target_74_ID:
628

# Drug_Target_74_Locus:
Xp22.2-p22.1

# Drug_Target_74_Molecular_Weight:
43296

# Drug_Target_74_Name:
Pyruvate dehydrogenase E1 component alpha subunit, somatic form, mitochondrial

# Drug_Target_74_Number_of_Residues:
390

# Drug_Target_74_PDB_ID:
1NI4

# Drug_Target_74_Pathway:
Not Available

# Drug_Target_74_Pfam_Domain_Function:
PF00676	E1_dh

# Drug_Target_74_Protein_Sequence:
>Pyruvate dehydrogenase E1 component alpha subunit, somatic form, mitochondrial precursor
MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTRED
GLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRA
HGFTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKNFYGGNGIVGAQVPLGAGIALA
CKYNGKDEVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVERAAAST
DYYKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMSDPGVS
YRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATADPEPP
LEELGYHIYSSDPPFEVRGANQWIKFKSVS

# Drug_Target_74_Reaction:
pyruvate + [dihydrolipoyllysine-residue acetyltransferase] lipoyllysine = [dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine + CO2

# Drug_Target_74_Signals:
None

# Drug_Target_74_Specific_Function:
The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components:pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_74_SwissProt_ID:
P08559

# Drug_Target_74_SwissProt_Name:
ODPA_HUMAN

# Drug_Target_74_Synonyms:
EC 1.2.4.1
PDHE1-A type I
Pyruvate dehydrogenase E1 component alpha subunit, somatic form, mitochondrial precursor

# Drug_Target_74_Theoretical_pI:
8.14

# Drug_Target_74_Transmembrane_Regions:
None

# Drug_Target_75_Cellular_Location:
Cytoplasm

# Drug_Target_75_Chromosome_Location:
Not Available

# Drug_Target_75_Drug_References:
17402939	Franklin E, Browne S, Hayes J, Boland C, Dunne A, Elliot G, Mantle TJ: Activation of biliverdin-IXalpha reductase by inorganic phosphate and related anions. Biochem J. 2007 Jul 1;405(1):61-7.

# Drug_Target_75_Essentiality:
Non-Essential

# Drug_Target_75_GenAtlas_ID:
BLVRA

# Drug_Target_75_GenBank_ID_Gene:
X93086

# Drug_Target_75_GenBank_ID_Protein:
1246749

# Drug_Target_75_GeneCard_ID:
BLVRA

# Drug_Target_75_Gene_Name:
BLVRA

# Drug_Target_75_Gene_Sequence:
>891 bp
ATGAATGCAGAGCCCGAGAGGAAGTTTGGCGTGGTGGTGGTTGGTGTTGGCCGAGCCGGC
TCCGTGCGGATGAGGGACTTGCGGAATCCACACCCTTCCTCAGCGTTCCTGAACCTGATT
GGCTTCGTGTCGAGAAGGGAGCTCGGGAGCATTGATGGAGTCCAGCAGATTTCTTTGGAG
GATGCTCTTTCCAGCCAAGAGGTGGAGGTCGCCTATATCTGCAGTGAGAGCTCCAGCCAT
GAGGACTACATCAGGCAGTTCCTTAATGCTGGCAAGCACGTCCTTGTGGAATACCCCATG
ACACTGTCATTGGCGGCCGCTCAGGAACTGTGGGAGCTGGCTGAGCAGAAAGGAAAAGTC
TTGCACGAGGAGCATGTTGAACTCTTGATGGAGGAATTCGCTTTCCTGAAAAAAGAAGTG
GTGGGGAAAGACCTGCTGAAAGGGTCGCTCCTCTTCACATCTGACCCGTTGGAAGAAGAC
CGGTTTGGCTTCCCTGCATTCAGCGGCATCTCTCGACTGACCTGGCTGGTCTCCCTCTTT
GGGGAGCTTTCTCTTGTGTCTGCCACTTTGGAAGAGCGAAAGGAAGATCAGTATATGAAA
ATGACAGTGTGTCTGGAGACAGAGAAGAAAAGTCCACTGTCATGGATTGAAGAAAAAGGA
CCTGGTCTAAAACGAAACAGATATTTAAGCTTCCATTTCAAGTCTGGGTCCTTGGAGAAT
GTGCCAAATGTAGGAGTGAATAAGAACATATTTCTGAAAGATCAAAATATATTTGTCCAG
AAACTCTTGGGCCAGTTCTCTGAGAAGGAACTGGCTGCTGAAAAGAAACGCATCCTGCAC
TGCCTGGGGCTTGCAGAAGAAATCCAGAAATATTGCTGTTCAAGGAAGTAA

# Drug_Target_75_General_Function:
Involved in oxidoreductase activity

# Drug_Target_75_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
7929092	Yamaguchi T, Komoda Y, Nakajima H: Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
8424666	Maines MD, Trakshel GM: Purification and characterization of human biliverdin reductase. Arch Biochem Biophys. 1993 Jan;300(1):320-6.
8631357	Maines MD, Polevoda BV, Huang TJ, McCoubrey WK Jr: Human biliverdin IXalpha reductase is a zinc-metalloprotein. Characterization of purified and Escherichia coli expressed enzymes. Eur J Biochem. 1996 Jan 15;235(1-2):372-81.

# Drug_Target_75_HGNC_ID:
HGNC:1062

# Drug_Target_75_HPRD_ID:
11229

# Drug_Target_75_ID:
816

# Drug_Target_75_Locus:
7p14-cen

# Drug_Target_75_Molecular_Weight:
33429

# Drug_Target_75_Name:
Biliverdin reductase A

# Drug_Target_75_Number_of_Residues:
296

# Drug_Target_75_PDB_ID:
Not Available

# Drug_Target_75_Pathway:
Not Available

# Drug_Target_75_Pfam_Domain_Function:
PF01408	GFO_IDH_MocA

# Drug_Target_75_Protein_Sequence:
>Biliverdin reductase A precursor
MNAEPERKFGVVVVGVGRAGSVRMRDLRNPHPSSAFLNLIGFVSRRELGSIDGVQQISLE
DALSSQEVEVAYICSESSSHEDYIRQFLNAGKHVLVEYPMTLSLAAAQELWELAEQKGKV
LHEEHVELLMEEFAFLKKEVVGKDLLKGSLLFTAGPLEEERFGFPAFSGISRLTWLVSLF
GELSLVSATLEERKEDQYMKMTVCLETEKKSPLSWIEEKGPGLKRNRYLSFHFKSGSLEN
VPNVGVNKNIFLKDQNIFVQKLLGQFSEKELAAEKKRILHCLGLAEEIQKYCCSRK

# Drug_Target_75_Reaction:
bilirubin + NAD(P)+ = biliverdin + NAD(P)H + H+

# Drug_Target_75_Signals:
None

# Drug_Target_75_Specific_Function:
Reduces the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor

# Drug_Target_75_SwissProt_ID:
P53004

# Drug_Target_75_SwissProt_Name:
BIEA_HUMAN

# Drug_Target_75_Synonyms:
BVR A
Biliverdin reductase A precursor
Biliverdin-IX alpha- reductase
EC 1.3.1.24

# Drug_Target_75_Theoretical_pI:
6.41

# Drug_Target_75_Transmembrane_Regions:
None

# Drug_Target_76_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_76_Chromosome_Location:
Not Available

# Drug_Target_76_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_76_Essentiality:
Non-Essential

# Drug_Target_76_GenAtlas_ID:
ACADS

# Drug_Target_76_GenBank_ID_Gene:
M26393

# Drug_Target_76_GenBank_ID_Protein:
337928

# Drug_Target_76_GeneCard_ID:
ACADS

# Drug_Target_76_Gene_Name:
ACADS

# Drug_Target_76_Gene_Sequence:
>1239 bp
ATGGCCGCCGCGCTGCTCGCCCGGGCCTCGGGCCCTGCCCGCAGAGCTCTCTGTCCTAGG
GCCTGGCGGCAGTTACACACCATCTACCAGTCTGTGGAACTGCCCGAGACACACCAGATG
TTGCTCCAGACATGCCGGGACTTTGCCGAGAAGGAGTTGTTTCCCATTGCAGCCCAGGTG
GATAAGGAACATCTCTTCCCAGCGGCTCAGGTGAAGAAGATGGGCGGGCTTGGGCTTCTG
GCCATGGACGTGCCCGAGGAGCTTGGCGGTGCTGGCCTCGATTACCTGGCCTACGCCATC
GCCATGGAGGAGATCAGCCGTGGCTGCGCCTCCACCGGAGTCATCATGAGTGTCAACAAC
TCTCTCTACCTGGGGCCCATCTTGAAGTTTGGCTCCAAGGAGCAGAAGCAGGCGTGGGTC
ACGCCTTTCACCAGTGGTGACAAAATTGGCTGCTTTGCCCTCAGCGAACCAGGGAACGGC
AGTGATGCAGGAGCTGCGTCCACCACCGCCCGGGCCGAGGGCGACTCATGGGTTCTGAAT
GGAACCAAAGCCTGGATCACCAATGCCTGGGAGGCTTCGGCTGCCGTGGTCTTTGCCAGC
ACGGACAGAGCCCTGCAAAACAAGGGCATCAGTGCCTTCCTGGTCCCCATGCCAACGCCT
GGGCTCACGTTGGGGAAGAAAGAAGACAAGCTGGGCATCCGGGGCTCATCCACGGCCAAC
CTCATCTTTGAGGACTGTCGCATCCCCAAGGACAGCATCCTGGGGGAGCCAGGGATGGGC
TTCAAGATAGCCATGCAAACCCTGGACATGGGCCGCATCGGCATCGCCTCCCAGGCCCTG
GGCATTGCCCAGACCGCCCTCGATTGTGCTGTGAACTACGCTGAGAATCGCATGGCCTTC
GGGGCGCCCCTCACCAAGCTCCAGGTCATCCAGTTCAAGTTGGCAGACATGGCCCTGGCC
CTGGAGAGTGCCCGGCTGCTGACCTGGCGCGCTGCCATGCTGAAGGATAACAAGAAGCCT
TTCATCAAGGAGGCAGCCATGGCCAAGCTGGCCGCCTCGGAGGCCGCGACCGCCATCAGC
CACCAGGCCATCCAGATCCTGGGCGGCATGGGCTACGTGACAGAGATGCCGGCAGAGCGG
CACTACCGCGACGCCCGCATCACTGAGATCTACGAGGGCACCAGCGAAATCCAGCGGCTG
GTGATCGCCGGGCATCTGCTCAGGAGCTACCGGAGCTGA

# Drug_Target_76_General_Function:
Lipid transport and metabolism

# Drug_Target_76_General_References:
11134486	Corydon MJ, Vockley J, Rinaldo P, Rhead WJ, Kjeldsen M, Winter V, Riggs C, Babovic-Vuksanovic D, Smeitink J, De Jong J, Levy H, Sewell AC, Roe C, Matern D, Dasouki M, Gregersen N: Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr Res. 2001 Jan;49(1):18-23.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
1692038	Naito E, Indo Y, Tanaka K: Identification of two variant short chain acyl-coenzyme A dehydrogenase alleles, each containing a different point mutation in a patient with short chain acyl-coenzyme A dehydrogenase deficiency. J Clin Invest. 1990 May;85(5):1575-82.
2565344	Naito E, Ozasa H, Ikeda Y, Tanaka K: Molecular cloning and nucleotide sequence of complementary DNAs encoding human short chain acyl-coenzyme A dehydrogenase and the study of the molecular basis of human short chain acyl-coenzyme A dehydrogenase deficiency. J Clin Invest. 1989 May;83(5):1605-13.
9383286	Corydon MJ, Andresen BS, Bross P, Kjeldsen M, Andreasen PH, Eiberg H, Kolvraa S, Gregersen N: Structural organization of the human short-chain acyl-CoA dehydrogenase gene. Mamm Genome. 1997 Dec;8(12):922-6.
9499414	Gregersen N, Winter VS, Corydon MJ, Corydon TJ, Rinaldo P, Ribes A, Martinez G, Bennett MJ, Vianey-Saban C, Bhala A, Hale DE, Lehnert W, Kmoch S, Roig M, Riudor E, Eiberg H, Andresen BS, Bross P, Bolund LA, Kolvraa S: Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: one of the variant alleles, 511C-->T, is present at an unexpectedly high frequency in the general population, as was the case for 625G-->A, together conferring susceptibility to ethylmalonic aciduria. Hum Mol Genet. 1998 Apr;7(4):619-27.

# Drug_Target_76_HGNC_ID:
HGNC:90

# Drug_Target_76_HPRD_ID:
06053

# Drug_Target_76_ID:
839

# Drug_Target_76_Locus:
12q22-qter

# Drug_Target_76_Molecular_Weight:
44298

# Drug_Target_76_Name:
Short-chain specific acyl-CoA dehydrogenase, mitochondrial

# Drug_Target_76_Number_of_Residues:
412

# Drug_Target_76_PDB_ID:
1JQI

# Drug_Target_76_Pathway:
Not Available

# Drug_Target_76_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_76_Protein_Sequence:
>Short-chain specific acyl-CoA dehydrogenase, mitochondrial precursor
MAAALLARASGPARRALCPRAWRQLHTIYQSVELPETHQMLLQTCRDFAEKELFPIAAQV
DKEHLFPAAQVKKMGGLGLLAMDVPEELGGAGLDYLAYAIAMEEISRGCASTGVIMSVNN
SLYLGPILKFGSKEQKQAWVTPFTSGDKIGCFALSEPGNGSDAGAASTTARAEGDSWVLN
GTKAWITNAWEASAAVVFASTDRALQNKGISAFLVPMPTPGLTLGKKEDKLGIRGSSTAN
LIFEDCRIPKDSILGEPGMGFKIAMQTLDMGRIGIASQALGIAQTALDCAVNYAENRMAF
GAPLTKLQVIQFKLADMALALESARLLTWRAAMLKDNKKPFIKEAAMAKLAASEAATAIS
HQAIQILGGMGYVTEMPAERHYRDARITEIYEGTSEIQRLVIAGHLLRSYRS

# Drug_Target_76_Reaction:
butanoyl-CoA + acceptor = 2-butenoyl-CoA + reduced acceptor

# Drug_Target_76_Signals:
None

# Drug_Target_76_Specific_Function:
Not Available

# Drug_Target_76_SwissProt_ID:
P16219

# Drug_Target_76_SwissProt_Name:
ACADS_HUMAN

# Drug_Target_76_Synonyms:
Butyryl-CoA dehydrogenase
EC 1.3.99.2
SCAD
Short-chain specific acyl-CoA dehydrogenase, mitochondrial precursor

# Drug_Target_76_Theoretical_pI:
8.12

# Drug_Target_76_Transmembrane_Regions:
None

# Drug_Target_77_Cellular_Location:
Not Available

# Drug_Target_77_Chromosome_Location:
Not Available

# Drug_Target_77_Drug_References:
17032644	Vickers TJ, Orsomando G, de la Garza RD, Scott DA, Kang SO, Hanson AD, Beverley SM: Biochemical and genetic analysis of methylenetetrahydrofolate reductase in Leishmania metabolism and virulence. J Biol Chem. 2006 Dec 15;281(50):38150-8. Epub 2006 Oct 10.
17115689	Argyrou A, Jin L, Siconilfi-Baez L, Angeletti RH, Blanchard JS: Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry. 2006 Nov 28;45(47):13947-53.

# Drug_Target_77_Essentiality:
Non-Essential

# Drug_Target_77_GenAtlas_ID:
DHFR

# Drug_Target_77_GenBank_ID_Gene:
J00140

# Drug_Target_77_GenBank_ID_Protein:
182724

# Drug_Target_77_GeneCard_ID:
DHFR

# Drug_Target_77_Gene_Name:
DHFR

# Drug_Target_77_Gene_Sequence:
>564 bp
ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC
GGGGACCTGCCCTGGCCACCGCTCAGGAATGAATTCAGATATTTCCAGAGAATGACCACA
ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC
AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT
ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT
GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG
CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG
CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT
GAAGTATATGAGAAGAATGATTAA

# Drug_Target_77_General_Function:
Coenzyme transport and metabolism

# Drug_Target_77_General_References:
1731871	Stockman BJ, Nirmala NR, Wagner G, Delcamp TJ, DeYarman MT, Freisheim JH: Sequence-specific 1H and 15N resonance assignments for human dihydrofolate reductase in solution. Biochemistry. 1992 Jan 14;31(1):218-29.
2248959	Davies JF 2nd, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J: Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry. 1990 Oct 9;29(40):9467-79.
3383852	Oefner C, D'Arcy A, Winkler FK: Crystal structure of human dihydrofolate reductase complexed with folate. Eur J Biochem. 1988 Jun 1;174(2):377-85.
6235374	Yang JK, Masters JN, Attardi G: Human dihydrofolate reductase gene organization. Extensive conservation of the G + C-rich 5' non-coding sequence and strong intron size divergence from homologous mammalian genes. J Mol Biol. 1984 Jun 25;176(2):169-87.
6323448	Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW: The functional human dihydrofolate reductase gene. J Biol Chem. 1984 Mar 25;259(6):3933-43.
6687716	Masters JN, Attardi G: The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase. Gene. 1983 Jan-Feb;21(1-2):59-63.
9374868	Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL: Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry. 1997 Nov 11;36(45):13897-903.

# Drug_Target_77_HGNC_ID:
HGNC:2861

# Drug_Target_77_HPRD_ID:
00519

# Drug_Target_77_ID:
365

# Drug_Target_77_Locus:
5q11.2-q13.2

# Drug_Target_77_Molecular_Weight:
21322

# Drug_Target_77_Name:
Dihydrofolate reductase

# Drug_Target_77_Number_of_Residues:
186

# Drug_Target_77_PDB_ID:
1MVT

# Drug_Target_77_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_77_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_77_Protein_Sequence:
>Dihydrofolate reductase
VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSI
PEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSV
YKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFE
VYEKND

# Drug_Target_77_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_77_Signals:
None

# Drug_Target_77_Specific_Function:
Not Available

# Drug_Target_77_SwissProt_ID:
P00374

# Drug_Target_77_SwissProt_Name:
DYR_HUMAN

# Drug_Target_77_Synonyms:
EC 1.5.1.3

# Drug_Target_77_Theoretical_pI:
7.60

# Drug_Target_77_Transmembrane_Regions:
None

# Drug_Target_78_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_78_Chromosome_Location:
Not Available

# Drug_Target_78_Drug_References:
17668068	Mailloux RJ, Beriault R, Lemire J, Singh R, Chenier DR, Hamel RD, Appanna VD: The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE. 2007 Aug 1;2(1):e690.

# Drug_Target_78_Essentiality:
Non-Essential

# Drug_Target_78_GenAtlas_ID:
OGDH

# Drug_Target_78_GenBank_ID_Gene:
D10523

# Drug_Target_78_GenBank_ID_Protein:
531241

# Drug_Target_78_GeneCard_ID:
OGDH

# Drug_Target_78_Gene_Name:
OGDH

# Drug_Target_78_Gene_Sequence:
>3009 bp
ATGTTTCATTTAAGGACTTGTGCTGCTAAGTTGAGGCCATTGACGGCTTCCCAGACTGTT
AAGACATTTTCACAAAACAGACCAGCAGCAGCTAGGACATTTCAACAGATTCGGTGCTAT
TCTGCACCTGTTGCTGCTGAGCCCTTTCTCAGTGGGACTAGTTCGAACTATGTGGAGGAG
ATGTACTGTGCTTGGCTGGAAAACCCCAAAAGTGTACATAAGTCATGGGACATTTTTTTT
CGCAACACGAATGCCGGAGCCCCACCGGGCACTGCCTACCAGAGTCCCCTTCCCCTGAGC
CGAGGCTCCCTGGCTGCTGTGGCCCATGCACAGTCCCTGGTAGAAGCACAGCCCAACGTG
GACAAGCTCGTGGAGGACCACCTGGCAGTGCAGTCACTCATCAGGGCATATCAGATACGA
GGGCACCATGTAGCACAGCTGGACCCCCTGGGGATTTTGGATGCTGATCTGGACTCCTCC
GTGCCCGCTGACATTATCTCATCCACAGACAAACTTGGGTTCTATGGCCTGGATGAGTCT
GACCTCGACAAGGTCTTCCACTTGCCCACCACCACTTTCATCGGGGGACAGGAATCAGCA
CTTCCTCTGCGGGAGATCATCCGTCGGCTGGAGATGGCCTACTGCCAGCATATTGGGGTG
GAGTTCATGTTCATCAATGACCTGGAGCAGTGCCAGTGGATCCGGCAGAAGTTTGAGACC
CCTGGGATCATGCAGTTCACAAATGAGGAGAAACGGACCCTGCTGGCCAGGCTTGTGCGG
TCCACCAGGTTTGAGGAGTTCCTACAGCGGAAGTGGTCCTCTGAGAAGCGCTTTGGTCTA
GAAGGCTGCGAGGTACTGATCCCTGCCCTCAAGACCATCATTGACAAGTCTAGTGAGAAT
GGCGTGGACTACGTGATCATGGGCATGCCACACAGAGGGCGGCTGAACGTGCTTGCAAAT
GTCATCAGGAAGGAGCTGGAACAGATCTTCTGTCAATTCGATTCAAAGCTGGAGGCAGCT
GATGAGGGCTCCGGAGATGTGAAGTACCACCTGGGCATGTATCACCGCAGGATCAATCGT
GTCACCGACAGGAACATTACCTTGTCCTTGGTGGCCAACCCTTCCCACCTTGAGGCCGCT
GACCCCGTGGTGATGGGCAAGACCAAAGCCGAACAGTTTTACTGTGGCGACACTGAAGGG
AAAAAGGTCATGTCCATCCTGTTGCATGGGGATGCTGCATTTGCTGGCCAGGGCATTGTG
TACGAGACCTTCCACCTCAGCGACCTGCCATCCTACACAACTCATGGCACCGTGCACGTG
GTCGTCAACAACCAGATCGGCTTCACCACCGACCCTCGGATGGCCCGCTCCTCCCCCTAC
CCCACTGACGTGGCCCGAGTGGTGAATGCCCCCATTTTCCACGTGAACTCAGATGACCCC
GAGGCTGTCATGTACGTGTGCAAAGTGGCGGCCGAGTGGAGGAGCACCTTCCACAAGGAC
GTGGTTGTCGATTTGGTGTGTTACCGGCGCAACGGCCACAACGAGATGGATGAGCCCATG
TTCACGCAGCCGCTCATGTACAAGCAGATCCGCAAGCAGAAGCCTGTGTTACAGAAGTAC
GCTGAGCTGCTGGTGTCGCAGGGTGTGGTCAACCAGCCTGAGTATGAGGAGGAAATTTCC
AAGTATGATAAGATCTGTGAGGAAGCTTTTGCCAGATCTAAAGATGAGAAGATCTTGCAC
ATTAAGCACTGGCTGGACTCTCCCTGGCCTGGCTTCTTCACCCTGGACGGGCAGCCCAGG
AGCATGTCCTGCCCCTCCACGGGTCTGACGGAGGATATTCTGACACACATCGGGAATGTG
GCTAGTTCTGTGCCTGTGGAAAACTTTACTATTCATGGAGGGCTGAGCCGGATCTTGAAG
ACTCGTGGGGAAATGGTGAAGAACCGGACTGTGGACTGGGCTCTAGCGGAGTACATGGCG
TTTGGCTCGCTCCTGAAGGAGGGCATCCACATTCGGCTGAGCGGCCAGGACGTGGAGCGG
GGCACATTCAGCCACCGCCACCATGTGCTCCATGACCAGAATGTGGACAAGAGAACCTGC
ATCCCCATGAACCATCTCTGGCCCAATCAGGCCCCCTATACTGTGTGCAACAGCTCACTG
TCTGAGTACGGCGTGCTGGGCTTTGAAGCTGGGCTTCGCATGGCCAGTCCTAATGCCCTG
GTCCTCTGGGAAGCCCAATTTGGTGACTTCCACAACACGGCCCAGTGTATCATCGACCAG
TTCATCTGCCCGGGACAAGCCAAGTGGGTGCGGCAGAATGGCATCGTGTTGCTGCTGCCC
CATGGCATGGAGGGCATGGGTCCAGAACATTCCTCCGCCCGCCCAGAGCGGTTCTTGCAG
ATGTGCAACGATGACCCAGATGTCCTGCCAGACCTTAAAGAAGCCAACTTCGACATCAAT
CAGCTATATGACTGCAATTGGGTTGTTGTCAACTGCTCCACTCCTGGCAACTTCTTCCAC
GTGCTACGACGCCAGATCCTGCTGCCATTCCGGAAGCCGTTAATTATCTTCACCCCCAAA
TCCCTGTTGCGCCACCCCGAGGCCAGATCCAGCTTTGATGAGATGCTTCCAGGAACCCAC
TTCCAGCGGGTGATCCCAGAAGATGGCCCTGCAGCTCAGAACCCAGAAAATGTCAAAAGG
CTTCTCTTCTGCACCGGCAAAGTGTATTATGACCTCACCCGGGAGCGCAAAGCACGCGAC
ATGGTGGGGCAGGTGGCCATCACAAGGATTGAGCAGCTGTCGCCATTCCCCTTTGACCTC
CTGCTGAAGGAGGTGCAGAAGTACCCCAATGCTGAGCTGGCCTGGTGCCAGGAGGAGCAC
AAGAACCAAGGCTACTATGACTACGTGAAGCCAAGACTTCGGACCACCATCAGCCGCGCC
AAGCCCGTCTGGTATGCCGGCCGGAACCCAGCGGCTGCTCCAGCCACCGGCAACAAGAAG
ACCCACTGA

# Drug_Target_78_General_Function:
Energy production and conversion

# Drug_Target_78_General_References:
1542694	Koike K, Urata Y, Goto S: Cloning and nucleotide sequence of the cDNA encoding human 2-oxoglutarate dehydrogenase (lipoamide). Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1963-7.
7622061	Koike K: The gene encoding human 2-oxoglutarate dehydrogenase: structural organization and mapping to chromosome 7p13-p14. Gene. 1995 Jul 4;159(2):261-6.

# Drug_Target_78_HGNC_ID:
HGNC:8124

# Drug_Target_78_HPRD_ID:
08938

# Drug_Target_78_ID:
182

# Drug_Target_78_Locus:
7p14-p13

# Drug_Target_78_Molecular_Weight:
113477

# Drug_Target_78_Name:
2-oxoglutarate dehydrogenase E1 component, mitochondrial

# Drug_Target_78_Number_of_Residues:
1002

# Drug_Target_78_PDB_ID:
Not Available

# Drug_Target_78_Pathway:
Not Available

# Drug_Target_78_Pfam_Domain_Function:
PF00676	E1_dh
PF02779	Transket_pyr

# Drug_Target_78_Protein_Sequence:
>2-oxoglutarate dehydrogenase E1 component, mitochondrial precursor
MFHLRTCAAKLRPLTASQTVKTFSQNRPAAARTFQQIRCYSAPVAAEPFLSGTSSNYVEE
MYCAWLENPKSVHKSWDIFFRNTNAGAPPGTAYQSPLPLSRGSLAAVAHAQSLVEAQPNV
DKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSSVPADIISSTDKLGFYGLDES
DLDKVFHLPTTTFIGGQESALPLREIIRRLEMAYCQHIGVEFMFINDLEQCQWIRQKFET
PGIMQFTNEEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLEGCEVLIPALKTIIDKSSEN
GVDYVIMGMPHRGRLNVLANVIRKELEQIFCQFDSKLEAADEGSGDVKYHLGMYHRRINR
VTDRNITLSLVANPSHLEAADPVVMGKTKAEQFYCGDTEGKKVMSILLHGDAAFAGQGIV
YETFHLSDLPSYTTHGTVHVVVNNQIGFTTDPRMARSSPYPTDVARVVNAPIFHVNSDDP
EAVMYVCKVAAEWRSTFHKDVVVDLVCYRRNGHNEMDEPMFTQPLMYKQIRKQKPVLQKY
AELLVSQGVVNQPEYEEEISKYDKICEEAFARSKDEKILHIKHWLDSPWPGFFTLDGQPR
SMSCPSTGLTEDILTHIGNVASSVPVENFTIHGGLSRILKTRGEMVKNRTVDWALAEYMA
FGSLLKEGIHIRLSGQDVERGTFSHRHHVLHDQNVDKRTCIPMNHLWPNQAPYTVCNSSL
SEYGVLGFEAGLRMASPNALVLWEAQFGDFHNTAQCIIDQFICPGQAKWVRQNGIVLLLP
HGMEGMGPEHSSARPERFLQMCNDDPDVLPDLKEANFDINQLYDCNWVVVNCSTPGNFFH
VLRRQILLPFRKPLIIFTPKSLLRHPEARSSFDEMLPGTHFQRVIPEDGPAAQNPENVKR
LLFCTGKVYYDLTRERKARDMVGQVAITRIEQLSPFPFDLLLKEVQKYPNAELAWCQEEH
KNQGYYDYVKPRLRTTISRAKPVWYAGRNPAAAPATGNKKTH

# Drug_Target_78_Reaction:
2-oxoglutarate + [dihydrolipoyllysine-residue succinyltransferase] lipoyllysine = [dihydrolipoyllysine-residue succinyltransferase] S-succinyldihydrolipoyllysine + CO2

# Drug_Target_78_Signals:
None

# Drug_Target_78_Specific_Function:
The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO(2). It contains multiple copies of three enzymatic components:2- oxoglutarate dehydrogenase (E1), dihydrolipoamide succinyltransferase (E2) and lipoamide dehydrogenase (E3)

# Drug_Target_78_SwissProt_ID:
Q02218

# Drug_Target_78_SwissProt_Name:
ODO1_HUMAN

# Drug_Target_78_Synonyms:
2-oxoglutarate dehydrogenase E1 component, mitochondrial precursor
Alpha-ketoglutarate dehydrogenase
EC 1.2.4.2

# Drug_Target_78_Theoretical_pI:
7.08

# Drug_Target_78_Transmembrane_Regions:
None

# Drug_Target_79_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_79_Chromosome_Location:
Not Available

# Drug_Target_79_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_79_Essentiality:
Non-Essential

# Drug_Target_79_GenAtlas_ID:
GLUD2

# Drug_Target_79_GenBank_ID_Gene:
X66310

# Drug_Target_79_GenBank_ID_Protein:
31815

# Drug_Target_79_GeneCard_ID:
GLUD2

# Drug_Target_79_Gene_Name:
GLUD2

# Drug_Target_79_Gene_Sequence:
>1677 bp
ATGTACCGCTACCTGGCCAAAGCGCTGCTGCCGTCCCGGGCCGGGCCCGCTGCCCTGGGC
TCCGCGGCCAACCACTCGGCCGCGTTGCTGGGCCGGGGCCGCGGACAGCCCGCCGCCGCC
TCGCAGCCGGGGCTCGCATTGGCCGCCCGGCGCCACTACAGCGAGTTGGTGGCCGACCGC
GAGGACGACCCCAACTTCTTCAAGATGGTGGAGGGCTTCTTCGATCGCGGCGCCAGCATC
GTGGAGGACAAGTTGGTGAAGGACCTGAGGACCCAGGAAAGCGAGGAGCAGAAGCGGAAC
CGGGTGCGCGGCATCCTGCGGATCATCAAGCCCTGCAACCATGTGCTGAGTCTCTCCTTC
CCCATCCGGCGCGACGACGGCTCCTGGGAGGTCATCGAAGGCTACCGGGCCCAGCACAGC
CAGCACCGCACGCCCTGCAAGGGAGGTATCCGTTACAGCACTGATGTGAGTGTAGATGAA
GTAAAAGCTTTGGCTTCTCTGATGACATACAAGTGTGCAGTGGTTGATGTGCCGTTTGGG
GGTGCTAAAGCTGGTGTTAAGATCAATCCCAAGAACTATACCGAAAATGAATTGGAAAAG
ATCACAAGGAGGTTCACCATGGAGCTAGCAAAGAAGGGCTTTATTGGTCCTGGCGTTGAT
GTGCCTGCTCCAGACATGAACACAGGTGAGCGGGAGATGTCCTGGATTGCTGATACCTAT
GCCAGCACCATAGGGCACTATGATATTAATGCACACGCCTGTGTTACTGGTAAACCCATC
AGCCAAGGGGGAATCCATGGACGCATCTCTGCTACTGGCCGTGGTGTCTTCCATGGGATT
GAAAACTTCATCAATCAAGCTTCTTACATGAGCATTTTAGGAATGACACCAGGGTTTAGA
GATAAAACATTTGTTGTTCAGGGATTTGGTAATGTGGGCCTACACTCTATGAGATATTTA
CATCGTTTTGGTGCTAAATGTATTGCTGTTGGTGAGTCTGATGGGAGTATATGGAATCCA
GATGGTATTGACCCAAAGGAACTGGAAGACTTCAAATTGCAACATGGGTCCATTCTGGGC
TTCCCCAAGGCAAAGCCCTATGAAGGAAGCATCTTGGAGGTCGACTGTGACATACTGATC
CCAGCTGCCACTGAGAAGCAGTTGACCAAATCCAACGCACCCAGAGTCAAAGCCAAGATC
ATTGCTGAAGGTGCCAATGGGCCAACAACTCCAGAAGCTGATAAGATCTTCCTGGAGAGA
AACATTTTGGTTATTCCAGATCTCTACTTGAATGCTGGAGGAGTGACAGTATCTTACTTT
GAGTGGCTGAAGAATCTAAATCATGTCAGCTATGGCCGTTTGACCTTCAAATATGAAAGG
GATTCTAACTACCACTTGCTCCTGTCTGTTCAAGAGAGTTTAGAAAGAAAATTTGGAAAG
CATGGTGGAACTATTCCCATTGTACCCACGGCAGAGTTCCAAGACAGTATATCGGGTGCA
TCTGAGAAAGACATTGTGCACTCTGCCTTGGCATACACAATGGAGCGTTCTGCCAGGCAA
ATTATGCACACAGCCATGAAGTATAACCTGGGATTGGACCTGAGAACAGCTGCCTATGTC
AATGCCATTGAAAAAGTCTTCAAAGTGTACAGTGAAGCTGGTGTGACCTTCACATAG

# Drug_Target_79_General_Function:
Replication, recombination and repair

# Drug_Target_79_General_References:
8207021	Shashidharan P, Michaelidis TM, Robakis NK, Kresovali A, Papamatheakis J, Plaitakis A: Novel human glutamate dehydrogenase expressed in neural and testicular tissues and encoded by an X-linked intronless gene. J Biol Chem. 1994 Jun 17;269(24):16971-6.

# Drug_Target_79_HGNC_ID:
HGNC:4336

# Drug_Target_79_HPRD_ID:
02143

# Drug_Target_79_ID:
830

# Drug_Target_79_Locus:
Xq24-q25

# Drug_Target_79_Molecular_Weight:
61435

# Drug_Target_79_Name:
Glutamate dehydrogenase 2, mitochondrial

# Drug_Target_79_Number_of_Residues:
558

# Drug_Target_79_PDB_ID:
1L1F

# Drug_Target_79_Pathway:
Not Available

# Drug_Target_79_Pfam_Domain_Function:
PF00208	ELFV_dehydrog
PF02812	ELFV_dehydrog_N

# Drug_Target_79_Protein_Sequence:
>Glutamate dehydrogenase 2, mitochondrial precursor
MYRYLAKALLPSRAGPAALGSAANHSAALLGRGRGQPAAASQPGLALAARRHYSELVADR
EDDPNFFKMVEGFFDRGASIVEDKLVKDLRTQESEEQKRNRVRGILRIIKPCNHVLSLSF
PIRRDDGSWEVIEGYRAQHSQHRTPCKGGIRYSTDVSVDEVKALASLMTYKCAVVDVPFG
GAKAGVKINPKNYTENELEKITRRFTMELAKKGFIGPGVDVPAPDMNTGEREMSWIADTY
ASTIGHYDINAHACVTGKPISQGGIHGRISATGRGVFHGIENFINEASYMSILGMTPGFR
DKTFVVQGFGNVGLHSMRYLHRFGAKCIAVGESDGSIWNPDGIDPKELEDFKLQHGSILG
FPKAKPYEGSILEVDCDILIPAATEKQLTKSNAPRVKAKIIAEGANGPTTPEADKIFLER
NILVIPDLYLNAGGVTVSYFEWLKNLNHVSYGRLTFKYERDSNYHLLLSVQESLERKFGK
HGGTIPIVPTAEFQDSISGASEKDIVHSALAYTMERSARQIMHTAMKYNLGLDLRTAAYV
NAIEKVFKVYSEAGVTFT

# Drug_Target_79_Reaction:
L-glutamate + H2O + NAD(P)+ = 2-oxoglutarate + NH3 + NAD(P)H + H+

# Drug_Target_79_Signals:
None

# Drug_Target_79_Specific_Function:
Important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission

# Drug_Target_79_SwissProt_ID:
P49448

# Drug_Target_79_SwissProt_Name:
DHE4_HUMAN

# Drug_Target_79_Synonyms:
EC 1.4.1.3
GDH
Glutamate dehydrogenase 2, mitochondrial precursor

# Drug_Target_79_Theoretical_pI:
8.67

# Drug_Target_79_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasm

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
11410692	Kim DS, Lee CB, Park YS, Ahn YH, Kim TW, Kee CS, Kang JS, Om AS: Effect of thyroid hormone on the alcohol dehydrogenase activities in rat tissues. J Korean Med Sci. 2001 Jun;16(3):313-6.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17608724	Dalfo D, Marques N, Albalat R: Analysis of the NADH-dependent retinaldehyde reductase activity of amphioxus retinol dehydrogenase enzymes enhances our understanding of the evolution of the retinol dehydrogenase family. FEBS J. 2007 Jul;274(14):3739-52. Epub 2007 Jul 2.
8490052	Suzuki Y, Ishiguro S, Tamai M: Identification and immunohistochemistry of retinol dehydrogenase from bovine retinal pigment epithelium. Biochim Biophys Acta. 1993 May 13;1163(2):201-8.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
ADH7

# Drug_Target_7_GenBank_ID_Gene:
L33179

# Drug_Target_7_GenBank_ID_Protein:
516618

# Drug_Target_7_GeneCard_ID:
ADH7

# Drug_Target_7_Gene_Name:
ADH7

# Drug_Target_7_Gene_Sequence:
>1125 bp
ATGGGCACTGCTGGAAAAGTTATTAAGTGCAAAGCAGCTGTGCTTTGGGAGCAGAAGCAA
CCCTTCTCCATTGAGGAAATAGAAGTTGCCCCACCAAAGACTAAAGAAGTTCGCATTAAG
ATTTTGGCCACAGGAATCTGTCGCACAGATGACCATGTGATAAAAGGAACAATGGTGTCC
AAGTTTCCAGTGATTGTGGGACATGAGGCAACTGGGATTGTAGAGAGCATTGGAGAAGGA
GTGACTACAGTGAAACCAGGTGACAAAGTCATCCCTCTCTTTCTGCCACAATGTAGAGAA
TGCAATGCTTGTCGCAACCCAGATGGCAACCTTTGCATTAGGAGCGATATTACTGGTCGT
GGAGTACTGGCTGATGGCACCACCAGATTTACATGCAAGGGCAAACCAGTCCACCACTTC
ATGAACACCAGTACATTTACCGAGTACACAGTGGTGGATGAATCTTCTGTTGCTAAGATT
GATGATGCAGCTCCTCCTGAGAAAGTCTGTTTAATTGGCTGTGGGTTTTCCACTGGATAT
GGCGCTGCTGTTAAAACTGGCAAGGTCAAACCTGGTTCCACTTGCGTCGTCTTTGGCCTG
GGAGGAGTTGGCCTGTCAGTCATCATGGGCTGTAAGTCAGCTGGTGCATCTAGGATCATT
GGGATTGACCTCAACAAAGACAAATTTGAGAAGGCCATGGCTGTAGGTGCCACTGAGTGT
ATCAGTCCCAAGGACTCTACCAAACCCATCAGTGAGGTGCTGTCAGAAATGACAGGCAAC
AACGTGGGATACACCTTTGAAGTTATTGGGCATCTTGAAACCATGATTGATGCCCTGGCA
TCCTGCCACATGAACTATGGGACCAGCGTGGTTGTAGGAGTTCCTCCATCAGCCAAGATG
CTCACCTATGACCCGATGTTGCTCTTCACTGGACGCACATGGAAGGGATGTGTCTTTGGA
GGTTTGAAAAGCAGAGATGATGTCCCAAAACTAGTGACTGAGTTCCTGGCAAAGAAATTT
GACCTGGACCAGTTGATAACTCATGTTTTACCATTTAAAAAAATCAGTGAAGGATTTGAG
CTGCTCAATTCAGGACAAAGCATTCGAACGGTCCTGACGTTTTGA

# Drug_Target_7_General_Function:
Energy production and conversion

# Drug_Target_7_General_References:
1592118	Pares X, Cederlund E, Moreno A, Saubi N, Hoog JO, Jornvall H: Class IV alcohol dehydrogenase (the gastric enzyme). Structural analysis of human sigma sigma-ADH reveals class IV to be variable and confirms the presence of a fifth mammalian alcohol dehydrogenase class. FEBS Lett. 1992 May 25;303(1):69-72.
7771649	Cheung B, Anderson JK, Holmes RS, Beacham IR: Human stomach class IV alcohol dehydrogenase: molecular genetic analysis. Alcohol Clin Exp Res. 1995 Feb;19(1):185-6.
7876099	Kedishvili NY, Bosron WF, Stone CL, Hurley TD, Peggs CF, Thomasson HR, Popov KM, Carr LG, Edenberg HJ, Li TK: Expression and kinetic characterization of recombinant human stomach alcohol dehydrogenase. Active-site amino acid sequence explains substrate specificity compared with liver isozymes. J Biol Chem. 1995 Feb 24;270(8):3625-30.
7876191	Zgombic-Knight M, Foglio MH, Duester G: Genomic structure and expression of the ADH7 gene encoding human class IV alcohol dehydrogenase, the form most efficient for retinol metabolism in vitro. J Biol Chem. 1995 Mar 3;270(9):4305-11.
7925371	Farres J, Moreno A, Crosas B, Peralba JM, Allali-Hassani A, Hjelmqvist L, Jornvall H, Pares X: Alcohol dehydrogenase of class IV (sigma sigma-ADH) from human stomach. cDNA sequence and structure/function relationships. Eur J Biochem. 1994 Sep 1;224(2):549-57.
8082805	Yokoyama S, Matsuo Y, Ramsbotham R, Yokoyama R: Molecular characterization of a class IV human alcohol dehydrogenase gene (ADH7). FEBS Lett. 1994 Sep 12;351(3):411-5.
8195208	Satre MA, Zgombic-Knight M, Duester G: The complete structure of human class IV alcohol dehydrogenase (retinol dehydrogenase) determined from the ADH7 gene. J Biol Chem. 1994 Jun 3;269(22):15606-12.
9228021	Xie P, Parsons SH, Speckhard DC, Bosron WF, Hurley TD: X-ray structure of human class IV sigmasigma alcohol dehydrogenase. Structural basis for substrate specificity. J Biol Chem. 1997 Jul 25;272(30):18558-63.

# Drug_Target_7_HGNC_ID:
HGNC:256

# Drug_Target_7_HPRD_ID:
02515

# Drug_Target_7_ID:
579

# Drug_Target_7_Locus:
4q23-q24

# Drug_Target_7_Molecular_Weight:
40006

# Drug_Target_7_Name:
Alcohol dehydrogenase class 4 mu/sigma chain

# Drug_Target_7_Number_of_Residues:
374

# Drug_Target_7_PDB_ID:
1D1S

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_7_Protein_Sequence:
>Alcohol dehydrogenase class 4 mu/sigma chain
MGTAGKVIKCKAAVLWEQKQPFSIEEIEVAPPKTKEVRIKILATGICRTDDHVIKGTMVS
KFPVIVGHEATGIVESIGEGVTTVKPGDKVIPLFLPQCRECNACRNPDGNLCIRSDITGR
GVLADGTTRFTCKGKPVHHFMNTSTFTEYTVVDESSVAKIDDAAPPEKVCLIGCGFSTGY
GAAVKTGKVKPGSTCVVFGLGGVGLSVIMGCKSAGASRIIGIDLNKDKFEKAMAVGATEC
ISPKDSTKPISEVLSEMTGNNVGYTFEVIGHLETMIDALASCHMNYGTSVVVGVPPSAKM
LTYDPMLLFTGRTWKGCVFGGLKSRDDVPKLVTEFLAKKFDLDQLITHVLPFKKISEGFE
LLNSGQSIRTVLTF

# Drug_Target_7_Reaction:
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Could function in retinol oxidation for the synthesis of retinoic acid, a hormone important for cellular differentiation. Medium-chain (octanol) and aromatic (m-nitrobenzaldehyde) compounds are the best substrates. Ethanol is not a good substrate but at the high ethanol concentrations reached in the digestive tract, it plays a role in the ethanol oxidation and contributes to the first pass ethanol metabolism

# Drug_Target_7_SwissProt_ID:
P40394

# Drug_Target_7_SwissProt_Name:
ADH7_HUMAN

# Drug_Target_7_Synonyms:
Alcohol dehydrogenase class IV mu/sigma chain
EC 1.1.1.1
Gastric alcohol dehydrogenase
Retinol dehydrogenase

# Drug_Target_7_Theoretical_pI:
8.08

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_80_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein

# Drug_Target_80_Chromosome_Location:
Not Available

# Drug_Target_80_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_80_Essentiality:
Non-Essential

# Drug_Target_80_GenAtlas_ID:
DHCR7

# Drug_Target_80_GenBank_ID_Gene:
AF096305

# Drug_Target_80_GenBank_ID_Protein:
4191398

# Drug_Target_80_GeneCard_ID:
DHCR7

# Drug_Target_80_Gene_Name:
DHCR7

# Drug_Target_80_Gene_Sequence:
>1428 bp
ATGGCTGCAAAATCGCAACCCAACATTCCCAAAGCCAAGAGTCTAGATGGCGTCACCAAT
GACAGAACCGCATCTCAAGGGCAGTGGGGCCGTGCCTGGGAGGTGGACTGGTTTTCACTG
GCGAGCGTCATCTTCCTACTGCTGTTCGCCCCCTTCATCGTCTACTACTTCATCATGGCT
TGTGACCAATACAGCTGCGCCCTGACCGGCCCTGTGGTGGACATCGTCACCGGACATGCT
CGGCTCTCGGACATCTGGGCCAAGACTCCACCTATAACGAGGAAAGCCGCCCAGCTCTAT
ACCTTGTGGGTCACCTTCCAGGTGCTTCTGTACACGTCTCTCCCTGACTTCTGCCATAAG
TTTCTACCCGGCTACGTAGGAGGCATCCAGGAGGGGGCCGTGACTCCTGCAGGGGTTGTG
AACAAGTATCAGATCAACGGCCTGCAAGCCTGGCTCCTCACGCACCTGCTCTGGTTTGCA
AACGCTCATCTCCTGTCCTGGTTCTCGCCCACCATCATCTTCGACAACTGGATCCCACTG
CTGTGGTGCGCCAACATCCTTGGCTATGCCGTCTCCACCTTCGCCATGGTCAAGGGCTAC
TTCTTCCCCACCAGCGCCAGAGACTGCAAATTCACAGGCAATTTCTTTTACAACTACATG
ATGGGCATCGAGTTTAACCCTCGGATCGGGAAGTGGTTTGACTTCAAGCTGTTCTTCAAT
GGGCGCCCCGGGATCGTCGCCTGGACCCTCATCAACCTGTCCTTCGCAGCGAAGCAGCGG
GAGCTCCACAGCCATGTGACCAATGCCATGGTCCTGGTCAACGTCCTGCAGGCCATCTAC
GTGATTGACTTCTTCTGGAACGAAACCTGGTACCTGAAGACCATTGACATCTGCCATGAC
CACTTCGGGTGGTACCTGGGCTGGGGCGACTGTGTCTGGCTGCCTTATCTTTACACGCTG
CAGGGTCTGTACTTGGTGTACCACCCCGTGCAGCTGTCCACCCCGCACGCCGTGGGCGTC
CTGCTGCTGGGCCTGGTGGGCTACTACATCTTCCGGGTGGCCAACCACCAGAAGGACCTG
TTCCGCCGCACGGATGGGCGCTGCCTCATCTGGGGCAGGAAGCCCAAGGTCATCGAGTGC
TCCTACACATCCGCCGACGGGCAGAGGCACCACAGCAAGCTGCTGGTGTCGGGCTTCTGG
GGCGTGGCCCGCCACTTCAACTACGTCGGCGACCTGATGGGCAGCCTGGCCTACTGCCTG
GCCTGTGGCGGTGGCCACCTGCTGCCCTACTTCTACATCATCTACATGGCCATCCTGCTG
ACCCACCGCTGCCTCCGGGACGAGCACCGCTGCGCCAGCAAGTACGGCCGGGACTGGGAG
CGCTACACCGCCGCAGTGCCTTACCGCCTGCTGCCTGGAATCTTCTAA

# Drug_Target_80_General_Function:
Involved in 7-dehydrocholesterol reductase activity

# Drug_Target_80_General_References:
10677299	Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, Kraft HG, Moebius FF, Glossmann H, Seedorf U, Gillessen-Kaesbach G, Hoffmann GF, Clayton P, Kelley RI, Utermann G: Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet. 2000 Feb;66(2):402-12.
10995508	Krakowiak PA, Nwokoro NA, Wassif CA, Battaile KP, Nowaczyk MJ, Connor WE, Maslen C, Steiner RD, Porter FD: Mutation analysis and description of sixteen RSH/Smith-Lemli-Opitz syndrome patients: polymerase chain reaction-based assays to simplify genotyping. Am J Med Genet. 2000 Sep 18;94(3):214-27.
11175299	Witsch-Baumgartner M, Ciara E, Loffler J, Menzel HJ, Seedorf U, Burn J, Gillessen-Kaesbach G, Hoffmann GF, Fitzky BU, Mundy H, Clayton P, Kelley RI, Krajewska-Walasek M, Utermann G: Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations. Eur J Hum Genet. 2001 Jan;9(1):45-50.
12949967	Langius FA, Waterham HR, Romeijn GJ, Oostheim W, de Barse MM, Dorland L, Duran M, Beemer FA, Wanders RJ, Poll-The BT: Identification of three patients with a very mild form of Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2003 Sep 15;122(1):24-9.
9465114	Moebius FF, Fitzky BU, Lee JN, Paik YK, Glossmann H: Molecular cloning and expression of the human delta7-sterol reductase. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1899-902.
9634533	Wassif CA, Maslen C, Kachilele-Linjewile S, Lin D, Linck LM, Connor WE, Steiner RD, Porter FD: Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet. 1998 Jul;63(1):55-62.
9653161	Fitzky BU, Witsch-Baumgartner M, Erdel M, Lee JN, Paik YK, Glossmann H, Utermann G, Moebius FF: Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8181-6.
9683613	Waterham HR, Wijburg FA, Hennekam RC, Vreken P, Poll-The BT, Dorland L, Duran M, Jira PE, Smeitink JA, Wevers RA, Wanders RJ: Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene. Am J Hum Genet. 1998 Aug;63(2):329-38.
9878250	Holmer L, Pezhman A, Worman HJ: The human lamin B receptor/sterol reductase multigene family. Genomics. 1998 Dec 15;54(3):469-76.

# Drug_Target_80_HGNC_ID:
HGNC:2860

# Drug_Target_80_HPRD_ID:
04174

# Drug_Target_80_ID:
34

# Drug_Target_80_Locus:
11q13.2-q13.5

# Drug_Target_80_Molecular_Weight:
54490

# Drug_Target_80_Name:
7-dehydrocholesterol reductase

# Drug_Target_80_Number_of_Residues:
475

# Drug_Target_80_PDB_ID:
Not Available

# Drug_Target_80_Pathway:
Not Available

# Drug_Target_80_Pfam_Domain_Function:
PF01222	ERG4_ERG24

# Drug_Target_80_Protein_Sequence:
>7-dehydrocholesterol reductase
MAAKSQPNIPKAKSLDGVTNDRTASQGQWGRAWEVDWFSLASVIFLLLFAPFIVYYFIMA
CDQYSCALTGPVVDIVTGHARLSDIWAKTPPITRKAAQLYTLWVTFQVLLYTSLPDFCHK
FLPGYVGGIQEGAVTPAGVVNKYQINGLQAWLLTHLLWFANAHLLSWFSPTIIFDNWIPL
LWCANILGYAVSTFAMVKGYFFPTSARDCKFTGNFFYNYMMGIEFNPRIGKWFDFKLFFN
GRPGIVAWTLINLSFAAKQRELHSHVTNAMVLVNVLQAIYVIDFFWNETWYLKTIDICHD
HFGWYLGWGDCVWLPYLYTLQGLYLVYHPVQLSTPHAVGVLLLGLVGYYIFRVANHQKDL
FRRTDGRCLIWGRKPKVIECSYTSADGQRHHSKLLVSGFWGVARHFNYVGDLMGSLAYCL
ACGGGHLLPYFYIIYMAILLTHRCLRDEHRCASKYGRDWERYTAAVPYRLLPGIF

# Drug_Target_80_Reaction:
cholesterol + NADP+ = cholesta-5,7-dien-3beta-ol + NADPH + H+

# Drug_Target_80_Signals:
None

# Drug_Target_80_Specific_Function:
Production of cholesterol by reduction of C7-C8 double bond of 7-dehydrocholesterol (7-DHC)

# Drug_Target_80_SwissProt_ID:
Q9UBM7

# Drug_Target_80_SwissProt_Name:
DHCR7_HUMAN

# Drug_Target_80_Synonyms:
7-DHC reductase
EC 1.3.1.21
Putative sterol reductase SR-2
Sterol Delta(7)-reductase

# Drug_Target_80_Theoretical_pI:
8.82

# Drug_Target_80_Transmembrane_Regions:
40-60
154-174
177-197
266-286
306-326
331-351
420-440

# Drug_Target_81_Cellular_Location:
Cytoplasm

# Drug_Target_81_Chromosome_Location:
Not Available

# Drug_Target_81_Drug_References:
16905546	Iskander K, Li J, Han S, Zheng B, Jaiswal AK: NQO1 and NQO2 regulation of humoral immunity and autoimmunity. J Biol Chem. 2006 Oct 13;281(41):30917-24. Epub 2006 Aug 10.
17031400	Jamieson D, Tung AT, Knox RJ, Boddy AV: Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. Br J Cancer. 2006 Nov 6;95(9):1229-33. Epub 2006 Oct 10.

# Drug_Target_81_Essentiality:
Non-Essential

# Drug_Target_81_GenAtlas_ID:
NQO2

# Drug_Target_81_GenBank_ID_Gene:
J02888

# Drug_Target_81_GenBank_ID_Protein:
190818

# Drug_Target_81_GeneCard_ID:
NQO2

# Drug_Target_81_Gene_Name:
NQO2

# Drug_Target_81_Gene_Sequence:
>696 bp
ATGGCAGGTAAGAAAGTACTCATTGTCTATGCACACCAGGAACCCAAGTCTTTCAACGGA
TCCTTGAAGAATGTGGCTGTAGATGAACTGAGCAGGCAGGGCTGCACCGTCACAGTGTCT
GATTTGTATGCCATGAACTTTGAGCCGAGGGCCACAGACAAAGATATCACTGGTACTCTT
TCTAATCCTGAGGTTTTCAATTATGGAGTGGAAACCCACGAAGCCTACAAGCAAAGGTCT
CTGGCTAGCGACATCACTGATGAGCAGAAAAAGGTTCGGGAGGCTGACCTAGTGATATTT
CAGTTCCCGCTGTACTGGTTCAGCGTGCCGGCCATCCTGAAGGGCTGGATGGATAGGGTG
CTGTGCCAGGGCTTTGCCTTTGACATCCCAGGATTCTACGATTCCGGTTTGCTCCAGGGT
AAACTAGCGCTCCTTTCCGTAACCACGGGAGGCACGGCCGAGATGTACACGAAGACAGGA
GTCAATGGAGATTCTCGATACTTCCTGTGGCCACTCCAGCATGGCACATTACACTTCTGT
GGATTTAAAGTCCTTGCCCCTCAGATCAGCTTTGCTCCTGAAATTGCATCCGAAGAAGAA
AGAAAGGGGATGGTGGCTGCGTGGTCCCAGAGGCTGCAGACCATCTGGAAGGAAGAGCCC
ATCCCCTGCACAGCCCACTGGCACTTCGGGCAATAA

# Drug_Target_81_General_Function:
Involved in oxidoreductase activity

# Drug_Target_81_General_References:
10433694	Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM: Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry. 1999 Aug 3;38(31):9881-6.
1691923	Jaiswal AK, Burnett P, Adesnik M, McBride OW: Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry. 1990 Feb 20;29(7):1899-906.
8182056	Jaiswal AK: Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem. 1994 May 20;269(20):14502-8.
9050836	Zhao Q, Yang XL, Holtzclaw WD, Talalay P: Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase) Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1669-74.
9367528	Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, Deng PS, Chen S: Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys. 1997 Nov 15;347(2):221-8.

# Drug_Target_81_HGNC_ID:
HGNC:7856

# Drug_Target_81_HPRD_ID:
01190

# Drug_Target_81_ID:
243

# Drug_Target_81_Locus:
6pter-q12

# Drug_Target_81_Molecular_Weight:
25822

# Drug_Target_81_Name:
Ribosyldihydronicotinamide dehydrogenase [quinone]

# Drug_Target_81_Number_of_Residues:
230

# Drug_Target_81_PDB_ID:
1SG0

# Drug_Target_81_Pathway:
Not Available

# Drug_Target_81_Pfam_Domain_Function:
PF02525	Flavodoxin_2

# Drug_Target_81_Protein_Sequence:
>Ribosyldihydronicotinamide dehydrogenase [quinone]
AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLS
NPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVL
CQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCG
FKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ

# Drug_Target_81_Reaction:
1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone = 1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone

# Drug_Target_81_Signals:
None

# Drug_Target_81_Specific_Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis

# Drug_Target_81_SwissProt_ID:
P16083

# Drug_Target_81_SwissProt_Name:
NQO2_HUMAN

# Drug_Target_81_Synonyms:
EC 1.10.99.2
NRH dehydrogenase [quinone] 2
NRH:quinone oxidoreductase 2
QR2
Quinone reductase 2

# Drug_Target_81_Theoretical_pI:
6.24

# Drug_Target_81_Transmembrane_Regions:
None

# Drug_Target_82_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_82_Chromosome_Location:
Not Available

# Drug_Target_82_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
12882707	Zhang HB, Chen SL, Liu JZ, Xiao B, Chen ZB, Wang HJ: [The changes of gene expression in multiple myeloma treated with thalidomide] Zhonghua Nei Ke Za Zhi. 2003 May;42(5):300-2.
15700717	Nikonova EV, Vijayasarathy C, Zhang L, Cater JR, Galante RJ, Ward SE, Avadhani NG, Pack AI: Differences in activity of cytochrome C oxidase in brain between sleep and wakefulness. Sleep. 2005 Jan 1;28(1):21-7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_82_Essentiality:
Non-Essential

# Drug_Target_82_GenAtlas_ID:
MT-ND2

# Drug_Target_82_GenBank_ID_Gene:
J01415

# Drug_Target_82_GenBank_ID_Protein:
2052363

# Drug_Target_82_GeneCard_ID:
MT-ND2

# Drug_Target_82_Gene_Name:
MT-ND2

# Drug_Target_82_Gene_Sequence:
>1042 bp
ATTAATCCCCTGGCCCAACCCGTCATCTACTCTACCATCTTTGCAGGCACACTCATCACA
GCGCTAAGCTCGCACTGATTTTTTACCTGAGTAGGCCTAGAAATAAACATGCTAGCTTTT
ATTCCAGTTCTAACCAAAAAAATAAACCCTCGTTCCACAGAAGCTGCCATCAAGTATTTC
CTCACGCAAGCAACCGCATCCATAATCCTTCTAATAGCTATCCTCTTCAACAATATACTC
TCCGGACAATGAACCATAACCAATACTACCAATCAATACTCATCATTAATAATCATAATA
GCTATAGCAATAAAACTAGGAATAGCCCCCTTTCACTTCTGAGTCCCAGAGGTTACCCAA
GGCACCCCTCTGACATCCGGCCTGCTTCTTCTCACATGACAAAAACTAGCCCCCATCTCA
ATCATATACCAAATCTCTCCCTCACTAAACGTAAGCCTTCTCCTCACTCTCTCAATCTTA
TCCATCATAGCAGGCAGTTGAGGTGGATTAAACCAAACCCAGCTACGCAAAATCTTAGCA
TACTCCTCAATTACCCACATAGGATGAATAATAGCAGTTCTACCGTACAACCCTAACATA
ACCATTCTTAATTTAACTATTTATATTATCCTAACTACTACCGCATTCCTACTACTCAAC
TTAAACTCCAGCACCACGACCCTACTACTATCTCGCACCTGAAACAAGCTAACATGACTA
ACACCCTTAATTCCATCCACCCTCCTCTCCCTAGGAGGCCTGCCCCCGCTAACCGGCTTT
TTGCCCAAATGGGCCATTATCGAAGAATTCACAAAAAACAATAGCCTCATCATCCCCACC
ATCATAGCCACCATCACCCTCCTTAACCTCTACTTCTACCTACGCCTAATCTACTCCACC
TCAATCACACTACTCCCCATATCTAACAACGTAAAAATAAAATGACAGTTTGAACATACA
AAACCCACCCCATTCCTCCCCACACTCATCGCCCTTACCACGCTACTCCTACCTATCTCC
CCTTTTATACTAATAATCTTAT

# Drug_Target_82_General_Function:
Energy production and conversion

# Drug_Target_82_General_References:
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1370613	Lin FH, Lin R, Wisniewski HM, Hwang YW, Grundke-Iqbal I, Healy-Louie G, Iqbal K: Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains. Biochem Biophys Res Commun. 1992 Jan 15;182(1):238-46.
1732158	Brown MD, Voljavec AS, Lott MT, Torroni A, Yang CC, Wallace DC: Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics. 1992 Jan;130(1):163-73.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
1900003	Johns DR, Berman J: Alternative, simultaneous complex I mitochondrial DNA mutations in Leber's hereditary optic neuropathy. Biochem Biophys Res Commun. 1991 Feb 14;174(3):1324-30.
3921850	Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985 Apr 18-24;314(6012):592-7.
6260957	Sanger F, Coulson AR, Barrell BG, Smith AJ, Roe BA: Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. J Mol Biol. 1980 Oct 25;143(2):161-78.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.
7530363	Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N: Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):532-6.
9461455	Rieder MJ, Taylor SL, Tobe VO, Nickerson DA: Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome. Nucleic Acids Res. 1998 Feb 15;26(4):967-73.
9475751	Wise CA, Sraml M, Easteal S: Departure from neutrality at the mitochondrial NADH dehydrogenase subunit 2 gene in humans, but not in chimpanzees. Genetics. 1998 Jan;148(1):409-21.

# Drug_Target_82_HGNC_ID:
HGNC:7456

# Drug_Target_82_HPRD_ID:
Not Available

# Drug_Target_82_ID:
721

# Drug_Target_82_Locus:
-

# Drug_Target_82_Molecular_Weight:
38962

# Drug_Target_82_Name:
NADH-ubiquinone oxidoreductase chain 2

# Drug_Target_82_Number_of_Residues:
347

# Drug_Target_82_PDB_ID:
Not Available

# Drug_Target_82_Pathway:
Not Available

# Drug_Target_82_Pfam_Domain_Function:
PF00361	Oxidored_q1
PF06444	NADH_dehy_S2_C

# Drug_Target_82_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 2
MNPLAQPVIYSTIFAGTLITALSSHWFFTWVGLEMNMLAFIPVLTKKMNPRSTEAAIKYF
LTQATASMILLMAILFNNMLSGQWTMTNTTNQYSSLMIMMAMAMKLGMAPFHFWVPEVTQ
GTPLTSGLLLLTWQKLAPISIMYQISPSLNVSLLLTLSILSIMAGSWGGLNQTQLRKILA
YSSITHMGWMMAVLPYNPNMTILNLTIYIILTTTAFLLLNLNSSTTTLLLSRTWNKLTWL
TPLIPSTLLSLGGLPPLTGFLPKWAIIEEFTKNNSLIIPTIMATITLLNLYFYLRLIYST
SITLLPMSNNVKMKWQFEHTKPTPFLPTLIALTTLLLPISPFMLMIL

# Drug_Target_82_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_82_Signals:
None

# Drug_Target_82_Specific_Function:
Not Available

# Drug_Target_82_SwissProt_ID:
P03891

# Drug_Target_82_SwissProt_Name:
NU2M_HUMAN

# Drug_Target_82_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 2

# Drug_Target_82_Theoretical_pI:
10.30

# Drug_Target_82_Transmembrane_Regions:
7-29; 59-81; 93-115; 149-171; 178-195; 200-219; 239-261; 276-298; 324-346

# Drug_Target_83_Cellular_Location:
Mitochondrion

# Drug_Target_83_Chromosome_Location:
Not Available

# Drug_Target_83_Drug_References:
17002315	Xu H, West AH, Cook PF: Overall kinetic mechanism of saccharopine dehydrogenase from Saccharomyces cerevisiae. Biochemistry. 2006 Oct 3;45(39):12156-66.
17223709	Xu H, Alguindigue SS, West AH, Cook PF: A proposed proton shuttle mechanism for saccharopine dehydrogenase from Saccharomyces cerevisiae. Biochemistry. 2007 Jan 23;46(3):871-82.
17542618	Xu H, West AH, Cook PF: Determinants of substrate specificity for saccharopine dehydrogenase from Saccharomyces cerevisiae. Biochemistry. 2007 Jun 26;46(25):7625-36. Epub 2007 Jun 2.

# Drug_Target_83_Essentiality:
Non-Essential

# Drug_Target_83_GenAtlas_ID:
AASS

# Drug_Target_83_GenBank_ID_Gene:
AF229180

# Drug_Target_83_GenBank_ID_Protein:
7264724

# Drug_Target_83_GeneCard_ID:
AASS

# Drug_Target_83_Gene_Name:
AASS

# Drug_Target_83_Gene_Sequence:
>2781 bp
ATGCTGCAAGTACATAGGACTGGACTGGGCAGGCTGGGGGTCAGCCTCTCCAAGGGTCTT
CACCACAAAGCTGTGTTGGCCGTCCGGAGGGAGGATGTGAACGCCTGGGAGAGAAGGGCC
CCGCTAGCTCCCAAGCACATCAAAGGCATCACCAATCTGGGATACAAGGTCTTGATACAG
CCTTCGAATCGGCGGGCCATTCATGATAAGGACTATGTCAAAGCTGGTGGCATTCTTCAG
GAGGATATTTCTGAAGCTTGTCTAATTTTAGGAGTTAAAAGACCTCCAGAGGAAAAATTA
ATGTCCAGGAAGACTTATGCATTTTTCTCCCACACAATAAAAGCTCAGGAGGCCAATATG
GGCTTGTTGGATGAGATTCTAAAACAGGAAATTCGCCTTATTGATTATGAGAAAATGGTG
GATCATAGAGGAGTACGGGTAGTGGCATTTGGACAGTGGGCTGGTGTGGCAGGAATGATC
AACATTTTACATGGAATGGGTTTAAGGCTCCTTGCTTTGGGACATCACACACCTTTTATG
CACATTGGCATGGCTCATAACTACAGGAATAGCAGTCAGGCTGTGCAAGCTGTCCGTGAT
GCTGGCTATGAAATATCTTTGGGTTTGATGCCTAAGTCAATAGGACCCTTAACATTTGTG
TTCACAGGAACTGGTAATGTTTCTAAGGGAGCCCAAGCAATCTTTAATGAGCTACCTTGT
GAATATGTGGAGCCCCATGAATTAAAAGAAGTTTCCCAAACTGGAGACCTCAGAAAAGTG
TATGGGACGGTGTTAAGTCGTCATCATCATCTTGTCAGGAAAACAGATGCTGTGTATGAT
CCTGCAGAGTATGACAAACATCCGGAGCGCTACATAAGTCGTTTTAATACTGATATTGCA
CCCTATACAACTTGCTTAATTAATGGAATCTACTGGGAACAAAACACTCCTCGCCTCCTA
ACCCGCCAAGATGCTCAGAGTCTCCTGGCTCCGGGCAAGTTCTCACCTGCTGGTGTGGAA
GGCTGCCCTGCATTACCACACAAACTCGTGGCAATATGTGACATTTCAGCTGACACAGGA
GGGTCTATAGAGTTTATGACTGAGTGTACAACAATAGAGCATCCCTTTTGCATGTATGAT
GCAGACCAGCATATTATTCATGACAGTGTTGAAGGCTCGGGGATCCTGATGTGTTCCATT
GACAATTTGCCGGCACAGCTCCCAATTGAAGCTACAGAATGCTTTGGAGACATGCTTTAC
CCTTATGTTGAAGAAATGATATTATCAGACGCGACACAGCCTCTTGAAAGTCAGAATTTT
TCTCCTGTGGTGAGAGATGCAGTGATTACATCCAACGGTACATTACCTGATAAATATAAA
TATATCCAGACACTCCGGGAGAGCAGGGAACGTGCTCAGTCACTTTCAATGGGCACCAGG
AGAAAGGTTTTGGTTCTTGGATCTGGCTACATATCTGAGCCTGTATTAGAATATTTATCA
AGAGATGGCAATATAGAAATAACAGTAGGATCTGACATGAAGAATCAAATTGAACAGTTA
GGCAAGAAATATAATATTAATCCTGTTAGCATGGACATTTGTAAACAAGAAGAGAAGCTG
GGCTTCTTGGTGGCAAAACAGGATCTTGTCATCAGCTTGTTGCCTTATGTATTGCACCCT
CTTGTGGCCAAGGCCTGCATCACAAACAAAGTTAACATGGTCACTGCAAGCTACATCACA
CCAGCACTAAAAGAATTGGAAAAGAGTGTGGAAGATGCTGGCATCACAATCATTGGTGAA
TTGGGATTGGACCCTGGTCTGGATCACATGTTAGCAATGGAAACAATAGATAAAGCCAAG
GAAGTGGGAGCCACGATTGAATCATATATTTCCTACTGTGGTGGGCTTCCAGCCCCTGAA
CATTCAAACAATCCATTGAGATATAAATTTAGCTGGAGTCCAGTGGGAGTTTTGATGAAT
GTAATGCAGTCTGCCACCTATCTGCTCGATGGAAAGGTTGTGAATGTTGCAGGAGGCATC
TCCTTTCTTGATGCCGTTACGTCCATGGATTTTTTTCCAGGATTAAATTTGGAAGGCTAT
CCTAACAGAGACAGTACGAAATATGCTGAGATTTATGGCATTTCTTCTGCTCACACTTTG
TTGCGGGGGACACTGAGATATAAGGGATATATGAAAGCTTTGAATGGATTTGTAAAATTA
GGTCTTATAAACAGAGAAGCGCTTCCTGCCTTTAGACCTGAGGCCAACCCTCTCACCTGG
AAACAACTCCTCTGTGACCTAGTTGGGATTTCACCCTCCTCTGAGCATGATGTGTTGAAG
GAAGCTGTTCTTAAGAAACTAGGAGGAGACAATACCCAGTTGGAGGCTGCTGAATGGTTG
GGCTTACTTGGGGATGAACAAGTTCCTCAGGCAGAGTCCATTCTGGATGCCCTCTCCAAG
CATTTGGTCATGAAGCTTTCCTATGGTCCTGAAGAAAAAGATATGATTGTGATGAGAGAC
AGCTTTGGAATCAGACATCCTTCTGGACATTTAGAACATAAAACGATTGATCTTGTGGCT
TATGGGGACATCAATGGCTTTTCAGCCATGGCTAAAACCGTGGGGTTACCCACCGCCATG
GCAGCCAAAATGTTGCTTGATGGTGAAATTGGAGCCAAAGGCCTAATGGGGCCCTTTTCA
AAGGAGATCTATGGACCAATATTGGAGCGAATTAAAGCAGAAGGCATTATATATACTACA
CAGAGTACAATTAAACCATAA

# Drug_Target_83_General_Function:
Amino acid transport and metabolism

# Drug_Target_83_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.

# Drug_Target_83_HGNC_ID:
HGNC:17366

# Drug_Target_83_HPRD_ID:
05489

# Drug_Target_83_ID:
83

# Drug_Target_83_Locus:
7q31.3

# Drug_Target_83_Molecular_Weight:
102133

# Drug_Target_83_Name:
Alpha-aminoadipic semialdehyde synthase, mitochondrial

# Drug_Target_83_Number_of_Residues:
926

# Drug_Target_83_PDB_ID:
Not Available

# Drug_Target_83_Pathway:
Not Available

# Drug_Target_83_Pfam_Domain_Function:
PF01262	AlaDh_PNT_C
PF03435	Saccharop_dh
PF05222	AlaDh_PNT_N

# Drug_Target_83_Protein_Sequence:
>Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor
MLQVHRTGLGRLGVSLSKGLHHKAVLAVRREDVNAWERRAPLAPKHIKGITNLGYKVLIQ
PSNRRAIHDKDYVKAGGILQEDISEACLILGVKRPPEEKLMSRKTYAFFSHTIKAQEANM
GLLDEILKQEIRLIDYEKMVDHRGVRVVAFGQWAGVAGMINILHGMGLRLLALGHHTPFM
HIGMAHNYRNSSQAVQAVRDAGYEISLGLMPKSIGPLTFVFTGTGNVSKGAQAIFNELPC
EYVEPHELKEVSQTGDLRKVYGTVLSRHHHLVRKTDAVYDPAEYDKHPERYISRFNTDIA
PYTTCLINGIYWEQNTPRLLTRQDAQSLLAPGKFSPAGVEGCPALPHKLVAICDISADTG
GSIEFMTECTTIEHPFCMYDADQHIIHDSVEGSGILMCSIDNLPAQLPIEATECFGDMLY
PYVEEMILSDATQPLESQNFSPVVRDAVITSNGTLPDKYKYIQTLRESRERAQSLSMGTR
RKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKL
GFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGE
LGLDPGLDHMLAMETIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMN
VMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTL
LRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLK
EAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRD
SFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFS
KEIYGPILERIKAEGIIYTTQSTIKP

# Drug_Target_83_Reaction:
N6-(L-1,3-dicarboxypropyl)-L-lysine + NADP+ + H2O = L-lysine + 2-oxoglutarate + NADPH + H+

# Drug_Target_83_Signals:
None

# Drug_Target_83_Specific_Function:
Bifunctional enzyme that catalyzes the first two steps in lysine degradation. The N-terminal and the C-terminal contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively

# Drug_Target_83_SwissProt_ID:
Q9UDR5

# Drug_Target_83_SwissProt_Name:
AASS_HUMAN

# Drug_Target_83_Synonyms:
Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor
EC 1.5.1.8
EC 1.5.1.9
LKR
LKR/SDH
LOR
Saccharopine dehydrogenase

# Drug_Target_83_Theoretical_pI:
6.62

# Drug_Target_83_Transmembrane_Regions:
None

# Drug_Target_84_Cellular_Location:
Not Available

# Drug_Target_84_Chromosome_Location:
Not Available

# Drug_Target_84_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_84_Essentiality:
Non-Essential

# Drug_Target_84_GenAtlas_ID:
MT-ND3

# Drug_Target_84_GenBank_ID_Gene:
J01415

# Drug_Target_84_GenBank_ID_Protein:
506832

# Drug_Target_84_GeneCard_ID:
MT-ND3

# Drug_Target_84_Gene_Name:
MT-ND3

# Drug_Target_84_Gene_Sequence:
>346 bp
ATAAACTTCGCCTTAATTTTAATAATCAACACCCTCCTAGCCTTACTACTAATAATTATT
ACATTTTGACTACCACAACTCAACGGCTACATAGAAAAATCCACCCCTTACGAGTGCGGC
TTCGACCCTATATCCCCCGCCCGCGTCCCTTTCTCCATAAAATTCTTCTTAGTAGCTATT
ACCTTCTTATTATTTGATCTAGAAATTGCCCTCCTTTTACCCCTACCATGAGCCCTACAA
ACAACTAACCTGCCACTAATAGTTATGTCATCCCTCTTATTAATCATCATCCTAGCCCTA
AGTCTGGCCTATGAGTGACTACAAAAAGGATTAGACTGAACCGAAT

# Drug_Target_84_General_Function:
Energy production and conversion

# Drug_Target_84_General_References:
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
3921850	Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985 Apr 18-24;314(6012):592-7.
6343397	Oliver NA, Greenberg BD, Wallace DC: Assignment of a polymorphic polypeptide to the human mitochondrial DNA unidentified reading frame 3 gene by a new peptide mapping strategy. J Biol Chem. 1983 May 10;258(9):5834-9.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.

# Drug_Target_84_HGNC_ID:
HGNC:7458

# Drug_Target_84_HPRD_ID:
Not Available

# Drug_Target_84_ID:
219

# Drug_Target_84_Locus:
-

# Drug_Target_84_Molecular_Weight:
13186

# Drug_Target_84_Name:
NADH-ubiquinone oxidoreductase chain 3

# Drug_Target_84_Number_of_Residues:
115

# Drug_Target_84_PDB_ID:
Not Available

# Drug_Target_84_Pathway:
Not Available

# Drug_Target_84_Pfam_Domain_Function:
PF00507	Oxidored_q4

# Drug_Target_84_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 3
MNFALILMINTLLALLLMIITFWLPQLNGYMEKSTPYECGFDPMSPARVPFSMKFFLVAI
TFLLFDLEIALLLPLPWALQTTNLPLMVMSSLLLIIILALSLAYEWLQKGLDWTE

# Drug_Target_84_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_84_Signals:
None

# Drug_Target_84_Specific_Function:
Not Available

# Drug_Target_84_SwissProt_ID:
P03897

# Drug_Target_84_SwissProt_Name:
NU3M_HUMAN

# Drug_Target_84_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 3

# Drug_Target_84_Theoretical_pI:
4.08

# Drug_Target_84_Transmembrane_Regions:
5-27; 55-77; 84-106

# Drug_Target_85_Cellular_Location:
Mitochondrion

# Drug_Target_85_Chromosome_Location:
Not Available

# Drug_Target_85_Drug_References:
10097178	Schuler F, Yano T, Di Bernardo S, Yagi T, Yankovskaya V, Singer TP, Casida JE: NADH-quinone oxidoreductase: PSST subunit couples electron transfer from iron-sulfur cluster N2 to quinone. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4149-53.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8369340	Albracht SP: Intimate relationships of the large and the small subunits of all nickel hydrogenases with two nuclear-encoded subunits of mitochondrial NADH: ubiquinone oxidoreductase. Biochim Biophys Acta. 1993 Sep 13;1144(2):221-4.
8938450	Hyslop SJ, Duncan AM, Pitkanen S, Robinson BH: Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13. Genomics. 1996 Nov 1;37(3):375-80.

# Drug_Target_85_Essentiality:
Non-Essential

# Drug_Target_85_GenAtlas_ID:
NDUFS7

# Drug_Target_85_GenBank_ID_Gene:
AC005329

# Drug_Target_85_GenBank_ID_Protein:
3342734

# Drug_Target_85_GeneCard_ID:
NDUFS7

# Drug_Target_85_Gene_Name:
NDUFS7

# Drug_Target_85_Gene_Sequence:
>642 bp
ATGGCGGTGCTGTCAGCTCCTGGCCTGCGCGGCTTCCGGATCCTTGGTCTGCGCTCCAGC
GTGGGCCTGGCTGTGCAGGCACGAGGTGTCCATCAGAGCGTGGCCACCGATGGCCCAAGC
AGCACCCAGCCTGCCCTGCCAAAGGCCAGAGCCGTGGCTCCCAAACCCAGCAGCCGGGGC
GAGTATGTGGTGGCCAAGCTGGATGACCTCGTCAACTGGGCCCGCCGGAGTTCTCTGTGG
CCCATGACCTTCGGCCTGGCCTGCTGCGCCGTGGAGATGATGCACATGGCAGCACCCCGC
TACGACATGGACCGCTTTGGCGTGGTCTTCCGCGCCAGCCCGCGCCAGTCCGACGTCATG
ATCGTGGCCGGCACACTCACCAACAAGATGGCCCCAGCGCTTCGCAAGGTCTACGACCAG
ATGCCGGAGCCGCGCTACGTGGTCTCCATGGGGAGCTGCGCCAACGGAGGAGGCTACTAC
CACTATTCCTACTCGGTGGTGAGGGGCTGCGACCGCATCGTGCCCGTGGACATCTACATC
CCAGGCTGCCCACCTACGGCCGAGGCCCTGCTCTACGGCATCCTGCAGCTGCAGAGGAAG
ATCAAGCGGGAGCGGAGGCTGCAGATCTGGTACCGCAGGTAG

# Drug_Target_85_General_Function:
Energy production and conversion

# Drug_Target_85_General_References:
10330338	Smeitink J, van den Heuvel L: Human mitochondrial complex I in health and disease. Am J Hum Genet. 1999 Jun;64(6):1505-10.
10360771	Triepels RH, van den Heuvel LP, Loeffen JL, Buskens CA, Smeets RJ, Rubio Gozalbo ME, Budde SM, Mariman EC, Wijburg FA, Barth PG, Trijbels JM, Smeitink JA: Leigh syndrome associated with a mutation in the NDUFS7 (PSST) nuclear encoded subunit of complex I. Ann Neurol. 1999 Jun;45(6):787-90.
8938450	Hyslop SJ, Duncan AM, Pitkanen S, Robinson BH: Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13. Genomics. 1996 Nov 1;37(3):375-80.

# Drug_Target_85_HGNC_ID:
HGNC:7714

# Drug_Target_85_HPRD_ID:
03491

# Drug_Target_85_ID:
337

# Drug_Target_85_Locus:
19p13.3

# Drug_Target_85_Molecular_Weight:
23564

# Drug_Target_85_Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial

# Drug_Target_85_Number_of_Residues:
213

# Drug_Target_85_PDB_ID:
Not Available

# Drug_Target_85_Pathway:
Not Available

# Drug_Target_85_Pfam_Domain_Function:
PF01058	Oxidored_q6

# Drug_Target_85_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial precursor
MAVLSAPGLRGFRILGLRSSVGPAVQARGVHQSVATDGPSSTQPALPKARAVAPKPSSRG
EYVVAKLDDLVNWARRSSLWPMTFGLACCAVEMMHMAAPRYDMDRFGVVFRASPRQSDVM
IVAGTLTNKMAPALRKVYDQMPEPRYVVSMGSCANGGGYYHYSYSVVRGCDRIVPVDIYI
PGCPPTAEALLYGILQLQRKIKRERRLQIWYRR

# Drug_Target_85_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_85_Signals:
None

# Drug_Target_85_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_85_SwissProt_ID:
O75251

# Drug_Target_85_SwissProt_Name:
NDUS7_HUMAN

# Drug_Target_85_Synonyms:
CI-20kD
Complex I-20kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase iron-sulfur protein 7, mitochondrial precursor
NADH-ubiquinone oxidoreductase 20 kDa subunit
PSST subunit

# Drug_Target_85_Theoretical_pI:
10.36

# Drug_Target_85_Transmembrane_Regions:
None

# Drug_Target_86_Cellular_Location:
Cytoplasm

# Drug_Target_86_Chromosome_Location:
Not Available

# Drug_Target_86_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_86_Essentiality:
Non-Essential

# Drug_Target_86_GenAtlas_ID:
MTHFD1

# Drug_Target_86_GenBank_ID_Gene:
J04031

# Drug_Target_86_GenBank_ID_Protein:
307178

# Drug_Target_86_GeneCard_ID:
MTHFD1

# Drug_Target_86_Gene_Name:
MTHFD1

# Drug_Target_86_Gene_Sequence:
>2808 bp
ATGGCGCCAGCAGAAATCCTGAACGGGAAGGAGATCTCCGCGCAAATAAGGGCGAGACTG
AAAAATCAAGTCACTCAGTTGAAGGAGCAAGTACCTGGTTTCACACCACGCCTGGCAATA
TTACAGGTTGGCAACAGAGATGATTCCAATCTTTATATAAATGTGAAGCTGAAGGCTGCT
GAAGAGATTGGGATCAAAGCCACTCACATTAAGTTACCAAGAACAACCACAGAATCTGAG
GTGATGAAGTACATTACATCTTTGAATGAAGACTCTACTGTACATGGGTTCTTAGTGCAG
CTACCTTTAGATTCAGAGAATTCCATTAACACTGAAGAAGTGATCAATGCTATTGCACCC
GAGAAGGATGTGGATGGATTGACTAGCATCAATGCTGGGAGACTTGCTAGAGGTGACCTC
AATGACTGTTTCATTCCTTGTACGCCTAAGGGATGCTTGGAACTCATCAAAGAGACAGGG
GTGCCGATTGCCGGAAGGCATGCTGTGGTGGTTGGGCGCAGTAAAATAGTTGGGGCCCCG
ATGCATGACTTGCTTCTGTGGAACAATGCCACAGTGACCACCTGCCACTCCAAGACTGCC
CATCTGGATGAGGAGGTAAATAAAGGTGACATCCTGGTGGTTGCAACTGGTCAGCCTGAA
ATGGTTAAAGGGGAGTGGATCAAACCTGGGGCAATAGTCATCGACTGTGGAATCAATTAT
GTCCCAGATGATAAAAAACCAAATGGGAGAAAAGTTGTGGGTGATGTGGCATACGACGAG
GCCAAAGAGAGGGCGAGCTTCATCACTCCTGTTCCTGGCGGCGTAGGGCCCATGACAGTT
GCAATGCTCATGCAGAGCACAGTAGAGAGTGCCAAGCGTTTCCTGGAGAAATTTAAGCCA
GGAAAGTGGATGATTCAGTATAACAACCTTAACCTCAAGACACCTGTTCCAAGTGACATT
GATATATCACGATCTTGTAAACCGAAGCCCATTGGTAAGCTGGCTCGAGAAATTGGTCTG
CTGTCTGAAGAGGTAGAATTATATGGTGAAACAAAGGCCAAAGTTCTGCTGTCAGCACTA
GAACGCCTGAAGCACCGGCCTGATGGGAAATACGTGGTGGTGACTGGAATAACTCCAACA
CCCCTGGGAGAAGGGAAAAGCACAACTACAATCGGGCTAGTGCAAGCCCTTGGTGCCCAT
CTCTACCAGAATGTCTTTGCGTGTGTGCGACAGCCTTCTCAGGGCCCCACCTTTGGAATA
AAAGGTGGCGCTGCAGGAGGCGGCTACTCCCAGGTCATTCCTATGGAAGAGTTTAATCTC
CACCTCACAGGTGACATCCATGCCATCACTGCAGCTAATAACCTCGTTGCTGCGGCCATT
GATGCTCGGATATTTCATGAACTGACCCAGACAGACAAGGCTCTCTTTAATCGTTTGGTG
CCATCAGTAAATGGAGTGAGAAGGTTCTCTGACATCCAAATCCGAAGGTTAAAGAGACTA
GGCATTGAAAAGACTGACCCTACCACACTGACAGATGAAGAGATAAACAGATTTGCAAGA
TTGGACATTGATCCAGAAACCATAACTTGGCAAAGAGTGTTGGATACCAATGATAGATTC
CTGAGGAAGATCACGATTGGACAGGCTCCAACGGAGAAGGGTCACACACGGACGGCCCAG
TTTGATATCTCTGTGGCCAGTGAAATTATGGCTGTCCTGGCTCTCACCACTTCTCTAGAA
GACATGAGAGAGAGACTGGGCAAAATGGTGGTGGCATCCAGTAAGAAAGGAGAGCCCGTC
AGTGCCGAAGATCTGGGGGTGAGTGGTGCACTGACAGTGCTTATGAAGGACGCAATCAAG
CCCAATCTCATGCAGACACTGGAGGGCACTCCAGTGTTTGTCCATGCTGGCCCGTTTGCC
AACATCGCACATGGCAATTCCTCCATCATTGCAGACCGGATCGCACTCAAGCTTGTTGGC
CCAGAAGGGTTTGTAGTGACGGAAGCAGGATTTGGAGCAGACATTGGAATGGAAAAGTTT
TTTAACATCAAATGCCGGTATTCCGGCCTCTGCCCCCACGTGGTGGTGCTTGTTGCCACT
GTCAGGGCTCTCAAGATGCACGGGGGCGGCCCCACGGTCACTGCTGGACTGCCTCTTCCC
AAGGCTTACATACAGGAGAACCTGGAGCTGGTTGAAAAAGGCTTCAGTAACTTGAAGAAA
CAAATTGAAAATGCCAGAATGTTTGGAATTCCAGTAGTAGTGGCCGTGAATGCATTCAAG
ACGGATACAGAGTCTGAGCTGGACCTCATCAGCCGCCTTTCCAGAGAACATGGGGCTTTT
GATGCCGTGAAGTGCACTCACTGGGCAGAAGGGGGCAAGGGTGCCTTAGCCCTGGCTCAG
GCCGTCCAGAGAGCAGCACAAGCACCCAGCAGCTTCCAGCTCCTTTATGACCTCAAGCTC
CCAGTTGAGGATAAAATCAGGATCATTGCACAGAAGATCTATGGAGCAGATGACATTGAA
TTACTTCCCGAAGCTCAACACAAAGCTGAAGTCTACACGAAGCAGGGCTTTGGGAATCTC
CCCATCTGCATGGCTAAAACACACTTGTCTTTGTCTCACAACCCAGAGCAAAAAGGTGTC
CCTACAGGCTTCATTCTGCCCATTCGCGACATCCGCGCCAGCGTTGGGGCTGGTTTTCTG
TACCCCTTAGTAGGAACGATGAGCACAATGCCTGGACTCCCCACCCGGCCCTGTTTTTAT
GATATTGATTTGGACCCTGAAACAGAACAGGTGAATGGATTATTCTAA

# Drug_Target_86_General_Function:
Nucleotide transport and metabolism

# Drug_Target_86_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
3053686	Hum DW, Bell AW, Rozen R, MacKenzie RE: Primary structure of a human trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. J Biol Chem. 1988 Nov 5;263(31):15946-50.
9519408	Allaire M, Li Y, MacKenzie RE, Cygler M: The 3-D structure of a folate-dependent dehydrogenase/cyclohydrolase bifunctional enzyme at 1.5 A resolution. Structure. 1998 Feb 15;6(2):173-82.
9611072	Hol FA, van der Put NM, Geurds MP, Heil SG, Trijbels FJ, Hamel BC, Mariman EC, Blom HJ: Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet. 1998 Feb;53(2):119-25.

# Drug_Target_86_HGNC_ID:
HGNC:7432

# Drug_Target_86_HPRD_ID:
01403

# Drug_Target_86_ID:
679

# Drug_Target_86_Locus:
14q24

# Drug_Target_86_Molecular_Weight:
101429

# Drug_Target_86_Name:
C-1-tetrahydrofolate synthase, cytoplasmic

# Drug_Target_86_Number_of_Residues:
934

# Drug_Target_86_PDB_ID:
1DIA

# Drug_Target_86_Pathway:
Not Available

# Drug_Target_86_Pfam_Domain_Function:
PF00763	THF_DHG_CYH
PF01268	FTHFS
PF02882	THF_DHG_CYH_C

# Drug_Target_86_Protein_Sequence:
>C-1-tetrahydrofolate synthase, cytoplasmic
APAEILNGKEISAQIRARLKNQVTQLKEQVPGFTPRLAILQVGNRDDSNLYINVKLKAAE
EIGIKATHIKLPRTTTESEVMKYITSLNEDSTVHGFLVQLPLDSENSINTEEVINAIAPE
KDVDGLTSINAGRLARGDLNDCFIPCTPKGCLELIKETGVPIAGRHAVVVGRSKIVGAPM
HDLLLWNNATVTTCHSKTAHLDEEVNKGDILVVATGQPEMVKGEWIKPGAIVIDCGINYV
PDDKKPNGRKVVGDVAYDEAKERASFITPVPGGVGPMTVAMLMQSTVESAKRFLEKFKPG
KWMIQYNNLNLKTPVPSDIDISRSCKPKPIGKLAREIGLLSEEVELYGETKAKVLLSALE
RLKHRPDGKYVVVTGITPTPLGEGKSTTTIGLVQALGAHLYQNVFACVRQPSQGPTFGIK
GGAAGGGYSQVIPMEEFNLHLTGDIHAITAANNLVAAAIDARIFHELTQTDKALFNRLVP
SVNGVRRFSDIQIRRLKRLGIEKTDPTTLTDEEINRFARLDIDPETITWQRVLDTNDRFL
RKITIGQAPTEKGHTRTAQFDISVASEIMAVLALTTSLEDMRERLGKMVVASSKKGEPVS
AEDLGVSGALTVLMKDAIKPNLMQTLEGTPVFVHAGPFANIAHGNSSIIADRIALKLVGP
EGFVVTEAGFGADIGMEKFFNIKCRYSGLCPHVVVLVATVRALKMHGGGPTVTAGLPLPK
AYIQENLELVEKGFSNLKKQIENARMFGIPVVVAVNAFKTDTESELDLISRLSREHGAFD
AVKCTHWAEGGKGALALAQAVQRAAQAPSSFQLLYDLKLPVEDKIRIIAQKIYGADDIEL
LPEAQHKAEVYTKQGFGNLPICMAKTHLSLSHNPEQKGVPTGFILPIRDIRASVGAGFLY
PLVGTMSTMPGLPTRPCFYDIDLDPETEQVNGLF

# Drug_Target_86_Reaction:
5,10-methylenetetrahydrofolate + NADP+ = 5,10-methenyltetrahydrofolate + NADPH + H+

# Drug_Target_86_Signals:
None

# Drug_Target_86_Specific_Function:
Not Available

# Drug_Target_86_SwissProt_ID:
P11586

# Drug_Target_86_SwissProt_Name:
C1TC_HUMAN

# Drug_Target_86_Synonyms:
C1-THF synthase

# Drug_Target_86_Theoretical_pI:
7.32

# Drug_Target_86_Transmembrane_Regions:
None

# Drug_Target_87_Cellular_Location:
Mitochondrion

# Drug_Target_87_Chromosome_Location:
Not Available

# Drug_Target_87_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_87_Essentiality:
Non-Essential

# Drug_Target_87_GenAtlas_ID:
MTHFD2

# Drug_Target_87_GenBank_ID_Gene:
X16396

# Drug_Target_87_GenBank_ID_Protein:
35071

# Drug_Target_87_GeneCard_ID:
MTHFD2

# Drug_Target_87_Gene_Name:
MTHFD2

# Drug_Target_87_Gene_Sequence:
>1035 bp
ATGTCTGCTTTGGCTGCCCGGCTGCTGCAGCCCGCGCACAGCTGCTCCCTTCGCCTTCGC
CCTTTCCACCTCGCGGCAGTTCGAAATGAAGCTGTTGTCATTTCTGGAAGGAAACTGGCC
CAGCAGATCAAGCAGGAAGTGCGGCAGGAGGTAGAAGAGTGGGTGGCCTCAGGCAACAAA
CGGCCACACCTGAGTGTGATCCTGGTTGGCGAGAATCCTGCAAGTCACTCCTATGTCCTC
AACAAAACCAGGGCAGCTGCAGTTGTGGGAATCAACAGTGAGACAATTATGAAACCAGCT
TCAATTTCAGAGGAAGAATTGTTGAATTTAATCAATAAACTGAATAATGATGATAATGTA
GATGGCCTCCTTGTTCAGTTGCCTCTTCCAGAGCATATTGATGAGAGAAGGATCTGCAAT
GCTGTTTCTCCAGACAAGGATGTTGATGGCTTTCATGTAATTAATGTAGGACGAATGTGT
TTGGATCAGTATTCCATGTTACCGGCTACTCCATGGGGTGTGTGGGAAATAATCAAGCGA
ACTGGCATTCCAACCCTAGGGAAGAATGTGGTTGTGGCTGGAAGGTCAAAAAACGTTGGA
ATGCCCATTGCAATGTTACTGCACACAGATGGGGCGCATGAACGTCCCGGAGGTGATGCC
ACTGTTACAATATCTCATCGATATACTCCCAAAGAGCAGTTGAAGAAACATACAATTCTT
GCAGATATTGTAATATCTGCTGCAGGTATTCCAAATCTGATCACAGCAGATATGATCAAG
GAAGGAGCAGCAGTCATTGATGTGGGAATAAATAGAGTTCACGATCCTGTAACTGCCAAA
CCCAAGTTGGTTGGAGATGTGGATTTTGAAGGAGTCAGACAAAAAGCTGGGTATATCACT
CCAGTTCCTGGAGGTGTTGGCCCCATGACAGTGGCAATGCTAATGAAGAATACCATTATT
GCTGCAAAAAAGGTGCTGAGGCTTGAAGAGCGAGAAGTGCTGAAGTCTAAAGAGCTTGGG
GTAGCCACTAATTAA

# Drug_Target_87_General_Function:
Coenzyme transport and metabolism

# Drug_Target_87_General_References:
2587219	Peri KG, Belanger C, Mackenzie RE: Nucleotide sequence of the human NAD-dependent methylene tetrahydrofolate dehydrogenase-cyclohydrolase. Nucleic Acids Res. 1989 Nov 11;17(21):8853.

# Drug_Target_87_HGNC_ID:
HGNC:7434

# Drug_Target_87_HPRD_ID:
05351

# Drug_Target_87_ID:
296

# Drug_Target_87_Locus:
2p13.1

# Drug_Target_87_Molecular_Weight:
37896

# Drug_Target_87_Name:
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial

# Drug_Target_87_Number_of_Residues:
350

# Drug_Target_87_PDB_ID:
Not Available

# Drug_Target_87_Pathway:
Not Available

# Drug_Target_87_Pfam_Domain_Function:
PF00763	THF_DHG_CYH
PF02882	THF_DHG_CYH_C

# Drug_Target_87_Protein_Sequence:
>Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial precursor [Includes: NAD-dependent methylenetetrahydrofolate dehydrogenase
MAATSLMSALAARLLQPAHSCSLRLRPFHLAAVRNEAVVISGRKLAQQIKQEVRQEVEEW
VASGNKRPHLSVILVGENPASHSYVLNKTRAAAVVGINSETIMKPASISEEELLNLINKL
NNDDNVDGLLVQLPLPEHIDERRICNAVSPDKDVDGFHVINVGRMCLDQYSMLPATPWGV
WEIIKRTGIPTLGKNVVVAGRSKNVGMPIAMLLHTDGAHERPGGDATVTISHRYTPKEQL
KKHTILADIVISAAGIPNLITADMIKEGAAVIDVGINRVHDPVTAKPKLVGDVDFEGVRQ
KAGYITPVPGGVGPMTVAMLMKNTIIAAKKVLRLEEREVLKSKELGVATN

# Drug_Target_87_Reaction:
5,10-methylenetetrahydrofolate + NAD+ = 5,10-methenyltetrahydrofolate + NADH + H+

# Drug_Target_87_Signals:
None

# Drug_Target_87_Specific_Function:
Not Available

# Drug_Target_87_SwissProt_ID:
P13995

# Drug_Target_87_SwissProt_Name:
MTDC_HUMAN

# Drug_Target_87_Synonyms:
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial

# Drug_Target_87_Theoretical_pI:
9.12

# Drug_Target_87_Transmembrane_Regions:
None

# Drug_Target_88_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_88_Chromosome_Location:
Not Available

# Drug_Target_88_Drug_References:
16934832	Inagaki E, Ohshima N, Takahashi H, Kuroishi C, Yokoyama S, Tahirov TH: Crystal structure of Thermus thermophilus Delta1-pyrroline-5-carboxylate dehydrogenase. J Mol Biol. 2006 Sep 22;362(3):490-501. Epub 2006 Jul 29.

# Drug_Target_88_Essentiality:
Non-Essential

# Drug_Target_88_GenAtlas_ID:
ALDH4A1

# Drug_Target_88_GenBank_ID_Gene:
U24267

# Drug_Target_88_GenBank_ID_Protein:
1353250

# Drug_Target_88_GeneCard_ID:
ALDH4A1

# Drug_Target_88_Gene_Name:
ALDH4A1

# Drug_Target_88_Gene_Sequence:
>1692 bp
ATGCTGCTGCCGGCGCCCGCGCTCCGCCGCGCCCTGCTGTCCCGCCCCTGGACCGGGGCC
GGCCTGCGGTGGAAGCACACCTCCTCCCTGAAGGTGGCCAACGAGCCCGTCTTAGCCTTC
ACGCAGGGCAGCCCTGAGCGAGATGCCCTGCAAAAGGCCTTGAAGGACCTGAAGGGCCGG
ATGGAAGCCATCCCATGCGTGATGGGGGATGAGGAGGTGTGGACGTCGGACGTGCAGTAC
CAAGTGTCGCCTTTTAACCATGGACATAAGGTGGCCAAGTTCTGTTATGCAGACAAGAGC
CTGCTCAACAAAGCCATTGAGGCTGCCCTGGCTGCCCGGAAAGAGTGGGACCTGAAGCCT
ATTGCAGACCGGGCCCAGATCTTCCTGAAGGCGGCAGACATGCTGAGTGGGCCGCGCAGG
GCTGAGATCCTCGCCAAGACCATGGTGGGACAGGGTAAGACCGTGATCCAAGCGGAGATT
GACGCTGCAGCGGAACTCATCGACTTCTTCCGGTTCAATGCCAAGTATGCGGTGGAGCTG
GAGGGGCAGCAGCCCATCAGCGTGCCCCCGAGCACCAACAGCACGGTGTACCGGGGTCTG
GAGGGCTTCGTGGCGGCCATCTCGCCCTTTAACTTCACTGCAATCGGCGGCAACCTGGCG
GGGGCACCGGCCCTGATGGGCAACGTGGTCCTATGGAAGCCCAGTGACACTGCCATGCTG
GCCAGCTATGCTGTCTACCGCATCCTTCGGGAGGCTGGCCTGCCCCCCAACATCATCCAG
TTTGTGCCAGCTGATGGGCCCCTATTTGGGGACACTGTCACCAGCTCAGAGCACCTCTGT
GGCATCAACTTCACAGGCAGTGTGCCCACCTTCAAACACCTGTGGAAGCAGGTGGCCCAG
AACCTGGACCGGTTCCACACCTTCCCACGCCTGGCTGGAGAGTGCGGCGGAAAGAACTTC
CACTTCGTGCACCGCTCGGCCGACGTGGAGAGCGTGGTGAGCGGGACCCTCCGCTCAGCC
TTCGAGTACGGTGGCCAGAAGTGTTCCGCCTGCTCGCGTCTCTACGTGCCGCACTCGCTG
TGGCCGCAGATCAAAGGGCGGCTGCTGGAGGAGCACAGTCGGATCAAAGTGGGCGACCCT
GCAGAGGATTTTGGGACCTTCTTCTCTGCAGTGATTGATGCCAAGTCCTTTGCCCGTATC
AAGAAGTGGCTGGAGCACGCGCGCTCCTCGCCCAGCCTCACCATCCTGGCTGGGGGCAAG
TGTGATGACTCCGTGGGCTACTTTGTGGAGCCCTGCATCGTGGAGAGCAAGGACCCTCAG
GAGCCCATCATGAAGGAGGAGATCTTCGGGCCTGTACTGTCTGTGTACGTCTACCCGGAC
GACAAGTACAAGGAGACGCTGCAGCTGGTTGACAGCACCACCAGCTATGGCCTCACGGGG
GCAGTGTTCTCCCAGGATAAGGACGTCGTGCAGGAGGCCACAAAGGTGCTGAGGAATGCT
GCCGGCAACTTCTACATCAACGACAAGTCCACTGGCTCGATAGTGGGCCAGCAGCCCTTT
GGGGGGGCCCGAGCCTCTGGAACCAATGACAAGCCAGGGGGCCCACACTACATCCTGCGC
TGGACGTCGCCGCAGGTCATCAAGGAGACACATAAGCCCCTGGGGGACTGGAGCTACGCG
TACATGCAGTGA

# Drug_Target_88_General_Function:
Energy production and conversion

# Drug_Target_88_General_References:
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
1395511	Hempel J, Eckey R, Berie D, Romovacek H, Agarwal DP, Goedde HW: Human liver glutamic gamma-semialdehyde dehydrogenase: structural relationship to the yeast enzyme. Comp Biochem Physiol B. 1992 Aug;102(4):791-93.
8621661	Hu CA, Lin WW, Valle D: Cloning, characterization, and expression of cDNAs encoding human delta 1-pyrroline-5-carboxylate dehydrogenase. J Biol Chem. 1996 Apr 19;271(16):9795-800.
9700195	Geraghty MT, Vaughn D, Nicholson AJ, Lin WW, Jimenez-Sanchez G, Obie C, Flynn MP, Valle D, Hu CA: Mutations in the Delta1-pyrroline 5-carboxylate dehydrogenase gene cause type II hyperprolinemia. Hum Mol Genet. 1998 Sep;7(9):1411-5.

# Drug_Target_88_HGNC_ID:
HGNC:406

# Drug_Target_88_HPRD_ID:
06009

# Drug_Target_88_ID:
271

# Drug_Target_88_Locus:
1p36

# Drug_Target_88_Molecular_Weight:
61720

# Drug_Target_88_Name:
Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial

# Drug_Target_88_Number_of_Residues:
563

# Drug_Target_88_PDB_ID:
Not Available

# Drug_Target_88_Pathway:
Not Available

# Drug_Target_88_Pfam_Domain_Function:
PF00171	Aldedh

# Drug_Target_88_Protein_Sequence:
>Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial precursor
MLLPAPALRRALLSRPWTGAGLRWKHTSSLKVANEPVLAFTQGSPERDALQKALKDLKGR
MEAIPCVVGDEEVWTSDVQYQVSPFNHGHKVAKFCYADKSLLNKAIEAALAARKEWDLKP
IADRAQIFLKAADMLSGPRRAEILAKTMVGQGKTVIQAEIDAAAELIDFFRFNAKYAVEL
EGQQPISVPPSTNSTVYRGLEGFVAAISPFNFTAIGGNLAGAPALMGNVVLWKPSDTAML
ASYAVYRILREAGLPPNIIQFVPADGPLFGDTVTSSEHLCGINFTGSVPTFKHLWKQVAQ
NLDRFHTFPRLAGECGGKNFHFVHRSADVESVVSGTLRSAFEYGGQKCSACSRLYVPHSL
WPQIKGRLLEEHSRIKVGDPAEDFGTFFSAVIDAKSFARIKKWLEHARSSPSLTILAGGK
CDDSVGYFVEPCIVESKDPQEPIMKEEIFGPVLSVYVYPDDKYKETLQLVDSTTSYGLTG
AVFSQDKDVVQEATKVLRNAAGNFYINDKSTGSIVGQQPFGGARASGTNDKPGGPHYILR
WTSPQVIKETHKPLGDWSYAYMQ

# Drug_Target_88_Reaction:
(S)-1-pyrroline-5-carboxylate + NAD+ + 2 H2O = L-glutamate + NADH + H+

# Drug_Target_88_Signals:
None

# Drug_Target_88_Specific_Function:
Irreversible conversion of delta-1-pyrroline-5- carboxylate (P5C), derived either from proline or ornithine, to glutamate. This is a necessary step in the pathway interconnecting the urea and tricarboxylic acid cycles. The preferred substrate is glutamic gamma-semialdehyde, other substrates include succinic, glutaric and adipic semialdehydes

# Drug_Target_88_SwissProt_ID:
P30038

# Drug_Target_88_SwissProt_Name:
AL4A1_HUMAN

# Drug_Target_88_Synonyms:
Aldehyde dehydrogenase 4A1
Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial precursor
EC 1.5.1.12
P5C dehydrogenase

# Drug_Target_88_Theoretical_pI:
8.20

# Drug_Target_88_Transmembrane_Regions:
None

# Drug_Target_89_Cellular_Location:
Isoform 1:Endoplasmic reticulum
cytoplasmic side. Mit
endoplasmic reticulum membrane
lipid-anchor

# Drug_Target_89_Chromosome_Location:
Not Available

# Drug_Target_89_Drug_References:
16814740	Roma GW, Crowley LJ, Barber MJ: Expression and characterization of a functional canine variant of cytochrome b5 reductase. Arch Biochem Biophys. 2006 Aug 1;452(1):69-82. Epub 2006 May 24.
17040106	Kurian JR, Chin NA, Longlais BJ, Hayes KL, Trepanier LA: Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. Chem Res Toxicol. 2006 Oct;19(10):1366-73.
17082011	Nussenzveig RH, Lingam HB, Gaikwad A, Zhu Q, Jing N, Prchal JT: A novel mutation of the cytochrome-b5 reductase gene in an Indian patient: the molecular basis of type I methemoglobinemia. Haematologica. 2006 Nov;91(11):1542-5.
17341833	Ikegami T, Kameyama E, Yamamoto SY, Minami Y, Yubisui T: Structure and properties of the recombinant NADH-cytochrome b5 reductase of Physarum polycephalum. Biosci Biotechnol Biochem. 2007 Mar;71(3):783-90. Epub 2007 Mar 7.
17401193	Kim S, Suga M, Ogasahara K, Ikegami T, Minami Y, Yubisui T, Tsukihara T: Structure of Physarum polycephalum cytochrome b5 reductase at 1.56 A resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Apr 1;63(Pt 4):274-9. Epub 2007 Mar 23.

# Drug_Target_89_Essentiality:
Non-Essential

# Drug_Target_89_GenAtlas_ID:
CYB5R3

# Drug_Target_89_GenBank_ID_Gene:
M28713

# Drug_Target_89_GenBank_ID_Protein:
553600

# Drug_Target_89_GeneCard_ID:
CYB5R3

# Drug_Target_89_Gene_Name:
CYB5R3

# Drug_Target_89_Gene_Sequence:
>906 bp
ATGGGGGCCCAGCTCAGCACGTTGGGCCATATGGTCCTCTTCCCAGTCTGGTTCCTGTAC
AGTCTGCTCATGAAGCTGTTCCAGGGCTCCACGCCAGCCATCACCCTCGAGAGCCCGGAC
ATCAAGTACCCGCTGCGGCTCATCGACCGGGAGATCATCAGCCATGACACCCGGCGCTTC
CGCTTTGCCCTGCCGCCACCCCAGCACATCCTGGGCCTCCCTGTCGGCCAGCACATCTAC
CTCTCGGCTCGAATTGATGGAAACCTGGTCGTCCGGCCCTATACACCAATCTCCAGCGAT
GATGACAAGGGCTTCGTGGACCTGGTCATCAAGGTTTACTTCAAGGACACCCATCCCAAG
TTTCCCGCTGGAGGGAAGATGTCTCAGTACCTGGAGAGCATGCAGATTGGAGACACCATT
GAGTTCCGGGGCCCCAGTGGGCTGCTGGTCTACCAGGGCAAAGGGAAGTTCGCCATCCGA
CCTGACAAAAAGTCCAACCCTATCATCAGGACAGTGAAGTCTGTGGGCATGATCGCGGGA
GGGACAGGCATCACCCCGATGCTGCAGGTGATCCGCGCCATCATGAAGGACCCTGATGAC
CACACTGTGTGCCACCTGCTCTTTGCCAACCAGACCGAGAAGGACATCCTGCTGCGACCT
GAGCTGGAGGAACTCAGGAACAAACATTCTGCACGCTTCAAGCTCTGGTACACGCTGGAC
AGAGCCCCTGAAGCCTGGGACTACGGCCAGGGCTTCGTGAATGAGGAGATGATCCGGGAC
CACCTTCCACCCCCAGAGGAGGAGCCGCTGGTGCTGATGTGTGGCCCCCCACCCATGATC
CAGTACGCCTGCCTTCCCAACCTGGACCACGTGGGCCACCCCACGGAGCGCTGCTTCGTC
TTCTGA

# Drug_Target_89_General_Function:
Coenzyme transport and metabolism

# Drug_Target_89_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
10807796	Wang Y, Wu YS, Zheng PZ, Yang WX, Fang GA, Tang YC, Xie F, Lan FH, Zhu ZY: A novel mutation in the NADH-cytochrome b5 reductase gene of a Chinese patient with recessive congenital methemoglobinemia. Blood. 2000 May 15;95(10):3250-5.
1400360	Shirabe K, Yubisui T, Borgese N, Tang CY, Hultquist DE, Takeshita M: Enzymatic instability of NADH-cytochrome b5 reductase as a cause of hereditary methemoglobinemia type I (red cell type). J Biol Chem. 1992 Oct 5;267(28):20416-21.
1707593	Katsube T, Sakamoto N, Kobayashi Y, Seki R, Hirano M, Tanishima K, Tomoda A, Takazakura E, Yubisui T, Takeshita M, et al.: Exonic point mutations in NADH-cytochrome B5 reductase genes of homozygotes for hereditary methemoglobinemia, types I and III: putative mechanisms of tissue-dependent enzyme deficiency. Am J Hum Genet. 1991 Apr;48(4):799-808.
1898726	Yubisui T, Shirabe K, Takeshita M, Kobayashi Y, Fukumaki Y, Sakaki Y, Takano T: Structural role of serine 127 in the NADH-binding site of human NADH-cytochrome b5 reductase. J Biol Chem. 1991 Jan 5;266(1):66-70.
2019583	Shirabe K, Yubisui T, Nishino T, Takeshita M: Role of cysteine residues in human NADH-cytochrome b5 reductase studied by site-directed mutagenesis. Cys-273 and Cys-283 are located close to the NADH-binding site but are not catalytically essential. J Biol Chem. 1991 Apr 25;266(12):7531-6.
2479590	Tomatsu S, Kobayashi Y, Fukumaki Y, Yubisui T, Orii T, Sakaki Y: The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. Gene. 1989 Aug 15;80(2):353-61.
3035541	Yubisui T, Naitoh Y, Zenno S, Tamura M, Takeshita M, Sakaki Y: Molecular cloning of cDNAs of human liver and placenta NADH-cytochrome b5 reductase. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3609-13.
3700359	Yubisui T, Miyata T, Iwanaga S, Tamura M, Takeshita M: Complete amino acid sequence of NADH-cytochrome b5 reductase purified from human erythrocytes. J Biochem (Tokyo). 1986 Feb;99(2):407-22.
6389526	Yubisui T, Miyata T, Iwanaga S, Tamura M, Yoshida S, Takeshita M, Nakajima H: Amino acid sequence of NADH-cytochrome b5 reductase of human erythrocytes. J Biochem (Tokyo). 1984 Aug;96(2):579-82.
7718898	Vieira LM, Kaplan JC, Kahn A, Leroux A: Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II. Blood. 1995 Apr 15;85(8):2254-62.
8119939	Shirabe K, Fujimoto Y, Yubisui T, Takeshita M: An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. J Biol Chem. 1994 Feb 25;269(8):5952-7.
9048929	Jenkins MM, Prchal JT: A high-frequency polymorphism of NADH-cytochrome b5 reductase in African-Americans. Hum Genet. 1997 Feb;99(2):248-50.
9639531	Bulbarelli A, Valentini A, DeSilvestris M, Cappellini MD, Borgese N: An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans. Blood. 1998 Jul 1;92(1):310-9.
9695975	Wu YS, Huang CH, Wan Y, Huang QJ, Zhu ZY: Identification of a novel point mutation (Leu72Pro) in the NADH-cytochrome b5 reductase gene of a patient with hereditary methaemoglobinaemia type I. Br J Haematol. 1998 Jul;102(2):575-7.
9886302	Higasa K, Manabe JI, Yubisui T, Sumimoto H, Pung-Amritt P, Tanphaichitr VS, Fukumaki Y: Molecular basis of hereditary methaemoglobinaemia, types I and II: two novel mutations in the NADH-cytochrome b5 reductase gene. Br J Haematol. 1998 Dec;103(4):922-30.

# Drug_Target_89_HGNC_ID:
HGNC:2873

# Drug_Target_89_HPRD_ID:
08942

# Drug_Target_89_ID:
178

# Drug_Target_89_Locus:
22q13.31-qter|22q13.2-q13.31

# Drug_Target_89_Molecular_Weight:
34104

# Drug_Target_89_Name:
NADH-cytochrome b5 reductase 3

# Drug_Target_89_Number_of_Residues:
300

# Drug_Target_89_PDB_ID:
1UMK

# Drug_Target_89_Pathway:
Not Available

# Drug_Target_89_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_89_Protein_Sequence:
>NADH-cytochrome b5 reductase
GAQLSTLGHMVLFPVWFLYSLLMKLFQRSTPAITLESPDIKYPLRLIDREIISHDTRRFR
FALPSPQHILGLPVGQHIYLSARIDGNLVVRPYTPISSDDDKGFVDLVIKVYFKDTHPKF
PAGGKMSQYLESMQIGDTIEFRGPSGLLVYQGKGKFAIRPDKKSNPIIRTVKSVGMIAGG
TGITPMLQVIRAIMKDPDDHTVCHLLFANQTEKDILLRPELEELRNKHSARFKLWYTLDR
APEAWDYGQGFVNEEMIRDHLPPPEEEPLVLMCGPPPMIQYACLPNLDHVGHPTERCFVF

# Drug_Target_89_Reaction:
NADH + 2 ferricytochrome b5 = NAD+ + H+ + 2 ferrocytochrome b5

# Drug_Target_89_Signals:
None

# Drug_Target_89_Specific_Function:
Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction

# Drug_Target_89_SwissProt_ID:
P00387

# Drug_Target_89_SwissProt_Name:
NB5R3_HUMAN

# Drug_Target_89_Synonyms:
B5R
Cytochrome b5 reductase
Diaphorase-1
EC 1.6.2.2

# Drug_Target_89_Theoretical_pI:
7.68

# Drug_Target_89_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasm

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17088060	Fonvielle M, Therisod H, Hemery M, Therisod M: New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):410-3. Epub 2006 Oct 17.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
GPD1

# Drug_Target_8_GenBank_ID_Gene:
L34041

# Drug_Target_8_GenBank_ID_Protein:
508487

# Drug_Target_8_GeneCard_ID:
GPD1

# Drug_Target_8_Gene_Name:
GPD1

# Drug_Target_8_Gene_Sequence:
>1050 bp
ATGGCTAGCAAGAAAGTCTGCATTGTAGGCTCCGGGAACTGGGGCTCAGCCATCGCCAAG
ATCGTGGGTGGCAATGCAGCCCAGCTCGCACAGTTTGACCCACGGGTGACCATGTGGGTA
TTTGAGGAAGACATTGGAGGCAAAAAGCTGACTGAGATCATCAACACGCAGCATGAGAAT
GTCAAATACCTGCCAGGGCACAAGTTGCCCCCAAATGTGGTGGCTGTCCCAGATGTGGTC
CAGGCTGCAGAGGATGCTGACATCCTGATCTTTGTGGTGCCCCATCAGTTCATCGGCAAG
ATCTGTGACCAGCTCAAGGGCCATCTGAAGGCAAACCCCACTGGCATATCTCTTATTAAG
GGGGTAGACGAGGGCCCCAATGGGCTGAAGCTCATCTCGGAAGTGATTGGGGAGCGCCTC
GGCATCCCCATGAGTGTGCTGATGGGGGCCAACATTGCCAGCGAGGTGGCTGATGAGAAG
TTCTGTGAGACAACCATTGGCTGCAAGGACCCGGCCCAGGGACAACTCCTGAAAGAGCTG
ATGCAGACACCAAACTTCCGTATCACAGTGGTGCAAGAGGTGGACACAGTAGAGATCTGT
GGAGCCTTAAAGAATGTAGTGGCCGTGGGGGCTGGCTTCTGTGATGGCCTGGGCTTTGGC
GACAACACCAAGGCGGCAGTGATCCGGCTGGGACTCATGGAGATGATAGCCTTCGCCAAG
CTCTTCTGCAGTGGCCCTGTGTCCTCTGCCACCTTCTTGGAGAGCTGTGGTGTTGCTGAC
CTGATCACTACCTGCTATGGAGGGCGGAACCGGAAAGTGGCTGAGGCCTTTGCGCGTACA
GGAAAGTCCATTGAGCAGCTGGAGAAAGAGTTGCTGAATGGGCAGAAACTGCAGGGGCCC
GAGACAGCCCGGGAGCTATACAGCATCCTCCAGCACAAGGGCCTGGTAGACAAGTTTCCC
TTGTTCATGGCTGTGTACAAGGTGTGCTACGAGGGCCAGCCAGTGGGTGAATTCATCCAC
TGCCTGCAGAATCATCCAGAACATATGTGA

# Drug_Target_8_General_Function:
Energy production and conversion

# Drug_Target_8_General_References:
2398890	Gwynn B, Lyford KA, Birkenmeier EH: Sequence conservation and structural organization of the glycerol-3-phosphate dehydrogenase promoter in mice and humans. Mol Cell Biol. 1990 Oct;10(10):5244-56.
7772607	Menaya J, Gonzalez-Manchon C, Parrilla R, Ayuso MS: Molecular cloning, sequencing and expression of a cDNA encoding a human liver NAD-dependent alpha-glycerol-3-phosphate dehydrogenase. Biochim Biophys Acta. 1995 May 17;1262(1):91-4.

# Drug_Target_8_HGNC_ID:
HGNC:4455

# Drug_Target_8_HPRD_ID:
00714

# Drug_Target_8_ID:
231

# Drug_Target_8_Locus:
12q12-q13

# Drug_Target_8_Molecular_Weight:
37463

# Drug_Target_8_Name:
Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic

# Drug_Target_8_Number_of_Residues:
348

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01210	NAD_Gly3P_dh_N
PF07479	NAD_Gly3P_dh_C

# Drug_Target_8_Protein_Sequence:
>Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic
ASKKVCIVGSGNWGSAIAKIVGGNAAQLAQFDPRVTMWVFEEDIGGKKLTEIINTQHENV
KYLPGHKLPPNVVAVPDVVQAAEDADILIFVVPHQFIGKICDQLKGHLKANPTGISLIKG
VDEGPNGLKLISEVIGERLGIPMSVLMGANIASEVADEKFCETTIGCKDPAQGQLLKELM
QTPNFRITVVQEVDTVEICGALKNVVAVGAGFCDGLGFGDNTKAAVIRLGLMEMIAFAKL
FCSGPVSSATFLESCGVADLITTCYGGRNRKVAEAFARTGKSIEQLEKELLNGQKLQGPE
TARELYSILQHKGLVDKFPLFMAVYKVCYEGQPVGEFIHCLQNHPEHM

# Drug_Target_8_Reaction:
sn-glycerol 3-phosphate + NAD+ = glycerone phosphate + NADH + H+

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
P21695

# Drug_Target_8_SwissProt_Name:
GPDA_HUMAN

# Drug_Target_8_Synonyms:
EC 1.1.1.8
GPD-C
GPDH-C

# Drug_Target_8_Theoretical_pI:
6.10

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_90_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_90_Chromosome_Location:
Not Available

# Drug_Target_90_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_90_Essentiality:
Non-Essential

# Drug_Target_90_GenAtlas_ID:
NDUFA11

# Drug_Target_90_GenBank_ID_Gene:
AJ539081

# Drug_Target_90_GenBank_ID_Protein:
28170654

# Drug_Target_90_GeneCard_ID:
NDUFA11

# Drug_Target_90_Gene_Name:
NDUFA11

# Drug_Target_90_Gene_Sequence:
>426 bp
ATGGCGCCGAAGGTTTTTCGTCAGTACTGGGATATCCCCGATGGCACCGATTGCCACCGC
AAAGCCTACAGCACCACCAGTATTGCCAGCGTCGCTGGCCTGACCGCCGCTGCCTACAGA
GTCACACTCAATCCTCCGGGCACCTTCCTTGAAGGAGTGGCTAAGGTTGGACAATACACG
TTCACTGCAGCTGCTGTCGGGGCCGTGTTTGGCCTCACCACCTGCATCAGCGCCCATGTC
CGCGAGAAGCCCGACGACCCCCTGAACTACTTCCTCGGTGGCTGCGCCGGAGGCCTGACT
CTGGGAGCACGCACGCACAACTACGGGATTGGCGCCGCCGCCTGCGTGTACTTTGGCATA
GCGGCCTCCCTGGTCAAGATGGGCCGGCTGGAGGGCTGGGAGGTGTTTGCAAAACCCAAG
GTGTGA

# Drug_Target_90_General_Function:
Not Available

# Drug_Target_90_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.

# Drug_Target_90_HGNC_ID:
HGNC:20371

# Drug_Target_90_HPRD_ID:
14818

# Drug_Target_90_ID:
598

# Drug_Target_90_Locus:
19p13.3

# Drug_Target_90_Molecular_Weight:
14721

# Drug_Target_90_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11

# Drug_Target_90_Number_of_Residues:
140

# Drug_Target_90_PDB_ID:
Not Available

# Drug_Target_90_Pathway:
Not Available

# Drug_Target_90_Pfam_Domain_Function:
Not Available

# Drug_Target_90_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11
APKVFRQYWDIPDGTDCHRKAYSTTSIASVAGLTAAAYRVTLNPPGTFLEGVAKVGQYTF
TAAAVGAVFGLTTCISAHVREKPDDPLNYFLGGCAGGLTLGARTHNYGIGAAACVYFGIA
ASLVKMGRLEGWEVFAKPKV

# Drug_Target_90_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_90_Signals:
None

# Drug_Target_90_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_90_SwissProt_ID:
Q86Y39

# Drug_Target_90_SwissProt_Name:
NDUAB_HUMAN

# Drug_Target_90_Synonyms:
CI-B14.7
Complex I-B14.7
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase subunit B14.7

# Drug_Target_90_Theoretical_pI:
8.89

# Drug_Target_90_Transmembrane_Regions:
20-42
57-79

# Drug_Target_91_Cellular_Location:
Not Available

# Drug_Target_91_Chromosome_Location:
Not Available

# Drug_Target_91_Drug_References:
15560738	Shen XY, Zacal N, Singh G, Rainbow AJ: Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem Photobiol. 2005 Mar-Apr;81(2):306-13.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7846157	Dzelzkalns VA, Obinger C, Regelsberger G, Niederhauser H, Kamensek M, Peschek GA, Bogorad L: Deletion of the structural gene for the NADH-dehydrogenase subunit 4 of Synechocystis 6803 alters respiratory properties. Plant Physiol. 1994 Dec;106(4):1435-42.
9950599	Carper DA, Sun JK, Iwata T, Zigler JS Jr, Ibaraki N, Lin LR, Reddy V: Oxidative stress induces differential gene expression in a human lens epithelial cell line. Invest Ophthalmol Vis Sci. 1999 Feb;40(2):400-6.

# Drug_Target_91_Essentiality:
Non-Essential

# Drug_Target_91_GenAtlas_ID:
MT-ND4

# Drug_Target_91_GenBank_ID_Gene:
J01415

# Drug_Target_91_GenBank_ID_Protein:
Not Available

# Drug_Target_91_GeneCard_ID:
MT-ND4

# Drug_Target_91_Gene_Name:
MT-ND4

# Drug_Target_91_Gene_Sequence:
>1378 bp
ATGCTAAAACTAATCGTCCCAACAATTATATTACTACCACTGACATGACTTTCCAAAAAA
CACATAATTTGAATCAACACAACCACCCACAGCCTAATTATTAGCATCATCCCTCTACTA
TTTTTTAACCAAATCAACAACAACCTATTTAGCTGTTCCCCAACCTTTTCCTCCGACCCC
CTAACAACCCCCCTCCTAATACTAACTACCTGACTCCTACCCCTCACAATCATGGCAAGC
CAACGCCACTTATCCAGTGAACCACTATCACGAAAAAAACTCTACCTCTCTATACTAATC
TCCCTACAAATCTCCTTAATTATAACATTCACAGCCACAGAACTAATCATATTTTATATC
TTCTTCGAAACCACACTTATCCCCACCTTGGCTATCATCACCCGATGAGGCAACCAGCCA
GAACGCCTGAACGCAGGCACATACTTCCTATTCTACACCCTAGTAGGCTCCCTTCCCCTA
CTCATCGCACTAATTTACACTCACAACACCCTAGGCTCACTAAACATTCTACTACTCACT
CTCACTGCCCAAGAACTATCAAACTCCTGAGCCAACAACTTAATATGACTAGCTTACACA
ATAGCTTTTATAGTAAAGATACCTCTTTACGGACTCCACTTATGACTCCCTAAAGCCCAT
GTCGAAGCCCCCATCGCTGGGTCAATAGTACTTGCCGCAGTACTCTTAAAACTAGGCGGC
TATGGTATAATACGCCTCACACTCATTCTCAACCCCCTGACAAAACACATAGCCTACCCC
TTCCTTGTACTATCCCTATGAGGCATAATTATAACAAGCTCCATCTGCCTACGACAAACA
GACCTAAAATCGCTCATTGCATACTCTTCAATCAGCCACATAGCCCTCGTAGTAACAGCC
ATTCTCATCCAAACCCCCTGAAGCTTCACCGGCGCAGTCATTCTCATAATCGCCCACGGG
CTTACATCCTCATTACTATTCTGCCTAGCAAACTCAAACTACGAACGCACTCACAGTCGC
ATCATAATCCTCTCTCAAGGACTTCAAACTCTACTCCCACTAATAGCTTTTTGATGACTT
CTAGCAAGCCTCGCTAACCTCGCCTTACCCCCCACTATTAACCTACTGGGAGAACTCTCT
GTGCTAGTAACCACGTTCTCCTGATCAAATATCACTCTCCTACTTACAGGACTCAACATA
CTAGTCACAGCCCTATACTCCCTCTACATATTTACCACAACACAATGGGGCTCACTCACC
CACCACATTAACAACATAAAACCCTCATTCACACGAGAAAACACCCTCATGTTCATACAC
CTATCCCCCATTCTCCTCCTATCCCTCAACCCCGACATCATTACCGGGTTTTCCTCTT

# Drug_Target_91_General_Function:
Energy production and conversion

# Drug_Target_91_General_References:
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
12022039	Silva WA Jr, Bonatto SL, Holanda AJ, Ribeiro-Dos-Santos AK, Paixao BM, Goldman GH, Abe-Sandes K, Rodriguez-Delfin L, Barbosa M, Paco-Larson ML, Petzl-Erler ML, Valente V, Santos SE, Zago MA: Mitochondrial genome diversity of Native Americans supports a single early entry of founder populations into America. Am J Hum Genet. 2002 Jul;71(1):187-92. Epub 2002 May 17.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1323207	Lertrit P, Noer AS, Jean-Francois MJ, Kapsa R, Dennett X, Thyagarajan D, Lethlean K, Byrne E, Marzuki S: A new disease-related mutation for mitochondrial encephalopathy lactic acidosis and strokelike episodes (MELAS) syndrome affects the ND4 subunit of the respiratory complex I. Am J Hum Genet. 1992 Sep;51(3):457-68.
1377597	Lu X, Walker T, MacManus JP, Seligy VL: Differentiation of HT-29 human colonic adenocarcinoma cells correlates with increased expression of mitochondrial RNA: effects of trehalose on cell growth and maturation. Cancer Res. 1992 Jul 1;52(13):3718-25.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
1959619	Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M: Electron transfer properties of NADH:ubiquinone reductase in the ND1/3460 and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy (LHON). FEBS Lett. 1991 Nov 4;292(1-2):289-92.
1959931	Kormann BA, Schuster H, Berninger TA, Leo-Kottler B: Detection of the G to A mitochondrial DNA mutation at position 11778 in German families with Leber's hereditary optic neuropathy. Hum Genet. 1991 Nov;88(1):98-100.
3201231	Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK: Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 1988 Dec 9;242(4884):1427-30.
3921850	Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985 Apr 18-24;314(6012):592-7.
6284948	Brown WM, Prager EM, Wang A, Wilson AC: Mitochondrial DNA sequences of primates: tempo and mode of evolution. J Mol Evol. 1982;18(4):225-39.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.
8644732	De Vries DD, Went LN, Bruyn GW, Scholte HR, Hofstra RM, Bolhuis PA, van Oost BA: Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. Am J Hum Genet. 1996 Apr;58(4):703-11.
9452107	Sudoyo H, Sitepu M, Malik S, Poesponegoro HD, Marzuki S: Leber's hereditary optic neuropathy in Indonesia: two families with the mtDNA 11778G>A and 14484T>C mutations. Hum Mutat. 1998;Suppl 1:S271-4.

# Drug_Target_91_HGNC_ID:
HGNC:7459

# Drug_Target_91_HPRD_ID:
Not Available

# Drug_Target_91_ID:
608

# Drug_Target_91_Locus:
-

# Drug_Target_91_Molecular_Weight:
51582

# Drug_Target_91_Name:
NADH-ubiquinone oxidoreductase chain 4

# Drug_Target_91_Number_of_Residues:
459

# Drug_Target_91_PDB_ID:
Not Available

# Drug_Target_91_Pathway:
Not Available

# Drug_Target_91_Pfam_Domain_Function:
PF00361	Oxidored_q1
PF01059	Oxidored_q5_N

# Drug_Target_91_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 4
MLKLIVPTIMLLPLTWLSKKHMIWINTTTHSLIISIIPLLFFNQINNNLFSCSPTFSSDP
LTTPLLMLTTWLLPLTIMASQRHLSSEPLSRKKLYLSMLISLQISLIMTFTATELIMFYI
FFETTLIPTLAIITRWGNQPERLNAGTYFLFYTLVGSLPLLIALIYTHNTLGSLNILLLT
LTAQELSNSWANNLMWLAYTMAFMVKMPLYGLHLWLPKAHVEAPIAGSMVLAAVLLKLGG
YGMMRLTLILNPLTKHMAYPFLVLSLWGMIMTSSICLRQTDLKSLIAYSSISHMALVVTA
ILIQTPWSFTGAVILMIAHGLTSSLLFCLANSNYERTHSRIMILSQGLQTLLPLMAFWWL
LASLANLALPPTINLLGELSVLVTTFSWSNITLLLTGLNMLVTALYSLYMFTTTQWGSLT
HHINNMKPSFTRENTLMFMHLSPILLLSLNPDIITGFSS

# Drug_Target_91_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_91_Signals:
None

# Drug_Target_91_Specific_Function:
Not Available

# Drug_Target_91_SwissProt_ID:
P03905

# Drug_Target_91_SwissProt_Name:
NU4M_HUMAN

# Drug_Target_91_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 4

# Drug_Target_91_Theoretical_pI:
9.67

# Drug_Target_91_Transmembrane_Regions:
23-45; 100-122; 143-165; 194-216; 221-243; 258-277; 284-303; 308-330; 351-373; 388-410

# Drug_Target_92_Cellular_Location:
Not Available

# Drug_Target_92_Chromosome_Location:
Not Available

# Drug_Target_92_Drug_References:
10814540	Lee PL, Halloran C, Cross AR, Beutler E: NADH-ferric reductase activity associated with dihydropteridine reductase. Biochem Biophys Res Commun. 2000 May 19;271(3):788-95.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3086306	Nakanishi N, Ozawa K, Yamada S: Determination of NADPH-specific dihydropteridine reductase in extract from human, monkey, and bovine livers by single radial immunodiffusion: selective assay differentiating NADPH- and NADH-specific enzymes. J Biochem (Tokyo). 1986 May;99(5):1311-5.
6820434	van der Heiden C, Brink W: Spectral studies of the interaction of the substrate 'quinonoid' 6-methyl dihydropterine and the coenzyme NADH used as marker in the dihydropteridine reductase assay. J Inherit Metab Dis. 1982;5(3):132-6.

# Drug_Target_92_Essentiality:
Non-Essential

# Drug_Target_92_GenAtlas_ID:
QDPR

# Drug_Target_92_GenBank_ID_Gene:
X04882

# Drug_Target_92_GenBank_ID_Protein:
30819

# Drug_Target_92_GeneCard_ID:
QDPR

# Drug_Target_92_Gene_Name:
QDPR

# Drug_Target_92_Gene_Sequence:
>735 bp
ATGGCGGCGGCGGCGGCTGCAGGCGAGGCGCGCCGGGTGCTGGTGTACGGCGGCAGGGGC
GCTCTGGGTTCTCGATGCGTGCAGGCTTTTCGGGCCCGCAACTGGTGGGTTGCCAGCGTT
GATGTGGTGGAGAATGAAGAGGCCAGCGCTACGATCATTGTTAAAATGACAGACTCGTTC
ACTGAGCAGGCTGACCAGGTGACTGCTGAGGTTGGAAAGCTCTTGGGTGAAGAGAAGGTG
GATGCAATTCTTTGCGTTGCTGGAGGATGGGCCGGGGGCAATGCCAAATCCAAGTCTCTC
TTTAAGAACTGTGACCTGATGTGGAAGCAGAGCATATGGACATCGACCATCTCCAGCCAT
CTGGCTACCAAGCATCTCAAGGAAGGAGGCCTCCTGACCTTGGCTGGCGCAAAGGCTGCC
CTGGATGGGACTCCTGGTATGATCGGGTACGGCATGGCCAAGGGTGCTGTTCACCAGCTC
TGCCAGAGCCTGGCTGGGAAGAACAGCGGCATGCCGCCCGGGGCAGCCGCCATCGCTGTG
CTCCCGGTTACCCTGGATACCCCGATGAACAGGAAATCAATGCCTGAGGCTGACTTCAGC
TCCTGGACACCCTTAGAATTCCTAGTTGAAACTTTCCATGACTGGATCACAGGGAAAAAC
CGACCGAGCTCAGGAAGCCTAATCCAGGTGGTAACCACAGAAGGAAGGACGGAACTCACC
CCAGCATATTTTTAG

# Drug_Target_92_General_Function:
Lipid transport and metabolism

# Drug_Target_92_General_References:
10408783	Smooker PM, Gough TJ, Cotton RG, Alliaudi C, de Sanctis L, Dianzani I: A series of mutations in the dihydropteridine reductase gene resulting in either abnormal RNA splicing or DHPR protein defects. Mutations in brief no. 244. Online. Hum Mutat. 1999;13(6):503-4.
11153907	Romstad A, Kalkanoglu HS, Coskun T, Demirkol M, Tokatli A, Dursun A, Baykal T, Ozalp I, Guldberg P, Guttler F: Molecular analysis of 16 Turkish families with DHPR deficiency using denaturing gradient gel electrophoresis (DGGE). Hum Genet. 2000 Dec;107(6):546-53.
2116088	Howells DW, Forrest SM, Dahl HH, Cotton RG: Insertion of an extra codon for threonine is a cause of dihydropteridine reductase deficiency. Am J Hum Genet. 1990 Aug;47(2):279-85.
3031582	Dahl HH, Hutchison W, McAdam W, Wake S, Morgan FJ, Cotton RG: Human dihydropteridine reductase: characterisation of a cDNA clone and its use in analysis of patients with dihydropteridine reductase deficiency. Nucleic Acids Res. 1987 Mar 11;15(5):1921-32.
3033643	Lockyer J, Cook RG, Milstien S, Kaufman S, Woo SL, Ledley FD: Structure and expression of human dihydropteridine reductase. Proc Natl Acad Sci U S A. 1987 May;84(10):3329-33.
7627180	Smooker PM, Cotton RG: Molecular basis of dihydropteridine reductase deficiency. Hum Mutat. 1995;5(4):279-84.
8262916	Su Y, Varughese KI, Xuong NH, Bray TL, Roche DJ, Whiteley JM: The crystallographic structure of a human dihydropteridine reductase NADH binary complex expressed in Escherichia coli by a cDNA constructed from its rat homologue. J Biol Chem. 1993 Dec 25;268(36):26836-41.
8326489	Dianzani I, Howells DW, Ponzone A, Saleeba JA, Smooker PM, Cotton RG: Two new mutations in the dihydropteridine reductase gene in patients with tetrahydrobiopterin deficiency. J Med Genet. 1993 Jun;30(6):465-9.
9744478	Dianzani I, de Sanctis L, Smooker PM, Gough TJ, Alliaudi C, Brusco A, Spada M, Blau N, Dobos M, Zhang HP, Yang N, Ponzone A, Armarego WL, Cotton RG: Dihydropteridine reductase deficiency: physical structure of the QDPR gene, identification of two new mutations and genotype-phenotype correlations. Hum Mutat. 1998;12(4):267-73.

# Drug_Target_92_HGNC_ID:
HGNC:9752

# Drug_Target_92_HPRD_ID:
02025

# Drug_Target_92_ID:
597

# Drug_Target_92_Locus:
4p15.31

# Drug_Target_92_Molecular_Weight:
25804

# Drug_Target_92_Name:
Dihydropteridine reductase

# Drug_Target_92_Number_of_Residues:
244

# Drug_Target_92_PDB_ID:
1HDR

# Drug_Target_92_Pathway:
Not Available

# Drug_Target_92_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_92_Protein_Sequence:
>Dihydropteridine reductase
MAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASATIIVKMTDSF
TEQADQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSH
LATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPPGAAAIAV
LPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELT
PAYF

# Drug_Target_92_Reaction:
a 5,6,7,8-tetrahydropteridine + NAD(P)+ = a 6,7-dihydropteridine + NAD(P)H + H+

# Drug_Target_92_Signals:
None

# Drug_Target_92_Specific_Function:
The product of this enzyme, tetrahydrobiopterin (BH-4), is an essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases

# Drug_Target_92_SwissProt_ID:
P09417

# Drug_Target_92_SwissProt_Name:
DHPR_HUMAN

# Drug_Target_92_Synonyms:
EC 1.5.1.34
HDHPR
Quinoid dihydropteridine reductase

# Drug_Target_92_Theoretical_pI:
7.45

# Drug_Target_92_Transmembrane_Regions:
None

# Drug_Target_93_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein (Probable)

# Drug_Target_93_Chromosome_Location:
Not Available

# Drug_Target_93_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_93_Essentiality:
Non-Essential

# Drug_Target_93_GenAtlas_ID:
MT-ND1

# Drug_Target_93_GenBank_ID_Gene:
V00662

# Drug_Target_93_GenBank_ID_Protein:
13004

# Drug_Target_93_GeneCard_ID:
MT-ND1

# Drug_Target_93_Gene_Name:
MT-ND1

# Drug_Target_93_Gene_Sequence:
>957 bp
ATACCCATGGCCAACCTCCTACTCCTCATTGTACCCATTCTAATCGCAATGGCATTCCTA
ATGCTTACCGAACGAAAAATTCTAGGCTATATACAACTACGCAAAGGCCCCAACGTGGTA
GGCCCCTACGGGCTACTACAACCCTTCGCTGACGCCATAAAACTCTTCACCAAAGAGCCC
CTAAAACCCGCCACATCTACCATCACCCTCTACATCACCGCCCCGACCTTAGCTCTCACC
ATCGCTCTTCTACTATGAACCCCCCTCCCCATACCCAACCCCCTGGTCAACCTCAACCTA
GGCCTCCTATTTATTCTAGCCACCTCTAGCCTAGCCGTTTACTCAATCCTCTGATCAGGG
TGAGCATCAAACTCAAACTACGCCCTGATCGGCGCACTGCGAGCAGTAGCCCAAACAATC
TCATATGAAGTCACCCTAGCCATCATTCTACTATCAACATTACTAATAAGTGGCTCCTTT
AACCTCTCCACCCTTATCACAACACAAGAACACCTCTGATTACTCCTGCCATCATGACCC
TTGGCCATAATATGATTTATCTCCACACTAGCAGAGACCAACCGAACCCCCTTCGACCTT
GCCGAAGGGGAGTCCGAACTAGTCTCAGGCTTCAACATCGAATACGCCGCAGGCCCCTTC
GCCCTATTCTTCATAGCCGAATACACAAACATTATTATAATAAACACCCTCACCACTACA
ATCTTCCTAGGAACAACATATGACGCACTCTCCCCTGAACTCTACACAACATATTTTGTC
ACCAAGACCCTACTTCTAACCTCCCTGTTCTTATGAATTCGAACAGCATACCCCCGATTC
CGCTACGACCAACTCATACACCTCCTATGAAAAAACTTCCTACCACTCACCCTAGCATTA
CTTATATGATATGTCTCCATACCCATTACAATCTCCAGCATTCCCCCTCAAACCTAA

# Drug_Target_93_General_Function:
Energy production and conversion

# Drug_Target_93_General_References:
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1417830	Johns DR, Neufeld MJ, Park RD: An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1551-7.
1674640	Huoponen K, Vilkki J, Aula P, Nikoskelainen EK, Savontaus ML: A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. Am J Hum Genet. 1991 Jun;48(6):1147-53.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
1900003	Johns DR, Berman J: Alternative, simultaneous complex I mitochondrial DNA mutations in Leber's hereditary optic neuropathy. Biochem Biophys Res Commun. 1991 Feb 14;174(3):1324-30.
1928099	Howell N, Bindoff LA, McCullough DA, Kubacka I, Poulton J, Mackey D, Taylor L, Turnbull DM: Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am J Hum Genet. 1991 Nov;49(5):939-50.
1959619	Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M: Electron transfer properties of NADH:ubiquinone reductase in the ND1/3460 and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy (LHON). FEBS Lett. 1991 Nov 4;292(1-2):289-92.
2018041	Howell N, Kubacka I, Xu M, McCullough DA: Leber hereditary optic neuropathy: involvement of the mitochondrial ND1 gene and evidence for an intragenic suppressor mutation. Am J Hum Genet. 1991 May;48(5):935-42.
3921850	Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985 Apr 18-24;314(6012):592-7.
6260957	Sanger F, Coulson AR, Barrell BG, Smith AJ, Roe BA: Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. J Mol Biol. 1980 Oct 25;143(2):161-78.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.
7530363	Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N: Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):532-6.
7733935	Nakagawa Y, Ikegami H, Yamato E, Takekawa K, Fujisawa T, Hamada Y, Ueda H, Uchigata Y, Miki T, Kumahara Y, et al.: A new mitochondrial DNA mutation associated with non-insulin-dependent diabetes mellitus. Biochem Biophys Res Commun. 1995 Apr 17;209(2):664-8.
8104867	Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R, et al.: Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics. 1993 Jul;17(1):171-84.
8723687	Jaksch M, Hofmann S, Kaufhold P, Obermaier-Kusser B, Zierz S, Gerbitz KD: A novel combination of mitochondrial tRNA and ND1 gene mutations in a syndrome with MELAS, cardiomyopathy, and diabetes mellitus. Hum Mutat. 1996;7(4):358-60.

# Drug_Target_93_HGNC_ID:
HGNC:7455

# Drug_Target_93_HPRD_ID:
Not Available

# Drug_Target_93_ID:
559

# Drug_Target_93_Locus:
-

# Drug_Target_93_Molecular_Weight:
35661

# Drug_Target_93_Name:
NADH-ubiquinone oxidoreductase chain 1

# Drug_Target_93_Number_of_Residues:
318

# Drug_Target_93_PDB_ID:
Not Available

# Drug_Target_93_Pathway:
Not Available

# Drug_Target_93_Pfam_Domain_Function:
PF00146	NADHdh

# Drug_Target_93_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 1
MPMANLLLLIVPILIAMAFLMLTERKILGYMQLRKGPNVVGPYGLLQPFADAMKLFTKEP
LKPATSTITLYITAPTLALTIALLLWTPLPMPNPLVNLNLGLLFILATSSLAVYSILWSG
WASNSNYALIGALRAVAQTISYEVTLAIILLSTLLMSGSFNLSTLITTQEHLWLLLPSWP
LAMMWFISTLAETNRTPFDLAEGESELVSGFNIEYAAGPFALFFMAEYTNIIMMNTLTTT
IFLGTTYDALSPELYTTYFVTKTLLLTSLFLWIRTAYPRFRYDQLMHLLWKNFLPLTLAL
LMWYVSMPITISSIPPQT

# Drug_Target_93_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_93_Signals:
None

# Drug_Target_93_Specific_Function:
Not Available

# Drug_Target_93_SwissProt_ID:
P03886

# Drug_Target_93_SwissProt_Name:
NU1M_HUMAN

# Drug_Target_93_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 1

# Drug_Target_93_Theoretical_pI:
6.53

# Drug_Target_93_Transmembrane_Regions:
4-23; 68-90; 100-122; 135-157; 172-191; 222-244; 254-273; 293-315

# Drug_Target_94_Cellular_Location:
Mitochondrion
matrix side (Potential)
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_94_Chromosome_Location:
Not Available

# Drug_Target_94_Drug_References:
17216441	Kabus A, Georgi T, Wendisch VF, Bott M: Expression of the Escherichia coli pntAB genes encoding a membrane-bound transhydrogenase in Corynebacterium glutamicum improves L-lysine formation. Appl Microbiol Biotechnol. 2007 May;75(1):47-53. Epub 2007 Jan 11.

# Drug_Target_94_Essentiality:
Non-Essential

# Drug_Target_94_GenAtlas_ID:
NNT

# Drug_Target_94_GenBank_ID_Gene:
U40490

# Drug_Target_94_GenBank_ID_Protein:
1110520

# Drug_Target_94_GeneCard_ID:
NNT

# Drug_Target_94_Gene_Name:
NNT

# Drug_Target_94_Gene_Sequence:
>3261 bp
ATGGCAAACCTATTGAAAACAGTGGTGACTGGCTGCTCGTGTCCTCTACTTAGCAATTTG
GGGTCCTGTAAGGGTCTACGTGTGAAGAAGGATTTTTTACGAACATTTTATACTCACCAA
GAACTGTGGTGTAAAGCGCCTGTAAAACCAGGAATTCCATATAAGCAACTGACTGTTGGA
GTCCCCAAAGAGATATTCCAAAATGAGAAGCGAGTGGCATTGTCTCCTGCTGGTGTTCAG
AACTTGGTCAAGCAGGGTTTTAATGTTGTCGTGGAATCGGGTGCGGGCGAAGCTTCCAAG
TTCTCAGATGATCACTATAGAGTGGCAGGTGCCCAAATCCAAGGGGCAAAGGAAGTGCTG
GCTTCTGATTTGGTGGTCAAAGTGCGAGCCCCTATGGTTAATCCAACATTAGGTGTTCAT
GAAGCTGACCTTTTAAAGACATCAGGAACGCTGATTAGTTTTATTTACCCAGCCCAAAAT
CCAGAGTTGCTAAATAAACTTTCCCAAAGAAAAACTACAGTTCTGGCAATGGACCAGGTT
CCAAGAGTCACAATTGCTCAGGGATATGATGCGCTAAGCTCCATGGCCAACATTGCGGGT
TATAAGGCTGTTGTCCTAGCAGCAAATCATTTTGGACGTTTTTTTACTGGTCAGATCACA
GCTGCTGGAAAAGTTCCTCCAGCTAAGATTCTGATAGTTGGTGGTGGTGTTGCTGGGCTT
GCTTCTGCAGGCGCCGAAAAGTCGATGGGTGCAATTGTTCGAGGATTTGACACAAGAGCT
GCCAGTTTGGAACAGTTCAAGTCTCTTGGTGCTGAGCCCTTGGAGGTGGACTTGAAGGAA
TCTGGTGAGGGACAAGGAGGATATGCAAAAGAGATGTCCAAAGAGTTCATTGAAGCTGAA
ATGAAACTCTTTGCTCAACAATGCAAGGAGGTAGACATCCTTATCAGCACAGCACTTATT
CCAGGTAAAAAAGCTCCAGTTTTATTTAATAAAGAAATGATTGAGTCAATGAAGGAAGGT
TCAGTTGTTGTGGATTTAGCTGCTGAGGCTGGTGGAAACTTTGAAACCACTAAGCCAGGA
GAACTCTACATTCATAAGGGAATTACTCACATAGGCTACACAGACCTGCCCAGCCGAATG
GCCACTCAGGCCAGCACCCTATATTCCAACAACATCACCAAACTCCTGAAGGCCATCAGC
CCGGACAAAGATAATTTTTATTTTGATGTGAAAGATGACTTTGACTTTGGTACGATGGGT
CATGTCATTAGAGGAACTGTAGTGATGAAAGATGGTAAAGTGATTTTCCCAGCTCCCACA
CCGAAAAATATTCCTCAAGGTGCCCCAGTAAAACAGAAGACAGTGGCTGAGCTGGAAGCT
GAAAAAGCAGCTACCATTACACCCTTCAGGAAGACAATGTCAACGGCTTCTGCATATACA
GCAGGTCTCACAGGGATACTGGGTTTGGGCATTGCGGCTCCCAATCTAGCCTTTTCTCAG
ATGGTGACCACTTTTGGCTTGGCTGGCATTGTGGGGTATCATACCGTCTGGGGAGTGACC
CCTGCTCTCCACTCACCACTGATGTCTGTGACAAATGCAATCTCAGGGCTGACTGCAGTT
GGTGGGTTGGCACTGATGGGAGGACATTTGTATCCTTCCACAACTTCTCAGGGCCTTGCT
GCTCTTGCTGCATTCATATCCTCTGTCAACATTGCAGGTGGCTTTCTGGTGACTCAGAGA
ATGCTGGACATGTTCAAGCGTCCCACTGACCCCCCAGAATACAACTACCTGTACCTGCTC
CCTGCCGGCACCTTTGTTGGTGGATATTTAGCTGCCCTCTACAGTGGTTATAACATTGAA
CAGATCATGTACCTAGGCTCGGGTTTGTGCTGTGTCGGTGCCTTGGCTGGCCTCTCCACC
CAGGGAACAGCACGTCTTGGCAATGCACTGGGCATGATTGGGGTTGCTGGAGGACTGGCA
GCCACCCTCGGAGTCCTAAAACCGGGCCCAGAATTACTAGCTCAGATGTCTGGAGCGATG
GCTTTGGGTGGTACCATTGGATTGACAATTGCCAAACGCATCCAGATTTCTGATTTACCT
CAATTAGTTGCTGCTTCACACAGTTTAGTGGGTTTGGCAGCTGTACTTACTTGCATAGCT
GAGTACATTATAGAATATCCACATTTTGCTCCGGATGCAGCAGCAAATCTCACCAAGATT
GTGGCCTACCTCGGCACTTACATTGGTGGCGTCACCTTTAGTGGGTCTCTCATTGCCTAT
GGAAAATTGCAGGGTCTCCTGAAATCTGCCCCTCTCCTACTGCCTGGAAGGCACTTACTC
AATGCAGGCTTACTGGCTGCTAGTGTGGGCGGGATAATCCCATTCATGGTGGACCCAAGC
TTTACTACTGGCATCACCTGTCTGGGTTCAGTGTCTGCTCTCTCTGCTGTCATGGGTGTG
ACTTTGACAGCTGCTATTGGGGGTGCTGACATGCCCGTCGTTATCACTGTGCTGAACAGC
TACTCAGGCTGGGCCCTGTGTGCAGAGGGCTTCCTGCTCAACAACAATCTGCTGACCATC
GTGGGTGCACTCATAGGCTCGTCTGGTGCTCCCCTGTCATACATCATGTGTGTGGCAATG
AATCGCTCCCTGGCTAATGTGATTCTTGGAGGCTATGGCACCACTTCAACAGCTGGTGGA
AAACCCATGGAAATTTCTGGCACACATACGGAAATCAACCTTGACAATGCAATTGACATG
ATTCGAGAAGCTAATAGCATTATTTTTACACCAGGCTATGGTCTCTGTGCAGCCAAAGCT
CAATACCCCATTGCTGATTTGGTAAAGATGCTCACTGAGCAAGGCAAAAAAGTCAGGTTT
GGAATTCACCCAGTTGCAGGCCGAATGCCTGGTCAGCTTAATGTGCTGCTGGCTGAGGCT
GGTGTGCCATATGACATTGTGTTGGAAATGGATGAGATCAACCATGATTTTCCAGATACT
GATTTGGTCCTTGTAATTGGAGCTAATGACACTGTTAATTCAGCAGCTCAAGAAGATCCC
AACTCTATTATTGCAGGCATGCCAGTCCTTGAGGTCTGGAAATCAAAGCAGGTGATTGTT
ATGAAGAGGTCTTTGGGTGTTGGCTATGCTGCAGTGGACAATCCAATCTTCTACAAACCT
AACACGGCCATGCTTCTAGGTGATGCCAAGAAAACATGTGACGCGCTCCAGGCGAAAGTT
AGAGAATCCTATCAGAAGTAA

# Drug_Target_94_General_Function:
Energy production and conversion

# Drug_Target_94_General_References:
10673423	White SA, Peake SJ, McSweeney S, Leonard G, Cotton NP, Jackson JB: The high-resolution structure of the NADP(H)-binding component (dIII) of proton-translocating transhydrogenase from human heart mitochondria. Structure. 2000 Jan 15;8(1):1-12.
8616157	Arkblad EL, Betsholtz C, Rydstrom J: The cDNA sequence of proton-pumping nicotinamide nucleotide transhydrogenase from man and mouse. Biochim Biophys Acta. 1996 Mar 28;1273(3):203-5.
9524818	Zieger B, Ware J: Cloning and deduced amino acid sequence of human nicotinamide nucleotide transhydrogenase. DNA Seq. 1997;7(6):369-73.

# Drug_Target_94_HGNC_ID:
HGNC:7863

# Drug_Target_94_HPRD_ID:
09715

# Drug_Target_94_ID:
11

# Drug_Target_94_Locus:
5p13.1-5cen

# Drug_Target_94_Molecular_Weight:
113897

# Drug_Target_94_Name:
NAD(P) transhydrogenase, mitochondrial

# Drug_Target_94_Number_of_Residues:
1086

# Drug_Target_94_PDB_ID:
1PT9

# Drug_Target_94_Pathway:
Not Available

# Drug_Target_94_Pfam_Domain_Function:
PF01262	AlaDh_PNT_C
PF02233	PNTB
PF05222	AlaDh_PNT_N

# Drug_Target_94_Protein_Sequence:
>NAD(P) transhydrogenase, mitochondrial precursor
MANLLKTVVTGCSCPLLSNLGSCKGLRVKKDFLRTFYTHQELWCKAPVKPGIPYKQLTVG
VPKEIFQNEKRVALSPAGVQNLVKQGFNVVVESGAGEASKFSDDHYRVAGAQIQGAKEVL
ASDLVVKVRAPMVNPTLGVHEADLLKTSGTLISFIYPAQNPELLNKLSQRKTTVLAMDQV
PRVTIAQGYDALSSMANIAGYKAVVLAANHFGRFFTGQITAAGKVPPAKILIVGGGVAGL
ASAGAAKSMGAIVRGFDTRAAALEQFKSLGAEPLEVDLKESGEGQGGYAKEMSKEFIEAE
MKLFAQQCKEVDILISTALIPGKKAPVLFNKEMIESMKEGSVVVDLAAEAGGNFETTKPG
ELYIHKGITHIGYTDLPSRMATQASTLYSNNITKLLKAISPDKDNFYFDVKDDFDFGTMG
HVIRGTVVMKDGKVIFPAPTPKNIPQGAPVKQKTVAELEAEKAATITPFRKTMSTASAYT
AGLTGILGLGIAAPNLAFSQMVTTFGLAGIVGYHTVWGVTPALHSPLMSVTNAISGLTAV
GGLALMGGHLYPSTTSQGLAALAAFISSVNIAGGFLVTQRMLDMFKRPTDPPEYNYLYLL
PAGTFVGGYLAALYSGYNIEQIMYLGSGLCCVGALAGLSTQGTARLGNALGMIGVAGGLA
ATLGVLKPGPELLAQMSGAMALGGTIGLTIAKRIQISDLPQLVAAFHSLVGLAAVLTCIA
EYIIEYPHFATDAAANLTKIVAYLGTYIGGVTFSGSLIAYGKLQGLLKSAPLLLPGRHLL
NAGLLAASVGGIIPFMVDPSFTTGITCLGSVSALSAVMGVTLTAAIGGADMPVVITVLNS
YSGWALCAEGFLLNNNLLTIVGALIGSSGAILSYIMCVAMNRSLANVILGGYGTTSTAGG
KPMEISGTHTEINLDNAIDMIREANSIIITPGYGLCAAKAQYPIADLVKMLTEQGKKVRF
GIHPVAGRMPGQLNVLLAEAGVPYDIVLEMDEINHDFPDTDLVLVIGANDTVNSAAQEDP
NSIIAGMPVLEVWKSKQVIVMKRSLGVGYAAVDNPIFYKPNTAMLLGDAKKTCDALQAKV
RESYQK

# Drug_Target_94_Reaction:
NADPH + NAD+ = NADP+ + NADH

# Drug_Target_94_Signals:
None

# Drug_Target_94_Specific_Function:
The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane

# Drug_Target_94_SwissProt_ID:
Q13423

# Drug_Target_94_SwissProt_Name:
NNTM_HUMAN

# Drug_Target_94_Synonyms:
EC 1.6.1.2
NAD(P) transhydrogenase, mitochondrial precursor
Nicotinamide nucleotide transhydrogenase
Pyridine nucleotide transhydrogenase

# Drug_Target_94_Theoretical_pI:
8.21

# Drug_Target_94_Transmembrane_Regions:
475-493
501-521
527-546
558-578
596-616
622-642
646-666
672-691
702-722
740-760
778-797
801-819
833-853
857-879

# Drug_Target_95_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_95_Chromosome_Location:
Not Available

# Drug_Target_95_Drug_References:
17209562	Belevich G, Euro L, Wikstrom M, Verkhovskaya M: Role of the conserved arginine 274 and histidine 224 and 228 residues in the NuoCD subunit of complex I from Escherichia coli. Biochemistry. 2007 Jan 16;46(2):526-33.
17444656	Chen CL, Zhang L, Yeh A, Chen CA, Green-Church KB, Zweier JL, Chen YR: Site-specific S-glutathiolation of mitochondrial NADH ubiquinone reductase. Biochemistry. 2007 May 15;46(19):5754-65. Epub 2007 Apr 20.

# Drug_Target_95_Essentiality:
Non-Essential

# Drug_Target_95_GenAtlas_ID:
NDUFA5

# Drug_Target_95_GenBank_ID_Gene:
U53468

# Drug_Target_95_GenBank_ID_Protein:
1373173

# Drug_Target_95_GeneCard_ID:
NDUFA5

# Drug_Target_95_Gene_Name:
NDUFA5

# Drug_Target_95_Gene_Sequence:
>351 bp
ATGGCGGGTGTGCTGAAGAAGACCACTGGCCTTGTGGGATTGGCTGTGTGCAATACTCCT
CACGAGAGGCTAAGAATATTGTACACAAAGATTCTTGATGTTCTTGAGGAAATCCCTAAA
AATGCAGCATATAGAAAGTATACAGAACAGATTACAAATGAGAAGCTGGCTATGGTTAAA
GCGGAACCAGATGTTAAAAAATTAGAAGACCAACTTCAAGGCGGTCAATTAGAAGAGGTG
ATTCTTCAGGCTGAACATGAACTAAATCTGGCAAGAAAAATGAGGGAATGGAAACTATGG
GAGCCATTAGTGGAAGAGCCTCCTGCCGATCAGTGGAAATGGCCAATATAA

# Drug_Target_95_General_Function:
Involved in oxidoreductase activity, acting on NADH or NADPH

# Drug_Target_95_General_References:
10343126	Tensing K, Pata I, Wittig I, Wehnert M, Metspalu A: Genomic organization of the human complex I 13-kDa subunit gene NDUFA5. Cytogenet Cell Genet. 1999;84(1-2):125-7.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
9021153	Russell MW, du Manoir S, Collins FS, Brody LC: Cloning of the human NADH: ubiquinone oxidoreductase subunit B13: localization to chromosome 7q32 and identification of a pseudogene on 11p15. Mamm Genome. 1997 Jan;8(1):60-1.
9048877	Pata I, Tensing K, Metspalu A: A human cDNA encoding the homologue of NADH: ubiquinone oxidoreductase subunit B13. Biochim Biophys Acta. 1997 Feb 7;1350(2):115-8.

# Drug_Target_95_HGNC_ID:
HGNC:7688

# Drug_Target_95_HPRD_ID:
03398

# Drug_Target_95_ID:
525

# Drug_Target_95_Locus:
7q32

# Drug_Target_95_Molecular_Weight:
13328

# Drug_Target_95_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5

# Drug_Target_95_Number_of_Residues:
115

# Drug_Target_95_PDB_ID:
Not Available

# Drug_Target_95_Pathway:
Not Available

# Drug_Target_95_Pfam_Domain_Function:
PF04716	ETC_C1_NDUFA5

# Drug_Target_95_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5
AGVLKKTTGLVGLAVCNTPHERLRILYTKILDVLEEIPKNAAYRKYTEQITNEKLAMVKA
EPDVKKLEDQLQGGQLEEVILQAEHELNLARKMREWKLWEPLVEEPPADQWKWPI

# Drug_Target_95_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_95_Signals:
None

# Drug_Target_95_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_95_SwissProt_ID:
Q16718

# Drug_Target_95_SwissProt_Name:
NDUA5_HUMAN

# Drug_Target_95_Synonyms:
CI-13kD-B
Complex I subunit B13
Complex I-13kD-B
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase 13 kDa-B subunit

# Drug_Target_95_Theoretical_pI:
5.81

# Drug_Target_95_Transmembrane_Regions:
None

# Drug_Target_96_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_96_Chromosome_Location:
Not Available

# Drug_Target_96_Drug_References:
17132781	Balaban RS: Maintenance of the metabolic homeostasis of the heart: developing a systems analysis approach. Ann N Y Acad Sci. 2006 Oct;1080:140-53.
17260964	Matsuzaki S, Szweda LI: Inhibition of complex I by Ca2+ reduces electron transport activity and the rate of superoxide anion production in cardiac submitochondrial particles. Biochemistry. 2007 Feb 6;46(5):1350-7.
17323923	Barker CD, Reda T, Hirst J: The flavoprotein subcomplex of complex I (NADH:ubiquinone oxidoreductase) from bovine heart mitochondria: insights into the mechanisms of NADH oxidation and NAD+ reduction from protein film voltammetry. Biochemistry. 2007 Mar 20;46(11):3454-64. Epub 2007 Feb 27.
17499024	Fisher N, Bray PG, Ward SA, Biagini GA: The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends Parasitol. 2007 Jul;23(7):305-10. Epub 2007 May 10.
17530440	Liu Y, Qiao DR, Zheng HB, Dai XL, Bai LH, Zeng J, Cao Y: Cloning and sequence analysis of the gene encoding 19-kD subunit of Complex I from Dunaliella salina. Mol Biol Rep. 2007 May 26;.

# Drug_Target_96_Essentiality:
Non-Essential

# Drug_Target_96_GenAtlas_ID:
NDUFA9

# Drug_Target_96_GenBank_ID_Gene:
AF050641

# Drug_Target_96_GenBank_ID_Protein:
5326823

# Drug_Target_96_GeneCard_ID:
NDUFA9

# Drug_Target_96_Gene_Name:
NDUFA9

# Drug_Target_96_Gene_Sequence:
>1134 bp
ATGGCGGCTGCCGCACAATCCCGGGTTGTCCGGGTCCTGTCAATGTCACGTTCTGCCATT
ACTGCAATAGCCACATCTGTGTGTCACGGCCCACCCTGTCGCCAGCTTCATCATGCCCTC
ATGCCTCATGGGAAAGGTGGACGTTCCTCAGTCAGTGGGATTGTGGCCACTGTGTTTGGA
GCAACAGGATTCCTGGGGCGATATGTTGTCAACCACCTTGGACGCATGGGGTCACAGGTA
ATCATACCCTATCGGTGTGATAAATATGACATCATGCACCTTCGTCCCATGGGTGACCTG
GGCCAGCTTCTGTTTCTGGAATGGGACGCGAGAGATAAAGATTCTATCCGACGAGTAGTA
CAACACAGCAATGTGGTCATCAATCTTATTGGACGAGACTGGGAAACCAAAAACTTTGAT
TTTGAGGATGTTTTTGTGAAGATTCCCCAAGCAATTGCTCAACTGTCCAAGGAAGCTGGA
GTTGAAAAATTCATTCATGTTTCACATCTGAATGCGAATATTAAAAGCTCTTCTAGATAT
TTGAGAAATAAGGCTGTTGGAGAGAAAGTAGTGAGAGATGCATTTCCGGAAGCCATTATC
GTAAAGCCGTCGGACATCTTTGGAAGAGAGGATAGATTCCTTAATTCTTTTGCAAGTATG
CATCGGTTTGGTCCTATACCCCTTGGTTCCTTGGGCTGGAAGACAGTTAAACAACCAGTA
TATGTCGTAGATGTATCCAAAGGAATTGTTAATGCAGTTAAGGATCCTGATGCCAATGGG
AAATCCTTTGCTTTCGTTGGTCCCAGTCGGTACCTCCTTTTCCACCTGGTGAAGTACATC
TTTGCTGTGGCTCACAGATTGTTCCTCCCATTCCCCTTGCCGCTTTTTGCCTATCGATGG
GTAGCAAGAGTCTTTGAAATAAGCCCATTTGAGCCCTGGATAACAAGGGATAAAGTGGAG
CGGATGCACATCACAGACATGAAATTGCCTCACCTGCCTGGCTTAGAAGACCTTGGTATT
CAGGCAACACCACTGGAACTCAAGGCCATTGAGGTGCTGCGGCGTCATCGCACTTACCGC
TGGCTGTCTGCTGAAATTGAGGATGTGAAGCCGGCCAAGACCGTCAACATTTAG

# Drug_Target_96_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_96_General_References:
8012384	Cross SH, Charlton JA, Nan X, Bird AP: Purification of CpG islands using a methylated DNA binding column. Nat Genet. 1994 Mar;6(3):236-44.
8486360	Baens M, Chaffanet M, Cassiman JJ, van den Berghe H, Marynen P: Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid. Genomics. 1993 Apr;16(1):214-8.

# Drug_Target_96_HGNC_ID:
HGNC:7693

# Drug_Target_96_HPRD_ID:
04832

# Drug_Target_96_ID:
335

# Drug_Target_96_Locus:
12p13.3

# Drug_Target_96_Molecular_Weight:
42510

# Drug_Target_96_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial

# Drug_Target_96_Number_of_Residues:
377

# Drug_Target_96_PDB_ID:
Not Available

# Drug_Target_96_Pathway:
Not Available

# Drug_Target_96_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_96_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial precursor
MAAAAQSRVVRVLSMSRSAITAIATSVCHGPPCRQLHHALMPHGKGGRSSVSGIVATVFG
ATGFLGRYVVNHLGRMGSQVIIPYRCDKYDIMHLRPMGDLGQLLFLEWDARDKDSIRRVV
QHSNVVINLIGRDWETKNFDFEDVFVKIPQAIAQLSKEAGVEKFIHVSHLNANIKSSSRY
LRNKAVGEKVVRDAFPEAIIVKPSDIFGREDRFLNSFASMHRFGPIPLGSLGWKTVKQPV
YVVDVSKGIVNAVKDPDANGKSFAFVGPSRYLLFHLVKYIFAVAHRLFLPFPLPLFAYRW
VARVFEISPFEPWITRDKVERMHITDMKLPHLPGLEDLGIQATPLELKAIEVLRRHRTYR
WLSAEIEDVKPAKTVNI

# Drug_Target_96_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_96_Signals:
None

# Drug_Target_96_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_96_SwissProt_ID:
Q16795

# Drug_Target_96_SwissProt_Name:
NDUA9_HUMAN

# Drug_Target_96_Synonyms:
CI-39kD
Complex I-39kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase 1 alpha subcomplex subunit 9, mitochondrial precursor
NADH-ubiquinone oxidoreductase 39 kDa subunit

# Drug_Target_96_Theoretical_pI:
10.37

# Drug_Target_96_Transmembrane_Regions:
None

# Drug_Target_97_Cellular_Location:
Not Available

# Drug_Target_97_Chromosome_Location:
Not Available

# Drug_Target_97_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_97_Essentiality:
Non-Essential

# Drug_Target_97_GenAtlas_ID:
MT-ND4L

# Drug_Target_97_GenBank_ID_Gene:
J01415

# Drug_Target_97_GenBank_ID_Protein:
337197

# Drug_Target_97_GeneCard_ID:
MT-ND4L

# Drug_Target_97_Gene_Name:
MT-ND4L

# Drug_Target_97_Gene_Sequence:
>297 bp
ATGCCCCTCATTTACATAAATATTATACTAGCATTTACCATCTCACTTCTAGGAATACTA
GTATATCGCTCACACCTCATATCCTCCCTACTATGCCTAGAAGGAATAATACTATCGCTG
TTCATTATAGCTACTCTCATAACCCTCAACACCCACTCCCTCTTAGCCAATATTGTGCCT
ATTGCCATACTAGTCTTTGCCGCCTGCGAAGCAGCGGTGGGCCTAGCCCTACTAGTCTCA
ATCTCCAACACATATGGCCTAGACTACGTACATAACCTAAACCTACTCCAATGCTAA

# Drug_Target_97_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_97_General_References:
11130070	Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature. 2000 Dec 7;408(6813):708-13.
12840039	Ingman M, Gyllensten U: Mitochondrial genome variation and evolutionary history of Australian and New Guinean aborigines. Genome Res. 2003 Jul;13(7):1600-6.
1757091	Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E: Normal variants of human mitochondrial DNA and translation products: the building of a reference data base. Hum Genet. 1991 Dec;88(2):139-45.
3921850	Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985 Apr 18-24;314(6012):592-7.
7219534	Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457-65.
7530363	Horai S, Hayasaka K, Kondo R, Tsugane K, Takahata N: Recent African origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):532-6.
8680405	Brown MD, Torroni A, Reckord CL, Wallace DC: Phylogenetic analysis of Leber's hereditary optic neuropathy mitochondrial DNA's indicates multiple independent occurrences of the common mutations. Hum Mutat. 1995;6(4):311-25.
8919866	Arnason U, Xu X, Gullberg A: Comparison between the complete mitochondrial DNA sequences of Homo and the common chimpanzee based on nonchimeric sequences. J Mol Evol. 1996 Feb;42(2):145-52.
9806551	Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B: Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998 Nov;20(3):291-3.

# Drug_Target_97_HGNC_ID:
HGNC:7460

# Drug_Target_97_HPRD_ID:
Not Available

# Drug_Target_97_ID:
300

# Drug_Target_97_Locus:
-

# Drug_Target_97_Molecular_Weight:
10741

# Drug_Target_97_Name:
NADH-ubiquinone oxidoreductase chain 4L

# Drug_Target_97_Number_of_Residues:
98

# Drug_Target_97_PDB_ID:
Not Available

# Drug_Target_97_Pathway:
Not Available

# Drug_Target_97_Pfam_Domain_Function:
PF00420	Oxidored_q2

# Drug_Target_97_Protein_Sequence:
>NADH-ubiquinone oxidoreductase chain 4L
MPLIYMNIMLAFTISLLGMLVYRSHLMSSLLCLEGMMLSLFIMATLMTLNTHSLLANIVP
IAMLVFAACEAAVGLALLVSISNTYGLDYVHNLNLLQC

# Drug_Target_97_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_97_Signals:
None

# Drug_Target_97_Specific_Function:
Not Available

# Drug_Target_97_SwissProt_ID:
P03901

# Drug_Target_97_SwissProt_Name:
NU4LM_HUMAN

# Drug_Target_97_Synonyms:
EC 1.6.5.3
NADH dehydrogenase subunit 4L

# Drug_Target_97_Theoretical_pI:
6.20

# Drug_Target_97_Transmembrane_Regions:
4-21; 26-48; 58-80

# Drug_Target_98_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_98_Chromosome_Location:
Not Available

# Drug_Target_98_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_98_Essentiality:
Non-Essential

# Drug_Target_98_GenAtlas_ID:
NDUFA10

# Drug_Target_98_GenBank_ID_Gene:
AF087661

# Drug_Target_98_GenBank_ID_Protein:
4191348

# Drug_Target_98_GeneCard_ID:
NDUFA10

# Drug_Target_98_Gene_Name:
NDUFA10

# Drug_Target_98_Gene_Sequence:
>1068 bp
ATGGCCTTGCGGCTCCTGAAGCTGGCAGCGACGTCCGCGTCCGCCCGGGTCGTGGCGGCG
GGCGCCCAGCGCGTGAGAGGAATTCATAGCAGTGTGCAGTGCAAGCTGCGCTATGGAATG
TGGCATTTCCTACTTGGGGATAAAGCAAGCAAAAGACTGACAGAACGCAGCAGAGTGATA
ACTGTAGATGGCAATATATGTACTGGAAAAGGCAAACTTGCAAAAGAAATAGCAGAGAAA
CTAGGCTTCAAGCACTTTCCTGAAGCGGGGATTCATTATCCAGACAGTACCACAGGAGAT
GGGAAGCCCCTCGCCACCGACTATAATGGCAACTGTAGTTTGGAGAAATTTTACGATGAT
CCGAGAAGCAATGATGGCAACAGTTACCGCCTGCAGTCCTGGTTGTACAGCAGTCGCCTG
CTGCAGTACTCAGATGCCTTGGAGCACTTGCTGACCACAGGACAAGGTGTTGTGTTGGAG
CGCTCCATCTTCAGTGACTTTGTGTTCCTGGAGGCGATGTACAACCAGGGATTCATCCGA
AAGCAGTGTGTGGACCACTACAACGAGGTGAAGAGCGTCACCATCTGCGATTACCTGCCC
CCCCACCTGGTGATTTACATCGATGTGCCCGTTCCAGAGGTCCAGAGGCGGATTCAGAAG
AAAGGAGATCCACATGAAATGAAGATCACCTCTGCCTATCTACAGGACATTGAGAATGCC
TATAAGAAAACCTTTCTCCCTGAGATGAGTGAAAAATGTGAGGTTTTACAGTATTCTGCA
AGGGAAGCTCAAGATTCAAAAAAGGTGGTAGAGGACATTGAATACCTGAAGTTCGATAAA
GGGCCGTGGCTCAAGCAGGACAATCGCACTTTATACCACCTGCGATTACTGGTTCAGGAT
AAGTTTGAGGTGCTGAATTACACAAGCATTCCTATCTTTCTCCCGGAAGTCACCATTGGA
GCTCATCAGACTGACCGTGTCTTACATCAGTTCAGAGAGCTGCCGGGCCGCAAGTACAGC
CCTGGGTACAACACCGAGGTGGGAGACAAGTGGATCTGGCTGAAGTGA

# Drug_Target_98_General_Function:
Nucleotide transport and metabolism

# Drug_Target_98_General_References:
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_98_HGNC_ID:
HGNC:7684

# Drug_Target_98_HPRD_ID:
11950

# Drug_Target_98_ID:
91

# Drug_Target_98_Locus:
2q37.3

# Drug_Target_98_Molecular_Weight:
40751

# Drug_Target_98_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial

# Drug_Target_98_Number_of_Residues:
355

# Drug_Target_98_PDB_ID:
Not Available

# Drug_Target_98_Pathway:
Not Available

# Drug_Target_98_Pfam_Domain_Function:
PF01712	dNK

# Drug_Target_98_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial precursor
MALRLLKLAATSASARVVAAGAQRVRGIHSSVQCKLRYGMWHFLLGDKASKRLTERSRVI
TVDGNICTGKGKLAKEIAEKLGFKHFPEAGIHYPDSTTGDGKPLATDYNGNCSLEKFYDD
PRSNDGNSYRLQSWLYSSRLLQYSDALEHLLTTGQGVVLERSIFSDFVFLEAMYNQGFIR
KQCVDHYNEVKSVTICDYLPPHLVIYIDVPVPEVQRRIQKKGDPHEMKITSAYLQDIENA
YKKTFLPEMSEKCEVLQYSAREAQDSKKVVEDIEYLKFDKGPWLKQDNRTLYHLRLLVQD
KFEVLNYTSIPIFLPEVTIGAHQTDRVLHQFRELPGRKYSPGYNTEVGDKWIWLK

# Drug_Target_98_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_98_Signals:
None

# Drug_Target_98_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_98_SwissProt_ID:
O95299

# Drug_Target_98_SwissProt_Name:
NDUAA_HUMAN

# Drug_Target_98_Synonyms:
CI-42kD
Complex I-42kD
EC 1.6.5.3
EC 1.6.99.3
NADH dehydrogenase 1 alpha subcomplex subunit 10, mitochondrial precursor
NADH-ubiquinone oxidoreductase 42 kDa subunit

# Drug_Target_98_Theoretical_pI:
8.68

# Drug_Target_98_Transmembrane_Regions:
None

# Drug_Target_99_Cellular_Location:
Mitochondrion
matrix side
mitochondrial inner membrane

# Drug_Target_99_Chromosome_Location:
Not Available

# Drug_Target_99_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_99_Essentiality:
Non-Essential

# Drug_Target_99_GenAtlas_ID:
NDUFA7

# Drug_Target_99_GenBank_ID_Gene:
AF050637

# Drug_Target_99_GenBank_ID_Protein:
4164452

# Drug_Target_99_GeneCard_ID:
NDUFA7

# Drug_Target_99_Gene_Name:
NDUFA7

# Drug_Target_99_Gene_Sequence:
>342 bp
ATGGCGTCCGCCACCCGTCTCATCCAGCGGCTGCGGAACTGGGCGTCCGGGCATGACCTG
CAGGGGAAGCTGCAGCTACGCTACCAGGAGATCTCCAAGCGAACTCAGCCTCCTCCCAAG
CTCCCTGTGGGTCCTAGCCACAAGCTCTCCAACAATTACTATTGCACTCGCGATGGCCGC
CGGGAATCTGTGCCCCCTTCCATCATCATGTCGTCGCAGAAGGCGCTGGTGTCAGGCAAG
CCAGCAGAGAGCTCTGCTGTAGCTGCCACTGAGAAGAAGGCGGTGACTCCAGCTCCTCCC
ATAAAGAGGTGGGAGCTGTCCTCGGACCAGCCTTACCTGTGA

# Drug_Target_99_General_Function:
Involved in NADH dehydrogenase (ubiquinone) activity

# Drug_Target_99_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
9878551	Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA: cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterization completed. Biochem Biophys Res Commun. 1998 Dec 18;253(2):415-22.

# Drug_Target_99_HGNC_ID:
HGNC:7691

# Drug_Target_99_HPRD_ID:
11885

# Drug_Target_99_ID:
446

# Drug_Target_99_Locus:
19p13.2

# Drug_Target_99_Molecular_Weight:
12420

# Drug_Target_99_Name:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7

# Drug_Target_99_Number_of_Residues:
112

# Drug_Target_99_PDB_ID:
Not Available

# Drug_Target_99_Pathway:
Not Available

# Drug_Target_99_Pfam_Domain_Function:
PF07347	CI-B14_5a

# Drug_Target_99_Protein_Sequence:
>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7
ASATRLIQRLRNWASGHDLQGKLQLRYQEISKRTQPPPKLPVGPSHKLSNNYYCTRDGRR
ESVPPSIIMSSQKALVSGKPAESSAVAATEKKAVTPAPPIKRWELSSDQPYL

# Drug_Target_99_Reaction:
NADH + H+ + ubiquinone = NAD+ + ubiquinol

# Drug_Target_99_Signals:
None

# Drug_Target_99_Specific_Function:
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

# Drug_Target_99_SwissProt_ID:
O95182

# Drug_Target_99_SwissProt_Name:
NDUA7_HUMAN

# Drug_Target_99_Synonyms:
CI-B14.5a
Complex I-B14.5a
EC 1.6.5.3
EC 1.6.99.3
NADH-ubiquinone oxidoreductase subunit B14.5a

# Drug_Target_99_Theoretical_pI:
10.80

# Drug_Target_99_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
LDHAL6A

# Drug_Target_9_GenBank_ID_Gene:
AY581313

# Drug_Target_9_GenBank_ID_Protein:
46405145

# Drug_Target_9_GeneCard_ID:
LDHAL6A

# Drug_Target_9_Gene_Name:
LDHAL6A

# Drug_Target_9_Gene_Sequence:
>999 bp
ATGGCAACTATCAAGAGTGAACTTATTAAGAATTTCGCGGAAGAGGAGGCCATTCATCAC
AATAAGATCTCCATTGTAGGAACTGGATCGGTTGGTGTGGCTTGTGCTATCAGCATCTTA
TTAAAAGGTTTGAGTGATGAACTTGTCCTTGTGGATGTTGATGAAGGCAAACTGAAGGGT
GAGACAATGGATCTTCAACATGGCAGCCCTTTTATGAAAATGCCAAATATTGTCTCCAGC
AAAGATTACCTGGTCACTGCAAACTCCAATCTAGTGATTATCACAGCAGGTGCACGCCAG
AAAAAAGGAGAAACACGCCTTGATTTAGTCCAGCGAAATGTATCCATCTTTAAATTAATG
ATTCCCAATATTACCCAGTACAGTCCTCACTGCAAACTGCTTATTGTTACTAATCCAGTG
GATATCTTAACTTATGTAGCCTGGAAGTTGAGTGGATTTCCCAAAAACCGTGTTATTGGA
AGTGGTTGTAATCTGGACTCTGCTCGTTTTCGTTACTTTATTGGGCAAAGGCTTGGCATC
CACTCTGAAAGCTGTCATGGGCTGATCCTTGGAGAGCATGGCGACTCAAGTGTTCCTGTG
TGGAGTGGTGTGAACATTGCTGGCGTCCCTCTGAAGGATCTGAACCCAGATATAGGAACT
GATAAAGATCCTGAGCAGTGGGAAAATGTCCACAAAAAAGTGATTTCCAGTGGCTATGAG
ATGGTCAAAATGAAAGGTTATACTTCTTGGGGCATTAGCCTATCTGTAGCTGATTTAACA
GAAAGTATTTTGAAGAATCTTAGGAGAGTGCATCCAGTTTCTACCCTAAGTAAGGGCCTC
TATGGAATAAATGAAGACATATTCCTTAGTGTCCCATGTATCCTGGGAGAGAATGGTATC
ACAGACCTCATAAAAGTAAAACTGACTCTTGAAGAGGAGGCCTGCTTGCAAAAGAGTGCA
GAAACACTTTGGGAAATTCAGAAGGAGCTCAAGCTTTAA

# Drug_Target_9_General_Function:
Energy production and conversion

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
HGNC:28335

# Drug_Target_9_HPRD_ID:
13980

# Drug_Target_9_ID:
326

# Drug_Target_9_Locus:
11p15.1

# Drug_Target_9_Molecular_Weight:
36508

# Drug_Target_9_Name:
L-lactate dehydrogenase A-like 6A

# Drug_Target_9_Number_of_Residues:
332

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_9_Protein_Sequence:
>L-lactate dehydrogenase A-like 6A
MATIKSELIKNFAEEEAIHHNKISIVGTGSVGVACAISILLKGLSDELVLVDVDEGKLKG
ETMDLQHGSPFMKMPNIVSSKDYLVTANSNLVIITAGARQKKGETRLDLVQRNVSIFKLM
IPNITQYSPHCKLLIVTNPVDILTYVAWKLSGFPKNRVIGSGCNLDSARFRYFIGQRLGI
HSESCHGLILGEHGDSSVPVWSGVNIAGVPLKDLNPDIGTDKDPEQWENVHKKVISSGYE
MVKMKGYTSWGISLSVADLTESILKNLRRVHPVSTLSKGLYGINEDIFLSVPCILGENGI
TDLIKVKLTLEEEACLQKSAETLWEIQKELKL

# Drug_Target_9_Reaction:
(S)-lactate + NAD+ = pyruvate + NADH + H+

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
Q6ZMR3

# Drug_Target_9_SwissProt_Name:
LDH6A_HUMAN

# Drug_Target_9_Synonyms:
EC 1.1.1.27

# Drug_Target_9_Theoretical_pI:
7.00

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB00157
